{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "fastText for Standard treatment guideline.ipynb",
      "provenance": [],
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "accelerator": "GPU"
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/WuraolaOyewusi/Simple-Natural-Language-Processing-Projects-for-Health-Sciences/blob/master/fastText_for_Standard_treatment_guideline.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "mstE_32cTdZ4",
        "colab_type": "text"
      },
      "source": [
        "##Text Download and Extraction from pdf"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "J-MxRZ5OS6kx",
        "colab_type": "code",
        "outputId": "698c5615-a720-417b-e6f8-73cf0422bcbb",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 314
        }
      },
      "source": [
        "!wget \"https://github.com/WuraolaOyewusi/Simple-Natural-Language-Processing-Projects-for-Health-Sciences/raw/master/Standard%20Treatment%20Guideline(Nigeria%2C2008)%20without%20index%20and%20appendices.pdf\""
      ],
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "--2019-12-26 14:53:07--  https://github.com/WuraolaOyewusi/Simple-Natural-Language-Processing-Projects-for-Health-Sciences/raw/master/Standard%20Treatment%20Guideline(Nigeria%2C2008)%20without%20index%20and%20appendices.pdf\n",
            "Resolving github.com (github.com)... 192.30.255.112\n",
            "Connecting to github.com (github.com)|192.30.255.112|:443... connected.\n",
            "HTTP request sent, awaiting response... 302 Found\n",
            "Location: https://raw.githubusercontent.com/WuraolaOyewusi/Simple-Natural-Language-Processing-Projects-for-Health-Sciences/master/Standard%20Treatment%20Guideline(Nigeria%2C2008)%20without%20index%20and%20appendices.pdf [following]\n",
            "--2019-12-26 14:53:07--  https://raw.githubusercontent.com/WuraolaOyewusi/Simple-Natural-Language-Processing-Projects-for-Health-Sciences/master/Standard%20Treatment%20Guideline(Nigeria%2C2008)%20without%20index%20and%20appendices.pdf\n",
            "Resolving raw.githubusercontent.com (raw.githubusercontent.com)... 151.101.0.133, 151.101.64.133, 151.101.128.133, ...\n",
            "Connecting to raw.githubusercontent.com (raw.githubusercontent.com)|151.101.0.133|:443... connected.\n",
            "HTTP request sent, awaiting response... 200 OK\n",
            "Length: 786572 (768K) [application/octet-stream]\n",
            "Saving to: ‘Standard Treatment Guideline(Nigeria,2008) without index and appendices.pdf’\n",
            "\n",
            "\r          Standard    0%[                    ]       0  --.-KB/s               \rStandard Treatment  100%[===================>] 768.14K  --.-KB/s    in 0.007s  \n",
            "\n",
            "2019-12-26 14:53:08 (102 MB/s) - ‘Standard Treatment Guideline(Nigeria,2008) without index and appendices.pdf’ saved [786572/786572]\n",
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "kn6puRSVnqcj",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "%%capture\n",
        "!pip install tika        #Tika is a Python Library to extract Text from Pdf\n",
        "!pip install fasttext"
      ],
      "execution_count": 0,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "9EQr6Geay2C0",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "%%capture\n",
        "import nltk\n",
        "from pprint import pprint\n",
        "from gensim.models import FastText\n",
        "import fasttext\n",
        "nltk.download('punkt')\n",
        "from nltk import word_tokenize\n",
        "from pprint import pprint\n",
        "from tika import parser\n",
        "import string\n",
        "from sklearn.decomposition import PCA\n",
        "import matplotlib.pyplot as plt"
      ],
      "execution_count": 0,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "UsDe7bW4n_1n",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "rawText = parser.from_file('Standard Treatment Guideline(Nigeria,2008) without index and appendices.pdf')"
      ],
      "execution_count": 0,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "j4GzopuRsIVV",
        "colab_type": "code",
        "outputId": "448f07ca-4034-4d44-925f-c9de8ab6d7e3",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 72
        }
      },
      "source": [
        "print(type(rawText))    #Tika parser returns a dictionary\n",
        "print(rawText.items())  #Returned dictionary contains metadata and content"
      ],
      "execution_count": 10,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "<class 'dict'>\n",
            "dict_items([('metadata', {'Content-Type': 'application/pdf', 'Last-Modified': '2019-12-06T10:06:35Z', 'Last-Save-Date': '2019-12-06T10:06:35Z', 'X-Parsed-By': ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.pdf.PDFParser'], 'X-TIKA:content_handler': 'ToTextContentHandler', 'X-TIKA:embedded_depth': '0', 'X-TIKA:parse_time_millis': '2920', 'access_permission:assemble_document': 'true', 'access_permission:can_modify': 'true', 'access_permission:can_print': 'true', 'access_permission:can_print_degraded': 'true', 'access_permission:extract_content': 'true', 'access_permission:extract_for_accessibility': 'true', 'access_permission:fill_in_form': 'true', 'access_permission:modify_annotations': 'true', 'date': '2019-12-06T10:06:35Z', 'dc:format': 'application/pdf; version=1.6', 'dcterms:modified': '2019-12-06T10:06:35Z', 'meta:save-date': '2019-12-06T10:06:35Z', 'modified': '2019-12-06T10:06:35Z', 'pdf:PDFVersion': '1.6', 'pdf:charsPerPage': ['5718', '6059', '5242', '5816', '5475', '5074', '5975', '6264', '5912', '5719', '4642', '4854', '5460', '5549', '5533', '4889', '4751', '5333', '5748', '6337', '5531', '5408', '5925', '5723', '5723', '5675', '5504', '5589', '6546', '5513', '6003', '6274', '5868', '6424', '6840', '5822', '6149', '6471', '6303', '6186', '5396', '6250', '6094', '5715', '5232', '5551', '5427', '5969', '5956', '5842', '5777', '5409', '5701', '5777', '6758', '6527', '6541', '6094', '5805', '5021', '4885', '5148', '5675', '5485', '3788', '5241', '5166', '6001', '5929', '6198', '4958', '6039', '5409', '5582', '5381', '5649', '5665', '5768', '6557', '3873', '5769', '4762', '5467', '6102', '5250', '5556', '4864', '6560', '6617', '6029', '5777', '6557', '6099', '7470', '5174', '5170', '5514', '4771', '6190', '5774', '6065', '6076', '4310', '5811'], 'pdf:docinfo:modified': '2019-12-06T10:06:35Z', 'pdf:docinfo:producer': 'www.ilovepdf.com', 'pdf:encrypted': 'false', 'pdf:hasXFA': 'false', 'pdf:hasXMP': 'false', 'pdf:unmappedUnicodeCharsPerPage': ['0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '1', '0', '0', '0', '0', '0', '0', '2', '0', '0', '0', '0', '0', '0', '0', '0', '1', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '10', '0', '1', '0', '0', '0', '0', '0', '1', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '5', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0'], 'resourceName': \"b'Standard Treatment Guideline(Nigeria,2008) without index and appendices.pdf'\", 'xmpTPg:NPages': '104'}), ('content', '\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\nCHAPTER 1: ALIMENTARY TRACT\\n\\nAmoebic dysentery\\n\\nAmoebic abscess\\n\\nChronic Carriers\\n\\nAmoebic dysentery\\n\\nAmoebic liver abscess\\n\\nGASTROINTESTINAL DISORDERS\\n\\nA common parasitic infection of the gastrointestinal\\nsystem caused by the protozoan\\n\\nIt may present as:\\n\\nFever/chills\\n\\nLiver abscess: swelling, pain in the right sub-costal area\\nIntracranial space-occupying lesion\\nLungs: cough and blood stained sputum\\nAmoeboma: swelling anywhere in the abdomen\\nAnal ulceration: may occur by direct extension from the\\nintestinal infection\\n\\nSymptom-free\\n\\nBacillary dysentery\\nAny other cause of bloody diarrhoea\\nCancer of the liver\\nOther causes of liver enlargement\\n\\nRupture of abscess into the lungs, peritoneum\\nSpace-occupying lesion in the brain\\nRight inguinal mass\\n\\nStool: microscopy for cysts and motile organisms\\n(amoebic dysentery)\\nFull Blood Count\\nChest radiograph (in amoebic liver abscess)\\nAbdominal Ultrasound Scan\\n\\nRehydrate adequately\\nEradicate the protozoa\\n\\nCorrect dehydration (see section on rehydration)\\nMetronidazole\\n\\n800 mg 8 hourly for 5 days\\n30 mg/kg/day in 3 divided doses for 5 days\\n\\nMetronidazole\\n800 mg 8 hourly for 10 days\\n50 mg/kg/day in 3 divided doses for 7-10 days\\n\\nAspiration is indicated to prevent spontaneous rupture of\\nabscesses.\\n\\nAMOEBIASIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNon-drug treatment\\n\\nEntamoebahistolytica\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild:\\n\\nAcquired through faeco-oral transmission.\\n\\nPersistent mucoid / bloody diarrhoea\\nAbdominal pain\\n\\nThis can occur in any of the following forms as a result of\\nspread via the blood stream:\\n\\ndiarrhoeas resulting from bacterial infection are usually\\nself-limiting. Appropriate systemic antibiotics are\\nhowever required when systemic infections occur.\\n- Amoxicillin 500 mg 8 hourly for 5 days\\nOr:\\n- Cotrimoxazole 960 mg 12 hourly for 3-5 days\\nOr:\\n- Ciprofloxacin 500 mg - 1 g orally 12 hourly for 5 days\\n- Azithromycin 500 mg daily for 3 days for resistant\\nstrains\\n\\nCiprofloxacin may induce tendinitis especially in\\nchildren .\\n\\nCiprofloxacin is not recommended for use in children\\nless than 18 years.\\n\\nAntidiarrhoeal medicines are not advised.\\n\\nSafe drinking water\\nSanitary disposal of human waste material\\n\\nAn acute severe diarrhoeal illness of worldwide\\nimportance; endemic in many developing countries.\\n\\nCaused by bacilli (classical and\\nspecies)\\n\\nExcessive secretion of fluid is mediated by the release\\nof enterotoxin (released by the bacilli), which acts on the\\nenterocytes of the small intestine via cyclicAMP.\\n\\nHighly infectious; spread by faeco-oral route.\\n\\nMild watery diarrhoea\\nSevere life-threatening diarrhoea leading to\\nhypovolaemic shock if untreated\\n\\nOccasionally, vomiting\\n\\nHypovolaemic shock with multiple end organ failure\\nleading to death\\n\\nHypoglycaemia\\nParalytic ileus\\n\\nStool microscopy, culture and sensitivity\\nFull Blood Count\\nUrea, Electrolytes and Creatinine\\n\\nRehydrate adequately and rapidly\\nEradicate the infective organism\\nPrevent spread of the infection\\n\\nIntravenous Ringer\\'s lactate/Darrow\\'s solutions\\nOral Rehydration Therapy\\nAntibiotic therapy\\n\\nTetracycline:\\n500 mg orally every 6 hours for 5 days\\n\\nNotable adverse drug reactions\\n\\nPrecaution\\n\\nPrevention\\n\\nCHOLERA\\nIntroduction\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nVibrio cholerae El Tor\\n.\\n\\nAdult:\\n\\nConsult a surgeon.\\n\\nTreat cyst carrier if patient is a food handler:\\nDiloxanide furoate\\n\\n500 mg every 8 hours for 10 days\\n20 mg/kg orally every 8 hours for 10\\n\\ndays\\n\\nMetronidazole is contraindicated in pregnancy.\\nAvoid alcohol during treatment and at least 48 hours after\\ntreatment.\\n\\nProvision of safe drinking water\\nSanitary disposal of faeces\\nRegular examination of food handlers and appropriate\\ntreatment where necessary.\\n\\nAn important cause of colonic diarrhoea in developing\\ncountries.\\nCaused by pathogenic species of Shigella A-D\\n( )\\nTransmitted via the faeco-oral route.\\n\\nMucoid bloody diarrhoea associated with severe central\\nand lower abdominal pain\\nTenesmus\\nModerate-grade pyrexia\\nSometimes only a mild, self-limiting diarrhoea lasting 2-\\n3 days\\nArticular features occasionally\\nSepticaemic spread with multi-system involvement\\noccasionally.\\n\\nAmoebic dysentery\\nIdiopathic enterocolits (ulcerative)\\n\\ninfection\\nColorectal cancer\\n\\nSepticaemia/bacteraemia\\nSevere rectal bleeding\\nIntestinal perforation\\nReiter\\'s syndrome\\n\\nStool microscopy, culture and sensitivity\\nFull Blood Count\\nUrea, Electrolytes and Creatinine\\n\\nAdequate rehydration\\nEradicate bacterial pathogens\\n\\nOral Rehydration Therapy (see rehydration under\\ndiarrhoea)\\n\\nParenteral hydration therapy (see rehydratrion under\\ndiarrhoea)\\n\\nAntibacterial drugs are not usually necessary: even\\n\\nAsymptomatic cyst carriers\\n\\nAdult:\\nChild over 25 kg:\\n\\ndysenteri, flexneri, boydii and sonnei .\\n\\nCampylobacter jejuni\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nBACILLARY DYSENTRY\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nOr:\\nDoxycycline:\\n\\n: 200 mg orally once daily for 5 days\\n12 - 18 years, 200 mg on first day, then 100 mg\\n\\ndaily\\n- Severe infections, 200 mg orally daily\\nErythromycin:\\n\\n: 250 - 500 mg orally every 6\\nhours for 5 days or 500 mg -1 g every 12 hours\\n\\n125 mg every 6 hours; 2 - 8 years: 250\\nmg every 6 hours\\n- Doses doubled in severe infection\\nOr:\\nSulfamethoxazole-trimethroprim (Co-trimoxazole)\\n\\n960 mg orally every 12 hours for 5 days\\n6 weeks - 6 months 120 mg 12 hourly; 6 months - 6\\n\\nyears 240 mg; 6 - 12 years 480 mg; 12 - 18 years 960 mg\\norally every 12 hours for 5 days\\n\\nMonitor fluid intake and output (vomitus, urine and\\nstool)\\n\\nProvide access to safe drinking water\\nFood hygiene\\nSafe disposal of human waste\\nCholera vaccine\\n\\nA clinical condition characterized by infrequent bowel\\nopening and/or passage of hard stools.\\n\\nInadequate fibre in diet (simple constipation)\\nDrugs e.g. antidepressants, narcotic analgesics, etc\\n\\nDiseases of the anus, rectum and colon e.g. fissures,\\nhaemorrhoids, cancer\\n\\nFunctional: irritable bowel syndrome\\nMetabolic diseases e.g. hypothyroidism, hypercalcaemia\\n\\nStools are often hard\\nAbdominal bloating\\nExcessive flatulence\\n\\nRelevant associated history to determine aetiology\\nshould be vigorously pursued\\n\\nPhysical examination should be thorough, and must\\ninclude a rectal examination\\n\\nMegacolon\\nAnal fissures/tears\\nHaemorrhoids\\nRectal bleeding\\n\\nStool examination including microscopy\\nProctoscopy/sigmoidoscopy\\n\\nAdult\\nChild:\\n\\nAdult and child over 8 years\\n\\nChild up to 2 years:\\n\\nAdult:\\nChild:\\n\\nSupportive measures\\n\\nPrevention\\n\\nCONSTIPATION\\nIntroduction\\n\\nAetiology\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\n1 2\\n\\nChapter 1: Alimentary Tract Standard Treatment Guidelines for Nigeria 2008\\n\\nSECTION A\\n\\n\\n\\nBarium enema\\nSerum hormonal levels e.g. thyroxine, triiodotyronine,\\n\\nthyroid stimulating hormone to exclude hypothyroidism\\n\\nIdentify and eliminate cause(s)\\nEvacuate hard faecal matter\\n\\nSituations where straining will exacerbate pre-existing\\nmedical/surgical conditions\\n- Angina\\n- Risk of rectal bleeding\\n- Increased risk of anal tear\\n\\nOther indications\\n- Drug-induced constipation\\n- To clear the alimentary tract before surgery or\\nradiological procedures\\n\\nAvoid precipitants\\nHigh fibre diet (including fruits and vegetables)\\nAdequate fluid intake\\n\\nStimulant laxatives\\n- Senna 7.5 mg tablet (as sennoside B)\\n\\n2 - 4 tablets at night\\n6 - 12 years 1 - 2 tablets at night (or in the morning\\n\\nif preferred)\\n12 - 18 years: 2 - 4 tablets at night\\nOr:\\n\\nBisacodyl tablets 10 mg orally at night; suppositories\\n10 mg per rectum at night\\n\\nLaxatives should generally be avoided. Most times\\nthese drugs are needed for only a few days\\n\\nA very common clinical problem the world over,\\nparticularly in developing countries.\\n\\nAccounts for significant morbidity and mortality,\\nespecially in children.\\n\\nInfective agents are recognized in about 70% of cases\\nand are transmitted by the faeco-oral route.\\n\\nViruses (particularly Rotavirus) are responsible for\\nover 70% of diarrhoeas in children below 2 years.\\n\\nMany bacteria and some parasites are also important\\naetiologic agents, particularly in adolescents and adults.\\n\\nEndemic and epidemic presentations can occur.\\nContamination of food and water by bacterial toxins can\\nalso lead to acute diarrhoea, sometimes with associated\\nvomiting (i.e. food poisoning). This is usually self-\\nlimiting.\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nCaution\\n\\nDIARRHOEA(Acute)\\nIntroduction\\n\\nIndications for use of laxatives\\n\\nMegacolon:\\nSaline enema\\nSurgical: resection of large bowel\\n\\nAdult:\\nChild :\\n\\nPersonal hygiene: hand-washing, care in food-handling\\n\\nInflammation of the gastric mucosa.\\nCan be acute or chronic.\\n\\nThe most important risk factors for acute gastritis\\ninclude use of drugs (NSAIDs in particular) and alcohol.\\n\\nH. infection is the most important risk factor for\\nchronic gastritis\\n\\nAll agents of gastritis work through the common path of\\ndisrupting the protective mucosal barrier of the stomach.\\n\\nAcute gastritis may evoke pain that mimics peptic ulcer\\ndisease; chronic gastritis is a precursor of peptic ulcer\\ndisease (type B gastritis) and gastric cancer (type A\\ngastritis).\\n\\nChronic gastritis is essentially asymptomatic\\nAcute gastritis evokes acute abdominal pain that mimics\\n\\npeptic ulcer disease (see peptic ulcer disease)\\nOccasionally acute gastritis may be haemorrhagic with\\n\\nmelaenal stools or rarely haematemesis\\n\\nAcute gastritis: haemorrhage\\nChronic gastritis: peptic ulcer disease; gastric cancer\\n\\nPeptic ulcer disease (acute gastritis)\\n\\nEndoscopy (macroscopic diagnosis)\\nHistology of gastric biopsy for definitive diagnosis\\n\\nEliminate pain (acute gastritis)\\nPrevent progression to peptic ulcer disease or gastric\\n\\ncancer\\nRe-establish normal histology\\n\\nAcute Gastritis:\\nAntacids\\n\\n- Magnesium trisilicate 1 - 2 tablets or suspension 10 mL\\norally three times daily or as required\\nOr:\\n\\nH receptor antagonist\\n\\n- Ranitidine 150 mg orally once daily as required\\nOr:\\n\\nProton Pump Inhibitors\\n- Omeprazole 20 mg orally once daily as required\\nTypeAgastritis:\\n\\nEndoscopic surveillance every 2 - 3 years for early\\ndetection of cancer\\nType B gastritis:\\n\\nEradication of H. using triple therapy with\\n- Clarithromycin 500 mg orally twice daily for 7 days\\nPlus:\\n- Amoxicillin 1g orally every 12 hours for 7 days\\nPlus:\\n\\nGASTRITIS\\nIntroduction\\n\\nClinical features\\n\\nComplications\\n\\nDifferential diagnosis\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\npylori\\n.\\n\\npylori\\n\\n2\\n\\nClinical features\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nWatery diarrhoea of varying volumes, sometimes with\\nvomiting: this is the commonest presentation, and\\nsuggests pathology in the small intestine.\\n\\nBloody mucoid stools: suggests disease in the colon\\nFever, abdominal pain and dehydration\\nFast and small volume pulse with low blood pressure:\\n\\nindicates significant fluid loss\\n\\nHypovolaemic shock with multiple organ failure\\nSepticaemia\\nIntestinal perforation\\nGastro-intestinal bleeding\\nParalytic ileus\\n\\nNon-infectious diarrhoea e.g. drug-induced\\nGut allergy (e.g. gluten)\\nPsychogenic stress\\nMetabolic and endocrine causes (e.g. thyrotoxicosis,\\n\\nuraemia, diabetes mellitus)\\n\\nStool examination including microscopy, culture and\\nsensitivity\\n\\nFull Blood Count\\nUrea, Electrolytes and Creatinine\\nSerology (e.g. Widal test)\\n\\nAchieve adequate hydration\\nEliminate infectious agent (where possible)\\nTreat complications\\n\\nRehydrate with:\\nOral Rehydration Therapy - ORT (low osmolarity) for\\n\\nmild to moderate dehydration\\n- 500 mLorally over 2 - 3 hours, 3 - 4 times daily\\n\\nIntravenous sodium chloride 0.9%\\n- 1 litre 2 - 6 hourly for moderate-to- severe dehydration\\n- Alternate with Darrow\\'s solution depending on serum\\npotassium\\nChildren:\\n\\nUse of zinc supplementation\\n- 20 mg per day for 10 - 14 days\\n- Under 6 months old: 10 mg per day\\n\\nSpecific anti-infective agents for infectious diarrhoeas\\ne.g. metronidazole for amoebiasis, giardiasis\\n\\nMonitor fluid intake/output\\n\\nHeart failure: from overhydration\\nInitial increase in diarrhoea with ORT: this is self\\n\\nlimiting\\nHyperkalaemia: from excessive use of potassium-\\n\\ncontaining fluids\\n\\nProvide access to safe drinking water\\nSanitary disposal of human waste\\n\\n- Omeprazole 20 mg orally for 7 days\\nOr:\\n- Metronidazole 400 mg orally every 8 hours for 7 days\\nPlus:\\n- Amoxicillin 500 mg orally every 8 hours for 7 days\\nPlus:\\n- Omeprazole 20 mg orally for 7 days\\n\\nAvoid risk factors (NSAIDs, alcohol, etc)\\n\\nAparasitic infection caused by\\nWorldwide in distribution but more common in\\n\\ndeveloping countries.\\nSpread by the faeco-oral route.\\n\\nInvasion of the upper small intestine by the parasite\\nevokes inflammation, leading to progressive villous\\natrophy.\\n\\nAcute disease: watery diarrhoea with abdominal\\nbloating\\n\\nChronic disease: diarrhoea, steatorrhoea and weight\\nloss from malabsorption syndrome- with lactose\\nintolerance, xylose malabsorption and vitamin B\\n\\ndeficiency\\n\\nDiseases related to Vitamin B deficiency\\n\\nOther causes of upper gastrointestinal malabsorption\\nsuch as coeliac disease and tropical sprue\\n\\nFull blood count\\nStool microscopy and faecal fat assessment\\nJejunal biopsy\\n\\nRehydrate adequately\\nEradicate parasite\\nReplace malabsorbed (deficient) nutrients\\n\\nMetronidazole\\n2 g orally daily for 3 days or 400 mg 8 hourly for 5\\n\\ndays\\n1 - 3 years 500 mg orally daily; 3 - 7 years 600 -\\n\\n800 mg daily; 7-10 years 1 g daily for 3 days\\nTinidazole\\n\\n40 mg/kg orally as a single dose; repeat after 1\\nweek\\n\\n50 to 75 mg/kg as a single dose; repeat after 1\\nweek\\n\\nVitamin B supplementation\\n\\nAvoidance of milk\\n\\nevery 12 hours\\n\\nevery 12 hours\\nPrevention\\n\\nGIARDIASIS\\nIntroduction\\n\\nPathogenesis\\n\\nClinical features\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nSupportive\\n\\nGiardia lamblia.\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\n12\\n\\n12\\n\\n12\\n\\n3 4\\n\\nChapter 1: Alimentary Tract Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nHAEMORRHOIDS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSurgery\\n\\nCaution\\n\\nPANCREATITIS\\nIntroduction\\n\\nMetallic taste and vomiting from metronidazole\\n\\nGood sanitary habits\\nUncontaminated water and food supplies\\n\\nEnlarged or varicose veins of the tissues at the anus or\\nrectal outlet.\\n\\nEngorgement of the vascular complex or thrombus\\noften leads to the symptoms of disease.\\n\\nThe pathophysiologic mechanisms are complex and\\nvary with the subject.\\nMay be external or internal.\\n\\nInternal haemorrhoids: typically painless but present\\nwith bright red rectal bleeding\\nMay become thrombosed and protrude into the anal\\ncanal\\n\\nExternal haemorrhoids when thrombosed cause acute\\nperineal pain with or without necrosis and bleeding\\n\\nFibrosed external haemorrhoids present as anal tags\\n\\nColorectal cancer\\nAdenomatous polyps\\nInflammatory bowel disease\\n\\nBleeding, necrosis, perineal sepsis, mucus discharge\\n\\nAnoscopy\\nFull blood count including blood film\\n\\nRelieve pain\\nPrevent complications\\n\\nIncrease fibre in foods\\nIncrease fluid intake\\nAvoid foods that cause constipation\\nStool softeners\\nRegular exercise\\n\\nSuppositories/ointments of preparations containing\\nhydrocortisone acetate with or without lidocaine\\nhydrochloride plus astringent(s)\\n\\nElastic band ligation\\nSclerosis, photocoagulaton, cryosurgery, excisional\\n\\nhaemorrhoidectomy\\n\\nEach drug treatment course should not exceed 7 days\\n\\nA state of inflammation of the pancreas, which can be\\n\\nNasogastric tube suctioning\\nDecrease pancreatic inflammation\\nPrevent, identify and treat complications\\n\\nCaution\\n\\nPrevention\\n\\nPEPTIC ULCER DISEASE\\nIntroduction\\n\\nAetiology/Predisposing factors\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\nDifferential diagnoses\\n\\nTreatment objectives\\n\\nAvoid narcotic analgesics which may cause spasm of\\nthe sphincter of Oddi and worsen pancreatitis\\n\\nControl alcohol ingestion\\n\\nCaused by peptic ulceration that involves the stomach,\\nduodenum and lower oesophagus.\\nAn increasingly common problem in developing\\ncountries.\\n\\nMost ulcers are duodenal\\n\\n. gut infection\\nUse of NSAIDs\\nSmoking\\n\\nRecurrent epigastric pain\\n- Often radiating to the back\\n- Worse at night\\n- Improved by antacids\\n- May be made worse by some food types (generally\\nbetter with bland diet)\\n\\nUpper gastrointestinal bleeding\\nPerforation\\nPenetration\\nGastric outlet obstruction\\nGastric cancer\\n\\nFull Blood Count\\nLiver Function Tests\\nUrea, Electrolytes and Creatinine\\nOccult blood test\\nStool microscopy\\nEndoscopy\\nDouble contrast barium meal\\nDirect/indirect detection of (by CLO test or by\\n\\nCO breath test)\\n\\nGastritis\\nDuodenitis\\nNon-Ulcer Dyspepsia\\nGastro-duodenal malignancy\\nOesophagitis\\nGall bladder diseases\\n\\nRelieve pain\\nPromote healing of ulcers\\nEradicate\\nPrevent/reduce recurrence\\n\\nH pylori\\n\\nH. pylori\\n\\nH. pylori\\n\\n2\\n\\nacute or chronic.\\n\\nVaried, but most important are:\\nGallstones\\nAlcohol ingestion\\nAbdominal trauma\\nInfections\\nIdiopathic in as many as 20-30% cases\\nOccurrence is worldwide, but commoner in areas of the\\n\\nworld where gallstones and alcohol ingestion are\\ncommon.\\n\\nAutolysis of pancreatic tissue by pancreatic enzymes as\\na result of “secretory block” in the pancreatic bed (often\\ncaused by stones) .\\n\\nAcute pancreatitis:\\nEpigastric pain: may radiate to the back in over 50% of\\n\\ncases\\nNausea, vomiting, abdominal distension\\nSevere abdominal tenderness with features of\\n\\nhypovolaemia in severe cases\\n\\nPeptic ulcer disease\\nCholecystitis\\n\\nSerum amylase: raised in 80% of acute cases\\nSerum lipase: if raised is more specific than serum\\n\\namylase\\nAlanine aminotransferase: a rise above 3-fold suggests\\n\\npancreatitis of gallstone origin\\nCT scan\\nAbdominal ultrasound: least useful in acute pancreatitis\\n\\nHypovolaemic shock\\nAcute renal and respiratory failure\\nPhlegmos\\nGastrointestinal bleeding\\nElectrolyte imbalance (hypo & hypercalcaemia)\\nPancreatic pseudocysts\\n\\nRelieve pain\\nPrevent complications\\n\\nRenal failure: haemodialysis\\nRespiratory failure: mechanical ventilation\\nGallstones: Endoscopic Retrograde Cholangio\\n\\nPancreatography (ERCP) with sphincterotomy\\nPancreatic pseudocyst: surgery\\n\\nAnalgesics\\nTreat specific complications\\n\\nAetiology\\n\\nPathophysiology\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nComplications\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\nBed rest\\nMonitor vital signs; fluid intaket/output\\n\\nDrug treatment\\n\\nAdjunct therapy\\n\\nSupportive therapy\\n\\nNotable adverse drug reactions\\n\\nTreatment of complications\\n\\nUPPER GASTROINTESTINALBLEEDING\\nIntroduction\\n\\nSymptomatic treatment with antacids may be used prior\\nto confirming the diagnosis of peptic ulcer disease\\n\\nTriple therapy with:\\n- Metronidazole 400 mg orally every 8 hours for 7 days\\nPlus:\\n- Amoxicillin 500 mg orally for 7 days\\nPlus:\\n- Omeprazole 20 mg orally every 12 hours for 7 days\\nOr:\\n- Clarithromycin 500 mg orally for 7\\ndays\\nPlus:\\n- Amoxicillin 1g orally for 7 days\\nPlus:\\n- Omeprazole 20 mg orally for 7 days\\n\\nMagnesium trisilicate suspension 15 mL orally three\\ntimes daily as required\\n\\nRegular meals\\nAvoidance of provocative factors (NSAIDs, alcohol,\\n\\nspicy foods etc.)\\n\\nGastric irritation, diarrhoea from triple therapy\\nDiarrhoea/constipation from adjunct therapy\\n\\nIntravenous omeprazole 20 mg 12 hourly for 5 days then\\nstandard triple therapy\\n\\nInterventional endoscopic treatment\\nBlood transfusion\\nSurgery\\n\\nSurgery\\n\\nRest the gut\\nSurgery\\n\\nBleeding from the lower oesophagus, stomach or\\nduodenum up to the level of ligament of Treitz.\\n\\nOccurs worldwide and is responsible for significant\\nmortality and morbidity.\\n\\nMajor causes include bleeding from:\\n- Peptic ulcer disease\\n- Oesophageal and gastric varices\\n- Mallory-Weiss tear\\n- NSAID-related mucosal bleeding\\n- Neoplasia\\n\\nBleeding is either from rupture of engorged varices or\\nfrom disruption of the oesophageal or gastro-duodenal\\n\\nH. pylori eradication\\n\\nMild upper gastrointestinal bleeding\\n\\nSevere upper gastrointestinal bleeding\\n\\nPerforation\\n\\nGastric outlet obstruction\\n\\nevery 8 hours\\n\\nevery 12 hours\\n\\nevery 12 hours\\n\\nevery 12 hours\\n\\n5 6\\n\\nChapter 1: Alimentary Tract Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nmucosa with ulceration or erosion into an underlying\\nvessel.\\n\\nDepends on whether the bleeding is acute or chronic,\\nmild or severe\\n\\nVarious presentations\\n- Haemetemesis\\n- Melaena\\n- Haematochezia\\n- Hypovolaemia\\n- Iron deficiency anaemia (with its associated\\n\\nsymptoms)\\n\\nBlack stools from ingestion of iron tablets\\nHaematemesis/melaena from previously swallowed\\n\\nblood (from the upper respiratory tract and oral cavity)\\n\\nHypovalaemic shock\\nCongestive heart failure from chronic severe anaemia\\n\\nUpper gastrointestinal endoscopy: picks up lesions in\\n90% of cases\\n\\nUpper gastrointestinal barium radiography: 80%\\ndetection rate\\n\\nSelective mesenteric arteriography\\nRadio isotope scanning\\nStool- occult blood test\\nFull Blood Count\\n\\nRestore and maintain haemodynamic status\\nControl bleeding\\nPrevent recurrence of bleeding\\n\\nCarefully monitor vital signs (pulse, blood pressure,\\nrespiration and temperature) as frequently as\\nnecessitated by the patient\\'s condition\\nInsert a nasogastric tube to aspirate gastric contents\\nand/or to introduce agents to constrict the blood vessels\\nBlood transfusion: whole blood (acute bleeding) or\\npacked cells (chronic) bleeding. Up to 5 - 6 pints of blood\\nmay be needed in severe cases\\n- Plasma expanders in the absence of blood\\nContinuous Central Venous Pressure (CVP) monitoring\\n\\nProton Pump Inhibitors\\n- Omeprazole 20 mg orally once daily for 4 weeks\\nOr:\\n- Omeprazole 40 mg by slow intravenous injection over\\n5 minutes once daily until patient can take orally\\n\\nAnti therapy set above.\\nEndoscopic treatment for actively bleeding ulcer or\\n\\nvisible non-bleeding vessel\\n- Injection therapy with 98% alcohol (total volume less\\nthan 1mL)\\nOr:\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\nBleeding peptic ulcers/erosions\\n\\nHelicobacter pylori\\n\\nAetiology\\n\\nImportant risk factors\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nVaries, depending on geographical region:\\nViruses, alcohol and drugs are the commonest aetiologic\\n\\nagents\\n\\nFamily history\\nAlcohol ingestion\\nPrevious blood transfusion\\nContamination of food and water by sewage\\nDrug ingestion\\nSexual contact\\n\\nAcute hepatitis:\\nMild-to-moderate jaundice\\nVague upper quadrant discomfort\\nWith or without mild fever\\nThere may be enlargement of the liver below the costal\\n\\nmargin with varying consistency (depending on the stage\\nof the liver disease)\\nChronic hepatitis:\\n\\nRe-occurence of jaundice may suggest a chronic illness\\n\\nLiver abscess\\nMetabolic liver disease/disorder\\n\\nFulminant hepatic failure\\nBleeding tendencies\\n\\nLiver Function Tests\\nSerologic markers of HepatitisA, B, C, D and E\\nAbdominal ultrasonography\\n\\nProvide supportive measures\\nPrevent progression to chronic phase\\n\\nHigh carbohydrate and low protein diet\\nDiscontinuation of hepatotoxic medication\\nBed rest\\n\\nSelf-limiting disease. No specific drug treatment\\n\\nAcute:\\nSelf-limiting to fulminant\\n\\nTreatment is supportive\\nChronic:\\n\\nInterferon alfa -2b: 10 million units subcutaneously\\nthree times weekly for 4 months\\n\\nLamivudine: 100 mg orally daily for 1year\\nLiver transplant\\n\\nChronic Hepatitis C:\\nInterferon alfa -2b\\n\\n- 3 million units subcutaneously 3 times weekly for 4\\nmonths\\n\\nRibavirin\\n- 400 mg orally twice daily for adults with body weight\\n\\nHepatitisA\\n\\nHepatitis B\\n\\n- Injection therapy with epinephrine (1:10,000) up to\\n1mL\\nOr:\\n- Thermal coagulation with heat probe\\nOr:\\n- Laser therapy\\n\\nIntravenous vasopressin 20 units over 20 minutes bolus\\nthen infusion of 0.1 - 0.5 units/min\\nPlus:\\nIntravenous nitroglycerin 40 microgram/min (titrated\\nupward to maintain systolic blood pressure above 90\\nmmHg)\\n\\nEndoscopic treatment\\nInjection sclerotherapy: equal volume mixture of 3%\\n\\nsodium tetradecyl sulfate, 98% ethanol, sodium chloride\\n0.9% injection (2-5 mL/site; maximum 50 mL)\\n\\nVariceal band ligation\\nRadiologic therapy\\nVenous embolization\\nTransjugular Intrahepatic Portosystemic Shunt (TIPS)\\nOesophageal transection and devascularization\\nLiver transplant\\n\\nSurgical repair or resection as appropriate\\n\\nMonitor vital signs and urine output to detect early\\nfeatures of hypovolaemic shock\\n\\nLook out for features of hepatic encephalopathy\\n\\nVasopressin can cause abdominal cramps. It lowers\\nblood pressure drastically and could worsen ischaemic\\nheart disease\\n\\nAvoid NSAIDs.\\nTreat infection\\n\\nblockers (propranolol 40 mg orally 12 hourly and\\ntitrate up to 160 mg depending on the heart rate)\\n\\nMaintenance sclerotherapy\\n\\nInflammation of the liver that can be caused by\\ninfective agents, drugs and other toxins\\n\\nThe most predominant and important presentation of\\nliver disease worldwide\\n\\nThe suffixes acute, chronic, viral, autoimmune,\\nalcoholic etc. define the agents causing hepatic injury or\\ntheir duration as the case may be\\n\\nBleeding varices\\n\\nPeptic ulcers/erosions/tumours\\n\\nPeptic ulcers/erosions related upper gastrointestinal\\nbleeding\\n\\nOesophageal varices\\n\\nSupportive\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nHEPATITIS\\nIntroduction\\n\\nH. pylori\\n\\nβ\\n\\nHEPATICAND BILIARYDISORDERS\\n\\nless than 65 kg; 400 mg in the morning and 600 mg in the\\nevening for adults weighing 65-85 kg; 600 mg twice daily\\nfor adults weighing over 85 kg\\n\\nInterferon alfa -2b: 3 million units subcutaneously 3\\ntimes weekly for 4 months\\nPlus:\\n\\nLamivudine: 100 mg orally once daily for 4 months\\n\\nLargely supportive\\n\\nInterferon alpha 2b and Ribavirin haematopoietic\\ntoxicity\\n\\nFlu-like illness\\nLeucopenia\\nPsychiatric-like symptoms\\nDevelopment of early resistance if therepy exceeds 1\\n\\nyear\\n\\nPrevention of faecal contamination of food and water\\nScreen blood and blood products for hepatotrophic\\n\\nviruses\\nImmunization against hepatitisA, B\\nReduction of drug misuse/abuse\\nPre-exposure prophylaxis (as for NPI/EPI)\\nPost-exposure prophylaxis\\n\\nAstate of disturbed central nervous system function as a\\nresult of hepatic insufficiency\\n\\nCharacterized by changes in personality, cognition,\\nmotor function, level of consciousness\\n\\nOne-year survival rate is 40%\\nNitrogenous substances, particularly ammonia, reach\\n\\nthe brain via portosystemic shunts leading to alteration of\\nneurotransmission\\n\\nReduced blood supply to the liver\\nInfection of the liver\\nBleeding into the gut\\nElectrolyte imbalance (hypokalaemia and\\n\\nhypomagnesaemia)\\nPoor bowel evacuation\\n\\nCognitive abnormalities: may be mild and recognizable\\nonly with psychometric testing but may be severe with\\nfrank confusion, altered level of consciousness and coma\\n\\nHyper-reflexia\\nFetor hepaticus\\nInsomnia\\nFlapping tremor (asterixis)\\n\\nIntracranial lesions (haemorrhage, tumour, abscess\\netc.)\\n\\nHepatitis D\\n\\nHepatitis E\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nHEPATIC ENCEPHALOPATHY\\nIntroduction\\n\\nPredisposing factors\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\n7 8\\n\\nChapter 1: Alimentary Tract Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nCNS infections (encephalitis, meningitis)\\nOther metabolic encephalopathies (uraemia,\\n\\nhyper/hypoglycaemia etc.)\\nHypertensive encephalopathy\\nAlcohol intoxication\\nDrug toxicity e.g. sedatives, heavy metals\\n\\nAs appropriate to identify possible precipitating factors\\nFull Blood Count\\nUrea, Electrolytes and Creatinine,\\nBlood sugar\\nMicroscopy and culture of the stool and blood\\n\\nReverse neuropsychiatric symptoms\\nMinimize nitrogenous substances\\nTreat precipitating factors\\n\\nLactulose syrup (10 g/15 mL)\\n- Initially 30 - 45 mL orally three times daily titrated to\\neither the resolution of symptoms or production of three\\nsoft stools per day\\nOr:\\n- As rectal retention enema 300 mL in 1 litre water\\nretained for 1 hour; duration usually for days or weeks\\nOr:\\n\\nMetronidazole 800 mg orally 12 hourly\\nTreat underlying cause(s) e.g hypokalaemia, anaemia,\\n\\ninfection\\n\\nLactulose: excess gas, diarrheoa\\nMetronidazole: peripheral neuropathy, dysgeusia\\n\\nAvoid precipitating factors\\n\\nAcommon clinical state of varying aetiologies\\nClassified as haemolytic, hepatic or obstructive\\nClinical jaundice occurs when the level of serum\\n\\nbilirubin exceeds 2.5 mg/dL\\nThe bilirubin may be conjugated, unconjugated or\\n\\nmixed\\n\\nDiseases of the liver and the biliary tract\\nConditions that cause excessive red cells haemolysis:\\n\\ninfections, haemoglobinopathies\\n\\nDiscolouration of the sclerae and other mucus\\nmembranes\\nWith or without pruritus (especially with cholestatic\\n\\njaundice)\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nJAUNDICE\\nIntroduction\\n\\nImportant causes\\n\\nClinical features\\n\\nSupportive measures\\nHigh carbohydrate, low protein diet\\nAdequate hydration\\nRectal wash out\\n\\nHepato-renal syndrome\\n\\nLFTs\\nPT, PTTK, Serum albumin\\nLiver biopsy\\nUltrasound examination of the liver\\nScreening for aetiologic factors in chronic liver disease\\n\\ne.g. viral markers for hepatotrophic viruses (e.g.\\nHepatitis B & C)\\n\\nPrevent further liver damage\\nPrevent deterioration of liver function\\nSymptomatic relief from anaemia, fatigue and oedema\\n\\nEncourage high fibre and low salt diet\\nEnhance opening of bowel\\nCorrection of anaemia\\nReduce oedema and ascites\\n\\nSpironolactone tablets 25 - 100 mg orally 12 hourly\\nFurosemide 20 - 80 mg orally 12 hourly\\nSalt-poor albumin for intractable ascites\\n\\nPropranolol 40 - 80 mg orally daily\\n\\nLiver transplant\\n\\nLactulose 30 mLorally twice daily\\n- Doses to be titrated upward until at least 3 bowel\\nmotions daily are achieved\\n\\nSaline rectal enema\\n\\nImmunization against hepatitis B, C\\nAbstinence from alcohol\\n\\nAdequate nutrition is the intake and utilization of\\nenergy-giving and body building foods and nutrients, to\\nmaintain well-being, and productivity.\\n\\n“Malnutrition” includes generalized malnutrition that\\nmanifests as stunting, underweight, wasting\\n(kwashiorkor and marasmus), obesity as well as\\ndeficiencies of micronutrients.\\n\\nKwashiorkor is protein-energy malnutrition .\\nMarasmus is malnutrition resulting from inadequate\\n\\ncalorie intake.\\n\\nObesity is a commonly nutritional disorder (results from\\nexcessive intake of calories).\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nPrevention\\n\\nKWASHIOKORAND MARASMUS\\nIntroduction\\n\\nEpidemiology\\n\\nAscites and pedal oedema\\n\\nPrevention of variceal bleeding\\n\\nReplacement of damaged liver\\n\\nPrevention of encephalopathy\\n\\nNUTRITIONALDISORDERS\\n\\nAssociated features of the underlying disease\\n\\nLFTs: determine levels and nature of bilirubin, liver\\nenzymes (AST,ALT,Alkaline phosphotase)\\n\\nAbdominal ultrasound scan: look out for canalicular\\ndilatations, biliary stones\\n\\nTreat underlying cause\\nPrevent complications\\n\\nSpecific treatment depends on the identified cause\\nColestyramine\\n\\n- 3 - 6 g orally 6 hourly in severe obstructive jaundice\\nPhenobarbital in neonatal jaundice\\n\\n- 5 - 8 mg/kg orally daily\\n\\nColestyramine: diarrhoea\\nPhenobarbital may cause dose-dependent respiratory\\n\\ndepression\\n\\nERCPsphincterotomy with stone removal\\nStent insertion\\nPancreatic head/duodenal head realignment\\n\\nAn advanced stage of chronic liver disease associated\\nwith permanent distortion of the liver architecture and\\nreplacement of some destroyed hepatocytes with fibrous\\ntissue\\n\\nAccompanied by some loss of liver function leading to\\ncertain recognized symptoms and signs\\n\\nSimilar to some causes of acute liver diseases\\nNo known aetiology in up to 30% of cases\\n\\nVaries with the extent of liver damage:\\nFatigue\\nAscites\\nPedal oedema\\nHaematemesis\\nLiver may be shrunken or enlarged below the costal\\n\\nmargin; it is typically firm\\n\\nGranulomatous lesion of the liver\\nPrimary or secondary neoplasms of the liver\\n\\nIntractable oedema\\nUpper gastrointestinal tract bleeding\\nCoagulopathy\\nHepatic encephalopathy\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNotable adverse drug reactions\\n\\nSurgical treatment\\n\\nLIVER CIRRHOSIS\\nIntroduction\\n\\nAetiology\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nObstructive jaundice\\n\\nSupportive measures\\nReassurance and monitoring\\nPhototherapy in neonatal jaundice\\n\\nHigh percentages in under-developed countries,\\nespecially sub-SaharanAfrica\\n\\nKwashiorkor:\\nGrowth retardation\\nMuscle wasting\\nAnaemia\\nApathy\\nMoon face\\nLack-luster skin\\nEasily plucked hair\\nPedal oedema\\nHypo-pigmented skin patches\\nExfoliation,\\nDiarrhoea\\n\\nMarasmus:\\nThin; protruding bones\\nHungry-looking\\n\\'old-looking face’\\nWhimpering cry\\n\\nFull Blood Count, ESR\\nStool microscopy\\nUrinalysis\\nSerum proteins\\nChest radiograph\\nMantoux test\\n\\nNutritional counselling\\nAdequate nutrient intake: may require assistance and\\n\\nspecial preparations e.g. nasogastric feeding, etc.\\nPeriodic growth monitoring\\n\\nMay be indicated where there are specific\\ninfections/infestations\\n\\nDeficiencies of minerals (iron, iodine, zinc, calcium,\\nphosphorus, magnesium, copper, potassium, sodium,\\nchloride, fluoride etc); folic acid and vitamins\\n\\nInadequate dietary intake\\nIncreased requirements\\nIncreased loss (e.g. worm infestation)\\n\\nGlobal; high percentages in under-developed countries,\\nespecially sub-SaharanAfrica\\n\\nIron: anaemia\\nIodine: goitre\\nZinc, copper: manifestations of enzyme and insulin\\n\\ndeficiencies\\nCalcium: rickets, osteomalacia\\nPhosphorus and fluoride: teeth and bone abnormalities\\n\\nClinical features\\n\\nInvestigations\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nMICRONUTRIENT DEFICIENCIES\\nDefinition\\n\\nAetiology\\n\\nEpidemiology\\n\\nClinical features\\n\\n9 10\\n\\nChapter 1: Alimentary Tract Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nVitamins:\\n- A: keratomalacia, corneal xerosis, night blindness\\n- B (thiamine): beri-beri\\n\\n- B (riboflavin): scrotal and vulval dermatoses, angular\\n\\nstomatitis, scars, magenta tongue, cheilosis\\n- B (niacin): scarlet and dry tongue, pellagra\\n\\n- Ascorbic acid: scurvy, petechiae and musculo-skeletal\\nhaemorrhages\\n- D: rickets, epiphyseal enlargement, muscle wasting,\\nbossing of skull bone, \\'thoracic rosary\\', persistently open\\nanterior fontanelle, genu valgum or varum\\n\\nBlood, urine and stool tests\\nOther investigations as appropriate\\n\\nCorrect nutrient deficiencies\\nEnsure adequate intake\\nPrevent complications\\n\\nAdministration of specific nutrients (as concentrates in\\nfoods)\\n\\nFood supplementation\\nTreat underlying diseases\\n\\nNutritional counselling\\nOptimal breastfeeding and appropriate weaning\\n\\npractices\\nAdequate intake of locally available, nutritious foods\\nPersonal/food/water hygiene\\nProphylactic therapies for malaria\\n\\nAmajor component of the metabolic syndrome.\\nBeing overweight or obese significantly increases the\\n\\nrisk of morbidity and mortality from Type 2 diabetes and\\nits co-morbidities.\\n\\nSuccessful weight reduction has a positive impact on\\nmorbidity and mortality outcomes.\\n\\nConstititional obesity is a result largely of diet and\\nlifestyle.\\n\\nBody mass index (BMI): calculation for overall obesity\\nWaist circumference: determination of central fat\\n\\ndistribution\\nBMI is calculated as follows\\n\\nBMI = weight in kg divided by height in m , expressed as\\n\\nkg/m\\n\\nUnderweight: <18.5 kg/ m\\n\\nNormal weight: 18.5 - 24.9 kg/ m\\n\\nOverweight: 25 - 29.9 kg/ m\\n\\nObesity (Class1): 30 - 34.9kg/m\\n\\nObesity (Class 2): 35 - 39.9 kg/m\\n\\nExtreme obesity (Class 3): > 40 kg/m\\nBMI represents overall adiposity\\n\\n1\\n\\n2\\n\\n6\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nTreatment\\n\\nPrevention\\n\\nOBESITY\\nIntroduction\\n\\nMeasurements for evaluation\\n\\nClassification of BMI\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\nPrevent complications\\n\\nAssess dietary intake, level of physical activity, BMI\\n(total body fat) and waist circumference (abdominal fat)\\non presentation and at regular monitoring\\n\\nAssess efficacy of weight loss measures\\nIntegrate weight control measures into the overall\\n\\nmanagement of diabetes mellitus and co-morbidities if\\n- BMI is >25\\n- Waist circumference is more than 102 cm and 88 cm in\\nmen and women respectively\\n\\nEducate patients and other family members\\nSet realistic goals\\nUse a multi-disciplinary approach to weight control\\nDietary changes and increased level of physical activity\\n\\nare the most economical means to loose weight\\nMaintain records of goals, instructions and weight\\n\\nprogress charts\\nSurgical intervention may be required in extreme cases\\n\\nManagement\\nThe pattern of distribution of fat in the body (whether\\n\\nmostly peripheral or central) is assessed by the use of the\\nwaist/hip ratio (WHR)\\nWaist/Hip ratio=Waist circumference (in cm) divided by\\nHip circumference (in cm)\\nWaist circumference: measure midway between the\\n\\nlower rib margin and the iliac crests\\nHip circumference: the largest circumference of the hip\\nWaist circumference better depicts central or upper\\n\\nbody obesity than waist/hip ratio\\n- Upper limits: 102 cm and 88 cm in men and women\\nrespectively\\n\\nNon-specific\\n- Always bear in mind the possibility of an underlying\\ncause: although these may not be common, specific\\ntherapy may be available\\n- Clinical presentation may therefore require specific\\ninvestigations to exclude conditions such as\\n\\nHypothyroidism\\nHypercortisolism\\nMale hypogonadism\\nInsulinoma\\nCNS disease that affects hypothalamic function\\n\\nCardiovascular:\\nCoronary disease\\nStroke\\nCongestive heart failure\\nPulmonary:\\n\\nObstructive sleep apnoea\\n\\'Obesity hypoventilation syndrome\\'\\n\\nEndocrine:\\nInsulin resistance and type 2 diabetes mellitus\\n\\nHepatobiliary:\\nGall stones\\n\\nReproductive:\\nMale hypogonadism\\nMenstrual abnormalities\\nInfertility\\n\\nCancers:\\nIn males, higher mortality from cancer of the colon,\\nrectum and prostate\\nIn females, higher mortality from cancer of the gall\\nbladder, bile ducts, breasts, endometrium, cervix and\\novaries\\nBone, joint and cutaneous disease:\\n\\nOsteoarthritis\\nGout\\nAcanthosis nigricans\\nIncreased risk of fungal and yeast infections\\nVenous stasis\\n\\nTo educate patient and care givers\\nAchieve an ideal body weight\\n\\nInvestigations\\n\\nComplications\\n\\nTreatment objectives\\n\\nCHAPTER 2: BLOOD AND BLOOD-FORMING\\nORGANS\\n\\nANAEMIAS\\nIntroduction\\n\\nMorphological classification\\n\\nClassification based on aetiology and pathogenesis\\n\\nAnaemia is a reduction in the haemoglobin\\nconcentration in the peripheral blood below the normal\\nrange expected for the age and sex of an individual\\n\\nThe determination of haemoglobin concentration\\nshould always take the state of hydration and altitude of\\nresidence of the individual into consideration\\n\\nIt can be classified on the basis of red cell morphology\\nand aetiology/pathogenesis\\n\\nMacrocytic\\nMegaloblastic\\n\\n- Folic acid deficiency\\n- Vitamin B deficiency\\n\\n- Inherited disorders of DNAsynthesis\\nNon-megaloblastic\\n\\n- Accelerated erythropoiesis\\n- Increased membrane surface area\\n- Obscure\\nHypochromic-microcytic\\n\\nIron deficiency\\nDisorders of globin synthesis\\nOther disorders of iron metabolism\\n\\nNormochromic-normocytic\\nRecent blood loss\\nHaemolytic anaemias\\nHypoplastic bone marrow\\nInfiltrated bone marrow\\nEndocrine abnormality\\nChronic disorders\\n\\n- Renal disease\\n- Liver disease\\n\\nBlood Loss:\\nAcute\\nChronic (leads to iron deficiency)\\n\\nIncreased red cell destruction (haemolytic anaemias):\\nCorpuscular defects (intracorpuscular or intrinsic\\n\\nabnormality)\\nDisorders of the membrane e.g elliptocytosis,\\n\\nspherocytosis\\nDisorders of metabolism e.g Glucose-6-Phosphate\\n\\nDehydrogenase deficiency\\nHaemoglobinopathy e.g sickle cell disease\\nParoxysmal Nocturnal Haemoglobinuria\\n\\nAbnormal haemolytic mechanisms (extra-corpuscular or\\nintrinsic abnormality):\\n\\nAutoimmune\\nRhesus-incompatibility, mismatched transfusion\\nHypersplenism\\nInfections e.g malaria,\\nDrugs and toxins\\n\\n12\\n\\nClostridium welchii\\n\\n11 12\\n\\nChapter 1: Alimentary Tract Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nOthers e.g. burns\\nDecreased red cell production:\\n\\nNutritional (due to deficiencies of substances essential\\nfor erythropoiesis)\\n- Iron\\n- Folate\\n- Vitamin B\\n\\n- Various deficiencies e.g. protein, ascorbic acid\\nBone marrow stem cell failure:\\nPrimary (idiopathic):\\n- Aplastic anaemia\\n- Pure red cell aplasia\\nSecondary:\\n- Drugs (phenylbutazone, cytotoxic agents, etc)\\n- Chemicals\\n- Irradiation\\nAnaemias associated with systemic disorders:\\n\\nInfection\\nLiver disease\\nRenal disease\\nConnective tissue disease\\nCancer (including leukaemia)\\nMarrow infiltration\\nThyroid or pituitary disease\\n\\nDepend on the degree of anaemia, severity of the\\ncausative disorder and age of the patient\\nThe clinical effects of anaemia are due to anaemia itself\\n\\nand the disorder(s) causing it\\nCommon:\\n\\nTiredness\\nLassitude\\nWeakness\\nDyspnoea on exertion\\nPalpitations\\nPallor\\n\\nLess common:\\nAngina of effort\\nFaintness\\nGiddiness\\nHeadache\\nRinging in the ears\\nHigh output state\\nCongestive cardiac failure\\n\\nCardiac failure\\nRespiratory failure\\n\\nCardiac failure\\nDeath\\n\\nHaematologic:\\nHaematocrit; haemoglobin concentration\\nRed cell indices\\nReticulocyte count\\nTotal leukocyte and differential counts\\n\\n12\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nNot necessary unless there is intolerance to oral iron\\nIndications for parenteral iron:\\n\\nAnaemia diagnosed in late pregnancy\\nCorrection of anaemia just before an operative\\nprocedure\\nHaemorrhage expected to continue unabated\\n\\nIron preparations:\\nIron dextran given as “total dose\" infusion\\n\\nDose in mL (of 50 mg/mL preparations) = [Patient\\'s wt.\\nin kg X (14 Hb in g/dL)] 10\\n\\nOral iron preparations:\\nNausea, epigastric pain, diarrhoea, constipation, skin\\n\\neruptions\\nReduce dosage and frequency of administration to\\n\\nreduce these effects\\nParenteral iron:\\n\\nLocal reactions: phlebitis and lymphadenopathy\\nSystemic reactions: may be early or late- headache,\\n\\nfever, vomiting; general aches and pains, backache,\\nchest pain, dyspnoea, syncope; death from anaphylaxis\\n\\nA test dose should be administered: 25 mg\\nintramuscularly or by intravenous infusion over 5 to 10\\nminutes\\n\\nTotal-dose infusion should be avoided in patients with\\nhistory of allergy\\n\\nResponse to therapy is satisfactory if administered\\ndose is limited to the minimal daily requirement\\n\\nTreatment with vitamin B (cobalamin) to replace\\n\\nbody stores\\n- Six-1000 micrograms intramuscular injections of\\nhydroxocobalamin given at 3 - 7 day intervals\\n\\nMaintenance therapy: patients will need to take\\nvitamin B for life\\n\\n- 1000 micrograms hydroxocobalamin intramuscularly\\nonce every 3 months\\n\\nToxic reactions are very rare and are usually not due to\\ncobalamin itself\\n\\nPharmacologic doses of folic acid produce\\nhaematological response in vitamin B -deficient\\n\\npatients but worsen the neurological complications\\nLarge doses of vitamin B also give haematological\\n\\nresponse in folate-deficient patients\\n\\nBalanced diet\\nPrompt treatment of all illnesses\\n\\nBlood transfusion is the administration of blood for\\ntherapy.\\n\\nIt is potentially hazardous: blood should be given only\\nif the dangers of not transfusing outweigh those of\\n\\n÷\\nNotable adverse drug reactions, caution\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nBLOOD TRANSFUSION\\nIntroduction\\n\\nMegaloblastic anaemia\\n\\n12\\n\\n12\\n\\n12\\n\\n12\\n\\nPlatelet count\\nErythrocyte sedimentation rate\\nBlood film examination for morphology of cells\\nThick and thin films for malaria parasites\\n\\nUrine analysis:\\nColour, pH, clarity, specific gravity\\nMicroscopic examination of fresh urine specimen\\nProtein\\nGlucose\\nOccult blood\\n\\nStool:\\nColour, consistency\\nExamination for ova and parasites\\nOccult blood\\n\\nPlasma:\\nBlood Urea Nitrogen (BUN)\\nTotal protein and albumin\\nBilirubin\\nCreatinine (if BUN is abnormal)\\n\\nOthers:\\nCoombs test for the presence of antibodies to red cells\\nHam\\'s test (acidified serum test)\\nBone marrow aspiration and trephine biopsy\\nHaemoglobin electrophoresis\\nSickling test (metabisulphite and solubility)\\nFamily studies\\n\\nRestore haemoglobin concentration to normal levels\\nPrevent/treat complications\\n\\nBed rest in severe cases: initially necessary, especially\\nwhen cardiovascular symptoms are prominent\\n\\nTreat cardiac failure by standard measures\\nBalanced diet with adequate protein and vitamins\\nCorrect dietary deficiencies (e.g. iron, folic acid)\\nBlood transfusion: a very important measure in the\\n\\ntreatment of anaemia, but should not be used as a\\nsubstitute for investigation, or specific treatment of the\\ncause\\n\\nArrest blood loss\\nTreat any underlying systemic disorder\\nRemove any toxic chemical agent or drug\\nCorrect anatomical gastro-intestinal abnormalities\\n\\nHaematinics e.g. iron, vitamin B folic acid\\n\\nThe specific haematinic indicated should be given alone\\nResponse to adequate treatment is important in\\n\\nconfirming diagnosis\\n\\nOral iron therapy:\\n- Ferrous sulfate 200 mg (containing 65 mg of iron) 1\\ntablet 2-3 times daily\\n\\nTreat for 3- 6 months to correct deficits in haemoglobin\\nand in stores\\nParenteral therapy:\\n\\nTreatment objectives\\n\\nSupportive measures\\n\\nDrug treatment\\n\\n12,\\n\\nIron deficiency\\n\\ntransfusion.\\nIndication(s) must be clearly established.\\nTransfusion of whole blood or red cell concentrates is\\n\\nimportant in the treatment of acute blood loss and of\\nanaemia.\\n\\nRed cells can be stored at 4ºC for 5 weeks in media that\\nare specially designed to maintain the physical and\\nbiochemical integrity of the erythrocytes and which\\nmaintain their viability after transfusion.\\n\\nCitrate Phosphate Dextrose with Adenine (CPDA) is\\ncommonly used for collections of whole blood.\\n\\nThe use of whole blood as a therapeutic agent has been\\nalmost completely replaced by the use of blood\\nfractions.\\n\\nAutologous blood transfusion:\\nTransfusion of the patient\\'s own blood to him /her\\n\\n- Safest blood for patients\\nThe three main types are:\\n\\n- Pre- deposit autologous transfusion\\n- Immediate pre-operative phlebotomy with\\nhaemodilution\\n- Intra-operative blood salvage\\nExchange transfusion:\\n\\nTo remove deleterious material from the blood, for\\nexample, in severe jaundice resulting from haemolytic\\ndisease of the newborn\\nAlternatives to red cell transfusion:\\n\\nPerfluorochemicals such as Fluosol-DA\\nPolymerised haemoglobin solutions with good\\n\\nintravascular recovery\\n\\nSymptomatic anaemias:\\n- Recurrent haemorrhage\\n- Haemolysis\\n- Bone stem cell failure\\n- Pure red cell aplasia\\n- Severe anaemia of chronic disorders\\n- Haematological malignancies (e.g. leukaemia,\\nlymphoma)\\n- Chemotherapy complicated by anaemia\\n\\nIn neonates:\\n- Severe acute haemorrhage\\n- Haemolytic disease of the new born\\n- Septicaemia\\n- Prematurity\\n\\nBleeding disorders:\\n- Congenital e.g. haemophilia\\n- Acquired e.g. disseminated intravascular coagulopathy\\n\\nPrevention or treatment of shock:\\n- Clinical situations in which there is need to restore\\nand/or maintain circulatory volume e.g. trauma,\\nhaemorrhage\\n\\nTo maintain the circulation (as in extracorporeal or\\ncardiac by-pass shunts)\\n\\nTypes of blood transfusion\\n\\nIndications for blood transfusion\\n\\nWhole blood preparations\\n\\n13 14\\n\\nChapter 2: Blood and Blood-Forming Organs Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nShould be limited to correction or prevention of\\nhypovolaemia in patients with severe acute blood loss\\n\\nJustified by the recognition that there is a relatively\\nrapid loss of platelets, leucocytes and some coagulation\\nfactors with liquid storage. There is also progressive\\nincrease in the levels of undesirable products such as\\npotassium, ammonia, and hydrogen ions\\n\\nFour types are in common use:\\n- Packed red blood cells\\n- Washed red blood cells\\n- Leucocyte-reduced red blood cells\\n- Frozen red blood cells\\n\\nObtained from liquid-stored blood by saline washing\\nusing a continuous-flow cell separator or from frozen\\nerythrocytes extensively washed to remove the\\ncytoprotective agents\\n\\nBest prepared by passing whole blood or packed cells\\nthrough specifically designed filters.\\n\\nThree main reasons for the use of leucocyte-reduced\\nred blood cells:\\n- To prevent non-haemolytic febrile reactions to white\\ncell and platelet antibodies in recipients exposed to\\nprevious transfusions or pregnancies\\n- To prevent sensitization of patients with aplastic\\nanaemia who may be candidates for bone marrow\\ntransplantation\\n- To minimize risk of transmission of viruses such as\\nHIV or cytomegalovirus\\n\\nInformed consent should be obtained from patients\\nexcept in life-threatening emergencies\\n\\nThe risks and benefits of the proposed transfusion\\ntherapy should be discussed with the patient and\\ndocumented in the patient\\'s medical records\\n\\nThere may be no time available to type, select and\\ncross-match compatible blood\\n\\nArare occurrence, except for\\n- Trauma\\n- Unexpected intra-operative haemorrhage\\n- Massive gastro-intestinal bleeding\\n- Ruptured aneurysm\\n\\nUncross-matched or partially cross-matched blood is\\nadministered; routine cross-match should be carried out\\nretrospectively to identify any incompatibility\\n\\nImmunological:\\nSensitization to red cell antigens\\nHaemolytic transfusion reactions\\n\\n- Immediate\\n- Delayed\\n\\nReactions due to white cell and platelet antibodies\\n\\nFresh Blood\\n\\nErythrocyte preparations\\n\\nWashed red blood cells\\n\\nLeucocyte-reduced red blood cells\\n\\nBlood for emergencies\\n\\nTransfusion therapy\\n\\nComplications of blood transfusion\\n\\nPrompt treatment of illnesses that could be complictated\\nby anaemia\\n\\nRegular medical check-ups\\n\\nA heterogeneous group of diseases characterized by\\ninfiltration of the blood, bone marrow and other tissues\\nby neoplastic cells of the haematopoietic system\\n\\nTwo main types\\n- Myeloid leukaemia\\n- Lymphoid leukaemia\\n\\nEach is further divided into acute and chronic\\nAcute leukaemias are defined pathologically as blast\\n\\ncell leukaemias or malignancies of immature\\nhaematopoietic cells. The bone marrow shows > 30%\\nblast cells\\n\\nTwo main groups of acute leukaemias\\n- Acute myeloid leukaemia (AML)\\n- Acute lymphoblastic leukaemia (ALL)\\n\\nChildhood leukaemias: patients aged <15 years\\nAdult leukaemias: patients aged >15 years\\nLeukaemias in adults aged > 60 years: an important\\n\\ngroup because\\n- Their responses to current treatment protocols both for\\nALLandAMLare inferior\\n- These patients are not usually considered for more\\nradical treatment approaches such as autologous or\\nallogeneic bone marrow transplantation\\n\\n80% of adult cases:AML\\n\\nMore common in industrialized than rural areas\\nEnvironmental agents implicated in the induction of\\ncertain types of leukaemia:\\n\\nIonising radiation: X-rays and other ionizing rays\\nChemical carcinogens\\n\\n- Benzene and other petroleum derivatives\\n- Alkylating agents\\nHost susceptibility e.g. genetic disorders:\\nBloom\\'s syndrome\\n\\nFanconi\\'s anaemia (AML)\\nAtaxia telangiectasia (ALL)\\nDown\\'s syndrome\\n\\nBlast transformation in pre-existing myeloproliferative\\ndisoders:\\n\\nAplastic anaemia (ALL)\\nOncogenic viruses:\\n\\nHTLV-1 (Human T-cell Lymphotropic virus 1):\\nimplicated in adult T cell leukaemia /lymphoma\\n\\nHAEMOSTASIS AND BLEEDING DISORDERS -\\nrefer for specialist care\\n\\nLEUKAEMIAS\\nIntroduction\\n\\nEpidemiology/predisposing conditions\\nAcute lymphoblastic leukaemia (ALL) and Acute\\nmyeloid leukaemia (AML)\\n\\n- Febrile transfusion reactions\\n- Post-transfusion purpura\\n\\nReactions due to white cell and plasma protein\\nantibodies\\n- Urticaria\\n- Anaphylaxis\\nNon-immunological:\\n\\nTransmission of disease\\nReactions due to bacteria and bacterial pyrogens\\nCirculatory overload\\nThrombophlebitis\\nAir embolism\\nTransfusion haemosiderosis\\nComplications of massive transfusion\\n\\nA minimum of three major procedures must be carried\\nout:\\n- Determine the recipient\\'sABO and Rhesus groups\\n- Select compatible donor blood\\n- Cross-match donor cells against recipient\\'s serum\\n\\nDonor blood should be screened for infective agents:\\nHIV, hepatitis B, and C viruses\\n\\nHaemoglobin concentration\\nHaematocrit\\nRed cell indices: MCH, MCV, MCHC\\nTotal leucocyte and differential counts\\nReticulocyte count\\nErythrocyte sedimentation rate\\nPlatelet count\\n\\nTo raise haemoglobin concentration and other blood\\nparameters to normal levels\\n\\nTo prevent blood transfusion complications\\n\\nTransfusion of red blood cells, platelet concentrates or\\nplatelet rich plasma as required\\n\\nProvision of fresh frozen plasma or other blood\\nproducts as necessary\\n\\nFurosemide 40 mg on administration of one unit of\\nblood\\nIn the event of transfusion reactions, stop the transfusion\\nimmediately and administer the following:\\n\\nPromethazine 25 mg intramuscularly or intravenously\\nEpinephrine 0.5 mL of 1:1000 solutions to be\\n\\nadministered subcutaneously\\nHydrocortisone sodium succinate 100 mg injection\\n\\nAppropriate nutrition\\nAdequate hydration\\n\\nFurosemide: dehydration and hypersensitivity\\nPromethazine: drowsiness, hypersensitivity\\n\\nAvoid/prevent accidents\\n\\nTests of Compatibility\\n\\nOther investigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nGeneral symptoms of anaemia\\nBleeding\\nInfections\\nAnorexia\\nWeight loss\\nLymphadenopathy (not common in AML except in the\\nmonocytic variant)\\nSkin :\\n\\nMacules, papules, vesicles\\nPyoderma gangrenosum\\nNeutrophilic dermatitis\\nLeukaemic cutis\\nGranulocytic sarcoma\\n\\nSepticaemia\\nMiliary tuberculosis\\nMalignant histiocytosis\\n\\nWorsening ill- health\\n\\nFull blood count with ESR, reticulocyte count\\nCoomb\\'s test\\nBone marrow examination\\nBiochemical tests: serum electrolytes, urea, creatinine,\\n\\nuric acid\\nLiver function tests\\nProthrombin time, partial thromboplasnime\\nHuman LeucocyteAntigen typing\\nHIV I and II\\nCytochemical tests\\n\\n- Peroxidase\\n- Sudan Black B\\n- Non-specific esterase reaction e.g. alpha napthyl\\n\\nacetate esterase\\nBone marrow cultures\\nCytogenetic studies\\nElectron microscopy\\nCell markers e.g. using a panel of antibodies combined\\n\\nwith flow cytometric analysis or the alkaline phosphase-\\nantialkaline phosphate (APAAP) technique to classify\\nthe blast cells into lymphoid or myeloid lineages\\n\\nAbdominal ultrasound/CT scans\\nImmunological classification\\nTerminal deoxynucleotidyl transferase demonstration\\n\\nin nuclei of B and T lymphocytes\\n\\nInduce remission to achieve complete remission\\nMaintain disease-free state\\n\\nAppropriate nutrition\\nAdequate hydration (at least 3 litres/24 hours)\\nErythrocyte transfusion as required\\nPlatelet concentrate transfusion as required\\nMaintain electrolyte balance\\n\\n15 16\\n\\nChapter 2: Blood and Blood-Forming Organs Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nDrug treatment\\nAcute lymphoblastic leukaemia\\n\\nAcute myeloblastic leukaemia\\n\\nAllopurinol 300 mg daily orally\\n\\nDaunorubicin 30 mg/m intravenously on days 8, 15, 22\\nand 29\\n\\nVincristine 1.4 mg/m to a maximum of 2 mg\\nintravenously on days 8, 15, 22 and 29\\n\\nPrednisolone 60 mg orally once daily from day 1 - 28\\n\\nL-asparaginase 1000 IU/m intravenously on days 12,\\n15, 18, 21, 24, 27, 30 and 33\\nOr:\\n\\nCyclophosphamide 650 mg/m intravenously on days 1\\nand 8; 14 and 22\\n\\nVincristine 1.4 mg/m intravenously to a maximum of 2\\nmg: days 1 and 8; 14 and 22\\n\\nCytosine Arabinoside 50 mg/ m subcutaneously 12\\nhourly for 12 days or bolus intravenous injection 100\\n\\nmg/m daily for 7 days\\n\\nPrednisolone 40 mg/m oral for 14 days\\n- Drugs are given every 28 days for 3 courses\\n\\nNervous system prophylaxis\\n\\n- Methotrexate 12.5 mg/m intrathecally twice weekly to\\na maximum of 15 mg i.e. 5 doses over 3 weeks.\\n\\nTo be given on day 29\\nCOAP regime to be given once provided WBC count is\\n\\n= 1x10 /Land platelet count is = 100 x10 /L\\n\\n6-Mercaptopurine 75 mg/m orally daily\\n\\nMethotrexate 20 mg/m orally weekly\\n- For 3 years if remission is maintained, otherwise re-\\nassessment\\n\\nTo be given every 3 months with\\n\\n- Vincristine 1.4 mg/ m to a maximum of 2 mg weekly\\non days1 and 8\\n\\nEither TAD or COAPas shown below:\\n\\nCytarabine 100 mg/m (continuous infusion) on days 1\\n\\nand 2, and 100 mg/m by intravenous\\ninfusion over 30 minutes on days 3 - 8\\n\\nThioguanine 100 mg/m orally on days\\n3 - 9\\n\\nDaunorubicin 60 mg/m by intravenous infusion over\\none hour on days 3 - 5\\nOr:\\n\\nCyclophosphamide 650 mg/m intravenously on days 1\\nand 8\\n\\nVincristine 1.4 mg/m intravenously to a maximum of 2\\nmg on days 1 and 8\\n\\nCytarabine 50 mg/m subcutaneously\\n\\nDVPRegime\\n\\nCOAPRegime\\n\\nConsolidation\\n\\nMaintenance\\n\\nPulse therapy (Intensification)\\n\\nTAD\\n\\nCOAP\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n9 9\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\nevery 12 hours\\n\\nevery 12 hours\\n\\nevery 12 hours\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nNotable adverse drug reactions caution\\n\\nAsymptomatic\\nAbdominal swelling/pain\\nLethargy\\nShortness of breath on exertion\\nWeight loss\\nUnexplained haemorrhage at various sites e.g. gums,\\n\\nintestinal/urinary tracts\\nIncreased sweating\\nVisual disturbances\\nGout\\nPriapism\\nSplenomegaly\\nAnaemia\\nHaemorrhage\\nFever\\nLymphadenopathy (rare in chronic phase)\\n\\nBlastic transformation\\nDeath\\n\\nAs above for acute leukaemia plus:\\nDetermination of Philadelphia chromosome\\nLactic dehydrogenase\\nSerum calcium\\n\\nInduce remission to achieve complete remission\\nMaintain disease-free state\\nAchieve absence of Philadelphia chromosome\\n\\nAppropriate nutrition\\nAdequate hydration\\nElectrolyte balance\\n\\nHydroxycarbamide (hydroxyurea)\\n20-30 mg/kg orally daily or 80 mg/kg every third\\n\\nday\\nNot recommended\\n\\nInterferon alpha\\n9 million units subcutaneously or intravenously\\n\\nthrice weekly for 6 - 12 months\\nOr:\\n\\nImatinib mesylate\\n- 400 mg orally daily\\n\\n,\\nThe above drugs (except the steroids) all cause profound\\n\\nmyelosuppression\\nProfound nausea, vomiting, diarrhoea and abdominal\\n\\ndiscomfort\\nSecondary malignancies\\nSteroids: Cushing\\'s syndrome, hypertension, diabetes\\n\\nmellitus, immunosuppression, infections\\nVincristine: neurotoxicity\\nCylophosphamide: alopecia, haemorrhagic cystitis\\nDaunorubicin: myelosuppression, alopecia,\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\n- To be used strictly under specialist supervision\\n\\nfor 7 days\\n\\nPrednisolone 40 mg/ m orally for 14 days\\n- Nervous system prophylaxis is not required\\n- Assess for remission after 3 courses\\n\\nCOAPevery 6 weeks for 2 years\\nIntrathecal treatment as forALL if there is CNS disease\\n\\nof the monocytic type\\n\\nAlso Chronic Myelogenous Leukaemia; Chronic\\nGranulocytic Leukaemia (CGL)\\n\\nA clonal disease that results from acquired genetic\\nchange in a pluri-potential haematopoietic stem cell\\n\\nAltered stem cell proliferation generates a population of\\ndifferented cells, and a greatly expanded total myeloid\\nmass\\n\\nMajority of patients have relatively homogenous\\ndisease characterized by:\\n- Splenomegaly\\n- Leucocytosis\\n- Presence of Philadelphia (Ph) chromosone in all\\nleukaemia cells\\n\\nMinority of patients have less typical disease (atypical\\nCML)\\n- These variants lack Ph chromosome. Examples:\\n- Chronic myelomonocytic leukaemia\\n- Chronic neutrophilic leukeamia\\n- Juvenile chronic myeloid leukaemia\\n\\nRare below the age of 20 years but occurs in all age\\ngroups\\nIncreased risk of developing CMLwith exposure to high\\n\\ndoses of irradiation\\nAbiphasic or triphasic disease, usually diagnosed in the\\n\\ninitial “chronic”or stable phase\\n\\nUntreated patient:\\n- <12% blast cells in blood or marrow\\nTreated patient:\\n- Normal or near-normal blood count without immature\\ngranulocytes in peripheral blood\\n\\nRising leucocyte count despite treatment\\nRapid leucocyte doubling time\\nImmature granulocytes in blood\\nBlast cells >5% but <30% in marrow\\nAnaemia (Hb <10 g/dL) not attributable to treatment\\n\\nThrombocytosis (>1000 x 10 /L)\\nAcquisition of specific new cytogenetic abnormalities\\nIncreasing marrow fibrosis\\n\\nMore than 30% blasts\\nOr:\\n\\nBlasts plus promyelocytes in blood or bone marrow\\n\\n2\\n\\n9\\n\\nMaintenance\\n\\nDistinguishing features between phases of CGL\\nChronic phase\\n\\nAccelerated phase\\n\\nBlastic transformation\\n\\nChronic Myeloid Leukaemia (CML)\\n\\nClassification\\n\\nEpidemiology, aetiology and natural history\\n\\ncardiotoxicity\\nAll are contraindicated in patients with history of\\n\\nhypersensitivity reactions to the respective medicines\\n\\nAvoid exposure to ionizing radiation\\nEarly detection and treatment\\n\\nNeoplastic proliferations of mature lymphocytes\\nThe diseases involve the blood bone marrow and other\\n\\ntissues\\nCharacterized by accumulation of small mature-looking\\n\\nCD5+ B lymphocytes in the blood, marrow and\\nlymphoid tissues\\n\\nB-cell disorders are more common\\nB-cell CLLis more common in males than females\\n\\n- Accounts for 60% of cases\\n- Rarely diagnosed below the age of 40 years\\n\\nAsymptomatic (30% of cases)\\nSymptoms of anaemia\\nLymph node enlargement (painless)\\nRare: pyrexia, sweating or weight loss\\nSevere chest infection/pneumonia\\nSplenomegaly (50% of cases)\\nHepatomegaly (not frequent)\\n\\nLow grade non-Hodgkin\\'s lymphomas with frequent\\nblood and bone marrow involvement (leukaemia /\\nlymphoma syndromes)\\n\\nTuberculosis\\nViral infections\\nToxoplasmosis\\n\\nRichter transformation\\nProgression of disease\\n\\nCell morphology:\\nSize\\nNuclear: cytoplasmic (N:C) ratio\\nRegularity or irregularity of the nuclear outline\\nCharacteristics of the cytoplasm (presence and length or\\n\\nabsence of azurophil granules)\\nDegree of nuclear chromatin condensation and its\\n\\npattern\\nProminence, frequency and localization of the\\n\\nnucleolus\\n\\nAs for anaemia and other leukaemias\\n\\nInduce remission to achieve complete remission\\nMaintain disease-free state\\n\\nAppropriate nutrition\\nAdequate hydration\\nMaintenance of electrolyte balance\\nBone marrow transplant\\n\\nPrevention\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nChronic Lymphocytic Leukaemia\\n\\n17 18\\n\\nChapter 2: Blood and Blood-Forming Organs Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nRed cell and platelet concentrate transfusion as required\\n\\nAllopurinol 100 mg orally every 8 hours\\n\\nChlorambucil 5 mg/m orally on days 1 to 3\\nPrednisolone 75 mg orally on day 1; 50 mg orally on\\n\\nday 2 and 25 mg orally on day 3\\n- Repeat every 2 weeks\\nOr:\\n\\nFludarabine 25 - 30 mg intravenously over 30 minutes\\non days 1-5\\n- Repeat every 4 weeks\\nOr:\\n\\nCombination chemotherapy\\n\\n- Cyclophosphamide 400 mg/m\\n\\n- Vincristine 1.4 mg/m\\n- Prednisolone 100 mg orally days 1 - 5\\n\\nRepeat every 3 weeks\\nOr:\\n\\nFludarabine 30 mg/m intravenously over 30 minutes\\non days 1 - 3\\n\\nCyclophosphamide 250 - 300 mg/m intravenously\\nover 30 minutes on days 1 - 3\\n- Repeat every 4 weeks\\n\\nAppropriate nutrition\\nAdequate hydration\\n\\nSame as for other leukaemias\\n\\nAvoid chemicals on body (e.g benzene)\\nAvoid ionizing radiation (X rays)\\nEarly detection and treatment\\n\\nSolid neoplasms that originate in lymph nodes or\\nother lymphatic tissues of the body\\n\\nAheterogeneous group of disorders\\n- Can arise at virtually any site\\n- More often occurs in regions with large\\nconcentrations of lymphoid tissues, e.g. lymph\\nnodes, tonsils, spleen and bone marrow\\n\\nTwo main groups:\\n- Hodgkin\\'s disease\\n- Non-Hodgkin\\'s lymphomas\\n\\nHodgkin\\'s disease is characterized by Reed-\\nSternberg cells (large binucleate cells with vesicular\\nnuclei and prominent eosinophilic nucleoli)\\n- Reed-Sternberg cells are occasionally found in\\nother clinical conditions e.g. hyperplastic or\\ninflammatory lesions of lymph nodes\\n\\nNon-Hodgkin\\'s lymphomas: a heterogeneous\\ncollection of lymphoproliferative malignancies\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nLYMPHOMAS\\nIntroduction\\n\\nChronic Lymphocytic Leukaemia\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\nVincristine 1.4 mg/m (maximum 2 mg) on days 1\\nand 8\\n\\nPrednisolone 100 mg orally on days 1 - 8\\n\\nMechlorethamine 6 mg/m intravenously on days 1\\nand 8\\n\\nVincristine 1.4 mg/m (maximum 2 mg)\\nintravenously on days 1 and 8\\n\\nProcarbazine 100 mg/m orally on days 1 4\\nPrednisolone 40 mg orally on days 1 - 14\\n\\nChlorambucil 6 mg/m orally on days 1 and 14\\n\\nVinblastine 6 mg/m (maximum 10 mg)\\nintravenously on days 1 and 18\\n\\nProcarbazine 100 mg/m orally on days 1 and 14\\nPrednisolone 40 mg orally on days 1 - 14\\n\\nAppropriate nutrition\\nAdequate hydration\\n\\nAll the drugs are contraindicated in patients with\\nhypersensitivity reactions to the respective\\nmedicines\\n\\nProfound nausea, vomiting, diarrhoea and\\nabdominal discomfort\\n\\nSecondary malignancies\\nMyelosuppression (except the steroids)\\nSteroids (prednisolone) may cause Cushing\\'s\\n\\nsyndrome, hypertension, diabetes mellitus,\\nsuppression of immunity, infections\\n\\nVincristine: neurotoxic\\nCyclophosphamide: alopecia and haemorrhagic\\n\\ncystitis\\nDoxorubicin: cardiotoxic\\n\\nAvoid unnecessary exposure to irradiation and\\nchemicals\\n\\nAgroup of conditions with pathological processes\\nresulting from the presence of Haemoglobin S\\nUsually inherited from the parents who have\\nthemselves inherited haemoglobin S\\nThe principal genotypes include:\\n- Homozygous sickle cell disease (SS)\\n- Sickle cell-haemoglobin C disease (SC)\\n- Sickle cell-ß thalassaemia (Sß thal)\\n\\nSickle cell-ß+ thalassaemia Type I (Sß+thal.Type\\nI)\\nSickle cell-ß+thalassaemia. Type II. (Sß+thal.\\n\\nType II)\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\nHodgkin\\'s lymphoma\\nMOPP\\n\\nChIVPP\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nSICKLE CELLDISEASE\\nIntroduction\\n\\n- Vary widely according to histological subtype,\\nstage and bulk of disease\\n\\nFull Blood Count (i.e. haemoglobin, haematocrit,\\nleucocyte and differential counts; red cell indices,\\nreticulocyte count)\\n\\nErythrocyte sedimentation rate\\nCoombs test\\nBone marrow aspiration and needle biopsy\\nSerum Urea, Electrolytes\\nSerum Uric acid\\nLiver Function Tests: transaminases-ALT, AST,\\n\\nALP; bilirubin; serum proteins\\nHIV screening\\nImmunoglobulins\\nChest X- ray\\n\\nExamination of post-nasal space\\nSerum copper level\\nNeutrophil alkaline phosphatase\\nTomograms of lung or mediastinum\\nSkeletal X-ray\\nAbdominal ultrasound scans\\nIntravenous pyelography\\nCT scans of chest and abdomen\\nSupplementary node biopsy\\n\\nInduce remission\\nRestore patient to disease-free state\\nMaintain state of well being\\n\\nAppropriate nutrition\\nAdequate hydration\\nRed cell and platelet concentrate transfusions as\\n\\nrequired\\n\\nMalaria prophylaxis: proguanil 200 mg orally daily\\nAntibiotics as indicated\\nAllopurinol 300 mg orally daily (when uric acid is\\n\\nhigh)\\n\\n(3 weekly):\\n\\nCyclophosphamide 750 mg/m intravenously on\\nday 1\\n\\nDoxorubicin 50 mg/m intravenously on day 1\\n\\nVincristine 1.4 mg/m (maximum of 2 mg)\\nintravenously on day 1\\n\\nPrednisolone 100 mg orally on days 1 - 5\\n(4 weekly):\\n\\nCyclophosphamide 750 mg/m intravenously on\\ndays 1 and 8\\n\\nDoxorubicin 25 mg/m intravenously on days 1 and\\n8\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nMandatory\\n\\nOptional\\n\\nNon-Hodgkin\\'s lymphomas\\nCHOP\\n\\nCHOP\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\n2\\n\\nSickle cell-ß+thalassaemia. Type III. (Sß+thal.\\nType III)\\n\\nInheritance of one normal gene controlling\\nformation of ß Haemoglobin (HbA), and a sickle\\ngene (HbS)\\n\\nTotal haemoglobin Ais more than haemoglobin S\\nNormal haemoglobin F\\n\\nInheritance of two abnormal allelemorphic genes\\ncontrolling formation of ß chains of haemoglobin, at\\nleast one of which is the sickle gene\\n\\nPolymerization of the sickle haemoglobin may\\nlead to vaso-occlusion\\n\\nRed cells have reduced deformability and easily\\nadhere to vascular endothelium, increasing the\\npotential for decreased blood flow and vascular\\nobstruction.\\n\\nAbnormalities in coagulation, leucocytes, vascular\\nendothelium, and damage to the membranes of red\\ncells contribute to sickling\\nHaemolytic anaemia and vasculopathy are the\\nresult of the various pathophysiologic processes\\nOrgan damage is on-going and is often silent until\\n\\nfar advanced\\nThe course of the disease is punctuated by episodes\\n\\nof pain\\n\\nVary widely from one patient to another:\\nPersistent anaemia/pallor\\nGrowth retardation (variable)\\nJaundice (variable)\\nBone pains (recurrent)\\nProminent facial bones due to increased bone\\n\\nmarrow activity\\nLeaner body build and less weight (on average)\\nSome fingers are shortened as a result of infarction\\n\\n(destruction due to blockage of blood supply)\\nHand-foot syndrome (painful and swollen hands\\n\\nand feet) in childhood\\nLife span on average shorter than normal\\nSexual development is delayed in both sexes:\\n\\nmenarche occurs at a mean age of 15.5 years (range\\n12 - 20 years) compared to non-sicklers (mean\\n13.2years)\\nImpotence can occur from prolonged priapism\\nHigh foetal loss in pregnancy\\n\\nPatient has acute symptoms/signs attributable\\ndirectly to sickle cell disease\\nTwo main types:\\n\\nPain (vaso-occlusive) crisis\\nAnaemia crisis\\n\\nSickle cell trait\\n\\nSickle cell disease\\n\\nSickle cell crises\\n\\nVaso-occlusive crises\\n\\nPathophysiology\\n\\nClinical features\\n\\n19 20\\n\\nChapter 2: Blood and Blood-Forming Organs Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nPainful\\n\\nPainless\\n\\nTender, swollen bones\\nAcute hepatopathy\\nAcute chest syndrome\\nPriapism\\n\\nHaematuria\\nCerebrovascular disease (accident) - in descending\\n\\norder of prevalence\\n- Thrombotic stroke\\n- Seizures\\n- Haemorrhage\\n\\nRetinopathy (commonest in SC patients)\\n\\nAcute splenic (or hepatic) sequestration\\nHyper-haemolytic (e.g. precipitated by malaria)\\nMegaloblastic (folic acid deficiency)\\nHypoplastic (due to infection or renal failure)\\nAplastic (e.g. due to epidemic parvo virus B19)\\n\\nConnective tissue disorders e.g. rheumatoid\\narthritis\\n\\nLiver disease\\nOther causes of failure to thrive\\n\\nKidneys:\\n- Hyposthenuria (reduced ability to concentrate\\n\\nurine/conserve body fluids)\\n- Haematuria\\n- Albuminuria\\n- Reduced kidney function\\n\\nLeg ulcers:\\n- Occur around ankles\\n- Heal slowly and tend to recur\\n\\nBones and Joints\\n- Osteomyelitis\\n- Avascular necrosis\\nThese may cause:\\n- Hip pain\\n- Limping gait\\n- Kyphoscoliosis when necrosis affects spinal\\nvertebral bones\\n\\nInfections:\\n- Salmonella osteomyelitis\\n- Pneumococcal pneumonia\\n- Pneumoccoccal meningitis (rare in adolescents\\n\\nand adults)\\n- Tonsillitis and pharyngitis\\n\\nBrain and nerves:\\n- Strokes, seizures (not common in adults)\\n- Meningitis (not common in adults)\\n- Cerebral haemorrhage\\n- Mental neuropathy (rare)\\n\\nCardiovascular/respiratory:\\n- Heart failure\\n\\nAnaemic crises\\n\\nDifferential diagnoses\\n\\nComplications\\n\\n- Emotional stress\\n\\nBlood transfusion (especially red cell transfusion)\\nAnti-pneumococcal vaccine\\n\\n(when patient is well with no\\ncomplaints):\\nProguanil\\n\\n200 mg orally daily\\nunder 1 year 25 mg daily; 1 - 4 years 50 mg; 5 -\\n\\n8 years 100 mg; 9 - 14 years 150 mg orally daily\\nPlus:\\n\\nFolic acid 5 mg orally daily\\n\\nParacetamol\\n1 g, every 4 - 6 hours to a maximum of 4 g\\n\\ndaily\\n1 - 5 years 120 - 250 mg; 6 -12 years 250 - 500\\n\\nmg; 12 -18 years 500 mg every 4 - 6 hours\\n(maximum 4 doses in 24 hours)\\nOr:\\n\\nAspirin (acetylsalicylic acid) 600 mg orally every 8\\nhours daily\\n- Not recommended for children under 16 years\\nOr:\\n\\nIbuprofen 200 mg every 8 hours daily (or other\\nnon-steroidal anti-inflammatory drugs)\\n- Not recommended for children under 16 years\\n\\nParenteral therapy:\\nDiclofenac sodium\\n\\n75 mg or 100 mg intramuscularly (as\\nnecessary)\\n- Not recommended for children\\nOral therapy:\\n\\nParacetamol\\n1 - 5 years 20 mg/kg every 6 hours (maximum\\n\\n90 mg/kg daily in divided doses) for 48 hours or\\nlonger if necessary and if adverse effects are ruled\\nout\\nThen:\\n15 mg/kg every 6 hours (maintenance)\\n6 - 12 years: 20 mg/kg (maximum 1 g) 6 hourly\\n(maximum 90 mg/kg daily in divided doses, not to\\nexceed 4 g for 48 hours or longer if necessary and if\\nadverse effects are ruled out\\nThen:\\n15 mg/kg every 6 hours (maximum 4 g daily)\\n12 - 18 years: 500 mg - 1g every 4 - 6 hour\\n(maximum 4 doses in 24 hours)\\n\\nDiclofenac potassium 50 mg every 12 hours daily\\nOr:\\n\\nDiclofenac sodium 100 mg once daily\\nOr:\\n\\nMorphine 15 mg every 8 - 12 hours daily\\n\\nAdjunct treatment\\n\\nDrug treatment\\nSteady state\\n\\nPain crises\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\ns\\n\\nMild pain\\n\\nModerate-to-severe painful crises\\n\\n- Pulmonary hypertension\\n- Acute chest syndrome\\n\\nFull Blood Count (haemoglobin, haematocrit, total\\nleucocyte count and differential counts, platelet\\ncounts)\\n\\nErythrocyte sedimentation rate\\nRed cell indices (MCH, MCHC, MCV)\\nReticulocyte count\\nSickling tests: solubility test; metabisulphite test\\nHaemoglobin electrophoresis\\n\\n- Using cellulose acetate paper at pH 8.4 (alkaline)\\nor citrate agar gel at pH 5.6 (acidic)\\n\\nSerum Electrolytes, Urea and Creatinine\\nLiver function tests (transaminases, bilirubin,\\n\\nserum albumin, alkaline phosphatase and\\nprothrombin time)\\n\\nUrinalysis; microscopy, culture and sensitivity:\\nSputum\\n\\n- Acid Fast Bacilli\\n- Microscopy, culture and sensitivity\\n\\nStool:\\n- Ova and parasites\\n- Occult blood\\n\\nUltra sound scan:\\n- Abdominal ultrasound scan\\n- Transcranial Doppler ultrasonography\\n\\nChest radiograph\\n\\nMaintain (or restore) a steady state of health\\nPrevent and treat complications\\nProvide accurate diagnosis, relevant health\\n\\neducation and genetic counselling to patients,\\nrelatives and heterozygotes\\n\\nImprove quality of life\\nProvide a positive self-image in affected persons\\n\\nCounselling and health education\\nEncouraging membership of support groups\\nProviding infection prophylaxis (antimalarial; anti-\\n\\npneumococcal, hepatitis B virus vaccines)\\nProviding folate supplementation\\nAvoiding pain-inducing conditions\\nProviding prompt treatment of symptoms\\nAdvising on contraception\\nSupervising pregnancy/Labour\\nProviding regular health checks\\nLimiting family size\\n\\nBalanced diet\\nAdequate fluid intake (at least 3 litres/24 hours)\\nAvoidance of pain-inducing conditions\\n\\n- Strenous physical exertion or stress\\n- Dehydration\\n- Sudden exposure to extremes of temperature\\n- Infections e.g. malaria\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nTreatment strategies\\n\\nNon-drug treatment\\n\\nAntimalarials\\nArtemisinin-based combination therapy (see\\n\\nsection on malaria)\\n\\nCounselling and health education\\nMembership of support group\\nRegular health checks\\n\\nParacetamol should be used with caution in\\npatients with hepatic impairment\\n\\nOpioid analgesics cause varying degrees of\\nrespiratory depression and hypotension\\n- They should be avoided when intracranial pressure\\nis suspected to be raised\\n\\nAdvice on the risks involved in marriages between\\ncarriers, and between sicklers\\n\\nAnti-pneumococcal vaccine\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\n21 22\\n\\nChapter 2: Blood and Blood-Forming Organs Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nCHAPTER 3: CARDIOVASCULAR SYSTEM\\n\\nANGINAPECTORIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nA symptom complex characterised by chest pain or\\ndiscomfort caused by transient myocardial ischaemia\\nusually due to coronary heart disease\\n\\nLess common in this environment though current\\nstudies show increasing prevalence\\n\\nIn 90% (or more) of cases there is a hereditary factor\\nMajor risk factors:\\n\\nHypertension\\nDiabetes mellitus\\nHypercholesterolemia\\nSmoking\\nObesity\\nMale sex\\nAge\\n\\nStable angina (chest discomfort on exertion and\\nrelieved by rest)\\n\\nUnstable angina (discomfort on exertion and at rest)\\nMyocardial infarction (chest pain or discomfort that\\n\\nlasts more than 30 minutes; may be associated with\\nsymptoms of cardiac failure, shock, arrhythmias)\\n\\nMyalgia\\nPericarditis\\nAortic dissection\\nPleurisy\\n\\nCardiac failure\\nMyocardial infarction\\nArrhythmias\\nSudden death\\n\\nFull Blood Count and differentials\\nUrea, Electrolytes and Creatinine\\nFasting blood glucose\\nUrinalysis; urine microscopy\\nElectrocardiograph: resting, treadmill exercise\\nEchocardiography (resting/exercise)\\nRadio nuclide studies\\nCardiac enzymes (CK-MB)\\nCoronary angiography\\n\\nRelieve discomfort\\nImprove quality of life\\nPrevent complications\\nRelieve the obstruction\\nAddress the risk factors present\\n\\nDietary manipulation (low salt, low cholesterol diet)\\nExercise\\nStop smoking\\nReduce alcohol consumption\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nCONGENITALHEART DISEASE\\nIntroduction\\n\\nClinical features\\n\\nSinus arrhythmias\\nAnxiety\\n\\nCardiac failure\\nStroke\\nPeripheral embolic phenomena\\nSudden death\\n\\nElectrocardiograph (resting, 24 hour Holter, 1 month\\nHolter monitoring)\\n\\nUrea, Electrolytes and Creatinine\\nEchocardiography\\nElectrophysiology\\n\\nAbolish the arrhythmias\\nTreat complications\\nPrevent further arrhythmias\\n\\nPacemaker insertion\\nAblation (electrophysiology)\\nCardioversion: acute arrhythmias\\n\\nDepends on the type of arrythmia\\nRefer to a specialist for appropriate management\\n\\nPatient education\\nEfficient systems to facilitate patient recovery\\n\\nAll anti-arrhythmias are pro-arrhythmics themselves\\nCardiac failure (all anti-arrhythmics)\\nBlindness (amiodarone)\\n\\nPrevention of conditions such as hypertension,\\nrheumatic heart disease, diabetes mellitus, ischaemic\\nheart disease, congenital heart diseases etc\\n\\nA heart defect that occurs during the formation of the\\nheart in utero\\n\\nCould be fatal (i.e. causes intrauterine death, or death at\\nanytime afterwards)\\n- An important cause of perinatal morbidity/mortality\\nClassified as\\n\\nCyanotic\\nAcyanotic\\n\\nWill depend on the type of the defect:\\nMild defects go unnoticed\\nStunted growth\\nCyanosis\\nFailure to thrive\\nHeart murmurs\\n\\nDrug treatment\\n\\nOther measures\\n\\nNotable adverse drug reactions caution and\\ncontraindications\\n\\nPrevention\\n\\nCARDIACARRHYTHMIAS\\nIntroduction\\n\\nClinical features\\n\\nß blockers\\n- Atenolol 50 - 100 mg daily\\n\\nNitrates\\n- Glyceryl trinitrate 0.3 - 1 mg sublingually, repeated as\\nrequired\\nOr:\\n- Isosorbide dinitrate 30 - 120 mg orally daily (up to 240\\nmg)\\n\\nCalcium channel antagonists\\n- Verapamil 80 - 120 mg orally 8 hourly\\n\\nAnti-platelets\\n- Aspirin (acetylsalicylic acid) 75 mg orally daily\\n\\nTreat as for acute myocardial infarction\\n\\nAngioplasty (PTCA)\\nCoronary artery bypass graft (CABG)\\nTreat/reduce risk factors\\nPatient education (very important)\\n\\n,\\n\\nß blockers\\n- Bradycardia\\n- Caution in asthmatics and patients with chronic\\no b s t r u c t i v e a i r w a y s d i s e a s e b e c a u s e o f\\nbronchoconstriction.\\n\\nNitrates: hypotension\\nCalcium channel antagonists: hypotension\\nAspirin, thrombolytics: bleeding\\n\\n- Avoid in recent stroke and in upper gastrointestinal\\nbleeding\\n\\nAvoid concurrent use of ß-blockers with verapamil\\n\\nNutrition education\\nAddress risk factors\\nHealthy living\\n\\nConditions in which cardiac rhythms become abnormal\\nUsually complicate acquired and congenital heart\\n\\ndiseases\\n- Abnormal arrangements of the cardiac impulse fibres\\nor fibrosis affect the conduction fibres\\n\\nMild arrhythmias might go unnoticed\\nMay present with:\\n\\nPalpitations\\nSudden collapse\\nDizziness\\nSyncope\\nNear-syncope\\n\\n- May be complicated by cardiac failure, stroke, etc\\n\\nUnstable angina\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nPrevention\\n\\nDEEPVENOUS THROMBOSIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nRheumatic heart disease\\nEndomyocardial fibrosis\\n\\nEmbolic phenomena\\nCardiac failure\\n\\nFull Blood Count and differentials\\nUrea, Electrolytes and Creatinine\\nChest radiograph\\nElectro cardiograhy\\nFoetal echocardiography\\nAngiography\\n\\nRelieve symptoms\\nTreat the definitive defect(s)\\n\\nLow salt diet\\n\\nTreatment of cardiac failure if present\\n- Digoxin, diuretics and potassium supplements\\n\\nOxygen\\nCounselling\\n\\nPre-conception nutrition education\\nAntenatal care\\nGenetic counselling\\n\\nFormation of blood clot(s) in the deep veins of the calf\\nmuscles or pelvis\\n\\nIt has the potential of being dislodged to the lungs,\\ncausing pulmonary embolism\\nBrought about by:\\n\\nHyper-coagulable states\\nLong periods of immobilization e.g. cardiac failure,\\n\\nfollowing surgery, long-distance travel, etc\\nMalignancies\\n\\nCould be asymptomatic\\nPain and swelling of the leg (calf muscles)\\n\\nCellulitis\\nInfarctive crisis in sicklers\\nAbscess (myositis)\\n\\nPulmonary embolism\\n\\nFull Blood Count and differentials\\nProthrombine time\\nKCCT\\nDoppler of the leg/pelvic vessels (veins)\\n\\n23 24\\n\\nChapter 3: Cardiovascular System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nEchocardiography\\nElectrocardiography\\nVenography (pelvic or calf veins)\\n\\nLyse the clot\\nPrevent clot from being dislodged\\nRelieve inflammation\\n\\nAvoid stasis\\n\\nAchieveAPTT of 1.5 to 2.5 of control:\\nHeparin 5000 - 10,000 units by intravenous injection\\n\\nfollowed by subcutaneous injection of 15,000 units every\\n12 hours or intravenous infusion at 15 - 25 units/kg/hour,\\nwith close laboratory monitoring\\n\\nWarfarin 1 - 5 mg orally daily for 6 - 12 weeks\\n\\nBleeding from heparin, warfarin\\nOsteoporosis (heparin)\\n\\nLow molecular weight heparin 5000 units\\nsubcutaneously every 12 hours\\n\\nEarly mobilization\\n\\nA clinical state (syndrome) in which the heart is unable\\nto generate enough cardiac output to meet up with the\\nmetabolic demands of the body\\n\\nThe commonest cause in Nigeria is hypertension\\nOther causes include dilated cardiomyopathy and\\n\\nrheumatic heart disease\\nCardiac failure can be classified as:\\n\\nLeft or right-sided\\nCongestive\\nAcute\\nChronic\\n\\n- Chronic cardiac failure is the commonest syndrome\\nencountered in our setting\\n\\nDifficulty with breathing on exertion\\nParoxysmal nocturnal dyspnoea\\nOrthopnoea\\nCough productive of frothy sputum\\nLeg swelling\\nAbdominal swelling\\nThe prominence of particular symptoms will depend on\\n\\nwhich side is affected\\nSigns include:\\n\\nOedema\\nTachycardia (about 100 beats per minute)\\nRaised jugular venous pressure\\nDisplaced apex\\nS3 or S4 or both ( With or without murmurs)\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nHEART FAILURE\\nIntroduction\\n\\nClinical features\\n\\n- Warfarin: monitor INR 2 - 2.5\\n- Important in atrial fibrillation\\n\\nPacemakers for arrythmias\\nVentricular assist devices\\n\\nDigoxin: arrhythmias\\nPotassium-sparing drugs: hyperkalaemia\\nACEIs: hypotension, hyperkalaemia\\n\\nThe dose and infusion rate for dopamine are critical\\n- Low dose infusion rates will cause excessive\\nhypotension\\n- Higher infusion rates will elevate the blood pressure\\n\\nThe use of blockers, atrial natriuretic peptide\\nanalogues and endothelin receptor antagonists should be\\nreserved for specialist care\\n\\nAdequate treatment of hypertension and diabetes\\nmellitus\\n\\nGood sanitation and personal hygiene (to prevent\\nrheumatic fever)\\n\\nAclinical syndrome in which there are high lipid levels:\\ncholesterol, or its fractions, or triglyceridaemia\\n\\nCan be primary (hereditary) or secondary - as a result of\\nother diseases\\n\\nIncidence in Nigeria is thought to be low but recent\\nstudies show increasing incidence in association with\\ndiabetes mellitus and hypertension\\n\\nAmajor risk factor for ischemia heart disease\\n\\nPatients present with complications of hypertension,\\nischaemic heart disease or the cause of secondary\\nhyperlipideaemia\\n\\nSigns include xanthomata, xanthelasmata, and corneal\\narcus\\n\\nPrimary hyperlipidaemia\\nSecondary hyperlipidaemia: diabetes mellitus,\\nnephrotic syndrome\\n\\nIschaemic heart disease\\nPeripheral vascular disease\\nStroke, hypertension\\n\\nUrea, Electrolytes and Creatinine\\nFasting blood glucose\\nLipid profile\\nUrine proteins\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nPrecautions\\n\\nPrevention\\n\\nHYPERLIPIDAEMIA\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nDo not combine potassium supplements with potassium-\\nsparing drugs\\n\\nβ\\n\\nChest: with or without crepitations\\nAbdomen: hepatomegaly\\n\\nBronchial asthma\\nChronic obstructive airways disease (COAD)\\nRenal failure\\nLiver failure\\n\\nThrombo-embolic phenomena: stroke, pulmonary\\nembolism\\n\\nPre-renal azotaemia\\nArrhythmias\\n\\nFull Blood Count with differentials\\nUrea, Electrolytes and Creatinine\\nFasting blood glucose\\nUrine micro-analysis\\nChest radiograph\\nElectrocardiography\\nEchocardiography\\n\\nRelieve symptoms\\nEnhance quality of life\\nPrevent complications\\nProlong life\\n\\nBed rest\\nLow salt diet\\nExercise (within limits of tolerance)\\n\\nDigoxin\\n- 125 - 250 micrograms daily (the elderly may require\\n62.5 - 125 micrograms daily)\\n\\nDiuretics\\n- Furosemide 40 - 80 mg intravenously or orally\\nOr:\\n- Bendroflumethiazide 5 mg orally daily\\nOr:\\n- Spironolactone 25 - 100 mg once, every 8 - 12 hours\\ndaily\\n\\nPotassium supplements\\n- Potassium chloride 600 mg orally once, every 8 - 12\\nhours daily depending on the serum levels of potassium\\n\\nVasodilators\\n- Angiotensin converting enzyme inhibitors (ACEIs)\\nCaptopril 6.25 - 25 mg every 12 hours\\nOr:\\nLisinopril 2.5 - 20 mg daily\\n\\nVenodilators\\n- Nitrates\\nGlyceryl trinitrate 0.3 - 1 mg sublingually and repeated as\\nrequired\\n\\nIonotropes\\n- Dopamine 2 - 5 microgram/kg/minute by intravenous\\ninfusion\\n\\nAnticoagulants\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSerum proteins (total and differential)\\n\\nLower lipid levels\\nPrevent complications\\nTreat complications\\n\\nStop smoking\\nReduce weight\\nExercise moderately and regularly\\nWater soluble fibre: oat, bran\\n\\nFluvastatin\\n- Initially 20 mg orally once daily at bedtime\\n- Adjust dose at 4-week intervals as needed and tolerated\\n- Maintenance 20 - 40 mg orally once daily in the\\nevening\\n- A 40 mg daily dose may be split and taken every 12\\nhours\\n\\nCaution in patients with history of liver disease, high\\nalcohol intake\\n\\nHypothyroidism should be adequately managed before\\nstarting treatment with a statin\\n\\nLiver function tests mandatory before and within 1 - 3\\nmonths of starting treatment; thereafter at intervals of 6\\nmonths for 1 year\\n\\nStatins may cause reversible myositis, headache,\\ndiarrhoea, nausea, vomiting, constipation, flatulence,\\nabdominal pain; insomnia\\n\\nDietary manipulation\\nEarly identification of individuals at risk\\n\\nA persistent elevation of the blood pressure above\\nnormal values (taken three times on at least two different\\noccasions with intervals of at least 24 hours)\\n\\nBlood pressure 140/90 mmHg irrespective of age is\\nregarded as hypertension\\n\\nThe commonest non-communicable disease in Nigeria\\nThe commonest cause of cardiac failure and stroke\\n\\nHypertension may be:\\nDiastolic and systolic\\nDiastolic alone\\nIsolated systolic\\n\\nLargely is asymptomatic until complicated (”silent\\nkiller”)\\n\\nNon-specific symptoms: headache, dizziness,\\npalpitations etc\\n\\nOther symptoms and signs depending on the target\\norgans affected e.g. cardiac or renal failure, stroke etc\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nHYPERTENSION\\nIntroduction\\n\\nClinical features\\n\\n�\\n\\n25 26\\n\\nChapter 3: Cardiovascular System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nWhite coat hypertension\\nAnxiety/fright/stress\\n\\nHeart:\\n- Heart failure, ischaemic heart disease\\n\\nBrain:\\n- Stroke (ischaemic, hemorrhagic)\\n\\nEye:\\n- Hypertensive retinopathy\\n\\nKidney:\\n- Renal failure\\n\\nLarge arteries:\\n- Aortic aneurysm\\n\\nFull Blood Count\\nUrinalysis; urine microscopy\\nUrea, Electrolytes and Creatinine\\nUric acid\\nFasting blood glucose\\nLipid profile\\nChest radiograph\\nElectrocardiography\\nEchocardiography (not in all cases)\\nAbdominal ultrasound\\nRenal angiography (not in all cases)\\n\\nEducate patient about disease and need for treatment\\nadherence\\nReduce blood pressure to acceptable levels\\nPrevent complications (primary, secondary, tertiary)\\nRehabilitate\\n\\n(lifestyle modification)\\nLow salt diet\\nAchieve/maintain ideal body weight (BMI 18.5 - 24.9\\n\\nkg/m )\\nStop smoking\\nReduce alcohol intake\\nRegular moderate exercise\\nReduce polysaturated fatty acid intake\\n\\nDiuretics:\\nThiazides\\n\\n- Bendroflumethiazide 2.5 - 10 mg orally daily\\nOr:\\n- Hydrochlorothiazide 12.5 - 50 mg orally daily\\nOr:\\n- Hydrochlorothiazide/amiloride 25/2.5 mg daily\\n\\nLoop diuretics\\n- Furosemide 40 - 80 mg orally daily\\nß-blockers:\\n\\nPropranolol 40 - 80 mg orally every 8 - 12 hours\\nOr:\\n\\nAtenolol 25 - 100 mg orally daily\\nCalcium channel antagonists:\\n\\nNifedipine retard 20 - 40 mg orally once or twice daily\\n\\n2\\n\\nThe sub-acute form usually occurs on damaged valves\\n(e.g. rheumatic heart disease, congenital heart disease),\\nshunts, and atherosclerotic lesions\\n\\nCausative organisms include staphylococci,\\nstreptococci enterococci; haemophilus, actinobacillus,\\ncardiobacterium, eikenella, and kingella species\\n(\\'HACEK\\' organisms)\\n\\nAcute:\\nHigh fever with rigors\\nDelirium\\nShock\\nDevelopment of new murmurs\\nSevere cardiac failure\\nAbscesses may form in many parts of the body (e.g.\\n\\nbrain)\\nSubacute:\\n\\nLow-grade fever\\nSigns of carditis\\nFinger clubbing\\nArthralgia\\nSplenonegaly\\nOsler\\'s nodules\\nJaneway lesions\\nRoth spots\\n\\nMyocarditis\\nRheumatic heart disease\\n\\nCardiac failure\\nDestruction of heart valves\\nSystemic embolism (could be infective)\\n\\nFull Blood Count and differentials; ESR\\nUrinalysis; urine microscopy\\nBlood cultures X 3 (the yield is higher at the time of\\n\\npyrexia)\\nEchocardiography\\n\\nStop the infection\\nTreat cardiac failure\\nPrevent coagulation disorders\\n\\nBed rest\\nLow salt diet\\n\\nInitiate therapy with:\\nBenzylpenicillin 7.2 g daily by slow intravenous\\n\\ninjection or intravenous infusion in 6 divided doses for 4 -\\n6 weeks\\n- May be increased up to 14.4 g daily if necessary (e.g. in\\nendocarditis)\\nPlus:\\nGentamicin 60 - 80 mg intravenously or intramuscularly\\n\\nevery 8 hours for 2 weeks\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nOr:\\nAmlodipine 2.5 - 10 mg orally once daily\\n\\nAngiotensin converting enzyme inhibitors:\\nCaptopril 6.25 - 50 mg orally once or every 8 - 12 hours\\n\\nOr:\\nLisinopril 2.5 - 20 mg orally once daily\\n\\nAngiotensin receptor blockers:\\nLosartan 50 - 100 mg orally daily\\n\\nOther vasodilators:\\nHydralazine 25 - 100 mg orally once daily or every 12\\n\\nhours\\nOr:\\n\\nPrazosin 0.5 - 1 mg orally daily\\nCentrally acting drugs:\\n\\nAlpha methyldopa 250 - 500 mg orally twice, three or\\nfour times daily\\nFixed combinations:\\n\\nReserpine plus dihydroergocristine plus clopamide\\n0.25/0.5/5 mg one-two tablets orally daily\\nOr:\\n\\nLisinopril plus hydrochlorothiazide 20/12.5 mg daily\\n\\nTreatment should be done by the experts\\nInvolves the administration of antihypertensives by the\\n\\nparenteral route (usually intravenous hydralazine or\\nsodium nitoprusside)\\n\\nPatient/care giver education\\n,\\n\\nAll antihypertensive drugs may themselves cause\\nhypotension\\nAngiotensin converting enzyme inhibitors, angiotensin\\n\\nreceptor blockers: angioedema; cough withACEIs\\nAlpha methyldopa, thiazides (and potentially other anti-\\n\\nhypertensive drugs): erectile dysfunction\\nSLE-like syndrome: hydralazine\\nDo not use blockers in asthmatics\\n\\nPublic education\\nIndividual approach\\nPopulation approach\\n\\nAmicrobial infection of the endocardium and the valves\\nof the heart\\n\\nMay be acute or sub-acute\\nSome acute cases occur in normal valves or may be part\\n\\nof systemic illness\\n\\nHypertensive emergencies\\n\\nSupportive measures\\n\\nNotable adverse drug reactions caution and\\ncontraindications\\n\\nPrevention\\n\\nINFECTIVE ENDOCARDITIS\\nIntroduction\\n\\nβ\\n\\nWeight reduction\\nExercise moderately and regularly\\n\\nAdvocacy for the positive lifestyle change\\n\\nFollowing bacteriological confirmation institute\\nappropriate antimicrobial therapy\\n\\nUnder local or no anaesthesia, for those who have NOT\\nhad endocarditis, and have NOT received more than a\\nsingle dose of a penicillin in the last one month:\\n\\nAdult:\\nChild under 5 years:\\n\\nAdult:\\nChild under 5 years:\\n\\nDental procedures under general anaesthesia, and no\\nspecial risk:\\n\\nAdult:\\n\\nChild under 5 years:\\n\\nAdult:\\n\\nChild under 5 years:\\n\\nAdult:\\n\\nChild under 5 years:\\n\\nStaphylococci:\\nFlucloxacillin\\n\\n- 250 mg - 2 g intravenously every 6 hours for 4 - 6\\nweeks\\nCandida:\\n\\nSystemic antifungals\\n\\nPenicillin: rashes, anaphylaxis\\nGentamicin: nephropathy\\n\\nProphylactic antibiotics for patients at risk who are\\nundergoing:\\n1.\\n\\nAmoxicillin\\n3 g orally 1 hour before procedure\\n\\n750 mg orally 1 hour before\\nprocedure; 5- 10 years: 1.5 g\\nFor penicillin-allergic patients or patients who have\\nreceived more than a single dose of a penicillin in the\\nprevious one month:\\n\\nAzithromycin\\n500 mg orally one hour before procedure\\n\\n200 mg orally; 5 - 10 years: 300 mg\\nPatients who have had endocarditis:\\n- Amoxicillin plus gentamicin intravenously as for\\nprocedures under general anaesthesia (see below)\\n\\nAmoxicillin\\n1 g intravenously at induction of anaesthesia; 500\\n\\nmg orally 6 hours later\\na quarter of adult dose; 5 - 10 years:\\n\\nhalf adult dose\\nOr:\\n\\n3 g orally 4 hours before induction, then 3 g orally\\nas soon as possible after the procedure\\n\\na quarter of adult dose; 5 - 10 years:\\nhalf adult dose\\nSpecial risk, e.g. previous infective endocarditis, or\\npatients with prosthetic valves:\\n\\nAmoxicillin plus gentamicin intravenously\\n1 g amoxicillin plus 120 mg gentamicin at\\n\\ninduction\\n- Then oral amoxicillin 500 mg 6 hours after procedure\\n\\na quarter of adult dose of amoxicillin\\nplus 2 mg/kg gentamicin intravenously at induction\\n5 - 10 years: half adult dose for amoxicillin; 2 mg/kg\\ngentamicin\\nPatients who are penicillin-allergic or have received more\\nthan a single dose of a penicillin in the last one month:\\n\\nVancomycin\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nDental procedures\\n\\n27 28\\n\\nChapter 3: Cardiovascular System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nAdult:\\n\\nAdult:\\n\\nChild under 10 years:\\n\\n1 g intravenously over at least 100 minutes\\nPlus\\n\\nGentamicin\\n120 mg intravenously\\n\\n- Given at induction or 15 minutes before procedure\\nVancomycin 20 mg/kg;\\n\\ngentamicin 2 mg/kg\\n2.\\n\\nAs for special risk patients undergoing dental\\nprocedures under general anaesthesia\\n3. s\\n\\nAs for genitourinary tract manipulation\\n\\nOccurs when an area of heart muscle is necrosed or\\npermanently damaged because of an inadequate supply\\nof oxygen (heart attack)\\n\\nReported to be uncommon in Nigeria, although recent\\nreports suggest a rising incidence\\n\\nPrecordial pain: discomfort, heaviness, tightening\\nlasting 30 minutes or more\\n\\nShortness of breath\\nPalpitations\\nCough productive of frothy sputum\\nSigns of right or left-sided cardiac failure and shock\\n\\nPulmonary embolism\\nAortic dissection\\nPericarditis\\n\\nCardiac failure\\nVentricular aneurysm\\nArrhythmias: heart block, ventricular tachycardia,\\n\\nventricular fibrillation, atrial fibrillation\\nSudden death\\n\\nFull Blood Count; ESR\\nUrea, Electrolytes and Creatinine\\nUric acid\\nFasting blood glucose\\nLipid profile\\nEnzyme assays:AST, CK-MB, and LDH\\nElectrocardiograph monitoring throughout admission\\nCoronary angiography (in case of secondary\\n\\nangioplasty)\\n\\nRelieve pain (discomfort)\\nRelieve obstruction\\nTreat complications\\nPrevent future episodes\\n\\nBed rest\\n\\nGenito-urinary tract manipulation\\n\\nObstetric , gynaecological and gastrointestinal\\nprocedures\\n\\nMYOCARDIALINFARCTION\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nMYOCARDITIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nHeparin or streptokinase: bleeding (risk of bleeding in\\nrecent stroke, diabetic retinopathy, brain tumours, peptic\\nulcer disease or surgery)\\n- Laboratory monitoring is essential: preferably daily,\\nand dose adjusted accordingly\\n\\nAspirin: dyspepsia\\nß-blockers: bradycardia\\n\\n- Should be avoided in patients presenting with this\\nsymptom\\n\\nTreat hypertension, diabetes mellitus, and\\nhyperlipidaemia\\n\\nStop smoking\\nNutrition education\\n\\nInflammatory process affecting the myocardium\\nA common disorder; usually occurs in association with\\n\\nendocarditis and pericarditis\\nPossible causes:\\n\\nInfections: viral, bacterial, protozoal\\nToxins e.g.scorpion sting\\nPoisons e.g. alcohol\\nDrugs e.g. chloroquine\\nAllergy e.g. to penicillin\\nDeficiencies e.g. thiamine\\nPhysical agents e.g. radiation\\n\\nLargely asymptomatic\\nA few may present with palpitations; symptoms of\\n\\ncardiac failure\\nPhysical examination:\\n\\nArrhythmias\\nTachycardia\\nRaised JVP\\nCardiomegaly\\nS3 or S4 (with or without murmurs of regurgitation in\\n\\nthe mitral/tricuspid areas)\\n\\nOther forms of cardiac failure, e.g. peripartum cardiac\\nfailure\\n\\nCardiac failure\\nArrhythmias\\nThrombus formation\\n\\nFull Blood Count and differentials\\nUrea, Electrolytes and Creatinine\\nElectrocardiography\\nEchocardiography\\nMyocardial biopsy\\n\\nEliminate/withdraw the offending agent(s)\\n\\nDietary control (low cholesterol)\\nExercise (later)\\nWeight reduction (later)\\nStop smoking\\n\\nAspirin (acetylsalicylic acid) 150 - 300 mg orally stat,\\nthen 75 - 150mg daily\\n\\nMorphine 10 mg by slow intravenous injection over 5\\nminutes (i.e. 2 mg/minute)\\n\\nUnfractionated heparin\\n5,000 - 10,000 units (75 units/kg) by intravenous\\n\\ninjection as loading dose followed by continuous\\ninfusion of 15 - 25 units/kg/hour\\n- 15,000 units 12 hours by subcutaneous injection\\n\\nlower loading dose, then 15 -\\n25/kg/hour by intravenous infusion, or 250 units/kg\\nevery 12 hours by subcutaneous injection\\nOr:\\n\\nLowmolecular weight heparin\\n- Enoxaparin: 30 mg intravenous bolus (optional) then 1\\nmg/kg subcutaneously every 12 hours for 7 - 8 days\\n\\nThrombolytics\\n- Streptokinase\\n\\n1,500,000 units by intravenous infusion over 60\\nminutes, then 250 units over 30 minutes according to\\ncondition (with monitoring)\\n\\n1 month - 12 years, initially 2,500 - 4,000 units/kg\\nover 30 minutes followed by continuous infusion of 500-\\n1,000 units/kg/hour for up to 3 days until reperfusion\\noccurs\\n- 12 - 18 years: initially 250,000 units intravenously\\nover 30 minutes, followed by intravenous infusion of\\n100,000 units/hour for up to 3 days until reperfusion\\noccurs\\n\\nRecombinant plasminogen activator (\\n)\\n\\n- Alteplase 15 mg intravenously over 1 - 2 minutes,\\nfollowed by intravenous infusion of 50 mg over 30\\nminutes then 35 mg over 60 minutes\\n\\nß blockers\\n- Atenolol 50 - 100 mg orally daily\\n- Propranolol 180 - 240 mg orally in 2 - 4 divided doses\\ndaily\\n\\nAngiotensin converting enzyme inhibitors\\n- Captopril 6.25 - 50 mg orally once, twice or three times\\ndaily\\n- Lisinopril 2.5 - 10 mg daily\\n\\nMaintenance anti-anginal therapy\\n\\nCoronary artery bypass graft (CABG)\\nSecondary or rescue PTCA\\n\\nTreat arrhythmias\\nOxygen: 100% at 5L/minute\\n\\nDrug treatment\\n\\nNon-drug therapy\\n\\nSupportive measures\\n\\nAdult:\\n\\nSmall adult or child:\\n\\nAdult:\\n\\nChild:\\n\\nuse by specialist\\nphysician\\n\\n(Total dose, 100 mg over 90 minutes; lower doses in\\npatients less than 65 kg\\n\\nTreat the effect on the heart\\nTreat complications\\n\\nBed rest\\n\\nTreat underlying cause(s)\\nAnti arrhythmics (depends on the type of arrhythmias)\\nAnticoagulant: warfarin\\nAnti-cardiac failure: digoxin, diuretics, potassium\\n\\nsupplements\\nSteroids: prednisolone (not in all cases)\\nMultivitamins\\nAnti-oxidants: ascorbic acid (vitamin C),vitamin E\\n\\nAntiarrhythmics may be pro-arrhythmic\\nAnticoagulants: bleeding\\nSteroids: fluid retention, dyspepsia\\nDiuretics: dehydration, electrolyte imbalance\\n\\nPrevent infection (viral, bacterial, etc)\\nPrevent exposure to toxins\\nNutrition education\\n\\nAn inflammation of the pericardium which may arise\\nfrom viral, bacterial, fungal or protozoal infections\\n\\nOther causes: metabolic, malignancy, connective tissue\\ndisease, radiation, trauma etc\\n\\nMay be acute or chronic\\n\\nAcute pericarditis:\\nChest pain\\n\\n- Retrosternal\\n- Sharp\\n- Radiating to the left shoulder\\n- Made worse by breathing or coughing\\n- Relieved by the upright position\\n\\nLow grade fever\\nPericardial friction rub\\n\\nChronic pericarditis:\\n- Insidious onset\\nThere may be:\\n- Dyspnoea on exertion\\n- Leg and abdominal swelling\\n\\nEndomyocardial fibrosis\\nSarcodosis\\nAmyloidosis\\n\\nPericardial tamponade\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nPAEDIATRIC CARDIAC DISORDERS\\n\\nPERICARDITIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\n(Refer for\\nSpecialist Care)\\n\\n29 30\\n\\nChapter 3: Cardiovascular System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nConstrictive pericarditis\\n\\nElectrocardiography\\nFull Blood Count and differentials\\nChest radiograph\\nEchocardiography\\n\\nRelieve distress from pain and tamponade\\nRelieve constriction\\nTreat the effect on the heart\\nTreat complications\\nEradicate the organism (if cause is infection)\\n\\nBed rest\\n\\nNSAIDs\\n- Indomthaem 50 mg orally every 8 hours\\nOr:\\n- Ibuprofen 400 - 800 mg orally every 12 hours\\n\\nSteroids\\n- Prednisolone 30 mg orally every 8 hours and tapered\\n\\nAnti-tuberculous drugs or other antimicrobial agents (if\\nmycobacterium or other microbes are causative)\\n\\nPericardiocentesis\\nPericardiectomy\\n\\nNSAIDs/steroids: dyspepsia and upper GI bleeding\\n\\nAvoid radiation\\nPrevent infection\\n\\n(Also see in Respiratory system)\\n\\nBlockage of the pulmonary artery or one of its branches\\nby a blood clot, fat, air, or clumped tumour cells\\n\\nThe most common form is thrombo-embolism; occurs\\nwhen\\n- A blood clot (generally a venous thrombus) becomes\\ndislodged from its site of formation and embolizes to the\\narterial blood supply of one of the lungs\\n\\nThe calf veins (deep vein thrombosis) and right\\nventricle are sources of embolism\\nSome predisposing factors:\\n\\nCongestive cardiac failure\\nTrauma\\nSurgery\\nProlonged immobilization\\nMalignancies\\nStroke\\n\\nDepend on how massive the embolism is:\\nNo symptoms\\nModerate-to-severe cases:\\n\\nDifficulty in breathing\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nPULMONARYEMBOLISM\\n\\nIntroduction\\n\\nClinical features\\n\\nStreptokinase\\n- 250,000 units over 30 minutes, then 100,000 units\\nevery hour for 24 - 72 hours\\nOr:\\n\\nRecombinant plasminogen activator (alteplase)\\n- 10 mg intravenously over 1 - 2 minutes, followed by\\nintravenous infusion of 90 mg over 2 hours\\n\\nHeparin, warfarin or streptokinase: bleeding\\nRisk of bleeding in:\\n- Recent stroke\\n- Diabetic retinopathy\\n- Brain tumours\\n- Peptic ulcer disease\\n- Surgery\\n\\nLow molecular weight heparin for immobilized patients\\nEarly mobilization of patients\\nAppropriate, moderate and frequent exercises\\n\\nOccurs when there is congestion of the lungs with fluid,\\nusually in a scenario of left-sided cardiac failure\\n\\nResults in stiffness of the lungs and flooding of the\\nalveoli, with difficulty in breathing\\n\\nMay also follow inflammatory processes\\nMay be acute or chronic\\n\\nDifficulty in breathing, with a sensation of drowning\\nCough productive of frothy (sometimes pink) sputum\\nCentral cyanosis\\nSweating, agitation etc\\nOther symptoms of left-sided cardiac failure\\n\\nExamination:\\nWide-spread crepitations\\nRhonchi (in severe cases)\\nOther signs of left-sided cardiac failure\\n\\nPulmonary embolism\\nPneumonia\\n\\nHypoxaemia\\nComa\\n\\nBlood gases\\nUrea, Electrolytes and Creatinine\\nEchocardiography\\nChest radiograph\\nElectrocardiography\\n\\nRelieve oedema\\nRelieve discomfort\\nTreat underlying cause\\n\\nTo be used by a specialist physician\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nPULMONARYOEDEMA\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nChest pain\\nSweating\\nCollapse (shock)\\nHaemoptysis\\n\\nSigns:\\nSmall volume pulse\\nLow blood pressure\\nCyanosis\\nRaised JVP\\nCool, clammy skin\\nPallor\\nTachycardia\\nFever\\nPleural friction rubs\\nLoud P2\\n\\nLobar pneumonia\\nMyalgia\\nPleuritis (pleurisy)\\n\\nRight-sided cardiac failure\\nHaemorrhagic pleural effusion\\n\\nFull Blood Count and differentials\\nElectrocardiograph\\n\\n- Sinus tachycardia\\n- New onset atrial fibrillation/flutter\\n- S wave in lead 1, Q wave in lead 3 and an inverted T\\nwave in lead 3\\n- QRS axis >90º, quite often\\n\\nChest radiograph\\nBlood gasses (arterial)\\nVentilation/perfusion lung scanning\\nPulmonary artery angiogram\\n\\nRelieve discomfort\\nRelieve the obstruction(s)\\nPrevent complications\\nPrevent further episodes\\n\\nBed rest\\nMobilization\\n\\nHeparin\\n- 5000 - 10,000 units intravenously stat, followed by\\n1000 - 2000 units per hour (APTT or INR 1.5 - 2.5 greater\\nthan normal)\\nOr:\\n\\nEnoxaparin\\n- 1.5 mg/kg (150 units/kg) subcutaneously every 24\\nhours, usually for at least 5 days (and until adequate oral\\nanticoagulation is established)\\nOr:\\n\\nWarfarin 1 - 5 mg (INR 1.5 - 2) for 6 - 12 weeks (as\\nmaintainance after initial parenteral anticoagulation)\\nOr:\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nBed rest\\nSit on bed with legs hanging down\\n\\nOxygen 3 - 5L/min\\nMorphine 10 mg stat\\nLoop diuretics\\n\\n- Furosemide 40 - 120 mg intravenously stat;\\nmaintenance with 40 - 500 mg daily in single or divided\\ndoses\\n\\nAminophylline 250 mg intravenously slowly over 10 -\\n15 minutes\\n\\nTreat underlying cause(s)\\n\\nNursing care (e.g.nurse in cardiac position)\\n\\nAminophylline, digoxin: arrhythmias\\nDiuretics,ACEIs: hypotension\\n\\nTreat cause(s) of cardiac failure or fluid overload (e.g.\\nrenal failure)\\n\\nJudicious administration of blood and intravenous\\nfluids\\n\\nA result of abnormal reaction of antibodies developed\\nagainst antigens of groupAß- haemolytic streptococcus\\n\\nInfection is usually of the throat; occasionally the skin\\nin a sensitized individual\\nAntibodies damage the heart(endocardium, myocardium\\nand pericardium)\\n\\nCommonest streptococcal strains inAfrica are C and G\\n\\nFever\\nArthralgia\\nAbnormal movements of the hands (upper hands)\\nDiagnosis: Duckett-Jones\\' diagnostic criteria\\n\\nMajor:\\nCarditis\\nSydenham\\'s chorea\\nErythema marginatum\\nSubcuoeous nodules\\nArthritis (migratory polyarthritis)\\n\\nMinor:\\nFever\\nLeucocytosis\\nArthralgia\\nRaised ESR\\nRaisedASO titre (> 200 IU)\\nPrevious history of rheumatic fever\\n\\n2 major criteria\\nOr:\\n\\n1 major 2 (or more) minor criteria\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nRHEUMATIC FEVER\\nIntroduction\\n\\nClinical features\\n\\nDiagnosis\\n\\nplus\\n\\n31 32\\n\\nChapter 3: Cardiovascular System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nMalaria\\nViral infection\\nPyrexia of undetermined origin\\nConnective tissue disease\\n\\nRheumatic heart disease\\nArrhythmias\\nCardiac failure\\n\\nFull Blood Count and differentials\\nASO titre\\nESR\\nElectrocardiograph\\nEchocardiography\\nChest radiograph\\nThroat swab for microscopy, culture and sensitivity\\n\\nRelieve symptoms\\nTreat the bacterial throat infection\\nReduce or abolish inflammatory process\\nTreat cardiac failure if present\\n\\nBed rest\\n\\nAntibiotics\\n- Penicillin V\\n\\n500 mg orally every 6 hours, increased up to 1g 6\\nhourly in severe infections\\n\\n1 month - 1 year 62.5 mg orally every 6 hour\\nincreased in severe infection to ensure at least 12.5\\nmg/kg/dose\\n1 - 6 years: 125 mg every 6 hours increased in severe\\ninfection to ensure at least 12.5 mg/kg/dose\\n6 - 12 years 250 mg every 6 hours, increased in severe\\ninfection to ensure at least 12.5 mg/kg/dose\\n12 - 18 years 500 mg every 6 hours, increased in severe\\ninfection up to 1 g/dose\\nOr\\n- Erythromycin\\n\\n250 - 500 mg orally every 6\\nhours 500 mg - 1 g every 12 hours; up to 4 g daily in\\nsevere infections\\n\\nup to 2 years, 125 orally mg every 6 hours; 2 - 8\\nyears 250 mg every 6 hours; doses doubled for severe\\ninfections\\n\\nSalicylates-Aspirin (acetylsalicylic acid)\\n300 mg - 1 g orally every 4 hours after food;\\n\\nmaximum dose in acute conditions 8 g daily\\nnot recommended for use\\n\\nSteroids (if salicylates are ineffective)\\n- Prednisolone\\n- Initially, up to 10 - 20 mg orally daily; up to 60 mg daily\\n\\nin severe disease (preferably taken in the morning\\nafter breakfast); dose can often be reduced within a\\nfew days, but may need to be continued for several\\n\\nAdult:\\n\\nChild: s\\n\\nAdult and child over 8 years:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nor\\n\\nElectrocardiography (resting/exercise)\\nLipid profile\\nEchocardiography\\nChest radiograph\\nCoronary angiography\\n\\nRelieve symptoms\\nPrevent recurrence of rheumatic attack\\nRepair and replace affected valves\\n\\nBed rest\\nLow salt diet\\n\\nTreat for heart failure if present\\nUse anticoagulants if necessary\\nProphylaxis against endocarditis (see Infective\\n\\nEndocarditis)\\n- Benzathine penicillin 720 mg (1.2 million units) intra\\nmusculary monthly for life\\nOther measures:\\n- Valve replacement\\n- Valve repair\\n- Treat endocarditis\\n\\nPenicillin may cause hypersensitivity reaction /\\nanaphylaxis\\n- Caution in patients with a history of penicillin allergy\\n\\nPersonal hygiene and good sanitation to prevent\\nrecurrence of rheumatic fever\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nweeks or months\\n- Maintenance 2.5 -15 mg orally daily\\n\\nBenzathine penicillin 720 mg (1.2 million units)\\nintramuscularly 3 - 4 weekly until the age of 25 years (or\\n10 years after the attack-whichever is longer)\\n\\nPenicillin: anaphylactic reaction\\nSalicylates; steroids: peptic ulceration\\nCushingoid effects are increasingly likely with doses of\\n\\nprednisolone above 7.5 mg daily\\n\\nGood sanitation.\\nSchool surveys - identify carriers of streptococcus and\\ntreat\\n\\nSecondary prevention and prophylaxis against\\nendocarditis\\n\\nAcomplication of rheumatic fever\\nAcommon cause of cardiac failure in Nigeria\\nInAfrica manifests later compared to Caucasians\\nThe mitral valve is most affected, followed by the aortic,\\n\\nthen the tricuspid\\nThe lesions can occur in various combinations of\\n\\nstenosis and regurgitation\\n\\nShortness of breath on exertion\\nParoxysmal nocturnal dyspnoea\\nOrthopnoea\\nLeg and abdominal swelling\\nCough with production of frothy sputum\\nPedal and sacral oedema\\nSmall volume pulse which may be irregular\\nWith or without tachycardia\\nWith or without hypotension\\nRaised JVP\\nDisplaced apex\\nLeft ventricular hypertrophy\\nRight ventricular hypertrophy\\nThrills\\nPalpable P2\\nSoft S1; loud P2\\nS3 or S4\\nSystolic/diastolic murmurs\\n\\nConstrictive pericarditis\\nEndomyocardial fibrosis\\nDilated cardiomyopathy\\n\\nArrhythmias e.g. atrial fibrillation, heart block\\nCardiac failure\\nEmbolic phenomena\\nEndocarditis\\n\\nProphylaxis against infective endocarditis\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nRHEUMATIC HEART DISEASE\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nCHAPTER 4: CENTRAL NERVOUS SYSTEM\\n\\nNON-PSYCHIATRIC DISORDERS\\n\\nDIZZINESS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigtions\\n\\nSimply means \\'light-headedness\\'\\nUsually due to impaired supply of blood, oxygen\\n\\nand glucose to the brain\\nMay suggest some form of unsteadiness, or could\\n\\nprecede a fainting spell\\nCauses:\\n\\nSide effects of medications, notably anti-\\nhypertensives and sedatives\\n\\nAnaemia\\nArrhythmias\\nFever\\nHypoglycaemia\\nBrain stem lesions\\nAlcohol overdose\\nExcessive blood loss\\nProlonged standing\\nAutonomic neuropathy (especially in diabetic\\n\\npatients)\\nMay be accompanied by vertigo (giddiness) in\\n\\nsome individuals\\nMay culminate in loss of consciousness\\n\\nLight-headedness\\nFeeling faint especially on attempting to stand or\\n\\nafter squatting\\nWeakness\\n\\nBenign positional vertigo\\nLabyrinthine disorders\\nHysteria\\nPremonitory symptoms of epilepsy\\nMigraine aura\\nWarning symptom of posterior circulation stroke\\n\\n(posterior inferior cerebellar artery)\\nCervical spondylosis with compression of vertebral\\n\\nartery\\nBrain tumour (acoustic neuroma)\\n\\nFalls with injury\\nStroke\\nIf due to intracranial tumour: raised intracranial\\n\\npressure with coning\\nIf due to other intracranial pathology: cranial nerve\\n\\npalsies\\n\\nFull Blood Count and differentials\\nElectrocardiography\\nEchocardiography\\nRandom blood glucose\\nX-ray sinuses\\n\\n33 34\\n\\nChapter 3: Cardiovascular System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nNeuro-imaging: CT scan, MRI, carotid Doppler etc\\n\\nDepends on the aetiological factor identified\\n\\nEliminate symptom\\nPrevent recurrence\\nDrug treatment will depend on underlying cause(s)\\n\\nStop all medicines suspected to be responsible\\nPhysiotherapy: pressure stockings\\n\\nAvoid precipitants\\n- These must be identified early for effective\\nprevention\\n\\nThe commonest neurological disease in Nigerian\\ncommunities\\n\\nDefined as pain or discomfort in the head and the\\nsurrounding structures\\nThey may be:\\n\\nPrimary (idiopathic)\\nSecondary\\n\\nTension type\\nMigraine with or without aura\\nCluster headache\\n\\nIntracranial space-occupying lesions like brain\\ntumours, subdural haematoma\\n\\nVascular lesions: strokes\\nInfections\\nFollowing generalized convulsions\\nMetabolic derangements\\nAlcohol hangover\\nDrugs\\nIrritation of sensory cranial nerves\\nInflammation or diseases of structures/organs in\\n\\nthe head region: eyes, nose, sinuses, ears, cervical\\nvertebrae\\n\\nSleep disorders (hypoxia)\\nBrain stem malformations\\nHIV infection\\n\\nDepend on the underlying type/cause(s):\\n\\nHeaviness in the head\\nCrawling sensation\\n“Peppery sensation”\\nTight-band sensation\\nPoor sleep\\nDisturbed concentration\\n\\nRecurrent, frequent, brief attacks of disturbing pain\\n\\nManagement\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nPrevention\\n\\nHEADACHES\\nIntroduction\\n\\nClinical features\\n\\nPrimary headache types\\n\\nSecondary causes\\n\\nAtypical headache\\n\\nTension type\\n\\nCluster type\\n\\nSecondary headaches\\nMedical or surgical management of identified\\n\\ncauses\\nAntibiotics for infections like meningitis, sinusitis\\nSteroids for vasculitis\\n\\nAspirin and other NSAIDs: use with caution in\\npatients with history of dyspepsia, and asthma\\n\\nTricyclic antidepressants: use with caution in\\npatients with cardiac symptoms\\n\\nTricyclic antidepressants: anticholinergic effects\\ne.g urinary retention in the elderly\\n\\nReduce stress levels\\nProphylactic medications if attacks last more than\\n\\n15 days a month, or are severely incapacitating (in\\nthe absence of other causes)\\n\\nEarly detection and correction of refractive errors,\\nsinusitis, oto-rhino-laryngologic and dental\\nproblems.\\n\\nAn infection of the meninges with presence of pus\\nand inflammatory cells in the cerebrospinal fluid\\n\\nA medical emergency, and associated with\\nconsiderable morbidity and mortality\\nMay be bacterial (pneumococcus, meningococcus,\\n\\ntubercle bacilli, ), viral, fungal,\\nprotozoal, neoplastic or chemical\\n\\nOrganism may vary with age of the patient\\nEpidemic meningitis is usually due to\\n\\nFever\\nHeadache\\nVomiting\\nPhotophobia\\nAlteration in level of consciousness\\nNeck stiffness and positive Kernig\\'s sign\\nMay present in epidemics\\n\\nOther presentations:\\nFever of unknown origin: chronic meningitis\\nMass lesion with focal neurological deficits:\\n\\ntuberculoma, empyema\\nStroke-like syndrome: resulting from inflammation\\n\\nof blood vessels\\nSeizures which may be uncontrolled and prolonged\\n\\n(status epilepticus)\\nAcute psychosis (Organic Brain Syndrome)\\nDementia\\n\\nSubarachnoid haemorrhage\\nTetanus\\nBrain abscess\\nCerebral malaria\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nMENINGITIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nHaemophilus\\n\\nNeisseria\\nmeningitidis\\n\\nin the head\\nPain around the eyes and forehead\\nRedness of the eyes\\nNasal stuffiness\\nDrooping of the eyelids\\n\\n- See below\\n: presence of additional\\n\\nsymptoms\\nFever\\nVomiting\\nNeck stiffness\\nAlteration in level of consciousness\\nConvulsions\\nCranial nerve deficits\\nLimb weakness (hemiparesis, quadriparesis)\\nPapilloedema as evidence of raised intracranial\\n\\npressure\\nEvidence of disease in other organs\\nEvidence of drug or alcohol abuse\\n\\nMeningitis\\nHysteria\\nRefractive error\\nCervical spondylosis\\nBrain tumour\\nHaemorrhagic stroke\\n\\nDepend on the cause and type\\nSome are benign with no sequelae\\nConing (depending on cause)\\nBlindness (following temporal arteritis, unrelieved\\n\\nraised intracranial pressure)\\n\\nNeuro-imaging: skull X-ray, computerized\\ntomographic scan, MRI\\n\\nElectroencephalography\\nCerebrospinal fluid examination for pressure, cells\\n\\nand chemistry\\nErythrocyte sedimentation rate\\n\\nEliminate pain\\nTreat the precipitating factor or disease\\nPrevent recurrence\\n\\nSimple analgesics and non-steroidal anti-\\ninflammatory agents\\nTricyclic antidepressants\\n\\n- Amitriptyline 10 - 25 mg daily at night\\nAnxiolytics\\n\\n- Lorazepam 1 - 2.5 mg at night. Use lower doses\\nfor the elderly patient\\n\\nMigraine headache\\n\\nSecondary headaches\\n\\nPrimary headaches\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNon-drug treatment\\nPsychotherapy\\nPhysiotherapy/biofeedback\\n\\nSepticaemia with meningism\\n\\nCranial nerve palsies\\nSubdural pus collection (empyema)\\nStroke\\nEpilepsy\\nHeat stroke\\n\\nSyndroVme of Inappropriate Anti-Diuretic\\nHormone secretion (SIADH)\\n\\nLumbar puncture for CSF analysis\\n- To demonstrate presence of inflammatory cells\\n(after exclusion of raised intracranial pressure by\\nfundoscopy or CT scan)\\n\\nFull Blood Count and differentials\\nBlood culture\\nErythrocyte sedimentation rate\\nRandom blood glucose\\nElectrolytes, Urea and Creatinine\\nChest radiograph\\nMantoux test (if tuberculosis is suspected)\\nHIV screening\\n\\nEliminate the organism\\nReduce raised intracranial pressure\\nCorrect metabolic derangements\\nTreat complications (if any)\\n\\nInitial therapy will depend on the age of the patient\\n(and causative agent)\\nBac t e r i a l i n f ec t i ons - th i rd gene ra t i on\\ncephalosporins:\\n\\nCeftriaxone is the drug of first choice\\n- 2 - 4 g daily by intravenous injection or by\\nintravenous infusion over 2 - 4 minutes\\nOr:\\n\\nPenicillin V 2 - 4 g by slow intravenous injection\\nevery 4 hours\\nOr:\\nChloramphenicol 100 mg/kg intravenously every 6\\n\\nhours\\n- May be useful for infection\\nTuberculosis:\\n\\nStandard anti-tuberculous drugs (including\\npyrazinamide and isoniazid for their good\\npenetration of the blood-brain\\nbarrier)\\nAnti-pyretics:\\n\\nAspirin (acetylsalicylic acid)\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNon-drug treatment\\nTepid-sponging\\nAttention to calories and fluid/electrolyte balance\\nPhysiotherapy (for passive muscle exercises)\\nNursing care (e.g. frequent turning and bladder\\n\\ncare) to prevent decubitus ulcers and urinary tract\\ninfection\\n\\nH. influenzae\\n\\n35 36\\n\\nChapter 4: Central Nervous System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild:\\n\\n300 mg - 1 g orally every 4 hours after food;\\nmaximum dose in acute conditions 8 g daily\\n\\nnot recommended for use\\nDiazepam (for seizures)\\n\\n10 - 20 mg at a rate of 0.5 ml per 30 seconds,\\nrepeated if necessary after 30 - 60 minutes; may be\\nfollowed by intravenous infusion to a maximum of 3\\nmg/kg over 24 hours\\n\\n300 - 400 micrograms/kg (maximum 20 mg)\\nby slow intravenous injection into a large vein for\\nprotracted or frequent recurrent convulsions\\n- Not required in single, short-lived convulsions\\nAcute cerebral decompression:\\n\\nFurosemide\\n40 - 80 mg every 8 hours by slow intravenous\\n\\ninjection (for a maximum of 6 doses)\\nneonate 0.5 - 1 mg/kg every 12 - 24 hours\\n\\n(every 24 hours in neonates born before 31 weeks\\ngestation)\\n1 month - 12 years: 0.5 - 1 mg/kg (maximum 4\\nmg/kg), repeated every 8 hours as necessary\\n12 - 18 years: 20 - 40 mg, repeated every 8 hours as\\nnecessary; higher doses may be required in resistant\\ncases\\nOr:\\nMannitol 20% solution\\n\\n50 - 200 g by intravenous infusion over 24\\nhours, preceded by a test dose of 200 mg/kg by slow\\nintravenous injection\\n\\nneonate 0.5 - 1 g/kg (2.5 - 5 ml/kg of 20%\\nsolution) repeated if necessary 1 - 2 times after 4 - 8\\nhours\\n1 month - 18 years: 0.5 - 1.5 g/kg (2.5 - 7.5 ml/kg of\\n20% solution); repeat if necessary 1 - 2 times after 48\\nhours\\n\\nTreat contacts during meningococcal epidemics\\nwith either ciprofloxacin or rifampicin\\n- Rifampicin\\n\\n600 mg orally every12 hours for 5 days\\n10 mg/kg orally for days\\n\\nUnder 1 year: 5 mg/kg orally for\\ndays\\n- Ciprofloxacin\\n\\n500 mg orally as a single dose\\n5 - 12 years 250 mg orally\\n\\nDiazepam\\n- Must be administered slowly intravenously to\\navoid respiratory depression\\n\\nChloramphenicol\\n- May cause aplastic anaemia\\n\\nMannitol\\n- May cause chills and fever\\n- Extravasation causes inflammation and\\n\\nChemoprophylaxis\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nevery12 hours 5\\nevery12 hours 5\\n\\nas a single dose\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nStroke\\nEpilepsy\\nBlindness\\n\\nNeuro-imaging\\nComputerized tomographic scan\\nMRI\\nElectroencephalography\\n\\nEliminate pain\\nPrevent recurrence\\n\\nAspirin (acetylsalicylic acid) tablets 300 - 900 mg\\nevery 4 - 6 hours when necessary maximum 4g daily.\\nChild and adolescent - not recommend (risk of\\n\\nreye’s syndrome)\\n- With an anti-emetic agent (e.g. metoclopramide),\\nor other non-steroidal anti-inflammatory agents plus\\nmetoclopramide\\n\\nErgotamine preparations (useful only during the\\naura phase)\\n\\n1 - 2 mg orally at first sign of attack;\\nmaximum 4 mg in 24 hours\\n- Do not repeat at intervals of less than 4 days;\\nmaximum 8 mg in any one week\\n\\nConsider for patients who:\\nSuffer at least 2 attacks a month\\nSuffer an increasing frequency of headaches\\nSuffer significant disability inspite of suitable\\n\\ntreatment for acute attacks\\nCannot take suitable treatment for acute attacks\\n\\nAvailable options are:\\nPropanolol\\n\\n- 40 mg orally every 8 - 12 hours\\nTricyclic antidepressants, notably amitryptiline\\n\\n- 10 mg orally at night, increased to a maintenance\\ndose of 50 - 75 mg at night\\n\\nSodium valproate\\n- Initially 300 mg orally every 12 hours, increased if\\nnecessary to 1.2 g daily in 2 divided doses\\nIn refractory cases:\\n\\nCyproheptadine\\n- An antihistamine with serotonin-antagonist and\\ncalcium channel-blocking properties\\n4 mg orally; a further 4 mg if necessary;\\nmaintainance 4 mg every 4 - 6 hours\\n\\nNon-drug treatment\\nManage in a quiet (and dark) room\\nPsychotherapy\\nPhysiotherapy/biofeedback\\n\\n- Not to be used more than twice in any one month\\nnot recommended\\n\\nAcute attack\\n\\nAdult:\\n\\nChild:\\nProphylaxis\\n\\nthrombophlebitis\\n- Contraindicated in congestive cardiac failure and\\npulmonary oedema\\n\\nImmunize against communicable diseases\\n- Meningococcus, heamophilus, streptococcus\\n(especially for sicklers).\\n\\nChemoprophylaxis (Rifampicin or ciprofloxacin)\\n- As determined by national policy\\n- For close contacts of clinical cases\\n\\nHeadache resulting from changes in the calibre of\\ncertain blood vessels in the brain with resulting\\nphysical, autonomic and emotional disturbance\\n\\nCan be very incapacitating\\nAffects more females than males, usually between\\n\\nthe ages of 15 and 50 years\\n\\nCommon migraine (or migraine without aura)\\n- Throbbing pain usually affecting one side of the\\nhead around the temples, associated nausea and\\nvomiting\\n- Dislike of light and noise\\n\\nClassical migraine (or migraine with aura):\\n- Attacks of pain preceded by seeing flashes of light\\n- Disturbances in the field of vision (scotomas)\\n- Visual hallucinations\\n\\nChildhood periodic syndromes:\\n- Abdominal pain and vomiting\\n- Alternating hemiplegia\\n- Benign positional vertigo\\n\\nBasilary artery migraine - predominantly brain\\nstem symptoms\\n- Dysarthria\\n- Vertigo\\n- Tinnitus\\n- Decreased hearing\\n- Diplopia\\n- Ataxia\\n\\nMay coexist with tension-type headache\\nMay present without headache (migraine\\n\\nequivalent) usually seen in psychiatry\\nMay present with complications: stroke-like\\n\\nmanifestations\\nOphthalmoplegia\\nStatus attacks: unrelieved, persistent headaches\\n\\nEpilepsy\\nHysteria\\nGlaucoma\\nMultiple sclerosis\\nBrain tumours\\n\\nPrevention\\n\\nMIGRAINE\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nVascular Headaches\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nPARKINSONISM\\nIntroduction\\n\\nClinical features\\n\\nAspirin and other NSAIDs: use with caution in\\npatients with history of dyspepsia and in asthmatics\\n\\nTricyclic antidepressants used with caution in\\npatients with cardiac symptoms\\n\\nErgotamine: use should not exceed 4 - 6 mg per\\nattack\\n- Caution in patients with vascular and renal\\ndisorders\\n- Not recommended for children\\n\\nOpiates: risk of addiction\\nß-blockers: slow down cardiovascular function;\\n\\nreduce sensitivity to hypoglycaemia in diabetics\\n\\nAvoid precipitants\\nThese must be identified for effective prevention\\n\\nReduce stress levels as much as possible\\nGive prophylactic medicines if attacks last more\\n\\nthan 15 days a month, or are severely incapacitating\\n(in the absence of other causes)\\n\\nSynonyms: \\'shaking palsy\\'; \\'paralysis agitans\\';\\n\\'akinetic-rigid syndrome\\'\\n\\nA common neuro degenerative disease that results\\nfrom deficiency of dopamine in the striato-nigral\\npathway\\nCauses:-\\n\\nDrugs:\\n- Antipsychotics e.g. phenothiazines\\n- Antihypertensives: alpha methyl dopa, reserpine\\n\\nInfections:\\n- Encephalitis\\n- Typhoid fever\\n\\nVascular diseases:\\n- Arteriosclerosis\\n\\nNeurotoxins\\n- Carbon monoxide\\n- Manganese\\n- Cyanide\\n- Heroin analogues\\n\\nHead trauma as in boxing\\nTumours\\nMetabolic diseases (Wilson\\'s disease)\\nIdiopathic:- Parkinson\\'s disease\\n\\nClassical disease:\\nRest tremors: coarse, distal tremors described as\\n\\npill-rolling type\\nRigidity\\nSlowness of movement; loss of arm swinging when\\n\\nwalking\\nRetropulsion, propulsion, turning en bloc\\n\\n37 38\\n\\nChapter 4: Central Nervous System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nPostural instability with frequent falls\\nGait changes: shuffling gait with flexed posturing\\n\\nMulti-infarct dementia\\nAlzheimer\\'s disease\\nNormal pressure hydrocephalus\\nBrain tumour\\nBenign essential tremor\\nDepression\\nCreutfeldt-Jakob disease\\n\\nRecurrent falls with attendant complications e.g.\\nsubdural haematoma\\n\\nDementia\\nDepression\\n\\nDiagnosis is essentially clinical\\nNeuro-imaging: CT scan/MRI for exclusion of\\n\\npossible differentials\\n\\nReplace dopamine\\nEnsure mobility and avoidance of falls\\n\\nL-dopa/carbidopa (dose expressed as levodopa)\\n- 50 mg orally every 6 - 8 hours increased by 100\\nmg once or twice weekly depending on response\\n\\nAnti-cholinergic drugs for tremors\\n- Trihexyphenidyl (benzhexol) 1 mg orally daily,\\nincreased gradually (usually 5 - 15 mg in 3 - 4\\ndivided doses up to a maximum of 20 mg)\\n\\nDopamine receptor agonists\\n- Bromocriptine 1 - 1.25 mg orally nocte in the first\\n\\nweek; 2 - 2.25 mg nocte in the 2 week; 2.5 mg twice\\n\\ndaily in the 3 week, 2.5 mg three times daily in the\\n\\n4 week, increasing by 2.5 mg every 1 - 2 weeks\\naccording to response (usual range is 10 - 40 mg\\ndaily)\\n- Ropinirole 1 - 3 mg orally once daily (in resistant\\ncases)\\n\\nPhysiotherapy for postural adjustments\\nAntidepressants\\n\\n- Amitryptiline for pain (which could be quite\\nincapacitating) especially with dopamine-\\nreplacement drugs\\n\\nDopamine replacement drugs: dyskinesia, pain\\n- Advisable to start with small doses and gradually\\nincrease\\n- There is need for dosage and timing adjustments\\nwhen side effects manifest\\n\\nDopa-agonists: postural hypotension; may cause\\nvomiting\\n\\nParkinsonism may occur in association with other\\nneurodegenerative diseases\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nnd\\n\\nrd\\n\\nth\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nElectroencephalography\\nNeuro-imaging: CT scan, MRI\\nRandom blood glucose\\nUrea, Electrolytes and Creatinine\\n\\nArrest convulsions/attacks\\nTreat underlying cause if identified\\nImprove quality of life\\n\\nDiazepam\\n10 - 20 mg by slow intravenous injection;\\n\\nrepeat if necessary in 30 - 60 minutes\\n200 - 300 micrograms/kg 1 mg per year of\\n\\nage\\nCould be given per rectum as rectal solution in\\n\\nrestless patients\\n- 500 micrograms/kg (up to a maximum of 30 mg)\\nin adults and children over 10 kg\\n\\nPhenytoin\\ninitially 15 mg/kg by slow intravenous\\n\\ninjection or infusion (with blood pressure and\\nElectrocardiograph monitoring) at a rate not more\\nthan 50 mg/minute; then 100 mg every 6-8 hours\\n\\nneonate- initial loading dose 20 mg/kg by slow\\nintravenous injection, then 2 - 4 mg/kg orally every 12\\nhours, adjusted according to response (usual maximum\\ndose 7.5 mg/kg every 12 hours)\\n1 month - 12 years: initially 1.5 - 2.5 mg/kg every 12\\nhours, adjusted according to response to 2.5 -\\n5mg/kg every 12 hours (usual maximum dose 7.5\\nmg/kg every 12 hours or 300 mg daily)\\n12 - 18 years: initially 75 - 150 mg every 12 hours,\\nadjusted according to response to 150 - 200 mg 12\\nhourly (usual maximum 300 mg every 12 hours)\\n\\nParaldehyde (see important precaution below)?\\n- Useful where facilities for rescucitation are poor\\n- Causes little respiratory depression when given\\nrectally\\n- Administer 10 - 20 mLper rectum as an enema\\n\\nneonate- 0.4 mL/kg (maximum 0.5 mL) as a single\\ndose; up to 3 months: 0.5 mL; 3 - 6 months: 1 mL; 6 - 12\\nmonths: 1.5 mL; 1 - 2 years 2 mL; 3 - 5 years 3 - 4 mL; 6 -\\n12 years 5 - 6 mL (administered as a single dose per\\nrectum) per kg body weight\\n- Not recommended in pregnancy\\n\\nCerebral decompression with mannitol 20%\\ninfusion or furosemide if indicated (see meningitis)\\n\\nPhenobarbital\\n60 - 180 mg orally daily\\n5-8 mg orally daily\\n\\nPhenytoin\\n\\nParenteral drugs are recommended for acute\\nattacks/status epilepticus\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nChild:\\n\\nAdult:\\nChild:\\n\\nor\\n\\nGeneralized epilepsies\\nMaintenance therapy in day-to-day care\\n\\n- Caution is advised to avoid falls\\nAnticholinergic drugs: constipation; memory\\n\\nproblems\\n- Contraindicated in the presence of glaucoma\\n\\nAvoid identified causative agents where feasible\\nTimely and appropriate treatment to prevent/reduce\\ncomplications\\n\\nA seizure results from abnormal excessive electrical\\ndischarge of brain cells\\n\\nEpilepsy is a condition characterized by recurrent\\n\\n2) seizures unprovoked by any immediate\\nidentifiable cause\\nMay be idiopathic or could follow:\\n\\n- Cerebral infections\\n- Metabolic derangements (glucose, electrolytes,\\nfluids)\\n- Stroke\\n- Tumours\\n- Head trauma\\n- Birth injury/asphyxia\\n- Drug abuse/overdosage/withdrawal\\n- Alcoholism\\n- Neuro-degeneration\\n\\nClassical attack with sudden loss of consciousness,\\nconvulsions (tonic and/or clonic)\\n\\nAbnormal sensation or perception\\nAutonomic disturbances: epigastric discomfort,\\n\\nsphincteric incontinence\\nSemi-purposive actions (automatisms)\\nAura\\nLoss of postural tone (sudden falls without\\n\\nconvulsions)\\nLimb paralysis (Todd\\'s paralysis) usually after\\n\\nattacks\\n\\nMigraine headache\\nSyncope\\nNarcolepsy\\nPanic attacks\\nCatatonic schizophrenia\\nTransient ischaemic attacks\\nHysteria\\nMénière\\'s disease\\n\\nStatus epilepticus\\nCardiac arrhythmias\\nRenal failure from myoglobinuria\\nCerebral hypoxia/anoxia resulting in brain damage\\n\\nPrevention\\n\\nSEIZURES/EPILEPSIES\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\n��\\n\\nSudden death\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nChild 1 month - 12 years:\\n\\nAdult:\\n\\nChild\\n\\n150 - 300 mg orally daily\\nneonate- initial loading dose by slow intravenous\\n\\ninjection then 2 - 4 mg/kg by mouth every 12 hours\\nadjusted according to response (usual maximum 7.5\\nmg/kg every 12 hours)\\n1 month - 12 years: 1.5 - 2.5 mg/kg orally every 12 hours\\n(usual maximum 7.5 mg/kg every 12 hours or 300 mg\\ndaily)\\n12 - 18 years: initially 75 - 150 mg every 12 hours,\\nadjusted according to response up to 150 - 200 mg every\\n12 hours (usual maximum 300 mg every 12 hours)\\n\\nSodium valproate\\n600 mg daily in 2 divided doses\\nneonate, initially 20 mg/kg orally or per\\n\\nrectum once daily; usual maintenance dose 10 mg/kg\\ntwice daily\\n1 month - 12 years: initially 5-7.5 mg/kg every 12\\nhours; maintenance 12.5 - 15 mg/kg every 12 hours\\n12 - 18 years: usually 300 mg every 12 hours,\\nincreased in steps of 200 mg at 3-day intervals; usual\\nmaintenance 500 mg - 1 g twice daily (maximum\\n1.25 g twice daily)\\n\\nCarbamazepine\\n100 - 200 mg orally 1-2 times daily\\n\\n- Not recommended in pregnancy\\ninitially 5 mg/kg orally at\\n\\nnight or 2.5 mg/kg twice daily, increased as\\nnecessary by 2.5 - 5 mg/kg every 3 - 7 days; usual\\nmaintenance 5 mg/kg every 8 - 12 hours\\n12 - 18 years: initially 100 - 200 mg 1 - 2 times daily,\\nincreased slowly to usual maintenance of 400-600\\nmg\\n\\nEthosuximide\\n500 mg daily initially; increase by 250 mg at\\n\\nintervals of 4 - 7 days to doses of 1 - 1.5 g daily\\n(maximum dose 2 g daily)\\n\\nover 6 years: same as adult dose\\nUp to 6 years: 250 mg daily; increase gradually to 20\\nmg/kg daily (maximum 1 g daily)\\n\\nPsychotherapy\\nHealth education to patients, relations and public\\nDiscourage harmful cultural practices e.g. burning,\\n\\nmutilation\\n\\nAntiepileptics: foetal damage if used in pregnancy\\n- Serial measurements of alpha-fetoprotein and\\nultrasound studies are necessary with close\\nmonitoring by an obstetrician\\n\\nPhenytoin: gingival hypertrophy; may not be the\\nfirst choice in young children\\n\\nPhenobarbital: sedation and mental dullness and\\nmay affect school performance in children\\n\\nPartial seizures\\n\\nAbsence attacks\\nevery 8 - 12 hours\\n\\nNon-drug treatment\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\n39 40\\n\\nChapter 4: Central Nervous System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nMost antiepileptics: skin rashes, especially\\nStevens-Johnson syndrome; exfoliative dermatitis\\n\\nIntroduce drugs singly because of possible\\ninteraction between drugs\\nDoses must be gradually increased to avoid toxicity\\n\\nand other side effects\\nDo not use paraldehyde if it has a brownish colour\\n\\nor the odour of acetic acid\\nAll antiepileptics must be withdrawn slowly so as\\n\\nnot to precipitate status epilepticus\\n\\nPrompt treatment of fever in children to avoid\\nfebrile convulsions\\n\\nPrevention of head injuries\\nTreat diseases of the brain early to avoid poor\\n\\nhealing and death of brain cells\\nImmunization of children against communicable\\n\\ndiseases\\nAddress causative factors (see above)\\nAvoid driving and swimming unattended, and\\n\\noperation of machinery\\n\\nA condition resulting from disruption of blood\\nsupply to brain cells with disability lasting more than\\n24 hours or resulting in death\\nCould result from:\\nOcclusion (ischaemic)\\nRupture of blood vessels with bleeding into the\\n\\nbrain substance or into the subarachnoid space\\n(haemorrhagic)\\n\\nClassical stroke:\\n- Sudden motor weakness, with/without speech,\\nvisual and sensory impairment\\n\\nSubarachnoid haemorrhage :\\n- Severe headache, neck stiffness and positive\\nKernig\\'s sign\\n\\nStroke-in-evolution:\\n- Gradual onset of deficit with progression\\n\\nMass lesion:\\n- Sudden rise in intracranial pressure\\n- Loss of consciousness, respiratory changes,\\npupillary changes\\n- Sudden death\\n\\nLacunar syndrome:\\n- Incomplete deficits: speech defects with clumsy\\nhand involvement\\n- Pure motor and/or pure sensory deficits\\n\\nDementia:\\n- Arises from small, recurrent strokes resulting in\\ncognitive impairment and functional dependence\\n\\nBrain tumour\\nSubdural haematoma\\n\\nPrevention\\n\\nSTROKE\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nadministered slowly to avoid respiratory depression\\nand laryngeal spasm\\n\\nTreat/control known risk factors\\n- Hypertension\\n- Diabetes mellitus\\n- Cardiac diseases\\n- Hyperlipidaemia\\n- Obesity\\n- Smoking\\n- Excessive alcohol consumption\\n\\nGive low dose aspirin (acetylsalicylic acid) to\\npatients at risk if tolerated\\n\\nLoss of consciousness and postural tone as a result\\nof diminished cerebral blood flow\\nMay be due to:\\n\\nVaso-vagal attack\\nCardiac causes\\nProlonged standing\\nSevere emotional disturbance\\n\\nThe more severe form is associated with various\\nheart diseases:\\n\\nArrhythmias (especially complete heart block)\\nHypertrophic cardiomyopathy\\n\\'Heart attack\\' (mycardial infarction )\\nAtrial myxoma\\nAortic stenosis\\nDissecting aneurysm\\n\\nOther causes:\\nPulmonary embolism\\nVertebro-basilar insufficiency\\nSubclavian steal syndrome\\nCarotid sinus pressure\\nMigraine headache\\n\\nSudden loss of consciousness\\nCold extremities\\nBluish discolouration of extremities ( cyanosis)\\nPulse irregularities (or pulselessness)\\nHypotension (or unrecordable blood pressure)\\nFainting induced by pressure on the neck\\nFainting induced by coughing, micturition\\n\\nEpilepsy\\nMyocardial infarction\\nStroke\\nAortic dissection\\nHysteria\\n\\nCerebral hypoxia/anoxia resulting in brain damage\\nStroke\\n\\nPrevention\\n\\nSYNCOPE\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nSudden death\\n\\nBrain abscess\\nMeningitis/encephalitis\\nCerebral malaria\\nMigraine headache\\nMultiple sclerosis\\nMetabolic derangements e.g. hypoglycaemia,\\n\\nhyperosmolar non-ketotic coma\\n\\nTentorial herniation with coning and death\\nCardiac arrhythmias\\nDepression\\nEpilepsy\\nDementia\\nParkinsonism\\nHyperglycaemia\\n\\nNeuro-imaging with CT scan/MRI to determine\\nstroke type and choice of management\\n\\nLumbar puncture for CSF analysis in suspected\\nsubarachnoid haemorrhage\\n\\nElectrocardiography\\nEchocardiography\\nCarotid Doppler ultrasound study\\nCerebral angiography\\nFull Blood Count with differentials\\nRandom blood glucose\\nUrea, Electrolytes and Creatinine\\nChest radiograph\\nHIV screening\\n\\nRestore cerebral circulation\\nLimit disability\\nTreat identified risk/predisposing factors\\nReduce raised intracranial pressure\\nTreat complications (if any)\\n\\nCerebral decompression if there is evidence of\\nraised intracranial pressure\\n- Furosemide 40 mg every 8 hours by slow\\nintravenous injection for 6 doses\\nAnd/Or:\\n- 20% mannitol 250 mL repeated every12 hours for\\n4 - 6 doses\\n\\nTreat underlying conditions such as diabetes\\nmellitus, hypertension, and thrombosis\\n\\nRebound cerebral oedema when mannitol is\\ndiscontinued\\n\\nThrombolytic agents: bleeding tendencies\\nDiazepam by the intravenous route must be\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution\\n\\nNon-drug treatment\\nAttention to calories, fluid balance\\nPhysiotherapy for passive muscle exercises\\nNursing care (frequent turning and bladder care) to\\n\\nprevent decubitus ulcers and urinary tract infection\\nRehabilitation\\n\\nInvestigations\\n\\nManagement\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nTHE UNCONSCIOUS PATIENT\\nIntroduction\\n\\nClinical features\\n\\nElectrocardiography\\nEchocardiography\\nNeuro-imaging: CT scan, MRI, carotid Doppler\\nRandom blood sugar\\n\\nDepends on the cause(s)\\n\\nRestore circulation and ensure brain perfusion\\nIdentify cause and treat accordingly\\nPrevent recurrence\\n\\nPhysiotherapy: pressure stockings\\n\\nSpecific treatment for cardiac arrhythmias: refer to\\ncardiologist\\n\\nIf hypotensive, give pressor agents\\n\\nAspirin and other NSAIDs: use with caution in\\npatients with history of dyspepsia, and in asthmatics\\n\\nAvoid prolonged standing\\nTreat underlying cardiac disease\\nAvoid dehydration or excessive fluid loss\\nGive aspirin tablets as anti-platelet agent\\n\\nAn unresponsive patient who may also have\\nbreathing and circulatory problems\\n\\nMay be neurological or may result from other\\nsystemic diseases\\nAn easy way of finding the cause is to think in terms\\n\\nof the vowels\\n: poplexy (stroke)\\n: pilepsy\\n\\n: nfections e.g. meningo-encephalitis\\n: verdosing with drugs, alcohol intoxication,\\n\\ntoxins\\n: raemia and other metabolic disorders\\n\\nOther causes include:\\nHead injury\\nBrain tumours (with complications)\\n\\nVarying levels of impaired consciousness:\\nComatose: no response to stimulus, however painful\\nSemi-comatose: some response to pain\\nStuporose: a state deeper than sleep; vigorous\\nstimulation required to stimulate response\\nOther features:\\nCessation of respiration or abnormal ventilatory\\npatterns: Cheyne-Stokes, ataxic, apneustic, gasping\\netc\\nUnresponsiveness or variable response to painful\\nstimuli\\n\\nA A\\nE E\\nI I\\nO O\\n\\nU U\\n\\n41 42\\n\\nChapter 4: Central Nervous System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nFeatures of the underlying cause(s)\\n- Stroke: may present with hemiparesis, facial\\nasymmetry, crossed-eye defects, speech defects etc\\n- Epilepsy: frothing or tongue biting; abrasions of\\nthe extremities; positive past history\\n- Infections: may present with fever, neck stiffness\\n- Drug overdosage/toxins: pin-point pupils;\\nrespiratory problems; suggestive history\\n- Uraemia: characteristic fetor; skin rashes; oedema;\\nsevere dehydration\\n- Head trauma: haematomas; subconjuctival\\nhaemorrhages\\n- Bleeding from orifices (if coma is due to trauma\\nor bleeding diathesis)\\nFeatures of raised intracranial pressure:\\n\\nSlow pulse (Cushing\\'s reflex)\\nRising blood pressure\\nPapilloedema\\n\\nStroke\\nPost-epilepsy state\\nSyncope\\nMycardial infarction\\nHysteria\\nSubstance abuse\\n\\nCerebral hypoxia/anoxia resulting in brain damage\\n\\nNeuro-imaging: CT scan, MRI\\nRandom blood glucose\\nUrea, Electrolytes and Creatinine\\nElectroencephalography\\nCerebrospinal fluid analysis\\nDrug levels/toxicology screen\\nFull Blood Count\\nBlood culture\\n\\nClear airway and restore breathing\\nMaintain circulation\\nEliminate the cause\\nPrevent complications: decubitus ulcers,\\n\\natelectasis, contractures etc\\nCorrect metabolic derangements\\n\\nPhysiotherapy to prevent contractures/deep vein\\nthrombosis, and for passive muscle exercises\\nNursing care (frequent turning and bladder care) to\\nprevent decubitus ulcers and infections\\n\\nInfections: appropriate antibacterial agent\\nEpilepsy: use effective parenteral anticonvulsant\\n\\ndrugs; diazepam (see Epilepsy)\\nRenal failure: dialysis\\nAppropriate treatment of other metabolic causes\\n\\nSubcutaneous Low Molecular Weight heparin to\\n\\nDifferential diagnoses\\n\\nComplication\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nPrevention\\n\\nANXIETYDISORDER\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nPsychosocial interventions\\nCognitive behavioural therapy\\nMarital and family therapy\\nGroup therapy\\n\\nOnly occasionally required, and following careful\\nassessment\\n\\n- Detoxification is required for severe withdrawal\\nsyndrome or delirium tremens\\n- This will involve the administration of a long-\\nacting benzodiazepine and thiamine supplements\\nover 7 - 10 days\\n\\nRehabilitation to\\n- Sustain abstinence\\n- Acquire an alcohol-free life style\\n- Prevent relapse\\n\\nHealth education (including school health\\neducation, peer group education and self help group\\ne.g .alcoholic anonymous)\\nGovernment regulation of alcohol use\\n\\nGeneralized anxiety disorder (GAD) is\\ncharacterized by exaggerated worry and tension,\\neven when there is little or no cause for anxiety\\nA chronic disorder affecting about 2 - 3% of the\\npopulation\\n\\nPre-occupations: often of diverse nature\\nPoor concentration\\nMuscle aches and headaches\\nIrritability\\nSweating\\nFatigue\\nInsomnia\\nShortness of breath\\n\\nMedical causes of suggestive symptoms and signs\\n(e.g. hyperthyroidsm)\\n\\nChronicity\\nCo-morbid depression\\nMedical morbidity (e.g. hypertension)\\n\\nTo exclude medical/physical cause(s)\\n\\nAchieve remission of symptoms\\nPrevent relapse\\n\\nCognitive-behavioural therapy\\n\\nNote\\n\\nprevent deep vein thrombosis (see Pulmonary\\nEmbolism)\\n\\nDiazepam, if required, should be administered\\nslowly intravenously to avoid respiratory depression\\n\\nAccessible, efficient and effective health care\\nservice delivery\\nEarly reporting/detection of ill-health\\nAdherence to medications and non-drug measures in\\nmanaging disease states\\nPublic Health Education\\nPromote awareness on avoidance of risk factors\\n\\nA disorder characterized by a wide spectrum of\\nproblems\\n\\nCentral feature is the use of alcohol which takes an\\nincreasingly dominant place in the user\\'s life in spite\\nof experience of harm related to drinking\\n\\nSocial and genetic factors are thought to be\\nimportant in pathogenesis\\n\\nA life time prevalence of about 0.2 - 0.5% in\\nNigerian adult males\\n\\nTolerance\\nWithdrawal episodes\\nCompulsive desire to use alcohol\\nAssociated physical, social, or occupational\\nimpairments\\n\\nDependence on (and withdrawal from) other\\nsubstances\\n\\nLiver cirrhosis\\nDamage to other organs (including the brain)\\nAccidents\\nDelirium tremens\\nIncreased mortality (reduce life expectancy)\\nFamily, social and occupational disability\\n\\nFull Blood Count and differentials\\nLiver function tests\\nOther invest igat ions as indicated for\\n\\nmedical/physical complications\\n\\nReduction in alcohol consumption as an interim\\nmeasure\\nAbstinence as the desired goal\\nRehabilitation\\nPrevention of relapse\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nALCOHOLISM (Alcohol dependence)\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nPSYCHIATRIC DISORDERS\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reaction, caution\\n\\nPrevention\\n\\nBIPOLAR DISORDERS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nDiazepam 10 - 20 mg orally daily\\nOr:\\n\\nImipramine 50 - 150 mg orally daily\\nOr:\\n\\nFluoxetine 20 - 60 mg orally daily\\n\\nRelaxation techniques\\nExercise\\nPsychotherapy\\n\\nThe risk of dependence (and withdrawal syndromes)\\nlimits the utility of benzodiazepines for treatments of\\nlong duration\\n\\nAvoid of undue and extreme stress\\nAvoid psycho-active substances\\n\\nAtype of mood disorder in which there is (typically)\\nalternation of a depressive phase and a manic or\\nhypomanic phase\\n\\nExperienced by about 1% of the adult population at\\nsome point in their lifetime\\n\\nAbout equal incidence between males and females\\nMay be precipitated by psychosocial stress; strong\\n\\ngenetic vulnerability often present\\n\\nDepressive phase:\\n- Low mood\\n- Impaired appetite and sleep\\n- Ideas of worthlessness or hopelessness\\n- Suicidal ideation\\n- Other depressive symptoms and signs\\n\\nManic or hypomanic phase:\\n- Elation\\n- Euphoria\\n- Irritability\\n- Expansive mood\\n- Disturbed sleep\\n- Grandiosity\\n- Disinhibition\\n\\nSchizo-affective disorder\\nSchizophrenia\\nOrganic mood/affective disorder (including effects\\n\\nof drug abuse)\\n\\nSocial and personal consequences of inappropriate\\nbehaviour (e.g. unplanned pregnancy, sexually-\\ntransmitted infections, etc)\\n\\nSuicide\\nIncreased risk of morbidity (reduce life expectancy)\\n(e.g. trauma and accidents)\\n\\n43 44\\n\\nChapter 4: Central Nervous System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nIncreased mortality\\n\\nInvestigations as indicated to rule out\\norganic/medical causes\\n\\nFull Blood Count and renal function tests (to\\ndetermine suitability of mood stabilizers)\\n\\nReduce risk to self and others\\nNormalize mood\\nReturn to full functional status\\nPrevent recurrence\\n\\nCognitive-behavioural therapy as sole treatment in\\nmild cases, and adjunct in all others\\n\\nElectroconvulsive therapy (ECT)\\n- An effective and essentially safe treatment for\\nsevere and acute presentations\\n- Acourse of 8 - 12 treatments are usually needed\\n\\nTreat underlying causes\\nLithium\\n\\n- 1 line drug following established diagnosis\\ninitially 1 - 1.5 g daily\\n\\nProphylaxis: initially 300 - 400 mg daily\\nnot recommended\\n\\n- Measure serum lithium concentration regularly (every\\nthree months on established regimens)\\n- Adjust dosage to achieve serum levels of 0.6 - 1.2\\nmEq/L\\n\\nSodium valproate\\n750 mg - 2 g mg orally/day\\nneonate, initially 20 mg/kg orally once daily;\\n\\nusual maintenance dose 10 mg/kg every 12 hours daily\\n1 month - 12 years: initially 5 - 7.5 mg/kg every 12 hours,\\nusual maintenance dose 12.5 -15 mg/kg every 12 hours\\n(up to 30 mg/kg twice daily)\\n12 - 18 years: initially 300 mg every 12 hours, increased\\nin steps of 200 mg daily at 3-day intervals; usual\\nmaintenance dose 0.5 - 1 g twice daily (maximum 1.5 g\\ndaily)\\n\\nCarbamazepine\\n600 - 1,800 mg orally daily\\n1 month - 12 years: initially 5 mg/kg orally at\\n\\nnight or 2.5 mg/kg twice daily, increased as necessary by\\n2.5 - 5 mg/kg every 3 - 7 days\\n- Maintenance dose 5 mg/kg 2 - 3 times daily, increased\\nslowly to usual maintenance of 400 - 600mg 2 - 3 times\\ndaily\\n\\nAntidepressants\\n- TCAs or SSRIs may be indicated in depressive\\nphase\\n\\nAntipsychotics\\n- Haloperidol 1.5 to 3 mg orally 2 - 3 times daily\\n(may be indicated in acute manic phase)\\n\\ninitially 12.5 - 25 micrograms/kg\\norally twice daily, adjusted according to response to\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nst\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild:\\n\\nChild 2 - 12 years:\\n\\nUsually transient but may be associated with\\nincreased morbidity (e.g. from falls) and mortality\\n\\nDetermined by any causal or contributing medical\\nconditions\\n\\nIdentify and ameliorate any causal or contributing\\nmedical conditions\\n\\nImprove cognition\\nNormalize behaviour\\n\\nNurse in a quiet, well-lit environment\\nSupport physical care, including food and fluid\\n\\nintake\\nProvide orienting cues\\nPhysical restraint judiciously used when indicated\\n\\nHigh-potency antipsychotics in low dosages for\\nsedation\\n- Haloperidol\\n\\n0.5 - 1 mg orally or parenterally\\n\\ninitially 12.5 - 25 micrograms/kg\\norally twice daily, adjusted according to response to\\nmaximum 10 mg daily; 12 - 18 years: initially 0.5 - 3 mg\\ndaily, adjusted according to response to lowest effective\\nmaintenance dose (as low as 5 -10 mg daily)\\n\\nBenzodiazepines\\n- For severe agitation (i.e. life-threatening features)\\nor patient seriously disrupting management\\n\\nGive reassurance to patient and relatives/caregivers\\n- The transient nature of condition\\n- No risk of “madness”\\n\\nClose nursing care is required to prevent injuries\\nand falls\\nAv o i d o v e r- m e d i c a t i o n , e s p e c i a l l y a s\\nantipsychotics and sedatives used may worsen\\ndelirium\\n\\nEarly treatment of infective and metabolic\\nconditions\\nCare with the use of drugs (especially\\nanticholinergic medications) in the elderly\\n\\nA disorder of mood and affect in which the\\npredominant emotion is sadness/unhappiness\\nCan occur alone (unipolar depression) or as part of\\nan alternation disorder in which elevation of mood\\nalso occurs (bipolar disorder)\\nVaries in severity from mild to severe\\nLife events, especially those involving loss, are\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nCaution\\n\\nPrevention\\n\\nDEPRESSION\\nIntroduction\\n\\nAdult: every 6 - 8\\nhours\\nChild 2 - 12 years:\\n\\nmaximum 10 mg daily\\n12 - 18 years: initially 0.5 - 3 mg daily, adjusted\\naccording to response to lowest effective maintenance\\ndose (as low as 5 -10 mg daily)\\n\\nPsychotherapy and social intervention for patient\\nand relatives/caregivers\\n\\n- More likely with doses above recommended upper\\nlimits\\n\\nLithium\\n- Gastrointestinal disturbances\\n- Tremors\\n- Confusion\\n- Myoclonic twitches\\n\\nCarbamazepine: hypersensitivity reactions\\nTransient memory impairment is common\\n\\nfollowing ECT\\n\\nNo primary preventive measures are clearly\\ndelineated\\n\\nAdherence to therapy with mood stabilizers until\\ndiscontinuation is considered prudent (this is\\nindividually determined)\\n\\nAtransient disorder of brain function\\nManifests as a global cognitive impairment and\\n\\nbehavioural disturbance\\nMore common at the extremes of life though it can\\n\\noccur at any age\\nIncidence up to 15% has been reported among\\n\\ngeneral medical inpatients; up to 40% among\\nacutely ill geriatric patients\\n\\nPoor detection and mis-diagnosis are common\\nThe most common causes are:\\n\\nTrauma\\nInfections\\nMetabolic derangements\\nSide effects of drugs\\n\\nDisturbance of consciousness\\nDisorientation\\nMemory deficits\\nLanguage disturbances\\nPerceptual disturbances\\nRapid fluctuations\\nDisruption of sleep-wake cycle\\nPsychomotor hyperactivity\\nMood alterations\\n\\nDementia\\nAcute (idiopathic) psychotic disorders\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nDELIRIUM\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\noften (but not always) the triggers\\nStrong genetic is vulnerability sometimes present\\nOccurs in about 2 - 5% of the population at any given\\ntime and in about 10 - 25% in their lifetime\\n\\nWomen are generally at an elevated risk\\n\\nSadness, unhappiness, feeling low\\nLoss of interest in usual activities\\nReduced energy\\nDisturbance of sleep and appetite\\nImpaired concentration\\nIdeas of worthlessness, guilt, or failure\\nMorbid or suicidal rumination or ideation\\nSomatic complaints of various types\\n\\nNormal grief reaction\\nMedical conditions causing lowering of mental and\\n\\nphysical activities (e.g. anaemia, hypothyroidism)\\nInfections (e.g. viral)\\n\\nWorsening of co-morbid physical illness\\nSuicide\\nRecurrence (in 50% or more)\\n\\nFull Blood Count and differentials\\nThyroid function test\\nIndicative infection screen\\n\\nNormalize mood\\nPrevent suicide attempts\\nReturn to active life\\nPrevent recurrence\\n\\nCognitive-behavioural treatment\\nInter-personal psychotherapy\\n\\nTricyclic antidepressants (TCAs)\\n- Amitriptyline in increasing doses up to 150 mg\\norally/day\\n- Fluoxetine 20 - 80 mg orally/day\\n\\nSupportive psychotherapy for patients and\\nfamily/caregivers\\n\\nTricyclic antidepressants:\\n- Dryness of the mouth\\n- Urinary retention\\n- Constipation\\n- Blurring of vision\\n\\nSelective Serotonin Reuptake Inhibitors (SSRIs)\\n- Sleep disturbance\\n- Sexual dysfunction\\n- Serotonin syndrome\\n\\nCardiac toxicity, especially in overdose with TCAs\\nand SSRIs\\nIncreased suicidal ideation in adolescents\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution\\n\\n45 46\\n\\nChapter 4: Central Nervous System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\n- Should be used with caution in patients with\\nepilepsy, history of mania, cardiac disease, diabetes\\nmellitus, and bleeding disorders\\n- Caution is also required in patients receiving\\nconcurrent electroconvulsive therapy (reports of\\nprolonged seizures with fluoxetine)\\n\\nRecurrence is reduced by continuing medication for\\nat least 6 months after acute symptoms resolve\\n\\nDifficulty in falling asleep or staying asleep\\nMay be primary and unrelated to any physical or\\n\\nmental disorder\\nMay relate to a mental disorder, medical or physical\\nconditions\\nMay be an adverse effect of medication (or\\npsychoactive substances)\\nAcommon, often chronic problem; tends to increase\\nwith age\\n\\nEarly insomnia: difficulty in initiating sleep\\nMiddle insomnia: difficulty in going back to sleep\\n\\nafter waking up at night\\nTerminal insomnia: early awakening, commonly 2\\n\\nhours or more before desiring to do so\\n\\nUseful to consider possible aetiological factors:\\nmedical, mental, situational, environmental\\n\\nPain is a common factor\\n\\nDeteriorating physical and/or mental health\\nDecline in overall well-being and quality of life\\n\\nMainly of the presumed underlying cause(s)\\n\\nTo improve sleep, especially sleep satisfaction\\nTo remove underlying/associated factors\\n\\nSleep hygiene\\nehavioural modifications to enhance relaxation\\n\\nAvoid habits and lifestyles that promote insomnia\\nImprove environmental/sleeping conditions\\n\\nTreat underlying cause(s)\\nAvoid sedatives: use for only short periods when\\n\\nindicated\\nShort-acting benzodiazepines e.g.\\n\\n- Nitrazepam 5 -10 mg at night for short term use\\n- For the elderly, 2.5 - 5 mg\\n- For early insomnia\\nOr:\\n\\nLonger-acting benzodiazepines e.g.\\n- Diazepam at low doses: 2.5 - 10 mg for no more\\n\\nPrevention\\n\\nINSOMNIA\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nB\\n\\nGeneral principles\\n\\ndaily (maximum 80 mg)\\nElderly: 20 - 40 mg (maximum 60 mg for elderly)\\nonce daily\\n- Discontinue if no improvement within 10 weeks\\n\\n: not recommended\\nOr:\\n\\nAmitryptiline 50 - 150 mg orally/day\\n\\nPsychotherapy\\nRelaxation techniques\\n\\nTricyclic antidepressants are cardiotoxic in\\noverdose\\n\\nIncreased risk of suicidal attempts by patients with\\npanic disorder\\n\\nNo specific primary prevention measures\\n\\nA serious psychotic disorder characterized by\\nmultiple impairments in emotional, behavioural,\\ncognitive, social, and occupational domains (among\\nothers)\\n\\nAffects about 1% of the population\\nOnset usually in late adolescence or early adulthood\\nStrong genetic component to its etiology;\\n\\nenvironmental factors, including pre-natal and\\nobstetric factors, also implicated\\n\\nDisorders of:\\nThought\\nPerception\\nSpeech\\nCognition\\nBehaviour\\nMotor function\\n\\nPsychosis of other origin (including those due to\\norganic factors)\\n\\nAffective psychosis\\nEpilepsy, especially of temporal lobe origin\\nDrug effect, e.g. amphetamine intoxication\\n\\nChronicity\\nSuicide\\nIncreased physical morbidity\\nIncreased mortality\\n\\nTo exclude organic causes of acute psychotic\\npresentations\\n\\nRelieve acute symptoms\\nReturn to full functional status\\nRehabilitate\\nPrevent relapse\\n\\nChild and adolescent under 18 years\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nSCHIZOPHRENIA\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nthan 2 - 3 weeks\\n- For middle insomnia\\n\\nRelaxation therapy: a useful adjunct for the most\\ncommon forms of insomnia\\n\\nBenzodiazepines: dependence and rebound\\ninsomnia\\n\\nReduced stress exposure\\nCaution with alcohol and psychoactive substances,\\n\\nsuch as coffee, kolanut.\\nDiscourage of misuse of “sleeping pills” e.g.\\n\\nBromazepam, diazepam\\n\\nA disorder characterized by episodic attacks of\\nextreme fear, mostly unrelated to specific objects or\\nsituations\\nAssociated with multiple somatic and cognitive\\nsymptoms\\n\\nEach attack lasts for about 5 - 30 minutes\\nOften begins abruptly\\nAffects about 0.5 - 1.0% of the population\\n\\nAfeeling of choking\\nPounding heart\\nChest pressure or pain\\nDizziness\\nShortness of breadth\\nTrembling\\nSweating\\nTingling or numbness in the hands or feet\\nHot flushes\\n\\nOther causes of intense fear (phobias, obsessive-\\ncompulsive disorders, etc)\\n\\nMedical causes (e.g. hyperthyroid states, episodic\\nhypoglycemia, etc)\\n\\nSeizure disorders\\n\\nPhobia\\nDepression\\nSuicide\\n\\nAs indicated to exclude medical aetiologies\\n\\nTo reduce intensity and frequency of attacks\\nTo reduce anticipatory anxiety\\n\\nCognitive-behavioural treatment\\n\\nFluoxetine\\ninitially 20 mg orally once daily, increased\\n\\nafter two weeks (if necessary) to 20 - 60 mg once\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nPANIC DISORDER\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nAdult:\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nPsycho-social interventions as indicated (including\\nsocial and occupational therapy)\\n\\nPsycho-education for patient and relatives /\\ncaregivers\\n\\nSupportive psychotherapy\\nECT (especially for catatonic forms)\\n\\nChlorpromazine\\ninitially 25 mg orally every 8 hours (or 75 mg at\\n\\nnight), adjusted according to response to usual\\nmaintenance dose of 75 - 300 mg daily\\n- Elderly: a third to half adult doses\\nBy deep intramuscular injection: 25 - 50 mg every 6 - 8\\nhours\\n\\n1 - 5 years: 500 micrograms/kg orally every 6 - 8\\nhourly (maximum 40 mg daily); 6 - 12 years: a third to\\nhalf adult dose (maximum 75 mg daily)\\n\\nHaloperidol\\ninitially 1.5 - 3 mg every 8 - 12 hours daily or 3 -\\n\\n5mg every 8 - 12 hours in severely affected or resistant\\npatients\\n- In resistant schizophrenia, up to 30 mg daily may be\\nneeded, adjusted according to response to the lowest\\neffective maintenance dose (as low as 5 - 10 mg daily)\\nElderly, initially half adult dose\\n\\ninitially 25 - 50 mg micrograms/kg daily in 2\\ndivided doses (maximum 10 mg)\\n\\nFluphenazine\\ninitially 2 - 10 mg every 8 - 12 hours, adjusted\\n\\naccording to response to 20 mg daily\\n- Doses above 20 mg daily (10 mg in elderly) only with\\nspecial precaution\\nOr:\\n25 - 100 mg intramuscularly fortnightly to monthly\\n\\nnot recommended\\n\\nSupportive psychotherapy\\nSocial and occupational therapy\\nCognitive therapy (as adjunct in the treatment of\\n\\npersisting psychotic experience)\\nRehabilitation\\n\\nExtrapyramidal and Parkinsonian symptoms (may\\nrequire anticholinergic medication)\\n\\nTardive dyskinesia\\nWeight gain\\nAgranulocytosis (monitor blood counts in patients\\n\\non clozapine)\\n\\nNo clear/specific scope for primary prevention at\\npresent\\n\\nSecondary and tertiary:\\n- Early and effective treatment\\n- Rehabilitation to reduce disability\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\n47 48\\n\\nChapter 4: Central Nervous System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nCHAPTER 5: DENTAL AND ORAL DISORDERS\\n\\nA C U T E N E C R O T I Z I N G U L C E R AT I V E\\nGINGIVITIS\\n\\nDefinition\\n\\nAetiology\\n\\nEpidemiology\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive therapy\\n\\n:\\n\\nApolymicrobial, endogenous infection\\n\\nFusiform and spirochaete bacteria\\n\\nIn developing countries, seen almost exclusively in\\nchildren\\n\\nRelated to poverty and malnutrition\\nIn industrialized countries, most common in young\\n\\nadults with neglected mouths; smoking and stress have\\nbeen associated\\n\\nCrater ulcers striating at the tips of the interdental\\npapillae\\n\\nUlcers spread along gingival margins\\nGingival soreness and bleeding\\nFoul breath\\nMetallic taste\\nIncreased salivation\\nCervical lymphadenopathy and fever in advanced\\n\\ncases\\n\\nPrimary herpetic gingivo-stomatitis\\nHIV-associated acute ulcerative gingivitis\\nGingival ulceration in acute leukaemia or aplastic\\n\\nanaemia\\n\\nSmears from ulcers show predominantly spirochaetes\\nand gram negative fusiform bacteria\\n\\nTreat infection\\nRestore oral health\\n\\nOral hygiene (debridement) is essential\\n\\nMetronidazole\\n200 mg orally 8 hourly for 3 days\\n1 - 3 years: 50 mg orally 8 hour for 3 days;\\n\\n3 - 7 years: 100 mg 12 hour ; 7 - 10 years: half adult\\ndose\\n\\nAscorbic acid\\nnot less than 250 mg orally daily (in divided\\n\\ndoses)\\n1 month - 4 years: 125 - 250 mg in 1 - 2 divided\\n\\ndoses\\n4 - 12 years: 250 - 500 mg daily in 1 - 2 divided doses; 12\\n- 18 years 500 mg - 1 g daily in 1 - 2 divided doses\\n\\nFerrous sulfate\\n200 mg orally three times daily taken before food\\n\\n6 - 12 years: half adult dose\\n\\nAdult:\\nChild: every s\\n\\nevery s\\n\\nAdult\\n\\nChild:\\n\\nAdult:\\nChild\\n\\nALVEOLAR OSTEITIS\\nIntroduction\\n\\nPredisposing factors\\n\\nClinical features\\n\\nDifferential diagnosis\\n\\nComplication\\n\\nTreatment objective\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nPrevention\\n\\nCELLULITIS\\nDefinition\\n\\nPathogenesis\\n\\nThe most frequent painful complication of extractions\\nCaused by destruction of the clot that normally fills the\\n\\nsocket\\n\\nExcessive extraction trauma\\nLimited local blood supply\\nLocal anesthesia\\nOral contraceptives\\nOsteosclerotic disease\\nRadiotherapy\\n\\nMore common in women\\nPain delayed for few days up to a week after extraction\\nDeep seated, throbbing pain\\nMucosa around socket is red and tender\\nNo clot in socket - bare whitish lamina dura exposed\\n\\nOsteomyelitis\\n\\nOsteomyelitis\\n\\nKeep open socket clean and protect exposed bone\\n\\nIrrigate with mild warm saline and antiseptic\\nFill with an obtudant dressing containing some non-\\n\\nirritant antiseptic\\nWarm saline mouth rinse\\n\\nLocal anaesthesia\\n- Lidocaine 2% (1in 80,000)\\n\\nCo-amoxiclav\\n- Severe dental infection with spreading cellulitis\\n- 250/125 mg orally every 8 hours for 5 days (dose\\ndoubled in severe infections)\\n\\nChlorhexidene gluconate 2%\\n- 10 mLfor mouth washes three times daily\\n\\nMinimal trauma during extractions\\nImmediately after extraction, squeeze socket edges\\n\\nfirmly together and hold for a few minutes till clot has\\nformed\\n\\nAntibiotics if patients have had irradiation, or have\\nPaget\\'s disease\\n\\nA rapidly spreading, poorly localized inflammation of\\nthe soft tissues particularly associated with streptococcal\\ninfection\\n\\nRapid spread is most likely related to release of large\\namounts of streptokinase and hyalurondinase which are\\nproduced by most strains of streptococci\\n\\nFollow-up treatment\\n\\nNotable adverse drug reactions, caution\\n\\nACUTE PERIAPICALABSCESS\\nDefinition\\n\\nAetiology\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nRehabilitation of the mouth\\nOnce the acute phase has subsided, oral hygiene should\\n\\nbe brought to as high a standard as possible to lessen the\\nrisk of recurrence\\n\\nSequestrectomy\\n\\nMetronidazole: nausea, vomiting, unpleasant taste;\\ndisulfiram-like effect with alcohol.\\n\\nAlocalized collection of pus in the periapical region of a\\ntooth\\n\\nMay develop either directly from acute periapical\\nperiodontitis or more usually from a chronic periapical\\ngranuloma\\n\\nGenerally the result of a mixed bacterial infection\\nCulture of the pus yields a wide range of different\\n\\norganisms\\n- Strict anaerobes (e.g. , )\\nusually predominante, but facultative anaerobes may be\\nfound\\n\\nPainful swelling at the root of tooth\\nSinus (may be present)\\nTooth is tender to biting or percussion\\nTooth mobility\\n\\nInflammatory radicular cyst\\nOsteomyelitis\\nPeriodontal abscess\\n\\nRadiographs (periapical)\\n\\nRemove source of infection e.g. fish-bone, other foreign\\nobjects\\n\\nDrain abscess using local anaesthesia\\nTreat residual infection\\n\\nExtraction (or endodontic treatment) i.e. root canal\\ntherapy\\n\\nAmoxicillin\\n250 mg orally every 8 hours for 5 to 7 days\\nup to 10 years 125 mg every 8 hours, doubled in\\n\\nsevere infections\\nMetronidazole\\n\\n200 mg orally every 8 hours for 3 days\\n1 - 3 years: 50 mg orally 8 hourly for 3 days; 3 - 7\\n\\nyears: 100 mg every 12 hours; 7 - 10 years: half adult dose\\n\\nprevotella porphyromonas\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild:\\n\\nThe fascial space infections may involve sublingual,\\nsubmandibular and/or parapharyngeal spaces\\n\\nLudwig\\'s angina is bilateral cellulitis of the sublingual\\nand submandibular spaces\\n\\nDiffuse, tense, painful swelling of the involved soft\\ntissues\\n\\nMalaise\\nElevated temperature\\nLudwig\\'s angina causes airway obstruction which can\\n\\nquickly result in asphyxia\\nSuppuration and abscess formation may occur later if\\n\\ntreatment is neglected or delayed\\n\\nExtension towards the eyes, and risk of cavernous sinus\\nthrombosis: cellulitis affecting maxillary teeth\\n\\nRespiratory difficulty: cellulitis affecting mandibular\\nteeth\\n\\nCulture (blood and swab) and sensitivity testing\\n\\nDrainage of the swelling to reduce pressure (oral drain\\nmay also be placed)\\n\\nSecure the airway by tracheostomy if necessary\\n\\nAggressive antibiotic treatment\\n- Intravenous co-amoxiclav (given over 3 to 4 minutes)\\nin combination with intramuscular gentamicin for 5 days\\nInjection co-amoxiclavulanate\\n\\n: 1,000/200 mg intravenoulsly every 8 hours\\n: neonate and premature infants, 25 mg/kg every 12\\n\\nhours; infants up to 3 months, 25 mg/kg every 8 hours, 3\\nmonths to 12 years, 25 mg/kg every 8 hours increased to\\n25 mg/kg every 6 hours in more severe infections\\nInjection gentamicin:\\n\\n: 3 - 5 mg/kg daily in divided doses every 8 hours\\n: up to 2 weeks: 3 mg/kg every 12 hours; 2 weeks -\\n\\n12 years: 2 mg/kg every 8 hours\\n\\nGentamicin may cause significant ototoxic and\\nnephrotoxic effects\\n\\nEarly treatment of carious teeth\\n\\nA progressive bacterial damage to teeth exposed to the\\nsaliva\\n\\nEnamel caries\\nDentine caries\\nRoot surface caries\\n\\nDevelops over time in the presence of certain interacting\\nvariables\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nPrecaution\\n\\nPrevention\\n\\nDENTALCARIES\\nDefinition\\n\\nClassification\\n\\nAetiology\\n\\nAdult\\nChild\\n\\nAdult\\nChild\\n\\n49 50\\n\\nChapter 5: Dental and Oral Disorders Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\n- Carbohydrate diet\\n- Viridans streptococci bacteria\\n- Susceptible tooth surface\\n\\nEnamel caries progress in the following stages:\\n- Early (sub-microscopic) lesion\\n- Phase of non-bacterial enamel crystal destruction\\n- Cavity formation\\n- Bacterial invasion of enamel\\n\\nCavity formation in affected tooth\\n- Starts as a white spot\\n\\nPain\\n- On exposure of the cavity to thermal changes or food\\nparticles\\n\\nPulpitis\\n- If not treated can cause apical periodontitis and\\ndentoalveolar abscess\\n\\nPeriapical radiographs\\nBitewing radiographs\\nElectric pulp testers\\nThermal test\\n\\nDepending on the stage of the lesion:\\nAmalgam filling, Glass Ionomer Cement (GIC)\\n\\ncomposite andAtraumatic Restorative Technique (ART)\\nfor enamel caries\\n\\nAmalgam filling, GIC for dentine caries\\nRoot Canal Therapy, pulp capping pulpotomy,\\n\\npulpectomy for pulpal involvement\\n\\nAnalgesics pre-operatively\\n- Paracetamol 1 g 4 - 6 hourly orally to a maximum of 4\\ng daily\\n\\nOral health education\\nRegular scaling and polishing\\nSystemic and topical fluoride application\\nFissure sealants\\nRoutine dental check-ups\\n\\nAn inflammatory response of the gingivae to plaque\\nbacteria\\n\\nThe most common type is chronic gingivitis\\n\\nChronic gingivitis is asymptomatic, low grade\\ninflammation of the gingivae\\n\\nGums become red and slightly swollen\\n\\nOral hygiene instructions\\n\\nPathogenesis\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nPrevention\\n\\nGINGIVITIS\\nIntroduction\\n\\nClinical features\\n\\nNon-drug treatment\\n\\nMay be asymptomatic, or painful, with difficulty in\\nswallowing\\n\\nDenture wearing\\nReduced salivation (e.g. drug induced)\\nAntibiotic therapy (especially broad spectrum)\\nPoorly controlled diabetes mellitus\\nSteroid therapy (chronic)\\nSalivary gland damage (e.g. post radiation)\\nMalnutrition\\nHIV infection\\nLeukaemia\\nIron, vitamin B , folic acid deficiency\\n\\nAgranulocytosis\\n\\nSmear of the affected region and Gram staining or PAS\\nwith or without potassium hydroxide to demonstrate\\nhyphae\\n\\nSwab sample for microscopy, culture and sensitivity\\nBiopsy and histopathologic examination\\nIden t i fy p red i spos ing fac to r s ( inc lud ing\\n\\nimmunosuppresion)\\n\\nManage any underlying predisposing factors\\nReplace worn dentures\\nProper counselling of patients as to use of dentures\\nDiet modification and improvement\\nChlorhexidine mouthwash three times daily for 1 - 2\\n\\nweeks\\n\\nTopical anti-fungal medication e.g\\n- Nystatin suspension\\n\\n100,000 units/mL 4 times daily , after food\\n(usually for 7 days)\\n- Continue for 48 hours after lesions have resolved\\n\\n1 month - 18 years, prophylaxis and treatment:\\n100,000 units 6 hourly after food for 7 days\\n- Continue for 48 hours after lesions have healed\\nImmunocompromised children:\\n- 500,000 units 6 hourly for 7 days\\nOr:\\n- Miconazole oral gel 2%\\n\\nplace 5 - 10 mL in the mouth after food and retain\\nnear lesions 4 times daily\\n\\nunder 2 years: 2.5 mL twice daily; 2 - 6 years: 5 mL\\ntwice daily; 6 - 12 years: 5 mL4 times daily; 12 - 18 years:\\n5 - 10 mL4 times daily\\n- Leave in the mouth after food and retain near lesions\\n\\nSome patients may require systemic antimicrobial\\nmedicines\\n- Fluconazole\\n\\n: 50 mg orally daily for 7 - 14 days\\n3 - 6 mg/kg on the first day, then 3 mg/kg daily\\n\\nFor neonates up to 2 weeks old: administer every 72\\nhours; 2 - 4 weeks old: administer every 48 hours\\n\\nPredisposing factors\\n\\nInvestigations\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\n2\\n\\nDefine extent of involvement\\n\\nAdult:\\n\\nChild\\n\\nAdult:\\n\\nChild\\n\\nAdult\\nChild:\\n\\nScaling and polishing\\nAntiseptic mouthwashes e.g. chlorhexidine gluconate\\n\\n2% three times daily for 1 - 2 weeks\\n- Hexetidine mouthwashes to alternate with warm\\nsaline mouthwashes\\n\\nAnalgesics\\n- Paracetamol\\n\\n1 g orally every 8 hours for 3 - 5 days\\n1 - 5 years: 125 - 250 mg, 6 - 12 years 250 - 500 mg\\n\\norally\\nAntibiotics\\n\\n- Amoxicillin\\n250 mg orally for 5 days\\n1 month - 1 year 62.5 mg orally every 8 hours;\\n\\ndose doubled in severe infections\\n1 - 5 years: 125 mg ; 5 - 12 years: 250 mg 8\\nhourly; 12 - 18 years 500 mg 8 hourly; all doses doubled\\nin severe infections\\n- Metronidazole\\n\\n200 mg orally for 5 days\\n1 - 3 years 50 mg orally ; 3 - 7 years:\\n\\n100 mg 12 hour ; 7 - 10 years: 100 mg\\n\\nMetronidazole: nausea, vomiting and metallic taste\\nMetronidazole is contraindicated in pregnancy\\nAvoid alcohol during treatment with metronidazole,\\n\\nand for at least 48 hours after\\n\\nOral health education\\nScaling and polishing every six months\\n\\nA clinical infection of mucous membranes due to the\\nfungus species\\n\\nis the most frequently isolated strain\\n\\nAcute oral candidosis\\nChronic oral candidosis\\nDenture association candidosis/denture stomatitis\\n\\nImmunosupression results in the (a\\nnormal oral commensal) becoming virulent\\n- It invades and proliferates in superficial epithelium\\n- Results in a thick plaque which is oedematous and not\\neasily rubbed off\\n\\nAcreamy/whitish, soft and friable slough located on the\\nsoft tissues of the oral cavity: tongue, palate, cheek,\\npharynx\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nNEOPLASMS OF THE ORAL CAVITY refer to\\nspecialist care\\n\\nORALTHRUSH (Candidiasis)\\nIntroduction\\n\\nClassification\\n\\nPathogenesis/aetiology\\n\\nClinical features\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild:\\n\\nCandida\\nCandida albicans\\n\\nCandida albicans\\n\\nevery 8 hours\\n\\nevery 8 hours\\n\\nevery 8 hours\\n\\nevery 8 hours\\nevery 8 hours\\n\\nevery s every 8\\nhours\\n\\nPERICORONITIS\\nIntroduction\\n\\nClassification\\n\\nAetiology\\n\\nClinical features\\n\\nInvestigations\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nPossible complications\\n\\nPERIODONTITIS\\nIntroduction\\n\\nClassification\\n\\nAn inflammatory condition of the gum/flap around a\\npartially erupted tooth\\nCommon around the lower last molars or wisdom teeth\\nUpper canine may also be affected\\n\\nAcute\\nChronic\\nAcute-on-chronic\\n\\nFood impaction and plaque accumulation under gum flap\\nTrauma to gum flap from opposing tooth\\nUlcerative gingivitis\\nReduced resistance\\nAnaerobes in plaque\\n\\nSoreness and tenderness around partially-erupted tooth\\nPain\\nSwelling\\nEnlargement of regional lymph nodes\\nFever\\nAbscess formation\\n\\nRadiographs\\n- To establish the position of the affected tooth and its\\nrelationship to the second molar\\n- May show impacted third molar\\n\\nWhen mouth opening is possible: careful irrigation under\\nthe gum flap to clear debris, using warm saline\\nmouthwash\\n- To be done frequently until stagnation area is removed\\n\\nOperculectomy\\nDisimpaction of the third molar by surgical extraction\\nOcclusal reduction of opposing tooth\\nExtraction of opposing tooth\\n\\nAppropriate antibiotics\\nAnalgesics\\nSupportive therapy\\n\\nCellulitis\\nLudwig\\'s angina\\nOsteomyelitis\\n\\nAn inflammatory condition of the periodontium:\\nperiodontal ligament, cementum, alveolar bone, gingivae\\n\\nAcute periodontitis\\nChronic periodontitis\\nJuvenile periodontitis\\nOther sub-classifications\\n\\n51 52\\n\\nChapter 5: Dental and Oral Disorders Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nAcute periodontitis\\n\\nChronic periodontitis\\n\\nJuvenile periodontitis\\n\\nRelatively uncommon\\nOf short duration; may be due to trauma, abscess or\\nulceration\\n\\nCharacterized by pain\\n- May be associated with bleeding, fever, swelling and\\nredness of the mucosa, unpleasant taste in the mouth\\n\\nAsequela of chronic gingivitis\\nSymptoms are the same as in the acute type, but with\\n\\nless pain and longer history\\n\\nInflammation\\nDestruction of the periodontal membrane fibres\\nResorption of the alveolar bone\\nMigration of the epithelial attachment along root\\n\\ntowards the apex\\nPocket formation around the tooth\\n\\nAn uncommon disease characterized by periodontal\\ndestruction, often in the absence of overt gingival\\ninflammation\\n\\nPrevalence 1:1000; male = female\\nOnset at puberty or earlier\\n\\nAffects the first permanent molar and incisors\\nActinobacillus, has been\\nisolated from the affected sites\\n\\nResults in drifting and loss of the first permanent molar\\nand incisors\\n\\nRadiology may reveal marked bone loss interdentally,\\ninter-radicularly and apically\\n\\nTooth loss\\nMalocclusion\\nTemporo-Mandibular Joint (TMJ) dysfunction\\nsyndrome\\n\\nControl of plaque bacteria by use of antiseptic solution\\nEstablishing a healthy gingival and periodontal\\n\\nattachment\\nOral hygiene instruction and motivation\\nRegular scaling and polishing\\nRoot planing\\nSplinting of mobile tooth\\nPeriodontal surgery\\nBone regenera t ive techniques e .g us ing\\n\\nPolytetrafluoroethylene (PTFE) membranes, Bio-Oss,\\nBio-membrane\\n\\nMetronidazole\\n: 200 mg orally every 8 hours for 5 days\\n\\n50 mg orally every 8 hours; 3 - 7 years:\\n100 mg every 12 hours; 7 - 10 years: 100 mg every 8\\n\\nClinical features\\n\\nEpidemiology\\n\\nClinical features\\n\\nInvestigation\\n\\nComplications\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nActinomycetes comitans\\n\\nAdult\\nChild 1 - 3 years:\\n\\nreversible pulpitis\\nTo remove the pulp in irreversible pulpitis\\n\\nReversible:\\n- Indirect pulp capping\\n- Direct pulp capping\\n- Conventional filling using amalgam, composite or\\nGIC\\n- Desensitization with strontium chloride\\n\\nIrreversible:\\n- Root canal therapy\\n- Extraction\\n\\nParacetamol\\n500 mg - 1 g orally every 4 - 6 hours (to a\\n\\nmaximum of 4 g) for 5 - 7 days\\nsame as adult dosing\\n\\n6 - 12 years: 250 -500 mg; 1 - 5 years: 125 - 250 mg; 3\\nmonths - 1 year: 125 - 250 mg for 5 - 7days\\n\\nNSAIDs may be required in some patients\\n\\nAspirin and other NSAIDs\\n- Gastrointestinal haemorrhage, allergic reactions\\n- Do not prescribe for patients with peptic ulcer disease\\n- May exacerbate symptoms in asthmatics\\n\\nPrevent dental caries (the most important cause of\\npulpitis)s\\n\\nSeek prompt dental attention\\n\\nAwide spectrum of disorders\\n\\nSalivary calculi\\nParotid papilla and duct strictures\\nSalivary fistulae\\nMucoceles and cysts\\nRanula\\n\\nDiseases which result from inflammation of the salivary\\nglands\\n- Mumps\\n- Suppurative parotitis\\n- Chronic sialadenitis\\n\\nDry mouth\\nIt can be caused by the following:\\n\\n- Sjogren\\'s syndrome\\n- Irradiation\\n- Dehydration\\n- Psychogenic\\n- Drugs\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nSALIVARYGLAND DISEASES\\nIntroduction\\n\\nAdult:\\n\\nChild over 50 kg:\\n\\nAspirin is contraindicated in children less than 16 years\\nas it may precipitate Reye\\'s syndrome\\n\\nDiseases due to obstruction\\n\\nSialadenitis\\n\\nXerostomia\\n\\nhours; 10 -18 years: 200 mg every 8 hours\\nPlus:\\nTetracycline 250 mg orally daily for up to 21 days\\n\\n: metronidazole and amoxicillin (or\\nerythromycin for those sensitive to penicillin)\\n\\nTetracyclines should not be given to children under 12\\nyears\\n\\nInflammation of the dental pulp\\nThe single most important disease process affecting the\\n\\ndental pulp\\nAccounts for virtually all pulpal disease of any clinical\\n\\nsignificance\\n\\nPain which is difficult to localize\\n- May radiate to the adjacent jaw and occasionally to the\\nface, ear or neck\\nMay be triggered by:\\n- Cold or hot stimulants\\n- Arecumbent position\\n- Occasionally by mastication when food particles get\\ninto a carious cavity\\n\\nImportant to determine whether pulpitis is reversible or\\nirreversible\\nReversible pulpitis:\\n\\nThe pulp can recover with removal of stimulus\\nPain lasts for only a few moments after removal of the\\n\\ninitiating stimulus\\nIrreversible pulpitis:\\n\\nThe pulp cannot recover even after removal of stimulus\\nCharacterized by pain which lingers for at least one\\n\\nminute after removal of stimulus\\nMay be spontaneous\\n\\nThe sequelae of untreated pulpitis (in the order in which\\nthey occur) are:\\n\\nReversible pulpitis\\nIrreversible pulpitis\\nPulpal necrosis\\nApical periodontitis\\nPeriapical abscess\\nCellulitis\\n\\nOf primary importance is the use of a pulp tester to test\\nthe vitality of the pulp\\nThe following can be used:\\n- Electric pulp tester\\n- Cold or hot water bath\\n- Ethyl chloride spray\\n- Hot gutta percha sticks\\n- Ice sticks\\n\\nTo exclude the pulp from the stimulus (or stimuli) in\\n\\nChild under 12 years\\n\\nPrecaution\\n\\nPULPITIS\\nIntroduction\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nSjogren\\'s syndrome\\n- Presents with dryness of the eyes and mouth (primary\\ntype)\\n- In the secondary type, dryness occurs in association\\nwith rheumatoid arthritis or other connective tissue\\ndisease\\n\\nThe next most common neoplasms of the mouth after\\nsquamous cell carcinomas\\n\\nAbove 70% develop in the parotid gland\\nOver three-quarters are benign\\nWomen are slightly more frequently affected\\n\\nThe modified WHO classification (1972) includes:\\n\\nAdenomas:\\n- Pleomorphic adenoma (\\'mixed tumour\\')\\n- Monomorphic adenomas\\n- Warthin\\'s tumour, oxyphoitic adenoma\\n\\nCarcinomas:\\n- Mucoepidermoid carcinoma\\n- Acinic cell carcinoma\\n- Adenocarcinoma\\n- Epidermoid carcinoma\\n- Undifferentiated carcinoma\\n- Malignant mixed tumour\\n\\n- Lymphomas\\n- Sarcomas\\n\\nBenign tumours are generally asymptomatic\\nenlargements\\nMalignant varieties are painful, irregular, ulcerative and\\n\\nmetastatic\\n\\nSialography\\n- Postero-anterior view of the skull\\n- Oblique lateral view of the jaws\\n\\nBenign and malignant lesions: surgical excision\\nMalignant lesions: radiotherapy and chemotherapy in\\n\\naddition to excision\\nSecondary bacterial infections: treat with antibiotics\\n\\ne.g. ampicillin/cloxacillin 250/250 mg every 6 hours for 5\\n- 7 days\\n- Adjust doses as appropriate for children\\n\\nThese disorders can be grouped under the following\\nconditions:\\nTemporo-Mandibular Joint (TMJ) pain-dysfunction\\nsyndrome\\n\\nOsteoarthritis\\nRheumatoid arthritis\\n\\nNeoplasms of the salivary gland\\n\\nEpithelial tumours\\n\\nNon-epithelial tumours\\n\\nClassification\\n\\nClinical features\\n\\nInvestigations\\n\\nManagement\\n\\nTEMPORO-MANDIBULAR JOINT DISORDERS\\nIntroduction\\n\\n53 54\\n\\nChapter 5: Dental and Oral Disorders Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nTrauma\\nDevelopmental defects\\nAnkylosis\\nInfection\\nNeoplasia\\n\\nThe most common problem in or around the TMJ\\n\\nEqual frequency between genders, but five times as\\nmany females seek treatment\\n\\nPatients are usually between 15 and 40 years\\nUnilateral or bilateral dull pain within the TMJ and/or\\n\\nsurrounding muscles, sometimes on waking or during\\neating or speech\\n\\nTMJ may lock in the open or closed positions,\\noccasionally\\n\\nTMJ sounds such as clicking, crunching or grating are\\noften described\\n\\nAssociated headache is usually located in the temporal\\nregion\\n\\nPain is cyclical and usually resolves, but may recur\\nMay be associated with psychological stress\\n\\nMigraine\\nPsychologic depression\\n\\nMost symptoms are self-limiting and do not require\\ntreatment\\n\\nTreatment should be conservative and reversible\\n\\nEducate patient about the condition, emphasizing its\\nfrequency and self-limiting nature\\n\\nSoft diet\\nApply moist heat to painful muscles\\nPhysiotherapy\\n\\nAnalgesics as appropriate\\nAnxiolytics\\n\\n- Diazepam 5 mg orally 1 hour before sleep, then 2 mg\\nevery 12 hours, for up to 10 days (maximum)\\n\\nOcclusal splints\\n\\nRare\\nIncreasing incidence after 50 years\\nJoint crepitus denotes degenerative joint disease\\nMay be accompanied by pre-auricular pain, but not\\n\\ninvolving the masticatory muscles\\nRadiographs (e.g. panoramic, trans-pharyngeal, trans-\\n\\ncranial, oblique, lateral, open and closed) show\\ndegenerative joint disease\\n\\nAdisease of unknown aetiology\\nAutoimmune mechanisms and immune complex\\n\\nformation have been implicated\\n\\nTMJ pain dysfunction syndrome\\n\\nOsteoarthritis\\n\\nRheumatoid arthritis\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nCHAPTER 6: DERMATOLOGY\\n\\nBACTERIALINFECTIONS\\n\\nCELLULITIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nA suppurative bacterial infection of the skin and soft\\ntissue, often with involvement of underlying structures:\\nfascia, muscles and tendons\\n\\nMost often due to ß-haemolytic streptococci or\\n\\nUsually (but not always) follows some discernible\\nwound\\n\\nOften a complication of immunosuppression like\\ndiabetes and HIV/AIDS\\n\\nAreas of oedema; rapidly spreading\\nErythema (rapidly becomes intense and spreads)\\nTenderness and warmth\\n\\n- Often accompanied by fever, lymphangitis, regional\\nlymphadenitis\\n\\nSystemic signs of toxicity\\nArea becomes infiltrated and pits on pressure\\nSometimes the central part becomes nodular and\\n\\nsurrounded by a vesicle that ruptures and discharges pus\\nand necrotic material\\n\\nErysipelas\\nDeep vein thrombosis\\n\\n- Unusual in immunocompetent adults; children and\\ncompromised adults are at higher risk immuno\\n\\nSepticaemia\\nGangrene\\nMetastatic abscesses\\nRecurrent cellulitis may predispose to chronic\\n\\nlymphoedema\\n\\nBlood culture\\nFull Blood Count with differentials\\nFasting blood glucose\\nHIV screening\\nWound swab for microscopy, culture and sensitivity\\nUrinalysis\\n\\nEradicate infection\\nTreat underlying immunosuppression\\nPrevent complications\\n\\nAmpicillin/cloxacillin\\n500 mg - 1 g orally every 6 hours for 5 - 7 days\\n\\na quarter adult dose; 5 - 10 years:\\nhalf adult dose\\nOr:\\nCloxacillin\\n\\n500 mg orally every 6 hours for 5 - 7 days\\n\\nStaphylococcus aureus\\n\\nAdult:\\nChild under 5 years:\\n\\nAdult:\\n\\nUsually begins in early adult life and affects females\\nmore frequently\\n\\nPatients rarely complain of pain from TMJ but clinical\\nexamination shows TMJ involvement in 50% of cases\\n\\nLimitation of mouth opening; softness, crepitus,\\nreferred pain, and tenderness on biting\\n\\nSevere disability is unusual\\n\\nClinical features include:\\nCondyle fracture or trauma arthritis\\nPain and trismus of traumatic arthritis resolve after one\\n\\nweek\\nMicro-trauma from parafunction may result in chronic\\n\\nsymptoms\\nDislocation is usually a result of trauma and is rare; very\\n\\nrarely it occurs after yawning\\n\\nAplasia of the condyle is extremely rare and may be\\nunilateral or bilateral\\n\\nHypoplasia of the condyle may be congenital or\\nacquired\\n\\nCause of congenital hypoplasia is not known; either one\\nor both condyles may be involved\\n\\nAcquired hypoplasia may be secondary to trauma,\\ninfection or radiation\\n\\nHyperplasia of the mandibular condyle is rare and self-\\nlimiting. Cause is unknown. It is generally unilateral with\\nresultant facial asymmetry, deviation of mandible to the\\nopposite side and malocclusion\\n\\nFollows trauma, infection or other inflammatory\\ncondition\\n\\nFollows penetrating trauma to joint or spread from\\nmiddle ear\\n\\nPrimary neoplasms arising from the structures of the\\nTMJ are extremely rare\\n\\nBenign tumours such as chondromas and osteomas are\\nmore frequent than sarcomas arising from bone or\\nsynovial tissues\\n\\nOthers are secondary carcinomas\\n\\nTrauma\\n\\nDevelopmental defects\\n\\nAnkylosis\\n\\nInfection\\n\\nNeoplasia\\n\\nChild under 5 years:\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\na quarter adult dose; 5 - 10 years:\\nhalf adult dose\\nCiprofloxacin\\n\\n250 - 750 mg orally every 12 hours for 5 - 7days\\nsee note on caution\\n\\nCeftriaxone\\n1 g intravenously or intramuscularly daily for 3\\n\\ndays\\nneonate, 20 - 50 mg/kg by intravenous infusion\\n\\nover 60 minutes; 1 month - 12 years, body weight less\\nthan 50 kg: 50 mg/kg by deep intramuscular injection or\\nintravenous injection over 2 - 4 minutes, or by\\nintravenous infusion\\n- Intramuscular injections over 1 g should be divided\\nover more than 1 site\\n- Doses of 50 mg/kg and more should be given by\\nintravenous infusion only\\n- Use only when there is significant resistance to other\\ndrugs\\n\\nMay need incision and drainage or debridement\\n\\nCiprofloxacin is contraindicated in growing adolescents\\nand children below 12 years; also contraindicated in\\npregnancy\\n\\nTreat any wound promptly\\n\\nInfection of a hair follicle by staphylococcal organisms,\\nthat leads to an inflammatory nodule, with a pustular\\ncentre\\n\\nA carbuncle is merely two or more confluent furuncles,\\nwith separate heads\\n\\nRecalcitrant cases may occur with a background of\\nimmune suppression\\n- Alcoholism:\\n- Malnutrition\\n- Blood dyscrasias\\n- Disorders of neutrophil function\\n- Diabetes\\n- AIDS\\n\\nMay occur in patients with atopic dermatitis\\nMay be iatrogenic\\n\\nCan be found on all body sites where hairs are present\\nStarts with a small, yellow creamy pustule that rapidly\\n\\nevolves into a red nodule, often with a central yellow\\nplug\\nAs the lesion expands, it becomes:\\n\\nPainful and tense\\nAssociated with local oedema, lymphangitis, regional\\n\\nlymphadenopathy and fever\\n- Eventually, the central part of the nodule becomes soft\\n\\nSurgical treatment\\n\\nCaution, contraindications\\n\\nPrevention\\n\\nFURUNCULOSIS (Boils)\\nIntroduction\\n\\nClinical features\\n\\n55 56\\n\\nChapter 5: Dental and Oral Disorders Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nand drains spontaneously\\nHealing occurs after about 1 - 2 weeks with scar\\n\\nformation\\n\\nFolliculitis\\nCutaneous myiasis\\nAcne inversa in the axilla or groin\\n\\nCellulitis\\nSepticaemia\\nCarvenous sinus thrombosis when the lesions are on the\\n\\nhead and neck\\n\\nWound swab for bacteriology and sensitivity\\nFull Blood Count with differentials\\nFasting blood glucose\\nHIV screening\\nUrinalysis\\n\\nTreat infection\\nCorrect predisposing factors\\nPrevent complications\\n\\nTopical antibiotics\\n- Gentamicin 0.3% cream\\n- Resistance may set in with prolonged use\\n\\nSystemic antibiotics\\nUsually unnecessary except for head and neck lesions, or\\nwhen the boil is accompanied by fever, chills, regional\\nlymphadenopathy, or a feeling of being unwell\\n- Co-trimoxazole\\n\\n960 mg orally every 12 hours for 5 - 10 days\\n6 weeks - 5 months: 120 mg; 6 months - 5 years:\\n\\n240 mg; 6 - 12 years: 480 mg taken orally every 12 hours\\nfor 5 - 10 days\\n- Erythromycin\\n\\n250 - 500 mg orally every 6\\nhours - 1 g 12 hourly for 5-10 days\\n\\nup to 2 years: 125 mg orally every 6 hours; 2 - 8\\nyears: 250 mg every 6 hours for 5 - 10days\\n\\nA small puncture wound often gives less of a scar than\\nallowing spontaneous rupture; it also reduces the pain\\nShould be under antibiotic cover to prevent septicaemia\\n\\nA superficial, highly contagious, bullous skin disorder\\ncaused by coagulase positive staphylococci and\\n\\noccasionally -haemolytic streptococci\\n\\nChildren are more commonly affected\\nInitial lesions are superficial vesicles, or bullae found\\n\\naround orifices: eyes, nose and ears\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nSurgical treatment\\n\\nIMPETIGO CONTAGIOSA\\nIntroduction\\n\\nClinical features\\n\\nAdult:\\nChild:\\n\\nAdult and child over 8 years\\n\\nChild:\\nor\\n\\n�\\n\\n- Strict personal hygiene\\nTreat underlying skin disease(s)\\n\\nSulphonamide and co-trimoxazole: fixed drug eruption\\n\\nInflammation of the superficial dermis and epidermis,\\nleading to disruption of the skin\\n\\nDermatitis and eczema are used interchangeably,\\nalthough eczema was initially used to refer to blistering\\ndermatitis, being derived from a Greek term meaning \\'to\\nboil over\\'\\n\\nAtopic dermatits is a hereditary disorder characterised\\nby dry skin, the presence of eczema, and onset less than 2\\nyears\\n\\nAtopic dermatitis looks different at different ages and\\nin people of different races\\nEssential features are:\\nPruritic, exudative, or lichenified eruptions on face,\\n\\nneck, upper trunk, wrists and hands, and in the\\nantecubital and popliteal folds\\n\\nPersonal or family history (in about 70% of cases) of\\n- Allergic manifestations e.g. asthma, hay fever, allergic\\nrhino-conjunctivitis, or eczema\\n\\nChronic or chronically relapsing dermatitis\\nDry skin\\nThe age at which eczema ceases to be a problem varies\\n\\n- Many children show a significant improvement by the\\nage of 5 years\\n- Most will have only occasional flare-ups by the time\\nthey are teenagers\\n- A few continue to have troublesome eczema in adult\\nlife, especially those children that suffer from hay fever\\n\\nThere is no “cure” for atopic eczema\\n\\nSeborrhoeic dermatitis (especially in the infant)\\nIrritant or allergic contact dermatitis\\nNummular dermatitis\\nScabies\\nPsoriasis (especially palmo-plantar)\\nIn infants certain immunodeficiency syndromes\\n\\nBacterial infections of the skin\\nEczema herpeticum\\nComplications of over treatment with steroids\\n\\nRAST or skin tests may suggest dust mite allergy\\nEosinophilia and increased serum IgE levels may be\\n\\npresent but are nonspecific\\nBlinded food challenges: for diagnosing food allergy\\n\\nNotable adverse drug reactions\\n\\nATOPIC DERMATITIS (Atopic eczema)\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDERMATITISAND ECZEMA\\n\\nBegins with a 2 mm erythematous macules which\\nquickly develop into vesicles or bullae\\n- Blisters are superficial and rupture easily, releasing a\\nthin straw-coloured seropurulent discharge\\n- The exudate dries to form loosely stratified golden\\nyellow crusts\\n\\nAuto-inoculation from fluid (from ruptured blister)\\nleads to multiple lesions\\n\\nAs the lesions spread peripherally and the skin clears\\ncentrally, large circles are formed by fusion of the\\nspreading lesions to produce gyrate patterns\\n\\nLesions heal without scarring, but may leave behind\\nerythema and hyperpigmentation\\nOther pruritic dermatoses may become impetiginized\\n(i.e.infected with the above organisms):\\n- Scabies\\n- Pediculosis\\n- Papular urticaria\\n- Atopic eczema\\n\\nRingworm\\nEcthyma\\nHerpes simplex\\n\\nRegional lymphadenopathy\\nCellulitis\\nRarely: septicaemia\\n\\nRarely: acute glomerulonephritis, if nephritogenic strain\\nof streptococcoci is involved\\n\\nWound swab for bacteriology and sensitivity\\n\\nTreat infection\\nTreat underlying pruritic dermatoses\\nPrevent complications\\n\\nDebrid crusted lesions with soap and water\\ndesloughing antibacterial agents\\n\\nDry weepy lesions with astringent such as potassium\\npermanganate, sodium chloride 0.9% solution,\\nhydrogen perioxide\\n\\nErythromycin\\n250 - 500 mg orally every 6\\n\\nhours 500 mg - 1 g every 12 hours for 5 - 10 days\\nup to 2 years: 125 mg orally every 6 hours; 2 - 8\\n\\nyears: 250 mg every 6 hours\\nOr:\\n\\nCo-trimoxazole\\n960 mg orally every 12 hours for 5 - 10 days\\n6 weeks - 5 months: 120 mg; 6 months - 5 years:\\n\\n240 mg; 6 - 12 years: 480 mg taken orally every 12 hours\\nfor 5 - 10 days\\n\\nDebride crusted lesions: Dislodging antibacterial agen\\nAvoid auto-inoculation e.g. with fingers, shaving\\nbrushes, handkerchiefs, or pillow cases\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\ne or\\n\\nor\\nAdult and child over 8 years:\\n\\nChild:\\n\\nAdult:\\nChild:\\n\\nSuppress inflammation\\nReduce itching\\nPrevent complications\\n\\nTopical:\\nHydrocortisone 1% or betamethasone valerate 0.1%\\n\\n- Apply twice a day until the skin improves then decrease\\nto once a day or less frequently as needed\\nSystemic therapy:\\n\\nSteroids (only to control acute exacerbations)\\n- Prednisolone\\n\\ninitially up to 10 - 20 mg orally daily\\n- Preferably taken as a single dose in the morning after\\nbreakfast\\n- In severe disease: up to 60 mg orally daily, as a short\\ncourse for 5-10 days\\nOr:\\n- Triamcinolone acetonide 40 mg by deep intramuscular\\ninjection, into gluteal muscle\\n\\nFailed maximal therapy; little improvement after\\nenvironmental changes\\n\\nChronic unbearable, unrelenting itch\\nErythroderma without infections\\nSocial setting in which other modalities are impossible\\n\\nDo not use on the face, axillae, diaper area or flexures\\nDo not use under occlusion\\nDo not use for an area greater than about 25% of total\\n\\nbody surface area\\nDo not use for more than 2 weeks consecutively and do\\n\\nnot give refills\\nDo not dispense more than 50 g per week\\nAlways use sparingly\\n\\nExclusive breastfeeding; milk substitute if need be\\nAttention to cleanliness especially in the diaper region\\nAvoid excessive bathing, vigorous rubbing, or chafing\\nAvoid unduly heavy, tight, or soiled clothing\\nTreat local infections\\nPat (rather than rub) skin dry after bath and immediately\\n\\nlubricate skin with petroleum jelly or emulsifying\\nointment\\n\\nShowers should be warm to cool, not hot\\nTub soaking is good, if followed by adequate lubrication\\nAvoid wool; its fibers are irritating\\nEmotional stress leads to increased scratching\\nIn patients and parents of affected children, other\\n\\npsychologic techniques may be useful\\nSecondary skin infection with bacteria such as\\n\\nmay worsen the dermatitis and\\nitching\\n\\nPatients must consciously be shielded from anyone\\nwith varicella or herpes simplex\\n\\nKeep finger nails trimmed short\\n\\nDrug treatment\\n\\nSmallpox vaccination is absolutely contraindicated\\n\\nAdjunctive measures\\n\\nAdult:\\n\\nStaphylococcus aureus\\n\\nCriteria for systemic steroid therapy\\n\\nGuidelines for the use of potent topical steroids in infants\\n\\n57 58\\n\\nChapter 6: Dermatology Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nSome kinds of soap may irritate and dehydrate the skin;\\nuse synthetic soap powders\\n\\nReassure patients and/or anxious parents\\nUse patient education handouts\\n\\nSteroids\\n- Increased susceptibility to and severity of infection\\n- Activation or exacerbation of tuberculosis, amoebiasis,\\nstrongyloidiasis\\n- Risk of severe chickenpox in non-immune patients\\n- Nausea, dyspepsia, hiccups\\n- Hypersensitivity reactions\\n- Atrophy of the skin; striae, telangiectasia, petechiae\\n- Glaucoma, cataracts\\n- Cushingoid syndrome, adrenal/pituitary suppression,\\nhyperglycaemia and diabetes mellitus\\n- Suppression of growth in children\\n- Menstrual irregularities\\n- Oedema\\n- Electrolyte imbalance\\n- Hypertension\\n- Pseudotumour cerebri\\n\\nAn acute or chronic dermatitis that results from direct\\nskin contact with chemicals or allergens\\nThese agents could be\\n\\nChemicals\\nAnimal or plant products\\nPhysical agents like heat, cold, ultraviolet rays or\\n\\nionizing radiation\\nContact dermatitis is classified as :\\n\\nIrritant dermatitis\\n- Acute irritant dermatitis\\n- Cumulative insult dermatitis\\n\\nAllergic contact dermatitis\\nPhototoxic dermatitis\\nPhoto-allergic dermatitis\\n\\nAcute phase\\n- Tiny vesicles, weepy and crusted lesions\\n\\nResolving or chronic contact dermatitis\\n- Scaling, erythema, and possibly thickened (lichenified)\\nskin\\n- Itching, burning, and stinging may be severe\\n\\nContact dermatitis is recognized by the distribution and\\nconfiguration of the lesion which usually corresponds to\\nthe contactant e.g\\n- Face: cosmetics\\n- Photodermatitis: airborne allergens e.g. dust, fumes,\\nsprays\\n- Neck: nickel necklace, perfume, and collars of garments\\n\\nAllergy tests, restriction diets and environmental\\nhypoallergenic changes will not cure eczema\\nNotable adverse drug reactions\\n\\nCONTACT DERMATITIS\\nIntroduction\\n\\nClinical features\\n\\nModerate-to-gross generalized enlargement of lymph\\nnodes in the absence of an underlying malignant\\nlymphoma (dermatopathic lymphadenopathy)\\nThe nodes are rubbery in consistency\\n\\nThe general picture is modified by the initial cause\\nPruritus is often intense if due to atopic eczema or\\n\\nlymphoma\\n\\nAll the causes of exfoliative dermatitis listed above\\n\\nHypothermia\\nHypoalbuminaemia\\nDehydration\\nHigh output cardiac failure\\nSepticaemia\\nEnteropathy\\nSteatorrhoea\\nAnaemia\\n\\nFull Blood count and differentials; ESR\\nUrea and Electrolytes\\nHistopathology\\nBlood culture\\n\\nRestore the skin to normal\\nTreat underlying disease\\nPrevent or treat complications\\n\\nSystemic steroids in high doses\\n- Prednisolone 40 - 60 mg orally per day\\n\\nTreat impetiginization and septicaemia as appropriate\\n(depending on results of culture and sensitivity)\\n\\nFurther treatment depends on the cause of exfoliative\\ndermatitis\\n\\nAdequate hydration\\nEmolients for skin (seeAtopic eczema)\\nKeep warm\\nAdequate nursing care\\nAppropriate nutrition and haematinics\\n\\nAvoid over-treatment of skin diseases and\\npolypharmacy, generally\\n\\nDo not abuse the skin with “medicated” soaps and\\nherbal concoctions\\n\\nGet appropriate management of skin disease(s) from\\nqualified personnel\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nAdjuvant therapy\\n\\nPrevention\\n\\n- Hands: various chemicals handled at home, at work\\nand at leisure hours\\n- Feet: shoes, socks, remedies for athletes\\' foot, etc\\n\\nAtopic dermatitis\\nSeborrhoeic dermatitis\\nPsoriasis\\nDermatophyte infection\\nLichen planus\\nFace: lupus erythematosus, pellagra, rosacea\\n\\nImpetiginization\\nSecondary dissemination\\n\\nPatch test\\nOccupational site assessment\\n\\nCure the dermatitis\\nIdentify cause(s) and avoid further contact\\n\\nAs for atopic dermatitis\\n\\nCounselling (after identifying the cause)\\nAllergen replacement\\n\\nRefers to the involvement of all or most of the skin\\nsurface by a scaly erythematous dermatitis\\n\\nUsually a secondary or reactive process to an\\nunderlying cutaneous or systemic disease\\nSome causes:\\n\\nContact dermatitis\\nAtopic eczema\\nSeborrhoeic dermatitis\\nDrug eruptions\\nLichen planus and lichenoid eruptions\\nCrusted scabies\\nPediculosis corporis\\nDermatophytosis\\nPsoriasis\\nPemphigus foliaceus\\nLymphomas and leukaemia\\nIchthyosiform erythroderma\\nPityriasis rubra pilaris\\n\\nMay be acute or chronic\\nThe irritating process is followed by a patchy erythema\\n\\nwhich spreads rapidly within 24 hours\\nPyrexia, malaise and shivering\\nScaling\\nIrritation and tightness\\nSkin feels cold\\nThe periorbital skin is inflamed and oedematous,\\n\\nresulting in ectropion, with consequent epiphora\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nEXFOLIATIVE DERMATITIS (Erythroderma)\\nIntroduction\\n\\nClinical features\\n\\nPARASITIC DERMATOSES\\n\\nCUTANEOUS LARVAMIGRANS (Creeping eruption)\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnosis\\n\\nComplications\\n\\nInvestigation\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nAn infection of the skin by various nematode larvae\\nwhich migrate, but never reach internal organs or\\ncomplete their life cycles\\n\\nMigration leads to twisting, winding linear skin lesions\\nproduced by the burrowing of larvae\\nVictims are usually:\\n\\nPeople who go barefoot at the beaches\\nChildren playing in sandboxes and crawling on the bare\\n\\nground\\nCarpenters and plumbers working under homes\\nGardeners\\nThe most common causes are cat and dog hookworm\\n\\n-\\n-\\n-\\n-\\n-\\n\\nShortly after entering the skin:\\nThe larvae elicit intense pruritus\\nTiny papules and even papulovesicles develop\\n\\nAs the larvae begin to migrate:\\nIntermittent stinging pain occurs\\nThin red, tortuous and minimally elevated lines are\\n\\nformed in the skin\\n- Rate of migration varies with the species\\n- Pruritus and excoriation promote secondary bacterial\\ninfections\\n\\nIntestinal infections with may\\nbe associated with perianal larva migrans syndrome\\ncalled larva currens\\' because of the rapidity of larval\\nmigration (up to 10 cm/hr)\\n- Larva currens is an autoinfection caused by penetration\\nof the perianal skin by\\n\\nRing worm\\n\\nSecondary bacterial infection\\nFatal hyperinfection in\\n\\nimmunocompromised patients\\n\\nNone useful to management\\n\\nEradicate the larvae\\nEradicate gut Strongyloides\\nTreat impetiginization\\nPrevent re-infection\\n\\nIvermectin\\n150 microgram/kg orally as a single dose\\n\\n: 200 micrograms/kg orally daily\\n\\nAncylostoma braziliense\\nAncylostoma caninum\\nNecator americanus\\nGnathostoma spinigerum\\nStrongyloides stercoralis\\n\\nStrongyloides stercoralis\\n\\nStrongyloides stercoralis\\n\\nStrongyloides stercoralis\\n\\nAdult:\\nChild over 5 years old\\n\\n\\'\\n\\n59 60\\n\\nChapter 6: Dermatology Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nfor 2 days\\nOr:\\n\\nAlbendazole\\n400 mg orally twice daily for 2 days, repeated after\\n\\n3 weeks if necessary\\n400 mg once or twice daily for 3 days,\\n\\nrepeated after 3 weeks if necessary\\nAntihistamines for pruritus\\nAntibiotics for secondary bacterial infections\\n\\nAvoid direct contact of skin with sand\\n\\nAn infection by a very long nematode,\\n\\nContracted through drinking water contaminated with\\nwater fleas (cyclops) infected with Dracunculus\\n\\nExcept for remote villages in Rajastan desert of India\\nand Yemen the disease is now only seen in Africa,\\nbetween the Sahara and Equator\\n\\nNigeria is one of the few countries with reports of\\n>1,000 new cases a year\\n\\nEfforts are currently going on to eradicate the disease in\\nNigeria\\n\\nIn the stomach, the larvae penetrate into the mesentery,\\nwhere they mature sexually in 10 weeks\\n\\nAdult:\\n\\nChild over 2 years:\\n\\nDracunculus\\nmedinensis\\n\\nPrevention\\n\\nGUINEAWORM DISEASE (Dracunculiasis)\\nIntroduction\\n\\nPathophysiology\\n\\nThe female worm burrows to the cutaneous surface to\\ndeposit her larvae, causing specific skin manifestations\\n\\nWhen the parasite comes in contact with water, the\\nworm rapidly discharges its larvae, which are ingested by\\nthe cyclops\\n\\nAs the worm approaches the surface it may be felt as a\\ncordlike thickening\\n\\nIt forms an indurated cutaneous papule\\nSeveral hours before the head appears at the skin surface\\n\\nthere is (at the point of emergence)\\n- Local erythema\\n- Burning sensation\\n- Pruritus\\n- Tenderness\\n\\nSoon after, the papule blisters and a painful ulcer\\ndevelops, usually on the leg\\n- Ulcer may occur on other parts of the body e.g the\\ngenitalia, buttocks, or arms\\n\\nSickle cell ulcer\\nStasis ulcer\\n\\nSecondary infection\\nCellulitis\\nErysipelas\\nProgressive lymphoedema\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nMYIASIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigation\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nPrevention\\n\\nONCHOCERCIASIS (River blindness)\\nIntroduction\\n\\nInvasion of mammalian tissue by fly larvae\\nFuruncular myiasis may be caused by\\n\\nor the Tumbu fly\\nLarvae of are often transferred by\\n\\nmosquitoes\\nUsual host is cattle. People living near cattle-rearing\\n\\nareas are particularly vulnerable\\nEggs, living larvae, or both are deposited on the skin or\\n\\nmucous membranes or on clothing\\n- Eggs hatch and produce larvae that then burrow into\\nthe skin and cause mild or severe inflammatory changes\\n\\nFuruncular myiasis looks like a furuncle (boil)\\nKey feature is the presence of a tiny hole in the\\n\\ninflammed erythematous papule\\nThere may be a sensation of motion within the furuncle\\nThere may be intermittent stinging sensation\\nIn accidental myiasis, there is a pre-existing lesion,\\n\\nusually a leg ulcer, wound or ulcerated basal cell\\ncarcinoma\\n\\nFuruncles and carbuncles\\n\\nSecondary bacterial infection\\n\\nNil\\n\\nExtract the maggot\\nTreat or prevent bacterial infection\\n\\nApply petrolatum: the maggot crawls out to avoid\\nasphyxiation\\nOr:\\n\\nExtract the maggot by compressing simultaneously\\nfrom beneath on both sides with a pair of spatulae\\n\\nPrevent bacterial infection with oral antibiotics if\\nlesions are multiple\\n\\nWound myiasis is flushed out surgically with\\nantiseptics: surgical debridement\\n\\nIron clothes that are dried in the open air\\n\\nA common chronic filarial disease in tropical regions\\nwhich frequently cause pruritus and blindness\\n\\nCausative organism is\\nThe microfilariae are transmitted by female ,\\n\\ntiny blackflies which breed along small, rapidly moving\\nstreams\\n\\nFemale worms release motile microfilariae into the\\nskin, subcutaneous issues, lymphatics, and eyes\\n\\nDermatobia\\nhominis Cordylobia anthropophaga\\n\\nD. hominis\\n\\nOnchocerca volvulus\\nSimulium\\n\\nOesteomyelitis\\nArthritis\\nTetanus\\n\\nRadiograph of the affected area\\n- If osteomyelitis and arthritis (or calcified worms) are\\nsuspected\\n\\nResolve local inflammation to permit easier removal of\\nthe worm\\n\\nExtract the worm\\nPrevent and treat complications\\n\\nMetronidazole\\n500 mg orally every 8 hours for 7 days\\n7.5 mg/kg orally every 8 hours\\n\\nOr:\\nMebendazole\\n\\n400 - 800 mg orally daily for 6 days\\nusually 100 mg orally twice daily for 3\\n\\ndays\\nOr:\\nIvermectin\\n\\n200 micrograms/kg orally as a single dose\\nconsult specialist companies\\n\\nTreat or prevent complications with antibiotics\\n\\nTraditionally:\\nExtract the worm slowly by winding it about a match\\n\\nstick or twig, removing 3 - 5 cm daily, with care not to\\nrupture it\\n- In the event of such an accident, the larvae escape into\\nthe tissues and produce fulminating inflammation\\n- The process appears to be facilitated by placing the\\naffected part in water several times a day\\n\\nMetronidazole\\n- Avoid high dose regimens in pregnancy\\n- Avoid drinking alcohol during treatment and at least 48\\nhours after\\n\\nIvermectin\\n- Oedema (face and limbs)\\n- Fever, pruritus, lymphadenitis, malaise, hypotension\\n- Should not be used in the presence of concurrent\\ninfection: risk of encephalopatic reactions to dying\\nmicrofilariae\\n- Should not be used in patients with central nervous\\nsystem diseases (e.g. meningitis): increased penetration\\nof ivermectin into the CNS\\n\\nCaution in early pregnancy\\n\\nProvide universal access to safe and portable water\\nIn hyperendemic areas, treat the whole population twice\\n\\nyearly with ivermectin\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild over 1 year:\\n\\nAdult:\\nChild:\\n\\nL. loa\\nL. loa\\n\\nWorm extraction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplication\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nInterval from exposure to onset of symptoms can be as\\nlong as 1 - 3 years\\n\\nSkin lesions\\n- May be localized or cover large areas\\n\\nIntense pruritus\\n- A cardinal symptom; may occur in the absence of the\\nskin lesions\\n\\nDermatitis\\n- Skin eventually becomes lichenified from chronic\\nscratching\\n- Post inflammatory confetti-like depigmentation on the\\nskin (“leopard skins”) may occur in late onchodermatitis\\n\\nOnchocercomata\\n- Subcutaneous nodules which develop on various sites\\nof the body and contain myriad adult worms which can\\nlive for up to 14 years.\\n\\nFirm, non-tender lymphadenopathy is a common\\nfinding in patients with chronically infected\\nonchocerciasis\\n- “Hanging groin” describes the pendulous loose,\\natrophic skin sac that contains these large nodes\\n\\nMicrofilariae in the eye may lead to visual impairment\\nand blindness\\n\\nScabies\\nPediculosis\\nPapular urticaria\\nPapulonecrotic tuberculids\\nPruritic papular eruption of HIV\\nOther causes of generalized pruritus without a rash\\nOther causes of subcutaneous nodules e.g\\n\\n- Sparganosis\\n- Paragonimiasis\\n- Gnathostomiasis\\n- Cysticercosis\\n- Echinococcosis\\n\\nBlindness\\n\\nSkin snips or punch biopsy for microfilariae\\nExcise nodule for adult worms\\nMazzotti test reaction\\nSlit lamp eye examination\\n\\nKill the microfilariae\\nEliminate source of microfilarial release\\nPrevent blindness\\n\\nIvermectin\\n- As a single oral dose of 150 microgram/kg in adults\\nand children over 5 years\\n- Repeat every 6 months for 2 years and yearly for 12 -\\n15 years or longer\\n\\n- Prednisolone 1 mg/kg orally should be started several\\nEye involvement\\n\\n61 62\\n\\nChapter 6: Dermatology Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\ndays before treatment with ivermectin\\n\\nExcise individual nodules (nodulectomy)\\n\\nNo food or alcohol should be taken for at least 2 hours\\nbefore or after dosage\\n\\nPregnant women should not receive ivermectin until\\nafter delivery\\n\\nBreastfeeding mothers should not be treated until the\\ninfant is at least 1 week old\\n\\nUse biodegradable insecticides to kill flies\\nNetting and repellents remain crucial.\\nProvide access to safe and portable water\\nIn hyperendemic areas, treat the whole population twice\\n\\nyearly with ivermectin\\n\\nDiseases due to blood sucking lice\\nCan be divided into three conditions:\\n\\nPediculosis capitis (head lice):\\n- Caused by\\n\\nPediculosis corporis (body lice):\\n- Caused by\\n\\nPhthiriasis pubis (pubic lice):\\n- Caused by Phthirus pubis\\nThe arthropods are transmitted from human to human\\nvia:\\n\\nDirect contact\\nSharing of combs, brushes, towels ( )\\nSharing clothing ( )\\nShearing underwear\\nSexual intercourse or any intimate personal contact (\\n\\nGenerally the only complaint is pruritus:\\nNits can easily be seen at the base of the hairs; careful\\n\\ninspection may reveal the adult louse\\nSecondary impetiginization is common because of the\\n\\nitching\\n- Cervical nodes may become enlarged\\n\\nChildren and individuals with long hair are more likely\\nto be affected\\n\\nHomeless people and refugees are also vulnerable\\nNo age or economic stratum is immune\\n\\n- School children who share school caps, hair brushes\\nand combs, pillow cases are particularly vulnerable\\n\\nPruritus may be the only symptom in some patients\\nChronic scratching may result in characteristic\\n\\nhemorrhagic puncta and linear excoriations\\nPatient eventually develops intensely pruritic papules\\n\\nSurgical\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nPEDICULOSIS (Lice)\\nIntroduction\\n\\nClinical features\\n\\nPediculus humanus var. capitis\\n\\nP. humanus var. corporis\\n\\nP. capitis\\nP. corporis\\n\\nP.\\npubis)\\n\\nPediculosis capitis:\\n\\nPediculosis corporis :\\n\\n- The cream is lathered through the hair, left on for 10\\nminutes and thoroughly rinsed out. A fine-tooth comb\\nshould be used to remove adherent nits\\n- Repeat treatment after a week\\nP. corporis:\\n\\nTreat dermatitis with antipruritics or corticosteroids\\nTreat secondary infection with oral antibiotics\\n\\nP. capitis:\\nAll contact individuals should be examined and treated\\n\\nas necessary\\nPillow cases should be disinfested as for clothing.\\n\\nP. corporis:\\nEradicate lice from clothing by laundering in hot water\\n\\nor machine-drying at a high temperature, followed by\\nironing the seams\\nP. pubis:\\n\\nTreatment is the same as for pediculosis capitis, with\\nthe exception that pediculosis of the eyelashes should be\\ntreated with an occlusive ophthalmic ointment applied to\\nthe eyelid margins for 10 days\\n- Affected persons\\' sexual contact(s) should be treated\\nsimultaneously\\n\\nAs stated under scabies\\n\\nImprove personal hygiene\\nDo not share hair combs, brushes, clothing, pants and\\n\\npillows\\n\\nAn intensely pruritic infestation caused by human mite\\n\\nContracted by close contact and rarely via fomites\\nOccurs commonly in children and inmates of\\n\\novercrowded institutions such as prisons and boarding\\nhouses\\n\\nInfection of households is common\\nSexual intercourse is also another possible method of\\n\\nspread among adults\\nSharing a bed or using the same underwear will also\\n\\nsuffice to contact the disease\\n\\nSevere pruritus worse at night is characteristic\\nThe typical lesion is the burrow\\n\\n- It is hardly seen because of the marked excoriation and\\nsecondary infection on the skin\\n\\nPapulo-pustular eruptions with excoriation and\\nimpetiginized. Characteristic sites of predilection:\\n\\nInterdigital spaces of the fingers\\nFlexural surfaces of the wrist\\nExtensor surfaces of the elbows and knees\\nAnterior axilliary area\\nNipples\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nSCABIES\\nIntroduction\\n\\nClinical features\\n\\nSarcoptes scabiei\\n\\nand nodules, numerous excoriations, secondary\\ninfections and even lymphadenopathy\\n\\nThe combination of excoriations, hyperpigmentation,\\nhealed scars and secondary impetiginization is quite\\ntypical and known as “vagabond\\'s skin”\\n\\nOvercrowding and poor personal hygiene promote\\ninfestation\\n\\nRefugees, destitutes and vagrants are particularly\\nvulnerable\\n\\nMost often found in the pubic and axillary hairs\\nOccasionally may be found on abdominal or trunk hairs\\nOn rare occasions may be seen on the scalp, eyebrows\\n\\nand even eyelashes\\nPruritus is also a symptom\\nClassic clinical finding is the maculae cerulae\\n\\n- Indistinct blue-grey or slate-coloured macules ranging\\nin size from several millimeters to several centimeters\\n- They result from the bite of the louse causing small\\nintracutaneous haemorrhages\\n- The colour is due to blood whose haemoglobin has\\nbeen altered by the saliva\\n\\nP. capitis:\\n- Seborrhoeic dermatitis\\n- Pityriasis amiantacea\\n- Peripilar keratin\\n- Hair casts\\n- Piedra\\n\\nP. corporis :\\n- Scabies\\n- Atopic dermatitis\\n- All pruritic dermatoses\\n\\nP. pubis:\\n- Scabies\\n- Candidiasis\\n- In the axillae trichomycosis axillaris\\n\\nSecondary bacterial infections\\nThe body louse serves as a vector for diseases:\\n\\nEpidemic typhus ( )\\nTrench fever ( )\\nRelapsing fever ( )\\n\\nP. capitis and pubis:\\n- Examine louse or the nits on epilated hair strands\\n(especially from behind the ears) under the microscope\\n\\nP. corporis :\\n- Examine the seams of clothing for nits and lice\\n\\nEradicate the lice\\nPrevent re-infection\\nTreat complications\\n\\nP. capitis:\\n1% permethrin cream rinse\\n\\nPediculosis pubis:\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nRickettsia prowazekii\\nBartonella quintana\\n\\nBorrelia recurrentis\\n\\nThe phallus (especially in adults)\\nGeneral immune status and experience with\\n\\nplay a role\\nIn a normal host, the initial infection is asymptomatic\\n\\nfor about 3 - 6 weeks during which time the individual is\\ncapable of transmitting the disease\\n- All family or living unit members must therefore be\\ntreated, not just the itching ones\\n\\nAfter a reinfestation, symptoms appear within 24 hours\\n\\nAn uncommon variant of scabies\\nPatient fails to mount a resistance and the mites\\n\\nproliferate dramatically\\nMay be found among HIV/AIDS patients,\\n\\ninstitutionalized inmates like prisoners, refugees, and\\npsychiatric patients\\n\\nInfantile acropustulosis\\nAtopic dermatitis\\nPapular acral dermatitis of childhood\\nDermatitis herpetiformis\\n\\nSecondary bacterial infection leading to acute\\nglomerulonephritis\\n\\nBurrow scraping on to a glass slide for microscopy\\nVideo dermatoscopy\\n\\nTreat the infestation\\nTreat secondary bacterial infection\\nRelieve pruritus\\n\\nScabicides:\\nPermethrin 5% cream\\n\\napply over the whole body and wash off after 8-12\\nhours\\n\\nsupervision required with application and rinsing\\nOr:\\n\\nBenzyl benzoate 25% in emulsion\\napply over the whole body; repeat without bathing\\n\\nnext day and wash off 24 hours later\\n- If necessary apply a third time\\n\\nBenzyl benzoate is an irritant and should be\\navoided in children\\nOr:\\n\\nPrecipitated sulfur 5 - 10% in petroleum jelly\\napply over all the body daily for 7 - 10\\n\\ndays\\nAntihelminthic:\\n\\nIvermectin\\nSingle 200 microgram/kg oral dose for crusted\\n\\nscabies\\n: 200 micrograms/kg daily for 2 days\\n\\nAntihistamine:\\nChlorphenamine\\n\\n4 mg orally every 4 - 6 hours; maximum 24 mg a\\n\\nS. scabiei\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nAdult and child:\\n\\nAdult:\\n\\nChild: over 5 years\\n\\nAdult:\\n\\nCrusted scabies (Norwegian scabies)\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\n63 64\\n\\nChapter 6: Dermatology Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nday\\n1 month - 2 years 1mg orally every 12 hours; 2 - 5\\n\\nyears: 1 mg every 4 - 6 hours; 6 - 12 years: 2 mg every 4 -\\n6 hours\\nTopical antipruritic:\\n\\nCrotamiton cream (for residual itching)\\napply every 8 - 12 hours\\nless than 3 years: apply once daily only\\n\\nAchronic, pruritic, papular skin disease\\nThe three cardinal features are:\\n\\nSkin lesions\\nMucosal lesions\\nHistopathologic features of band-like infiltration of\\n\\nlymphocytes and melanophages in the upper dermis\\nSome of the drugs known to cause lichen planus (LP):\\n\\nChloroquine\\nQuinacrine\\nQuinidine\\nGold\\nStreptomycin\\nTetracycline\\nNSAIDs\\nPhenothiazines\\nHydrochlorothiazide\\n\\nLP has been found in children, young and middle-aged\\nadults\\n\\nThe skin lesions are flat-topped polygonal papules with\\na characteristic colour\\n- Violaceous in fair skinned people but slate-grey on\\nblack skin\\n\\nItching is mild-to-severe\\nLike psoriasis, lesions often occur on sites of trauma\\n\\nand scratch marks (Koebner\\'s or isomorphic\\nphenomenon)\\n\\nWickham\\'s striae are fine white streaks present on the\\ntops of papules\\n\\nThe lesions are distributed mainly on:\\n- Flexor surfaces of the wrist\\n- Lumbar area\\n- The penis, tongue, buccal and vaginal mucous\\nmembranes\\n\\nOn the buccal mucous membrane it may present as\\nwhite reticulate pattern or plaque which may after\\nseveral years transgress into squamous cell carcinoma\\nThe nails are also affected with:\\n- Pitting, roughening and splitting (trachyonychia)\\n- Thickening (pachyonychia)\\n- Encroachment of the nail fold on the nail plate\\n(pterygium ungium)\\n\\nTotal destruction of all 20 nails may precede,\\n\\nChild:\\n\\nAdult:\\nChild:\\n\\nPAPULOSQUAMOUS DISORDERS\\nLICHEN PLANUS\\nIntroduction\\n\\nClinical features\\n\\nSystemic corticosteroids\\nPrednisolone\\n\\n20 - 40 mg orally daily for several weeks with\\nreduction of dosage or switch to alternate-day therapy as\\nsoon as improvement is seen\\n\\nnot recommended for children for this indication\\nOr:\\n\\nTriamcinolone acetonide 40 mg intramuscularly once\\nor twice (at a 6-week interval)\\nOr:\\n\\nCiclosporin\\n2.5 mg/kg daily in two\\n\\ndivided doses\\n- If good results not achieved within two weeks increase\\nrapidly to maximum 5 mg/kg daily\\n\\nSee Psoriasis\\n\\nAvoid precipitating drugs\\n\\nAcommon, mild, inflammatory exanthem\\nTends to be seasonal\\n\\n- More common during the fall, winter and spring in\\ntemperate countries\\n- In Nigeria more common during the early part of the\\nrainy season (though cases are seen throughout the year)\\n\\nCommon among siblings or other family/household\\nmembers\\n\\nThe seasonal clustering and household concurrence are\\nsuggestive of an infective origin\\n- Increasingly regarded as a delayed reaction to a viral\\ninfection (most likely Human Herpes Virus 7)\\n\\nLargely a disease of adolescents and in young adults,\\nbut it has been described all age groups\\n\\nRarely, there is an observable prodrome of pharyngitis,\\nmalaise and mild headache\\n\\nThe initial lesion in 20 - 80% of cases (“herald patch”)\\nis often larger than the later lesions and precedes the\\ngeneral eruption by 1 - 30 days\\n- Often found on the trunk, but may appear on the face or\\nextremities\\n- Oval with a collarette of scales\\n- May be diagnosed as “ringworm” before the other\\nlesions appear\\n\\nOther lesions consist of multiple erythematous macules\\nprogressing to small, red papules on the trunk\\n\\nSun-exposed areas are spared\\nPapules enlarge and become oval with long axes parallel\\n\\nto each other, and following lines of cleavage: the so-\\ncalled “Christmas tree” pattern\\n\\nPruritus is mild or absent\\nSome lesions may be atypical: vesicular, crusted,\\n\\nAdult:\\n\\nChild:\\n\\nAdult and child over 16 years:\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nPITYRIASIS ROSEA\\nIntroduction\\n\\nClinical features\\n\\naccompany, or follow the onset of skin lesions\\nThe hair follicles in the scalp may also be affected\\n\\n(lichen planopilaris) with post-inflammatory scarring\\nalopecia\\n\\nHepatitis C infection is found with greater frequency in\\nlichen planus than in controls\\n\\nHealing of the skin lesions leave post-inflammatory\\nhyperpigmentation\\n\\nConsider other papulosquamous disorders:\\nPsoriasis\\nPityriasis rosea\\nLupus erythematosus\\nSecondary syphilis\\nLichen striatus\\nParap soriasis\\nPityriasis rubra pilaris\\nNummular eczema\\n\\nOral lesions:-\\n- Erosive lesions may mimic\\n\\nAphthous stomatitis and herpes simplex\\n- White plaques may be confused with\\n\\nPre-malignant leukoplakia\\nWhite sponge naevus\\n\\n20-nail dystrophy\\nRarely, squamous cell carcinoma of oral and\\n\\nhypertrophic lichen planus\\n\\nHistopathology\\nHepatitis C antigen\\n\\nRelieve itching\\nClear lesions\\nSuppress inflammation\\n\\nTopical corticosteroids:\\nBeclomethasone dipropionate 0.1% cream\\n\\n- Apply 1 - 2 times daily\\n- Not licensed for use in children under one year\\n\\nBethamethasone valarate 0.1% cream and ointment\\n- Apply 1 - 2 times daily\\n\\nScalp lesions:\\n\\nClobetasol propionate 0.05% lotion\\n- Apply thinly 1 - 2 times daily for up to 4 weeks\\nMouth lesions:\\n\\nTriamcinolone acetonide 0.1% in adhesive base\\n- Apply a thin layer 2 - 4 times daily for a maximum of 5\\ndays; do not rub in\\nOr:\\n\\nTretinoin 0.025% cream\\napply thinly 1 - 2 times daily\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nFor isolated or hyperkeratotic lesions apply\\ncorticosteroids under occlusion or use intralesional\\ntriamcinolone (see Psoriasis)\\n\\nAdult and child:\\n\\nTopical corticosteroids\\n\\npurpuric, follicular, lichenoid, and psoriasiform\\nAvariant, inverse pityriasis rosea also occurs\\n\\n- Believed to be commoner in blacks\\n- Affects the face, neck, distal extremities and the\\nflexures\\n\\nUse of ampicillin early in the course of the eruption\\ncauses an explosive exacerbation of eruptions which\\nbecome more inflammatory and urticarial\\n- Lesions may become impetiginized\\n\\nThe disease persists for about 6 weeks but may last for 3\\n- 4 months\\n\\nHealing may occur with postinflammatory\\nhyper/hypopigmentation\\n\\nRecurrences are uncommon (about 1%) but the lesions\\nare usually mild and localized\\n\\nSecondary syphilis\\nExanthematic or pityriasis rosea-like drug eruptions\\nLichen planus\\nGuttate psoriasis\\nTinea corporis\\nTinea versicolor\\nSeborrhoeic dermatitis\\nViral exanthems\\nPityriasis lichenoides chronica\\n\\nNone\\n\\nNon-specific\\nVDRL\\n\\n- If secondary syphilis is suspected (e.g. lesions on\\npalms and soles with/without lymphadenopathy)\\n\\nTo relieve symptoms (if any)\\nReassure patients about the harmless, self-limiting\\n\\nnature of the eruption\\n\\nTopical:\\nUrea cream\\n\\n- Useful as a hydrating agent: apply twice daily\\nSystemic:\\n\\nOral antihistamine\\n- If pruritus is bothersome (see Urticaria)\\nSystemic corticosteroids:\\n- If complicated by ampicillin exanthematic eruption\\n\\nTriamcinolone acetonide 40 mg intramuscularly as a\\nsingle dose\\nAntibiotics:\\nIf lesions are impetiginized\\n\\nErythromycin 500 mg orally every 6 hours for 14 days\\n,\\n\\nAntihistamine; Triamcinolone: see Urticaria\\n\\nUnknown\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNotable adverse drug reactions caution\\n\\nPrevention\\n\\nPSORIASIS\\nIntroduction\\n\\n65 66\\n\\nChapter 6: Dermatology Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nA chronic inflammatory skin disease which is\\ncharacterized by\\n- Increased epidermal proliferation\\n- Epidermal thickening\\n- Erythematous lesions with silvery white scales\\n\\nAffects people of all ages in all countries\\nCause remains largely unknown but it has been\\n\\nvariously attributed to genetic, climatic, nutritional,\\necological and immunological factors\\nTriggers include:\\n\\nStreptococcal or viral infections\\nEmotional crises\\nPregnancy and delivery\\nTrauma (Köebner phenomenon)\\nDiet\\nAlcohol\\nCigarette smoking\\nHypocalcemia\\nStress\\nInfections e.g. streptococcal pharyngitis\\n\\nMay occasionally be provoked or exacerbated by drugs:\\nACE inhibitors\\nCalcium channel blockers\\n\\n- adrenoceptor antagonists\\nChloroquine\\nLithium\\nNon-SteroidalAnti-inflammatory Drugs (NSAIDs)\\nTerbinafine\\nLipid lowering drugs\\n\\nLesions are characterized by:\\nSharp borders\\nErythema\\nIncreased scales\\nWhen scratched, scales fall off as tiny flakes that\\n\\nresemble scrapings from a candle (Candle sign)\\nIf the scales are removed (exposing the dermal papillae)\\n\\npunctate bleeding from the enlarged capillaries occur\\n(Auspitz sign)\\n\\nEruptive lesions may be intensely or mildly pruritic, or\\nmay be asymptomatic\\n\\nAll lesions begin as small scaly macules but may take\\ndivergent paths as they spread centrifugally\\nPatterns seen may be:\\n- Guttate\\n- Follicular\\n- Numular\\n- Geographic\\n- Erythrodermic\\n- Annular\\n- Gyrate or serpenginous\\n\\nFavoured sites are\\n- Knees and elbows\\n- Scalp\\n- Palms and soles\\n- Nails\\n\\nβ\\n\\nClinical features\\n\\npsoriasis)\\n- Initiate under medical supervision\\n- Start with 0.1%; carefully apply to lesions only, leave\\nin contact for 30 minutes, then wash off thoroughly\\n- Repeat application daily, gradually increasing strength\\nto 2% and contact time to 60 minutes at weekly intervals\\n- Wash hands thoroughly after use\\n- Avoid contact with eyes and healthy skin\\n\\nCoal tar solution (for chronic psoriasis)\\n- Use either alone or in combination with exposure to\\nultraviolet light\\n- Apply 1 - 4 times daily, preferably starting with a lower\\nstrength preparation\\n\\nCoal tar bath\\n- Use 100 mL in bath of tepid water and soak for 10 - 20\\nminutes\\n- Use once daily, to once every 3 days for at least 10 - 20\\nminutes, and for at least 10 baths\\n- Often alternated with ultraviolet (UVB) rays, allowing\\nat least 24 hours between exposure and treatment with\\ncoal tar\\n- Urea 10% cream or ointment (for dry scaling and\\nitching skin)\\n- Apply twice daily, preferably to damp skin\\n\\nVitamin D analogue calcipotriol\\n- Suitable for childhood psoriasis\\nCombination therapy with calcipotriol and high-potency\\n(Class I) steroids may provide:\\n- Greater response rates, fewer side effects, and steroid\\nsparing, allowing a shift to a less potent topical steroid or\\nless frequent use of a Class I steroid\\n\\nSalicylic acid 3 - 5% in cold cream or hydrophilic\\nointment (for thick scaling)\\n\\nTazarotene 0.05% and 0.1% gels\\n- May be combined with topical steroids for mild- to-\\nmoderate plaque psoriasis\\n\\nTacrolimus ointment 0.1% or 0.03%\\n- For psoriasis in the flexures, face and penis, when\\npotent steroids cannot be used and other agents are poorly\\ntolerated\\n\\nIntra-lesional corticosteroid injections of triamcinolone\\nare frequently used\\n- Triamcinolone acetonide suspension 10 mg/mL may\\nbe diluted with sterile saline to make a concentration of\\n2.5 - 5 mg/mL\\n- For nail lesions inject triamcinolone in the region of\\nthe matrix and the lateral nail fold\\n\\nSoften scales with salicylic acid 3% in mineral/olive\\noil, massage in and leave on overnight\\n- Then shampoo with a tar shampoo, and remove scales\\nmechanically with a comb and brush\\n- Repeat daily until the scales are gone\\n- If 3% is not very effective, use 6% salicylic acid\\nOr:\\n\\nSmall lesions and nail psoriasis\\n\\nScalp\\n\\nIntertriginous regions such as the gluteal cleft, groin,\\npenis, labia, axillae, beneath the breasts and between the\\ntoes are involved (inverse psoriasis or psoriasis inversa)\\n\\nThere could also be other organ involvement e.g.\\npsoriatic arthritis\\n\\nThe disease runs a chronic and highly variable course\\n(waxes and wanes)\\n- New lesions may replace older, regressing ones\\n- Unstable lesions may evolve into psoriatic\\nerythroderma or generalized pustular psoriasis\\n\\nHIV/AIDS can lead to the onset or worsening of\\npsoriasis\\n\\nGuttate psoriasis:\\nPityriasis lichenoides et varioliformis acuta\\nPityriasis rosea\\nSecondary syphilis (psoriasiform syphilis)\\n\\nScalp, face, chest lesions:\\nSeborrhoeic dermatitis\\n\\nLupus erythematosus\\nChronic truncal psoriasis:\\n\\nNummular dermatitis\\nLichen planus\\nSmall plaque parapsoriasis\\nTinea corporis\\nPityriasis rubra pilaris\\n\\nIntertriginous areas:\\nCandidiasis\\nIntertrigo\\nHailey-Hailey disease\\n\\nNail:\\nTinea unguium\\nLichen planus\\nTrachyonychia\\n\\nErythroderma\\nArthritis mutilans\\n\\nHistopathology\\n\\nTo retard epidermal proliferation\\nReduce inflammation\\nPrevent complications\\n\\nChoice of treatment depends on the site, severity and\\nduration of the disease, previous treatment, and the age\\nof the patient\\nTopical treatment:\\n\\nCorticosteroid ointment\\n- Hydrocortisone for the face and flexures\\n- Betamethasone or clobetasol for the scalp, hands and\\nfeet\\n- Application is followed by an occlusive dressing of a\\npolyethylene film, which may remain in place for 12 - 24\\nhours to augment effectiveness\\n\\nDithranol ointment 0.1% - 2% (for moderately severe\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nFluocinolone acetonide 0.01% in oil\\n- Apply and leave under a shower cap at night and\\nshampoo in the morning\\n- After shampooing and while the hair is still wet,\\nmassage thoroughly into the scalp skin\\n- Attempting to remove scales by excessive brushing,\\nscrubbing, or combing may result in sufficient trauma to\\nworsen psoriasis (Koebner\\'s effect)\\n\\nUltraviolet light (UVL)\\n- For psoriasis involving more than 30% of the body\\nsurface\\n\\n290 - 320 nm ultraviolet B (UVB) three times weekly\\nfor 18 - 24 treatments\\n- Lubricating the skin surface with mineral oil or\\npetroleum jelly before UVL produces uniform\\npenetration by reducing the reflection of light from the\\ndisrupted skin surface\\n\\nPUVA(psoralen plus ultravioletA)\\n- For patients who have not responded to standard UVB\\ntreatment\\n\\nSevere psoriasis unresponsive to outpatient UVL, may\\nbe treated in a day care centre with the Goeckerman\\n- Use of crude coal tar for many hours and exposure to\\nUVB light\\nSystemic therapy:\\n\\nAntibiotics to eliminate streptococcal pharyngitis\\nAciteritin\\n\\nInitially 25 - 30 mg orally daily for 2 - 4 weeks;\\nadjusted according to response. Usual range 25 - 50 mg\\ndaily (maximum 75 mg)\\n- For pustular, erythrodermic and plaque types, and\\npsoriatic arthritis\\n\\nsevere extensive psoriasis resistant to other forms\\nof therapy, palmo-plantar pustular psoriasis\\n1 month - 12 years: 500 micrograms/kg orally once daily\\nwith food or milk; occasionally up to 1 mg/kg/day\\n\\nMethotrexate\\n20 mg orally once weekly\\nnot licensed for this indication\\n\\nIndicated for:\\n- Psoriatic erythroderma\\n- Moderate-to-severe psoriatic arthritis\\n- Acute pustular psoriasis (von Zumbusch type)\\n- Involvement of more than 20% total body surface\\n- Localized pustular psoriasis that causes functional\\nimpairment (e.g. hands)\\n- Lack of response to phototherapy, PUVA, or retinoids\\n\\nCyclosporine\\n- Induction therapy is 2.5 - 3.0 mg/kg given in a divided\\ndose twice daily\\n- Can be increased to 5.0 mg/kg/day until a clinical\\nresponse is noted. The dose is then tapered\\n- On discontinuation a severe flare-up may occur,\\nsuggesting that an alternative treatment (e.g.\\n\\nAdult:\\n\\nChild:\\n\\nTo be administered under expert supervision in both\\nadults and children\\n\\nAdult:\\nChild:\\n\\n67 68\\n\\nChapter 6: Dermatology Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nphototherapy or acitretin) should be instituted as the\\ncyclosporine dose is reduced\\n\\nTNF inhibitors (Efaluzimab)\\n- Indicated for moderate-to-severe chronic plaque\\npsoriasis unresponsive to, or intolerant of other systemic\\ntherapy or photochemotherapy\\n- Initially 700 micrograms/kg by subcutaneous\\ninjection then 1 mg/kg weekly\\n- Discontinue if inadequate response after 12 weeks\\n- Not recommended for children and adolescents\\n\\nDiet: fish oils rich in 3 polyunsaturated fatty acids\\nPatient education\\nEmotional support\\n\\nCoal tar:\\nContraindicated in inflammed, broken or infected skin\\n\\n- May cause irritation, photosensitivity reactions\\nHypersensitivity\\nSkin, hair, fabrics and bathtubs discoloured brown and\\n\\nsmelly\\nDithranol:\\n\\nIrritant: avoid contact with eyes and healthy skin\\nContraindicated in hypersensitivity; avoid use on face,\\n\\nacute eruptions, and excessively inflamed areas\\n- Discontinue use if excessive erythema occurs or\\nlesions spread\\n\\nConjunctivitis following contact with eyes\\nStaining of skin, hair, and fabrics brown\\n\\nVitamin D (calcipotriol):\\n\\nMay irritate the skin (stinging)\\nVery expensive\\n\\nUrea:\\nAvoid application to face or broken skin; avoid contact\\n\\nwith eyes\\nMay cause transient stinging and local irritation\\n\\nSteroids:\\nWhen extensive areas are treated or when there is\\n\\nerythrodermic psoriasis, sufficient may be absorbed to\\ncause adrenal suppression\\n\\nMay induce tachyphylaxis\\nRebound often occurs after stopping treatment,\\n\\nresulting in a more unstable form of psoriasis\\nIntralesional injection may cause reversible atrophy at\\n\\nthe injection site\\nSalicylic acid:\\n\\nWidespread application may lead to salicylate toxicity\\nUltraviolet light:\\n\\nBurning of skin may cause Koebner\\'s phenomenon\\nand an exacerbation\\n\\nIncreased risk of skin cancer particularly in persons\\nwith fair complexions and albinos. Examine\\nperiodically\\n\\nUse protective glasses to prevent cataracts\\nCauses premature ageing of the skin\\n\\nAdjuvant therapy\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nΩ-\\n\\n3\\n\\nCommon in tropical climate (which is hot and humid)\\nInfection could be spread by fomites\\nThe mycoses caused by dermatophytes are called\\n\\ndermatophytosis, tinea, or ringworm\\nOn certain parts of the body they have distinctive features\\ncharacteristic of that particular site; therefore the tineas\\nare divided into:\\n\\nTinea capitis (scalp)\\nTinea barbae (beard)\\nTinea faciei (face)\\nTinea corporis (trunk)\\nTinea cruris (groin)\\nTinea manuum (hand)\\nTinea pedis (feet)\\nTinea unguium or onychomycosis (nail)\\n\\nVaried: depending on the site of the body involved\\nPruritis is a notable symptom\\n\\nTinea capitis:\\nScalp involvement is seen predominantly in children\\nLesions are varied in appearance: usually scaly, dry and\\n\\nannular, with or without alopecia\\nSome appear diffuse and scaly and may involve the\\n\\nwhole of the scalp\\nInflamed, pustular lesions (kerion) may develop when\\n\\ninfection is from animal to man\\nPruritus usually leads to excoriation of lesions and\\n\\nsecondary bacterial infection\\nHypersensitivity to the presence of the fungal elements\\n\\nmay occur at distant sites (“Id” reaction)\\nTinea barbae:\\n\\nRingworm of the beard is not a common disease\\nOccurs chiefly among those in agricultural pursuits,\\n\\nespecially those in contact with farm animals\\nLesions present as severe, deep folliculitis with\\n\\nerythema, nodular infiltrates, scales and pustules\\nMarked regional lymphadenopathy is the rule\\n\\nTinea faciei:\\nFungal infection of the face (apart from the beard)\\n\\n- Frequently misdiagnosed, since the typical ringworm\\nnot commonly seen on the face\\n\\nErythematous, slightly scaling, indistinct borders are\\nusually seen\\n\\nPeople who use corticosteroids such as cosmetic\\nbleaching creams are prone to T. faciei\\n\\nThe steroid effect makes the lesions atypical hence,\\nT.incognito\\nTinea corporis:\\n\\nOne or more circular, sharply circumscribed, slightly\\nerythematous, dry, scaly patches\\n\\nLesions may be slightly elevated, particularly at the\\nborders, where they are more inflammed and scaly than at\\nthe central parts\\n\\nProgressive central clearing produces annular outlines\\nthat give them the name “ringworm”\\n\\nIn the presence of immune suppression from underlying\\n\\nClinical features\\n\\nShould be administered only by experienced\\ndermatologists\\n\\nPrevention\\n\\nDERMATOPHYTE INFECTIONS (Tinea)\\nIntroduction\\n\\nMethotrexate:\\nMay cause blood disorders (bone marrow\\n\\nsuppression), liver damage, pulmonary toxicity, GIT\\ndisturbances\\n- If stomatitis and diarrhoea occur, stop treatment\\n- Renal failure, skin reactions, alopecia, osteoporosis,\\narthalgia, myalgia, ocular irritation, may also occur\\n- May precipitate diabetes\\n- Monitor before and throughout treatment: blood\\ncounts and hepatic and renal function tests\\n- Contraception during and for at least 6 months after\\ntreatment for both males and females\\n- Contraindicated in pregnancy and breast feeding.\\nFolic acid may be given to reduce toxicity\\nCyclosporin:\\n\\nNephrotoxic: monitor kidney function\\nOther side effects- hypertrichosis, hyperuricaemia,\\n\\nt h r o m b o c y t o p e n i a , m a l i g n a n c i e s a n d\\nlymphoproliferative disorders\\n(similar to other immunosuppressive therapies)\\nAciteritin:\\n\\nSeeAcne- isotretinoin\\nTacrolimus:\\n\\nSeeAtopic eczema\\nEfalizumab:\\n\\nThrombocytopenia, hepatic and renal impairment.\\nMonitor platelet count during initial herapy, then every 3\\nmonths\\nContraindicated in immunodeficiency, severe infection,\\n\\nactive tuberculosis; history of malignancy; pregnancy\\nand breastfeeding\\n\\nMay cause influenza-like symptoms, leucocytosis,\\narthralgia, paradoxical exacerbation of psoriasis or\\ndevelopment of variant forms including psoriatic\\narthritis (discontinue treatment)\\n\\nExpensive\\n\\nAvoid exacerbating factors e.g. abrasions, scatches,\\nharsh fibre bathing sponges, and the drugs listed above\\n\\nPrevent streptococcal sore throat and treat promptly\\nwhen it occurs\\n\\nSuperficial fungal infection that affects keratinized\\ntissues\\n\\nFungi that usually cause only superficial infections on\\nthe skin are called dermatophyte- classified in three\\ngenera:\\n\\nCan be acquired from humans, animals, soil or\\nvegetable matter\\n\\nSUPERFICIALFUNGALINFECTIONS\\n\\nMicrosporum, Trichophyton and Epidermophyton\\n\\nillness, or chronic use of topical steroid creams lesions\\nmay be very extensive and atypical in appearance (Tinea\\nincognito)\\nTinea cruris:\\n\\nOccurs more commonly in adult men\\nLeads to severe itching in the groins (crotch)\\nPresents as slowly spreading erythematous patches with\\n\\nscaly borders on the upper inner aspects of the thighs\\n\\nTo clear lesions and prevent recurrence\\n\\nKetoconazole\\n- 2% cream apply twice daily\\nMiconzole\\n- 2% cream apply twice daily\\n\\nFluconazole\\n50 mg orally daily for 2 - 4 weeks; up to 6 weeks in\\n\\ntinea pedis\\n1 month - 18 years 3 mg/kg (maximum 50 mg)\\n\\ndaily for 2 - 4 weeks; up to 6 weeks in tinia pedis\\n\\nFluconazole: numerous drug interactions\\nHepatotoxicity during long-term daily therapy\\n\\nDo not share combs, hair brushes, school caps, shoes,\\nsocks or underwears\\n\\nKeep the feet dry; avoid tight-fitting covered shoes\\nAerate the feet as often as possible\\nUse good antiseptic powder on the feet after bathing e.g.\\n\\nTolnaftate 1% powder\\nReduce perspiration and enhance evaporation from the\\n\\ncrural areas by wearing loose pants (e.g. boxer pants)\\nmade of absorbent cotton fabric\\n\\nApply plain talcum powder or antifungal powders in the\\nflexures e.g. armpits, under the breasts, in the groins\\n\\nAvoid exposure to animals with ringworm ( )\\nespecially cats, dogs and (less commonly), horses and\\ncattle\\nExcessive perspiration is the most common predisposing\\nfactor in adult T. corporis\\n- Avoid excessively hot, humid environments, or take a\\ncold shower after sweating\\n\\nSuperficial yeast infection of the skin caused by\\nspecies (normal commensals on the\\n\\nskin)\\nCommon in warm humid climates\\n\\nPredisposing factors:\\nOcclusion of the skin with pomades and greases\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nPITYRIASIS VERSICOLOR Tinea versicolor\\nIntroduction\\n\\nTopical\\n\\nSystemic\\n\\nAdult:\\n\\nChild:\\n\\nM. canis\\n\\nMalassezia furfur\\n\\n( )\\n\\n69 70\\n\\nChapter 6: Dermatology Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nImmune suppression\\nHyperhidrosis\\nHeat\\n\\nUsually asymptomatic (or just mild itching)\\nMay be generalized in the immuno-compromised\\nFine scaly, guttate or nummular patches, particularly on\\n\\nyoung adults who perspire freely\\nIndividual patches are dirty, yellowish/brownish/\\n\\nhypopigmented macules (hence the term versicolor)\\nLarger irregular patches may evolve\\nSometimes follicular tendency is marked; more\\n\\nnoticeable at the advancing edges of the irregular patches\\nSites of predilection:\\n\\n- Sternal region\\n- Sides of the chest\\n- Shoulders\\n- Upper back\\n- Face\\n\\nSeborrhoeic dermatitis\\nPityriasis alba\\nPityriasis rosea\\nLeprosy\\n\\nNone usually; only of cosmetic significance\\nM. furfur sepsis\\n\\n- From contamination of the lipid-containing medium in\\ni m m u n o c o m p r o m i s e d p a t i e n t s r e c e i v i n g\\nhyperalimentation through tubes\\n\\nSkin scraping for KOH microscopy\\n\\nImprove appearance of skin\\n\\nTopical:\\nSelenuim sulphide shampoo\\n\\n- Apply on affected areas daily, leave on for 10 - 30\\nminutes minutes and wash off\\n- Continue for 3 weeks\\n\\nKetoconazole shampoo\\n- Use as above\\n\\nMiconazole cream\\n- For limited areas\\n- Apply twice daily for 3 weeks\\n\\nDeal with underlying predisposing factor(s)\\n\\nAvoid hot, humid environments or clothings that\\npromote perspiration\\n\\nTake a cold shower after perspiration\\nUse any of the above shampoo washes once a month if\\n\\npredisposed\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nPrevention\\n\\nHERPES ZOSTER\\n\\nVIRALINFECTIONS\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild:\\n\\napply 3 - 4 times daily\\nmay not be suitable for children because of its\\n\\nirritant properties\\nTopical local anaesthetics\\n\\n- Helpful in some patients\\n\\nAciclovir\\n- Ensure adequate hydration\\n- Caution in pregnancy and breastfeeding\\n- May cause nausea, vomiting, dizziness\\n- Fatigue pruritus and photosensitivity\\n\\nA common infection caused by a large epidermotropic\\npox virus\\n\\nCommon in children\\nSpread by direct human to human contact\\nIn adults it is often transmitted during sexual intercourse\\n\\nIndividual lesions are smooth-surfaced, firm, dome-\\nshaped, pearly papules; average diameter 3 - 5 mm\\n\\nSome “giant” lesions may be up to 1.5 cm in diameter\\nCharacteristic central umbilication\\nSpontaneous resolution is expected\\nHost response plays an important role\\nChildren with widespread molluscum contagiosum\\n\\nusually have atopic dermatitis\\nConsider HIV in adults\\n\\nViral warts\\nGiant molluscum contagiosum may mimic basal cell\\n\\nepithelioma\\n\\nSecondary bacterial infection\\n\\nHistopathology of the expressed pasty core\\n\\nEradicate the skin lesions\\n\\nLight electrosurgery with a fine needle\\nCryotherapy with trichloroacetic acid 35% - 100%\\nCurettage and paint with iodine\\n\\nCimetidine\\n40 mg/kg/day orally for 2 months\\nnot licensed for use in children less than 1 year. 1\\n\\nmonth - 12 years: 5 - 10 mg/kg (maximum 400 mg) 4\\ntimes daily 12 - 18 years: 400 mg orally 4 times daily\\n\\nAntibiotics\\n- To prevent or treat secondary infection\\n\\nAvoid direct skin contact with an infected person\\n\\nNotable adverse drug reactions, caution\\n\\nMOLLUSCUM CONTAGIOSUM\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nPrevention\\n\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnosis\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nA second infection with varicella-zoster virus (VZV),\\nusually in adults and limited to a dermatome\\nSynonyms:\\n\\nZoster, from the Greek “zostrix”, meaning belt\\nShingles, from the Latin “cingulus”, also meaning belt\\n\\nVesicles arranged in one or more dermatomes\\nunilaterally\\n\\nInitial pruritus, pain and paraesthesia\\nMultidermatomal and disseminated forms may occur\\n\\nin immuno-compromised states especially HIV infection\\nThe early rash is vesicular, later becomes pustular and\\n\\nthen ulcerates\\nThe whole episode may last 2 weeks\\n\\nChicken pox\\n\\nPain may persist long after rash has healed (post-\\nherpetic neuralgia)\\nDissemination of infection in the immunocompromised\\nHemorrhagic and necrotic lesions\\nRamsay-Hunt syndrome (Herpes zoster of the ear\\n\\nresulting in severe ear pain, hearing loss and vertigo)\\nVisual impairment due to corneal ulcers (Zoster\\n\\nophthalmicus-V1)\\n\\nHIV screening for all patients\\nFull Blood Count with differentials\\nESR\\n\\nProvide symptomatic relief\\nTreat secondary infection\\nTreat any identified predisposing factor\\n\\nDrying agents e.g. zinc oxide 5% (calamine) lotion\\n- Apply twice daily\\n\\nAciclovir\\n800 mg orally five times daily for 5 - 7 days\\n\\n- Continue for at least 3 days after complete healing\\n12 - 18 years: 5 mg/kg orally every 8 hours usually\\n\\nfor 5 days\\nOr:\\n\\nAciclovir cream 5%\\napply five times daily for 5 - 10 days\\nnot listed for this indication in children\\n\\nOral antibiotics to treat or prevent secondary bacterial\\ninfection\\n\\nAmitriptyline\\n10 - 25 mg orally initially, gradually increased to 75 mg\\ndaily\\nOr:\\n\\nCapsaicin 0.075% cream\\n- For use after lesions have healed\\n\\nExclude Hodgkin\\'s disease and leukaemia\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\nChild:\\n\\nHerpetic neuralgia\\n\\nVARICELLA (Chickenpox)\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution\\n\\nVaricella Zoster virus is Human Herpes Virus 3\\nTransmission is by direct contact with the lesions and\\n\\nby the respiratory route\\nInitial replication occurs in the nasopharynx and\\n\\nconjunctivae\\nAfter the primary infection, the virus remains dormant\\n\\nin nervous tissue\\n- Reactivation later in life is typically manifested as\\nHerpes zoster\\n\\nIncubation period is 10 - 21 days\\nVesicular eruptions consist of delicate “teardrop”\\n\\nvesicles on an erythematous base\\nThe eruption starts with faint macules that develop\\n\\nrapidly into vesicles within 24 hours\\nSuccessive fresh crops of vesicles appear for a few days,\\n\\nmainly on the trunk, face, and oral mucosa\\nNew lesions usually stop appearing by the fifth day; the\\n\\nmajority is crusted by the sixth day\\n- Most disappear in less than 20 days without a scar,\\nexcept larger and secondarily infected lesions\\n\\nLow grade fever\\nMalaise\\nHeadaches\\nThe severity of the disease is age-dependent\\n\\n- Adults have more severe disease and a greater risk of\\nvisceral disease\\n\\nVariola minor\\nDisseminated zoster in immunosuppressed patients\\nWidespread papular urticaria\\nCoxsackie and ECHO viruses eruption\\n\\nSecondary bacterial infection\\nPneumonia\\nCerebellar ataxia and encephalitis\\nReye\\'s syndrome\\n\\nTzanck smear\\nDirect fluorescent antibody (DFA) staining\\nPolymerase Cham. Reaction (PCR)\\n\\nRelieve itching and treat secondary bacterial infection\\nReduce severity and scarring\\n\\nAciclovir\\n10 mg/kg intravenously three times daily for 7\\n\\ndays in immunocompromised patients\\nsee Herpes zoster\\n\\nAntihistamine for pruritus\\nCo-trimoxazole or erythromycin for secondary\\n\\ninfection\\n\\nAciclovir\\n\\nAdult:\\n\\nChild:\\n\\n71 72\\n\\nChapter 6: Dermatology Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\n- Ensure adequate hydration\\n- Caution in pregnancy and breastfeeding\\n- May cause nausea, vomiting, dizziness, fatigue pruritus\\nand photosensitivity\\n\\nIsolate patients from non-immune persons\\n\\nInfections caused by human papilloma viruses (HPV);\\ninclude more than 80 types\\n\\nTransferred between humans, or from animals to\\nhumans\\n\\nCause cutaneous tumours which tend to regress\\nspontaneously but may rarely progress into cutaneous\\nmalignancies\\n\\nInfection may be clinical, subclinical, or latent\\nClinical lesions are visible by gross inspection\\nSubclinical lesions may be seen only by aided\\n\\nexamination (e.g. the use of acetic acid soaking)\\nLatent infection:\\n\\n- HPV virus or viral genome is present in apparently\\nnormal skin\\n- Thought to be common, especially in genital warts,\\nand explains in part the failure of destructive methods to\\neradicate warts\\n\\nIncubation period is highly variable; from weeks to\\nyears\\n\\nAuto-inoculation is the rule\\nLesions may also occur on scratches (Koebner\\n\\nphenomenon)\\nLesions are classified according to their positions and\\nshape:\\n\\nFirm growths with rough surface; round or irregular,\\ngreyish or brown\\n\\nGenerally appear on areas that are frequently injured,\\nsuch as the fingers, around the nails (periungual warts);\\nknees, face and scalp\\n\\nDevelop on the soles of the feet, where they are usually\\nflattened by the pressure of walking\\n- Areactive callus forms around lesions\\n\\nMultiple warts may coalesce, resembling a tile or\\nmosaic floor (mosaic warts)\\n\\nMay be extremely tender\\nUnlike corns and calluses, plantar warts tend to bleed\\n\\nfrom many tiny spots, like pinpoints when pared down\\nwith a blade\\n\\nLong, thin, small growths that usually crop up on the\\neyelids, face, neck, or lips\\n\\nPeople who chronically use corticosteroids as cosmetic\\nbleaching creams are prone to multiple filiform warts\\n\\nPrevention\\n\\nVIRALWARTS (Verrucae)\\nIntroduction\\n\\nClinical features\\n\\nCommon warts\\n\\nPlantar warts\\n\\nFiliform warts\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nACNE VULGARIS (Pimples)\\nIntroduction\\n\\nClinical features\\n\\nSalicylic acid with lactic acid plaster\\n- Apply carefully to wart; rub wart surface gently with\\nfile or pumice stone once weekly\\n- May need to treat for as long as 3 months\\n\\nPodophyllum resin\\n- Apply weekly under supervision e.g. in genitourinary\\nclinic\\n\\nImiquimod 5% cream\\n- Apply thinly once daily on 3 alternate days per week\\nuntil lesions resolve (maximum 16 weeks)\\n\\nSalicylic acid plaster\\n- Avoid broken skin\\n- Not suitable for anogenital region or large areas\\n\\nPodophyllum\\n- Avoid normal skin and open wounds\\n- Keep away from face\\n- Should not stay on treated skin for more than 6 hours\\nbefore washing\\n\\nWomen with genital HPV infection should have routine\\ncervical cytologic screening\\n- Pappanicolaou (PAP) smear to detect cervical dysplasia\\n\\nOne of the most common skin diseases\\nAdisorder of the pilosebaceous follicles\\nTypically first appears during puberty when androgenic\\n\\nstimulation triggers excessive production of sebum\\nMany factors interact to produce acne in a given patient\\n\\n- Genetics\\n- Sebum production\\n- Hormones\\n- Bacteria\\n- Properties of the sebaceous follicle\\n- Immunologic\\n\\nOver-production of stratum corneum cells\\n(hyperkeratosis) obstructs the hair follicles at the\\nfollicular mouth producing open comedones, or\\nblackheads\\n\\nJust beneath the follicular opening in the neck of the\\nsebaceous follicle it caues microcomedones (closed\\ncomedones, or whiteheads)\\n\\nThere is an overgrowth of gram-positive bacteria in the\\nobstructed follicle: or\\n\\n; distally\\n\\nRupture of the comedonal contents into the dermis\\ninduces a foreign body reaction and inflammation\\n\\nMISCELLANEOUS DISORDERS\\n\\nPropionibacterium acnes\\nStaphylococcus epidermidis Pityrosporum\\novale\\n\\nPlane warts\\n\\nGenital warts\\n\\nCommon warts\\n\\nPlane warts\\n\\nGenital warts\\n\\nMore common in children and young adult.\\nUsually appear in groups as smooth, yellow-brown,\\n\\nsmall, flat papules; most frequently on the face\\n\\nOccur most often on warm, moist surfaces of the body\\nIn men, usual sites are the end and shaft of the penis, and\\n\\nbelow the foreskin (if uncircumcised)\\nIn women, lesions occur on the vulva, vaginal wall,\\n\\ncervix, and skin surrounding the vaginal area\\nMay develop in the perianal region or rectum\\n\\n- Especially in homosexual men, and in women who\\nengage in anal sex\\n\\nUsually appear 1 - 6 months after infection as soft\\nerythematous papules, which may be greyish if\\nhyperkeratotic\\nNew lesions develop rapidly and all coalesce, producing\\n\\na cauliflower-like picture\\nMay grow rapidly in pregnant women, and\\n\\nimmunocompromised patients\\n\\nKeratoacanthoma\\nSquamous cell carcinoma\\nSeborrhoeic keratosis\\nHypertrophic lichen planus\\nTuberculosis verrucosa cutis\\nPalmoplantar keratoderma\\nArsenical keratoses\\n\\nEpidermodysplasia verruciformis\\nSyringomas\\nDermatosis papulosa nigra\\nLichen planus\\nLichen nitidus\\n\\nCondyloma lata\\nPemphigus vegetans\\n\\nSquamous cell carcinoma of the perianal skin\\nCervical carcinoma from anogenital warts\\nObstructive laryngeal papillomatosis in babies infected\\n\\nthrough maternal birth canal\\n\\nHistopathology if in doubt\\n\\nTreatment depends on their location, type, and severity,\\nas well as duration of lesions\\n\\nEradicate the skin lesions\\nPrevent complications\\n\\nLiquid nitrogen freeze\\nElectro-desiccation\\nLaser surgery\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nManagement\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nAlmost every individual has some degree of acne during\\npuberty, with spontaneous resolution occurring in early\\nadult life\\nOccasionally, the disease persists into the fourth decade,\\n\\nor even remains a life-long problem\\nFavoured sites are the face, upper back and upper chest\\n\\nand shoulders\\nThere may be mild soreness, pain, or itching\\nMay present differently in different age groups\\n\\n- Pre-teens often present with comedones as their first\\nlesions\\n- Teenage acne is invariably inflammatory and the lesions\\ninclude firm red papules, pustules, abscesses, indurated\\nnodules, cysts and rarely interconnecting draining sinus\\ntracts\\n\\nInflammatory acne can be classified as mild, moderate,\\nor severe\\n\\nMild acne:\\n- Few-to-several inflammatory papules and pustules, but\\nno nodules\\n\\nModerate acne:\\n- Several-to-many papules, pustules, and a few to several\\nnodules\\n\\nSevere acne (acne conglobata):\\n- Numerous fistulated comedones; extensive\\ninflammatory papules; pustules; many cysts, abscesses,\\nnodules, and draining sinuses\\n- The lesions may be generalized, involving even the\\nbuttocks\\n- Excoriation of acne papules and microcomedones are\\ncommon, and scarring may result\\n- Usually, multiple shallow erosions or crusts are found\\n\\nAcne rosacea\\nDermatosis papulosa nigra\\nSteatocystoma multiplex\\nSyringoma\\nTrichoepithelioma\\nWarts\\nAngiofibromas of tuberous sclerosis\\nMolluscum contagiosum\\nSteroid acne from the use of systemic steroids or topical\\n\\nfluorinated steroids on the face (often as cosmetic skin\\nlightening creams)\\n\\nSome drugs may produce acneiform eruptions\\n- Androgens\\n- Adrenocorticotropic hormone (ACTH)\\n- Glucocorticoids\\n- Hydantoins\\n- Isoniazid\\n- Halogens\\n\\nPsychosocial problems from cosmetic disfigurement\\nPost-inflammatory pigmentary changes\\nPitted scars\\nKeloids\\n\\nDifferential diagnoses\\n\\nComplications\\n\\n73 74\\n\\nChapter 6: Dermatology Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nAcne fulminans (acute febrile ulcerative acne\\nconglobata with polyarthritis and leukemoid reaction)\\n\\nUsually, none required\\nIn the presence of unusual acne, hirsutism, premature\\npubarche, or androgenic alopecia (especially when\\nassociated with obesity and/or menstrual irregularities):\\n\\nScreen for hyperandrogenism\\nBlood levels of free testosterone,\\ndehydroepiandrosterone, and androstenedione\\n\\n- If raised, test response of the hormones and cortisol to\\ndexamethasone suppression\\n\\nReduce severity of acne\\nPrevent complications\\n\\nTopical treatment only:\\nTretinoin cream\\n\\n0.025% 0.05% 0.1% cream or gel applied\\nnightly\\n\\napply thinly 1 - 2 times daily\\nOr:\\n\\nBenzoyl peroxide\\n2.5% 5% water-based or alcohol-based gels,\\n\\napplied twice daily\\napply 1 - 2 times daily preferably\\n\\nafter washing with soap and water\\n- Start with lower strength preparations\\nInfantile acne:\\n\\napply 1 - 2 times daily\\n- Start with lower strength preparations\\nOr:\\n\\nClindamycin or erythromycin gel or solution twice\\ndaily\\n\\napply twice daily\\nOr:\\n\\nAzelaic acid 20% cream\\napply twice daily; initially once daily\\n\\nfor sensitive skin\\n- Suitable for acne patients with atopic dermatitis\\n\\nSalicylic acid solution 2%\\napply up to 3 times daily\\n\\n- Tretinoin may be used at night and benzoyl peroxide\\nor topical antibiotics in the morning because they have\\ndifferent modes of action and are complementary\\n- It may take 8 - 12 weeks before observable\\nimprovement occurs\\n\\nTreat as above\\n\\nTopical and systemic drugs:\\nTetracycline\\n\\n500 mg orally every 12\\nhours\\nOr:\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\nComedonal acne\\n\\nMild inflammatory acne\\n\\nModerate inflammatory acne\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild 12-18 years:\\n\\nChild 1 month to 2 years; neonate:\\n\\nAdult and child:\\n\\nAdult and child:\\n\\nAdult and child:\\n\\nAdult and child over 12 years:\\n\\nor or\\n\\nor\\n\\nComedone extraction\\nIntralesional injection for deeper papules and\\n\\noccasional cysts\\nDilute suspensions of triamcinolone acetonide\\n\\n- 2.5 mg/mL 0.05 mLper lesion\\nLaser, dermabrasion for cosmetic improvement of scars\\n\\nTopical preparations:\\nCreams and water-based gels are less irritating than\\n\\nalcohol/acetone-based gels\\n- Always initiate treatment with lower strength and\\nincrease as tolerance develops to initial irritant reaction\\n- Occasionally contact sensitivity may occur\\n\\nBenzoyl peroxide\\n- May bleach fabrics, hair and skin\\n- Avoid contact with eyes, mouth, and mucous\\nmembranes\\n\\nAntibiotic resistance may occur\\n- Avoid the use of different oral and topical antibiotics at\\nthe same time\\n- Vaginitis and perianal itching due to Candida may\\noccur\\n- Tetracyclines, minocycline and doxycycline are\\ncontraindicated in pregnancy and in children less than 12\\nyears\\n- May reduce the effectiveness of oral contraceptives\\n- Often cause GIT symptoms\\n- Minocycline and doxycycline may cause\\nphotodermatitis\\n- Erythromycin cannot be used in conjunction with\\nastemizole or terfenadine, as serious cardiovascular\\ncomplications may occur\\n\\nSalicylic acid\\n- Significant absorbtion may occur from the skin in\\nchildren\\nIsotretinoin:\\n\\nDry skin, lips and eyes\\nDecreased night vision\\nEpistaxis\\nHypercholesterolaemia\\nHypertriglyceridaemia\\nPseudotumour cerebri and headaches\\nDepression\\nMusculoskeletal or bowel symptoms\\nThinning of hair\\nBony hyperosteoses\\nPremature epiphyseal closure in children\\n\\n- Absolutely contraindicated during pregnancy\\n(teratogenicity)\\n- Obtain informed consent before use; start oral\\ncontraceptives one month before commencing therapy\\nand continue for another month after conclusion of\\ntherapy\\n- Women of childbearing age are strongly advised to\\navoid pregnancy for up to 3 years following cessation of\\n\\nor\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nDoxycycline\\n100 mg orally every 12\\n\\nhours\\nOr:\\n\\nMinocycline\\n50 - 100 mg orally every 12\\n\\nhours\\nOr:\\n\\nErythromycin\\n500 mg - 1 g every 12 hours\\n\\nInfants requiring oral therapy: 250 mg once daily or 125\\nmg every 12 hours\\nOr:\\n\\nClarithromycin 250 - 500 mg orally every 12 hours\\n- In patients who do not tolerate any of the tetracyclines\\nor who fail to improve\\n\\nReview patient in 6 weeks and 3 - 4 months later\\n- If there is marked improvement, taper the dose by 250\\nmg for tetracycline every 6 - 8 weeks while treating with\\ntopicals to arrive at the lowest systemic dose needed to\\nmaintain clearing\\n\\nOral contraceptives containing a non-androgenic\\nprogestin\\nCo-cyprinidiol:\\n- A mixture of cyproterone acetate and ethinylestradiol\\n2000 parts to 35 parts\\n- 1 tablet orally daily for 21 days starting on day 1 of\\nmenstrual cycle and repeated after a 7-day interval,\\nusually for several months\\n- For with severe acne refractory to prolonged\\nantibiotic therapy\\nOr:\\n\\nSpironolactone may be added as an antiandrogen\\n50 - 200 mg orally daily\\n\\nStart with systemic antibiotics as above\\nOral isotretinoin (13-cis retinoic acid)\\n\\n0.5 - 1 mg/kg/day for 20 weeks for a cumulative\\ndose of at least 120 mg/kg\\n\\n500 micrograms/kg once daily,\\nincreased if necessary to 1 mg/kg in 1 - 2 divided doses\\n- Occasionally, acne does not respond or promptly recurs\\nafter therapy, but may clear after a second course\\n- At least a 4-month rest period from the drug is\\nrecommended before a second treatment course is\\nconsidered\\n\\nPrednisolone 1.0 mg/kg daily for 7 - 10 days then taper\\noff rapidly as isotretinoin is started\\nSuccess has been reported with dapsone but only in toxic\\n\\ndoses (100 mg three or four times daily)\\n\\nUse non-irritating cleansing agents to reduce facial\\nsheen and bacterial flora\\n\\nEmotional support\\n\\nAdult and child over 12 years:\\n\\nAdult and child over 12 years:\\n\\nAdult and child over 12 years:\\n\\nwomen\\n\\nAdult:\\n\\nAdult:\\n\\nChild 12 - 18 years:\\n\\nAntibiotic-resistant acne\\n\\nSevere acne\\n\\nAcne fulminans\\n\\nAdjuvant measures\\n\\ntherapy\\n- Check cholesterol and triglyceride levels every 2 - 4\\nweeks while on therapy\\n- Dapsone at such high doses is likely to cause\\nmethhaemoglobinemia\\n- Where leprosy is still endemic (e.g. Nigeria), reserve\\nfor treatment of leprosy\\n\\nAvoid\\n- Oil-based cosmetics, hair styling mousse, face creams\\nand hair sprays\\n- Medicines that may induce acne\\n\\nCommonly known as itching\\nThe most common unpleasant experience involving the\\n\\nskin; provokes a desire to scratch\\nMay be elicited by many normally occurring stimuli e.g\\n\\n- Light touch\\n- Temperature change\\n- Emotional stress\\n- Chemical, mechanical, thermal and electrical stimuli\\n\\nMediated by the release of chemical substances e.g.\\nhistamine, kinins, and proteases\\n- Prostaglandin E lowers the threshold for histamine-\\ninduced pruritus, while enkephalins, pentapeptides\\nwhich bind to opiate receptors in the brain modulate pain\\nand itching centrally\\n\\nAt a low level, may merely be annoying\\nMay actually torture the patient, interfere with sleep and\\n\\nlead to less than optimal performance\\nThere are great variations from person to person\\n\\n- In the same person there may be variation in reactions\\nto the same stimuli\\n\\nIn the elderly, senile pruritus due to dry skin may be\\nparticularly bothersome\\n\\nPsychologic trauma, stress, absence of distractions,\\nanxiety, and fear may all enhance itching\\n\\nTends to be most severe at the time of undressing for\\nbed\\n\\nThere are also regional variations\\n- The ear canals, eyelids, nostrils, and perianal and\\ngenital areas are especially susceptble to pruritus\\n\\nMay be localized or generalized\\nMay or may not be associated with skin lesions\\nExcoriations are typically linear and occur where the\\n\\npatient can reach with his hands\\n- The middle of the back is typically spared except when\\nthe patient has used a back scratcher\\n- The scratch is usually erythematous, with many tiny\\nerosions scattered along it\\n- Fresh marks are usually weepy or bloody; older ones\\n\\nPrevention\\n\\nPRURITUS\\nIntroduction\\n\\nClinical features\\n\\n75 76\\n\\nChapter 6: Dermatology Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\ncrusted\\n- Lesions may become impetiginized\\n\\nIn addition to excoriations, some patients may have\\nsmooth, shiny fingernails (the polished nails of chronic\\npruritus)\\n\\nPruritus without skin lesions suggests\\n- Biliary obstruction\\n- Diabetes mellitus\\n- Uraemia\\n- Lymphoma\\n- Hyperthyroidism\\n- Adverse reaction to medicines e.g. Histamine\\n\\nliberators, opioids\\n- Occult scabies\\n- Pediculosis\\n- Onchodermatitis\\n- Dermatitis herpetiformis\\n- Atopic eczema in remission\\n- HIV/AIDS\\n- Systemic mastocytosis\\n\\nPolycythaemia vera is a notable cause of pruritus;\\nusually induced by temperature changes\\n\\nSome patients complain of pruritus provoked by bath\\nor immediately post-bath\\nFactors include:\\n- Aquagenic pruritus\\n- Temperature-dependent pruritus due to cold/heat\\n- Cholinergic pruritus (when the core temperature is\\nincreased and there is sweating)\\n- Allergy to bath sponge or soap\\n- Mechanical scrubbing of the skin with coarse sponge\\ncausing degranulation of mast cells\\n- A forceful jet of water from the shower may trigger\\npruritus in some cases.\\n\\nAll the above causes of pruritus\\n\\nSleep disturbance\\nLess than optimal performance at home, work or\\n\\nschool\\nEmotional disturbance\\nSuicidal ideation\\n\\nAs suggested by meticulous history and physical\\nexamination\\n\\nSuppress itch\\nIdentify and treat cause(s)\\nImprove quality of life\\nPrevent complications\\n\\nHydroxyzine hydrochloride\\ninitially 25 mg at night, increased if necessary to\\n\\n25 mg 3 - 4 times daily\\n6 months - 6 years: initially 5 - 15 mg daily,\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nAdult:\\n\\nChild:\\n\\nChild:\\n\\nAdult and child:\\n\\nAdult and child:\\n\\nAdult:\\n\\nnot recommended because of associated burning\\nOr:\\n\\nUrea 10% hydrocortisone cream 1 %,\\ndilute with aqueous cream in first 1 week\\n\\nof use if stinging occurs\\nOr:\\n\\nEmulsifying ointment BP\\ncan be used as soap substitute; rub on\\n\\nskin before rinsing off completely\\nOr:\\n- Doxepin hydrochloride\\n\\napply thinly 3 - 4 times daily (coverage should be\\nless than 10% body surface area)\\n\\nColestyramine:\\nCounsel patients\\nOther drugs should be taken at least 1 hour before, or 4 -\\n\\n6 hours after colestyramine to reduce possible\\ninterference with absorption\\n\\nMay cause constipation and gastrointestinal discomfort\\nInterferes with the absorption of fat-soluble vitamins\\n\\n- Supplements of vitaminsA, D and K may be required\\nActivated charcoal:\\n\\nRisk of aspiration in drowsy or comatose patients\\nRisk of intestinal obstruction in patients with reduced\\n\\ngastro-intestinal motility\\nBlack stools\\n\\nSoduim cromoglycate:\\nOccasional nausea, rashes, and joint pain\\n\\nKetotifen:\\nDrowsiness; dry mouth; slight dizziness; CNS\\n\\nstimulation; weight gain\\nDriving, swimming and operating machines should be\\n\\navoided\\nEnhances the effects of alcohol\\n\\nDoxepin:\\nCaution in patients with glaucoma, urinary retention,\\n\\nand severe liver impairment\\nMay cause drowsiness, local burning, stinging,\\n\\nirritation and dry mouth\\n\\nUse a cleansing bar (instead of soap) for baths\\nPat rather than rub skin dry after bath and immediately\\n\\nlubricate skin with petroleum jelly or emulsifying\\nointment\\n\\nAn eruption of evanescent wheals or hives which can\\nresult from many different stimuli on an immunologic or\\nnon-immunologic basis\\n\\nThe most common immunologic mechanism is\\nhypersensitivity mediated by IgE\\n- Another mechanism involves activation of the\\ncomplement cascade.\\n\\nAdverse drug reactions, caution and contraindications\\n\\nPrevention\\n\\nURTICARIAANDANGIOEDEMA\\nIntroduction\\n\\nincreased if necessary to 50 mg daily in divided doses\\nOver 6 years: initially 15 - 25 mg daily, increased if\\nnecessary to 50 - 100 mg daily in divided doses\\n\\nSodium cromoglycate\\n200 mg orally taken before bath and immediately\\n\\nafter\\n100 mg orally 4 times daily before\\n\\nmeals\\n- Dose may be increased after 2 - 3 weeks to a maximum\\nof 40 mg/kg daily, reduced according to response\\nOr:\\n\\nKetotifen\\n2 mg orally taken before bath (with food)\\n\\n1 mg orally twice daily\\n\\nDoxepin\\ninitially 75 mg orally daily in divided doses or as a\\n\\nsingle dose at bedtime\\n- Increased if necessary to a maximum of 300 mg daily\\nin 3 divided doses\\nUp to 100 mg may be given as a single dose\\nElderly: initially 10 - 50 mg daily; range of 30 - 50 mg\\ndaily may be adequate\\n\\nColestyramine\\n4 - 8 g orally daily in water (or other suitable\\n\\nliquid)\\n1 g orally once daily mixed with\\n\\nwater; 1 - 6 years: 2 g once daily; 6 - 12 years: 4 g once\\ndaily; 12 - 18 years: 4 - 8 g daily, adjusted according to\\nresponse in all age groups\\n\\nActivated charcoal\\n50 g orally initially then 50 g every 4 hours.\\n\\n- Treat vomiting with an anti-emetic because it may\\nreduce the efficacy of charcoal treatment\\nIn cases of intolerance reduce the dose and increase\\nfrequency of administration (e.g. 25 g every 2 hours or\\n12.5 g every hour). This may however compromise\\nefficacy\\nOr:\\n\\nUltra Violet B therapy\\n\\nCorticosteroid creams for inflammatory skin disease\\nOr:\\n\\nCrotamiton cream 10%\\napply topically 2 - 3 times daily\\napply once daily for child below 3 years; over 3\\n\\nyears: apply 2 - 3 times daily\\nOr:\\n\\nCapsaicin cream 0.75%\\napply topically 3 - 4 times daily\\n\\nAquagenic pruritus, mastocytosis, and pruritus of\\nneurofibromatosis\\n\\nDepressed, itchy individuals\\n\\nPruritus associated with partial biliary obstruction and\\nprimary biliary cirrhosis\\n\\nPruritus of renal failure\\n\\nLocalized pruritus\\n\\nAdult:\\n\\nChild 2 - 14 years:\\n\\nAdult:\\nChild 3 years and over:\\n\\nAdult:\\n\\nNot recommended for children\\n\\nAdult:\\n\\nChild 1 month - 1 year:\\n\\nAdult:\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nThe activation of cutaneous mast cells and their release\\nof mediators is the unifying feature of most urticaria\\n\\nMast cells are found in the immediate vicinity of blood\\nvessels\\n- They release preformed mediators (histamine, heparin\\nand various enzymes) as well newly manufactured ones\\n(prostaglandins, leukotrienes)\\n\\nA hive or urticarial lesion is the result of localized\\noedema in the dermis\\nCauses:\\n\\nMedications\\nFood\\nAero-allergens\\nLatex; seminal fluid (contact urticaria)\\nInsect antigens (bees, wasps or hornet toxins)\\nInfections and infestations (parasitic, fungal, bacterial\\n\\nand viral)\\nForeign proteins (antisera, vaccinations)\\nPhysical stimuli (pressure, heat, cold, cholinergic\\n\\nstimuli, water, light and irradiations)\\nAuto-immune disorders, enzyme defects (C1 esterase\\n\\ninihibitor deficiency)\\nPsychosocial conflicts (stress, depression)\\nExcessive mast cells (mastocytoma, urticaria\\n\\npigmentosa)\\nPseudoallergy (mast cell degranulators e.g. NSAIDS;\\n\\ndyes, preservatives, contact urticaria)\\nSerum sickness\\nMalignancies\\nIdiopathic\\n\\nMay be acute or chronic:\\nAcute urticaria is of sudden onset and lasts less than 6\\n\\nweeks\\nChronic urticaria persists for more than 6 weeks with\\n\\neither:\\n- Daily emergence of new wheals (chronic continuous)\\nor\\n- Occasional hive-free periods (chronic recurrent)\\n\\nThe typical urticarial reaction is similar to the triple\\nresponse of Lewis\\n- Initial erythema\\n- Next oedema (the hive)\\n- Finally an erythematous ring surrounding the hive\\nUrticarial lesions may:\\n- Vary in size and shape over minutes to hours\\n- Present an orange-skin appearance\\n- Become bullous\\n\\nThe pruritus associated with urticaria is usually extreme\\nExcoriations are extremely unusual because the lesions\\n\\nare almost invariably rubbed, not scratched\\nDermographism is characterized by wheal and erythema\\nafter minor stroking of, or pressure on the skin\\n- Commonly found under pressure areas e.g. the belt line\\n- May persist for years, but spontaneous regression\\nusually occurs within 2 years\\n\\nClinical features\\n\\n77 78\\n\\nChapter 6: Dermatology Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nAngioedema is the involvement of deeper vessels\\n- Characterized by painless, deep, subcutaneous swelling\\n- Often involves periorbital, circumoral and facial\\nregions; palms, soles and the genitalia\\n- May target the gastrointestinal and respiratory tracts,\\ncausing abdominal pain, coryza, asthma and respiratory\\nproblems\\n- Respiratory tract involvement may cause airway\\nobstruction\\n- Anaphylaxis and hypotension may also occur\\n\\nGyrate erythemas\\nUrticarial vasculitis\\nMastocytosis\\nPityriasis rosea (early lesions)\\n\\nBullous lesions:\\nPemphygus\\nPemphygoid\\nErythema multiforme\\nFixed drug eruption\\n\\nAngioedema:\\n“Calabar swelling”\\nCellulitis\\nIdiopathic scrotal oedema of children\\nMelkerson-Rosenthal syndrome\\n\\nCold uriticaria:\\nCryoglobulinemia\\nImmune complex diseases\\nSystemic lupus erythematosus and other collagen\\n\\nvascular diseases\\nMacroglobulinemia\\nMycoplasma infections (cold hemagglutinins)\\nSyphilis\\nFamilial cold urticaria\\nAcquired cold urticaria\\n\\nEmotional distress in chronic cases\\nFatality\\n\\nSuggested by meticulous history and physical\\nexamination\\n\\nTo alleviate symptoms\\nEliminate and treat cause\\n\\nChlorphenamine maleate\\n4 mg orally every 4 - 6 hours (maximum 24 mg\\n\\ndaily)\\nunder 1 year, not recommended\\n\\n1 - 2 years: 1 mg every 12 hours; 2 - 5 years: 1mg every 4 -\\n6 hours (maximum 6 mg daily); 6 - 12 years: 2 mg every 4\\n- 6 hours (maximum12 mg daily)\\n- If less sedation is required (e.g. day time)\\n\\nCetirizine\\n10 mg orally daily or 5 mg\\n\\nevery 12hours\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nAdult:\\n\\nChild:\\n\\nAdult and Child over 6 years:\\n\\nVITILIGO\\nIntroduction\\n\\nClinical features\\n\\nA disease characterized by acquired loss of\\nmelanocytes, leading to areas of depigmentation\\n\\nSometimes associated with uveitis and other\\nautoimmune phenomena\\n- Many autoantibodies can be demonstrated in vitiligo\\npatients; those against melanocytes may rarely be\\ndemonstrable\\n\\nThere is also a neural hypothesis\\n- Vitiliginous patches often follow a dermatome\\n- A neurochemical mediator responsible for destroying\\nthe melanocytes has therefore been suggested\\n\\nThere is also an occupational vitiligo\\n- Due to chemically induced depigmentation\\n- Seen among workers who are in contact with para-\\nphenolic compounds or hydroquinones (but this is\\nconsidered a different disorder)\\n\\nAll ages are affected\\nThe dermatomal type is more common in the paediatric\\n\\nage\\nThe completely depigmented patches have distinct\\n\\nborders\\n- A few patients may have inflammatory vitiligo with\\nraised erythematous borders\\n- Some may have hypopigmented skin between the\\ndepigmented and normal skin (trichrome vitiligo)\\nThe distribution may be:\\n\\nGeneralized (autoimmune type)\\nSegmental (dermatomal type)\\nThe hairs on the patches eventually turn white (acquired\\n\\npoliosis)\\nThe generalized type may be symmetrically distributed\\n\\nin the extremities\\n- Generalized vitiligo continues to spread while new\\nlesions develop for years\\n\\nSpontaneous repigmentation may occur\\nFavoured sites are\\n\\n- Extensor surfaces of the extremities\\n- Face and peri-orificial surfaces (around the mouth,\\neyes, nipples, umbilicus, penis, vulva, and anus)\\n\\nFocal vitiligo may affect one non-dermatomal site e.g.\\nlips, vulva or penis\\nUniversal vitiligo applies to cases where the entire body\\n\\nsurface is depigmented\\nGeneralized vitiligo may be associated with\\n\\n- Hyperthyroidism\\n- Hypothyroidism\\n- Pernicious anaemia\\n- Diabetes mellitus\\n- Addison\\'s disease\\n\\nLocal loss of pigment may occur around a naevus and\\nmelanomas, the so-called halo phenomenon\\n\\nVitiligo-like leucoderma occurs in about 1% of\\nmelanoma patients\\n\\nChild\\n\\nAdult:\\nChild under 12 years elderly\\n\\nAdult and Child over 6 years:\\nChild\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\n2 - 6 years: 5 mg orally daily or 2.5 mg every 12\\nhours\\nOr:\\n\\nAcrivastine\\n8 mg orally every 8 hours\\n\\nand : not recommended\\nOr:\\n\\nLoratadine\\n10 mg orally daily\\n\\n2 - 5 years 5 mg daily\\n\\nAdd Doxepin (oral form discontinued)\\napply thinly 3 - 4 times daily; usual maximum 3 g\\n\\nper application (total daily maximum 12 g)\\nnot recommended for children under 12 years\\n\\nOr:\\n(For symptomatic dermographism and chronic urticaria)\\n\\n:\\nRanitidine hydrochloride\\n\\n150 mg orally every 12 hours or 300 mg at night\\n- Not to be used alone for the treatment of urticaria\\n\\nSystemic corticosteroids\\n- Prednisolone 0.5 to 1.0 mg/kg orally daily\\n\\nTo relieve itching:\\nTepid or cold tub baths or showers\\nAdd starch, or sodium bicarbonate, menthol, or\\nmagnesium sulfate to bath water\\nDo not scrub the body with sponge (it promotes\\ndegranulation of cutaneous mast cells)\\nAvoid medicines likely to cause urticaria/angioedema\\nEliminate any suspected food\\nCounselling\\n\\nChlorphenamine maleate:\\nPatients not to drive or operate machinery\\n\\nRanitidine:\\nTachycardia, agitation, visual disturbances, alopecia,\\n\\ngynaecomastia and impotence\\nCaution in hepatic impairment, pregnancy and in breast\\n\\nfeeding\\nCetirizine, loratadine, and acrivastine:\\nHeadache, dry mouth, drowsiness, dizziness and nausea\\nCaution in the elderly especially if renal function is\\n\\ncompromised\\nDoxepin:\\n\\nCaution in cardiac disease\\nContraindicated in recent myocardial infarction,\\n\\narrhythmias, glaucoma and severe liver disease\\nMay cause dry mouth, sedation, blurred vision,\\n\\nconstipation, nausea, difficulty with micturition\\n\\nEliminate/avoid any identified/possible causal factor(s)\\n\\nIf persistent and chronic urticaria\\n\\nRefractory cases\\n\\nAdd\\n\\nAdjuvant measures\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\n- Usually a good prognostic sign since it suggests an\\neffective immune reaction against the tumour cells\\n\\nSegmental vitiligo affects only one part of the body\\n- It spreads rapidly in that area and then stabilizes\\n- It is not associated ith autoimmune diseases\\n- Favoured sites are the trigeminal area or an intercostal\\nnerve distribution (zosteriform pattern)\\n\\nJust as with albinism, the interplay between the\\nmelanocytes of the eyes, ears, and skin is apparent\\nThe prototype is Vogt-Koyanagi-Harada syndrome:\\n\\nVitiligo of the face, eyelashes, and scalp hair in\\nassociation with\\n- Uveitis\\n- Dysacoussis\\n- Alopecia areata\\n\\nChemical vitiligo affects sites of contact with the\\nchemicals\\n- When the chemicals are inhaled or a substantial\\nquantity is absorbed through the skin, the distribution of\\nthe white patches may simulate the generalized\\nautoimmune type\\n\\nPost-burns depigmentation\\nTertiary stage of pinta\\nMorphoea\\nLichen sclerosis\\nPityriasis alba\\nTinea versicolor\\nPiebaldism\\nHypomelanosis of Ito\\n\\nEmotional problems due to cosmetic disfigurement\\n\\nExclude other autoimmune diseases if clinically\\nsuggestive\\n\\nSee also notes on caution below\\n\\nRe-pigmentation\\nImprove cosmetic appearance\\nEmotional support\\n\\nCorticosteroids\\n- Hydrocortisone 1% or betamethasone valerate\\n\\n0.1% apply once or every 12 hours (for focal or\\nlimited lesions)\\n\\napply 1 - 2 times daily\\nPsoralens\\n\\n- 8-methoxypsoralen (MOP)\\n0.05% - 0.1% in combination with ultraviolet-A\\nradiation (PUVA) for focal or limited lesions\\n\\napply twice weekly\\nTacrolimus\\n\\n0.1% ointment twice daily for 24 weeks\\nTopical depigmentation\\n\\n- Monobenzyl ether of hydroquinone\\n20%, apply twice daily for 3 - 6 months (if more then\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nTopical\\n\\nAdult:\\n\\nChild:\\n\\nAdult and child:\\n\\n79 80\\n\\nChapter 6: Dermatology Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\n50% of the body is affected)\\n\\nSystemic 8-methoxypsoralen (or 5-methoxypsoralen)\\n0.5 mg/kg orally\\n\\nThe initial UVAdose is 1 or 2 J/cm , gradually increased\\nTwo or three treatments are done per week for 3 - 6\\nmonths\\n\\nSystemic corticosteroids\\n- May occasionally be used to arrest the autoimmune\\nprocess\\n- Prednisolone tablets 0.5 - 1.0 mg/kg orally day\\n\\nPigmented skin grafted onto vitiliginous patches\\n- Often the transferred melanocytes repigment the\\ndepigmented areas\\nThe various techniques include:\\n- Suction blister grafts\\n- Mini-punch grafts\\n- Transfer of either pure melanocyte cultures or mixed\\nepidermal cultures to a prepared site\\n\\nCamouflage (cover-up cosmetics)\\nPatient education and emotional support\\n\\nCorticosteroids:\\nSee Dermatitis and Eczema\\n\\n8-MOP:\\nInadvertent sunburns with blistering\\n\\nSystemic psoralen is contraindicated in:\\n- Known photosensitivity\\n- Porphyria\\n- Liver disease\\n- Systemic lupus erythematosus\\n\\nIf systemic therapy is to be used the following should\\nbe done before therapy\\n- Ophthalmological examination\\n- Full Blood Count\\n- Liver function tests\\n- AntinuclearAntibody Test\\nMonobenzylether of hydroquinone:\\n\\nDepigmentation at distant sites\\nAcquired ochronosis\\n\\nUnknown\\n\\nSystemic\\n\\nSurgical\\n\\nAdult:\\n\\nPUVA therapy should be supervised by an experienced\\ndermatologist\\n\\n2\\n\\nAdjuvant measures\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nmonths - 1 year: 125 - 250 mg for 5 - 7days\\nSystemic decongestant\\n\\n- Psuedoephedrine\\n60 mg orally every 4 - 6 hours (up to 4 times daily)\\n6 - 12 years: 30 mg (5 mLof syrup) 3 times daily; 2\\n\\n- 5 years 15 mg, (2.5 mL)\\n\\nBed rest and adequate fluids\\n\\nMany preparations of pseudoephedrine contain\\nantihistamines and may cause drowsiness\\n\\nAvoid ear drops\\n\\nGood general health and clean airy environment to\\nreduce incidence of upper respiratory infections (colds)\\n\\nA manifestation of hyperplasia/hypertrophy of the\\nadenoid tissue in the nasopharynx\\n\\nUsually occurs in children aged 2 - 6 years\\nExcessively large adenoids may cause obstruction of the\\n\\nnasopharyngeal airway with symptoms of nasal\\nobstruction\\n\\nLarge adenoids may encroach on the Eustachian tube\\nopenings causing secretory otitis media with deafness in\\nthe child\\n\\nChronic infection of adenoid tissue is also often present\\nSymptoms usually subside spontaneously as adenoids\\n\\nregress physiologically and become atrophic with age\\n\\nNasal obstruction and mouth-breathing\\nSnoring at night\\nObstructive sleep apnoea\\nProgressive deafness due to secretory otitis media\\n\\nAllergic rhinitis\\nSinusitis\\nOtitis media\\n\\nSinusitis\\nRecurrent otitis media\\nPneumonitis\\n\\nX-ray of nasopharynx\\nXray sinuses and chest\\n\\nTo significantly improve nasopharyngeal airway and\\nthereby improve nasal breathing\\n\\nTreat concurrent infection\\n\\nAdenoidectomy in severe cases\\n\\nDecongestants\\n- Psuedoephedrine syrup\\n6 - 12 years: 30 mg (5 mLof syrup) orally every 8 hours; 2\\n\\nAdult:\\nChild:\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nADENOID DISEASE\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nCHAPTER 7: EAR, NOSEAND THROAT\\n\\nACUTE OTITIS MEDIA\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nAcute inflammation of the middle ear due to pyogenic\\norganisms\\n\\nUsually secondary to upper respiratory infection\\nspreading from nasopharynx\\n\\nCommon in infants and young children; more frequent\\nduring winter and rainy periods\\nUsual organisms are streptococcus pneumococcus and\\n\\nstaphylococcus\\n\\nMain symptoms:\\nEarache\\nFever\\nDeafness\\nEar discharge\\nMalaise\\nIn babies, irritability\\nClinically increasing inflammation and redness of the\\n\\neardrum\\nLater, perforation and pulsating mucopurulent\\n\\ndischarge\\n\\nAcute otitis externa\\nReferred otalgia\\n\\nAcute mastoiditis\\nFacial nerve paralysis\\nLabyrinthitis\\nIntracranial\\n\\n- Meningitis\\n- Brain abscesses\\n- Lateral sinus thrombosis\\n\\nEar swab for culture and sensitivity- swab taken\\nproperly without contamination\\n\\nFull Blood Count\\n\\nControl infection\\nRestore normal hearing\\n\\nEar toilet and antiseptic dressings\\nMyringotomy for persistent mucopurulent collection in\\n\\nmiddle ear with bulging eardrum\\n\\nAntibiotics\\n- Amoxicillin\\n\\n500 mg -1 g orally every 8 hours for 5 - 7 days\\n40 mg/kg orally every 8 hours Analgesics\\n\\n- Paracetamol\\n500 mg - 1 g orally every 4 - 6 hours (to a\\n\\nmaximum of 4 g) for 5 - 7 days\\nsame as adult dosing\\n\\n6 - 12 years: 250 -500 mg; 1 - 5 years: 125 - 250 mg; 3\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nChild over 50 kg:\\n\\n- 5 years 2.5 mL\\nOr:\\n- Ephedrine nasal drops (0.5%)\\nInstil into nostrils twice daily and at night time\\n\\nAntibiotic\\n- Amoxicillin syrup 125 - 250 mg orally every 8 hours for\\n5 - 7 days\\n\\nA chronic inflammatory condition of the middle ear\\nmucosa with recurrent ear discharge\\n- Often over a period of years\\n\\nOccurs in two clinical varieties\\n- The more common simple type with a central eardrum\\nperforation\\n- The much less common, serious type often associated\\nwith the presence of cholesteatoma\\n\\nBacteriology is usually mixed, mostly gram negative\\norganisms (Proteus, Pseudomonas)\\n\\nMain complaints: recurrent ear discharge and increasing\\ndeafness\\n\\nPain is uncommon\\nDischarge is mucoid in the simple type but thick and\\n\\nfoul-smelling in the serious variety\\nUsually central eardrum perforation is of varying size\\n\\n- Cholesteatoma and marginal or attic perforation is seen\\nin the serious type\\n\\nGenerally more with the serious type:\\nIntracranial suppuration\\n\\n- Extradural abscess\\n- Meningitis\\n- Brain abscess\\n\\nLateral sinus thrombosis\\nFacial nerve paralysis\\nLabyrinthitis\\n\\nEar swab taken properly for microscopy, culture and\\nsensitivity\\n\\nAudiogram: conductive deafness\\nX-ray of the masto ids : shows scleros is ,\\n\\nhypopneumatization\\n\\nTo give the patient a safe and dry ear\\nTo preserve or restore hearing as much as possible\\n\\nCareful ear toilet and regular ear dressing with antiseptic\\npack\\n\\nWith dry ear, persistent perforation may be closed\\nsurgically (myringoplasty) to protect middle ear and\\nimprove hearing\\n\\nIn the serious type with cholesteatoma not responding to\\ntreatment, mastoid operation is done to clear out disease\\nand prevent complications\\n\\nCHRONIC OTITIS MEDIA\\nIntroduction\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\n81 82\\n\\nChapter 7: Ear, Nose and Throat Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nCaution\\n\\nEPISTAXIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nAntibiotic\\n- Co-amoxiclav\\n\\n500/125 mg orally every 8 hours for acute\\nexacerbations up to 14 days\\n\\n6 - 12 years: 250 mg orally every 12 hours; under\\n6 years: 125 mg every12 hours\\n\\nProtect ears from water with Vaseline/cotton wool\\nwhile bathing\\n\\nTopical treatment with ototoxic antibiotics is\\ncontraindicated in the presence of a perforation\\n\\nAcondition of bleeding from the nose\\nAclinical presentation rather than a disease entity on its\\n\\nown\\nBleeding is most often from ruptured vessels in the\\n\\nanterior nasal septum, sometimes from the posterior\\nnose especially in the elderly\\n\\nCan arise from a wide variety of causes\\n(in the nose)\\n\\nTrauma\\nInflammation of nose or sinuses\\n\\n- Acute e.g. acute rhinitis/sinusitis\\n- Chronic e.g. tuberculosis, leprosy\\n\\nNeoplasms\\n\\nBleeding diatheses\\nBlood dyscrasias\\nHypertension\\n\\nBleeding from nose; often spontaneous but may follow\\nobvious trauma or injury\\n\\nVarying amounts of blood, from few drops to torrential\\nlife-threatening haemorrhage\\n\\nOften intermittent; most bleeds stop spontaneously\\n\\nVarious pathological conditions, both local and\\nsystemic present with nasal bleeding\\n\\nHaemorrhagic shock\\nFatality\\n\\nFull Blood Count, including platelet count\\nBleeding and clotting time; partial thromboplastin time\\nUrea and Electrolytes and Creatinine\\nX-ray sinuses\\nCT scan\\n\\nTo arrest bleeding in actively bleeding cases\\nReplace significant blood losses and treat shock\\n\\nAdult:\\n\\nChild:\\n\\nIf infection does not settle with systemic antibiotics refer\\nto specialist\\n\\nLocal\\n\\nManifestation of systemic diseases\\n\\nIn the lower airways objects may remain for long\\nperiods, with unexplained chest symptoms\\n\\nAcute laryngitis\\nAcute laryngeal oedema\\nBronchopneumonia\\nPulmonary tuberculosis\\n\\nLife-threatening asphyxia\\nLung collapse and atelectasis\\n\\nRadiograph of neck and chest\\n\\nTo maintain the airway and adequate respiratory function\\nRemove the foreign object as expeditiously as possible\\n\\nImmediate removal under anaesthesia by direct\\nlaryngoscopy or bronchoscopy as appropriate\\n\\nTracheostomy where necessary to maintain airway\\n\\nAntibiotic prophylaxis if necessary (for 3 days)\\n- Amoxicillin\\n\\n6 - 12 years: 250 mg orally every 12 hours; under 6\\nyears: 125 mg orally every 12 hours\\n\\nSteroid\\n- Hydrocortisone (for pneumonitis)\\n\\ninitially 25 mg by intravenous or\\nintramuscular injection every 8 hours; 1 - 6 years:\\ninitially 50 mg every 8 hours; 6 - 12 years: initially 100\\nmg every 8 hours; 12 - 18 years: initially 100 - 500 mg 3\\ntimes daily, adjusted in all age groups according to\\nresponse\\n\\nOxygen\\nSteam inhalation/nebulizer\\n\\nVigilant supervision of young children\\n\\nAcommon presentation in ENT emergency practice\\nChildren usually involved as they insert various objects\\n\\ninto ears while playing: beads, plastic toys, seeds, etc\\nLive insects may also crawl into the ear in adults/children\\n\\nSymptoms are often absent\\nLittle pain (sometimes)\\nSensation of blockage may be reported by older children\\nObject usually seen with good light in the ear canal\\n\\nImpacted wax\\nOtitis externa\\n\\nOtitis externa\\nPerforation of tympanic membrane from inexpert\\n\\nattempts at removal\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nPrevention\\n\\nFOREIGN BODIES IN THE EAR\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nChild:\\n\\nChild 1 month - 1 year:\\n\\nIdentify and treat aetiological factors\\n\\nPressure and compression of the nose between fingers\\nto arrest bleeding\\n\\nCotton wool pack soaked in epinephrine 1:1000 may be\\nplaced on bleeding area before compression to induce\\nvasoconstriction\\n\\nNasal packing with lubricated ribbon gauze\\nArrest of posterior bleed with rubber tampon or\\n\\nimprovised Foley\\'s catheter balloon\\nCauterization of bleeding point or dilated vessels in\\n\\nanterior nasal septum\\n- Diathermy cautery (electrical) or chemical cautery\\nwith silver nitrate stick\\n\\nTreat underlying aetiologies\\nSedation if necessary\\n\\n- Diazepam 5 mg orally twice daily for 1 - 2 days\\nAntibiotics if infection is present\\n\\n- Amoxicillin\\n500 mg orally every 8 hours for 5 - 7 days\\n250 - 500 mg orally for 5 - 7 days\\n\\nOther drugs depending on identified causative factors\\n\\nIntravenous infusion, crystalloids and blood as\\nnecessary\\n\\nBed rest\\n\\nAvoid/treat predisposing conditions\\n\\nChildren (most commonly) may aspirate pieces of play\\nobjects or food items accidentally into the airway\\n\\nMay present as serious emergencies with imminent\\nasphyxia\\n\\nThe object if arrested at laryngeal level causes acute\\nupper respiratory obstruction\\n\\nSharp objects such as fish bone or pins may be impacted\\non the vocal cord and the resulting oedema causes\\nprogressive obstruction\\n\\nSmall objects such as seeds may traverse the larynx and\\nbecome arrested in the trachea or bronchus lower down\\n\\nVegetables such as peanuts often cause severe reaction\\nin the lungs with pneumonitis\\n\\nDifficulty in breathing with stridor occurs immediately\\nor progressively\\n\\nInitial dyspnoea and cough may subside if the object\\npasses down. Symptoms gradually return later\\nSevere cases: stridor and severe cyanosis with imminent\\n\\nasphyxia requiring immediate intervention to prevent a\\nfatal outcome\\n\\nTwo-way stridor often occurs with tracheal foreign\\nbodies\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nPrevention\\n\\nFOREIGN BODIES IN THEAIRWAYS\\nIntroduction\\n\\nClinical features\\n\\nAdult:\\nChild:\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nPrevention\\n\\nFOREIGN BODIES IN THE NOSE AND\\nRHINOLITHS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplication\\n\\nInvestigation\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nPrevention\\n\\nMASTOIDITIS\\nIntroduction\\n\\nRemove object expeditiously without damage to ear\\nstructures or causing undue pain to patient\\n\\nRemoval by ear syringing\\nRemoval with appropriate hook, or alligator forceps\\nExamination and removal under anaesthesia if difficult\\n\\nin the clinic\\n\\nVigilant supervision of young children\\n\\nChildren often insert various objects into the nostrils\\nwhile playing: pieces of plastic toys, rolled paper, foam,\\nseeds, some metal objects, etc\\n\\nThe objects may remain undetected for long periods,\\nparticularly organic items, until they become infected\\n\\nTypically result in foul smelling unilateral nasal\\ndischarge\\nSome inorganic objects may (after long periods) become\\ncoated by hard calcific deposits and become known as\\nrhinoliths\\n\\nOften no indication or symptom\\nMay be accidentally noticed by parent\\nLater, complaints of foul purulent unilateral nasal\\n\\ndischarge of unknown origin\\n\\nAcute or chronic rhinitis\\nSinusitis\\nNasal growth/polyp\\n\\nSecondary infection: rhinosinusitis\\n\\nRadiograph of nose: for metallic or radio-opaque objects\\n\\nRemove object safely with little discomfort to patient\\n\\nCareful removal with appropriate hook or forceps\\nRemoval under anaesthesia as necessary\\n\\nVigilant supervision of young children\\n\\nDevelops as a complication of acute suppurative otitis\\nmedia, mostly in children\\n\\nFollows acute otitis media (untreated or inadequately\\ntreated), or due to particularly virulent organisms\\n\\nInfection spreads from the tympanum posteriorly into\\nthe mastoid antrum and aircells\\n\\nColliquative necrosis of the air cells and suppuration in\\nthe mastoid bone follows\\n\\n83 84\\n\\nChapter 7: Ear, Nose and Throat Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nA subperiosteal abscess forms behind the ear in a child\\nwith a discharging ear\\n\\nFever\\nPain behind the ear\\nMucopurulent ear discharge\\nProgressive inflammatory swelling over the mastoid\\n\\nregion\\nSwelling is tender and fluctuant\\n\\nSuppurating post-aural lymphadenitis from otitis\\nexterna\\n\\nSpread of infection into cranial cavity with:\\nExtradural abscess\\nMeningitis\\nBrain abscess\\nLateral sinus thrombophlebitis\\n\\nEar swab for microscopy, culture, culture and\\nsensitivity\\n\\nRadiographs of the mastoid\\n\\nControl and eradicate infection\\nPrevent more serious complications\\n\\nCortical mastoidectomy to open the mastoid\\n- Exenterate the infected air cells and drain the mastoid\\n\\nLarge doses of parenteral antibiotics\\n- Amoxicillin\\n\\n500 mg -1 g intravenously every 6 - 8 hours for 7\\ndays\\n\\n50 - 100 mg/kg intravenously every 6 - 8 hours in\\ndivided doses daily for 7 days\\n- Ceftriaxone\\n\\n1 g every 12 hours intravenously for 7 days\\nby intravenous infusion over 60 minutes\\n\\nNeonates: 20 - 50 mg/kg once daily, by deep\\nintramuscular injection, intravenous injection over 2 - 4\\nminutes, or by intravenous infusion\\n1 month - 12 years (body weight under 50 kg) 50 mg/kg\\nonce daily, up to 80 mg/kg in severe infections\\n\\nAnalgesics\\n- Paracetamol\\n\\n500 mg -1 g orally every 4 - 6 hours (to a\\nmaximum of 4 g) for 5 - 7 days\\n\\nsame as adult dosing\\n6 - 12 years: 250 - 500 mg; 3 months - 5 years: 125 - 250\\nmg taken orally every 4 - 6 hours for 5 - 7 days\\n\\nBed rest: in-patient care\\nIntravenous infusion as appropriate\\n\\nAdequate and timely treatment of acute otitis media\\n\\nClinical features\\n\\nDifferential diagnosis\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nPrevention\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nChild over 50 kg:\\n\\ndaily if necessary or, 10 - 20 mg every 8 - 12 hours\\nnot recommended under 2 years\\n\\n5 - 10 years: 10 - 25 mg orally daily in 1 - 2 divided doses;\\n2 - 5 years: 5 - 15 mg daily in 1 - 2 divided doses\\n\\nTopical steroid\\n- Beclomethasone nasal spray\\n\\n100 micrograms (i.e. 2\\nsprays) into each nostril twice daily\\n- Or 50 micrograms into each nostril every 8 hours\\n- Reduce dose to 50 micrograms into each nostril twice\\ndaily when symptoms are controlled\\n\\nDecongestant\\n- Psuedoephedrine\\n\\n60 mg orally 4 - 6 hourly (up to 4 times daily)\\n6 - 12 years: 30 mg (5 mL of syrup) orally every 8\\n\\nhours; 2 - 5 years: 2.5 mL\\n\\nDrowsiness with antihistamine drugs\\nAvoid prolonged use of medications\\n\\nAvoid known allergenic substances, inhalants, foods, etc\\n\\nInflammation of the external ear\\nMay be:\\n\\nInfective: bacteria or fungi\\nReaction of the canal skin to chemical irritant(s)\\nPart of a generalized dermatitis\\nLocalised otitis externa or furuncle (boil) is a\\n\\nStaphylococcal infection of a hair follicle in the canal\\nDiffuse otitis externa may be bacterial or fungal or\\n\\nreactive\\n- May be acute or chronic\\nBacterial infection often follows trauma from scratching\\n\\nthe canal skin\\nFungal otitis (otomycosis) commonly follows\\n\\nswimming in the tropics, usually infection by\\n\\nPain and itching\\nEar discharge\\nSensation of blockage due to accumulated debris in\\n\\ncanal\\nDeafness is variable\\nCanal is red and swollen, full of inflammatory debris\\n\\n- In otomycosis whitish mass of debris with black spots\\n\\nOtitis media\\nAcute mastoiditis\\n\\nAcute perichondritis\\n\\nEar swab, taken properly for microscopy, culture and\\nsensitivity\\n\\nChild:\\n\\nAdult and child over 6 years:\\n\\nAdult:\\nChild:\\n\\nAspergillus\\nniger\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nOTITIS EXTERNA\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nNASALALLERGY\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nHypersensitivity of the nasal mucosa to various foreign\\nsubstances, of the atopic type\\nManifests as recurrent episodes of sneezing, rhinorrhoea\\nand nasal obstruction whenever patient comes in contact\\nwith the offending allergen\\n\\nSymptoms are attributed to the effect of histamine and\\nother chemical substances released from ruptured mast\\ncells in the nasal mucosa\\nCommon allergens are pollens of various plants, flowers\\n\\nand trees; house-dust; hairs; some foods; fungi and\\ncosmetics\\n\\nAcommon condition and affects all age groups\\nMay be familial, often associated with allergic asthma\\n\\nor dermatitis\\n\\nRepeated episodes of sneezing\\nWatery nasal discharge\\n\\nNasal obstruction with itching and conjunctival\\nirritation whenever patient is in contact with allergen\\n\\nNasal mucosa may be congested or sometimes normal\\nat the time of clinical examination\\n\\nPresentation may be seasonal as with pollen allergy, or\\nperennial with allergy to house dust, etc\\n\\nNasal polyps may develop\\n\\nChronic rhinitis from other causes\\nVasomotor rhinitis\\nChronic sinusitis\\n\\nChronic sinusitis\\nPharyngitis\\n\\nSkin tests for allergens: intradermal or prick tests\\nSmear of nasal secretions for eosinophilia\\n\\nSerological tests: radio-immunoassay for IgE antibodies\\nSinus X-ray\\n\\nControl or suppress the allergic symptoms\\nPrevent allergic reactions\\n\\nElimination of allergens\\nHyposensitisation by vaccination\\n\\nAntihistamines\\n- Chlorphenamine\\n\\n4 mg orally every 4 - 6 hours; maximum 24 mg\\ndaily\\n\\nnot recommended under 1 year\\n6 - 12 years: 2 mg orally every 4 - 6 hours; maximum 12\\nmg daily; 2 - 5 years: 1 mg every 4 - 6 hours; maximum 6\\nmg daily\\nOr:\\n- Promethazine\\n\\n25 mg orally at night, increased to 25 mg twice\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nUrinalysis for glycosuria\\nBlood glucose estimation in cases of recurrent\\n\\nfurunculosis to exclude diabetes mellitus\\n\\nControl infection / inflammation\\nRelieve discomfort\\n\\nCareful ear toilet to clear out debris\\nDaily dressing with antiseptic gauze packed with\\n\\nAcriflavin in spirit\\nFurunculosis: dressing with magnesium sulfate wick or\\n\\nsteroid and antibiotic ointment dressing\\n\\nAntibiotics\\n- Amoxicillin\\n\\n500 mg -1 g orally every 8 hours for 5 - 7 days\\n40 mg/kg orally in every 8 hours for 5 - 7 days\\n\\n- Neomycin/hydrocortisone ear drops\\ninstil 2 - 3 drops 3 - 4 times daily\\n\\nAnalgesics\\n- Paracetamol\\n\\n500 mg -1 g orally every 4 - 6 hours (to a maximum\\nof 4 g) for 5 - 7 days\\n\\nsame as adult dosing\\n6 - 12 years: 250 - 500 mg; 3 months - 5 years: 125 - 250\\nmg taken orally every 4 - 6 hours\\n\\nPrevent water from entering ear for one month\\n\\nAvoid trauma to ear canal (especially scratching)\\nKeep ears dry\\n\\nThe main common local complication of acute\\ntonsillitis\\n\\nA virulent streptococcal infection; may spread beyond\\nthe tonsillar capsule into the peri-tonsillar space, causing,\\nfirst cellulitis, and later suppuration in the space\\n\\nMore common in adults with tonsillitis\\n\\nFollows an attack of acute tonsillitis\\nIncreasing pain, fever and dysphagia\\nTrismus- spread of oedema and infection to pterygoid\\n\\nmuscles\\nOften referred pain to ipsilateral ear\\nDifficulty in opening mouth for examination; mouth\\n\\nfull of saliva\\nAffected tonsil displaced downwards and medially,\\n\\nwith swelling above and lateral to it, all inflamed and\\noedematous\\n\\nUvula pushed to opposite side\\n\\nParapharyngeal abscess\\nRetropharyngeal abscess\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nPrevention\\n\\nPERITONSILLARABSCESS (Quinsy)\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nAdult:\\nChild:\\n\\nAdult and child:\\n\\nAdult:\\n\\nChild over 50 kg:\\n\\n85 86\\n\\nChapter 7: Ear, Nose and Throat Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nTonsillar tumours\\n\\nSepticaemia\\nParapharyngeal suppuration/abscess\\n\\nThroat swab\\nFull Blood Count with differentials\\n\\nRapid control of infection\\nRelief of pain and discomfort\\n\\nIncision and drainage, preferably under local anaesthetic\\nwhen suppuration is definite\\n\\nAntibiotics\\n- Amoxicillin\\n\\n500 mg -1 g intravenously every 6 hours for 7\\ndays\\n\\n50 - 100 mg/kg orally every 8 hours\\nAnalgesics\\n\\n- Paracetamol\\n500 mg - 1 g orally every 4 - 6 hours (to a\\n\\nmaximum of 4 g) for 5 - 7 days\\nsame as adult dosing\\n\\n6 - 12 years: 250 - 500 mg; 3 months - 5 years: 125 - 250\\nmg taken orally 4 - 6 hourly for 5 - 7 days\\nOr:\\n- Aspirin (Acetysalicylic acid)\\n\\n300 - 900 mg orally every 4 - 6 hours when\\nnecessary; maximum 4 g\\nNot recommended in children (risk of Reye\\'s syndrome)\\n\\nIntravenous infusion\\nBed rest\\n\\nAspirin may cause gastrointestinal irritation\\n\\nElective tonsillectomy is advised after an episode of\\nquinsy to prevent further (more severe) attacks\\n\\nA common cause of persistent sore throat in young and\\nmiddle-aged adults, usually unaccompanied by other\\nsymptoms\\n\\nOften secondary to chronic nasal conditions with nasal\\nobstruction e.g\\n- Vasomotor rhinitis\\n- Nasal polyps\\n- Septal deviation\\n\\nObstruction causes mouth breathing with dryness of the\\nthroat\\nOther causes:\\n\\nSecondary inflammation from postnasal discharge of\\nsinusitis\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nPHARYNGITIS (Sore Throat)\\nIntroduction\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild over 50 kg:\\n\\nAdult:\\n\\n- Mucopurulent postnasal discharge (“drip”)\\n\\nAcute rhinitis (coryza)\\nAllergic rhinitis\\nVasomotor rhinitis\\n\\nOrbital cellulitis (complicating ethmoidal sinusitis)\\nCavernous sinus thrombosis (sphenoidal sinusitis)\\nIntracranial infection\\n\\n- Subdural abscess\\n- Meningitis\\n- Cerebral abscess\\n- Dural vein thrombophlebitis\\n\\nOsteomyelitis of frontal or maxillary bones\\nChronic pharyngotonsillitis\\nChronic laryngitis and bronchitis\\n\\nNasal swab for microscopy, culture and sensitivity\\nX-ray of sinuses: four-view\\nAntrum roof puncture/lavage: specimen for culture\\nCT scan in complicated cases\\n\\nControl and eradicate infection\\nRestore adequate drainage of sinuses\\n\\nAntrum wash-out/lavage\\nTrephining of frontal sinus\\nRadical surgery for non-responsive cases\\n\\n- Intranasal antrostomy\\n- Caldwell-Luc operation\\n- Fronto-ethmoidectomy\\n\\nAntibiotics\\n- Amoxicillin\\n\\n500 mg - 1 g orally every 8 hours for 5 - 7 days\\n40 mg/kg orally every 8 hours for 5 - 7 days\\n\\nOr:\\nAmoxicillin/clavulanic acid\\n\\n500/125 mg orally every 12 hours\\n0.25 mL/kg of 125/31 mg suspension orally every\\n\\n8 hours; dose doubled in severe infections\\n1 - 6 years: 5 mL of 250/62 mg suspension every 8 hours;\\ndose doubled in severe infections\\n6 - 12 years: 5 mL of 250/62 mg suspension every 8\\nhours; dose doubled in severe infections\\n12 - 18 years: one 250/125 mg strength tablet every 8\\nhours, daily increased in severe infection to one 500/125\\nstrength tablet every 8 hours daily\\nOr:\\n\\nCotrimoxazole\\n960 mg orally every 12 hours\\n\\n120 mg orally every 12 hours;\\n6 months - 5 years: 240 mg every 12 hours; 6 - 12 years:\\n480 mg every 12 hours\\n- Ceftriaxone\\n\\n1 g intravenously or intramuscularly every 12\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild 6 weeks to 5 months:\\n\\nAdult:\\n\\nChronic exposure to irritants such as tobacco smoke\\nand alcohol\\n\\nSecondary infection from carious teeth\\n\\nPersistent sore throat with no systemic upset or\\ndysphagia\\n\\nSore throat is often worse in the mornings\\n\\nChronic tonsillitis\\nPharyngeal or laryngeal tumour\\n\\nMore often related to the primary sources of irritation or\\ninfection\\n\\nThroat swab: microscopy, culture and sensitivity\\nX-ray of paranasal sinuses\\n\\nControl symptoms by identifying and treating primary\\ncauses\\n\\nTreat sinusitis\\nSurgery for obstructive nasal conditions\\nTreat dental caries\\n\\nAppropriate antibacterial agent if indicated\\n\\nReduction or avoidance of exposure to known irritants-\\ntobacco, alcohol, etc\\n\\nInflammation of the mucosal lining of the paranasal\\nsinuses\\n\\nMay be acute or chronic and affect one or more of the\\nsinuses\\n- Most commonly the maxillary sinus or antrum (in very\\nyoung children the ethmoidal sinuses)\\n\\nAcute sinusitis is often sequel to acute rhinitis\\n- Common organisms are streptococcus, pneumococcus,\\nand haemophilus\\n\\nChronic sinusitis is more insidious\\n- May be associated with chronic rhinitis and allergy but\\nother factors such as air pollution, smoking, dental sepsis\\nand poor general health may be contributory\\nBacteriology is mixed: sometimes Gram negative and\\nfungal organisms\\n\\nRhinorrhoea\\nNasal obstruction\\nFever with pain over affected sinus in acute cases\\nLess dramatic symptoms in chronic sinusitis\\n\\n- Intermittent nasal obstruction and discharge over a\\nlong period\\n- Little pain\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nSINUSITIS\\nIntroduction\\n\\nClinical features\\n\\nhours for 7 days for patients with severe or nosocomial\\ndisease\\n\\nby intravenous infusion over 60 minutes\\nNeonates: 20 - 50 mg/kg once daily, by deep\\nintramuscular injection, intravenous injection over 2 - 4\\nminutes, or by intravenous infusion\\n1 month - 12 years (body weight under 50 kg) 50 mg/kg\\nonce daily, up to 80 mg/kg in severe infections\\n\\nDecongestant\\n- Psuedoephedrine tablets\\n\\n60 mg orally twice daily until congestion improves\\n15 mg orally 3 - 4 times daily; 6 - 12\\n\\nyears: 30 mg 3 - 4 times daily; 12 - 18 years: 60 mg 3 - 4\\ntimes daily\\n\\nAnalgesic\\n- Paracetamol\\n\\n500 mg -1 g orally every 4 - 6 hours (to a maximum\\nof 4 g) for 5 - 7 days\\n\\nsame as adult dosing\\n6 - 12 years: 250 - 500 mg; 3 months - 5 years: 125 - 250\\nmg taken orally every 4 - 6 hours for 5 - 7 days\\n\\nSteam inhalations with menthol\\nTreat contributory nasal pathology as appropriate\\n\\n- Allergy, nasal polyps, septal deviations, dental\\npathology, etc\\n\\nAmoxicillin\\n- Minor gastrointestinal disturbance\\n\\nCotrimoxazole\\n- Fixed drug eruption\\n- Nausea and vomiting\\n- Erythema multiforme\\n- Steven-Johnson syndrome\\n\\nAvoid airway irritants, smoking, and alcohol\\nAvoid air pollution\\nMaintain good general health and nutrition\\n\\nAn inflammatory condition of the palatine tonsils, most\\ncommon in children\\n\\nIn half or more cases infection is by beta-haemolytic\\nstreptococcus, in others viral\\n\\nTypically an acute infection\\nChronic tonsillitis presents usually as recurrent acute\\n\\ninfection\\nEssentially a disease of children but also occurs in\\n\\nyoung adults\\n\\nFever\\nSore throat\\nDysphagia\\n\\nChild:\\n\\nAdult:\\nChild 2-6 years:\\n\\nAdult:\\n\\nChild over 50 kg:\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nTONSILLITIS\\nIntroduction\\n\\nClinical features\\n\\n87 88\\n\\nChapter 7: Ear, Nose and Throat Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nSystemic upset and malaise\\nTonsils are swollen, inflamed and covered with\\n\\npurulent exudates\\nJugulo-digastric lymph nodes are enlarged and tender\\n\\nInfectious mononucleosis\\nVincent\\'s angina\\nAgranulocytosis\\n\\nQuinsy : main common complication\\nParapharyngeal infection/abscess\\nRheumatic fever and nephritis following streptococcal\\n\\ntonsillitis\\n\\nThroat swab for microscopy, culture and sensitivity\\nFull Blood Count\\n\\nControl the infection\\nControl pain\\nPrevent further episodes\\n\\nOral hydration\\nSalt/warm water gargle\\nTonsillectomy in chronic cases with frequent recurrent\\n\\ntonsillitis\\n\\nAntibiotics\\n- Amoxicillin\\n\\n250 - 500 mg orally every 8 hours for 5 - 7 days\\n40 mg/kg orally every 8 hours for 5 - 7 days\\n\\nThe parenteral route may be required when there is\\nvomiting or severe dysphagia\\nOr:\\n- Cotrimoxazole\\n\\n960 mg orally every 12 hours 5 - 7 days\\n120 mg orally every 12\\n\\nhours; 6 months - 5 years: 240 mg every 12 hours; 6 - 12\\nyears: 480 mg every 12 hours\\nAnalgesic\\n\\n- Paracetamol\\n500 mg -1 g orally every 4 - 6 hours (to a\\n\\nmaximum of 4 g) for 5 - 7 days\\n: same as adult dosing\\n\\n6 - 12 years: 250 - 500 mg; 3 months - 5 years: 125 - 250\\nmg taken orally every 4 - 6 hours for 5 - 7 days\\n\\nBed rest\\nIntravenous infusion as necessary\\n\\nCotrimoxazole\\n- Fixed drug eruption\\n- Nausea and vomiting\\n- Erythema multiforme\\n- Steven-Johnson syndrome\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild 6 weeks to 5 months:\\n\\nAdult:\\n\\nChild over 50 kg\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSensation of blockage and some degree of deafness are\\nthe most common complaints\\n\\nSometimes, pain and irritation\\nEar discharge in some cases\\nQuantity seen varies\\n\\n- May be soft or hard\\n- May be impacted in the deep meatus\\n\\nForeign bodies\\nOtitis externa\\n\\nSuperimposed infection: otitis externa\\nHearing impairment\\n\\nEvacuate the wax and clear the ear\\n\\nRemoval with probe and cotton wool: for soft wax\\nEar syringing: for hard wax, often after preliminary\\n\\nsoftening with oily drops\\nOccasionally, removal under anaesthesia if syringing is\\n\\nunsuccessful\\n\\nEar drops to soften and loosen wax\\n- Warm olive oil\\nOr:\\nChlorobutanol 5% paradichlorobenzene 2%, arachis\\n(peanut) oil 57.3%\\n\\nTRACHEOSTOMY\\nIntroduction\\n\\nClinical features\\n\\nComplications\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nWAX IN THE EAR\\nIntroduction\\n\\nA surgical procedure in which an opening is created\\ninto the trachea from the outside, commonly to bypass an\\nupper respiratory obstruction\\n\\nMay also be done to provide easier access for care of\\nthe chest in some seriously ill patients\\n- Also for respiratory support and artificial ventilation\\nin patients with respiratory insufficiency or paralysis\\n\\nMost cases are done to by-pass upper airway\\nobstruction:\\n- Acute infections of the larynx\\n- Trauma\\n- Foreign body aspiration\\n- Acute laryngeal oedema\\n- Vocal cord paralysis\\n- Tumours\\n\\nSome cases are done as part of, or to facilitate major\\nhead and neck surgery\\n\\nAn appropriate-sized tracheostomy tube, portex or\\nmetal, is inserted to maintain the opening\\n\\nAcute presentation with clinical features of airway\\nobstruction, stridor and incipient asphyxia following\\ntrauma\\n\\nAcute inflammatory conditions of the larynx, which\\nwould require the operation as an emergency\\n\\nProgressive lesions: may require less urgent\\nintervention in anticipation of likely obstruction\\n\\nCases with medical indications requiring respiratory\\nsupport are usually done on a more elective basis\\n\\nHaemorrhage\\nInfection: wound and chest\\nDamage to nerves and large vessels in the neck\\n\\nTo secure the airway\\n\\nPostoperative care of tracheostomy preferably in an\\nintensive care unit, with suction, humidification, stoma\\ncare as appropriate\\n\\nBroad spectrum antibiotic cover\\n\\nWax (or cerumen) is a normal product of the human\\nexternal ear\\n- A dark brownish mixture of the secretions of the\\nceruminous and sebaceous glands in the outer third of the\\nexternal auditory canal\\nSmall quantities are produced continuously and function\\nto lubricate the canal\\n\\nQuantities produced and the consistencies vary\\n- May be excessive in some people, causing deafness,\\near ache, secondary infection and even vertigo\\n\\nCHAPTER 8: ENDOCRINE SYSTE\\n\\nDIABETES MELLITUS\\nIntroduction\\n\\nClinical features\\n\\nA group of metabolic diseases characterized by chronic\\nhyperglycaemia\\n\\nResults from defects in insulin secretion, insulin action\\nor both\\n\\nIt is associated with acute as well as long-term\\ncomplications affecting the eyes, kidneys, feet, nerves,\\nbrain, heart and blood vessels\\nIts classification has been revised by the WHO and is\\nbased on aetiology:\\n\\nType 1:\\n- Results from destruction (usually autoimmune) of the\\npancreatic cells\\n- Insulin is required for survival\\n\\nType 2:\\n- Characterized by insulin resistance and/or abnormal\\ninsulin secretion (either may predominate); both are\\nusually present\\n- It is the most common type of diabetes\\n\\nOther specific types of diabetes- less common, and\\ninclude:\\n- Genetic disorders\\n- Infections\\n- Diseases of the exocrine pancreas\\n- Endocrinopathies\\n- Drugs\\n\\nGestational diabetes: appears for the first time in\\npregnancy\\n\\nType 1 diabetes:\\nPatients present at a young age (usually teens or\\n\\ntwenties); earlier presentation may also occur\\nRapid onset of severe symptoms: weight loss, thirst and\\n\\npolyuria\\nBlood glucose levels are high and ketones are often\\n\\npresent in the urine\\nIf treatment is delayed, ketoacidosis (DKA) and death\\n\\nmay follow\\nThe response to insulin therapy is dramatic and\\n\\ngratifying\\nMisclassification of patients as “Type 1” is relatively\\n\\ncommon\\n- Insulin-treatment is not the same as insulin-dependence\\nType 2 diabetes:\\n\\nMost patients present with the classical symptoms\\nincluding polyuria, polydipsia and polyphagia\\n\\nSome patients present with sepsis, diabetic coma\\n(hyperosmolar non-ketotic states)\\n\\nA minority is asymptomatic and therefore identified at\\nscreening\\n\\nThe patients usually do not seek medical attention early\\nbecause of the insidious nature of the disease\\n\\nMany present at diagnosis with features of diabetic\\n\\nβ\\n\\n89 90\\n\\nChapter 7: Ear, Nose and Throat Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\ncomplications\\n- Visual difficulties from retinopathy\\n- Pain and/or tingling in the feet from neuropathy\\n- Foot ulcerations\\n- Stroke\\nGestational diabetes (GDM):\\n\\nDiabetes which arises in pregnancy\\nMust be distinguished from existing diabetes in women\\n\\nwho become pregnant\\nOf particular importance because it is associated with\\n\\npoor pregnancy outcomes, especially if not recognised\\nand not treated\\nParticular problems associated with GDM:\\n\\nFoetal macrosomia\\nEclampsia\\nIntra-uterine growth retardation\\nBirth difficulties\\nNeonatal hypoglycaemia\\nNeonatal respiratory distress\\n\\nStraightforward in the majority of cases\\nMay pose a problem for those with a minor degree of\\n\\nhyperglycaemia, and in asymptomatic subjects\\n- In these circumstances, two abnormal blood glucose\\nresults on separate occasions are needed to make the\\ndiagnosis\\n- If the results of point blood glucose testing are\\nequivocal, an oral glucose tolerance test should be\\nperformed\\n- If diagnosis remains in doubt maintain surveillance\\n\\nDiagnosis\\n\\nValues for the Diagnosis of Categories of Hyperglycaemia\\n\\nGlucose Tolerance State Venous plasma (mmol/L) Venous plasma (mg/dL)\\n\\nDiabetes mellitus\\n\\nImpaired glucose tolerance\\n\\nAND\\n\\nImpaired fasting glycaemia\\n\\nFasting 7 126\\n\\n2 hour post-75 g glucose load 11.1 200\\n\\nFasting < 7.0 < 110\\n\\n2 hour post-75 g glucose load 7.8 and < 11.1 140 and < 200\\n\\nFasting 6.1 and < 7.0 5.6 and < 6.1\\n\\nUnless there is unequivocal hyperglycaemia with acute metabolic decompensation or obvious symptoms, the\\ndiagnosis of diabetes should always be confirmed by repeating the test on another day\\n\\n� �\\n\\n� �\\n\\n� �\\n\\n� �\\n\\nwith periodic re-testing until the diagnostic situation\\nbecomes clear\\n\\nTake into consideration additional risk factors for\\ndiabetes before deciding on a diagnostic or therapeutic\\ncourse of action\\n\\nSymptoms of hyperglycaemia\\n:\\n\\nRandom venous plasma glucose 11.1 mmol/L\\n\\nfasting venous plasma glucose 7.0 mmol/L\\n- Confirms the diagnosis of diabetes\\n\\nIn asymptomatic subjects, a single abnormal blood\\nglucose result is inadequate to make a diagnosis of\\ndiabetes\\n- Abnormal values must be confirmed at the earliest\\npossible date using any of the following\\n- Two separate fasting or random blood samples\\n\\n:\\n- A75 g oral glucose tolerance test\\n\\nThe diagnosis of diabetes must be confirmed\\nbiochemically prior to initiation of any therapy\\n\\nPlus\\n\\nor\\n\\nOr\\n\\n�\\n\\n�\\n\\n91 92\\n\\nManagement\\n\\nNon-drug treatment\\n\\nGoals:\\nEarly diagnosis\\nPrevent and/or reduce short and long term morbidities\\nPrevent premature mortality\\nImprove quality of life and productivity of affected\\n\\npersons\\nPromote self care practices and empowerment of people\\n\\nwith diabetes\\nReduce the personal, family and societal burden of\\n\\ndiabetes\\nAchievement of these goals is dependent on:\\n\\nSuccessful establishment of diabetes health care team,\\nand infrastructure to support it, including provision of\\neducation for health care professionals and for people\\nliving with diabetes\\n\\nTreatment of hyperglycaemia\\nTreatment of co-morbidities\\nPrevention and treatment of macrovascular and\\n\\nmicrovascular complications\\n\\nThe provision of knowledge and skills to people with\\ndiabetes mellitus\\n- To empower them to render self-care in their\\nmanagement\\n\\nShould be locally applicable, simple and effective\\nAll members of the diabetes care team should be trained\\n\\nto provide the education\\nIt must empower people with diabetes as well as their\\n\\nfamilies\\n- Provide them with adequate knowledge of diabetes and\\nits sequelae\\n- Create the right attitudes and provide resources to\\nprovide appropriate self care\\n\\nThe effectiveness of the programme must be evaluated\\nand modified as necessary\\n\\nDiabetes is serious but can be controlled\\nComplications can be prevented\\nThat the cornerstones of therapy are education, diet and\\n\\nexercise\\nTheir metabolic and blood pressure targets\\nHow to look after their feet and thus prevent ulcers and\\n\\namputations\\nHow to avoid other long term complications\\nThat regular medical check ups are essential\\nWhen to seek medical help\\n\\n- One of the cornerstones of diabetes management\\n- Based on the principle of healthy eating in the context\\nof social, cultural and psychological influences on food\\nchoices\\n- Dietary modification (and increasing level of physical\\n\\nCore components of diabetes care\\n\\nEducation\\n\\nDiet\\n\\nPriciples of Diabetes Education\\n\\nWhat people with diabetes need to know\\n\\nactivity) should be the first step in the management of\\nnewly diagnosed persons with Type 2 diabetes\\n- Should be maintained throughout the course of diabetes\\nmanagement\\n\\nTo achieve an ideal body weight\\n- An appropriate diet should be prescribed along with an\\nexercise regimen\\n- Caloric restrictions should be moderate and yet provide\\na balanced nutrition\\n- Eat at least three meals a day. Binge eating should be\\navoided\\n- Asnack between meals can be healthy for certain groups\\nof people\\n- The diet should be individualized, based on traditional\\neating patterns, be palatable and affordable\\n- Animal fat, salt, and so-called diabetic foods should be\\navoided\\n- Pure (simple sugars) in foods and drinks should be\\navoided\\n- Eating plans should be high in carbohydrates and fibre,\\nvegetables and fruits should be encouraged\\n- Dietary instructions should be written out,\\n\\n: someone at home should be available\\nto interpret to him/her\\n- Food quantities should be measured in volumes using\\navailable household items (e.g. cups), or be countable (e.g\\nnumber of fruits or slices of yam or bread)\\n- Weighing scales are generally unaffordable and/or\\ndifficult to understand\\n- Appetite suppressants generally yield poor and/or\\nunsustainable weight reductions and are expensive\\n\\n- One of the essentials in the prevention and management\\nof Type 2 diabetes mellitus\\nRegular physical activity:\\n\\nImproves metabolic control\\nIncreases insulin sensitivity\\nImproves cardiovascular health\\nHelps weight loss\\nGives a sense of well-being\\n\\nTwo main types of physical activity:\\nAerobic or endurance exercise e.g. walking, running\\nAnaerobic or resistance exercise (e.g. lifting weights)\\n\\n- Both types of activity may be prescribed to persons with\\ntype 2 diabetes mellitus; the aerobic form is usually\\npreferred\\n\\nDetailed evaluation\\n- Cardiovascular, renal, neurological and foot\\nassessments\\n- Evaluation should be done before a formal exercise\\nprogramme is commenced\\n- The presence of chronic complications excludes certain\\nforms of exercises\\nPrescribed physical activity programmes should be\\n\\nGoals of dietary management of Type 2 diabetes mellitus\\n\\nGeneral principles and recommendations\\n\\neven if the\\nperson is illiterate\\n\\nPhysical activity\\n\\nChapter 8: Endocrine System Standard Treatment Guidelines for Nigeria 2008\\n\\n\\n\\nappropriate for:\\n- The age\\n- Socio-economic status\\n- State of physical fitness\\n- Lifestyle\\n- Level of control\\n\\nExercise generally improves metabolic control, but can\\nprecipitate acute complications like hypoglycaemia and\\nhyperglycaemia\\n\\nPhysical activity should :\\n- Be regular (about 3 days/week)\\n- Last at least 20 - 30 minutes per session\\n- Be at least of moderate activity\\n\\nActivities like walking, climbing steps (instead of\\ntaking lifts) should be encouraged\\n\\nFor sedentary persons with diabetes, a gradual\\nintroduction using a low intensity activity like walking is\\nmandatory\\n\\nAvoid exercising if :\\n- Ambient glycaemia is > 250 mg/dLblood glucose\\n- Patient has ketonuria\\n- Blood glucose is less than 80 mg/dL\\n\\nTo avoid exercise-induced hypoglycaemia in patients\\non insulin\\n- Increase peri-exercise carbohydrate intake\\n- Reduce insulin dose\\n- Adjust injection site (avoid exercising muscles site)\\n\\nFor persons with type 2 diabetes mellitus on long acting\\ninsulin secretagogues\\n- Extra carbohydrate should be taken before and after the\\nexercise\\n\\nIn those on short acting secretagogues (e.g. glipizide,\\nrepaglinide) the post exercise dose should be omitted\\n\\nGlycaemia should be monitored (using strips and\\nmeters) before and after planned physical activity\\n- Delayed hypoglycaemia may occur\\n\\nProper foot wear must always be worn during exercise\\nFor a prescribed formal activity, the exercise session\\n\\nshould consist of:\\n- Awarm-up period of 5 - 10 minutes\\n- The activity proper: 20 - 60 minutes\\n- Acool-down period of 5 - 10 minutes\\n\\nIn most parts of Africa, prescribing formal exercise in\\ngyms or requiring special equipment is a recipe for non-\\nadherence to the exercise regimen\\n\\nPatients should be encouraged to integrate increased\\nphysical activity into their daily routine\\n- The programme should impose minimum (if any) extra\\nfinancial outlay in new equipment and materials\\n\\nOral hypoglycaemic agents:\\n- For Type 2 diabetes mellitus\\n\\nIndicated :\\n- When individualized targets are not met by the\\ncombination of dietary modifications and physical\\nactivity/exercise\\n\\nDrug treatment\\n\\n- (In some cases) at the first presentation of diabetes (i.e.\\nfasting blood glucose more than 11 mmol/L or random\\nblood glucose more than 15 mmol/L)\\nMay be used as monotherapy or in combination therapy,\\n\\ntargeting different aspects in the pathogenesis of\\nhyperglycaemia in Type 2 diabetes mellitus\\n- i.e. increasing insulin production and release,\\ndecreasing insulin resistance and/or decreasing hepatic\\nglucose production\\n\\nInitial monotherapy in non-obese patients\\nAdd-on as combination therapy\\n\\nGlibenclamide 1.25 - 10 mg orally twice daily\\ninitially 2.5 mg orally daily with, or\\n\\nimmediately after breakfast, adjusted according to\\nresponse; maximum 15 mg daily\\n- Indicated for Type 2 diabetes, maturity-onset diabetes\\nof the young, under specialist care\\n\\nWeight gain\\nHypoglycaemia\\nSyndrome of inappropriateADH secretion\\nBlood dyscrasias\\nHeart burn\\nAbdominal pain\\n\\nAllergy to sulpha drugs\\nLiver impairment\\nSevere renal failure\\nPregnancy\\nAge > 80 years\\n\\nIndicated in:\\nMonotherapy in obese Type 2 diabetes mellitus\\nCombination therapy\\nMetabolic syndrome\\nAllergy to sulphonylureas\\n\\nMetformin 500 mg - 1 g orally twice or three times\\ndaily\\n\\ninitially 500 mg orally once daily,\\nadjusted according to response at intervals of not less\\nthan 1 week; maximum 2 g daily in 2-3 divided doses\\n- Under specialist supervision ONLY\\n- Not licensed for use in children less than 10 years old\\n\\nGastrointestinal upset/nausea/loose bowel motions\\nMetallic taste\\nLactic acidosis\\n\\nImpaired hepatic and renal function\\nCongestive cardiac failure\\nContrast studies\\nChronic obstructive airways disease\\nAlcoholism\\n\\nSulphonylureas\\n\\nBiguanides\\n\\nImportant notes on Oral Glucose Lowering Agents\\n(OGLAs)\\n\\nAdult:\\nChild 12 - 18 years:\\n\\nAdult:\\n\\nChild 10 - 18 years:\\n\\nNotable adverse drug reactions\\n\\nContraindications\\n\\nNotable adverse drug reactions\\n\\nContraindications\\n\\nSulphonylureas and biguanides are the agents most\\nwidely available\\n- Stocking these agents would meet the diabetes care\\nneeds of most diabetes facilities\\n\\nThe choice of OGLAs should be informed by:\\n- Lifestyle\\n- Degree of control\\n- Access to medicines\\n- Economic status\\n- Mutual agreement between the doctor and the person\\nwith diabetes\\n\\nMonotherapy with any of the drugs should be the initial\\nchoice\\n- Use of stepped-care approach is recommended\\n\\nIf overweight (BMI > 25 kg/m ) or if insulin resistance\\nis the major abnormality\\n- Metformin should be the first choice\\n- If metformin is contraindicated thiazolidinediones may\\nbe used\\n\\nAvoid metformin and long acting sulphonylureas in\\nelderly patients\\n- Instead, use short acting sulphonylureas and/or glinides\\nor glitazones\\n\\nCombination therapy using OGLAs with different\\nmechanisms of action is indicated if monotherapy with\\none of the agents has failed\\n\\nThe rapid acting secretagogues (glinides) and the alpha\\nglucosidase inhibitors make for flexibility in the\\nglycaemic management of Type 2 diabetes mellitus but\\nare relatively very expensive\\n\\nWhen oral combination therapy fails, insulin should be\\nadded to the treatment regimen or should replace the\\nOGLAs\\n\\n2\\n\\nSecondary failure of OGLAs is said to be common (5 -\\n10% of patients annually) although no reports from\\nAfrica are available\\n\\nInsulin is increasingly being used\\n- In combination with OGLAs or as monotherapy in the\\nmanagement of Type 2 diabetes to achieve optimum\\ntargets\\n- Hyperglycaemic emergencies\\n- Peri-operatively, especially major or emergency\\nsurgeries\\n- Organ failure: renal, liver, heart etc\\n- Pregnancy\\n- LatentAutoimmune Diabetes ofAdults (LADA)\\n- Sensitivity to OGLAs\\n\\nRegimen and dose of insulin therapy will vary from\\npatient to patient\\n\\nTwo forms of insulin therapy are often used in\\ncombination with OGLAtherapy\\n- Intermediate/long acting insulin plus OGLA pre\\nmixed insulin\\n\\nInsulin Therapy in Type 2 Diabetes\\n\\n- or -\\n\\nReferral to an endocrinologist should be considered if\\nmore than 30 units of insulin are required per day\\n\\nChapter 8: Endocrine System Standard Treatment Guidelines for Nigeria 2008\\n\\n93 94\\n\\nTime Course ofAction of Insulin Preparations\\n\\nVery rapid acting\\n(insulin analogues) 10 min 1 h 3 h Immediately\\n\\nbefore meals\\n\\nShort-acting 30 min 2 - 5 h 5 - 8 h 30 min before\\nmeals\\n\\nIntermediate-acting\\n(NPH or lente) 1 - 3 h 6 - 12 h 16 - 24 h Once or twice daily\\n\\nBiphasic mixtures\\n(30/70; premixed) 30 min 2 - 12 h 16 - 24 h Once or twice daily\\n\\nInsulin Preparation Onset ofAction PeakAction Duration ofAction Injections per day\\n\\n\\n\\nMonitoring glycaemic control\\n\\nCornerstones of management\\n\\nScreening for GDM\\n\\nClinical and laboratory methods are employed\\nHbA1c tests are desirable standard tests but are\\n\\nunavailable in most of the primary and secondary health\\nfacilities inAfrica\\n\\nFasting plasma glucose performed in the laboratory in\\nplace of HbA1c is the best alternative\\n- Its average for repeated measurements gives a reliable\\nindication of the control\\n\\nGlycosuria is a poor means of assessment of control\\nSelf Blood Glucose Monitoring (SBGM) should be\\n\\nencouraged\\nResults of self urine testing or blood glucose tests\\n\\nshould be recorded in a logbook\\nClinic protocols should set out in some detail, the\\n\\nparameters to be monitored at the initial visits, at regular\\nfollow-up visits, and at annual reviews\\n\\nAt the initiation of insulin therapy, appropriate advice\\non SBGM and diet should be given\\n\\nExamples are obesity, hypertension and dyslipidaemias\\n- See relevant chapters\\n\\nPeople with diabetes are at increased risk of foot ulcers\\nand amputations which are major causes of morbidity\\nand disability\\n\\nBoth foot ulcers and amputations can be prevented by\\neducation, anticipation, early recognition and prompt\\nmanagement\\nThe most common predisposing factors for ulcers and\\namputations are:\\n\\nPeripheral neuropathy with loss of sensation\\nPoor foot hygiene\\nPeripheral vascular disease\\nDeformities and abnormal biomechanics\\nUnsuitable or no footwear\\n\\nRegular inspection and examination of the foot at risk\\nIdentify the at-risk foot\\nEducation of healthworkers, people with diabetes and\\n\\ntheir families\\nAppropriate footwear\\nEarly treatment of non-ulcerative and ulcerative foot\\n\\nproblems\\n\\nGestational diabetes mellitus (GDM) is any degree of\\nglucose intolerance in pregnancy\\n\\nIf inadequately managed, GDM is associated with\\nincreased risk of perinatal morbidity and mortality\\n\\nDiagnosis and prompt institution of therapy reduce the\\nrisks of poor outcomes\\n\\nWhen:\\n\\nTreatment of co-morbidities\\n\\nIntroduction\\n\\nIntroduction\\n\\nDiabetic foot problems\\n\\nDiabetes in pregnancy\\n\\nfirst recognised\\n\\nChapter 8: Endocrine System Standard Treatment Guidelines for Nigeria 2008\\n\\n- Between 24 and 28 weeks of gestation\\nWho: Women with\\n\\n- High risk for GDM\\n\\n- BMI 25 kg/m\\n- Previous history of GDM\\n- Glycosuria\\n- Previous large baby (> 4 kg)\\n- Poor obstetric history\\n- Family history of diabetes\\n- Known IGT / IFG\\n\\nCombined health care team- obstetrician, diabetologist,\\ndiabetes educator, and paediatrician/neonatologist\\n\\nInitial therapy is dietary modification\\n- Spread carbohydrate over 3 small to moderate sized\\nmeals and 2 - 3 snacks/day\\n- Consider an evening snack to prevent starvation ketosis\\n- Energy intake should provide for desirable weight gain\\nduring pregnancy\\n- For obese women a 30 - 33% calorie restriction is\\nadvised\\n\\nDaily SBGM (urine glucose monitoring) is not useful\\nin pregnancy\\n\\nInitiate insulin therapy if:\\n- Fasting plasma glucose is > 5.8 mmol/L\\n- 1 hour post-prandial glucose is > 8.6 mmol/L\\n- 2 hour post-prandial plasma glucose is >7.5 mmol/L\\n\\nModify insulin regimen to achieve above targets\\nRegular assessment of maternal wellbeing should\\n\\ninclude blood pressure and urine protein\\nRegular surveillance for foetal well-being\\nDelivery at 38 weeks gestation recommended\\nWithdraw therapy for diabetes after birth\\nRe-assess classification of maternal status at 6 weeks\\n\\npost partum\\n\\nThese are:\\nDiabetic ketoacidosis\\nNon-ketotic hyperosmolar states\\nHypoglycaemia\\nLactic acidosis\\n\\n- Acute hyperglycaemic complications may present\\nwith coma or altered levels of consciousness in people\\nwith diabetes\\n\\nStroke\\nSeizures\\nTrauma\\nDrug overdose\\nEthanol intoxication\\n\\nSevere uncontrolled diabetes requiring emergency\\n\\n�\\n2\\n\\nManagement\\n\\nDifferential diagnoses\\n\\nIntroduction\\n\\nAcute metabolic complications of diabetes mellitus\\n\\nDiabetic ketoacidosis\\n\\ntreatment with insulin and intravenous fluids\\nBlood ketones (acetoacetate and 3-hydroxbutyrate)\\n\\nconcentration > 5 mmol/L\\nCarries a high mortality inAfrica\\n\\n- Through late presentation, delayed diagnosis and\\ninadequate treatment\\n\\nPresents at any age although there is a well defined peak\\nat puberty\\nCauses include:\\n\\nInfection\\nManagement errors\\nNew cases of diabetes (treatment not commenced)\\nNo obvious cause in about 40% of cases\\n\\nRepeated vomiting or inability to take adequate oral\\nfluids\\n\\nHyperventilation\\nAny disturbance of consciousness\\nPersistent ketonuria\\nPresence of infections\\n\\nFluids and electrolytes\\n- One litre per hour for 3 hours; thereafter according to\\nneed\\n- Sodium chloride 0.9% injection\\n- Hypotonic (half-normal) saline: 75 mmol/L if plasma\\nsodium exceeds 150 mmol/L\\n- Glucose 5% when blood glucose level falls below14\\nmmol/L\\nPlus:\\n\\nPotassium (K ) replacement\\n- To be added into each litre of fluid\\n\\nPlasma K less than 3.5 mmol/L:\\nAdd 40 mmol KCl\\n\\nPlasma K 3.5 - 5.5 mmol/L:\\nAdd 20 mmol KCl\\n\\nPlasma K greater than 5.5mmol/L:\\nDo not add KCl\\n\\nPlus:\\nInsulin\\n\\n- To be added into intravenous fluid for rehydration\\n- Initially, 5 - 10 units/hour; by continuous intravenous\\ninfusion\\n- Maintenance 2 - 4 units/hour, titrated against blood\\nglucose levels (until able to eat)\\nIntramuscular injections:\\n- 20 units immediately, then 5 - 10 units/hour, titrated\\nagainst blood glucose levels\\nOther measures:\\n\\nTreat precipitating cause (e.g. infection, myocardial\\ninfarction)\\n\\nCorrect hypotension (should respond to adequate fluid\\nreplacement)\\n\\nPass nasogastric tube if consciousness is impaired\\nVentilate if adult respiratory distress syndrome develops\\n\\nIndications for immediate hospital admission\\n\\nInitial treatment plan for Diabetic Ketoacidosis in adults\\n\\n+\\n\\n+\\n\\n+\\n\\n+\\n\\n- 100% oxygen by intermittent positive pressure\\nventilation\\n\\nIntravenous dexamethasone, mannitol for cerebral\\noedema (see cerebral oedema)\\n\\nTreat specific thromboembolic complications if they\\noccur\\n\\nCharacterized by the insidious development of:\\nMarked hyperglycaemia (usually > 50 mmol/L)\\nDehydration\\nPre-renal uraemia\\n\\n- Significant hyperketonaemia does not develop\\nTwo-thirds of cases occur in previously undiagnosed\\n\\ncases of diabetes\\nUsually affects middle- aged or elderly patients and\\n\\ncarries a mortality of over 30%\\nPrecipitating factors include:\\n\\nInfections\\nDiuretic treatment\\nDrinking glucose-rich beverages\\n\\nRehydration\\nInsulin therapy\\nElectrolyte replacement\\n\\n- In a manner similar to that used for diabetic ketoacidosis\\n\\nAffects over 70% of patients on insulin therapy\\n\\nEngaging in more exercise than usual\\nDelay or omission of a snack or main meal\\nAdministration of too much insulin\\nEating insufficient carbohydrate\\nOverindulgence in alcohol\\nOverdosing with sulphonylureas\\n\\nIn the presence of low blood glucose (< 2 mmol/L)\\ncharacteristic symptoms and signs include:\\n\\nLight headedness\\nHeadaches\\nTremulousness\\nPalpitations\\nSweating\\nFeeling of hunger\\nTachycardia\\nHypertension (usually systolic)\\nStroke-like presentations\\nComa\\n\\nOral glucose if patient is conscious\\nIf patient is unconsious:\\n\\nDiabetic non-ketotic hyperosmolar state\\n\\nHypoglycaemia\\n\\nIntroduction\\n\\nTreatment\\n\\nIntroduction\\n\\nCommon causes of hypoglycaemia in persons with\\ndiabetes mellitus\\n\\nAcute management\\n\\n95 96\\n\\n\\n\\nAetiology\\n\\nClinical features\\n\\nDifferential diagnosis\\n\\nComplications\\n\\nGrave\\'s disease (80% of patients)\\nMultinodular goitre\\nAutoimmune functioning solitary thyroid nodule\\nThryroiditis (sub-acute or postpartum)\\nIodine induced- drugs such as :\\n\\n- Amiodarone\\n- Radiographic contrast media\\n- Iodine prophylaxis programmes\\n\\nExtra-thyroidal sources of thyroid hormone excess\\n- Factitious hyperthyroidism\\n- Struma ovarii\\n\\nTSH-induced:\\n- Inappropriate TSH secretion by the pituitary\\n- Choriocarcinoma\\n- Hydatiform mole\\n\\nFollicular carcinoma of the thyroid with metastasis\\n\\nAgoit may or may not be present\\n- May be diffuse or nodular\\nDermatological:\\n\\nIncreased sweating and pruritus\\nPretibial myxoedema\\nPigmentation, vitiligo\\nPalmar erythema.\\n\\nCardiorespiratory:\\nDyspnoea on exertion\\nAngina and cardiac failure\\nIncreased pulse pressure\\nExacerbation of asthma\\n\\nGastrointestinal:\\nWeight loss despite increased appetite\\nDiarrhoea\\nSteatorrhoea\\n\\nNeuromuscular:\\nTremors, nervousness, irritability, emotional lability\\n\\nand psychosis\\nMuscle weakness and proximal myopathy\\n\\nReproductive:\\nLoss of libido, impotence\\n\\nAmenorrhoea/oligomenorrhoea\\nInfertility and spontaneous abortions\\n\\nOcular:\\nLid lag lid retraction\\nGrittiness, excessive lacrimation\\nExophthalmos diplopia\\nPapilloedema\\n\\nOthers:\\nIncreased thirst\\nFatigue and apathy\\n\\nSimple goitre\\nMalignant tumours of the thyroid\\n\\nHyperthyroid crisis (thyroid storm)\\nCompression of the trachea\\n\\nCardiac failure\\nLoss of visual acuity\\nInfertility\\nPeriodic paralysis\\n\\nSpecific:\\nSerum T , T and TSH levels\\n\\nMeasurement of I intake by the thyroid gland\\nNon-specific:\\n\\nLiver function tests\\n- Slightly raised concentrations of bilirubin, alanine\\naminotransferase\\n\\nSerum calcium\\n- Mild hypercalcaemia\\nFasting blood glucose\\n- Glycosuria may be present\\n\\nAchieve normal metabolic rates\\nObtain normal serum T , T and TSH Levels\\n\\nPrevent complications\\n\\nAntithyroid drugs\\n- Carbimazole\\n\\nstarting dose 30 - 60 mg orally in divided doses\\ndaily\\nMaintenance: 10 - 15 mg oral daily\\n\\nneonate, initially 250 micrograms/kg orally every\\n8 hours until euthyroid then adjust as necessary\\n1 month - 12 years: initially 250 micrograms/kg\\n(maximum 10 mg every 8 hours) until euthyroid then\\nadjusted as necessary\\n12 - 18 years: initially 10 mg every 8 hours until\\neuthyroid then adjusted as necessary\\n- Higher initial doses occasionally required, particularly\\nin thyrotoxic crisis\\n\\nPropylthiouracil\\nstarting dose 300 - 450 mg orally in divided doses\\n\\ndaily\\nMaintenance: 100 - 150 mg orally in 2 or 3 divided doses\\ndaily\\n\\nneonate, initially 2.5 - 5 mg/kg orally every 12\\nhours until euthyroid, then adjusted as necessary\\n1 month - 1 year: initially 2.5 mg/kg every 8 hours until\\neuthyroid; 1 - 5 years: 20 mg/kg 8 hourly until euthyroid;\\n5 - 12 years: initially 50 mg every 8 hours until euthyroid;\\n12 - 18 years: initially 100 mg every 8 hours until\\neuthyroid\\n- Higher doses occasionally required particularly in\\nthyrotoxic crisis\\n- Duration of treatment usually is 18 - 24 months\\n\\nβ- adrenergic blocking drugs\\n- Propranolol 80 - 160 mg orally daily in divided doses\\n- Symptoms and signs of hyperthyroidism due to\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\n3 4\\n\\n3 4\\n\\n131\\n\\nAdult:\\n\\nChild:\\n\\nChild and carers to inform doctor immediately if sore\\nthroat, mouth ulcers,bruising, fever, malaise or non-\\nspecific illness develops\\n\\nAdult:\\n\\nChild:\\n\\nChapter 8: Endocrine System Standard Treatment Guidelines for Nigeria 2008\\n\\nIntravenous glucose\\n- 50% glucose given as a bolus of 40 - 50 mL\\nOr:\\n- 20% glucose 100 - 150 mL followed by 8 - 10% glucose\\ninfusion if necessary\\nOr:\\n\\nInjectable glucagon\\n- 1 mg intramuscularly stat\\nIf hypoglycaemia is due to long acting sulphonylureas, or\\nlong and intermediate acting insulin or alcohol\\n\\nProlonged intravenous glucose infusion (5 - 10% for 12\\n- 24 hours; even longer) may be necessary\\nIf intravenous access is impossible:\\n\\nConsider nasogastric or rectal glucose\\nOr:\\nGive glucagon 1 mg intramuscularly\\n\\nAs a last resort:\\nAdminister epinephrine (adrenaline)\\n\\n- 1 mLof 1 in 1,000 strength, subcutaneously stat\\nOn recovery:\\n\\nGive a long acting carbohydrate snack\\nAttempt to identify the cause of hypoglycaemia and\\n\\ncorrect it\\nAssess the type of insulin used, injection sites and\\n\\ninjection techniques\\n- Lipohypertophy can alter the rate of absorption\\n\\nEnquire into, and correct inappropriate habits of eating,\\nexercise and alcohol consumption\\n\\nReview other drug therapy and renal function\\nAdjust insulin or OGLAdosages as appropriate\\n\\nGeneralised obesity, central obesity and physical\\ninactivity are the major modifiable risk factors, and\\nshould be avoided/corrected\\n\\nPrevention of diabetes\\n\\nOnset of diabetes can be delayed in people at high risk\\nby active lifestyle modification\\n- Lifestyle modification should be the cornerstone of\\npreventative strategies in the following categories of\\npeople:\\n\\nAge > 45years\\n\\nOverweight and obesity (BMI > 25 kg/m )\\nPhysical inactivity\\nFirst degree relatives with diabetes\\nPrevious gestational diabetes\\nPreviously identified IGT or IFG\\nDyslipidaemia\\nHypertension\\n\\nThe components of lifestyle modification should include\\n(but not be limited to) the following:\\n- Lose 5 - 10% weight\\n- Reduce fat intake (< 30% of total daily calories)\\n- Reduce saturated fat intake (< 10% of total daily\\ncalories)\\n- Increase fibre intake to > 15 g/1000 kcal\\n- TraditionalAfrican diets are high in fibre content\\n- Increase levels of physical activity e.g.brisk walking\\nproducing a heart rate >150/min\\n- Exercise should last for at least 30 minutes and should\\nbe undertaken at least three times a week\\n- Reduce high alcohol intake\\n\\nAclinical syndrome which results from exposure of the\\nbody to excess levels of the thyroid hormones,\\nThyroxine (T ) and Tri-iodothyronine (T )\\n\\nMore females are affected than males (usually in the\\nratio of 5:1)\\n\\n2\\n\\nHYPERTHYROIDISM (Thyrotoxicosis)\\nIntroduction\\n\\n4 3\\n\\nDiabetic Ketoacidosis\\n\\nHyperventilation\\nDehydration Tachypnoea;\\nKaussmaul breathing\\nAcetone breath\\nMore common in insulin-\\ndependent persons; may occur\\nin Type 2 diabetes Warm skin\\nNormal or low blood pressure\\nH y p e r g l y c a e m i a a n d\\nglycosuria\\nH y p e r k e t o n a e m i a a n d\\nketonuria\\nFall in blood pH\\nIncreased free fatty acid\\nLevels in blood\\n\\nHyperosmolar non-ketotic\\nstate\\n\\nNo hyperventilation\\nDehydration more severe\\nMarked polydipsia and\\npolyuria\\nAbsence of acetone breath\\nUsually seen in Type 2\\ndiabetes\\nNormal, low or elevated blood\\npressure\\nHyperglycaemia more marked\\nAbsence of ketones in blood\\nand urine\\nNo change in blood pH\\nNormal fatty acid levels\\n\\nHypoglycaemic coma\\n\\nNormal breathing\\nNo dehydration\\nAbsence of acetone breath\\nMay occur in all categories of\\npersons with diabetes\\nCold, clammy skin; profuse\\nsweating\\nSystolic hypertension may\\nprecede coma\\nLow blood glucose\\nAbsence of ketones in blood\\nand urine\\nNo change in pH\\n\\nLactic acidosis\\n\\nHyperventilation\\nAbsence of acetone odour\\nCommon in those taking\\nbiguanides\\nDiagnosis made only\\nwhen other causes of\\nmetabolic acidosis have\\nbeen excluded\\nBlood lactate levels not\\ncommonly measured\\n\\nSome important features of the main types of diabetic emergencies are shown below:\\n\\n97 98\\n\\n\\n\\nadrenergic stimulation may respond to these agents\\nIodine\\n\\nUsed in:\\n- The emergency management of thyroid storm\\n- Thyrotoxic patients undergoing emergency surgery\\n- For the preoperative preparation of thyrotoxic patients\\nselected for subtotal thyroidectomy\\nAqueous iodide oral solution (Lugol\\'s solution):\\n- Iodine 5%, potassium iodide 10% in purified water;\\ntotal iodine 130 mg/mL\\n\\n2 - 3 drops of saturated potassium iodide solution\\norally 3 or 4 times daily (300 - 600 mg/day)\\n\\nneonate 0.1 - 0.3 mLorally every 8 hours; 1 month\\n- 18 years: 0.1 - 0.3 mLevery 8 hours\\nThyrotoxic crisis:\\n\\n0.2 - 0.3 mL8 hourly\\n- Dilute with milk or water\\n\\nRadioactive sodium iodine (I )\\n- Used in patients who are past child bearing age\\n- Dosage difficult to gauge; the response of the gland is\\nunpredictable\\n- Up to 25% of patients given enough radioactive iodine\\nto achieve euthyroidism may develop hypothyroidism\\nwithin one year\\n- High incidence of recurrence of hyperthyroidism if\\nsmaller doses are used\\n\\nIndications include:\\nPatients < 21 years who should not receive radio iodine\\nPersons who cannot tolerate other agents because of\\n\\nhypersensitivity, or for other reasons\\nPatients with very large goiters, having compressive\\n\\nsymptoms or signs\\nSome patients with toxic adenoma and multinodular\\n\\ngoitres\\n\\nAppropriate care of any system affected e.g eye care,\\ntreatment of heart failure\\n\\nThyroid storm would require judicious intravenous\\nfluid use, corticosteroids and treatment of the\\nprecipitating cause\\n\\nCarbimazole and propylthiouracil\\n- May cause severe bone marrow suppression\\n(including pancytopemia and agranulocytosis)\\n- They are contraindicated in breastfeeding mothers\\n\\nRefers to subnormal amounts of thyroid hormones in\\nthe circulation, and the clinical features associated with\\nthis\\n\\nAdult:\\n\\nChild:\\n\\nChild 1 month - 1 year:\\n\\n131\\n\\nSurgery\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nHYPOTHYROIDISM (Myxoedema)\\nIntroduction\\n\\nAetiology\\n\\nChild 1 month - 2 years:\\n\\nAdult:\\n\\nChild 12 - 18 years:\\n\\ninitially 15 micrograms/kg\\norally once daily, adjusted in steps of 25 micrograms\\ndaily every 2 - 4 weeks until metabolism normalizes\\n2 - 12 years: initially 5 - 10 micrograms/kg once daily\\nadjusted in steps of 25 micrograms daily every 2 - 4\\nweeks until metabolism normalizes\\n12 - 18 years: initially 50 - 100 micrograms once daily,\\nadjusted in steps of 50 micrograms daily every 3 - 4\\nweeks until metabolism normalizes (usual dose 100 - 200\\nmicrograms daily\\nOr:\\nLiothyronine sodium (1-tri-iodothyronine sodium)\\n\\ninitially 10 - 20 micrograms orally daily, gradually\\nincreased to 60 micrograms daily in 2 - 3 divided doses\\n- Small initial doses in the elderly\\nIn hypothyroid coma:\\n- 5 - 20 micrograms by slow intravenous injection,\\nrepeated every 12 hours (as often as every 4 hours if\\nnecessary)Alternatively:\\n- 50 micrograms by slow intravenous injection initially\\nthen 25 micrograms every 8 hours, reducing to 25\\nmicrograms daily\\n\\n10 - 20 micrograms orally daily,\\ngradually increased to 60 micrograms daily in 2 - 3\\ndivided doses\\nIn hypothyroid coma:\\n1 month - 12 years: 2 - 10 micrograms by slow\\nintravenous injection every 8 hours (up to every 4 hours\\nif necessary);\\n- Reduce to 1 - 5 micrograms in patients with\\ncardiovascular disease\\n12 - 18 years: 5 - 20 micrograms, repeated every 12 hours\\n(up to every 4 hours if necessary)\\n- Reduce to 10 - 20 micrograms in patients with\\ncardiovascular disease\\n\\nTreat anaemia, constipation and other complications as\\nappropriate\\n\\nImmediate mechanical ventilation in myxoedema\\ncoma\\n\\n- T should not be used alone for long term replacement\\n\\ntherapy\\n- Monitor serum levels of hormones to ensure that\\npatients are not exposed to cardiac risks\\n\\nIodinated salt to prevent iodine deficiency\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\n3\\n\\nMay be primary or secondary\\nPrimary hypothyroidism more common\\n\\n- Probably an autoimmune disease; may occur as a\\nsequel to Hashimoto\\'s thyroiditis\\n- Post therapeutic hypothyroidism (medical or\\nsurgical)\\nSecondary hypothyroidism:\\n\\nOccurs when there is failure of the hypothalamic-\\npituitary axis due to\\n- Deficient secretion of TRH from the hypothalamus\\nOr:\\n- Lack of secretion of TSH from the pituitary\\n\\nGenerally in striking contrast to those of\\nhyperthyroidism; may be quite subtle, with an insidious\\nonset\\nIn adults:\\n\\nDull facial expression, slow speech and poor memory\\nPuffiness of the hands, feet and face\\nLethargy and fatigue\\nThinning, dryness and loss of hair\\nHypothermia\\nBradycardia\\n\\nReduced systolic and increased diastolic blood\\npressure\\n\\nWeight gain\\nDecreased reflexes\\nConstipation\\nMenstrual abnormalities\\n\\nIn infants:\\nMental and physical retardation\\n\\n- If not corrected, cretinism\\n\\nEndogenous depression\\nReactive depression\\n\\nMyxoedema coma\\nCretinism in the young\\n\\nTotal serum T and T levels\\n\\nTSH stimulation test\\nTRH test\\n\\nEstablish cause\\nEstablish the severity of hypothyroidism\\nRestore normal body functions\\nPrevent complications\\n\\nReplacement therapy\\n- Levothyroxine sodium (thyroxine sodium)\\n\\ninitially 20 - 100 micrograms (50 micrograms\\nfor those over 50 years) orally daily, preferably before\\nbreakfast\\n- Adjusted in steps of 50 micrograms every 3 - 4 weeks\\nuntil metabolism normalizes (usually 100 - 200\\nmicrograms daily)\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\n3 4\\n\\nAdult:\\n\\nCHAPTER 9: EYE DISORDERS\\n\\nACUTEANTERIOR UVEITIS (Iritis)\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment\\n\\nCaution\\n\\nPrevention\\n\\nACUTE KERATITIS\\nIntroduction\\n\\nClinical features\\n\\nInflammation of the iris (with or without the cilliary\\nbody)\\n\\nUsually occurs without any associated systemic\\ninflammation\\n\\nTends to recur\\n\\nEyeball is tender\\nPhoptophobia due to cilliary spasms\\nExudation into anterior chamber\\nFlare and cells\\nKeratic precipitates\\nHypopion\\nPosterior synechiae\\nMiosis due to spasm of sphincter pupillae\\n\\nInfective conjunctivitis\\nAcute iritis\\nAcute glaucoma\\n\\nSecondary glaucoma\\nCataracts\\n\\nChest radiograph to exclude sarcoidosis and tuberculosis\\nSpinal X-ray (especially lumbrosacral segment) to\\n\\nexclude ankylosing spondilytis\\n\\nCorticosteroid drops for treatment of inflammation:\\nBetamethasone sodium phosphate 0.1%\\n\\n- Apply eye drops every 1 - 2 hours until inflammation is\\ncontrolled then reduce frequency\\n- Subconjunctival injection of steroid if severe\\n\\nAtropine sulfate 0.5% or 1%\\n- 1 drop up to 4 times daily\\n\\nAvoid atropine drops if there is risk of acute glaucoma\\n\\nNo real preventive measures\\n\\nInfection or inflammation of the cornea\\nCould be secondary to trauma\\nSometimes associated with infective conjunctivitis\\nCould occur de novo\\n\\nIrritation, pain\\nRed eye (conjunctival congestion)\\nEye discharge: watery; purulent if bacterial\\nPhotophobia\\nVisual impairment, depending on the site and size of\\n\\nulcer and if interstitial\\n\\nChapter 8: Endocrine System Standard Treatment Guidelines for Nigeria 2008\\n\\n99 100\\n\\n\\n\\nHypopion, if associated with uveitis (no hypopion if\\nviral)\\n\\nUlceration of cornea, which stains with fluorescene; no\\nulcer in interstitial keratitis\\n\\nExogenous\\n- Marginal ulcers secondary to bacterial conjunctivitis\\n( )\\n- Central ulcers (Pneumococcus, , fungi)\\n\\nKeratomalacia (VitaminAdeficiency)\\nExposure (7th cranial nerve palsy or dysthyroid eye\\n\\ndisease)\\nEndogenous\\n\\n- Interstitial keratitis of congenital syphilis\\n- Interstitial keratitis of Herpes zoster\\n\\nInfective conjunctivitis\\nAcute iritis\\nAcute glaucoma\\n\\nCorneal perforation\\n\\nCorneal scraping for microscopy, culture and sensitivity\\n\\nAntibiotic drops (if bacterial)\\n- Chloramphenicol eye drops 0.5%\\n- Apply 1 drop at least every 2 hours, and then reduce\\nfrequency as infection is controlled and continue for 48\\nhours after healing\\n\\nAtropine drops\\n- 1 drop up to 4 times daily\\n\\nAntivirals (if dendritic ulcer)\\n- Idoxuridine 5% in dimethylsulfoxide\\n\\napply to lesions 4 times\\ndaily for 4 days, starting at first sign of attack\\n\\n: not recommended\\nTopical steroids\\n\\n- Only for interstitial keratitis where there is no active\\nulcer\\n\\nLateral tarsorrhaphy for exposure keratopathy\\n\\nNever use topical steroids in the presence of an active\\nulcer\\n\\nTreat initial infection or trauma promptly to avoid\\nprogression to keratitis\\n\\nCould occur on it own or in association with\\ngeneralized atopy (asthma, eczema, spring catarrh)\\n\\nItching of the eyes with grittiness\\n\\nAetiology\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nDrug treatment\\n\\nNon-drug measures\\n\\nCaution and contraindications to treatment\\n\\nPrevention\\n\\nALLERGIC CONJUNCTIVITIS\\nIntroduction\\n\\nClinical features\\n\\nS. aureus\\nHerpes simplex\\n\\nAdult and child over 12 years:\\n\\nChild under 12 years\\n\\nChemicals e.g., alkali or acid\\n\\nEyelids: peri-orbital haematoma and oedema\\nConjunctivae: subconjunctival haemorrhage and\\n\\nchemosis\\nCornea: abrasion or oedema\\nAnterior chamber: hyphaema from tears of the iris or\\n\\ncilliary body\\nIris: traumatic mydriasis\\nTraumatic uveitis\\nAngle recession\\nLens: dislocation into anterior or posterior chambers;\\n\\ncataract\\nVitreous haemorrhage\\nRetina: peripheral tear leading to retinal detachment;\\n\\noedema with haemorrhage (Commotio Retinae)\\nChoroid: tear with haemorrhage\\nRupture of the eyeball, usually posteriorly (rare)\\nOptic nerve: avulsion\\nBlow out fracture of the orbital wall\\n\\nLacerations of eyelids, conjunctivae, cornea, sclerae, or\\ncorneo-sclera\\n\\nUveal prolapse with or without lens extrusion\\nIntraocular foreign body\\nEndophthalmitis\\n\\nAcids coagulate surface proteins\\nAlkalis penetrate into the anterior chamber causing\\n\\nuveitis\\n- Symblepharon: adhesions between bulbar and tarsal\\nconjunctivae\\n\\nConjuctivitis\\nEndophthalmitis\\nOrbital cellulitis\\n\\nRuptured globe\\nEndophthalmitis\\nReversible blindness (compression of optic nerve by\\n\\norbital haematoma)\\nIrreversible blindness (optic nerve avulsion)\\nCorneal opacity/scarring\\n\\nOrbital radiographs\\nOrbital ultrasound\\n\\nTreat individual injury\\n\\nSuture lacerations\\nRemove foreign bodies with magnet if possible, or by\\n\\nvitrectomy\\nParenteral antibiotics, if infected\\nEvisceration (removal of the contents of the eyeball) if\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nManagement\\n\\nBlunt injury\\n\\nSharp Injury\\n\\nChemical burns\\n\\nBlunt injuries\\n\\nSharp injuries\\n\\n- May be associated with itchy ears and throat, or\\nsinusitis\\n\\nBrownish discolouration of the conjunctiva\\nEyelid oedema\\nRed eyes occasionally, with watering when acute\\n\\nFollicles on the bulbar conjunctiva especially at the\\nlimbus\\n\\nPapillae on the tarsal conjunctiva (seen on eversion of\\nthe eyelid)\\n\\nPhlycten in tuberculosis- appears as a yellow nodule\\nwith surrounding leash of engorged vessels\\n\\nExogenous allergens\\n- Topical drugs - atropine, penicillin\\n- Cosmetics\\n- Pollen from plants and flowers (hay fever or spring\\ncatarrh)\\n- House dust mite and animals\\n\\nEndogenous allergens\\nPhlyctenular conjunctivitis caused by tuberculo-protein\\n\\nTrachoma\\nOther forms of conjunctivitis\\n\\nPannus formation\\nKeratoconus\\nCorneal plaques\\n\\nSkin sensitivity test to detect allergen\\n\\nAntiinflammatory preparations\\n-Antazoline sulfate 0.5%, xylometazoline hydrochloride\\n0.05%\\n\\napply 2 - 3 times daily\\n- Sodium cromoglycate eye drops\\n\\napply four times daily\\n- Diclofenac sodium 0.1% eye drops\\n\\napply once daily\\nPhlyctenular conjuntivitits:\\n\\nTreat for tuberculosis using standard regimen\\n\\nXylometazoline is a sympathomimetic; use with caution\\nin patients susceptible to angle closure glaucoma\\n\\nSystemic absorption of antazoline and xylometazoline\\nmay result in interactions with other drugs\\n\\nAvoid allergen(s) as much as possible in cases where\\nit/they have been identified\\n\\nInjuries to the eye could be caused by blunt or sharp\\nobjects or chemicals\\n\\nBlunt injuries e.g. a fist or a ball hitting the eye\\nSharp injuries e.g. glass, metal, broom stick, etc\\n\\nAetiology\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigation\\n\\nDrug treatment\\n\\nCaution\\n\\nPrevention\\n\\nEYE INJURIES\\nIntroduction\\n\\nAetiology\\n\\nAdult and child over 5 years:\\n\\nAdult and child:\\n\\nAdult and child:\\n\\nruptured globe, or if infection not settling on antibiotics\\n\\nCopious rinsing of eyeball and fornices with sodium\\nchloride 0.9% or clean water at site\\n\\nIn hospital, copious rinsing again, to dilute offending\\nagent\\n\\nRemove particles from eye e.g. lime or cement\\nAntibiotic ointment\\nRodding of fornices with ointment to prevent\\n\\nsymblepharon\\nTopical steroids for uveitis once cornea is re-epithelized\\nVitamin C (ascorbic acid)\\n\\nAvoid the use of topical steroids in active corneal\\nulceration\\n\\nAvoid the use of harmful traditional eye medications;\\nmay cause more complications\\n\\nWearing of appropriate protective eye goggles for sports,\\nwelding and when working with chemicals\\n\\nForeign bodies are usually in the form of small particles\\nof metal, vegetable matter or insects which embed on the\\nsurface of the eye\\n\\nOccasionally a high velocity material, usually a metal\\ncould be propelled into the eye\\n\\nMay be embedded on the tarsal or bulbar conjunctiva,\\nthe cornea or inside the eye\\n- Intraocular foreign body (IOFB)\\n\\nIOFBs may be in the anterior chamber, iris, lens or\\nvitreous; on the retina or even behind the eyeball after\\ndoubly perforating the eye\\n\\nCorneal abrasion\\nEndophthalmitis\\n\\nPerforation of the eye\\nEndophthalmitis\\nRetinal toxicity from a metallic IOFB\\n\\nRadiograph of the orbit with a localizing ring\\n\\nRemoval of subtarsal, conjunctival or corneal foreign\\nbody under magnification e.g. slit lamp microscope\\n\\nUltrasound should be avoided in an eye with a\\nperforating wound\\n\\nAppropriate protective goggles for sports, welding,\\ngame hunting etc\\n\\nChemical burns\\n\\nCaution and contraindications\\n\\nPrevention\\n\\nFOREIGN BODIES IN THE EYE\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigation\\n\\nManagement\\n\\nCaution\\n\\nPrevention\\n\\nStandard Treatment Guidelines for Nigeria 2008\\n\\n101 102\\n\\nChapter 9: Eye Disorders\\n\\n\\n\\nINFECTIVE CONJUNCTIVITIS\\nIntroduction\\n\\nClinical features\\n\\nAetiology\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigation\\n\\nNon-drug measures\\n\\nDrug treatment\\n\\nThe commonest cause of a red eye is infective\\nconjunctivitis which could be caused by bacteria or\\nviruses\\n\\nRed eye (generalized)\\nEye discharge: purulent or catarrhal, worse on waking\\n\\nfrom sleep\\nEye discomfort: grittiness\\nPhotophobia: mild\\nSwollen eyelids in ophthalmia neonatorum\\n\\nPneumococcus\\n\\nGonococcus: ophthalmia neonatorum\\nUse of infected urine to treat a red eye\\nTRIC agent (chlamydia)\\nAdenovirus: Epidemic keratoconjunctivitis (\\'Apollo\\')\\n\\nAllergic conjunctivitis\\nAcute keratitis\\nAcute iritis/uveitis\\nAcute glaucoma\\n\\nCorneal affectation which could lead to perforation\\nEndophthalmitis\\n\\nConjunctival swab for microscopy, culture and\\nsensitivity\\n\\nDark glasses for photophobia\\n\\nAntibiotic eyedrops or ointments\\n- Chloramphenicol 0.5%\\n- Apply one drop at least every 2 hours until infection is\\ncontrolled then reduce frequency and continue for 48\\nhours after healing\\n\\nSulphonamide drops or tetracycline drops or ointment\\n\\nAntibiotic drops to prevent secondary bacterial\\ninfection\\n- Chloramphenicol 0.5% drops\\n\\napply every 4 hours for no\\nmore than 5 days\\n\\nGentamicin sulfate 0.3% applied as stated above\\nOr:\\n- Ofloxacin 0.3% solution applied as stated above\\nPlus:\\n- Asystemic cephalosporin e.g. ceftriaxone\\n\\n1 g every 12 hours intravenously for 7 days\\nby intravenous infusion over 60 minutes\\n\\nNeonates: 20 - 50 mg/kg once daily, by deep\\n\\nStaphylococcus aureus\\n\\nHaemophillus influenzae\\n\\nAdult and child over 2 years:\\n\\nAdult:\\nChild:\\n\\nInclusion conjunctivitis\\n\\nEpidermic keratoconjunctivitis\\n\\nOphthalmia Neonatorum\\n-\\n\\nApply 1 drop at least every 2 hours, and then reduce\\nfrequency as infection is controlled\\nOr:\\nOfloxacin 0.3% eye drops\\nApply twice daily. (not to be used for more than 10 days)\\nOr:\\nTetracycline 1% eye ointment\\nApply 3 times daily for one week or more, depending on\\nthe severity of the condition\\n\\nCiprofloxacin 10 mg/kg per dose intramuscularly 12\\nhourly for 2 days\\nOr:\\n\\nCeftriaxone 100 mg/kg by deep intramuscular injection\\nor intravenous injection over 2 - 4 minutes every 24 hours\\n- By intravenous infusion: 1 g daily, 2 - 4 g in severe\\ninfections\\n\\nneonate, infuse over 60 minutes, 20 - 50 mg/kg\\ndaily (maximum 50 mg/kg daily)\\nChild under 50 kg: 20 - 50 mg/kg daily by deep\\nintramuscular injection or by intravenous injection over 2\\n- 4 minutes, or by intravenous infusion; up to 80 mg/kg\\ndaily in severe infections\\n\\nDo not use steroids eyedrops\\nPenicillin drops are not effective in the treatment of\\n\\nopthalmia neonatorum\\n\\nApply tetracycline eye ointment or silver nitrate drops\\nin both eyes of neonates immediately after delivery\\n\\nProper antenatal care for early detection of infection in\\nmothers\\n\\nInflammation of the sclera and episclera\\nUsually self-limiting but relapses may occur\\n\\nUsually unilateral and associated with collagen disorders\\n\\nDull, deep-seated pain in the eye\\nLocalized conjunctival congestion\\n\\nPterygium\\nPhlyctenular conjunctivitis\\nTrauma to the eye\\n\\nThinning of the sclera\\nAnterior staphyloma\\nScleral perforation\\n\\nInvestigate for collagen diseases\\n\\nTopical steroids or NSAIDs for the duration of symptoms\\n\\nPlus\\n\\nChild:\\n\\nCaution\\n\\nPrevention\\n\\nSCLERITIS / EPISCELITIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nManagement\\n\\nintramuscular injection, intravenous injection over 2 - 4\\nminutes, or by intravenous infusion\\n1 month - 12 years (body weight under 50 kg) 50 mg/kg\\nonce daily, up to 80 mg/kg in severe infections\\n\\n- Systemic erythromycin\\n250 - 500 mg orally every 6\\n\\nhours (or 500 mg - 1 g every 12 hours)\\n1 month - 2 years: 125 mg orally every 6 hours; dose\\ndoubled in severe infections\\n2 - 8 years: 250 mg 6 hourly; 8 - 18 years: 250 - 500 mg 6\\nhourly; dose doubled in severe infections\\n\\nSteroid drops are absolutely contraindicated\\n\\nWash hands thoroughly after any unhygienic procedure\\nAvoid sharing towels used for cleaning face\\n\\nInfection in both eyes of a newborn baby in the first one\\nmonth of life, without obstruction of the nasolacrimal\\nducts\\n\\nSwollen eyelids:\\n- It may be impossible to see the baby\\'s eye because of\\nthe swelling\\n\\nRed eyes:\\n- The conjunctivae are less inflamed in chlamydial\\ninfection\\n\\nPus:\\n- Oozes out when the eyelids are opened\\n\\nFever:\\n- May or may not be present\\n\\nBacterial:\\n- Especially : starts within 3 days\\nafter birth\\n- Chlamydia ( usually starts 1 week after birth)\\n\\nChemicals:\\nOthers\\n\\nLid oedema following prolonged difficult labour\\n\\nCorneal perforation\\nEndophthalmitis\\n\\nConjunctival swab for microscopy, culture and\\nsensitivity\\n\\nCopious irrigation to wash pus from the eyes with cooled\\nboiled water or sodium chloride 0.9%\\n\\nTopical antibiotics\\n- Gentamicin 0.3% eye drops\\n\\nChlamydia\\n\\nAdult and child over 8 years:\\n\\nNeisseria gonorrhoea\\n\\nCaution and contraindications\\n\\nPrevention\\n\\nOPHTHALMIANEONATORUM\\nIntroduction\\n\\nClinical features\\n\\nAetiology\\n\\nDifferential diagnosis\\n\\nComplications\\n\\nInvestigation\\n\\nNon-drug measures\\n\\nDrug treatment\\n\\nTreat arthritis if active\\n\\nAvoid prolonged use of steroids\\n\\nNo real preventive measures available\\n\\nExternal stye\\n- Infection of the lash follicle and its associated gland of\\nZeis or Moll\\n\\nInternal stye (chalazion)\\n- Infection of the meibomian gland\\n\\nPainful lump growing on the eyelid\\nRed swollen area on the eyelid (like a boil)\\nPain in the affected area of the eyelid\\nChalazion: firm, painless lump on the eyelid, usually the\\n\\nupper lid\\n\\nVarious eyelid cysts and tumours\\n\\nPre-septal cellulitis\\nOrbital cellulitis\\nCavernous sinus thrombosis\\n\\nIf recurrent, screen for diabetes\\n\\nApply warm wet pads for 15 minutes 4 times daily until\\nthe stye drains\\nIncision and curettage (if there is still a chalazion lump),\\n\\nas soon as the infection settles\\n\\nAntibiotic eye ointment to stop infection\\n- Chloramphenicol ointment apply 4 times daily for 2\\nweeks\\n\\nSystemic antibiotics\\n- Amoxicillin 250 - 500 mg orally every 8 hours for 5 - 7\\ndays\\n\\nDiscourage the use of traditional eye medication\\n\\nClean eyelids regularly and thoroughly\\nFor recurrent styes, use baby shampoo to clean the\\n\\neyelashes regularly\\n\\nInfective conjunctivitis including ophthalmia\\nneonatorum\\n\\nAllergic conjunctivitis\\nKeratitis\\n\\nCaution\\n\\nPrevention\\n\\nSTYE (HORDEOLUM)\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nNon-drug measures\\n\\nDrug treatment\\n\\nCaution\\n\\nPrevention\\n\\nTHE RED EYE\\nCauses\\n\\nChapter 9: Eye Disorders Standard Treatment Guidelines for Nigeria 2008\\n\\n103 104\\n\\n\\n\\nScleritis/episcleritis\\nTrauma to the eye\\n\\nCaused by , an organism\\nmidway between a bacterium and virus\\n\\nThe organism is found in the conjunctival as well as\\ncorneal epithelium and is responsible for two different\\nconditions:\\n- Trachoma (a severe disease)\\n- Inclusion conjunctivitis (milder)\\n\\nTrachoma is commonly associated with poverty and\\nunhygienic living conditions\\n\\nAcute phase:\\nIrritable red eye\\nMucopurulent discharge\\nEyelid oedema, pain, photophobia in severe cases\\n\\nChronic phase:\\nFollicles on tarsal conjunctivae\\nPapillae\\nSuperficial punctate keratitis\\nPannus formation on superior cornea\\n\\nEnd stage:\\nEyelid scarring with trichiasis, entropion\\nConjunctival scarring\\nLimbal scarring with Herbert\\'s pits\\nCorneal scarring\\n\\nOther forms of infective conjunctivitis (especially viral)\\nAllergic/vernal conjunctivitis\\nCorneal scarring from other diseases\\n\\nTrichiasis\\nEntropion\\nCorneal scarring\\n\\nConjunctival scraping for microscopy\\n- Immunofluorescence or Eliza test\\n\\nGiemsa staining for trachoma inclusion bodies\\n\\nTopical:\\nTetracycline ointment applied 4 times a day for 6 weeks\\n\\nSystemic:\\nErythromycin, tetracycline (not recommended for\\n\\nyoung children) or the newer antibiotics e.g.\\nazithromycin as appropriate\\n- Azithromycin\\n\\n500 mg orally once daily for 3 days\\n10 mg/kg (maximum 500 mg)\\n\\norally once daily for 3 days; over 6 months (body weight\\n15 - 25 kg) 200 mg once daily for 3 days; body weight 26\\n\\nSee relevant sections\\n\\nChlamydia trachomatis\\n\\nAdult:\\nChild over 6 months:\\n\\nTRACHOMA\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nDrug treatment\\n\\nCHAPTER 10: GENITO-URINARY SYSTEM\\n\\nPre-renalAcute Renal Failure\\n\\nIntrinsic renal failure\\n\\nPost renalAcute Renal Failure\\n\\nNEPHROLOGY\\n\\nAsyndrome characterized by rapid decline in glomerular\\nfiltration rate with retention of nitrogenous waste\\nproducts, disturbance of extracellular fluid volume,\\nelectrolytes and acid-base homeostasis\\n\\nHypovolaemia (e.g. from haemorrhage, severe\\ndiarrhoea and vomiting etc)\\n\\nLow cardiac output (e.g myocarditis)\\nRenal hypoperfusion (e.g. from use of angiotensin\\n\\nconverting enzyme inhibitors)\\nSystemic vasodilatation (e.g. sepsis)\\nHyperviscosity syndromes (e.g polycythaemia)\\n\\nRenovascular obstruction (e.g. renal vein thrombosis)\\nGlomerular disease e.g. glomerulonephritis\\nAcute tubular necrosis (e.g. from ischemia)\\nInterstitial nephritis (e.g. infections, allergic, from\\n\\nantimicrobials like rifampicin)\\nIntratubular deposition and obstruction (e.g. uric acid,\\n\\noxalate stones)\\nRenal allograft rejection\\n\\nUreteric obstruction (from calculi, blood clots etc)\\nBladder neck obstruction from prostate hypertrophy\\nUrethral obstruction (e.g. from strictures, congenital\\n\\nurethral valves)\\n\\nThirst, dizziness, hypotension, tachycardia in pre-renal\\nARF\\n\\nOliguria (not invariable)\\nOedema, hypertension\\nFlank pain, hesitancy, nocturia, in post-renalARF\\n\\nVolume overload\\nHyperkalaemia\\nMetabolic acidosis\\nUraemic encephalopathy\\nHypertension\\n\\nAcute-on-chronic renal failure\\nChronic renal failure\\n\\nUrine microscopy: casts (granular, hyaline)\\nUrinalysis: proteinuria, haemauria\\nSerum Electrolytes, Urea and Creatinine\\nFull Blood Count with differentials\\nAbdominal ultrasound scan\\n\\nACUTE RENALFAILURE\\nIntroduction\\n\\nClassification/aetiology\\n\\nClinical features\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\n- 35 kg: 300 mg once daily for 3 days; body weight 36 - 45\\nkg: 400 mg once daily for 3 days\\n\\nIndicated for the treatment of trichiasis, entropion,\\ncorneal scarring\\n\\nCorneal graft, but entropion must be corrected first\\n\\nSystemic tetracycline is contraindicated in young\\nchildren\\n\\nImprove personal and public hygiene\\nTreat the whole community with topical or systemic\\n\\nantibiotics\\nPrompt surgery for trichiasis and entropion to prevent\\n\\nblindness from corneal scarring\\n\\nThe spectrum of eye diseases under Vitamin A\\ndeficiency\\n\\nRanges from night blindness to conjunctival xerosis, to\\nBitot\\'s spots, corneal xerosis and finally keratomalacia\\n\\nNight blindness\\nDryness of the conjunctiva and cornea (xerosis)\\nTearing\\nBitot\\'s spots\\nCorneal degeneration (keratomalacia)\\n\\nMeasles keratoconjunctivitis\\n\\nCorneal perforation\\nCorneal scarring\\nBlindness\\n\\nConjunctival impression cytology (where available)\\nSerum VitaminAlevels\\n\\nNutrition education\\n\\nVitaminAcapsules 200,000 IU orally daily for two days,\\nthen one capsule after one week\\nTopical antibiotics and antivirals where applicable\\nPadding the eye (for active corneal ulceration)\\n\\nAvoid the use of harmful traditional eye medication\\n\\nDistribution of massive dose capsules of vitamin A to\\naffected communities\\n\\nNutrition and health education\\nFortification of foods with vitaminA\\n\\nSurgical treatment\\n\\nCaution and contraindications\\n\\nPrevention\\n\\nXEROPHTHALMIA\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnosis\\n\\nComplications\\n\\nInvestigations\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nCaution\\n\\nPrevention\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive therapy\\n\\nPrevention\\n\\nCHRONIC KIDNEYDISEASE\\n\\nIntroduction\\n\\nAetiology\\n\\nClinical features\\n\\nCorrect primary haemodynamic abnormality\\nCorrect biochemical abnormalities\\nPrevent further renal damage\\n\\nFluid challenge (where indicated)\\nLow potassium, low salt, low protein diet\\nAvoid or discontinue nephrotoxic drugs\\n\\nAntihypertensive drugs (see treatment of hypertension)\\nLoop diuretics\\n\\nFurosemide:\\n- Initially 250 mg by intravenous infusion over 1 hour at\\na rate not exceeding 4 mg/minute\\n- Give another 500 mg by intravenous infusion over 2\\nhours if urine output is satisfactory\\n- Effective dose can be repeated every 24 hours\\n- If no response, dialysis is probably required\\n\\nRegular intermittent haemodialysis\\nPeritoneal dialysis\\n\\nClose attention to cardiovascular function and\\nintravascular volume in high risk patients, especially\\nthose with pre-existing renal insufficiency\\n\\nAvoid hypovolaemia (especially in patients on\\nnephrotoxic drugs)\\n\\nAdequate hydration and sodium loading in patients to\\nbe exposed to radiocontrast dye investigations (for\\nexample)\\n\\nAlso chronic renal failure\\n\\nA progressive and persistent deterioration in kidney\\nstructure and function ultimately resulting in\\naccumulation of nitrogenous waste products and\\ndisruption of acid-base homeostasis.\\n- Also associated with derangement in the kidney\\'s\\nosmoregulatory, metabolic and endocrine function\\n\\nHypertension\\nDiabetes mellitus\\nChronic glomerulonephritis\\nSystemic lupus erythematosus\\nChronic pyelonephritis\\nGenetic e.g. adult polycystic kidney disease, Alport\\'s\\n\\nsyndrome\\n\\nNocturia\\nOliguria\\nBleeding tendencies\\nAnaemia\\nHypertension (not invariable)\\n\\nChapter 9: Eye Disorders Standard Treatment Guidelines for Nigeria 2008\\n\\n105 106\\n\\n\\n\\nBody swelling\\nPruritus\\nBone pains\\n\\nHyperkalaemia\\nSevere anaemia\\nHypertensive heart disease\\nAtherosclerosis\\nUraemic pericarditis\\nRenal osteodystrophy\\nMetabolic acidosis\\n\\nUrine\\n- Urinalysis\\n- Urine microscopy, culture and sensitivity\\n\\nBlood\\n- Serum Electrolytes, Urea and Creatinine\\n- Creatinine clearance\\n- Full Blood Count; ESR\\n- Serum lipids\\n- Serum proteins\\n- Serum calcium and phosphate\\n\\nAbdominal ultrasound scan\\n\\nSlow down rate of decline of GFR\\nManage hypertension\\nControl hypertension\\nProvide renal replacement therapy (if in end stage)\\n\\nDiet: low salt, low protein, low potassium\\nAvoid nephrotoxic agents\\n\\nAnthypertensive agents (see treatment of hypertension)\\nDiuretics (furosemide at doses appropriate for clinical\\n\\ncondition)\\nVitamin D and calcium supplements\\nErythropoietin\\n\\n- Initially 50 units/kg 3 times weekly; adjusted according\\nto response in steps of 25 units/kg 3 times weekly at\\nintervals of at least 4 weeks\\n- Maintenance dose (when Hb concentration 10 -12\\ng/100 mLis achieved)\\n- Total 75 - 300 units/kg weekly, as a single dose or in\\ndivided doses\\n\\nIron supplements\\n- Ferrous sulphate\\n\\n200 mg orally 3 times daily\\n6 - 18 years: prophylactic 1 tablet (200 mg) daily;\\n\\ntherapeutic 200 mg 2 - 3 times daily\\nTreat hyperkalaemia (see chapter on hyperkalaemia)\\nPhosphate binding agents\\n\\nCalcium carbonate:\\n500 mg - 1.25 g orally\\n\\n- Starting dose usually 500 mg - 1 g orally 2 times daily\\nafter meals\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug Treatment\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nMembranous glomerulopathy\\nMebrano- proliferative glomerulonephritis\\nMesangio-proliferative glomerulonephritis\\n\\nGeneralized body swelling\\nPassage of frothy urine\\n\\nPeripheral arterial or venous thrombosis\\nAcceleration of atherosclerosis\\nProtein malnutrition\\nVitamin D deficiency\\nIncreased susceptibility to infections\\nIron-resistant microcytic hypochromic anaemia\\n\\nOther causes of body swelling\\n- Congestive heart failure\\n- Decompensated chronic liver disease\\n- Protein losing enteropathy\\n\\nBlood:\\n- Serum proteins\\n- Serum lipids\\n\\nUrine:\\n- Urinalysis\\n- 24 hour urine collection for protein estimation\\n- Abdominal ultrasound scan\\n- Renal biopsy\\n\\nReduce proteinuria\\nEradicate peripheral oedema\\n\\nDiuretics e.g. loop diuretics like furosemide\\nGlucocorticoids (e.g. prednisolone)\\n\\n- If renal biopsy and histology reveal a steroid-responsive\\ncause of the nephrotic syndrome\\n\\nCytotoxic drugs (e.g.cyclophosphamide) in some\\nsteroid-resistant cases\\n\\nAvoid nephrotoxins\\nTreat bites and stings to preve β haemolytic\\n\\nstreptococcal infection\\n\\nA clinical syndrome resulting from replacement of the\\nnormal hydrogen peroxide-producing sp.\\nin the vagina by high concentrations of anaerobic\\nbacteria, such as\\n\\nThe cause of the microbial alteration is not fully\\n\\nClinical features\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nPrevention\\n\\nBACTERIALVAGINOSIS\\nIntroduction\\n\\nnt\\n\\nSEXUALLY TRANSMITTED INFECTIONS\\n\\nLactobacillus\\n\\nGardnerella vaginalis\\nMycoplasma hominis\\nMobiluncus curtisii\\n\\nChild:\\n\\nAdult:\\nChild 5 - 12 years:\\n\\nDefinitive treatment is renal transplantation\\n\\n1 month - 1 year: 120 mg 3 - 4 times daily with\\nfeeds; 1 - 6 years: 300 mg; 6 - 12 years: 600 mg; 12 - 18\\nyears: 1.25 g; all 3 - 4 times daily prior to, or with meals\\nand adjusted as necessary\\nAluminium hydroxide:\\n\\n300 - 600 mg orally 3 times a day with meals\\n1 - 2 capsules orally 3 - 4 times daily;\\n\\n12 - 18 years: 1 - 5 capsules 3 - 4 times daily; adjusted as\\nnecessary\\n\\nHaemodialysis\\nPeritoneal dialysis\\n\\nSee furosemide\\nPotential for adverse drug reactions with drugs\\n\\neliminated primarily by the kidneys e.g. aminoglycoside\\nantibiotics, NSAIDs, metformin, etc\\n\\nCalcium-containing phosphate-binding agents are\\npreferred in children but are contraindicated in\\nhypercalcaemia or hypercalciuria\\n\\nAppropriate management of known causes of chronic\\nrenal failure e.g. hypertension and diabetes mellitus\\n\\nCautious use of nephrotoxic agents: avoid their use in\\npatients with low renal reserves\\n\\nEarly detection and treatment of renal disease when\\nrenal function is still adequate\\n\\nAclinical complex characterized by\\n\\n- Proteinuria of 3.5 g per 24 hours\\n- Hypoalbuminaemia\\n- Generalized oedema\\n- Hyperlipidaemia; lipiduria\\n- Hypercoagulability\\n\\nIdiopathic in a significant proportion of cases\\nKnown causes include:\\n\\nIn f l ammatory d i seases of the g lomeru l i\\n(glomerulopathies)\\n- Viral infections e.g.Hepatitis B, HIV\\n- Immunologic disorders e.g. SLE\\n\\nAllergies: insect bites, poisonous plants\\nIntravenous drugs e.g. heroin\\nOthers:\\n\\n- Diabetes mellitus\\n- Carcinomas\\n- Amyloid deposition\\n\\nMinimal change disease\\nFocal segmental glomerulosclerosis\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nNEPHROTIC SYNDROME\\nIntroduction\\n\\nAetiology\\n\\nHistologic types\\n\\n�\\n\\nunderstood\\nThe associated malodour is due to the release of amines\\n\\nproduced by anaerobic bacteria that decarboxylate lysine\\nto caverdine, and arginine to putrescine\\nPredisposing factors are the use of antiseptic/antibiotic\\n\\nvaginal preparations or vaginal douching\\n\\nMalodorous and increased white vaginal discharge that\\nis homogenous, low in viscosity, and uniformly coats the\\nvaginal walls\\n\\nThe fishy-smelling discharge is particularly noticeable\\nafter sexual intercourse; usually no pruritus or inflamed\\nvulvae\\n\\nOther causes of vaginal discharge: see Gonorrhoea\\n\\nAcute salpingitis\\nPremature rupture of membranes\\nPreterm delivery and low birth weight\\n\\nHomogeneous milky discharge with pH > 4.5 (pH > 6.0\\nhighly suggestive)\\n\\nFishy odour from the biogenic amines; altered by\\naddition of 10% KOH (Sniff test)\\n\\nClue cells on a wet mount\\n- Clue cells are normal vaginal epithelial cells studded\\nwith bacteria, giving the cells a granular\\nappearance\\n\\nTo eliminate the organisms\\n\\nRecommended regimen:\\n- Metronidazole 400 mg orally, every12 hous for 7 days\\nAlternative regimen:\\n- Metronidazole 2 g orally, as a single dose\\nOr:\\n- Metronidazole 0.75% gel 5 g intravaginally, twice daily\\nfor 7 days\\n\\nMetronidazole: see Trichomoniasis\\nAdvise to return if symptoms persist as re-treatment may\\n\\nbe needed\\n\\nMetronidazole 200 orally, every 8 hours for 7 days, after\\nthe first trimester\\nOr:\\n2 g orally, as a single dose\\n\\nIf treatment is imperative in the first trimester of\\npregnancy\\n- Give metronidazole 2 g orally as a single dose\\n\\nMetronidazole:\\nCauses a disulfiram-like reaction with alcohol\\nAvoid high doses in pregnancy and breast feeding\\nMay cause nausea, vomiting, unpleasant taste, furred\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objective\\n\\nDrug therapy\\n\\nNotable adverse drug reactions, caution\\n\\nN o t a b l e a d v e r s e r e a c t i o n s , c a u t i o n a n d\\ncontraindications\\n\\nRecommended regimen for pregnant women\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 10: Genito-Urinary System\\n\\n107 108\\n\\n\\n\\ntongue, and gastro-intestinal disturbances\\nGenerally not recommended for use in the first trimester\\n\\nof pregnancy\\n\\nReduce or eliminate predisposing factors such as\\nantiseptic/antibiotic vaginal preparations or vaginal\\ndouching\\n\\nTreat symptomatic pregnant women\\nScreen pregnant women with a history of previous pre-\\n\\nterm delivery to detect asymptomatic infections\\nRetreat pregnant women with recurrence of symptoms\\n\\nounselling, ompliance, ondom use and ontact\\ntreatment\\n\\nAn infectious disease caused by ,\\na small gram-negative bacillus\\n\\nCommon in the tropics, especially in Africa, the Far\\nEast, and the Caribbean\\n\\nPersons may present with chancroid outside endemic\\nregions; sporadic outbreaks of infection occur in Europe\\nand NorthAmerica\\n\\nIncubation period is about 3 - 7 days\\nBegins as a small, tender papule, changing into a\\n\\npustule which rapidly progresses to a painful ulcer with a\\nbright red areola\\n\\nNeither the edge nor base of the ulcer is indurated\\n(unlike syphilis)\\n- The ulcer feels soft, hence the name \\'soft sore\\' (ulcus\\nmolle)\\n\\nWith superimposed bacterial infection it often feels\\nindurated\\n\\nThe ulcers may be multiple due to auto-inoculation\\nSites of predilection in men are the prepuce, frenulum,\\n\\nglans or shaft of the penis\\nIn women the labia, fourchette, vestibule, clitoris,\\n\\ncervix, or perineum are favored sites\\nLesions may cause dyspareunia, pain on voiding or\\n\\ndefaecation and vaginal discharge\\nWomen may be asymptomatic carriers\\nAbout 7 - 14 days after the appearance of the ulcer, a\\n\\nbubo appears\\n- Amass of glands matted together, often adherent to the\\noverlying skin\\n\\nThe glands above the inguinal ligament are usually\\naffected, and often there is a unilateral enlargement\\n\\nCentral softening is often found and if untreated the\\nbubo may rupture and discharge through a fistula\\n\\nThe combination of a painful genital ulcer and\\nsuppurative inguinal adenopathy is almost\\npathognomonic of chancroid\\n\\nPatient may present with bubo, the initial ulcer having\\n\\nPrevention\\n\\nCHANCROID (Ulcus Molle, Soft Chancre)\\nIntroduction\\n\\nClinical features\\n\\nC C C C\\n\\nHaemophilus ducreyi\\n\\n- Patients should therefore be followed up weekly until\\nthere is clear evidence of improvement\\n\\nCiprofloxacin and ceftriaxone (see gonorrhoea)\\nErythromycin and azithromycin (see chlamydia)\\n\\nounselling, ompliance, ondom use and ontact\\ntreatment\\n\\n(Other than Lymphogranuloma venereum)\\n\\nThe chlamydiae occupy a special place between bacteria\\nand viruses\\n- They are a large group of obligate intracellular\\norganisms\\n\\nhas a number of serovars and\\ncauses many different human infections\\n- Eye: trachoma; inclusion conjunctivitis\\n- Genital tract: lymphogranuloma venereum, non-\\ngonococcal urethritis, cervicitis, salpingitis\\n- Respiratory tract: pneumonia\\n\\nimmunotypes D - K are isolated in about\\n50% of cases of non-gonococcal urethritis and cervicitis\\nby appropriate techniques\\n\\nInfections are asymptomatic, but when an incubation\\nperiod can be determined, it is usually about 10 - 20 days\\nCo-infection with gonococci and chlamydiae is common\\n\\nis an important cause of non-gonococcal\\nurethritis in males, and in females cervicitis, salpingitis,\\nor pelvic inflammatory disease\\n\\nUrethral or cervical discharge tends to be less painful,\\nless purulent, and watery in chlamydial compared with\\ngonococcal infection\\n\\nOn physical examination, the cervix may show contact\\nbleeding in addition to the discharge\\n\\nA patient with urethritis or cervicitis and absence of\\ngram-negative diplococci on Gram stain and of\\n\\non culture is assumed to have chlamydial\\ninfection\\n\\nEpididymo-orchitis and sterility in males\\nPelvic inflammatory disease (PID) and infertility in\\n\\nfemales\\nAdverse pregnancy outcomes\\nConjunctivitis and pneumonia in the newborn\\n\\nOther causes of urethral and vaginal discharge (see\\nGonorrhoea)\\n\\nMicroscopy, culture and sensitivity (of discharge)\\nDirect immunofluorescence assay\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nCHLAMYDIALINFECTION\\n\\nIntroduction\\n\\nClinical features\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nC C C C\\n\\nChlamydia trachomatis\\n\\nC. trachomatis\\n\\nC. trachomatis\\n\\nN.\\ngonorrhoeae\\n\\nhealed\\nAtypical lesions have been reported in HIV-infected\\n\\nindividuals\\n- More extensive, or multiple lesions sometimes\\naccompanied by systemic manifestations such as fever\\nand chills\\n\\nProgressive ulceration and amputation of the phallus,\\nparticularly in HIV patients\\n\\nOther causes of genital ulcers:\\nSyphilis\\nHerpes\\nGranuloma inguinale\\nLymphogranuloma venereum\\nFixed drug eruption\\nErythema multiforme\\nBehcet\\'s disease\\nTrauma\\nTuberculous chancre\\nCancers\\n\\nMicroscopy, culture and sensitivity of discharge from\\nulcer\\nSerological tests e.g. complement fixation (CF);\\nmicroimmuno-fluorescence (MIF) test; PCR\\n\\nSame as for Gonorrhoea\\n\\nRecommended regimen:\\nCiprofloxacin\\n\\n500 mg orally every 12 hours for 3 days\\nOr:\\n\\nErythromycin 500 mg orally every 6 hours for 7 days\\nOr:\\n\\nAzithromycin 1 g orally as a single dose\\nAlternative regimen:\\n\\nCeftriaxone, 250 mg by intramuscular injection, as a\\nsingle dose\\n\\nKeep ulcerative lesions clean\\nAspirate fluctuant lymph nodes through the\\n\\nsurrounding healthy skin, preferably from a superior\\napproach to prevent persistent dripping and sinus\\nformation\\n\\nIncision and drainage, or excision of nodes may delay\\nhealing and is not recommended\\n\\nAll patients should be followed up until there is clear\\nevidence of improvement or cure\\n\\nIn patients infected with HIV, treatment may appear to\\nbe less effective, but this may be a result of co-infection\\nwith genital herpes or syphilis\\n\\nChancroid and HIV infection are closely associated\\nand therapeutic failure is likely to be seen with increasing\\nfrequency\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug therapy\\n\\nAdjuvant therapy\\n\\nFollow-up\\n\\nEnzyme-linked immunoassay\\nDNAprobe test\\nLigase chain reaction (LCR)\\n\\nSame as for gonococcal infection\\n\\nRecommended regimen:\\nDoxycycline 100 mg orally, every 12 hours for 7 days\\n\\nOr:\\nAzithromycin 1 g orally, in a single dose\\n\\nRecommended regimen:\\nErythromycin 500 mg orally every 6 hours for 7 days\\n\\nOr:\\nAmoxycillin 500 mg orally every 8 hours for 7 days\\n\\nTypically has an incubation period of 10 - 14 days\\ncompared to 2 - 3 days for gonococcal opthalmia\\nRecommended regimen:\\n\\nErythromycin syrup 50 mg/kg per day orally, every 6\\nhours for 14 days\\nAlternative regimen:\\n\\nTrimethoprim 40 mg with sulfamethoxazole 200 mg\\norally, every 12 hours for 14 days\\n\\nThere is no evidence that additional therapy with a\\ntopical agent provides further benefit\\n\\nIf inclusion conjunctivitis recurs after therapy has been\\ncompleted, erythromycin treatment should be reinstituted\\nfor 2 weeks\\n\\nIt is important to treat the mother and her sexual partner\\n\\nDoxycycline and tetracycline\\n- Caution in patients with hepatic impairment, systemic\\nlupus erythematosus and myasthenia gravis\\n- Antacids, aluminium, calcium, iron, magnesium and\\nzinc salts, and milk decrease the absorption of\\ntetracyclines\\n- Deposition of tetracyclines in growing bones and teeth\\n(by binding to calcium) causes staining and occasionally\\ndental hypoplasia\\n- Should not be given to children under 12 years, or to\\npregnant or breast-feeding women\\n- With the exception of doxycycline and minocycline,\\ntetracyclines may exacerbate renal failure and should not\\nbe given to patients with kidney disease\\n- May cause nausea, vomiting and diarrhoea;\\nhypersensitivity reactions. Headache and visual\\ndisturbances may indicate benign intracranial\\nhypertension\\n- Candidal superinfection with prolonged therapy\\n\\nAzithromycin and Erythromycin\\n- Erythromycin estolate is contraindicated during\\npregnancy because of drug-related hepato-toxicity; only\\nerythromycin base or erythromycin ethylsuccinate should\\n\\nTreatment objectives\\n\\nDrug therapy\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nChlamydial infection during pregnancy\\n\\nNeonatal chlamydial conjunctivitis\\n\\nNote\\n\\nChapter 10: Genito-Urinary System Standard Treatment Guidelines for Nigeria 2008\\n\\n109 110\\n\\n\\n\\nbe used\\n- Erythromycin should not be taken on an empty\\nstomach\\n- Caution in persons with arrhythmias\\n- Infants should be followed up for symptoms and signs\\nof infantile hypertrophic pyloric stenosis (has been\\nreported in infants less than 6 weeks exposed to this\\ndrug)\\n\\nOfloxacin\\nSee ciprofloxacin- Gonorrhoea\\n\\nAmoxicillin\\n- Caution where there is a history of allergy\\n- Erythematous rashes common in glandular fever,\\n\\ncytomegalovirus infection, acute or chroni\\nlymphocytic\\nleukaemia with pityriasis rosea, and allopurinol use\\n\\nounselling, ompliance, ondom use and ontact\\ntreatment\\n\\nCaused by a gram-negative\\naerobic diplococcus\\n\\nIt prefers the columnar epithelium of the urethra, the\\ncervical canal, the rectum and the conjunctivae.\\n\\nThe keratinizing epithelium of the adult vagina is quite\\nresistant to but that of the pre-pubertal\\ngirls, pregnant women and the elderly is more easily\\ncolonized\\n\\nOccasionally reaches the bloodstream\\ncausing sepsis\\n\\nPresents as foul-smelling urethral discharge of pus\\nwith dysuria 2 - 6 days after exposure\\n\\nSome patients have a scanty discharge that cannot be\\ndistinguished from non-gonococcal urethritis\\n\\nOften asymptomatic during the day but there may be\\na drop of discharge in the morning\\n\\nUrethral orifice is usually inflamed; there may be\\nbalanitis because of the irritation from the discharge and\\nsecondary infection\\n\\nAbout half of infected males are asymptomatic\\nAscending infection is common and may lead to\\n\\ninflammation of the epididymis (epididymitis)\\nEpididymitis usually manifests by acute onset of\\n\\nunilateral testicular pain and swelling, often with\\ntenderness of the epididymis and vas deferens\\n- Occasionally there is erythema and oedema of the\\noverlying skin\\n- The adjacent testis is often also inflamed (orchitis),\\ngiving rise to epididymo-orchitis\\n\\nLocal complications (now uncommon):\\n\\nPrevention\\n\\nGONORRHOEA\\nIntroduction\\n\\nClinical features\\n\\nComplications\\n\\nC C C C\\n\\nGonorrhoea in males\\n\\nNeisseria gonorrhoeae,\\n\\nN. gonorrhoeae,\\n\\nN. Gonorrhoeae\\n\\nis the commonest presentation in women\\nUrethritis: the urethra becomes the most common site in\\n\\nwomen who have had hysterectomy\\nThe most frequent complaint is discharge, often\\n\\naccompanied with burning on urination\\nOver 50% of infected women are asymptomatic\\n\\nOropharyngeal gonorrhoea from orogenital sex (fellatio)\\nmay present as sore throat\\n\\nLocal:\\nInfections of Skene\\'s periurethral glands and Bartholin\\'s\\nlabial glands; a Bartholin\\'s gland abscess may cause pain\\non sitting or walking\\n\\nVulvitis\\nAscending infection to the endometrium, fallopian tubes,\\novaries and peritoneum (pelvic inflammatory disease)\\n\\nEctopic pregnancy\\nInfertility\\nPerihepatic abscess (Fitz-Hugh-Curtis syndrome)\\n\\nRisk of disseminated gonococcal infection during\\npregnancy and menstruation\\n\\nRisk to the newborn infant:\\n- Premature rupture of membranes\\n- Premature labour\\n- Chorioamnionitis\\n- Septic abortion\\n- Ophthalmia neonatorum\\n- Oropharyngeal gonorrhoea\\n\\nOther causes of vaginal discharge:\\nAccentuation of physiological discharge\\n\\n- Premenstrually\\n- At the time of ovulation\\n- In pregnancy\\n- Use of contraceptive pills or an intrauterine device\\nInfective causes:\\n- Candidiasis\\n- Trichomoniasis\\n- Bacterial vaginosis\\n- Chlamydia\\n- Cervical herpes genitalis\\n- Cervical warts\\n- Syphilitic chancre\\n- Toxic shock syndrome (\\n- -haemolytic streptococcal infection,\\ninfection\\nNon-infective causes:\\n- Cervical ectropion\\n- Cervical polyp(s)\\n- Neoplasia e.g. cancer of the cervix\\n- Retained products (tampon, post-abortion, post-natal)\\n- Trauma\\n- Semen (post-coital)\\n- Contact irritants and sensitizers e.g. from douches or\\nfeminine hygiene sprays\\n- Bullous diseases of the mucous membranes\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nStaphylococcus aureus)\\nMycoplasmaβ\\n\\nLittré abscess involving periurethral glands\\nParaurethral abscesses\\nProximal urethral involvement with frequency and\\n\\nterminal haematuria\\n\\nCowper\\'s gland abscess involving the bulbourethral\\nglands, producing a swelling behind the base of the\\nscrotum that can produce a proximal or Cowper\\'s\\nstricture\\n\\nProstatitis\\nProctitis\\nUrethral stricture leading to hydroureters and\\n\\nhydronephrosis\\nChronic epididymo-orchitis leading to sterility\\nContaminated fingers or other fomites can also lead to\\n\\ninfection of the eyes- gonococcal conjunctivitis\\n- Haematogenous spread leading to meningitis, arthritis\\netc\\n\\nUrethral discharge:\\nSpermatorrhoea/prostatorrhoea (sexual arousal)\\n\\nand can also\\ngive rise to urethral discharge and balanitis\\nAscending infections:\\n\\na common cause in the insertive male\\nhomosexuals\\n- Other organisms may be transmitted non-sexually\\nfollowing genitourinary infections, surgery and\\ninstrumentation (including catheterization)\\nScrotal swelling (epididymo-orchitis):\\nIn older men, where there may have been no risk of STIs,\\n\\nother general infections may be responsible, e.g.\\nspp. or\\n\\nTuberculous epididymo-orchitis, secondary to lesions\\nelsewhere, especially in the lungs or bones\\n\\nBrucellosis, caused by\\n\\n- Orchitis is usually clinically more evident than an\\nepididymitis\\n\\nIn pre-pubertal children the usual aetiology is coliform,\\npseudomonas infection or mumps virus\\nNon-infectious causes of scrotal swelling:\\n\\nTrauma (haematocoele)\\nTesticular torsion\\nTumour\\nHydrocoele of the tunica vaginalis\\nCyst of epididymis\\nVaricocoele\\nInguinoscrotal hernia\\n\\nUrethral swab for microscopy and culture and\\nsensitivity\\n\\nInflammation of the cervix and cervical canal (cervicitis)\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nClinical features\\n\\n- Trichomonas vaginalis Candida albicans\\n\\nEscherichia coli,\\n\\nEscherichia coli, Klebsiella Pseudomonas\\naeruginosa\\n\\nBrucella melitensis or Brucella\\nabortus\\n\\nGonorrhoea in women\\n\\nInvestigations\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nDifferential diagnoses\\n\\nTreatment objectives\\n\\nDrug therapy\\n\\nEndocervical swab (through a vaginal speculum) for\\nmicroscopy, culture and sensitivity\\n\\nSexual abuse is a common cause of gonorrhoea in\\nyoung girls\\nUsually symptomatic in young girls\\nPruritus and dysuria are common complaints\\nDischarge may cause irritant dermatitis of the upper\\nthighs\\n\\nOther causes of vaginal discharge in young girls:\\nAvaginal foreign body such as a small toy, bead, or\\n\\neven a piece of food\\nOther infections caused by , and\\nIntestinal bacteria or pin worms due to inadequate\\n\\ncleaning after defeacation\\n\\nGonococcal conjunctivitis in the neonate can be\\nacquired perinatally\\nPurulent conjunctivitis; the lids swell; eyes are red and\\n\\ntender\\nIf not treated promptly, the cornea may be eroded and\\n\\nperforated, leading to secondary glaucoma,\\nconophthalmus and blindness\\nAbout 30% of babies infected will also have\\n\\noropharyngeal gonorrhoea\\n\\nThe silver nitrate prophylaxis can produce a chemical\\nconjunctivitis, usually appearing 6 - 8 hours after\\ntreatment and resolving over 24 hours\\n\\nThe most common cause of neonatal conjunctivitis in\\nmost countries is .\\n- staphylococci, streptococci and\\nsp. can also cause conjunctivitis in the neonate\\n\\nEliminate the organism in the patient and sexual\\npartner(s)\\n\\nPrevent re-infection\\nPrevent complications\\nCounsel and screen for possible co-infection with HIV\\n\\nso that appropriate management can be instituted\\n\\nRecommended regimen:\\nCiprofloxacin 500 mg orally, as a single dose\\n\\nOr:\\nCeftriaxone 125 mg by intramuscular injection, as a\\n\\nsingle dose\\n\\nRecommended regimen:\\nCeftriaxone 50 mg/kg by intramuscular injection, as a\\n\\nsingle dose, to a maximum of 125 mg\\nOr:\\n\\nSpectinomycin 25 mg/kg by intramuscular injection as\\n\\nGonorrhoea in children\\n\\nOphthalmia neonatorum\\n\\nT. vaginalis C. albicans\\n\\nC. trachomatis\\nE. coli, Pseudomonas\\n\\nNeonatal gonococcal conjunctivitis\\n\\nChapter 10: Genito-Urinary System Standard Treatment Guidelines for Nigeria 2008\\n\\n111 112\\n\\n\\n\\na single dose, to a maximum of 75 mg/kg\\n\\nSingle-dose ceftriaxone and kanamycin are of proven\\nefficacy\\n\\nThe addition of tetracycline eye ointment to these\\nregimens is of no documented benefit\\n\\n- Systemic therapy, as well as local irrigation with\\nsaline or other appropriate solution\\n- Irrigation is particularly important when the\\nrecommended therapeutic regimens are not available\\n- Careful hand washing by personnel caring for infected\\npatients is essential\\n\\nReview patients after 48 hours\\n\\nCiprofloxacin\\n- Avoid in pregnancy and breast feeding; children\\nbelow 12 years\\n- Reduce dose in renal impairment\\n\\nCeftriaxone\\n- Caution in persons with known sensitivity to beta-\\nlactam antibiotics\\n- May cause diarrhoea (and rarely antibiotic-associated\\ncolitis); nausea, vomiting and abdominal discomfort\\n\\nSpectinomycin\\n- Nausea, dizziness, fever and urticaria\\n\\nounselling, ompliance, ondom use and ontact\\ntreatment\\n\\nOcular prophylaxis provides poor protection against\\nconjunctivitis\\n\\nClean the eyes carefully immediately after birth\\nThe application of 1% silver nitrate solution or 1%\\n\\ntetracycline ointment to the eyes at the time\\nof delivery is strongly recommended as a prophylactic\\nmeasure\\n\\nInfants born to mothers with gonococcal infection\\nshould receive additional antibiotic treatment (as those\\nwith clinical neonatal conjunctivitis)\\n\\nA mildly contagious disease caused by\\n\\nCurrently rare in several parts ofAfrica\\nEndemic in Southeast Asia, Southern India, the\\nCaribbean and SouthAmerica\\n\\nA chronic mildly contagious disease with a potentially\\nprogressive and destructive character\\n\\nNote\\n\\nC C C C\\n\\nof all infants\\n\\nAdjunctive therapy for gonococcal ophthalmia\\n\\nPrevention of ophthalmia neonatorum\\n\\nFollow-up\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nGRANULOMA INGUINALE (Donovanosis;\\nGranuloma venereum)\\nIntroduction\\n\\nClinical features\\n\\nC.\\ntrachomatis\\n\\nKlebsiella\\ngranulomatis\\n\\nAll treatment should be for a minimum of 14 days\\n\\nChlamydia trachomatis\\n\\nNote\\n\\nC C C C\\n\\n(Climatic bubo; lymphogranuloma inguinale;\\nlymphopathia venereal; Durand-Nicolas-Favre\\nDisease)\\n\\nPrimary stage\\n\\nThe addition of a parenteral aminoglycoside such as\\ngentamicin should be carefully considered for treating\\nHIV-infected patients\\n\\nPatients should be followed up clinically until signs and\\nsymptoms have resolved\\n\\nSulfamethoxazole/trimethoprim\\n- Contraindicated in persons with hypersensitivity to\\nsulfonamides or trimethoprim; porphyria\\n- Caution required in renal impairment (avoid if severe);\\nhepatic impairment (avoid if severe); maintain adequate\\nfluid intake (to avoid crystalluria)\\n- May cause nausea, vomiting, diarrhoea, headache,\\nhypersensitivity reactions, including fixed drug eruption,\\npruritus, photo-sensitivity reactions, exfoliative\\ndermatitis, and erythema nodosum\\n\\nOthers\\n- See Chlamydia\\n\\nounselling, ompliance, ondom use and ontact\\ntreatment\\n\\nA chronic disease caused by\\n(serotypes L1, L2, L3), an obligate intracellular\\nmicroorganism\\n\\nMost common inAsia,Africa, and SouthAmerica\\nIn Europe and North America, it is most prevalent\\n\\namong homosexuals, immigrants from endemic areas\\nand people returning from endemic areas, such as\\nsoldiers, seamen, and vacationers\\n\\nA chronic granulomatous, locally destructive disease\\nthat is characterized by progressive, indolent,\\nserpiginous ulceration of the groins, pubes, genitals and\\nanus\\n\\nMay be classified into primary, secondary, and late\\nstages\\n\\nAfter an incubation period of 7 - 15 days, a papule or\\nsmall non-indurated painless ulcer appears\\n- Usually goes unnoticed\\n\\nExtra-genital lesions (rectal, oral) have also been\\ndescribed\\n\\nWomen probably act as asymptomatic carriers\\nPatients are very rarely seen at the primary stage\\n\\nFollow-up\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nLYMPHOGRANULOMAVENEREUM\\n\\nIntroduction\\n\\nClinical features\\n\\nIncubation period ranges from 10 - 40 days\\nThe early lesion is a papule or nodule which soon\\n\\nbecomes ulcerated and has an offensive discharge\\nThe floor of the ulcer may be covered with a dirty grey\\n\\nmaterial; its walls may be overhanging, or a\\npapillomatous fungating mass may arise from the growth\\nof vegetations\\n\\nProgressive indolent, serpiginous ulceration of the\\ngroins, pubis, genitals and anus may form. Pain on\\nwalking may be excrutiating\\n\\nPersisting sinuses and hypertrophic depigmented\\nscars are fairly characteristic\\n\\nRegional lymph nodes are not enlarged but with\\ncicatrisation, the lymph channels may be blocked\\ncausing pseudoelephantiasis of the genitalia\\nBoth the fibrotic scarring and elephantiasis-like lesion\\ncould cause obstructed labour\\n\\nSubcutaneous extension and abscesses may occur and\\nform a pseudo-bubo in the inguinal region\\n\\nHealing is unlikely without treatment; the locally\\ndestructive lesion may eventually involve the groins,\\npubis and anus\\n\\nA squamous cell carcinoma may arise from chronic\\nlesions.\\n\\nSyphilis\\nChancroid\\nLymphogranuloma venereum\\nLupus vulgaris\\nDeep mycosis\\nAmoebic ulcer\\nPyoderma gangrenosum\\nSquamous cell and basal cell carcinoma\\n\\nObstructed labour\\nSquamous cell carcinoma\\n\\nDirect microscopy\\n\\nSame as for gonococcal infection\\n\\nRecommended regimen:\\nAzithromycin\\n\\n- 1 g orally on first day, then 500 mg orally, once a day\\nOr:\\n\\nDoxycycline\\n- 100 mg orally every 12 hours\\n\\nTherapy should be continued until the lesions have\\ncompletely epithelialized\\nAlternative regimen:\\n\\nErythromycin\\n- 500 mg orally every 6 hours\\nOr:\\n\\nTetracycline 500 mg orally every 6 hours\\nOr:\\n\\nTrimethoprim 80 mg/sulfamethoxazole 400 mg, 2\\ntablets orally, 12 hourly\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug therapy\\n\\nSecondary stage\\n\\nLate stage\\n\\nAbout 3 - 6 weeks post-contact a uni-or bilateral massive\\ninguinal lymphadenopathy (bubo) appears\\n\\nThe glands elongate along the Poupart\\'s ligament to\\nbecome sausage shaped\\n\\nBuboes progress to involve the glands above and below\\nthe ligament, so that the depression formed by the\\nligament which separates these two groups of glands\\ngives the “sign of the groove”\\n\\nPain in the gland is usual, and as the glands are matted\\ntogether, the overlying skin develops an erythematous or\\nviolaceous hue\\n\\nThe glands eventually become fluctuant, break down\\nand discharge\\n\\nInguinal lymphadenopathy occurs in only 20 - 30% of\\nwomen with LGV\\n\\nThere is primary involvement of the rectum, vagina,\\ncervix, or posterior urethra, which drain to the deep iliac\\nor perirectal nodes\\n- This may produce symptoms of lower abdominal or\\nback pain\\nSystemic symptoms usually present with:\\n- Fever\\n- Malaise\\n- Arthritis\\n- Loss of weight\\n\\nSkin manifestations (erythema nodosum, papulo-\\npustular lesions and photodermatosis)\\n- Raised ESR\\n\\nSpontaneous remission is common, though some patients\\nenter the late stage\\nCharacterized by disfiguring and destructive sequelae\\n\\nImpairment of the lymphatic drainage from fibrotic\\nscarring leads to distant oedema and gross elephantiasis\\nof the genitalia\\n- There could be associated anorectal and vaginal\\nstrictures\\n\\nSystemic spread of in the secondary\\nstage resulting in arthritis, pneumonia, hepatitis or rarely\\nperihepatitis\\n\\nOther rare systemic complications include pulmonary\\ninfection, cardiac involvement, aseptic meningitis, and\\nocular inflammatory disease\\n\\nThe late stage may be complicated by the genito-\\nanorectal syndrome\\n- Reported more in homosexual men, and women who\\nengage in receptive anal intercourse\\nPatients may also complain of fever, pain, and tenesmus.\\nObstructed labour from elephantiasis of the vulva\\n\\nBuboes:\\n- Chancroid\\n- Infections of the lower limbs\\n- Hodgkins disease and other lymphomas\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nC. trachomatis\\n\\nChapter 10: Genito-Urinary System Standard Treatment Guidelines for Nigeria 2008\\n\\n113 114\\n\\n\\n\\n- Plague\\n- Tularemia\\nLate stage:\\n- Tuberculosis\\n- Deep mycosis of the genitalia\\n- Squamous cell or basal cell carcinoma\\n\\nCulture and cell typing of the isolate from an aspirate of\\ninvolved lymph node\\n\\nSerological tests e.g. CFT and MIF; PCR\\n\\nSame as for gonorrhoea\\n\\nRecommended regimen:\\nDoxycycline\\n\\n- 100 mg orally every 12 hours for 14 days\\nOr:\\n\\nErythromycin\\n- 500 mg orally every 6 hours for 14 days\\nAlternative regimen:\\n\\nTetracycline\\n- 500 mg orally every 6 hours for 14 days\\n\\nAspirate fluctuant lymph nodes through healthy skin\\nIncision and drainage or excision of nodes may delay\\n\\nhealing and is not recommended\\nSome patients with advanced disease may require\\n\\ntreatment for longer than 14 days, and sequelae such as\\nstrictures and/or fistulae may require surgery\\n\\nSee Chlamydia\\n\\nounselling, ompliance, ondom use and ontact\\ntreatment\\n\\nInfection caused by the spirochaete\\n\\nOccurs worldwide\\nCan be classified as:\\n\\nCongenital (transmitted from mother to child )\\nAcquired (through sex or blood transfusion)\\nAcquired syphilis may be early or late\\nPrimary syphilis is characterized by an ulcer or chancre\\n\\nat the site of infection or inoculation\\nManifestations of secondary syphilis include a skin\\n\\nrash, condyloma lata, mucocutaneous lesions and\\ngeneralized lymphadenopathy\\n\\nEarly syphilis: primary, secondary and early latent\\nstages\\n\\nPrimary syphilis: an ulcer or chancre at the site of\\ninfection or inoculation\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nAdjuvant measures\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nSYPHILIS\\nIntroduction\\n\\nC C C C\\n\\nTreponema\\npallidum\\n\\nin utero\\n\\nPrevent complications\\nCounsel and screen for possible co-infection with HIV\\n\\nso that appropriate management can be instituted\\n\\nRecommended regimen:\\nBenzathine benzylpenicillin\\n\\n- 4 g (2.4 million units) by intramuscular injection, at a\\nsingle session\\n- Because of the volume involved, this dose is usually\\ngiven as two injections at separate sites\\nAlternative regimen:\\n\\nProcaine benzylpenicillin\\n- 2 g (1.2 million units) by intramuscular injection,\\ndaily for 10 consecutive days\\n\\nDoxycycline\\n- 100 mg orally, every 12 hours for 14 days\\nOr:\\n- Tetracycline 500 mg orally, every 6 hours for 14 days\\n\\nErythromycin\\n- 500 mg orally, every 6 hours for 14 days\\n\\nBenzylpenicillin (Penicillin G)\\n- Caution in patients with history of allergy; atopic\\npatients; in severe renal impairment, neurotoxicity; high\\ndoses may cause convulsions\\n- Contraindicated in penicillin hypersensitivity\\n- May cause hypersensitivity reactions including\\nurticaria, fever, joint pains, rashes, angioedema,\\nanaphylaxis, serum\\nsickness-like reaction, rarely intestitial nephritis,\\nhaemolytic anaemia, leucopaenia, thrombocytopaenia\\nand coagulation disorders\\n\\nOther antibiotics\\n- See Chlamydia\\n\\nounselling, ompliance, ondom use and ontact\\ntreatment\\n\\nAll infants born to seropositive mothers should be\\ntreated with a single intramuscular dose of benzathine\\npenicillin\\n- 50,000 units/kg, whether or not the mothers were\\ntreated during pregnancy (with or without penicillin)\\n\\nPrevention of congenital syphilis is feasible\\n- Programmes should implement effective screening\\nstrategies for syphilis in pregnant women\\n\\nScreening for syphilis should be conducted at the first\\nprenatal visit\\nSome programmes have found it beneficial to repeat the\\n\\ntests at 28 weeks of pregnancy and at delivery in\\npopulations with a high incidence of congenital syphilis\\n\\nDrug therapy\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nAlternative regimen for penicillin-allergic (non\\n-pregnant) patients\\n\\nAlternative regimen for penicillin-allergic pregnant\\npatients\\n\\nC C C C\\n\\nSecondary syphilis: skin rash, condyloma lata,\\nm u c o c u t a n e o u s l e s i o n s a n d g e n e r a l i z e d\\nlymphadenopathy\\n\\nLate syphilis: late latent syphilis, gummatous,\\nneurological and cardiovascular syphilis\\n\\nAfter an incubation period of 2 - 4 weeks (full range 90\\ndays) the first lesion of syphilis may appear at the site of\\nexposure, most commonly, the genitals\\nChancres may also be located on the lips or tongue; ano-\\n\\nrectal chancres frequently seen in male homosexuals\\n- Begins as a small, dusky-red macule which soon\\ndevelops into a papule\\n\\nThe surface of the papule erodes to form an ulcer which\\nis typically round and painless with a clean surface and\\nexudes a scanty yellow serous discharge teeming with\\nspirochaetes\\n\\nLesion is indurated and feels firm or hard on palpation;\\nsurrounding skin is oedematous\\n\\nRegional inguinal (or generalized) lymphadenopathy\\nfollows\\n\\nThe glands are painless, moderately enlarged (not\\nbuboes), discrete and never suppurate\\n\\nAtypical lesions may be seen for various reasons e.g.\\nbacterial superinfection, trauma or co-infection with\\nchancroid.\\nEven without treatment, the primary lesion(s) gradually\\n\\nheals up and will disappear after approximately 3 - 8\\nweeks, sometimes leaving a thin atrophic scar which is\\neasily overlooked\\n\\nOther causes of genital ulcers:\\nChancroid\\nHerpes\\nLymphogranuloma venerum\\nGranuloma inguinale\\nTrauma\\nFixed drug eruption\\nBehcet\\'s disease\\nErythema multiforme\\nTuberculous ulcer\\nAmoebic ulcer\\nCancer\\n\\nPhimosis and paraphimosis\\nLate syphilis: gummatous, neurological and\\ncardiovascular syphilis\\n\\nDark field examination and direct fluorescent antibody\\ntests of lesion exudates or tissue\\nVDRL; RPR\\n\\nEliminate the organism in the patient and sexual\\npartner(s)\\n\\nPrevent re-infection\\n\\nThis section is only on primary syphilis\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nTRICHOMONIASIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nCaused by the flagellated protozoan,\\n\\nAn extremely common infection, almost always\\ntransmitted via sexual contact\\nWomen are far more frequently affected and more likely\\n\\nto have symptoms\\nMen are more likely to be asymptomatic and serve as\\n\\ncarriers\\n\\nVaginal discharge: a white-yellow frothy discharge is\\ncharacteristic\\n\\nBurning sensation\\nDysuria\\nDyspareunia\\nThe liabia are often swollen\\nThe cervix may have punctuated haemorrhages\\n\\nproducing a strawberry-like surface when viewed with a\\ncolposcope\\n\\nSome men may have dysuria or a minimal urethral\\ndischarge and balanoposthitis\\n\\nCo-infection with is common\\n\\nOther causes of vaginal discharge or urethral discharge:\\nsee Gonorrhoea\\n\\nAcute salpingitis\\nAdverse pregnancy outcomes, particularly premature\\n\\nrupture of membranes, pre-term delivery and low birth\\nweight\\n\\nMicroscopy and culture of vaginal discharge\\n\\nEliminate the organism in the patient and sexual\\npartner(s)\\n\\nPrevent re-infection\\nPrevent complications\\nCounsel and screen for possible co-infection with HIV\\n\\nso that appropriate management can be instituted\\n\\nRecommended regimen:\\nMetronidazole\\n\\n- 2 g orally in a single dose\\nOr:\\n\\nTinidazole\\n- 2 g orally in a single dose\\nAlternative regimen:\\n\\nMetronidazole\\n- 400 mg or 500 mg orally every 12 hours for 7 days\\nOr:\\n\\nTinidazole\\n- 500 mg orally every 12 hours for 5 days\\n\\nOther 5-nitroimidazoles are also effective, both in single\\nand in multiple dose regimens\\n\\nTrichomonas\\nvaginalis\\n\\nN. gonorrhoeae\\n\\nNote\\n\\nChapter 10: Genito-Urinary System Standard Treatment Guidelines for Nigeria 2008\\n\\n115 116\\n\\n\\n\\nAsymptomatic women with trichomoniasis should be\\ntreated with the same regimen as symptomatic women\\n\\nRecommended regimens for male urethral infections:\\nsame as for women\\n\\nPatients not cured with the repeated course of\\nmetronidazole may be treated with a regimen consisting\\nof metronidazole 2 g orally daily, together with 500 mg\\napplied intravaginally each night for 3 - 7 days\\n\\nVaginal preparations of metronidazole are available in\\nmany parts of the world, but are only recommended for\\nthe treatment of refractory infections,\\n\\nMetronidazole\\n- 5 mg/kg orally, every 8 hours for 5 days\\nInfants with asymptomatic trichomoniasis, or urogenital\\ncolonization persisting past the fourth month of life\\nshould be treated with metronidazole\\n\\nMetronidazole\\nCauses a disulfiram-like reaction with alcohol\\n\\n- Avoid high doses in pregnancy and breast feeding\\n- May cause nausea, vomiting, unpleasant taste, furred\\ntongue, and gastro-intestinal disturbances\\n- Generally not recommended for use in the first trimester\\nof pregnancy\\n\\nounselling, ompliance, ondom use and ontact\\ntreatment\\n\\nInflammation of the vagina and vulva, usually evolving\\nfrom vaginal discharge and secondary external irritation\\n\\nis the commonest cause of candidal\\nvulvo-vaginitis; has also been\\nidentified\\n\\nCandidal vaginitis is most common in :\\n- Pregnancy\\n- Patients with diabetes mellitus\\n- Those on long-term antibiotic therapy or oral\\ncontraceptives\\n- Conditions associated with immunosuppression -\\nCorticosteroid use\\n\\nUsually not acquired through sexual intercourse\\nBecause of the close proximity between the anus and\\nfemale genitalia, re-infections may occur from the\\ngastrointestinal tract\\n\\nUp to 20% of women with the infection may be\\nasymptomatic\\n\\nIf symptoms occur, they usually consist of vulval\\nitching, soreness and a non-offensive vaginal discharge\\nwhich may be curdy\\n\\nnot for the primary\\ntherapy of trichomoniasis\\n\\nCandida albicans\\nCandida glabrata\\n\\nRecommended regimen for neonatal infections\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nVULVO-VAGINALCANDIDIASIS\\nIntroduction\\n\\nClinical features\\n\\nC C C C\\n\\ninvasive or systemic)\\n\\nReduce or eliminate predisposing factors\\nAfter defecation cleaning should be done backwards to\\n\\nprevent faecal contamination of the vulva and vagina\\n\\nA common cause of lower urinary tract obstruction\\namong elderly males\\n\\nNon-cancerous increase in size of the prostate gland\\nIncrease in size impacts on the urethra and partially or\\n\\ntotally obstructs urine outflow\\nOccurs after the age of 40 years; cause is uncertain\\nSymptoms are due to mechanical obstruction or spasms\\n\\nof the smooth muscles around the bladder neck and\\nprostate\\n\\nLower urinary tract symptoms\\nIrritative symptoms:\\n\\nFrequency\\nUrgency\\nNocturia\\nUrge incontinence\\n\\nObstructive symptoms:\\nPoor stream\\nHesitancy\\nStraining\\nIntermittency\\nRetention of urine\\nHaematuria\\nRecurrent urinary tract infections\\nProgressive renal failure\\n\\nEnlarged prostate; firm and symmetrical\\n\\nProstate cancer\\nBladder cancer\\nBladder calculi\\nUrethral stricture\\nProstatitis\\nNeurogenic bladder\\n\\nAcute or chronic urine retention\\nRecurrent urinary tract infections\\nBladder calculi\\nHaematuria\\nHydroureter/hydronephrosis\\nProgressive renal failure\\n\\nUrinalysis\\nUrine microscopy, culture and sensitivity\\n\\nPrevention\\n\\nBENIGN PROSTATIC HYPERPLASIA\\nIntroduction\\n\\nClinical features\\n\\nDigital rectal examination:\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nUROLOGY\\n\\nClinical examination:\\nVulval erythema (redness) or excoriations from\\n\\nscratching\\nVulval oedema\\nErosions and crusting on the adjacent intertriginous skin\\nAlthough treatment of sexual partners is not\\n\\nrecommended, it may be considered for women who\\nhave recurrent infections\\n\\nA minority of male partners may have balanitis, which\\nis characterized by erythema of the glans penis or\\ninflammation of the glans penis and foreskin\\n(balanoposthitis)\\n\\nOther causes of vaginal discharge: see Gonorrhoea in\\nwomen\\n\\nEmotional problems because of the recurrent nature of\\nthe infection, and dyspareunia\\nVery serious emotional problems in a non-sexually\\n\\nactive person wrongly “accused” by parents, spouse or\\nhealth care providers\\n\\nPositive KOH examination\\nCulture of vaginal discharges\\n\\nCure the infection\\nPrevent recurrence\\n\\nRecommended regimen:\\nClotrimazole 1 % vaginal cream\\n\\n- Insert 5 g at night as a single dose; may be repeated\\nonce if necessary\\nOr:\\n\\nMiconazole 2% intravaginal cream\\n- Insert 5 g applicator once daily for 10 - 14 days or twice\\ndaily for 7 days\\nOr:\\n- Clotrimazole 500 mg intravaginally, as a single dose\\nOr:\\n- Fluconazole 150 mg orally, as a single dose\\n\\n- Clotrimazole 1% cream apply twice daily for 7 days\\nOr:\\n- Miconazole 2% cream twice daily for 7 days\\n\\nFluconazole:\\n- Caution in patients with renal impairment\\n- Avoid in pregnancy and breastfeeding\\n- Monitor liver function\\n- Discontinue if signs or symptoms of hepatic disease\\ndevelop (risk of hepatic necrosis)\\n- May cause nausea, abdominal discomfort, diarrhoea,\\nflatulence, headache, skin rash and Steven-Johnson\\nsyndrome\\n- Discontinue treatment or monitor closely if infection is\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug therapy\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nRecommended topical regimen for balanoposthitis\\n\\nSerum Urea, Electrolytes and Creatinine\\nProstate SpecificAntigen (PSA)\\nTrans-rectal ultrasound\\nAbdominal ultrasound scan\\nFull Blood Count\\n\\nRelieve obstruction\\nTreat or prevent complications\\n\\nSurgery: open prostatectomy or transurethral resection\\n\\nHigh intensity focused ultrasound\\nTransurethral balloon dilatation\\nIntraurethral stent\\nTransurethral vaporization of the prostate\\nIntermittent self-catheterization\\n\\nAlpha adrenergic blockers\\n- Prazosin, doxazosin, tamsulosin\\n\\nDoses are titrated from 1 -10 mg depending on\\nindividual response\\n- 400 microgram orally daily as single dose for\\ntamsulosin\\n\\n5-Alpha reductase inhibitors\\n- Finasteride 5 mg orally daily\\n\\nAlpha-adrenergic blockers: dizziness, syncopal attacks,\\ntachycardia\\n- Should therefore to be taken at night before going to\\nbed\\n\\n5- Alpha reductase inhibitors: loss of libido, erectile\\ndysfunction, gynaecomastia\\n\\nThe most commonly diagnosed malignancy affecting\\nmen beyond the middle age\\n\\nThe commonest malignancy of the genitourinary tract\\nExact cause is not known\\nAbout 90% are adenocarcinomas\\n\\nIncreasing age\\nFamilial and genetic factors\\nHigh levels of testosterone and dihydrotestosterone\\n\\nLower urinary tract symptoms\\nFrequency\\nUrgency\\nNocturia\\nPoor stream\\nStraining\\nTerminal dribbling\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution\\n\\nCARCINOMAOF THE PROSTATE\\nIntroduction\\n\\nRisks factors\\n\\nClinical features\\n\\nMinimally invasive procedures\\n\\nChapter 10: Genito-Urinary System Standard Treatment Guidelines for Nigeria 2008\\n\\n117 118\\n\\n\\n\\nHaematuria\\n\\nLow back pain\\nParaplegia\\nPathological fractures\\nPedal oedema\\nAzotaemia\\nWeight loss\\nRectal Examination: hard, nodular, asymmetrical\\n\\nprostate\\n\\nBenign prostatic hyperplasia\\nChronic prostatitis\\nBladder cancer/calculi\\nProstatic calculi\\nUrethral stricture\\n\\nUrinary retention\\nUrinary tract infection\\nHydroureter/hydronephrosis\\nProgressive renal failure\\nParaplegia\\nPathological fractures\\nLymphoedema\\n\\nProstate Specific Antigen\\nProstate biopsy\\nTrans-rectal ultrasound\\nAbdominal ultrasound\\nCT scan\\nLiver function tests\\nChest radiograph\\nSerum Urea, Electrolytes and Creatinine\\nFull Blood Count\\n\\nAim at cure for early disease\\nPalliation for advanced disease\\n\\nWatchful waiting\\nRadical prostatectomy\\nRadiotherapy (brachytherapy or external beam\\n\\nradiation)\\nBilateral orchidectomy\\nCryoablation therapy\\nLaser therapy\\n\\nLHRH agonist:\\nGoserelin acetate\\n\\n- 3.6 mg by subcutaneous injection into the anterior\\nabdominal wall every 28 weeks\\nAnti-androgens:\\n\\nCyproterone acetate\\n- 100 mg orally twice daily for long term palliative\\ntherapy\\nOr:\\n\\nBicalutamide 50 mg orally daily in advanced cases,\\n\\nFeatures of metastasis\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nAndrogen replacement in those with androgen\\ndeficiency:\\n\\nTestosterone enanthate\\n- 250 mg intramuscularly every 2-4 weeks\\nOr:\\n\\nOral methyl testosterone or fluoxymesterone\\n120 - 160 mg daily for 2 - 3 weeks; maintenance 40 - 120\\nmg daily\\nIntra-corporal administration of:\\n\\nProstaglandin E\\n\\n- 5 - 15 microgram\\n5-Phosphodiesterase inhibitors:\\n\\nSildenafil citrate\\n- 25 - 100 mg one hour before intercourse\\n\\nAndrogens\\n- Not to be given to patients with prostate carcinoma\\n\\nPhosphodiesterase inhibitors\\n- Altered vision, headache, dizziness and nasal\\ncongestion\\n- Contraindicated in patients taking nitrates\\n- Should be used with caution in patients with ischaemic\\nheart disease\\n\\nFailure to achieve conception after one year of regular,\\nunprotected sexual intercourse in a couple trying to\\nachieve pregnancy\\n\\nPrimary :\\n- When the man has never impregnated a woman\\n\\nSecondary:\\n- When the man had impregnated a woman in the past\\n\\nMale factor is responsible for about 50% of infertile\\nunions\\n\\nVital points in the history:\\nDuration of infertility\\nAbility to have erection, penetration and ejaculation\\nFamily history of infertility\\nHistory of systemic disease e.g. diabetes mellitus,\\n\\nhypertension, chronic liver disease and tuberculosis\\nHistory of sexually transmitted infections and urinary\\n\\ntract infections\\nHistory of genital trauma\\nHistory of surgery: herniorraphy, orchidopexy, urethral\\n\\nsurgeries, etc\\nExamination:\\n\\nGynaecomastia\\nPenis: epispadias, hypospadias, penile deformities\\nScrotum: absence of testis, small sized testis,\\n\\nvaricocoeles, hard and irregular epididymis\\n\\nSemen analysis x 3\\n\\n1\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nMALE INFERTILITY\\nIntroduction\\n\\nClinical features\\n\\nInvestigations\\n\\nwith orchidectomy\\nOr:\\n\\nFlutamide 250 mg orally three times daily\\nOr:\\n\\nDiethyl stilbestrol 3 mg orally daily\\nCytotoxic chemotherapy:\\n\\nDocetaxel 75 mg/m every 3 weeks\\n\\nAnti-androgens:\\n- Loss of libido\\n- Gynaecomastia\\n- Impotence\\n\\nDiethyl stilbestrol:\\n- Fluid retention\\n- Hypertension\\n- Thrombo-embolic disease\\n- Loss of libido\\n- Gynaecomastia\\n\\nPersistent inability to obtain and sustain an erection\\nsufficient for sexual intercourse\\n\\nMay be non-organic (psychogenic) or organic,\\nresulting from physical causes\\n- Vascular, neurologic or endocrine dysfunction\\n\\nOther causes include drugs and trauma\\n\\nInability to obtain or sustain erection\\nHistory suggestive of possible causes e.g. drugs,\\n\\nsystemic disease like hypertension, diabetes mellitus\\nWith or without gynaecomastia\\nWith or without penile deformity, plaques or impaired\\n\\nsensation\\n\\nPsychological disturbances\\nInfertility\\n\\nFull Blood Count\\nHormonal assay (LH, FSH, testosterone, prolactin)\\nSerum Urea, Electrolytes and Creatinine\\nBlood glucose\\nNocturnal penile tumescence test\\n\\nTo obtain and sustain erection\\n\\nPsychotherapy\\nUse of vacuum suction devices\\nPlacement of intracorporal prosthesis\\nMicrosurgical vascular anastomosis\\n\\n2\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nERECTILE DYSFUNCTION (Impotence)\\nIntroduction\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objective\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\n- Contraindicated in patients with cardiovascular\\ndiseases\\n\\nHormone profile (LH, FSH, testosterone, and prolactin)\\nScrotal ultrasound\\nTrans-rectal ultrasound\\nTesticular biopsy\\nVasography\\n\\nTo improve semen quality and restore reproductive\\ncapability\\n\\nSurgical options:\\nVaricocoelectomy\\nVasovasotomy\\nEpididymo-vasotomy\\nTransurethral resection of obstructed ejaculatory duct\\nAssisted reproductive techniques:\\nIntra-uterine insemination\\nIn vitro fertilization\\nGamete intra-fallopian tube transfer\\nIntra-cytoplasmic sperm injection\\n\\nCongenital mucosal folds situated in the\\nprostatic/membranous urethra, causing urine outflow\\nobstruction\\n\\nOccurs in males\\n- The most common mechanical cause of renal\\ndeterioration in children\\n\\nObstructive urinary symptoms\\nUrinary retention\\nFailure to thrive\\nDistended bladder with palpable kidneys\\n\\nAnterior urethral valves\\nCongenital bladder neck hypertrophy\\nCongenital urethral stricture\\nMeatal stenosis\\nPosterior urethral polyp\\n\\nRecurrent urinary tract infections\\nSepticaemia\\nBladder dysfunction\\nBladder stones\\nHydroureter/hydronephrosis\\nProgressive renal impairment\\nFailure to thrive\\n\\nUrinalysis\\nUrine microscopy, culture and sensitivity\\nFull Blood Count\\nSerum Urea, Electrolytes and Creatinine\\nAbdominal ultrasound\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nPOSTERIOR URETHRALVALVES\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nChapter 10: Genito-Urinary System Standard Treatment Guidelines for Nigeria 2008\\n\\n119 120\\n\\n\\n\\nMicturating cysto-urethrogram\\nUrethrocystoscopy\\n\\nTo relieve obstruction\\nTreat any complications\\n\\nValve resection with endoscopes\\nValve avulsion with valvotomes\\n\\nNone\\n\\nCorrect dehydration and electrolyte imbalance\\nTreat infection with appropriate antibiotics\\nUrinary diversion: vesicostomy\\n\\nNot applicable\\n\\nPersistent penile erection that continues beyond, or is\\nnot related to sexual stimulation\\nPredisposing factors:\\n\\nThromboembolic disorders e.g. sickle cell disease,\\nleukaemia\\n\\nSpinal injuries\\nPerineal and genital trauma\\n\\nDrugs e.g. chlorpromazine, prazosin and prostaglandins\\n\\nPersistent painful erection lasting several hours\\nPenis is rigid and tender but the glans penis and corpus\\n\\nspongiosum are soft\\n\\nErectile dysfunction\\n\\nFull Blood Count\\nHaemoglobin electrophoresis\\nColour Doppler/duplex ultrasound\\n\\nTo increase venous drainage from the corpora cavernosa\\nDecrease arterial inflow in high flow priapism\\nTreat the primary cause(s)\\n\\nShunting procedures\\n- Caverno-glandular shunt\\n- Caverno-spongiosum shunt\\n- Caverno-saphenous shunt\\n\\nSpinal or epidural anaesthesia\\n\\nIntracavernosal injection of alpha adrenergic agonist:\\nPhenylephrine\\n\\n- 250 - 500 microgram\\nOr:\\n\\nEphedrine\\n- 50 - 100 mg\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nPrevention\\n\\nPRIAPISM\\nIntroduction\\n\\nClinical features\\n\\nComplication\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nPerineal pain\\nHaemospermia\\nPainful ejaculation\\nRectal examination: enlarged, tender, firm prostate\\n\\nBenign prostatic hypertrophy\\nCystitis\\nUrethral stricture\\nProstate cancer\\n\\nProstatic abscess\\nProstatic calculi\\nInfertility\\nSepticaemia\\n\\nUrinalysis\\nUrine microscopy, culture and sensitivity\\nProstatic massage: microscopy, culture and sensitivity\\n\\n(chronic prostatitis only)\\nTrans-rectal ultrasound\\nBiopsy: culture and histology\\nUrethrocystoscopy (chronic prostatitis only)\\nFull Blood Count; ESR\\n\\nTo eradicate causative organisms\\nControl pain\\n\\nAntibiotics (based on local sensivity\\n- Ciprofloxacin 500 mg orally every 12 hours for 28 days\\nOr:\\n- Cotrimoxazole 960 mg orally every 12 hours for 28\\ndays\\n\\nAnti-inflammatory drugs\\n- Non-steroidal e.g. diclofenac, ibuprofen etc\\n- Steroids e.g. prednisolone, dexamethasone\\n\\nAlpha blockers e.g. prazocin, doxazocin\\nHormonal therapy e.g. finasteride, cyproterone\\n\\nProstatic massage (chronic prostatitis only)\\nPhysiotherapy\\nSitz baths\\n\\nAclinical situation in which the testis is absent from the\\nscrotum\\n\\nMay be bilateral or unilateral\\nCauses include:\\n\\nUndescended testis\\nEctopic testis\\nRetractile testis\\nAbsent (vanishing) testis\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNon-drug treatment\\n\\nSCROTALMASSES\\n\\nIntroduction\\nThe empty scrotum\\n\\nSupportive measures\\n\\nPrevention\\n\\nPROSTATITIS\\nIntroduction\\n\\nClinical features\\n\\nAdequate hydration\\nPain relief\\n\\nAvoid causative drugs\\n\\nAn inflammation of the prostate or pain in the prostate,\\nsimilar to that caused by an inflammation\\n\\nAccounts for 2% of prostatic pathology\\nClassified into:\\n\\nAcute bacterial prostatitis\\nChronic bacterial prostatitis\\nChronic non-bacterial prostatitis\\nProstatodynia\\n\\nRisk factors:\\nDuctile reflux\\nUrinary tract infection\\nIndwelling urethral catheterization\\nPenetrating anal sex\\nSexually transmitted infections\\n\\nResults from direct spread of ascending urethral\\ninfection or reflux of infected urine into the prostatic\\nducts\\n- is the main causative organism. Others are\\nklebsiella, pseudomonas, S\\n\\nCaused by , Klebsiella, Mycoplasma and\\nChlamydia\\n\\nAn inflammation of indeterminate cause\\n\\nSystemic features\\n- Fever\\n- Chills\\n- Malaise\\n- Nausea\\n\\nLocal features\\n- Dysuria\\n- Frequency\\n- Haematuria\\n- Urethral discharge\\nRectal examination:\\n- Hot boggy, swollen and very tender prostate\\n\\nVoiding symptoms: dysuria, frequency, urgency,\\nhaematuria\\n\\nPoor stream\\nUrethral discharge\\nLow back pain\\n\\nAcute bacterial prostatitis\\n\\nChronic bacterial prostatitis\\n\\nNon-bacterial prostatitis\\n\\nAcute prostatitis\\n\\nChronic prostatitis\\n\\nE. coli\\ntreptococcus faecalis and\\n\\nStaph aureus\\n\\nE. coli\\n\\nAtrophic testis\\nSurgical removal (for treatment of other conditions)\\n\\nThe testis is arrested in its normal path of descent\\nUnilateral arrest is more common than bilateral arrest\\nIncidence at birth is about 3% in full term infants, 30%\\n\\nin preterm infants and 1% in adulthood\\n\\nAbsence of one or both testes from the scrotum\\nPain from trauma to the testis\\nInfertility (in adulthood)\\n\\nThe testis, if palpable cannot be manipulated into the\\nscrotum\\n\\nInguinal hernia may be present on the affected side\\n\\nTorsion of the spermatic cord\\nTrauma to the testis\\nMalignancy\\nInfertility\\n\\nUrinary 17-ketosteroids, gonadotropins\\nSerum testosterone\\nUltrasonography\\nComputed tomography\\nLaparoscopy\\nMagnetic Resonance Imaging\\n\\nHormone therapy:\\nHuman chorionic gonadotropin\\n\\n- 1,500 units/week intramuscularly, for a total of 9\\ninjections\\n- Applicable only to special cases\\nSurgical treatment:\\n\\nIn those with undescended testes\\n- Bring testis down and fix it in the scrotum\\n\\nTwisting of the spermatic cord with compromise of the\\nblood supply to the testis\\n\\nAn uncommon affliction that is most commonly seen in\\nadolescent males.Afew cases occur in infancy\\n\\nPain in one testicle: of sudden onset, severe in intensity\\nand radiates to the lower abdomen\\n\\nNausea and vomiting\\nSwollen, high lying testis with reddening of the scrotal\\n\\nskin\\nTenderness. Pain can be increased by lifting the testicle\\n\\nup\\nAbsence of the cremasteric reflex\\nAbnormal lie of the testis on the opposite side\\n\\nUndescended testis\\n\\nAtrophic testis\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\nManagement\\n\\nTORSION OF THE TESTIS\\nIntroduction\\n\\nClinical features\\n\\nChapter 10: Genito-Urinary System Standard Treatment Guidelines for Nigeria 2008\\n\\n121 122\\n\\n\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nTreatment\\n\\nURETHRALSTRICTURE\\nIntroduction\\n\\nClinical features\\n\\nAcute epididymo-orchitis\\nMumps orchitis\\nTrauma to the testis\\nStrangulated inguinal hernia\\nInsect bites\\nInflammatory vasculitis (Henoch-Schönlein purpura)\\nIdiopathic scrotal oedema\\nTesticular tumour\\nFournier\\'s gangrene\\n\\nTesticular atrophy\\nSympathetic orchidopathy\\nAbnormal sperm count\\nInfertility\\n\\nColour Doppler sonography\\n- An absence of arterial flow is typical\\n\\nRadionuclide scan using Tc-99m pertechnetate\\n- The twisted testis is avascular\\n\\nDetorsion\\nFixation of the testis to prevent recurrence\\n\\nFixation on the affected side and prophylactic fixation\\non the opposite side\\n\\nAn abnormal narrowing or loss of distensibility of any\\npart of the urethra, as a result of fibrosis\\n\\nOne of the commonest causes of urine retention in\\ntropicalAfrica\\n\\nVery rare in females.\\nMay result from trauma or inflammation; may be\\n\\niatrogenic\\nTraumatic causes:\\n\\nPenetrating or blunt injury to the urethra\\n- From pelvic fractures or falling astride an object\\nInfective causes:\\n\\nGonococcal urethritis or non-gonococcal urethritis\\nfrom chlamydia, tuberculosis or schistosomiasis\\nIatrogenic causes:\\n\\nUrethral instrumentations e.g. catheterization and\\nurethroscopy\\n\\nMay be congenital\\nMay be complete or partial, single or multiple\\nCan affect any part of the urethra, anterior or posterior\\n\\nDysuria\\nFrequency\\nUrgency\\nPoor stream\\nStraining\\nHesitancy\\n\\nSix - 24 months later:\\nIntermittent, painless terminal haematuria (may be\\n\\ntotal)\\nSymptoms of bladder irritability: dysuria, frequency,\\n\\nurgency, strangury\\n\\nTuberculous cystitis\\nAbacterial cystitis\\nBladder carcinoma\\n\\nBladder fibrosis and contracture\\nUreteral stricture\\nUrethral stricture\\nBladder calculi\\nBladder cancer\\n\\nUrine examination for schistosomal ova\\nCystoscopy: tubercles, sandy patches, nodules, ulcers\\nPlain abdominal radiograph (KUB)\\nIntravenous urogram\\nSerological tests\\nFull Blood Count\\n\\nTo eradicate the fluke and ova\\nPrevent complications\\n\\nPraziquantel\\n- The schistosomicide with the most attractive\\ncombination of effectiveness, broad-spectrum activity\\nand low toxicity\\n\\nSingle oral dose of 50 mg/kg\\n20 mg/kg orally, repeated after 4 - 6\\n\\nhours\\n- In infection, 20 mg/kg 3 times daily for\\none day after initial dose\\nOr:\\n\\nMetrifonate\\n10 mg/kg orally, fortnightly for three doses\\n\\nNausea, epigastric pain, pruritus, headache, dizziness\\n\\nProvision of and access to pipe-borne water\\nImprovement in socio-economic conditions\\nMass chemotherapy in endemic areas\\nEradicating the intermediate hosts (water snails)\\n\\nOccurrence of stone(s) in the kidney, ureter, bladder or\\nurethra\\n\\nIncidence in Nigeria is 7 - 34 per 100,000\\nStones are different wih respect to their composition\\n\\n- Oxalate stones, phosphate stones, uric acid stones and\\ncystine stones\\nFactors promoting stone formation:\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreament objectives\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nURINARYTRACT CALCULI\\nIntroduction\\n\\nAdult:\\nChild over 4 years:\\n\\nS.japonicum\\n\\nAdult:\\n\\nDribbling\\nExamination of the external genitalia may reveal:\\n\\nUrethral indurations\\nPeriurethral or perineal abscess\\nUrinary fistula\\n\\nBenign prostatic hypertrophy\\nProstate cancer\\nBladder calculi\\nBladder neck stenosis\\n\\nUrinary tract infections\\nUrethral/bladder calculi\\nUrinary retention\\nFournier\\'s gangrene\\nPerineal urinary fistulae\\nProgressive renal failure\\n\\nUrinalysis\\nUrine microscopy, culture and sensitivity\\nUrethroscopy\\nUrethrogram\\nUroflowmetry\\nAbdominal ultrasound\\nSerum Urea, Electrolytes and Creatinine\\nFull Blood Count\\n\\nTo restore urethral patency\\n\\nNone\\n\\nSerial dilatation/bouginage\\nEndoscopic direct visual urethrotomy\\nUrethroplasty: excision and end-to-end anastomosis\\nSubstitution urethroplasty\\n\\nEnsure prevention of sexually transmitted infections\\nPrompt and appropriate treatment of sexually\\n\\ntransmitted infections\\nCare and attention to asepsis during instrumention\\n\\nprocedures involving the urethra\\n\\nAcommon parasitic infection of the urinary tract caused\\nby a body fluke,\\n\\nAcquired while bathing/wading in infected water\\nEndemic in many parts ofAfrica\\nGets to the urinary tract through the blood vessels after\\n\\npenetrating the skin\\n\\nSoon after penetration of the skin:\\nPricking sensation and itching (cercarial dermatitis)\\n\\nFour weeks later:\\nIntermittent fever, malaise, urticaria and cough\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objective\\n\\nDrug treatment\\n\\nNon-drug treatment\\n\\nPrevention\\n\\nURINARYSCHISTOSOMIASIS\\n1ntroduction\\n\\nClinical features\\n\\nSchistosoma haematobium\\n\\nObstruction to urine outflow\\nInfection in the urinary tract\\nCrystallization on foreign bodies\\nDehydration\\nChange in pH\\nIn-born errors of metabolism\\n\\nRenal and ureteric stones:\\nSudden onset loin pain radiating to the groin\\nHaematuria\\nNausea and vomiting\\n\\nStones in the bladder:\\nFrequency\\nUrgency\\nDifficulty in passing urine\\n\\nStones in the urethra:\\nUrinary retention\\n\\nAcute pyelonephritis\\nRenal tumour\\nAcute appendicitis\\nOther causes of urinary obstruction e.g. enlarged\\n\\nprostate, urethral strictures\\n\\nRecurrent and intractable urinary tract infection\\nSecondary hydronephrosis\\nProgressive renal failure\\nPeriurethral abscess/urethral fistula\\n\\nUrinalysis\\nUrine culture\\nSerum calcium, phosphate and albumin\\nIntravenous urography (IVU)\\nUltrasonography\\nComputerized tomography (non-contrast enhanced)\\n\\nRelieve symptoms\\nRemove stones\\nPrevent recurrence\\n\\nIncreased fluid intake\\nEndoscopic Short Wave Lithotripsy (ESWL)\\nEndoscopic removal of stones\\nOpen surgical removal\\n\\nAnalgesics\\nAntibiotics to treat infections\\n\\nDrugs used to prevent recurrence:\\nThiazide diuretics\\n\\n- Hydrochorothiazide 5 mg orally daily\\nOr:\\n\\nPotassium citrate\\n- 60 mEq orally daily\\nOr:\\nAllopurinol 100 mg orally daily\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nChapter 10: Genito-Urinary System Standard Treatment Guidelines for Nigeria 2008\\n\\n123 124\\n\\n\\n\\nCHAPTER 11: INFECTIOUS\\nDISEASES/INFESTATIONS\\n\\nFEVERS: MANAGEMENTAPPROACH\\nIntroduction\\n\\nInvestigations\\n\\nAleading cause for seeking medical care\\nIn health, temperature is controlled within limits (in\\n\\nadults at a mean of 36.8 C) with diurnal variations of\\n\\nabout 0.5 C\\n\\'Fever\\' is elevation of body temperature that exceeds the\\n\\nnormal daily variation and occurs in conjunction with an\\nincrease in hypothalamic set point\\nIn children younger than 5 years of age:\\n\\nArectal temperature greater than 38 C\\n\\nOral temperature above 37.8 C\\n\\nAxillary temperature above 37.2 C\\nImportant points in the history are:\\n\\nChronology of symptoms\\nOccupational history\\nTravel history\\nGeographic region\\nFamily history\\n\\nPhysical examination:\\nVital signs (axillary temperatures are unreliable)\\nSkin, lymph nodes, eyes, nail beds, CNS, chest,\\n\\nabdomen, cardiovascular, musculo-skeletal and nervous\\nsystems\\n\\nRectal examination is imperative\\nThe penis, prostate, scrotum and testes (for men)\\nPelvic examination (for women)\\n\\nThe number of investigations will depend on the clinical\\ncircumstances. On occasions, patients may need to be\\nextensively investigated\\nGeneral:\\n\\nFull Blood Count\\nDifferential white blood cell count\\nUrinalysis with examination of the urinary sediment\\nExamination of any abnormal fluid collection\\n\\nMicrobiology:\\nSmears and culture of specimens from the throat,\\n\\nurethra, anus, cervix, and vagina (as indicated)\\nSputum smears; culture\\nBlood culture\\nUrine microscopy, culture and sensitivity\\nCerebrospinal fluid examination\\nAbnormal fluid collection: specimens for microscopy,\\n\\nculture and sensitivity testing\\nChemistry:\\n\\nUrine examination\\nSerum urea, electrolytes and creatinine\\nBlood glucose\\nLiver function tests\\nCerebrospinal fluid examination\\n\\nRadiology:\\nChest radiograph\\n\\n°\\n\\n°\\n\\n°\\n\\n°\\n\\n°\\n\\n- Food is contaminated by when prepared\\nunhygienically by individuals who are carriers\\n- Subsequent growth of in the food and\\nenterotoxin production occurs if the food is not cooked at\\ntemperatures sufficient to kill the bacteria, or is not\\nrefrigerated\\n\\nFood-borne botulism\\nNon-typhoidal Salmonellosis\\nShigellosis\\n\\nfood poisoning\\nCampylobacter food poisoning\\n\\nfood poisoning\\nfood poisoning\\n\\nNorwalk virus food poisoning\\nHepatitisAvirus food poisoning\\nGiardiasis\\nHelminthic parasitic food poisoning\\n\\nStaphylococcal food poisoning:\\nNausea\\nDiarrhoea 2 - 6 hours after eating food contaminated by\\n\\nenterotoxin\\nFood-borne botulism:\\n\\nIncubation period is 18 - 36 hours, but depending on\\ntoxin dose, can extend from a few hours to several days\\n\\nSymmetric descending paralysis\\nDiplopia\\nDysarthria/dysphagia\\nNausea, vomiting and abdominal pain may precede or\\n\\nfollow the onset of paralysis\\nNon-typhoidal Salmonellosis:\\n\\nDiarrhoea\\nNausea\\nVomiting\\nAbdominal cramps\\nFever\\nHeadache\\nMyalgia\\n\\nShigellosis:\\nFever\\nSelf-limiting watery diarrhoea\\nBloody diarrhoea\\nDysentry\\n\\n- Frequent passage, 10 - 30 times/day of small volume\\nstools containing blood, mucus and pus\\n\\nAbdominal cramps\\nTenesmus\\n\\nCampylobacter food poisoning:\\nA prodrome with fever, headache, myalgia and/or\\n\\nmalaise\\n12 - 48 hours later:\\n\\nDiarrhoea and abdominal pain\\nE.coli food poisoning:\\n\\nWatery diarrhoea accompanied by cramps\\nL. monocytogenes food poisoning:\\n\\nCommon source of outbreaks of acute gastritis\\n\\nS.aureus\\n\\nS.aureus\\n\\nE. coli\\n\\nListeria monocytogenes\\nYersinia enterocolitica\\n\\nClinical features\\n\\nOther investigations as may be indicated in the clinical\\ncirmcumstances\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nComplications\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution\\n\\nFOOD POISONING\\nIntroduction\\n\\nHeat stroke in adults\\nFebrile convulsions in children\\nComplications associated with underlying cause(s) of\\n\\nfever\\n\\nTo lower the temperature\\nTo treat underlying causes\\n\\nTepid sponging\\nLiberal oral sips of water (if clinical state is not a\\n\\ncontraindication)\\n\\nParacetamol\\n500 mg - 1 g orally every 4 - 6 hours; maximum 4 g\\n\\ndaily\\n3 months - 1 year: 60 - 125 mg; 1 - 5 years: 120 -\\n\\n250 mg; 6 - 12 years: 250 - 500 mg; repeated every 4 - 6\\nhours if necessary to a maximum of 4 doses in 24 hours\\n- Infants under 3 months should not be given paracetamol\\nunless advised by a doctor\\n\\nAspirin: (acetylsalicylic acid)\\n300 - 900 mg orally (with or without food) very 4 -\\n\\n6 hours if necessary; maximum 4g daily\\nTreat the identified (or suspected) cause of fever\\n\\nunder 16 years, not recommended because of the\\nrisk of Reye\\'s syndrome\\n\\nParacetamol:\\nLiver damage (and less frequently, renal damage)\\n\\nfollowing over dosage\\nAspirin\\nGastrointestinal discomfort, nausea\\nUlceration with occult bleeding\\nHearing disturbances such as tinnitus (rarely deafness)\\n\\nUse with caution in the following clinical conditions:\\nAsthma\\nAllergic disease\\nImpaired renal or hepatic function\\nPregnancy\\nBreastfeeding\\nElderly\\nDehydration\\n\\nAspectrum of disorders arising from:\\nInfections acquired by eating contaminated food\\nClinical problems that result from eating food\\n\\ncontaminated with toxins\\nClinical sequelae from inherently poisonous animals,\\n\\nplants or mushrooms\\nClinical forms:\\n\\nStaphylococcal food poisoning:\\n\\nNot a major cause of sporadic diarrhoea\\nNorwalk virus food poisoning:\\n\\nAbrupt onset of nausea and abdominal cramps\\nfollowed by vomiting and/or diarrhoea\\nHepatitisAvirus food poisoning:\\n\\nMay cause large outbreaks of diarrhoea and vomiting\\nfrom contaminated food, water, milk and shellfish\\n- Intrafamily and intrainstitutional spread common\\n\\nEssentially clinical\\nLaboratory confirmation of the specific microbe(s)\\n\\ninvolved\\n\\nOther causes of acute onset diarrhoea, nausea,\\nabdominal cramps and vomiting with or without\\nsystemic manifestations\\n\\nFluid and electrolyte derangements\\nOthers\\nBy no means limited to the stated organisms\\n\\nShigellosis:\\nDehydration\\nRectal prolapse\\nProtein-losing enteropathy\\nMalnutrition\\nHaemolytic-uraemic syndrome\\nToxic megacolon\\nPerforation\\n\\nCampylobacter food poisoning:\\nBacteraemia\\nCholecystitis\\nPancreatitis\\nCystitis\\nMeningitis\\nEndocarditis\\nArthritis\\nPeritonitis\\nCellulitis\\nSeptic abortion\\n\\nRestore fluid and electrolyte balance\\nNeutralize toxin\\nEradicate microbe\\n\\nGastric lavage in food-borne botulism\\n\\nAppropriate fluid and electrolyte replacement\\nTrivalent (types A, B, and E) equine anti-toxin should\\n\\nbe administered as soon as possible after specimens are\\nobtained for laboratory analysis for food-borne botulism\\n\\nEmetics in food-borne botulism\\nAdminister appropriate medicines\\n\\nOral Rehydration Therapy\\nPlus:\\n\\nAmoxicillin 50 - 100 mg/kg/day orally every 8\\n\\nDiagnosis\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nTreatment objectives\\n\\nNon-drug measures\\n\\nDrug treatment\\n\\n-\\n\\nShigellosis\\n\\nAdult:\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 11: Infectious Diseases/Infestations\\n\\n125 126\\n\\n\\n\\nhours; up to 2 g/day\\n125 mg every 8 hours, doubled in\\n\\nsevere infections\\nOr:\\nTrimethoprim/sulfamethoxazole (co-trimoxazole)\\n\\n960 mg orally every 12 hours for 5 days\\n120 mg orally; 6 months - 5\\n\\nyears: 240 mg; 6 - 12 years: 480 mg given every 12 hours\\nfor 5 days\\nOr:\\nCeftriaxone:\\n\\n1 g intravenously slowly\\n50 mg/kg/day intravenously for 5 days\\n\\nFluid and electrolyte replacement\\nPlus:\\n\\nErythromycin\\n250 mg orally every 6 hours for 5 - 7 days\\n30-50 mg/kg orally every 6 hours for 5 - 7 days\\n\\nCiprofloxacin\\n500 - 750 mg orally every 12 hours\\n\\nOr:\\n200 - 400 mg 12 hourly by intravenous infection over 30 -\\n60 minutes\\n\\nnot recommended\\n\\nAmoxicillin\\nPlus:\\n\\nGentamicin\\nTreat specific complications as appropriate e.g\\n\\n- Antibiotic-unresponsive toxic megacolon: colectomy\\n- Haemolytic-uraemic syndrome: dialysis\\n- Malnutrition from protein-losing enteropathy:\\nnutritional support; optimal nutritional management\\n\\nAppropriate environmental and personal hygiene\\n- Hand washing with soap and water\\n- Decontamination of water supplies\\n- Use of sanitay latrines or toilets\\n\\nIdentify and treat chronic carriers among food handlers\\nHygienic preparation and storage of food\\nEnsure that food is cooked at temperatures sufficient to\\n\\nkill bacteria\\nRefrigerate food whenever possible\\nEncourage exclusive breastfeeding\\nEncourage measures measures to reduce the burden of\\n\\nmalnutrition (with its attendant predisposition to severe\\ninfections)\\n\\nAdminister a pentavalent vaccine (A, B, C, D, and E)\\nfor persons at high of botulism\\n\\nReport new cases to public health authorities\\n\\nChild up to 10 years:\\n\\nAdult:\\nChild weeks to 5 months:\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nChild and adolescent:\\n\\nCampylobacter food poisoning\\n\\nfood poisoning\\n\\nL.monocyogenes food poisoning\\n\\nE. coli\\n\\nPrevention\\n\\nAbdominal pain\\nWeight loss\\nVulvo-vaginitis\\nPelvic/perineal granulomas\\n\\nAbdominal pain\\nAnorexia\\nBloody or mucoid diarrhoea\\nRectal prolapse\\nGrowth retardation\\n\\nDistinguished by its ability to replicate in the human\\nhost\\n- Can thus persist for decades without further exposure of\\nthe host to exogenous infective larvae\\n\\nRecurrent urticaria: buttocks and wrists\\nPruritic raised erythematous skin lesions: advance as\\n\\nrapidly as 10 cm/hour along the course of larval\\nmigration\\n- The pathognomonic serpiginous eruption\\n\\nMid-epigastric abdominal pain\\nNausea\\nDiarrhoea\\nGastrointestinal bleeding\\nMild chronic colitis\\nWeight loss\\nSmall bowel obstruction\\n\\nIn the first week after infection (gut invasion):\\nDiarrhoea\\nAbdominal\\nPain\\nConstipation\\nNausea\\nVomiting\\n\\nIn the second week after infection (muscle invasion):\\nFever\\nPeriorbital and facial oedema\\nHaemorrhages (subconjunctival, retinal and nail bed)\\nMaculopapular rash\\nHeadache\\nCough\\nDyspnoea\\nDysphagia\\nTachyarrhythmias\\nHeart failure\\nEncephalitis\\nPneumonitis\\n\\n- See Urology\\n\\nOther causes of acute-onset diarrhoea and/or vomiting\\n-Other conditions depending on the predominant clinical\\n\\nTrichuriasis\\n\\nStrongyloidiasis\\n\\nTrichinellosis\\n\\nSchistosomiasis\\n\\nDisseminated strongyloidiasis in patients with\\nunsuspected infection who are given glucocorticoids\\ncan be fatal\\n\\nDifferential diagnoses\\n\\nHELMINTHIASIS\\nIntroduction\\n\\nClinical features\\n\\nParasitic worm infestations can arise from different\\ngroups:\\n\\nAscaris\\nAncylostoma (hookworm)\\nEnterobius (pinworm)\\nTrichiuris (whipworm)\\n\\n- and\\n\\n- and\\nRound worm infestations are associated with rural\\n\\nliving and poor hygiene\\n- Prevalent among school children and young adults\\n- Acquired through soil and faeco-oral contamination\\n\\nFlat worms and tape worms are acquired by eating\\nunder-cooked contaminated meat or fish\\n\\nBladder worms ( ) are acquired by\\nwading through streams and ponds contaminated with\\nthe vector snails\\n\\nDepend on the infecting helminth:\\n\\nLung phase:\\nIrritating, non-productive cough\\nBurning substernal discomfort, aggravated by coughing\\n\\nor deep inspiration\\nDyspnoea\\nBlood-tinged sputum\\n\\nIntestinal phase:\\nUsually no symptoms\\nPain\\nFeatures of small bowel obstruction\\nFeatures of perforation\\nIntussusception\\nVolvulus\\nBiliary tree occlusion: biliary colic, cholecystitis,\\n\\ncholangitis, pancreatitis, intrahepatic abscess\\nEffects of migration of an adult worm up the oesophagus:\\n\\nCoughing\\nOral expulsion of the worm\\n\\nMost are asymptomatic\\nMaculo-papular dermatitis\\nMild transient pneumonitis\\nEpigastric pain, often with post-prandial accentuation\\nDiarrhoea\\nWeakness\\nShortness of breath\\nSkin depigmentation\\n\\nPerianal pruritus, worse at night owing to the nocturnal\\nmigration of the female worms\\n\\nSkin excoriation and bacterial superinfection\\n\\nNematodes (round worms)\\n\\nCestodes (flat worms/tapeworms)\\n\\nTrematodes (flukes)\\n\\nAscariasis\\n\\nHookworm\\n\\nEnterobiasis\\n\\nTaenia solium T. saginata\\n\\nSchistosoma haematobium S. mansoni\\n\\nS. haematobium\\n\\npresentation\\n\\nStool examination for ova and parasites\\nUrine examination: microscopy\\n\\n: eosinophilia and anaemia may be present\\nSerology and CT scan may be required in some\\n\\ninstances\\n\\nMebendazole\\n100 mg orally every 12 hours for 3 days\\n\\nIron supplementation may be given if anaemia is\\npresent\\n\\nMebendazole\\n100 mg orally every 12 hours for 3 days\\n\\nOr:\\nPiperazine phosphate\\n\\n4 g (i.e. the contents of one satchet) stirred into\\nwater or milk and taken at bedtime\\n- Reapeat after 14 days\\n\\n1 - 6 years: 750 mg (i.e. 5 mL) orally in the\\nmorning, repeated after 14 days\\nInfants 3 months - 1 year: 2.5 mL orally in the morning,\\nrepeated after 14 days\\n- Repeated treatments may be necessary\\n\\nMebandazole\\n100 mg orallyevery 12 hours for 3 days\\n\\nPyrantel embonate\\n10 mg/kg orally once\\n\\n- Repeat dose 2 weeks later; several treatments may be\\nnecessary\\n\\nPraziquantel\\n40 mg/kg given orally at once\\n\\n- Provides up to 80% cure rates\\n20 mg/kg followed after 4 - 6 hours by\\n\\na further dose of 20 mg/kg\\n\\nPraziquantel\\n40 mg/kg given orally at once\\n\\nOr:\\n- 20 mg/kg followed by another 20 mg/kg after 4 - 6\\nhours\\n\\n20 mg/kg followed after 4 - 6 hours by\\na further dose of 20 mg/kg (20 mg/kg 3 times daily for one\\nday for infections)\\n\\nAvoid mebendazole in pregnant women\\nSide effects of praziquantel include abdominal pain,\\n\\nheadache, dizziness and skin rashes\\n\\nInvestigations\\n\\nDrug Treatment\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nHaematology\\n\\nHookworm\\n\\nAscaris\\n\\nTrichiuris\\n\\nEnterobius\\n\\nTrematodes\\n\\nCestodes\\n\\nAdult and child:\\n\\nAdult and child:\\n\\nAdult:\\n\\nChild:\\n\\nAdult and child:\\n\\nAdult and child:\\n\\nAdult:\\n\\nChild over 4 years:\\n\\nPraziquantel is effective in all human cases caused by all\\nschistosomes\\n\\nAdult:\\n\\nChild over 4 years:\\n\\nS.japonicum\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 11: Infectious Diseases/Infestations\\n\\n127 128\\n\\n\\n\\nPrevention\\n\\nH U M A N I M M U N O D E F I C I E N C Y V I R U S\\nINFECTION\\nIntroduction\\n\\nClinical features\\n\\nGood personal and food hygiene\\nAccess to safe and potable water\\nRegular deworming\\nAdequate cooking of food and meats\\n\\nHuman Immunodeficiency Virus (HIV) is a retrovirus\\nwhich infects primarily CD4 T cells (T helper cells)\\n\\nInfection leads to a progressive destruction of the\\nimmune system with a consequent myriad of\\nopportunistic infections and the development of certain\\nmalignancies\\n\\nAcquired Immuno Deficiency Syndrome (AIDS) is\\ndefined as the presence of an AIDS-defining illness (see\\ntable 1) with a positive antibody test for HIV\\n\\nSexual transmission through vaginal and anal sex is the\\ncommonest route globally and in Nigeria, accounting for\\nabout 80%\\n\\nTransfusion of infected blood and blood products\\nUse of contaminated instruments; sharing needles,\\n\\ntattooing and occupational exposures\\nMother-to-child transmission of HIV: from an infected\\n\\nmother to her baby during pregnancy, at delivery and,\\nafter birth through breast-feeding\\n\\nTransient early acute symptoms: commonly “flu” -like\\nillness, often not recognized in the first 2 - 3 weeks of\\nHIV infection:\\n\\nGeneralized lymphadenopathy\\nSore throat\\nFever\\nSkin rash\\n\\nAsymptmatic period:\\nThe individual feels well despite on-going viral\\n\\nreplication\\nInitial symptoms:\\n\\nGeneralized lymphadenopathy\\nWasting syndrome/fever/night sweats\\nNeurologic disease\\nEarly immune failure\\nOral thrush\\nHerpes zoster\\nHairy leukoplakia\\nAIDS (opportunistic infections)\\nRecurrent bacterial pneumonias\\nPulmonary and extrapulmonary tuberculosis\\nPneumocytis carinii infection\\nKaposi sarcoma\\nViral infections including cytomegalo virus\\n\\nOther protozoan infect ions including\\n\\nHIV transmission\\n\\ncryptosporidium, cryptocooccocus.\\nSystemic fungal infections\\nOther cancers (lymphomas, cervical cancer, etc.)\\n\\nClinical Stage I:\\nAsymptomatic\\nGeneralised lymphadenopathy\\nPerformance scale 1: asymptomatic, normal activity\\n\\nClinical Stage II:\\nWeight loss < 10% of body weight\\nMinor mucocutaneous manifestations (seborrhoeic\\n\\ndermatitis, prurigo, fungal nail infections, recurrent oral\\nulcerations, angular cheilitis)\\n\\nHerpes zoster within the last five years\\nRecurrent upper respiratory tract infections (i.e.\\n\\nbacterial sinusitis)\\nAnd/or performance scale 2: symptomatic, normal\\n\\nactivity\\nClinical Stage III:\\n\\nWeight loss > 10% of body weight\\nUnexplained chronic diarrhoea, > 1 month\\nUnexplained prolonged fever (intermittent or constant)\\n\\n> 1 month\\nOral candidiasis (thrush)\\nOral hairy leucoplakia\\nPulmonary tuberculosis within the past year\\nSevere bacterial infections (i.e. pneumonia,\\n\\npyomyositis)\\nAnd/or performance scale 3: bedridden < 50% of the\\n\\nday during last month\\nClinical Stage IV:\\n\\nHIV wasting syndrome\\nPneumocystic carinii pneumonia\\nToxoplasmosis of the brain\\nCryptosporidiosis with diarrhoea > 1 month\\nCryptococcosis, extrapulmonary\\nCytomegalovirus disease of an organ other than liver,\\n\\nspleen or lymph node (e.g. retinitis)\\nHerpes simplex virus infection, mucocutaneous\\n\\n(>1month) or visceral\\nProgressive multifocal leucoencephalopathy\\nAny disseminated endemic mycosis\\nCandidiasis of oesophagus, trachea, bronchi\\nAtypical mycobacteriosis, disseminated or lungs\\nNon-typhoid salmonella septicaemia\\nExtrapulmonary tuberculosis\\nLymphoma\\nKaposi sarcoma\\n\\nHIV encephalopathy\\nAnd/or performance scale 4: bedridden > 50% of the\\n\\nday during last month\\n1: Weight loss of > 10% plus either unexplained\\nchronic diarrhoea > 1 month, or chronic weakness and\\nunexplained prolonged fever > 1 month.\\n\\nStaging of HIV/AIDS\\nWHO Staging System for HIV Infection and Disease in\\nAdults andAdolescents\\n\\n1\\n\\n2\\n\\n2: Clinical findings of disabling cognitive and/or motor\\ndysfunction interfering with activities of daily living,\\nprogression over weeks or months in absence of\\nconcurrent illness or condition other than HIV infection\\nthat could explain the finding\\n\\nDifferential diagnoses\\nTuberculosis\\nMalignancies\\nDiabetes mellitus\\nOther wasting syndromes\\n\\nChapter 11: Infectious Diseases/Infestations Standard Treatment Guidelines for Nigeria 2008\\n\\nCDC classification\\n\\nCD4 StageA Stage B Stage C\\nAsym. Symp. AIDS indicator\\nPGL notAor C condition\\n\\n> 500 A1 B1 C1\\n\\n200 - 500 A2 B2 C2\\n\\n< 200 A3 B3 C3\\n\\nWHO Improved Clinical Staging\\n\\nLaboratory indices Clinical stage\\n\\nLymphocytes CD4 Stage 1 Stage 2 Stage 3 Stage 4\\n\\nAsym.PGL Early HIV Intermed. LateAIDS\\n\\n(ARC)\\n\\nA > 2000 > 500 1A 2A 3A 4A\\n\\nB 1000 - 2000 200 - 500 1B 2B 3B 4B\\n\\nC < 1000 < 200 1C 2C 3C 4C\\n\\n129 130\\n\\n\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nFull Blood Count and differentials\\nVDRL(or RPR)\\nTuberculin test (PPD)\\nSputum smears for TB\\nElectrolytes, Urea and Creatinine\\nBlood glucose\\nLiver function tests\\nLipid studies (fasting trigycerides, LDL, HDL)\\nHBV, HCV serology\\nCervical (PAP) smears\\nCD4 T cell counts\\nHIV RNAlevel (viral load)\\nHIV DNA(paediatric diagnosis <18 months of age)\\nGenotype and phenotype assays for resistance testing\\n\\nClinical: prevent disease progression\\nImmunological: restore immunity\\nVirological: control or suppress viral replication\\nPublic health: reduce infectivity\\n\\nInitiation of therapy depends on availability of CD4 cell\\n\\nCriteria for initiating ART based on Nigerian ART\\nguidelines\\nAdults andAdolescents\\n\\ncount testing\\nIf CD4 testing is available:\\n\\nWHO Stage IV disease irrespective of CD4 cell count\\n\\nWHO Stage III disease with CD4 cell counts < 350/mm\\n\\nWHO Stage I or II disease with CD4 cell counts\\n\\n200/mm\\nIf CD4 testing is unavailable:\\nWHO Stage IV disease irrespective of total lymphocyte\\n\\ncount (TLC)\\nWHO Stage III disease irrespective of TLC\\n\\nWHO Stage II disease with a TLC 1200/mm\\n\\nATLC of 1200/mm does not predict a CD4 cell count\\n\\nof 200/mm in asymptomatic patients\\n\\nTLC of 1200/mm may not be used as criterion for the\\ninitiation of therapy in asymptomatic patients (WHO\\nStage 1 disease)\\n\\nChildren are monitored using CD4 percentage (CD4 %)\\ni.e. percentage of lymphocytes that are CD4 cells\\n\\nCD4% of an HIV-negative child is around 40%\\nDiagnosis depends on the age of the child and\\n\\navailability of virological testing\\n\\nSerological diagnosis is unreliable as maternally-\\nderived antibodies may persist for up to 15 - 18 months\\n\\n3\\n\\n3\\n\\n3\\n\\n3\\n\\n3\\n\\n3\\n\\n�\\n\\n�\\n\\n�\\n\\n�\\n\\n�\\n\\nChildren\\n\\nChildren < 18 months\\n\\nDiagnosis of HIV has to be made by identifying HIV\\nDNAusing PCR\\n\\nIf HIV status is virologically-proven ART is\\nrecommended when the child has:\\n\\nWHO Paediatric Stage III disease irrespective of CD4\\n%\\n\\nWHO Paediatric Stage II disease, with consideration of\\nusing CD4 <20% to assist in decision making\\nOr:\\n\\nWHO Paediatric Stage I (asymptomatic) and CD4\\n<20%\\n- If HIV-seropositive status is not virologically proven\\nbut CD4 cell assays are available, ART can be initiated\\nwhen the child has :\\n\\nWHO Stage II or III disease and CD4 <20%\\n- In such cases, HIV antibody testing must be repeated at\\nage 18 months to definitively confirm that the child is\\nHIV infected\\n- Only children with confirmed infection should have\\nARV therapy continued\\n\\nART can be initiated when child has:\\nWHO Paediatric Stage III disease (e.g. clinical AIDS)\\n\\nirrespective of CD4 count\\nWHO Paediatric Stage II disease with CD4 <15%\\n\\nOr:\\nWHO Paediatric Stage I disease (e.g. asymptomatic-\\n\\nappendix I) and CD4 <15% (Appendix I)\\nFor children > 8 years adult criteria for initiation of\\n\\ntherapy are applicable\\n\\n- d4T / 3TC / NVPor EFZ\\n\\n- TDF/3TC/NVPor EFZ\\nOr:\\n- ABC/3TC/NVPor EFZ\\n\\nPregnant women with CD4 count <250 cells/mm or\\nwomen who are likely to become pregnant\\n- ZDV / 3TC / NVP\\n\\nNevirapine (NVP)\\n- 200 mg orally once daily for 2 weeks; then 200 mg\\ntwice daily\\n\\nEfavirenz (EFV)\\n- 600 mg orally once daily; 800 mg once daily when\\nusing anti-tuberculosis drug\\n\\nZidovudine (ZDV)\\n- 250 - 300 mg orally twice daily\\n\\nStavudine (d4T)\\n- 40 mg orally twice daily\\n- If weight <60 kg: 30 mg twice daily\\n\\nLamivudine (3TC)\\n- 150 mg orally twice daily\\n\\nHIV-seropositive children aged <18 months\\n\\nHIV-seropositive children aged >18 months\\n\\nPreferred first line regimen (adults and adolescents)\\n\\nAlternative first line regimens\\n\\nAlternative first line drugs for special category of adults\\n\\nAdult dosages\\n\\nDrug treatment\\n\\n3\\n\\nDidanosine (ddI)\\n- 400 mg orally once daily\\n- If weight < 60 kg or combined with TDF: 250 mg once\\ndaily\\n\\nTenofovir (TDF)\\n- 300 mg once daily\\n\\nAbacavir (ABC)\\n- 300 mg orally twice daily\\n\\nIndinavir (IDV)\\n- 800 mg orally three times daily\\n\\nNelfinavir (NFV)\\n- 1.25 g orally twice daily\\nOr:\\n- 750 mg three times daily\\n\\nLopinavir/Ritonavir (LPV/r)\\n- 3 capsules (498 mg) orally twice daily\\n\\nSaquinavir (SQV)\\n- 1.2 g orally three times daily\\n\\nAmprenavir (AMP)\\n- 1.2 g twice daily\\n\\nRitonavir (RTV)\\n- 100 mg orally twice daily\\n\\nAtazanavir (ATV)\\n- 400 mg orally once daily\\n\\n- d4T or ZDV/ 3TC / NVPor EFV\\n- EFV for age 3 years and above; avoid liquid\\n\\nformulations\\n\\n- ddI/3TC/NVPor EFV\\n- EFV for age 3 years and above, avoid liquid\\n\\nformulations\\n\\nChildren with tuberculosis require rifampicin-containing\\nregimen for TB treatment\\n- D4T ZDV/3TC/EFV (3 years and above)\\n\\nAdults/Adolescents and Pregnant Women:\\n- (ZDV or dT4) + 3TC + NVP during non-rifampicin-\\ncontaining continuation phase\\nOr:\\n- (ZDV or dT4) +3TC + EFV during rifampicin-\\ncontaining intensive or continuation phase\\n\\nThe three drugs reserved for the first line regimens are\\nreplaced with three totally new drugs-second line\\nregimens\\n- If resistance testing cannot be done (see second line\\ntreatment regimens)\\n\\nWhere resistance testing is available, the failing drug\\nmay be identified and replaced\\n\\nChildren\\nPreferred first line regimen\\n\\nAlternative first line regimens\\n\\nAlternative first line drugs for special category of\\nchildren\\n\\nFirst line recommendations for HIV/TB patients\\n\\nManagement of virological treatment failure\\nTreatment failure due to resistance\\n\\nor\\nAge less than 3 years: please refer to paediatric HIV\\nconsultant\\n\\nChapter 11: Infectious Diseases/Infestations Standard Treatment Guidelines for Nigeria 2008\\n\\nCD4 count (cells/mm )\\n3\\n\\n> 500\\n\\n200 - 500\\n\\n< 200\\n\\n< 100\\n\\n< 50\\n\\nInfectious complications\\n\\nAcute HIV, candidal vaginitis\\n\\nPneumococcal and other bacterial\\npneumonias, pulmonary TB, Herpes\\nzoster, oropharyngeal candidiasis, oral\\nhairy leukoplakia, Kaposi sarcoma\\n\\nM i l l i a r y / e x t r a p u l m o n a r y T B ,\\npneumocystis carinii pneumonia (PCP),\\ndisseminated histoplasmosis and\\ncoccidiomycosis, progressive multifocal\\nleukoencephalopathy (PML)\\n\\nD i s s e m i n a t e d h e r p e s s i m p l e x ,\\nt o x o p l a s m o s i s , c r y t o c o c c o s i s ,\\nc r y p t o s p o r i d i u m , c h r o n i c\\nmicrosporidiosis, and oesophageal\\ncandidiasis\\n\\nDisseminated cytomegalovirus (CMV),\\ndisseminated Mycobacterium avium\\ncomplex (MAC)\\n\\nNon-infectious complications\\n\\nPGL, Gui l l a in -Bar re syndrome,\\nmyopathy, aseptic meningitis\\n\\nCervical cancer, anaemia, lymphomas\\n\\nWast ing, per iphera l neuropathy,\\nprogressive polyradiculopathy, HIV-\\nassociated dementia, cardiomyopathy\\n\\nCentral nervous system lymphomas\\n\\n131 132\\n\\n\\n\\nRecommended second line regimens\\nAdults and adolescents\\nFirst line Second line\\n\\nNote\\n\\nFirst line Second line\\n\\nd4T or ZDV/3TC/NVPor EFV TDF/FTC/IDV/r or SQV/r or LPV/r\\nOr:\\nABC/ddI/IDV/r or SQV/r or LPV/r\\nOr:\\n\\nTDF/FTC/NVPor EFV ZDV/3TC or ddI/IDV/r or SQV/r or LPV/r\\nOr:\\n\\nABC/3TC/NVPor EFV TDF/FTC/IDV/r or SQV/r or LPV/r\\n\\nThe dose of ddI should be reduced from 400 mg to 250 mg when co-administering with TDF in an adult > 60 kg\\nReduce dose to 125 mg in adult < 60 kg\\nIDV/r, LPV/r and SQV/r require secure cold chain for storage\\nCo-formulations of the medications above may be used to reduce the pill burden\\n\\nd4T or ZDV/3TC/NVPor EFV d4T or ZDV/3TC/ABC/LPV/r (preferred) or NFV\\nOr: Or:\\nddI/3TC/NVPor EFV ZDV/3TC/LPV/r (preferred) or NFV\\n\\nLPV/r requires secure cold chain\\nAll treatment failures at first and second level health facilities should be referred to a paediatric consultant\\n\\nChildren\\n\\nChild dosages\\nDidanosine (ddI)\\n\\n- 2 weeks - 8 months: 100 mg/m orally twice daily\\n\\n- > 8 months: 120 mg/m twice daily\\nLamivudine (3TC)\\n\\n- <1 month: 2 mg/kg orally twice daily\\n- >1 month: 4 mg/kg orally twice daily\\n- Adolescents < 50 kg: 2 mg/kg orally twice daily\\n\\nStavudine (d4T)\\n- 1mg/kg orally twice daily up to a maximum of 40 mg\\nper dose\\n\\nZalcitabine (ddC)\\n- Not available\\n\\nZidovudine (ZDV)\\n\\n- 160 mg/m orally every 8hours\\nEfavirenz (EFZ)\\n\\n- Taken orally once daily\\n- 10 to <15 kg: 200 mg; 15 to < 20 kg 250 mg; 20 to <25\\nkg 300 mg; 25 to <32.5 kg 350 mg; 32.5 to <40 kg 400\\nmg; >40 kg 600 mg\\n\\nNevirapine (NVP)\\n- 15 - 30 days: 5 mg/kg orally once daily for 14 days, then\\n\\n120 mg/m twice daily for 14 days, and 200 mg/m twice\\ndaily\\n\\n- 1month - 13 years: 120 mg/m twice daily for 14 days,\\n\\nthen 200 mg/m twice daily\\nIndinavir (IDV)\\n\\n2\\n\\n2\\n\\n2\\n\\n2 2\\n\\n2\\n\\n2\\n\\n- <4 years: not used\\n\\n- 4 - 17 years: 500 mg/m orally twice daily; (maximum\\n800 mg) three times daily\\n\\nNelfinavir (NFV)\\n- <1 year: 40 - 50 mg/kg orally three times daily; or 65 -\\n75 mg/kg twice daily\\n- 1 - 13 years: 55 - 65 mg/kg twice daily\\n\\nLopinavir/rotinavir (Lop/r)\\n- 7 kg to <15 kg: lopinavir 12 mg/kg, rotinavir 3 mg/kg\\norally twice daily with food\\n- 15 - 40 kg: lopinavir 10 mg/kg, rotinavir 2.5 mg/kg\\norally twice daily with food\\n- >40 kg lopinavir 400 mg, rotinavir 100 mg orally\\ntwice daily with food\\n\\nNevirapine (NVP)\\n- Life-threatening skin rash (Stevens-Johnson\\nsyndrome); occurs in < 5% of patients, usually within 8\\nweeks of treatment\\n- DRESS syndrome ( rug ash, osinophilia and\\nystemic ymptoms): manifests as fever, athralgia, etc\\n\\n- Hepatitis and jaundice reported\\nEfavirenz (EFV)\\n\\n- Morbilliform rash may appear; usually not life-\\nthreatening\\n- CNS side effects in about 50% of patients (usually\\nself-limiting)\\n\\n2\\n\\nNotable adverse drug reactions, caution and\\nContraindications\\n\\nd r e\\ns s\\n\\n- Hallucinations\\n- Insomnia\\n- Abnormal dreams\\n- Somnolence\\n- Amnesia\\n- Abnormal thinking\\n- Confusion\\n- Euphoria\\n\\n- Foetal abnormalities observed in animal models;\\nefavirenz should not be used in pregnant women or\\nwomen who might become pregnant while on therapy\\n\\nZidovudine (ZDV)\\n- Bone marrow suppression resulting in:\\n- Anaemia with macrocytosis\\n- Thrombocytopaenia\\n- Leucocytopaenia\\n- Gastro-intestinal intolerance is fairly common:\\nhypersalivation, nausea, abdominal discomfort\\n\\nStavudine (d4T)\\n- Peripheral neuropathy presenting with painful\\nsensations in the lower limbs more than the upper limbs\\n- Lactic acidosis with hepatic steatosis\\n- Stop treatment or switch to a drug less toxic to\\nmitochondria (worse when d4T is used in combination\\nwith ddI)\\n- Peripheral fat atrophy\\n- Ascending motor weakness resembling Guillain-\\nBarre syndrome\\n\\nLamivudine (3TC)\\n- No major side effect but class side effects may occur\\n\\nDidanosine (ddI)\\n- Dose-related pancreatitis; worse when combined with\\nhydroxycarbamide (hydroxyurea)\\n- Peripheral neuropathy; worse if combined with d4T\\n- Lactic acidosis (a class adverse effect)\\n\\nTenofovir (TDF)\\n- Infrequent; not more than what is observed in placebos\\nin controlled trials\\n- Renal insufficiency and bone demineralization\\n\\nAbacavir (ABC)\\n- Life-threatening hypersensitivity in 3 - 9% of patients\\n- Lactic acidosis with or without hepatic steatosis\\n\\nIndinavir (IDV)\\n- Class-specific events\\n- Nephrolithiasis with or without haematuria in 10 -\\n28% of patients; (fluid intake should be increased)\\n- Alopecia\\n\\nNelfinavir (NFV)\\n- Diarrhoea: 10 - 30% of patients; (should be managed\\nwith agents such as loperamide)\\n- Fat accumulation\\n- Hyperlipidaemia\\n\\nLopinavir/ritonavir (LPV/r)\\nWell tolerated except for occasional class adverse\\n\\nFor these reasons, EFV is contraindicated in patients\\nwho already have psychiatric manifestations\\n\\nChapter 11: Infectious Diseases/Infestations Standard Treatment Guidelines for Nigeria 2008\\n\\nreactions:\\n- Gastrointestinal\\n- Hepatic transaminitis especially in patients with chronic\\nhepatitis B or C\\n- Hyperlipidaemia\\n- Fat accumulation\\n\\nSaquinavir (SQV)\\nGIT intolerance in 5 - 30% leading to:\\n- Nausea\\n- Abdominal pain\\n- Diarrhoea\\n\\nAmprenavir (AMP)\\n- Class adverse effects\\n- GIT intolerance; oral paraesthesia in 28% of patients\\nOral solution contains propylene glycol which may\\nprecipitate:\\n- Seizures\\n- Stupor\\n- Tachycardia\\n- Hyperosmolality\\n- Lactic acidosis\\n- Renal failure\\n- Haemolysis\\n\\nRitonavir (RTV)\\n- Class side effects\\n- Perversion of taste\\n- Circumoral and peripheral paraesthesia\\n- Hepatotoxicity\\n- Aesthenia\\n\\nAtazanavir (ATV)\\n- Unconjugated hyperbilirubinaemia\\n- Gastrointestinal effects\\n- No effect on lipids\\n\\nRefer to standard texts for possible drug-drug\\ninteractions in all cases\\n\\nMechanisms with established merit:\\nPrevention of mother-to-child transmission (PMTCT)\\nProphylacticAZT/NVPor HAART\\nCaesarian section\\nInfant feeding choices (Exclusive Formula)\\nSafer sex (condom use)\\nPost exposure prophylaxis among healthworkers\\nTreatment of STIs\\nVoluntary counselling and testing (VCT)\\nNeedle exchange programmes for IVUs\\n\\nMechanisms with anticipated (potential) merit:\\nReduction of viral load with HAART\\nPost exposure prophylaxis following sexual exposure\\n\\n(rape)\\nSexual risk reduction\\nPromotion of safer sex and low-risk behaviour\\n\\nAbstinence\\n\\nOral solution is contraindicated in children below 4\\nyears; should be changed to capsules as soon as possible\\n\\nNote\\n\\nA:\\n\\nPrevention\\n\\n133 134\\n\\n\\n\\nB:\\nC:\\n\\nD:\\nE:\\nF:\\n\\nBe faithful (mutual fidelity to infected partner)\\nConsistent and correct use of male and female\\ncondoms\\nDelay onset of sexual activity\\nExamine yourself\\nFind out your status\\nScreening and treatment of sexually transmitted\\n\\ninfections\\nEncourage Partner Disclosure and Voluntary\\n\\nConfidential Couple Counselling (VCCCT)\\nPromote the rights and protection of children and\\n\\nwomen\\n\\nAn infectious protozoan disease transmitted by the\\nfemaleAnopheles mosquito\\n\\nAmajor public and private health problem and indeed a\\ncause and consequence of national underdevelopment\\n\\nFour species of the parasite cause the disease in\\nhumans: , , and\\n\\nP. accounts for 98% of all cases of malaria\\nin Nigeria and is responsible for the severe form of the\\ndisease\\n\\nPrincipal mode of spread: bites from infected female\\nAnopheles mosquito\\n\\nPeak feeding times are usually dusk and dawn, but also\\nthroughout the night\\nOther uncommon modes are:\\n\\nBlood transfusion\\nMother-to-child transmission\\n\\nUncomplicated\\nThere are no life-threatening manifestations\\nComplicated\\nP. asexual parasitaemia, with the presence\\n\\nof clinical and/or laboratory life-threatening features\\n\\nThese are non-specific:\\nFever\\nChills\\nHeadache\\nMalaise\\nAches and body pain\\nWeakness\\nTiredness\\nPallor\\nAnorexia\\nVomiting\\nBitterness in the mouth\\nExcessive sweating\\nPallor\\nHepatosplenomegaly\\nJaundice\\n\\nMalaria is severe when there is:\\n\\nMALARIA\\nIntroduction\\n\\nClassification\\n\\nClinical features\\n\\nPlasmodium falciparum vivax ovale\\nmalariae\\n\\nfalciparum\\n\\nfalciparum\\n\\nRepeated vomiting\\nProstration\\nImpaired consciousness\\nSevere anaemia\\nCirculatory collapse\\nHypoglycaemia\\nPulmonary oedema\\nAbnormal bleeding\\nJaundice\\nHaemoglobinuria\\nFebrile seizures\\nRenal failure\\nHyperparasitaemia\\n\\nAsevere form of malaria\\nOccurs usually in children and in non-immune adults\\nManifests with diffuse and symmetric encephalopathy;\\n\\nfocal neurologic signs are unusual\\nRequires prompt and effective therapy to avoid fatality\\n\\nAbsence of fever does not exclude a diagnosis of\\nmalaria\\n\\nMicroscopic diagnosis should not delay appropriate\\ntreatment if there is a clinical suspicion of severe malaria\\n\\nTyphoid fever\\nMeningitis\\nEncephalitis\\nSepticaemia\\nOther causes of fever\\n\\nHypoglycaemia\\nLactic acidosis\\nHaematological abnormalities\\nLiver dysfunction\\nPneumonia\\nSepticaemia\\nNon-cardiogenic pulmonary oedema\\nCerebral malaria\\n\\'Blackwater\\' fever\\nAcute tubular necrosis\\n\\nAnaemia\\nPreterm contractions/preterm labour\\nAbortions\\nLow birth weight\\nIntrauterine deaths\\nCongenital malaria\\n\\nHyperreactive malaria splenomegaly\\nQuartan malaria nephropathy\\nPossibly, Burkitt\\'s lymphoma\\n\\nBlood smear for malaria parasites\\nPacked cell volume; haemoglobin concentration\\n\\nCerebral malaria\\n\\nDiagnosis of malaria\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nEarly\\n\\nIn pregnancy\\n\\nLate\\n\\nWhite cell count with differentials\\nBlood sugar\\nUrinalysis\\nElectrolytes and Urea; Creatinine\\nStool microscopy for ova; occult blood\\nChest radiograph\\nCerebrospinal fluid biochemistry; microscopy, culture\\n\\nand sensitivity\\n\\nEradicate parasitaemia\\nPrevent severe malaria\\nAttend to the immediate threats of life\\nPrevent complications\\nProvide personal protection against malaria\\nProvide chemoprophylaxis in susceptible groups\\n\\nIt is vital to prevent severe disease, therefore as soon as a\\npresumptive diagnosis of malaria is made:\\n\\nInsert artesunate suppository per rectum as a single\\ndose\\n\\nRe-insert if expelled; in young children the buttocks\\nmay need to be held or taped together for 10 minutes to\\nensure retention of the rectal dose\\nArtemisin-based combination therapy is the treatment of\\n\\nchoice\\n< 40 kg: 10 mg/kg; 40 - 59\\n\\nkg: 400 mg (one 400 mg suppository); 60 - 80 kg: 800 mg\\n(two 400 mg suppositories); >80 kg: 1,200 mg (three 400\\nmg suppositories)\\n\\n30 - 39 kg: 300 mg (three 100 mg suppositories);\\n20 - 29 kg: 200 mg (two 100 mg suppositories); 9 - 19 kg:\\n100 mg (one 100 mg suppository); 5 - 8.9 kg: 50 mg (one\\n50 mg suppository)\\n- Dose should be given ONCE and followed as soon as\\npossible by definitive therapy for malaria\\n\\nArtemisin-based combination therapy is recommended\\nMonotherapy with dihydroartemisin or other artemisinin\\nderivatives is not recommended\\n\\nArtemether-lumefantrine (20 mg/120 mg)\\n4 standard tablets orally\\n\\nevery 12 hours\\n9 - 14 years: 3 tablets twice daily for 3 days; 4 - 8\\n\\nyears 2 tablets every 12 hours for 3 days\\n6 months - 3 years: 1 tablet every 12 hours for 3 days\\n- Not recommended for children under 3 months or <5 kg\\nOr:\\n\\nArtesunate-amodiaquine (4 mg/10 mg base)\\n4 standard tablets every 12 hours\\n1 - 2 standard tablets orally every 12 hours,\\n\\nadjusted according to age or body weight\\n\\nQuinine or artemisinin derivatives given parenterally are\\nthe drugs of choice\\n- Quinine:\\n\\nTreatment objectives\\n\\nDrug treatment\\nUncomplicated malaria\\n\\nDefinitive treatment\\n\\nSevere malaria\\n\\nAdult and child over 16 years\\n\\nChild:\\n\\nAdult and child over 14 years:\\n\\nChild:\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nIn all cases, patient\\'s progress should be monitored and\\nmanagement changed as deemed necessary\\n\\n20 mg/kg of salt to a maximum of 1.2 g loading\\ndose intravenously, diluted in 10 ml/kg isotonic fluid\\nover 4 hours\\n- 8 hours after start of the loading dose: 10 mg/kg salt to\\na maximum of 600 mg over 4 hours, every 8 hours until\\nthe patient is able to take orally\\n- Then change to tablets 10 mg/kg 8 hourly for 7 days\\ngive full dose of artemether-lumefantrine\\n\\n20 mg/kg of salt as loading dose diluted in 10\\nmL/kg of 4.3% glucose in 0.18% saline or in 5% glucose\\nover 4 hours 12 hours later, give 10 mg salt/kg as infusion\\nover 4 hours, and every 8 hours until patient is able to take\\norally\\nChange to tablets 10 mg/kg every 8 hours to complete a\\ntotal of 7 days\\nOr:\\n- Where intravenous access is not possible, give quinine\\ndihydrochloride 20 mg/kg salt as loading dose, diluted to\\n60 -100 mg/ml intramuscularly in different sites\\n- 8 hours after loading dose, give 10 mg/kg 8 hourly\\nuntil patient is able to take orally\\n- Thereafter, change to tablets 10 mg/kg 8 hourly for 7\\ndays or give a full dose of artemether-lumefantrine\\nOr:\\n- Artesunate\\n\\n2.4 mg/kg intravenous bolus; repeat 1.2 mg/kg\\nafter 12 hours then 1.2 mg/kg daily for 7 days\\n\\nintravenous use reserved for specialists\\n- Once patient can tolerate oral medication give a full\\ndose of artemether-lumefantrine\\nOr:\\n- Artemether\\n- 3.2 mg/kg intramuscular loading dose followed by 1.6\\nmg/kg daily for 6 days\\nAlternatively:\\n- Once patient can tolerate oral medication, give full\\ndose of artemether-lumefantrine\\n\\nParacetamol (oral/rectal) for symptomatic relief of fever\\nIf temperature is >38.5°C, wipe with wet towel, and fan\\n\\nto lower the temperature\\nPulmonary oedema\\n\\n- Nurse in cardiac position\\n- Give oxygen\\n- Furosemide 2 - 4 mg/kg intravenously\\n- Exclude anaemia as the cause of heart of the heart\\nfailure\\n\\nRenal failure\\n- Give fluids if patient is dehydrated: 20 ml/kg of sodium\\nchloride injection 0.9%, and challenge with furosemide 1\\n- 2 mg/kg\\n- Catheterize to monitor urinary output\\n- If no urine within the next 24 hours, refer for peritoneal\\nor haemodialysis\\n\\nor\\n\\nSupportive measures\\n\\nChapter 11: Infectious Diseases/Infestations Standard Treatment Guidelines for Nigeria 2008\\n\\n135 136\\n\\n\\n\\nProfuse bleeding\\n- Transfuse with screened fresh whole blood\\n- Give pre-referral treatment and refer urgently\\n\\nIf meningitis is suspected, and can not be excluded\\nimmediately by lumbar puncture, give appropriate\\nantibiotics\\n\\nOther severe diseases should be treated accordingly\\n\\nCorticosteroids and other anti-inflammatory agents;\\nagents used for cerebral oedema e.g. urea, adrenaline,\\nheparin\\n- Have no role in the treatment of severe malaria\\n\\nPersonal protection\\n- Reduce the frequency of mosquito bites by avoiding\\nexposure to mosquitoes at their peak feeding times\\n- Use insect repellants\\n- Put on suitable clothing\\n- Use insecticide-impregnated bed nets (ITN)\\n\\nChemoprohylaxis-\\n- Indicated for:\\n- Children born to non-immune mothers in endemic areas\\n- Pregnant women (see section on antenatal care)\\n- Travellers to endemic areas\\n\\nMefloquine 5 mg base/kg weekly, giving an adult dose\\nof 250 mg base/week\\nOr:\\n\\n1.5 mg of salt/kg administered daily (100 mg of salt\\ndaily)\\n- If tablets are available, an appropriate fraction can be\\ngiven to child aged 8 - 13 years\\n- Contraindicated in children <8 years and in pregnant\\nwomen\\n- Commence one week before departure and continue\\nuntil 4 weeks after leaving the region\\n\\nChemoprophylaxis is not recommended for\\nindividuals living with areas of intense transmission\\n\\n(see Sickle Cell Diseases)\\n\\nAn acute disease of the CNS caused by a bullet-shaped\\nrhabdovirus that affects all mammals\\nThe virus is a single-stranded RNA virus found in\\n\\nanimals, in all regions as urban rabies or sylvatic rabies\\nTransmitted by infected secretions, usually saliva\\nMost exposures are through bites of an infected animal;\\n\\nocassionally contact with a virus-containing aerosol or\\nthe ingestion or transplant of infected tissues may initiate\\nthe disease process\\n\\nHuman infection is through contact with un-\\nimmunized domestic animals\\n\\nDogs are the most important vectors worldwide\\n\\nTreatments not recommended\\n\\nPrevention\\n\\nRABIES\\nIntroduction\\n\\nClinical features\\n\\nPeople with sickle cell anaemia should have regular\\nchemoprophylaxis\\n\\nThere are four stages:\\nAnon-specific prodrome of 1 - 4 days consisting of\\n\\n- Fever\\n- Headache\\n- Malaise\\n- Myalgia\\n- Anorexia\\n- Nausea\\n- Vomiting\\n- Sore throat\\n- Cough\\n- Paraesthesia\\n\\nAn acute encephalitic stage\\n- Excitement\\n- Agitation\\n- Confusion\\n- Hallucinations\\n- Combativeness\\n- Bizarre aberrations of thought\\n- Muscle spasms\\n- Meningismus\\n- Seizures\\n- Focal paralysis\\n- Hydrophobia\\n\\nBrainstem dysfunction\\n- Diplopia\\n- Facial paralysis\\n- Optic neuritis\\n- Difficulty with deglutition\\n- Priapism\\n- Spontaneous ejaculation\\n- Coma\\n\\nDeath or recovery\\n\\nGullain-Barré syndrome\\nOther causes of viral encephalitis\\nPoliomyelitis\\nAllergic encephalomyelitis\\n\\nInappropriate secretion ofADH\\nDiabetes insipidus\\nCardiac arrythmias\\nAdult Respiratory Distress Syndrome (ARDS)\\nGastro Intestinal (GI) bleeding\\nThrombocytopenia\\nParalytic ileus\\n\\nFull Blood Count and differentials\\nUrea and Electrolytes\\nCulture of secretions\\nCerebro Spinal Fluid (C SF) analysis\\nSerology\\nPulmonary Chain Reaction (PCR)\\n\\nDisinfect wound; avoid early suturing\\nProvide passive immunization with antirabies\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nantiserum\\nProvide active immunization with the vaccine\\n\\nThe wound or site of exposure should be:\\nCleansed under running water\\nWashed for several minutes with soapy water\\nDisinfected and dressed simply\\n\\nUnimmunized persons or those whose prophylaxis is\\nprobably incomplete\\n- Rabies (cell mediated) vaccine\\nAdult: 1 ml by deep subcutaneous or intramuscular\\ninjection in the deltoid region on days 0, 3,7,14 and 30\\nPlus:\\nRabies immunoglobulin given on day 0\\n\\nsame as for adult\\nFor fully immunized persons:\\n\\n- Rabies (cell mediated) vaccine\\n1 ml by deep subcutaneous or intramuscular\\n\\ninjection in the deltoid region on days 1 and 3\\nsame as for adult\\n\\nShould be initiated as soon as possible after exposure\\nThe decision to initiate PEPshould include:\\nWhether the individual came into physical contact with\\n\\nsaliva or another substance likely to contain rabies virus\\nWhether rabies is known or suspected in the species and\\n\\narea associated with the exposure\\nThe circumstances surrounding the exposure e.g.\\n\\nwhether the bite was provoked or unprovoked\\n- Consider the use of rabies vaccine whenever a patient\\nhas been attacked by an animal in an environment where\\nrabies is enzootic, even if there is no direct evidence of\\nrabies in the attacking animal\\n- Pregnancy not a contraindication\\n\\nAllay anxiety: reassure\\nOther measures as appropriate for clinical situation\\n\\nConcomitant chloroquine administration interferes with\\nantibody response to rabies vaccine\\n\\nThere are no specific contraindications\\n\\nShould be offered to persons at high risk of exposure\\nand/or contact with rabies virus:\\n\\nVeterinnarians\\nCave explorers\\nLaboratory workers who handle the rabies virus\\nAnimal handlers\\nWorkers in quarantine stations\\nField workers who are likely to be bitten by infected\\n\\nwild animals\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nWound care\\n\\nPost-exposure prophylaxis (PEP)\\n\\nPre-exposure prophylaxis\\n\\nIt should not be sutured immediately\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nCertain port officials\\nBat handlers\\n\\nPersons living in (or travelling to) areas where rabies is\\nenzootic and/or where there is limited access to prompt\\nmedical care\\n\\nThose caring for patients caring for patients with rabies\\n- Although there is no proven evidence of human-human\\ntransmission\\nPregnancy is not a contraindication: if there is substantial\\n\\nrisk of exposure, and rapid access to post-exposure\\nprophylaxis is limited, give pre-exposure prophylaxis\\nRabies vaccine:\\n- 1 ml by deep subcutaneous or intramuscular injection in\\nthe deltoid region on days 0, 7 and 28\\nBooster doses every 2 - 3 years for those at continued risk\\n\\nA common, infectious disease affecting individuals of\\nall ages and sexes, particularly the socio-economically\\ndeprived\\nAneurologic disorder characterized by increased muscle\\n\\ntone and spasm that is caused by tetanospasmin, a\\npowerful protein toxin elaborated by\\nThe bacteria are found in the soil, inanimate environment,\\nanimal faeces and occasionally in human faeces\\nPortals of entry:\\n\\nUmbilical stump\\nFemale genital mutilation (FGM)\\nMale circumcision\\nAbortion sites\\nPenetrative wounds (e.g. nail puncture or intramuscular\\n\\ninjection)\\nHead injury; scalp wounds\\nTraditional scarification (e.g. for tribal identity)\\nTrado-medical incisions\\nPost-operative surgical sites\\nChronic otitis media\\n\\nClinical forms:\\nGeneralized tetanus\\nNeonatal tetanus\\nLocalized tetanus\\nCephalic tetanus\\n\\nLock jaw\\nDysphagia\\nStiffness or pain in the neck, shoulder and back muscles\\nRigid abdomen and stiff proximal limb muscles\\nThe hands and feet are relatively spared\\n\\nPoor feeding\\nRigidity\\nSpasms\\n\\nTETANUS\\nIntroduction\\n\\nClinical features\\n\\nClostridium tetani\\n\\nGeneralized tetanus\\n\\nNeonatal tetanus\\n\\nChapter 11: Infectious Diseases/Infestations Standard Treatment Guidelines for Nigeria 2008\\n\\n137 138\\n\\n\\n\\nLocalized tetanus\\n\\nCephalic tetanus\\n\\nIncreased tone; spasms are restricted to the muscles near\\nthe wound\\n\\nPrognosis is excellent\\n\\nFollows head injury or ear infection\\nTrismus\\n\\nDysfunction of one or more cranial nerves, often the 7\\nnerve\\n\\nMortality is high\\n\\nEntirely clinical\\n\\nAlveolar abscess\\nStrychnine poisoning\\nDystonic drug reactions\\nHypocalcaemic tetani\\nMeningitis/encephalitis\\nAcute abdomen\\n\\nAutonomic dysfunction\\n- Labile or sustained hypertension\\n- Tachycardia\\n- Dysarrhythmias\\n- Hyperpyrexia\\n- Profuse sweating\\n- Peripheral vasoconstriction\\n- Cardiac arrest\\n\\nAspiration pneumonia\\nFractures\\nMuscle rupture\\nDeep vein thrombophlebitis\\nPulmonary emboli\\nDecubitus ulcers\\nRhabdomyolysis\\n\\nWound swab for microscopy, culture and sensitivity\\nCerebrospinal fluid for biochemistry; microscopy,\\n\\nculture and sensitivity\\nFull Blood Count; ESR\\nUrinalysis; urine microscopy, culture and sensitivity\\nBlood glucose\\nElectrocardiography\\nSerum Electrolytes, Urea and Creatinine\\nElectromyography\\n\\nEliminate the source of toxin\\nNeutralize unbound toxin\\nPrevent muscle spasms\\nMonitor the patient\\'s condition and provide support\\n\\n(especially respiratory support) until recovery\\n\\nAdmit patient to a quiet room\\nProtect airway\\nExplore wounds\\nCleanse and thoroughly debride the wound\\n\\nth\\n\\nDiagnosis\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nProvide intubation or tracheostomy for hypoventilation\\nPhysiotherapy\\nMonitor bowel, bladder and renal function\\nPrevent decubitus ulcers\\n\\nAntibiotics\\n- Benzylpenicillin (Penicillin G)\\n\\n0.6 - 2.4 g daily by slow intravenous injection or\\ninfusion in 2 - 4 divided doses; higher doses in severe\\ninfections\\n\\n1 month - 18 years, 100 mg/kg in 4 divided doses\\n,every 6 hours; dose doubled in severe infections\\n(maximum 2.4 g ,every 4 hours)\\n1 - 4 weeks: 75 mg/kg daily in 3 divided doses, every 86\\nhours; dose doubled in severe infection\\nPreterm neonate and neonate under 7 days: 25 mg/kg\\n,every 12 hours; dose doubled in severe infection\\nOr:\\n- Metronidazole\\n\\n500 mg intravenously ,every 6 hours for 10 days\\nneonate, initially 15 mg/kg by intravenous\\n\\ninfusion then 7.5 mg/kg twice daily; 1 month - 12 years:\\n7.5 mg/kg (maximum 400 mg) every 8 hours; 12 - 18\\nyears: 400 mg every 8 hours\\n\\nAntitoxin\\n- Human tetanus immune globulin (TIG)\\n\\n250 units by intramuscular injection, increased to\\n500 units if:\\n- The wound is older than 12 hours\\n- There is risk of heavy contamination\\n- Patient weighs more than 90 kg\\n\\n- Administer antitoxin before manipulating the wound\\nControl of muscle spasm\\n\\n- Diazepam\\n20 mg intravenously slowly stat and titrate up to\\n\\n250 mg/day in infusion\\n1 month - 18 years: 100 - 300 micrograms/kg\\n\\nrepeated every 1 - 4 hours by slow intravenous injection\\n- Could also be administered by intravenous infusion or\\nby nasoduodenal tube as follows\\n3 - 10 mg/kg over 24 hours, adjusted according to\\nresponse\\nOr:\\n\\nPhenobarbital (dilute injection, 1 in 10 with water for\\ninjection)\\n\\n10 mg/kg intravenously at a rate of not more than\\n100 mg/minute, up to maximum total dose of 1g\\n\\n5 - 10mg/kg at a rate not more than 30 mg/minute\\nTreat autonomic dysfunction with\\n\\n- Vasopressors, chronotropic agents if necessary\\nHydration\\n\\n- To control insensitive and other fluid losses\\nEnteral or parenteral nutrition\\n\\n- As determined by clinical situation\\n\\nDrug treatment\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nA second dose of 250 units should be given after 3 - 4\\nweeks if patient immunosuppressed or if active\\nimmunization with tetanus vaccine is contraindicated\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nTreat intercurrent infections\\n\\nDiazepam is adsorbed from plastics of infusion bags\\nand giving sets; causes drowsiness and light headedness;\\nhypotension\\n\\nBenzyl penicillin: hypersensitivity reactions\\nMetronidazole: taste disturbances\\nPhenobarbital: caution in renal and hepatic impairment\\n\\n- May cause paradoxical excitement, restlessness and\\nconfusion in the elderly; hyperkinesia in children\\n\\nActive immunization of all partially or un-immunized\\nadults, those recovering from tetanus, all pregnant\\nwomen, infants and un-immunized (missed) children\\n\\nHealth education\\nImprovement in socio-economic status\\n\\nAfrican trypanosomiasis is an acute or chronic disease\\ncaused by namely\\n\\nrhodesiense (EastAfrica)\\ngambiense (WestAfrica)\\n\\n(Gambian Sleeping Sickness)\\nTwo clinical stages:\\n\\nEarly stage\\nCNS stage\\n\\nEarly stage:\\nAnodule or chancre following a bite\\nFever\\nHeadache\\nDizziness\\nWeakness\\nSignificant posterior cervical (Winterbottom sign) and\\n\\nsupraclavicular lymphadenopathy\\nSplenomegaly\\n\\nCNS stage:\\nOccurs six months to several years later\\nCharacterized by behavioural changes with\\n\\nhallucinations, delusions, and disturbances of sleep with\\ndrowsiness during the day and terminating with stupor\\n\\nPeripheral blood film for the detection of\\ntrypanosomes\\n\\nRapid Card Agglutination Trypanosomiasis Test\\n(CATT) for antibody detection\\n\\nPresumptive\\n- Based on the clinical suspicion and history of\\nexposure to the tsetse fly\\n\\nA finding of the trypanosome in peripheral blood,\\nlymph node aspirate or CSF is confirmatory\\n\\nNotable adverse drug reactions, caution and\\ncontrainndications\\n\\nPrevention\\n\\nTRYPANOSOMIASIS (Sleeping sickness)\\nIntroduction\\n\\nClinical features\\n\\nInvestigations\\n\\nDiagnosis\\n\\nTrypanosoma brucei\\nT. brucei\\nT. brucei\\n\\nDifferential diagnsoses\\n\\nTreatment\\n\\nCaution\\n\\nPrevention\\n\\nTUBERCULOSIS\\nIntroduction\\n\\nMalaria fever\\nMeningitis\\nViral infections involving the CNS\\n\\nSuramin\\n5 mg/kg on day 1, 10 mg/kg on day 3,\\n\\nand 20 mg/kg on days 5, 11, 17, 23 and 30\\n\\nMelarsoprol\\n2.0 - 3.6 mg/kg intravenously in 3 divided doses\\n\\nfor 3 days, followed 1 week later with 3.6 mg/kg\\nintravenously in 3 divided doses for 3 days\\n10 - 21 days later: 3.6 mg/kg intravenously in 3 divided\\ndoses for 3 days\\n\\nUrine should be examined for casts and protein before\\nand after treatment treatment with suramin\\n\\nLumbar puncture follow-up for at least 1 year after\\ntreatment with melasoprol is required\\n\\nSurveillance and treatment\\nChemoprophylaxis\\n\\nVector control by selective clearing of vegetation and\\nuse of insecticides\\n\\nOne of the oldest diseases known to affect humans,\\nglobally\\n\\nNearly one third of the global population (i.e. 2 billion)\\npeople are infected with\\nand at risk of developing the disease\\n\\nMore than 8 million people develop active tuberculosis\\n(TB) every year; about 2 million die\\n\\nMore than 90% of global TB cases and deaths occur in\\nthe developing world where 75% of cases are in the most\\neconomically productive age group (15 - 54 years)\\n\\nusually affects the lungs although in up\\nto one third of cases other organs are involved\\n\\nIf properly treated, TB caused by drug-susceptible\\nstrains is curable in virtually all cases; however if\\nuntreated it may be fatal within 5 years in more than half\\nof cases\\n\\nTransmission usually takes place through the airborne\\nspread of droplet nuclei produced by patients with\\ninfectious pulmonary TB and aerosolized by coughing\\n- As many as 3,000 infectious nuclei per cough can be\\nproduced\\n- Droplet nuclei could also by spread by sneezing and\\nspeaking\\n\\nPoverty and widening gap between rich and poor,\\nhunger, neglect of the disease, the collapse of health\\ninfrastructure plus the impact of HIV pandemic\\n\\nEarly stage\\n\\nLate stage\\n\\nAdult and child:\\n\\nAdult:\\n\\nMycobacterium tuberculosis\\n\\nM. tuberculosis\\n\\nChapter 11: Infectious Diseases/Infestations Standard Treatment Guidelines for Nigeria 2008\\n\\n139 140\\n\\n\\n\\ncontribute to the worsening global burden of TB\\n\\nThe probability of contact with a case of TB\\nThe intimacy and duration of that contact\\nDegree of infectiousness of the case\\nThe shared environment of the contact (crowding in\\n\\npoorly ventilated rooms)\\n\\nInnate susceptibility to disease\\nLevel of function of the individual\\'s cell mediated\\n\\nimmunity\\nAge\\n- Incidence highest during late adolescence and early\\nchildhood, women aged 25 - 34 years and the elderly\\n\\nThe outcome of infection by M.tuberculosis is affected\\nby the presence of:\\n\\nHIV co- infection\\nSilicosis\\nLymphoma\\nLeukaemia\\nChronic renal failure and haemodialysis\\nInsulin dependent diabetes mellitus\\nImmunosuppressive treatment\\nMalnutrition\\nOld, self-healed fibrotic TB lesions\\n\\nGenerally non-specific:\\nFever (low grade and intermittent)\\nNight sweats\\nWasting\\nAnorexia\\nGeneral malaise\\nWeakness\\nCough (initially non-productive, subsequently\\n\\nproductive of purulent and/or blood streaked sputum)\\nHaemoptysis\\nChest pain\\nDyspnoea\\nAdult respiratory distress syndrome (ARDS)\\nPallor\\nFinger clubbing\\n\\nPainless swelling of lymph nodes (usually cervical and\\nsupracervical sites\\n- Usually discrete in early disease; may become inflamed\\nand have a fistulous tract draining caseous material)\\n\\nFever\\nPleuritic chest pain\\nDyspnoea\\nDullness to percussion\\nAbsence of breath sounds\\n\\nDeterminants of transmission: from exposure to\\ninfection (exogenous factors)\\n\\nDeterminants of developing TB: from infection to\\ndisease (endogenous factors)\\n\\nOther diseases\\n\\nExtrapulmonary TB\\n\\nClinical features\\n\\nLymph node TB\\n\\nPleural TB\\n\\nTB of the upper airways\\nNearly always a complication of advanced cavitatory\\n\\npulmonary TB\\nMay involve the laynx, pharynx and epiglottis\\nHoarseness\\nDysphagia\\nDysphonia\\nChronic productive cough\\n\\nUrinary frequency\\nDysuria\\nHaematuria\\nFlank pain\\n\\nWeight bearing joints are affected: spine, hips and knees\\n\\nParaparesis\\nParaplegia\\n\\nHeadache\\nMental changes\\nConfusion\\nLethargy\\nAltered sensorium\\nNeck rigidity\\nOcular nerve paresis\\nHydrocephalus\\n\\nCommonly affects the terminal ileum and caecum\\nAbdominal pain (may be similar to that of appendicitis)\\nDiarrhoea\\nIntestinal obstruction\\nHaematochezia\\nPalpable mass\\nFever\\nWeight loss\\nNight sweats\\nTB peritonitis\\n\\nFever\\nDull retrosternal pain\\nFriction rub\\nCardiac tamponade\\n\\nFever\\nNight sweats\\nAnorexia\\nWeakness\\nWeight loss\\nCough\\nHepatomegaly\\nSplenomegaly\\nLymphadenopathy\\nChoroidal tubercles (pathognomonic)\\nMeningitis\\n\\nGenitourinary TB\\n\\nSkeletal TB\\n\\nSpinal TB (Pott\\'s disease)\\n\\nTB meningitis\\n\\nGastrointestinal TB\\n\\nPericardial TB\\n\\nMilitary TB\\n\\nThere are no clinical findings specific for a diagnosis of\\n\\npulmonary TB; a history of contact with a smear positive\\npulmonary TB case, respiratory symptoms for more than\\n2-3 weeks not responding to broad spectrum antibiotics,\\nand weight loss, failure to thrive may suggest TB\\n\\nSalmonella\\ntyphi S. paratyphi\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nComplications\\n\\nTreatment objectives\\n\\nTreatment\\n\\nTYPHOID FEVER\\nIntroduction\\n\\nWill vary depending on the system affected:\\nAsthma\\nBronchiectasis\\nWhooping cough\\nInhaled foreign body\\nCardiac disease\\nCarcinomas\\nIntracranial space-occupying lesions\\nOsteoarthritis, etc\\n\\nSputum forAAFB, microscopy, culture and sensitivity\\nTuberculin skin test\\nChest radiograph\\nFull Blood Count; ESR\\nHIV screening\\nUrinalysis; microscopy, culture and sensitivity\\nCSF microscopy, culture, sensitivity; chemistry\\nNucleic acid amplication\\nDrug susceptibility testing\\nOthers: IVP, bone biopsy, etc as indicated\\n\\nLung abscess\\nDestroyed lung syndrome\\nPressure effects from enlarged lymph nodes\\nObstructive uropathy\\nChronic kidney disease\\nInfertility\\nSkeletal deformities (varum and valgus; kyphosis,\\n\\nscoliosis)\\n\\nCure the disease\\nPrevent death from active TB or its late effects\\nPrevent relapse of TB\\nDecrease transmission of TB\\nPrevent the development of acquired drug resistance\\n\\nRegimen should include at least 4 drugs in the initiation\\nphase\\n\\nStandardized regimens are the choice in settings where\\nsusceptibility testing of reserve drugs is not available\\n\\nA systemic disease characterized by fever and\\nabdominal pain, caused by dissemination of\\n\\nor .\\nTransmitted only through close contact with acutely\\n\\ninfected individuals or chronic carriers (from ingestion\\nof contaminated food or water)\\n\\nIncidence of chronic carriage is higher among women\\nand persons with biliary abnormalities: gall stones,\\ncarcinoma of the gall bladder; also higher in persons with\\ngastrointestinal malignancies\\n\\nIncubation period ranges from 3 - 21 days\\n\\nProlonged fever (38.8 C to 40.5 C)\\nAprodrome of non-specific symptoms:\\n\\n- Chills\\n- Headache\\n- Anorexia\\n- Cough\\n- Weakness\\n- Sore throat\\n- Dizziness\\n- Muscle pains\\nGastro-intestinal:\\n\\nDiarrhoea or constipation\\nAbdominal pain\\nRash (rose spots)\\nHepato-splenomegaly\\nEpistaxis\\nRelative bradycardia\\n\\nNeuropsychiatric symptoms\\nIntestinal perforation\\nGastro-intestinal haemorrhage\\nPancreatitis\\nHepatitis\\nSplenic abscesses\\nMeningitis\\nNephritis\\nPneumonia\\nOsteomyelitis\\nChronic carrier state\\n\\nSpecimens for culture may be obtained from the blood,\\nstool, urine, bone marrow; gastric and intestinal\\nsecretions\\n\\nFull Blood Count\\n- Leucopenia, neutropenia, leucocytosis can develop\\nearly, especially in children; late if complicated by\\nintestinal perforation or secondary infection\\n\\nLiver function tests\\n- Values may be elevated\\n\\nElectrocardiography\\n- ST and T wave abnormalities may be present\\n\\nSerological tests\\n- Widal test gives high rates of false positives and\\nnegatives\\n\\nEliminate and\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\nNon-specific\\n\\nTreatment objectives\\n\\n° °\\n\\nA positive culture is the \\'gold standard\\' for the diagnosis\\nof typhoid fever\\n\\nThere are no diagnostic tests other than positive cultures\\n\\nS. typhi S. paratyphi\\n\\nChapter 11: Infectious Diseases/Infestations Standard Treatment Guidelines for Nigeria 2008\\n\\n141 142\\n\\n\\n\\nPrevent complications\\nPrevent chronic carrier status\\n\\nCeftriaxone\\n1 g daily by deep intramuscular injection or by\\n\\nintravenous injection over at least 2 - 4 minutes; 2 - 4 g\\ndaily in severe infection\\n- May also be given by intravenous infusion\\n\\nneonate, 20 - 50 mg/kg daily by intravenous\\ninjection over 60 minutes; infant and child under 50 kg:\\n20 - 50 mg/kg daily; up to 80 mg/kg in severe infection;\\nover 50 kg: adult dose\\n\\nOr:\\nCiprofloxacin\\n\\n500 - 750 mg orally every 12 hours\\nOr:\\n200 - 400 mg every 12 hours by intravenous infection\\nover 30 - 60 minutes\\n\\nnot recommended\\nParenteral fluid administration\\nTreat complications\\n\\nCiprofloxacin:\\nDiarrhoea, nausea, vomiting, abdominal discomfort,\\n\\nheadache (which are themselves features of the disease)\\nShould be given with caution in pregnancy and during\\n\\nbreastfeeding\\n- Not recommended for children or adolescents\\n\\nNursing care\\nEnteral or parenteral nutrition\\n\\nEliminate Salmonella by effective treatment of cases,\\nimproved sewage management, improved water\\ntreatment and improved food hygiene (production,\\ntransit, storage and utilization)\\n\\nTyphoid immunization is recommended for those at risk\\n- Not a substitute for scrupulous personal and\\nenvironmental hygiene\\n\\nIdentify, and treat chronic carriers with amoxicillin or\\nciprofloxacin daily for 4 - 6 weeks\\n- In patients with urolithiasis and schistosomiasis\\nappropriate treatment should be instituted\\n\\nCorrect anatomic abnormalities associated with the\\ndisease surgically\\n- Cholecystectomy may be required in some cases\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution\\n\\nNon-drug treatment\\n\\nPrevention\\n\\nAdult:\\n\\nChild:\\n\\nDoses of 50 mg/kg and above should be given by\\nintravenous infusion only\\nIntramuscular doses over 1 g should be divided between\\nmore than one site; single intravenous doses above 1 g\\nshould be given by intravenous infusion only\\n\\nAdult:\\n\\nChild and adolescent:\\n\\nCHAPTER 12: MUSCULOSKELETAL SYSTEM\\n\\nBACK PAIN\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nA common complaint which most adults will have had\\nat one time or the other\\n\\nDefined as any pain of the back, at any site between the\\nneck and the buttocks\\n\\nLow back pain is the commonest; involves essentially\\nthe lumbosacral/coccygeal spine\\n\\nMost cases result from mechanical causes and usually\\nlast less than six weeks\\nCauses include:\\n\\nSpondylosis\\nIntra-spinal abscess\\nTumours (primary or secondary)\\nOsteoporosis\\nOsteomyelitis\\nTrauma\\nPregnancy\\n\\nPatients will complain of aches, pains, or sometimes\\npeppery sensation\\n\\nPain is usually worsened on bending forward if due to a\\ndisc pathology\\n-Worsened when the intra-abdominal pressure is\\nincreased as in sneezing and coughing\\nWorsened on extension of the back if it is due to\\n\\napophyseal lesion\\n- Most back pains are from mechanical causes and are\\nself-limiting\\n\\nThere are danger or \\'red flag\\' features that indicate more\\nserious causes as infections, or malignanacy\\n- Starting for the first time in persons aged 50 years and\\nabove\\n- Worsened at night\\n- Worse on lying supine\\n- Associated with constitutional disturbances such as\\nfever, loss of weight, anorexia, anaemia\\n- Associated with radicular pain\\n- Associated with structural abnormalities such as\\nkyphosis or scoliosis\\n\\nPancreatic or gall bladder, stomach, or intestinal\\ndisorders with referred pain\\n\\nRetro-peritoneal tumours\\nAlcoholic gastritis\\nAortic aneurysms\\nTumours or inflammation of the pleura, pericardium\\nMetastatic bone disease\\nPsychosomatic disorders\\nPelvic inflammatory disease\\n\\nComplications of underlying cause(s) or pressure\\neffects on the spinal cord and nerve roots\\n\\nFull Blood Counts; ESR\\nC-Reactive Protein\\nCalcium, phosphate, alkaline phosphatase levels\\nRadiograph of the lumbosacral spine, myelogram\\nCT Scan\\nMR1\\nBone densitometry\\n\\nTreat underlying cause\\nRelieve pain\\nTreat complications\\n\\nParacetamol\\n- 1 g orally every 8 hours\\n\\nNSAIDs\\n- Ibuprofen 1.2 - 1.8 g orally in 3 - 4 divided doses daily\\n\\nNarcotic analgesics\\n- Morphine 10 mg orally every 4 hours (if necessary)\\n\\nAntidepressants\\n- Amitriptyline initially 25 mg orally daily\\n\\nPhysical therapy\\nAcupuncture\\nSurgery\\n\\nNSAIDs\\n- Individuals vary in their responses\\n- Should not be taken on empty stomach because of\\nincreased risk of gastric erosions and bleeding\\n- Particular caution in the elderly; paracetamol is very\\nuseful in treating pain of mild to moderate severity\\n- Combinations of different NSAIDs increases gastro-\\ntoxicity without conferring any advantage\\n- Interaction with antihypertensive medicines may lead\\nto poor blood pressure control\\n- Interaction with warfarin: increased risk of bleeding\\n\\nMorphine\\n- Nausea and vomiting; constipation; drowsiness;\\ndifficulty with micturition; biliary spasm; hypotension\\n- Dependence\\n\\nArises from a disorder of uric acid metabolism\\nDeposition of uric acid crystals in joints results in\\n\\nrecurrent episodes of arthritis, usually in one joint\\nDeposition of uric acid crystals in tissues and joint\\n\\ndestruction may occur if untreated\\n\\nAcute presentation: acute gout\\nChronic tophaceous gout: there is deposition of uric acid\\n\\nin tissues such as skin and kidneys\\nMost common in men aged 30 years and over\\nIt has also been seen in post-menopausal women,\\n\\nespecially those on diuretic therapy\\nSudden onset of pain in a joint: usually the ankles, foot,\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNon-drug treatment\\n\\nNotable adverse effects, caution and contraindications\\n\\nGOUT\\nIntroduction\\n\\nClinical features\\n\\nor knee\\nMay also present as arthritis in the big toe: podagra\\nArthritis may be recurrent before attention is sought\\nAffected joint is exquisitely warm to touch, painful and\\n\\nswollen\\nThere may be a skin reaction over the affected joint\\nThe attack may be accompanied by fever and other\\n\\nconstitutional symptoms\\nIf untreated, subsequent attacks may be polyarticular or\\n\\nmore painful\\n\\nJoint-destruction if untreated\\nNephrolithiasis and renal failure\\nSeptic arthritis\\n\\nSeptic arthritis\\nOsteoarhritis\\nCellulitis\\nGonococcal arthritis\\nTraumatic synovitis\\n\\nSerum uric acid\\n- Normal: 2 - 6 mg/100 mL in females; 2 - 7 mg/100 mL\\nin males\\n- Normal during acute attacks in 20% of patients\\n- Always elevated in chronic tophaceous gout\\n\\nSynovial fluid analysis and examination under\\npolarized light microscopy for intracellular crystals of\\nuric acid\\n\\n24 hour-urine for uric acid\\nRadiographs of affected joints\\n\\nLower serum uric acid if above 9 mg/100mL in acute\\nattacks\\n\\nLower the serum uric acid level in chronic tophaceous\\ngout\\n\\nPrevent joint deformity\\n\\nDietary control: restrict purine intake by avoiding red\\nmeat, alcohol, offals of animals, salmon and sardines\\n\\nWeight reduction\\nPhysical exercise\\nAvoid using inflammed joint(s) during acute attacks\\nAvoid operating on tophi deposits\\n\\nNon SteroidalAnti-inflammatory Drugs (NSAIDs):\\nIndomethacin\\n\\n- 50 mg orally three or four times daily\\nOr:\\n\\nIbuprofen\\n- 1.2 - 1.8 g orally daily in 3 - 4 divided doses\\nOr:\\n\\nNaproxen\\n- 500 mg orally three times daily for 3 days then 500 mg\\ntwice daily thereafter\\nOr:\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 12: Musculoskeletal System\\n\\n143 144\\n\\n\\n\\nDiclofenac sodium\\n- 75 mg orally twice daily\\nOral corticosteroids:\\n\\nPrednisolone\\n- 40 mg in divided doses for 3 days, tapered over 2\\nweeks\\nIntra-articular steroids:\\n\\nTriamcinolone\\n- 5 - 40 mg by intra-articular/intradermal injection\\naccording to patient\\'s size (maximum 80 mg); may be\\nrepeated when relapse occurs\\nOr:\\n\\nMethylprednisolone\\n- 4 - 80 mg (depending on patient\\'s size) intra-\\narticularly; may be repeated at intervals of 7 - 35 days\\nUricosuric agents:\\n\\nAllopurinol\\n- Initially 100 mg orally once daily then maintenance\\n300 - 400 mg/day\\nOr:\\n\\nProbenecid\\n- 250 mg orally twice daily for 1 week, then 500 mg\\ntwice daily\\n- Increase up to 3 g/day\\n\\n,\\n\\nAllopurinol\\n- Hypersensitivity rashes\\n- Reduce dose in renal insufficiency\\n\\nProbenecid\\n- Blood dyscrasias\\n\\nNSAIDs\\n- Risk of peptic ulceration, bleeding, perforation, renal\\ninsufficiency, cardiac decompensaton\\n\\nUricosuric agents\\n- Not to be used during acute gout: arthritis may worsen\\nor evolve into polyarticular disease\\n\\nAvoid alcohol\\nPrevent/treat obesity\\nAvoid drugs that elevate serum uric acid\\n\\nA heterogenous group of diseases manifesting with\\nsymptoms and signs in the synovial joints, attributable to\\ndysfunction of the articular cartilage and subchondral\\nbone\\n\\nIt is the end result of all forms of diseases in the joints\\n- When such changes occur in the intervertebral disc, it\\nis called spondylosis\\n\\nAffects mostly females 40 years and above. If less than\\n40 years, underlying causes e.g. trauma or repetitive\\n\\nNotable adverse drug reactions caution and\\ncontraindications\\n\\nPrevention\\n\\nOSTEOARTHRITIS\\nIntroduction\\n\\nClinical features\\n\\ninjuries should be looked for\\nAffects mostly weight-bearing joints such as knees,\\n\\nankles. Other joints such as hips (especially in sickle cell\\ndisease), hands and spine may be affected\\n\\nPresenting features are:\\n- Pain\\n- Morning stiffness of short duration\\n- Swelling\\n- Creakiness while walking\\n- Loss of function and deformity\\n\\nJoint deformity\\nSeptic arthritis\\n\\nRheumatoid arthritis\\nGouty arthritis\\nBenign Hypermobility Syndrome\\nBursitis\\nPsoriatic arthritis\\n\\nNone diagnostic:\\nRadiographs of affected joints\\nInvestigations to exclude other differentials\\n\\nReduce pain\\nEnhance mobility\\nPrevent deformity\\n\\nPatient education\\nExercise\\nPhysiotherapy\\nHydrotherapy\\nOccupational therapy\\nIntra-articular lavage\\n\\nParacetamol\\n- 500 mg -1 g orally every 8 hours\\n\\nNSAIDs\\n- Orally or local application\\n- Ibuprofen\\n\\n400 - 800 mg orally every 8 hours\\n- Naproxen\\n\\n500 mg orally every 12 hours\\n- Diclofenac sodium\\n\\n75 - 150 mg orally in 2-3 divided doses daily\\nNarcotic analgesics\\n\\n- Morphine\\n5 - 20 mg orally every 4 hours\\n\\nAnti-depressants for night pain\\n- Amitriptyline\\n\\n25 - 75 mg orally daily in divided doses or as a\\nsingle dose at bedtime\\n\\nCapsaicin cream\\n0.075% cream, apply small amounts up to 3 - 4 times\\ndaily\\n\\nIntra-articular steroids\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nAdult:\\n\\nAdult:\\n\\nAdult:\\n\\nAdult:\\n\\nAdult:\\n\\n- See Gout\\nHyaluronate\\n\\n- Injected into the joint (usually the knee), results in pain\\nrelief in 1 - 6 months, but increases inflammation in the\\nshort term\\n\\nGlucosamine/chondroitin (triple strength i.e. 750/600\\nmg) one tablet orally every 12 hours\\n\\nIntractable pain\\nDeformity\\nDisability\\n\\nAcupuncture\\nOsteopathy\\nTranscutaneous Electrical Nerve Stimulation (TENS)\\n\\nNSAIDs\\n- Gastro-intestinal side effects which may be mild (e.g.\\ndyspepsia, nausea, constipation and diarrhoea) or serious\\n(e.g. perforation, ulceration, bleeding and stenosis)\\n- May also cause pruritus, rashes, fixed drug eruptions;\\ndizziness and drowsiness; renal insufficiency/renal\\nfailure, especially in the elderly\\n\\nReduce weight\\nRegular exercise\\nTreat early\\n\\nAchronic inflammatory disease of unknown cause\\nPossibly occurs as a result of auto-immunity\\nAffects primarily the peripheral joints in a symmetric\\n\\npattern; may affect other organs\\n\\nClinical manifestations are usually preceeded by\\nconstitutional symptoms such as fatigue, malaise, fever,\\nweight loss, loss of appetite\\nJoint involvements are characterized, serially or\\nsimultaneously, by the following\\n\\nSignificant joint morning stiftness\\nPolyarthritis\\nArthritis of joints of the hands\\nBilaterally symmetrical arthritis\\n\\n- Any joint could be affected but mostly the knees,\\nankles, hips, shoulders, elbows; not joints of the back\\n\\nRheumatoid nodules\\nLymph glands enlargement\\nAnaemia\\nHepatosplenomegaly\\n\\nSystemic Lupus Erythematosus\\nPolyarticular gout\\n\\nIndications for surgery\\n\\nAlternative therapies\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nRHEUMATOIDARTHRITIS\\nIntroduction\\n\\nClinical features\\n\\nOther clinical features\\n\\nDifferential diagnoses\\n\\nFibromyalgia syndrome\\nSjogren\\'s syndrome\\nOsteoarthritis\\nHepatitis B\\n\\nChronic pain\\nJoint instability and deformity\\nPulmonary fibrosis\\nIschaemic heart disease\\nEye involvement\\nMalignancies: lymphoma\\n\\nFull Blood Count; ESR\\nRheumatoid factor\\nSynovial fluid analysis\\nRadiographs of affected joints\\n\\nReduce pain and disability\\nLimit joint damage\\nImprove quality of life\\n\\n-\\nEducation\\nPhysiotherapy\\n\\n- Improve mobility\\n- Increase muscle power\\n- Reduce pain and disability\\n\\n- Paracetamol\\n500 mg orally three times daily\\n\\n120 - 250 mg; 6 -12 years: 250 - 500\\nmg; 12 - 18 years: 500 mg every 4 - 6 hours (maximum 4\\ndoses in 24 hours)\\n\\nNon-steroidal anti-inflammatory drugs\\n- Ibuprofen\\n\\n400 - 800 mg orally every 8 hours\\n(and body weight >5 kg), 5 mg/kg\\n\\norally3 - 4 times daily preferably after food; in severe\\nconditions and weight >5 kg, maximum 30 mg/kg in 3 - 4\\ndivided doses\\n3 months - 1 year and body weight >5 kg: 50 mg 3 - 4\\ntimes daily; in severe conditions up to 30 mg/kg in 3 - 4\\ndivided doses\\n1 - 4 years: 100 mg every 6 - 8 hours daily; in severe\\nconditions up to 30 mg/kg in 3 - 4 divided doses\\n4 - 7 years: 150 mg every 8 hours; in severe conditions up\\nto 30 mg/kg in 3 - 4 divided doses, maximum 2.4 g daily\\n7 - 10 years: 200 mg every 8 hours; in severe conditions\\nup to 30 mg/kg in 3 - 4 divided doses, maximum 2.4 g\\ndaily\\n10 - 12 years: 300 mg every 8 hours; in severe conditions\\nup to 30 mg/kg in 3 - 4 divided doses, maximum 2.4 g\\ndaily\\n12 - 18 years: 300 - 400 mg very 6 - 8 hours daily,\\npreferably after food, increased if necessary to maximum\\n2.4 g daily\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon drug treatment\\n\\nDrug treatment\\n\\nThere is no cure\\n\\nAdult:\\nChild 1 - 5 years:\\n\\nAdult:\\nChild 1-3 months:\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 12: Musculoskeletal System\\n\\n145 146\\n\\n\\n\\n- Diclofenac potassium\\n25 - 50 mg orally every 8 hours\\n\\n75-100 mg daily in 2-3 divided doses\\nCorticosteroids\\n\\n- Prednisolone: low dose, up to 15 mg orally daily\\n- Triamcinolone and methylprednisolone into joints\\n(See Gout)\\n\\nDisease ModifyingAnti-Rheumatic Drugs (DMARDs)\\n- Methotrexate\\n\\n10 - 25 mg orally once weekly\\n\\n10 - 15 mg/m once weekly,\\n\\nincreased if necessary to a maximum of 25 mg/m once\\nweekly: by oral, subcutaneous or intramuscular route\\n- Azathioprine\\n\\n50 - 150 mg orally daily\\ninitially 1 mg/kg daily, adjusted\\n\\naccording to response to a maximum of 3 mg/kg daily\\n(Consider withdrawal if no improvement within 3\\nmonths)\\n- Hydroxychloroquine sulphate\\n\\ninitially 400 mg orally daily in divided doses;\\nmaintenance 200 - 400 mg (but not exceeding 400 mg)\\ndaily\\n\\n5 - 6.5 mg/kg orally (maximum\\n400 mg) once daily\\nOr:\\n- Chloroquine base\\n\\n150 mg orally daily (maximum 2.5 mg/kg daily)\\nup to 3 mg/kg orally daily\\n\\n- To be administered on expert advice\\n\\nNSAIDs\\n- May cause severe gastrointestinal side effects e.g.\\npeptic ulceration, bleeding, perforation\\n- Renal and cardiac failure especially in elderly persons\\n(should be used with caution)\\n\\nDMARDs\\n- Bone marrow suppression\\n- May also cause lymphoma\\n\\nMethotrexate\\n- Pulmonary fibrosis, hepatotoxicity\\n- Regular Full Blood Count including differentials,\\nrenal and liver function tests are required\\n- Concomitant administration of folic acid may reduce\\nmucosal and gastrointestinal side effects\\n\\nAn inflammation of synovial tissues by bacteria, with\\nproduction of pus into the joint space\\n\\nAlso variously called suppurative, purulent or infective\\narthritis\\n\\nAdult:\\nChild 14-18 years:\\n\\nAdult:\\n\\nChild 1 month - 18 years:\\n\\nAdult:\\nChild 1 month - 18 years:\\n\\nAdult:\\n\\nChild 1 month - 18 years:\\n\\nAdult:\\nChild:\\n\\nIn unresponsive cases, refer for specialist care\\n\\n2\\n\\n2\\n\\nor\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nSEPTICARTHRITIS\\nIntroduction\\n\\nRare, but may cause a lot of illness and early joint\\ndestruction or deformity\\nSeptic arthritis is broadly categorized as:\\n\\nGonococcal\\nNon-gonococcal\\n\\n, streptococci, candida species, ,\\nHIV, hepatitis B virus\\n\\nFrequency in most studies is about 2 - 10 cases per\\n100,000\\nMay occur on its own, or in association with other forms\\n\\nof arthritis such as gout, rheumatoid arthritis and\\nosteoarthritis\\n\\nCausative organisms are mostly , and\\nstreptococci. Other organisms include\\n\\nTypical presentations:\\nFever\\nHot, painful and distended joint with pus\\nMarkedly decreased range of motion\\nOccasionally, septic arthritis may present with a\\n\\nmigratory polyarthralgia and dermatitis, especially with\\ngonococcal infection\\n\\nConstitutional symptoms such as nausea, vomiting,\\nheadaches, loss of weight, loss of appetite may also be\\nseen\\n\\nMalaria fever\\nAcute gouty arthritis\\nOsteoarthritis\\nRheumatoid arthritis\\n\\nIrreversible joint destruction\\nDegenerative joint disease\\nOsteomyelitis\\nSoft tissue injury\\n\\nFull Blood Count and differentials\\nESR\\nBlood cultures\\nUrethral, cervical and rectal cultures\\nSynovial fluid analysis\\nMain radiographs of affected regions\\nUltrasonography\\n\\nInitiate appropriate antibiotics therapy early to prevent\\njoint damage\\n\\nPrevent septicaemia arising from the joint\\n\\nAntibiotic choice (based on culture report)\\n- Cefriaxone 1 g intravenously every 24 hours\\n\\n- There can be a change to oral antibiotics after the first\\nweek\\n\\nJoints infected with respond to 1 week\\nof intravenous ceftriaxone followed by ciprofloxacillin\\n\\nS. aureus M.tuberculosis\\n\\nS.aureus\\nH.influenzae,\\n\\nNeisseria gonorrhoeae\\n\\nTreatment may be continued for 4 weeks\\n\\nN. gonorrhoeae\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\n500 mg orally twice a day for another 1 week\\n\\nNeedle aspiration\\nArthroscopic drainage and lavage\\nOpen drainage and lavage\\n\\nEffective treatment of the primary infective agents and\\nother predisposing disease states e.g. sickle cell disease,\\ncomplicated fractures\\n\\nAttention to asepsis in joint manipulation procedures\\nand during intra-articular diagnostic/therapeutic\\ninterventions\\n\\nA chronic, multisystemic, auto-immune inflammatory\\ndisease that affects virtually any organ in the body\\n\\nTypically runs a relapsing and remitting course\\nAffects mainly women of child-bearing age\\nParticularly common among Blacks and Asians, in\\n\\nwhom it runs a more devastating course\\n\\nAffects one or more organs simultaneously\\nSkin and joints most affected but may also affect the\\n\\ncentral nervous system and kidneys\\nOnset usually preceded by constitutional symptoms:\\n\\nFever\\nMarked weight loss\\nLoss of appetite\\nAches and pains all over the body\\n\\nTypical characteristics are seen serially or\\nsimultaneously:\\n\\nJoint pains\\nMalar rash\\nDiscoid skin rash\\nPhotosensitivity\\nMouth or pharyngeal ulcers\\nPleurisy\\nPericarditis\\nRenal failure\\nNephritis\\nNephritic syndrome\\nSeizures\\nPsychosis\\nPeripheral neuropathy\\nTransverse myelitis\\nEye involvement\\nRecurrent abortions\\n\\nOpportunistic infections\\nAvascular necrosis\\nPremature atherosclerotic disease\\nMyocardial infarction\\n\\nMalaria\\n\\nSurgical measures\\n\\nPrevention\\n\\nSYSTEMIC LUPUS ERYTHEMATOSUS\\nIntroduction\\n\\nClinical features\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nRheumatoid arthritis\\nTyphoid fever\\nHepatitis\\nFibromyalgia syndrome\\nScleroderma\\nMixed connective tissue disease\\nBenign hypermobility syndrome\\nDrug-induced SLE\\n\\nOpportunistic infections\\nAvascular necrosis\\nPremature atherosclerotic disease\\nMyocardial infarction\\n\\nFull Blood Count: leucopaenia, thrombocytopaenia,\\nanaemia\\n\\nESR, CRP\\nUrine analysis and microscopy: albuminuria, casts,\\n\\nhaematuria\\nUrea, Electrolytes and Creatinine\\nLE cell test\\nSerology:ANA,Anti-ds DNA,Anti-SM\\nRo/Ssa; La/SSB,Anti-Cardiolipin antibody\\nRadiographs of affected joints\\nEchocardiogram\\nMRI\\n\\nReduce pain\\nImprove mobility\\nPrevent such organ involvement as kidney and brain\\n\\nPatient education\\nPhysiotherapy\\nOccupational therapy\\nAdequate nutrition\\nExercise to prevent contractures\\n\\nNon-SteroidalAnti-inflammatory drugs (NSAIDs)\\n- See above\\n\\nAnti-malarials\\n- Hydroxychloroquine\\n\\n200 mg orally daily\\n5 - 6.5 mg/kg orally (maximum\\n\\n400 mg) once daily\\nOr:\\nChloroquine\\n\\n150 - 300 mg base daily\\nup to 3 mg/kg orally daily\\n\\nCorticosteroids\\n- Pulse methylprednisolone\\n\\n1 g/day intravenously for 3 days\\n- Used for organs or life-threatening exarcerbations\\nOr:\\n- Prednisolone\\n\\n0.5 mg - 1 mg/kg orally daily\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nThere is no cure for the disease\\n\\nAdult:\\nChild 1 month - 18 years:\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nAdult:\\n\\nChapter 12: Musculoskeletal System Standard Treatment Guidelines for Nigeria 2008\\n\\n147 148\\n\\n\\n\\nImmunosuppressives\\n- Methotrexate\\n\\n7.5 mg - 15 mg orally weekly\\n\\n10 - 15 mg/m once weekly,\\n\\nincreased if necessary to a maximum of 25 mg/m once\\nweekly: by oral, subcutaneous or intramuscular route\\nOr:\\n- Azathioprine\\n\\n2.3 mg/kg orally daily\\ninitially 1 mg/kg daily, adjusted\\n\\naccording to response to a maximum of 3 mg/kg daily\\nOr:\\n- Cyclophosphamide\\n\\n500 - 750 mg/m intramuscularly or intravenously\\nmonthly\\n\\nnot listed for this indication\\n\\nNSAIDs:\\n- Gastrointestinal side effects: perforation, bleeding,\\nulceration\\n- Renal failure\\n- Cardiac failure\\n- Hepatotoxicity\\n- CNS involvement\\n\\nMethotrexate\\n- Pulmonary fibrosis\\n- Hepatocellular damage\\n- Immune suppression\\nAzathioprine\\n\\n- Risk of neoplasia\\n- Hepatocellular damage\\n- Bone marrow suppression\\n\\nCyclophosphamide\\n- Haemorrhagic cystitis\\n- Ovarian failure\\n- Bone marrow suppression\\n- Bladder malignancy\\n\\nNo primary prevention\\nRelapses can be prevented by:\\n\\nAvoiding ultraviolet light exposure to sun\\nAnti-malarial therapy\\nTreating hypertension adequately\\nCorrecting dyslipidaemia\\nACE inhibitors (to limit renal damage)\\n\\nAdult:\\n\\nChild 1 month - 18 years:\\n\\nAdult:\\nChild 1 month - 18 years:\\n\\nAdult:\\n\\nChild:\\n\\n2\\n\\n2\\n\\n2\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nChapter 13: OBSTETRICS AND\\nGYNAECOLOGY\\n\\nABORTION\\nIntroduction\\n\\nClinical features\\n\\nExpulsion from the mother\\'s uterus of a growing and\\ndeveloping embryo or foetus prior to the stage of viability\\n(about 20 weeks), with foetal weight less than 50 g\\n\\nOne of the leading causes of maternal mortality and\\nmorbidity in Nigeria\\nMay be:\\n\\nSpontaneous\\n- Occurring from natural causes\\n\\nInduced\\n- Brought about purposefully by drugs or mechanical\\nmeans\\n\\nAccidental\\n- Due to a fall, blow or other injury\\n\\nComplete\\n- With complete expulsion or extraction from the mother\\nof a foetus or embryo, and of any other products of\\nconception\\n\\nIncomplete\\n- Parts of the products of conception have been expelled\\nbut some (usually the placenta) remain in the uterus\\n\\nIllegal (criminal)\\n- Termination of a pregnancy without legal justification\\n\\nLegal\\n- With or without medical justification but done in a\\nmanner that is legal\\n\\nSolitary\\n- Asingle experience of an abortion\\n\\nHabitual\\n- When a woman has had three or more consecutive,\\nspontaneous abortions\\n\\nThreatened abortion:\\nCramp like pains\\nSlight show of blood\\nMay or may not be followed by the expulsion of the\\n\\nfoetus\\nOccurs during the first 20 weeks of intrauterine life (\\'pre\\n\\nviability\\' period)\\nImminent /incipient/impending abortion:\\n\\nCopious vaginal bleeding\\nUterine contractions\\nCervical dilatation\\n\\nInevitable abortion:\\nRupture of the membranes in the presence of cervical\\n\\ndilatation in a pre-viable pregnancy\\nAmpular/tubal abortion:\\n- Abortion of pregnancy in the ampulla of the fallopian\\ntube or the tube itself\\n- Rupture of an oviduct, the seat of ectopic pregnancy\\n- Extrusion of the products of pregnancy through the\\nfimbriated end of the oviduct\\n\\n- Aborted ectopic pregnancy, the pregnancy having\\noriginated in the fallopian tube\\nSeptic abortion:\\n\\nComplicated by fever, endometritis and parametritis\\n\\nAntepartum haemorrhage\\nEctopic pregnancy\\nHydatidiform mole\\nCarcinoma of the cervix\\nRape\\n\\nPelvic ultrasound scan\\nAbdominal radiograph\\nChest radiograph\\nMicroscopy, culture and sensitivity test of vaginal\\n\\ndischarge\\nUrinalysis; urine microscopy, culture and sensitivity\\nFull Blood Count\\nBlood Group\\n\\nEndometritis\\nParametritis\\nPeritomitis\\nHaemorhage\\nHIV infection\\nSecondary infertility\\nPerforation of the uterus and/or intestines\\nRupture of the bladder\\n\\nRestore haemostasis\\nPrevent/treat complications\\nProvide health education\\n\\nNursing care\\nPsychological support\\nPersonal hygiene\\n\\nTreat infection(s)\\nReplace fluid, electrolyte, and blood losses\\nComplete incomplete abortion\\nSurgical correction of complication(s)\\n\\nPromote personal and family understanding of basic\\nreproductive health\\n- Universal basic education\\n- Girl child education\\n- Moral instruction\\n\\nProtect vulnerable groups (young females) from undue\\nexposure to their male folks\\n- At home\\n- In school\\n- Within peer groups\\nLegislation against street hawking for vulnerable groups\\n\\nProvide access to Primary Health Care and referral to\\nefficient and effective higher levels of care\\n\\nEnforce existing laws on the criminality of abortion\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nComplications\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nPrevention\\n\\nReview existing laws on abortion with a view to\\npromoting and protecting the overall wellbeing of mother\\nand unborn child\\n\\nANC is clinical assessment of mother and foetus,\\nwith an overall goal of obtaining the best possible\\noutcomes for both\\n\\nAn excellent example of preventive health care, as it\\ndeals mainly with normal individuals with an emphasis\\non the practice of health promotion\\n\\nAvailability, accessibility and utilization of ANC\\nremain poor in Nigeria as in many other developing\\nnations\\n\\nAssessment and management of maternal risk and\\nsymptoms\\n\\nAssessment and management of foetal risk\\nPrenatal diagnosis and management of foetal\\n\\nabnormality\\nDiagnosis and management of perinatal\\n\\ncomplications\\nDecisions regarding timing and mode of delivery\\nParental education regarding pregnancy and\\n\\nchildbirth\\nParental education regarding child-rearing\\n\\nCommunity care, supervised predominantly by the\\nmidwife\\n\\nShared care between the woman\\'s general practitioner,\\nmidwife and obstetrician, with visits interspersed\\nbetween all health professionals concerned- basic care\\ncomponent\\n- 75% of pregnant women usually qualify for this\\n\\nHospital-only\\ncare:\\n- In cases where there is increased risk to the mother,\\nfoetus, or both- specialized care component\\n- A critical 25% of women will usually fall under this\\ncategory\\n\\nPreviously, antenatal visits were:\\n- Monthly until 28 weeks gestation, then fortnightly until\\n36 weeks, and weekly thereafter until delivery, resulting\\nin up to 14 hospital visits during pregnancy\\nBest available evidence indicates that there is no\\n\\ndifference in outcome between a four-visit schedule\\nand a twelve-visit schedule\\n-Current trends favour fewer visits, while\\nestablishing clearly defined objectives to be\\nachieved at each visit\\n\\nPre-conception visit\\n\\n1 ANC visit\\n\\nANTENATAL CARE (ANC)\\nIntroduction\\n\\nAims of antenatal care\\n\\nProviders of antenatal care\\n\\nSchedule of visits during pregnancy\\n\\nst\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 13: Obstetrics and Gynaecology\\n\\n149 150\\n\\n\\n\\n- Best before, and not later than the 12 week\\n\\n2 ANC visit\\n\\n- Scheduled around the 26 week\\n\\n3 ANC visit\\n\\n- Scheduled around the 32 week\\n\\n4 ANC visit\\n\\n- Between the 36 and 38 week\\nPostnatal visit- scheduled within 1 week postnatally\\n\\nAssess the general health and well-being of the\\npatient\\nTake appropriate action based on the outcome\\n\\nassessment\\nGeneral advice regarding nutrition and life style\\n\\nShould be in the 1 trimester, preferably before the\\n\\n12 week\\nShould last between 30 - 40 minutes\\nKey objective is to obtain the patient\\'s medical and\\n\\nobstetric history:\\n- Assess the woman\\'s eligibility to follow the basic\\ncomponent of the new WHO model using the\\nclassifying form which contains 18 sets of questions\\nActivities during the visit should include:\\nPhysical examination\\n\\n- General examination including height and weight\\n- Blood pressure\\n- Chest and heart auscultation\\n- SFH and abdominal palpation\\n- Vaginal examination; specifically for PAP smear\\nif the woman has not done one in the past 2 years;\\nalso for women with past history suggestive of\\ncervical incompetence\\n\\nAssessment for referral\\n- Any medical or obstetric conditions that require\\nspecialized care\\n\\nInvestigations\\n-Urinalysis for bacteriuria, proteinuria and\\nglycosuria\\n- Haemoglobin genotype\\n- Blood group\\n- HIV screening\\n- VDRL\\n- Haemoglobin concentration/packed cell volume\\n\\nIron\\nFolate\\n\\nTetanus toxoid- 1 injection\\nTreat for syphilis if VDRLis positive\\nRefer if other investigation results so require\\nAllow time for advice, questions and answers, and\\n\\nscheduling of next appointment\\n\\nth\\n\\nnd\\n\\nth\\n\\nrd\\n\\nnd\\n\\nth\\n\\nth th\\n\\nst\\n\\nth\\n\\nst\\n\\nThis model is suited for the basic care component;\\nthe specialized care component is better managed\\nwith the 12-visit schedule\\nActivities during each visit\\n\\nInterventions\\n\\nPre-conception visit\\n\\n1 ANC visit\\nst\\n\\nMaintain complete clinic records of all transactions\\nof the visit\\n\\nShould be close to, or at 26 week\\nExpected to take about 20 minutes\\n\\nActivities during the visit should include:\\nReview of history for any changes\\n\\nAssessment of adherence to routineANC medicines\\nAssess for referral\\n\\n- Update the risk status and refer if the need arises\\nPhysical examination\\n\\n- General examination: pallor, oedema\\n- Blood pressure\\n- SFH\\n\\nUrinalysis for bacteriuria, proteinuria\\nFor nulliparous women and those with a history of\\n\\nhypertension or pre-eclampsia/eclampsia\\nHaemoglobin concentration/packed cell volume\\n\\nonly if there is evidence of anaemia\\n\\nIron\\nFolic acid\\nMalaria prophylaxis\\n\\n- Intermittent treatment with sufadoxine /\\npyrimethamine\\n\\n- One full treatment dose in the 2 and 3 trimesters\\n- Last dose not later than 1 month before the\\nExpected Date of Delivery\\nOr:\\n- Proguanil 100 - 200 mg orally daily\\n\\nMaintain complete clinic records as well as ANC\\ncard records\\n\\nShould be around the 32 week\\nExpected to take about 20 minutes\\n\\nActivities during the visit:\\nReview history for any changes\\nAssess adherence to routineANC medicines\\nExtra attention to advice on\\n\\n- What to do if labour occurs\\n- What to do if membranes rupture\\n- Birth spacing and counselling on contraception\\n\\nAssess for referral\\nPhysical examination\\n\\n- General examination: pallor, oedema, dyspnoea\\n- Breast examination\\n- Blood pressure\\n- Abdomen: SFH palpation for twin gestation\\n\\n- Haemoglobin concentration or packed cell volume\\ncompulsory for all in this visit\\n- Urinalysis: bacteriuria, proteinuria; for nullipara\\na n d t h o s e w i t h h y p e r t e n s i o n , p r e -\\neclampsia/eclampsia\\n\\n2 ANC visit\\n\\n3 ANC visit\\n\\nnd\\n\\nrd\\n\\nth\\n\\nnd rd\\n\\nnd\\n\\nInvestigations\\n\\nInterventions\\n\\nInvestigations\\n\\nInterventions\\n\\nIron\\nFolic acid\\n\\nTetanus toxoid (2 injection)\\nAntimalarials\\nMaintain complete records: clinic as well as ANC\\n\\ncard records\\n\\nThe final visit before labour or delivery\\n\\nShould take place about or between the 36 - 38\\nweeks\\nActivities during the visit include:\\n\\nReview history for any changes\\nAssessment of adherence to routineANC medicines\\n\\nPhysical examination\\n- General examination\\n- Blood pressure\\n- Abdomen: SFH, foetal lie and presentation;\\npresence of multiple gestations\\n- Advise on the concept of prolonged pregnancy and\\n\\nthe need to present if still not in labour by the 41\\nweek\\n\\nUrine: proteinuria; only in nullipara, hypertension,\\npre-eclampsia/eclampsia\\n\\nAssess for referral\\n\\nIron\\nFolic acid\\nMalaria prophylaxis\\nAdvice, questions and answers; scheduling next\\n\\nappointment\\nMaintain complete records: clinic as well as ANC\\n\\ncard records\\n\\nQuinine is safe and can be used in all trimesters\\n\\nArtemisinin-based combinations are safe in the 2\\n\\nand 3 trimesters\\n- Artemether-lumefantrine is considered safe\\n\\nShould hold within 1 week postpartum\\nOffer contraception\\nComplete tetanus prophylaxis with tetanus toxoid\\nContinue interventions: iron, folic acid and malaria\\n\\nprophylaxis\\n\\nAnaemia is the most common complication of\\npregnancy in Sub-SaharanAfrica\\n\\nIt is a diminution below normal of the total\\ncirculating haemoglobin mass\\n\\nWorld Health Organization definition of anaemia\\n- Haemoglobin concentration less than 11 g/dL or a\\nhaematocrit less than 33% in peripheral blood\\n\\nFor practical purposes in developing and tropical\\n\\nnd\\n\\nth th\\n\\nst\\n\\nnd\\n\\nrd\\n\\n4 ANC visit\\n\\nPostnatal visit\\n\\nth\\n\\nInvestigations\\n\\nInterventions\\n\\nANAEMIAIN PREGNANCY\\nIntroduction\\n\\nMalaria treatment for breakthrough episodes\\n\\ncountries a haemoglobin concentration of 10 g/dLor\\nhaematocrit of 30% is taken as cut off\\n- Below these levels there may be adverse foetal and\\nmaternal outcomes\\n\\nMild\\n- PCV 25 - 29%\\n\\nModerate\\n- PCV 20 - 24%\\n\\nSevere\\nPCV < 20%\\n\\nVaries; depends on the severity\\n- May be asymptomatic or symptomatic\\n\\nGeneralised weakness\\nLassitude\\nEasy fatigability\\nHeadaches\\nDyspnoea on mild exertion\\nAnkle swelling\\n\\nPallor\\nJaundice may or may not be present\\nPedal oedema\\nTachypnoea\\nTachycardia\\nHaemic murmurs\\nPseudo-toxaemia\\n\\n- Systolic hypertension, oedema and albuminuria\\nThere may, or may not be clinical evidence of\\n\\ncausative pathology\\n- Sickle cell facies, urinary tract symptoms, etc\\n\\nHepatomegaly: not invariable\\nSplenomegaly: not invariable\\nAnaemic heart failure in extreme cases\\n\\nNutritional deficiencies\\n- Iron, folic acid, protein, vitamin C; trace elements,\\nand rarely vitamin B\\n\\nPhysiological demands of pregnancy\\nExcessive red cell haemolysis as in malaria,\\n\\nhaemoglobinopathies\\nInfections: urinary tract infection, HIV/AIDS\\nHookworm infestation\\nExcessive sweating in the tropics\\nAntepartum haemorrhage\\nBone marrow pathologies\\nMiscellaneous: e.g. bleeding duodenal ulcer\\n\\nAbortion\\nCardiac failure\\nReduced ability to tolerate blood loss at delivery\\nReduced ability to tolerate anaesthesia\\nDiminished resistance to infection\\n\\nClassification\\n\\nClinical presentation\\n\\nSymptoms\\n\\nSigns\\n\\nDifferential diagnoses\\n\\nComplications\\n\\n12\\n\\nMaternal\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 13: Obstetrics and Gynaecology\\n\\n151 152\\n\\n\\n\\nPreterm labour\\nPrecipitate labour\\nDeath\\n\\nAbortion\\nIntrauterine growth restriction\\nIntrauterine foetal death\\nStill birth\\nPrematurity\\nRisk of developing anaemia within 2 - 3 months of\\n\\nbirth if mother suffered iron deficiency anaemia\\n\\nHaematocrit\\nHaemoglobin concentration\\nWhite blood cell count and differentials\\nBlood picture\\nReticulocyte count\\nBlood smear\\nMidstream urine: microscopy, culture and\\n\\nsensitivity\\nStool analysis: ova, cysts, parasites, occult blood\\nGroup and cross-match blood\\nHaemoglobin genotype\\nBlood Group\\nVDRL\\nHIV screening\\nUrinalysis\\nUltrasound scan (e.g. of abdomen, pelvis)\\nBone marrow biopsy if bone marrow involvement\\n\\nis suspected\\n\\nCorrect haematocrit\\nTreat underlying cause(s)\\n\\n- See differential diagnoses\\nFoetal surveillance\\n\\n- Of growth and wellbeing for IUGR and\\nintrauterine asphyxia\\n\\nOral haematinics\\n- For mild and moderate anaemia\\n\\nFerrous sulfate\\n- 200 mg daily and folic acid 5 mg daily\\n\\nVitamin C (ascorbic acid)\\n- 100 mg three times daily\\n\\nParenteral iron: indicated in\\n- Mild to moderate anaemia, near term\\n- Malabsorption of oral iron, or when it causes\\nserious gastroenteritis\\nAdministration:\\n\\nCalculate haemoglobin deficit\\nFor each 1 g/dL deficit, 250 mg of iron dextran\\n\\ninjection is required\\nAdditionally, 50% of the total calculated is added\\n\\nonto the deficit value to take care of the iron stores\\nAdminister by deep intramuscular injection into\\n\\nthe gluteal muscle, by slow intravenous injection or\\nby intravenous Infusion (after a negative test dose)\\n\\nFoetal\\n\\nCorrection of haematocrit\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nIntramuscular injection\\n- 250 mg daily; after a negative test dose of 25 mg\\n\\nIntravenous\\n- If the total calculated dose of iron dextran is less\\nthan 1,500 mg it can be given over 8 hours in one litre\\nof sodium chloride 0.9%\\n- If greater than 1,500 mg, it should be given in\\ndivided doses daily, not exceeding 1,500 mg/day\\n\\nBlood transfusion\\n\\n- Consider as from the 37 week for mild anaemia\\n\\nand from the 32 week for moderate anaemia\\n- Usually, packed cells under furosemide cover\\nIndications:\\n\\nSevere anaemia irrespective of gestational age\\nCardiac failure\\nModerate anaemia detected in labour or during an\\n\\nabortion, or co-existing with other conditions such as\\nsepsis, renal failure, haemorrhage or eclampsia\\n\\nCounselling on contraception; adequate spacing of\\npregnancies\\n\\nMalaria prophylaxis in pregnancy\\nChemoprophylaxis against helminthiasis\\nPrompt and appropriate treatment of febrile\\n\\nillnesses in pregnancy\\nImprovement in the socioeconomic status of the\\n\\npeople\\nProvision of accessible and affordable maternity\\n\\ncare facilities\\n\\nThe second most common malignancy and the\\nleading cause of death among women in developing\\ncountries\\n- 75% of the patients present in advanced stages; lack of\\norganized screening programmes for detection of the pre-\\nclinical stages in many countries\\n\\nAetiology not known but several risk factors have\\nbeen implicated:\\n\\nEarly sexual exposure\\nMultiple sexual partners\\nApromiscuous male partner\\nHistory of sexually transmitted infections\\n\\nparticularly Human Papilloma Virus infection;\\nHerpes simplex type 2; chlamydiae\\n\\nEarly first child birth\\nHigh parity\\n\\nAntihistamine (chlorphenamine injection),\\nepinephrine and hydrocortisone injection must be\\navailable: iron dextran could cause severe\\nanaphylaxis\\n\\nth\\n\\nnd\\n\\nPrevention\\n\\nCANCER OF THE CERVIX\\nIntroduction\\n\\nAetiology/risk factors\\n\\nLow socio-economic status\\nSmoking\\nMicronutrient deficiency\\nOral contraceptive usage\\nPoor sexual hygiene\\n\\nTwo age groups with highest incidence: 35 - 40\\nyears; 45 - 55 years\\n\\nMay be asymptomatic\\n- Picked up in the early stage by routine PAP smear\\nscreening\\n\\nAbnormal vaginal bleeding\\n- Postcoital\\n- Contact\\n- Spontaneous\\n- Inter-menstrual\\n- Post-menopausal\\n\\nVaginal discharge\\n- Becomes offensive in advanced disease\\n\\nPyometria with uterine enlargement\\nHaemorrhagic, ulcerative or fungating lesion on\\n\\nthe cervix, with extension on to the vagina wall in\\nadvanced stages\\n\\nVesico-vaginal fistula in advanced stages\\nRecto-vaginal fistula in advanced stages\\nCachexia\\n\\n- The presence of a lesion on the cervix\\n\\nBased on :\\n- Typical history of risk factors\\n- Histological confirmation of malignancy\\n\\nEndometrial cancer\\nEndometrial hyperplasia\\nEndometrial polyps\\nEndometritis: particularly atrophic\\nChoriocarcinoma\\nCervicitis\\nCervical polyps\\nCervical erosion\\nVaginal lesions: vaginitis, vaginal malignancy\\nFunctioning tumours of the ovary leading to\\n\\nendometrial hyperplasia and vaginal bleeding\\nIatrogenic: hormonal drugs and IUCD in-situ\\nBlood disorders: bleeding dyscrasias, leukaemia\\n\\nPacked cell volume; haemoglobin concentration\\nUrinalysis\\nBlood Group\\nWhite cell count, differentials\\nElectrolytes and Urea\\nLiver function tests\\nMidstream urine specimen for microscopy, culture\\n\\nand sensitivity\\nChest radiograph\\nHIV screening\\n\\nClinical features\\n\\nPresumptive Diagnosis\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nIntravenous urography\\n\\nExamination UnderAnaesthesia\\n- Staging and Biopsy\\n\\nTreatment of invasive carcinoma of the cervix\\n- Surgery\\n- Radiotherapy\\n- Surgery plus radiotherapy\\n- Chemo-radiation\\nTreatment options will depend on\\n\\nThe skill of the surgeon\\nAvailability of facilities\\nThe stage of the disease\\nAge of the patient\\nAbility of available personnel to manage untoward\\n\\neffects of the modality of treatment chosen\\n\\nSurgery or radiotherapy (as primary modes of treatment\\nrespectively)\\n- Radiotherapy can be used as primary mode of\\ntreatment in all stages of the disease\\n\\nThis is for life\\nRegular cytology of vault smears for early\\n\\ndetection and prompt treatment of recurrence\\n\\nAdequate screening programmes:\\nPapanicolaou smear\\n\\nVisual inspection of the cervix after acetic acid\\nlavage (VIA)\\n\\nTesting for the human papilloma virus DNA\\nSpecific programmes targeted at eliminating or\\n\\nmitigating the effects of recognized risk factors\\n\\nArare but potentially serious clinical entity\\nOccurs in about 1% of all pregnancies\\n\\nIncidence and prevalence of all heart disease varies\\nfrom place to place\\n- Rheumatic heart disease is more commonly found in\\nless affluent societies while congenital heart disease now\\naccounts for approximately 50% of cardiac diseases in\\npregnancy in the UK\\n\\nRheumatic heart diseases\\n- Mitral >Aortic > Tricuspid > Pulmonary\\n\\nCardiomyopathies\\n- Particularly peripartum cardiomyopathy which\\ncould be either congestive or obstructive\\n\\nPre-existing hypertensive heart disease\\nIschaemic heart disease\\n\\nAcyanotic heart disease\\n\\nPrinciples of management\\n\\nFollow up\\n\\nPrevention\\n\\nCARDIAC DISEASE IN PREGNANCY\\nIntroduction\\n\\nStages I to IIA\\n\\nTypes of cardiac diseases in pregnancy\\nAcquired\\n\\nCongenital\\n\\nChapter 13: Obstetrics and Gynaecology Standard Treatment Guidelines for Nigeria 2008\\n\\n153 154\\n\\n\\n\\n- Atrial septal defect, ventricular septal defect,\\npatent ductus arteriosus, etc\\n\\nCyanotic heart disease\\n- Tetralogy of Fallot, Eisenmenger\\'s syndrome\\n\\nAcquired forms of cardiac disease appear to be more\\nlethal in association with pregnancy, in women aged 25\\nyears or more, and in third or later pregnancies\\n\\nCongenital malformations are more prevalent in\\nyounger women and in those of lower parity\\n\\nThe New York Heart Association Guidelines (1965)\\nis used.\\n- Relies on the cardiac response to physical activity;\\nmay not bear any relationship to the extent of the lesion\\npresent\\n\\nClasss 1\\n- No limitation of physical activity\\n\\nClass 2\\n- Slight to moderate limitation of physical activity:\\nordinary day-to-day activities cause dyspnoea\\n\\nClass 3\\n- Marked limitation of activity. Minimal exertion\\ncauses dyspnoea\\nClass 4\\n- Symptoms at rest; unable to carry out any\\nphysical activity without dyspnoea; orthopnoea\\nmay be present\\n\\nPalpitations\\nNasal stuffiness\\nDizziness; light headedness; syncope\\nEpigastric or subxiphoid pain; bloating, heartburn\\nHeat intolerance, sweating and flushing\\n\\nPlethoric facies\\nOdema (legs; occasionally hands and face)\\nVaricose veins\\nBounding pulses and capillary pulsations\\nCapillary telangiectasia\\nProminent jugular venous pulsations\\nLateral displacement of cardiac apex\\nSinus tachycardia; ectopic beats\\nThird heart sound\\n\\nWidely split S and S heart sounds\\n\\nMurmurs\\nCrepitations\\n\\nFull Blood Count\\nSerum Electrolytes, Urea and Creatinine\\nUrinalysis\\nBlood Glucose\\nEchocardiography (Doppler)\\nElectrocardiography\\nSerial blood cultures (if infective endocarditis is\\n\\nClinical features\\n\\nOther symptoms\\n\\nSigns\\n\\nInvestigations\\n\\nSeverity of heart disease in pregnancy\\n\\n1 2\\n\\nsuspected)\\n\\nFully evaluate patient in conjunction with a\\ncardiologist\\n\\nSurgically correct any defect that is amenable\\nCounsel on the following points:\\n\\n- Risk of maternal death\\n- Possible reduction of maternal life expectancy\\n- Risk of foetus developing congenital heart disease;\\nfoetal growth restriction\\n- Possibility of pre-term labour\\n- Need for frequent hospital attendance; possibly\\nadmission\\n- Need for intensive maternal and foetal monitoring in\\nlabour\\n\\nJoint management with the cardiologist\\nExtreme vigilance: most features of cardiac failure are\\n\\npresent in pregnancy\\nWatch out for respiratory tract infection or urinary tract\\n\\ninfection and treat aggressively\\nWatch out for anaemia, obesity and multiple\\n\\ngestations for intensive care. Intensive care also\\nrequired when other medical or psychological\\nconditions co-exist\\n\\nExamination:\\n- Ankle and sacral oedema\\n- Pulse rate and rhythm\\n- Blood pressure\\n- Jugular venous pressure\\n- Basal crepitations\\n- Symphysio-fundal height (SFH) measurement\\n\\nCompetent dental care:\\n- Full inspection\\n- Advise on oral hygiene\\n- Dental treatment e.g. tooth extraction should be done\\nunder antibiotic cover to prevent infective endocarditis\\n\\nAdmission\\n- Individualised; usually when complications or\\nintercurrent illnesses occur\\n\\nElastic stockings or tights to prevent pooling of blood\\nin the veins of the lower limb\\n\\nAnticoagulation\\n- Indicated for example in patients with congenital\\nheart disease, with pulmonary hypertension; artificial\\nvalve\\nreplacements; those with atrial fibrillation\\n- Heparin safer in pregnancy; warfarin is teratogenic\\n\\nTermination of pregnancy and sterilization\\n- Best option in severe debilitating cases\\n\\nManage as if non-pregnant (in conjunction with a\\ncardiologist)\\n\\nChest radiograph is better avoided in pregnancy\\nManagement\\n\\nSupportive measures\\n\\nPre-pregnancy\\n\\nAntenatal Care\\n\\nCongestive Cardiac Failure\\n\\nFoetal surveillance:\\n- Ultrasound scan particularly for cardiac anomaly at\\n22 weeks\\n\\nDelivery:\\n- Either for maternal or foetal indications\\n\\nCardiac surgery in pregnancy if indicated\\n\\nAvoid induction of labour if possible\\nProphylactic antibiotics to prevent bacterial\\n\\nendocarditis\\nCareful fluid balance\\nAvoid the supine position\\nEpidural anesthesia by a senior anesthetist\\n\\nShorten 2 stage with low cavity forceps delivery\\nOxytocin for third stage; ergometrine is\\n\\ncontraindicated\\nOxygen should be available and used if needed\\n\\nMortality:\\n- 25 - 50% in Eisenmenger\\'s syndrome; 5% in\\ntetralogy of Fallot; 1% in rheumatic heart disease\\n\\nCongestive cardiac failure:\\n- Greatest risk in the immediate post-partum period\\n\\nRheumatic heart disease:\\nIntrauterine growth restriction; pre-term delivery\\n\\nCyanotic congenital heart disease:\\nPoor outcomes; up 40% foetal loss\\n\\nUncorrected coarctation of aorta:\\nFoetal growth restriction in > 10% of cases\\nPre-maturity\\nSmall for gestation age\\nIntrauterine growth restriction\\nIntrauterine foetal death\\n10 - 15% chance of baby having congenital heart\\n\\ndisease\\n\\nThe occurrence of generalized convulsions,\\nassociated with signs of pre-eclampsia during\\npregnancy, labour, or within 7 days of delivery; not\\ncaused by epilepsy or other convulsive disorders\\n\\nReferred to as atypical eclampsia if it occurs\\n- In the absence of high blood pressure\\n- After 7 days post-partum\\nIncidence is widely variable. Worldwide range reported\\nto be 1 in 100 - 1 in 3,448 pregnancies\\n\\nIn Nigeria, it is commoner among unbooked patients\\n\\nNot exactly known. Its precursor is pre-eclampsia\\nA disease of primigravidae, or multigravidae with\\n\\npregnancy for a new consort\\n\\nManagement of labour in women with cardiac disease\\n\\nnd\\n\\nComplications\\n\\nECLAMPSIA\\nIntroduction\\n\\nAetiology\\n\\nMaternal\\n\\nFoetal\\n\\nClinical features\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nManagement\\n\\nTreatment objectives\\n\\nGeneralized tonic-clonic seizures, usually heralded\\nby:\\n- Headaches\\n- Dizziness and blurring of vision\\n- Nausea and vomiting\\n- Epigastric pain\\n- Rapidly progressive oedema\\n\\nExaggerated tendon reflexes\\nOliguria\\nHypertension\\nWorsening proteinuria\\n\\nCerebral haemorrhage\\nDisseminated intravascular coagulopathy\\nRenal failure\\nCardiopulmonary failure\\nLiver dysfunction (as in HELLPsyndrome)\\nFatality\\n\\nPrematurity\\nIntrauterine growth restriction\\nIntrauterine foetal death\\nBrain damage\\nDeath\\n\\nIdiopathic epilepsy: sometimes accompanied by\\ntransient proteinuria\\n\\nCerebral malaria: sometimes accompanied by\\nhypertension and albuminuria\\n\\nPneumococcal meningitis\\nHyper and/or hypo-glycaemia, particularly among\\n\\ndiabetics\\nTerminal phase of severe anaemia\\nTerminal phase of hepatic failure\\nSevere infections and septicaemia\\nOthers:\\n\\n- Uraemia\\n- Brain tumours or abscesses\\n- Cerebral haemorrhage\\n- Poisoning (accidental or intentional)\\n- Hysteria\\n\\nHaemoglobin concentration/haematocrit\\nBedside crude clotting time\\nHaemoglobin genotype\\nPlatelet count\\nBlood Group\\nSerum Urea and Electrolytes; Creatinine\\nLiver function tests\\nUrinalysis\\n\\nStabilise the patient\\n\\nMaternal\\n\\nFoetal\\n\\nManage in conjunction with the physician\\n\\nChapter 13: Obstetrics and Gynaecology Standard Treatment Guidelines for Nigeria 2008\\n\\n155 156\\n\\n\\n\\nDeliver foetus by the safest and most expeditious\\nroute\\n\\nPrevent complications\\n\\nControl (and prevent further) fits\\nControl blood pressure\\nMaintain the airway\\nEnsure adequate urinary output\\nMonitor\\n\\nIntravenous diazepam\\n- 10mg stat to abort seizures or prevent fits during\\nexamination; then\\n- Intravenous infusion of glucose 5% in water with 40\\nmg of diazepam added, and titrated against the patient\\'s\\nlevel of consciousness\\n\\nMagnesium sulfate (see details below)\\n\\nCalcium gluconate should always be available to\\nmanage toxicity\\n\\nIntravenous infusion of magnesium sulfate\\n- Loading dose: 4 g by slow intravenous injection over\\na period not less than 5 minutes (preferably over 10 - 15\\nminutes)\\n- Maintenance: 10 g in 1litre of sodium chloride 0.9%,\\ngiven by intravenous infusion at a rate of 1g per hour\\n\\nThe intramuscular magnesium sulfate (Pritchard)\\nregimen\\n- Loading dose: 4 g by slow intravenous injection over\\na period not less than 5 minutes, then 10 g\\nintramuscularly, 5 g by deep intramuscular injection\\ninto each buttock\\n- Maintenance therapy: 5 g by deep intramuscular\\ninjection, 2.5 g in each buttock every 4 hours\\n\\nContinue for 24 hours after last convulsion, or\\ndelivery.\\n\\nMagnesium sulfate\\n- 2 - 4 g intravenously over 5 minutes\\n- Give lower dose (2 g) if the patient is small and/or\\nweight is less than 70 kg\\n\\nContinue with intravenous infusion or give the next\\nintramuscular dose if\\n- Patellar reflexes are normal\\n- Respiratory rate is > 16 cycles/minute\\n- Urine output is > 25 mL/hour (or > 100 mLin 4 hours)\\n\\nConsider reducing the dose if\\n- Renal function is impaired\\n- Respiratory depression occurs\\n- Urine output is < 100 mLin 4 hours\\n\\nMore frequent monitoring is required in the first two\\n\\nStabilization\\n\\nControlling fits\\n\\nMonitoring during magnesium sulfate therapy\\n\\nTreatment packs are contained in cardboard boxes\\ncontaining magnesium sulfate for the loading dose, 24-\\nhour maintenance therapy and treatment of one\\n(recurrent) convulsion. Syringes, swabs, drip sets and\\nfluids also contained in treatment packs;\\n-\\n\\nRecurrent convulsions\\n\\nonly\\n\\nhours on intravenous therapy\\n\\nAbsent patellar reflexes:\\nStop magnesium sulfate treatment\\nAdminister oxygen by face mask\\n1 g calcium gluconate by slow intravenous injection\\n\\nIf respiratory rate is abnormal:\\nStop further magnesium sulfate\\n\\nIf there are no respiratory abnormalities or abnormal\\npatellar reflexes:\\n\\nReduce the dose by half\\nRespiratory arrest:\\n\\nStop magnesium sulfate treatment\\nIntubate and ensure ventilation (manage with the\\n\\nanaesthetist)\\nCalcium gluconate 1 g by slow intravenous injection\\n\\nIntravenous hydralazine\\n- 5 mg bolus slowly over 15 minutes, stat. Further\\nboluses can be given every 20 - 30 minutes as long as\\ndiastolic blood\\npressure is 110 mg and above\\nOr:\\n\\nLabetalol\\n- 20 mg intravenously as a bolus\\n- Repeat after 15 - 20 minutes (if need be, increasing\\nthe doses)\\n\\nIntermittent suction of the nostrils and oropharynx\\nInsert an airway\\n\\nIndwelling Foley\\'s catheter for strict fluid input and\\noutput monitoring\\n\\n- Quarter-hourly vital signs\\n- Record any further fits\\n\\nInduction of labour\\n- Is the first option if the cervix is favourable,\\nparticularly if the patient is not yet in established labour\\n- Can be done by the use of escalating doses of oxytocin\\ninfusion or with misoprostol tablets\\n\\nElective forceps delivery\\n- Should be done if patient is in the second stage to\\nreduce the stress and cardiovascular changes, especially\\npeaks of elevated blood pressure that accompany\\nexpulsive efforts at this stage in labour\\nEmergency Caesarean section is indicated when:\\n- Cervix is unfavourable for induction\\n- There is foetal distress\\n- Patient is unconscious (unless delivery is imminent)\\n- Vaginal delivery is unlikely within 6 - 8 hours from the\\nonset of the first eclamptic fit and there is an obstetric\\nindication for a Caesarean section\\n\\nContinue parenteral anticonvulsant for another 24\\n\\nMagnesium toxicity\\n\\nDelivery\\n\\nPost partum\\n\\nControl of blood pressure\\n\\nThe airway\\n\\nUrinary output\\n\\nMonitoring\\n\\nhours after delivery (or after last seizure), whichever\\ncomes first\\n\\nAdequate antenatal, intrapartum and postpartum care\\nEarly detection of pregnancy-induced hypertension\\nAggressive management\\nThis is the \\'gold standard\\' towards achieving good\\n\\nfoetal and maternal outcomes\\n\\n- Occurs in 15.6% of cases\\n- Adequate counselling on the need for early booking,\\nregular antenatal clinic attendance and hospital delivery\\nin subsequent deliveries required\\n\\nPregnancy in which the conceptus implants either\\noutside the uterus (fallopian tube, ovary or abdominal\\ncavity) or in an abnormal position within the uterus\\n(cornua, cervix, angular and rudimentary horn)\\n\\nThe most common surgical emergency in women in\\nmany developing countries\\n\\nAsubstantial cause of maternal mortality\\n- Rapidity with which haemorrhage and shock occur\\n- Pre-rupture diagnosis is elusive, with consequent delay\\nin surgical management\\n\\nThe clinical subsets include:\\nAcute ectopic gestation\\n\\n- 25% or less of cases\\nSub-acute ectopic gestation\\n\\n- 75% of cases\\n“Silent” ectopic/chronic ectopic gestation\\n\\nAmenorrhoea\\nFeatures of acute abdomen particularly lower\\n\\nabdominal pain\\nVaginal bleeding or brownish discharge\\nSevere pallor\\nShoulder tip pain\\nDifficulty with sitting on hard surfaces\\nFeatures of shock with cardiovascular collapse:\\n\\nhypotension and tachycardia\\nThe uterus is slightly enlarged with tenderness on one\\n\\nside\\n- Some advise that examination should be avoided if\\nthere is a strong suspicion of an ectopic pregnancy\\n\\nPositive cervical excitation tenderness\\n\\nSlow-leaking ectopic prior to rupture, with most of the\\nsigns and symptoms of acute ectopic gestation but in the\\nmildest form\\n\\nAsymptomatic\\n- May just be picked up during a pelvic examination in\\nthe course of booking or antenatal clinic, or found on\\n\\nPrevention\\n\\nECTOPIC PREGNANCY\\nIntroduction\\n\\nClinical features\\n\\nRe-occurence\\n\\nAcute Ectopic Gestation\\n\\nSub-acute Ectopic Gestation\\n\\n“Silent”/Chronic Ectopic Gestation\\n\\nultrasound for another pelvic pathology\\n\\nShock\\nSterility (with the loss of both tubes)\\nOften requires blood transfusion (with its attendant cost\\n\\nand risk of blood-borne infections)\\n5 - 20% risk of having another ectopic gestation\\nFatality\\n\\nRequires a high index of suspicion particularly in the\\ncase of atypical, slow-leaking or chronic ectopic\\ngestation where diagnosis could be difficult\\n\\nFor unruptured ectopic pregnancy:\\nAcute pelvic inflammatory disease\\nAdnexial torsion\\nIncomplete abortion\\nEndometriosis\\nDegenerating uterine fibroid\\nAcute appendicitis\\nAccidented ovarian cysts\\n\\nHaemoglobin concentration/packed cell volume\\nBlood grouping and cross matching\\nUrinalysis\\nUltrasound scan of the pelvis/abdomen\\nSerum ß-hCG (where available) especially in silent\\n\\ncases\\nParacentesis abdominis (should be considered)\\nLaparoscopy\\n\\n- Final arbiter when the diagnosis is in doubt\\n\\nDepend on the clinical subset\\nPreserve maternal life\\n\\nImmediate resuscitation (fluids/blood)\\nStop haemorrhage: by surgery\\nReplace lost blood\\n\\nSurgery\\n- Salpingectomy (total or partial) for ruptured ectopic\\npregnancy\\n- Partial salpingectomy if the remaining segment of the\\ntube is about 4 cm long; this could be used for\\nreconstructive surgery subsequently\\n- Salpingostomy for unruptured cases\\n\\nNon-surgical options\\n- Used in unruptured cases: expectant management and\\nmedical agents\\n\\nExpectant management\\n- Monitor pregnancy by -hCG levels\\n- Vaginal scans: spontaneous resorption can occur\\nprovided gestation sac is < 4 cm and hCG is < 1,500 IU\\n\\nMedical treatment\\n- Methotrexate\\nAdministered systemically or locally to induce\\n\\nComplications\\n\\nDiagnosis\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nGeneral principles and treatment modalities\\n\\nAcute ectopic\\n\\nChapter 13: Obstetrics and Gynaecology Standard Treatment Guidelines for Nigeria 2008\\n\\n157 158\\n\\n\\n\\ndissolution of trophoblastic tissue ( )\\n- Hyperosmolar glucose solution, potassium chloride\\nand prostaglandins can also been used\\n\\nAuto transfusion\\n- During surgery for ectopic gestation; very important\\nin developing countries\\n- Inadequate blood banking services\\n- The risks of transfusion with donated blood are\\navoided\\n- Use only fresh blood\\n\\nOn discharge:\\n- Counsel for contraception and advise to report\\nimmediately to the hospital if a pregnancy is suspected\\nso that its site can be confirmed\\n\\nAclinical situation in which vomiting in early pregnancy\\nconsidered to be physiological becomes persistent or\\nsevere enough to disturb the patient\\'s health and/or\\nrequire hospitalization\\n\\nOccurs in approximately a third to 50% of women\\n- Often the first sign of pregnancy, beginning at\\n\\nabout the 6 week and stops spontaneously before\\n\\nthe 14 week\\nGenerally limited to the early morning but may\\n\\noccur at other times of the day\\nCause is essentially unknown, but hypotheses\\ninclude\\n\\nHormonal:\\n- Increased sensitivity to placental hormones such\\nas hCG, estrogen or progesterone\\n\\nPsychogenic :\\n- The woman thinks she should have early morning\\nsickness because generations before her have had it\\n\\nPersistent and severe vomiting that leads to\\nelectrolyte and nutritional derangements\\n\\nIt is a diagnosis of exclusion. Concerted effort must be\\nmade to exclude the under listed causes of pathological\\nvomiting:\\n\\nMultiple gestations\\nHydatidiform mole\\nMalaria in pregnancy\\n\\nGastrointestinal disorders:\\nHeartburn due to hiatus hernia: a common cause of\\n\\nvomiting in late pregnancy\\nEnteritis\\nAppendicitis\\nPeptic ulcer disease\\nHepatitis\\nAcute fatty liver of pregnancy\\nPancreatitis\\nCholescystitis\\nUrinary tract disorders: pyelonephritis\\n\\nHYPEREMESIS GRAVIDARUM\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nth\\n\\nth\\n\\nRu 486 Acute polyhydramnios\\n- Commonly associated with monozygotic twinning\\nand diabetic pregnancies\\n\\nPre-eclampsia\\nAccidents to ovarian cysts\\n\\n- Torsion, haemorrhage, infection and rupture\\nRed degeneration in a fibroid\\n\\nBiochemical abnormalities\\n- Usually sequel to vomiting, starvation and\\ndehydration\\n- Ketosis, electrolyte imbalance (alkalosis and\\nhypokalaemia); vitamin deficiencies\\nIn neglected or poorly managed cases:\\n\\nSevere weight loss\\nTachycardia\\nHypotension\\nOliguria\\nNeurologic disorders from vitamin B deficiency\\n\\nRetinal haemorrhages\\nJaundice (from hepatic necrosis)\\nOesophageal tears and spontaneous rupture of the\\n\\noesophagus\\nMendelson\\'s syndrome\\nFoetal loss\\nMaternal mortality\\n\\nFull Blood Count with differentials\\nUrea, Electrolytes and Creatinine\\nLiver function tests\\nMidstream urine for microscopy, culture and\\n\\nsensitivity\\nUrinalysis for ketones\\nBlood film for malaria parasites\\nUltrasound scan of the pelvis/abdomen\\n\\nAdmit\\nStrict intake-output monitoring\\nIntravenous fluid therapy to:\\n\\n- Correct electrolyte disturbances\\n- Provide calories\\n- Rehydrate the patient\\n\\nAnti-emetics\\nThose which have been proven not to be teratogenic:\\n- Meclozine 25 mg orally\\nOr:\\n- Cyclizine 50 mg orally\\nOr:\\n- Promethazine 25 mg orally\\n\\nTotal parenteral nutrition\\n- In severe cases\\n\\nIn persistent and intractable cases with significant\\nmaternal complications, termination of pregnancy may\\nbe considered\\n\\nComplications\\n\\nInvestigations\\n\\nManagement\\n\\n1\\n\\nAll of these are taken three times daily\\n\\nJAUNDICE IN PREGNANCY\\nIntroduction\\n\\nUsually indicates a liver/biliary disorder and becomes\\nclinically apparent when the serum bilirubin exceeds 2 -\\n2.5 mg/dL\\n\\nMany indicators of liver disease in the non-pregnant\\nState are normal findings in pregnancy. These\\n\\ninclude:\\n- Spider naevi\\n- Decreased plasma albumin\\n- Increased alkaline phosphatase\\n\\nChapter 13: Obstetrics and Gynaecology Standard Treatment Guidelines for Nigeria 2008\\n\\nIMMUNIZATION SCHEDULES\\nIntroduction\\n\\nTetanus immunization for the pregnant woman is geared towards protecting the mother (and baby) against tetanus\\n\\nTetanus Immunization Schedule in Pregnancy\\n\\nTIMING OF IMMUNIZATION\\n\\n1 dose at booking or on 1 contact\\n\\n2 dose at 4 weeks after 1 dose\\n\\n3 dose at 6 months after 2 dose\\n\\n4 dose at 1 year after 3 dose or in next\\npregnancy\\n\\n5 dose at 1 year after 4 dose or in next\\npregnancy\\n\\nst st\\n\\nnd st\\n\\nrd nd\\n\\nth rd\\n\\nth th\\n\\nPROTECTION OFFERED\\n\\nConfers no protection\\n\\nConfers protection for 3years\\n\\nConfers protection for 5years\\n\\nConfers protection for 10\\nyears\\n\\nConfers protection for life\\n\\nAt Delivery\\n\\nAt Birth\\n\\n6 Weeks\\n\\n10 Weeks\\n\\n14 Weeks\\n\\n9 Months\\n\\n15 Months\\n\\nVitamin A to Mother\\n\\nBCG; POLIO ; HBV\\n\\nDPT ; POLIO ; HBV\\n\\nDPT ; POLIO\\n\\nDPT ; POLIO ; HBV\\n\\nMEASLES; YELLOW FEVER; 1\\nDose Vitamin A\\n\\nVitamin A\\n\\n0 1\\n\\n1 1 2\\n\\n2 2\\n\\n3 3 3\\n\\n1\\n\\n2\\n\\nst\\n\\nImmunization and VitaminASchedule\\n\\n159 160\\n\\n\\n\\n- Increased serum lipids\\nProthrombin time, transaminases and bilirubin are\\n\\nunaltered in normal pregnancy\\nJaundice occurs in about 1 in 1,500 - 2,000 pregnancies\\n\\nHyperemesis gravidarum\\nPre-eclampsia and eclampsia as seen with HELLP\\n\\nsyndrome\\nAcute yellow atrophy (acute fatty liver in pregnancy;\\n\\nacute hepatic failure)\\nIntra-hepatic cholestasis of pregnancy\\nCholestasis in pregnancy\\nGallstones\\n\\nViral hepatitis\\nHaemolytic jaundice\\nAdverse reactions to drugs e.g. chlorpromazine,\\n\\ntetracycline\\nCogenital hyperbilirubinaemias such as Dubin-\\n\\nJohnson syndrome\\nLiver cirrhosis\\n\\nA rare and serious disorder associated with high\\nmortality\\n\\nOccurs in the order of 1: 10,000 pregnancies\\nUnknown aetiology\\nTypically noted in primigravidae, occurring after the\\n\\n30 week or few days after birth\\nThe jaundice is classically obstructive\\nOnset usually sudden with\\n\\n- Abdominal pain (right upper quadrant)\\n- Headaches\\n- Nausea and vomiting\\n- Progressive jaundice\\n- Encephalopathy\\n- Hypertension is not uncommon\\n\\nPerilobular fatty infiltration of the liver cells\\n\\nEarly diagnosis is mandatory\\n- Clinical features with evidence of deranged LFTs and\\nof renal failure\\n\\nThe management it requires a combined team of\\nobstetrician, physician and anesthetist\\n\\nDeliver the baby as soon as possible (frequently by\\nCaesarean section)\\n\\nTransfusion with blood, fresh frozen plasma, platelets\\nas indicated\\n\\nDialysis\\n\\nAetiology\\n\\nClinical features\\n\\nHistology\\n\\nManagement\\n\\nDefinitive treatment\\n\\nSupportive measures\\n\\nComplications\\n\\nAetiology peculiar to pregnancy\\n\\nAetiology not peculiar to pregnancy\\n\\nAcute yellow atrophy\\n\\nth\\n\\nThere is no place for liver biopsy because of bleeding\\ncomplications\\n\\nDisseminated intravascular coagulopathy\\nHypotension\\n\\nSignificant risk of maternal and foetal death due to:\\nMaternal liver failure\\nMetabolic disturbance\\nEncephalopathy\\nOverwhelming haemorrhage associated with clotting\\n\\ndefects\\n\\nGood\\nPost-natally, liver function returns to normal over a few\\nweeks and there is no evidence of long-term liver\\ndysfunction\\n\\nUncommon, in the order of 1: 2,000 pregnancies\\nCommon in certain southern American countries\\n\\nparticularly Chile\\nPresents commonly in late third trimester, after\\n\\n36weeks\\nClinically significant because of its association with\\n\\nIUGR and IUFD (mechanism unclear)\\nIt is not as a rule associated with maternal\\n\\ncomplications\\n\\nGeneralized pruritus\\nDecreased foetal movements\\nUpper abdominal pain\\nDark urine\\nSteatorrhea\\nOccasionally there is jaundice (particularly in the later\\n\\nstages of the disease)\\n\\nLiver function tests:\\n- Mildly deranged\\n- Serum bilirubin and bile salts may be elevated\\n\\nViral hepatitis\\nEarly HELLPsyndrome\\nAcute fatty liver\\n\\nCareful maternal follow-up with LFTs\\nFoetal surveillance: by growth (serial USS biometry)\\n\\nand wellbeing (CTG) monitoring\\nIf all is well induce at 38 weeks\\n\\n(Difficult to manage)\\nTopical agents offer little help\\nColestyramine\\n\\n- To bind bile salts\\nVitamin K\\n\\n- To decrease bleeding tendencies\\n- (Colestyramine binds fat soluble vitamins)\\n\\nAntihistamines\\n- May offer brief respite\\n\\nUrsodeoxycholic acid and colestyramine (orally)\\n\\nPrognosis\\n\\nClinical features\\n\\nInvestigations\\n\\nDifferential diagnoses\\n\\nManagement\\n\\nCholestasis of pregnancy\\n\\nManagement of associated pruritus\\n\\ndecrease itching and normalize liver function\\n10 - 15 mg/kg daily in 2 - 4 divided doses\\n\\n10 - 15 mg/kg twice daily; total\\ndose may be given in 3 divided doses\\n\\nQuite high\\n\\nGood\\n- Complete recovery in days to weeks\\n\\nIntermittent bilirubinaemia (conjugated)\\nOften chronic and familial\\nNo itching, usually asymptomatic\\nCause is unknown\\n\\nNone is required\\n\\nAlso termed \\'recurrent obstructive jaundice\\' or\\n\\'idiopathic cholestasis\\'\\n\\nThought to be due to the effect of high estrogen levels\\non the liver, which results in decreased conjugation of\\nbilirubin\\n\\nArare condition\\n- Incidence of 1:500 pregnancies\\n\\nMore commonly seen in Scandinavians\\nIts exact etiology is unknown\\n\\nIntense pruritus due to retention of bile salts\\nThe most common presenting symptom and may occur\\n\\nin the absence of other symptoms\\nOnset of symptoms usually in the third trimester\\nJaundice is not often seen\\n\\nBilirubinuria\\nElevated bile acids\\nElevated alkaline phosphatase\\nElevated liver transferase enzymes\\nProthrombin time\\n\\nHaemorrhage\\nPreterm labour\\nSteatorrhea\\n\\nFoetal distress\\nStill-birth\\nPerinatal death\\nPrematurity and its problems\\nMeconium staining of the liquor\\n\\nCareful maternal follow-up with LFTs\\nFoetal surveillance: by growth (serial USS biometry)\\n\\nAdult:\\nChild 1 month - 18 years:\\n\\nAlways exclude viral disease, gallstones and treatment\\nwith chlorpromazine\\n\\nRecurrence\\n\\nPrognosis\\n\\nTreatment\\n\\nClinical features\\n\\nInvestigations\\n\\nComplications\\n\\nManagement\\n\\nDubin-Johnson syndrome\\n\\nIntra-hepatic cholestasis of pregnancy\\n\\nMaternal\\n\\nFoetal\\n\\nand well-being (CTG) monitoring\\nIf all is well, induce at 38 weeks\\n\\n- See Cholestasis of pregnancy\\n\\nRisk of recurrence is 50%\\nCan be precipitated by oestrogen-containing oral\\n\\ncontraceptive pills\\n\\nThe most common cause of jaundice in pregnancy,\\naccounting for about 40% of the causes\\n\\nIncidence during pregnancy is probably no more than\\nin the normal population\\n\\nPregnancy does not alter the course of the disease\\nHepatitisAvirus does not affect the foetus\\n\\n- Unlike other hepatotrophic viral infections, which\\ncarry a significant risk of vertical transmission\\n(particularly in the third trimester)\\n\\nAsevere attack may influence foetal outcome\\n- Slight increase in premature labour and stillbirths (as\\nseen in any severe medical illness)\\n\\nAvoid any further damage to the liver by drugs\\nBed rest\\nAdequate nutrition\\nIf hepatitis B is present then the infant requires\\n\\nprotection with immunoglobulins against HBsAg\\n- Hepatitis B immunoglobulin by intramuscular\\ninjection\\n\\n200 units as soon as possible after birth\\n1 month - 5 years: 200 units; 5 - 10 years: 300\\n\\nunits; 10 - 18 years: 500 units\\nAvoid breastfeeding\\nDelivery room personnel must exercise great care in\\n\\ndealing with these patients, as all their body fluids are\\nhighly infectious\\n\\nImmediate delivery if hepatitis becomes fulminant\\n\\nAscending pelvic infection involving the upper genital\\ntract\\n\\nUsually involves sexually transmitted organisms\\ne.g. and\\n- It may also be caused by organisms endogenous to the\\nlower genital tract\\n\\nIn severe cases, organisms may migrate via the\\nperitoneum to the upper abdomen causing perihepatic\\nadhesions: the so- called “violin strings” (Fitz-Hugh-\\nCurtis syndrome)\\n\\nResponsible for significant morbidity in women,\\naccounting for about 30% of all gynaecological\\nadmissions in sub-SaharanAfrica\\n\\nIt is thought that 3% of women have Pelvic\\n\\nManagement of pruritus\\n\\nRecurrence\\n\\nViral hepatitis\\n\\nTreatment\\n\\nPELVIC INFLAMMATORYDISEASE\\nIntroduction\\n\\nNeonate:\\nChild\\n\\nNeisseria gonorrhoeae Chlamydia trachomatis\\n\\nChapter 13: Obstetrics and Gynaecology Standard Treatment Guidelines for Nigeria 2008\\n\\n161 162\\n\\n\\n\\nInflammatory Disease (PID) during their lifetime\\n\\nAge:\\n- Peak incidence between 15 - 25 years\\n\\nSexual activity:\\n- Multiplicity of sexual partners\\n\\nUse of intrauterine contraceptive devices :\\n- Usually within the first 4 months of use\\n\\nPrevious episode(s) of PID\\n\\n(the Westrom triad):\\nLower abdominal pain and tenderness\\nCervical excitation tenderness\\nAdnexial tenderness\\n\\nFever ( 38 C)\\nLeucocytosis\\nPurulent vaginal discharge\\nAdnexial mass\\n\\nBased on the presence of the Westrom triad of\\nsymptomatology one of the minor criteria\\n\\nConfirmation by demonstration of causative\\norganism(s) on microscopy, culture and sensitivity\\ntesting\\n\\nAcute appendicitis\\nOvarian cyst accident\\nEndometriosis\\nUrinary tract infections\\nRenal disorders (e.g. nephrolithiasis)\\nPelvic adhesions\\nLower lobe pneumonia\\nEctopic gestation\\n\\nPelvic abscess\\nSepticaemia\\nChronic pelvic pain\\nEctopic gestation\\nInfertility\\nFitz-Hugh-Curtis syndrome\\nRecurrence (about 25% rates)\\n\\nPacked cell volume\\nHaemoglobin genotype\\nBlood Group\\nWhite Blood Cell count\\nElectrolytes and Urea\\nMidstream urine microscopy, culture and sensitivity\\nEndocervical swab\\nHigh vaginal swab culture: to exclude trichomoniasis,\\n\\nbacterial vaginosis\\nUrethral swab\\nUltrasound scan: to exclude cyesis, ectopic gestation,\\n\\nadnexial mass (e.g. ovarian mass)\\n\\nRisk factors\\n\\nClinical features\\n\\nDiagnosis\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nMajor criteria\\n\\nMinor criteria\\n\\nplus\\n\\n0\\n\\nIndications for admission\\n\\nUncertain diagnosis\\nIntolerance of oral medication or non-response to\\n\\noutpatient therapy\\nPresence of a pelvic mass\\nPresence of an intrauterine device\\nUpper abdominal pain\\nNon-adherence to therapy\\nPregnancy\\nNulliparity\\n\\nRehydrate adequately\\nEradicate the infecting organism(s)\\nPrevent complications\\n\\nAppropriate antibiotics for an adequate period\\n- The antibiotic chosen should cover all possible\\ncausative organisms while awaiting culture/sensitivity\\nresults\\nOut patient therapy while awaiting culture results:\\n\\nCeftriaxone (or equivalent cephalosporin)\\n- 1 g intramuscularly stat\\nPlus:\\n\\nDoxycycline\\n- 100 mg orally every 12 hours for 14 days\\nPlus or minus:\\n\\nMetronidazole\\n- 400 mg orally every 12 hours for 14 days\\n\\nIf no response in 48 - 72 hours\\n- Admit, re-evaluate and give appropriate intravenous\\ntherapy\\n\\n- Ceftriaxone/doxycycline/metronidazole\\nOr:\\n- Clindamycin/gentamicin/metronidazole\\n\\nSubsequently, the patient should continue therapy with\\nDoxycycline\\n\\n- 100 mg orally every 12 hours\\nPlus:\\n\\nMetronidazole\\n- 400 mg orally every 8 hours for 10-14 days\\n\\nEncourage the use of barrier contraceptive with\\nspermicides\\n\\nModify risky sexual behaviour: avoid multiplicity of\\nsexual partners\\nContact tracing: to break the existing chain of infection\\n\\nand prevent recurrence\\nPrompt diagnosis and treatment to prevent long term\\n\\ncomplications\\n\\nPerformance of the act of sexual intercourse by force,\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nPrevention\\n\\nRAPE\\nIntroduction\\n\\nInpatient triple therapy\\n\\nTriple antibiotic regimen to be continued for 48 hours\\nafter the patient improves clinically\\n\\nduress, intimidation or without legal consent (as with a\\nminor)\\nA growing social disorder afflicting the poor and rich,\\nalike, with devastating and longstanding emotional\\nconsequences for the afflicted, family and society at\\nlarge\\nAn enormous societal problem that appears to be poorly\\nrecognized and grossly under-reported\\nAn average of one in five adult women may have\\n\\nexperienced sexual assault during her lifetime\\nAdult women are much more likely to be raped by a\\n\\nspouse, ex-spouse, or acquaintance than by a stranger\\nThe girl-child is much more likely to be raped by her\\n\\nclose male associates (non-strangers), not excluding her\\nfather, uncle, brother, cousin, neighbour, school teacher,\\nfamily driver, security personnel, and even faith-based\\ninstructor\\n\\nMental illness, alcohol and drug abuse appear to be\\npredisposing factors; neglect and inattentiveness to the\\nneeds of the girl-child also contribute\\n\\nIndirect presentation\\nVague symptoms\\nPhysical features:\\n\\n- Perineal pain\\n- Bleeding per vaginam\\n- Bruised face/body\\n- Arthritis\\n- Disordered gait\\n\\nPsychological symptoms/disorders\\n- Sadness\\n- Depression\\n- Refusal to respond to simple questions\\n- Avoidance of eye contact\\n- School/work absenteeism\\n\\nVaginitis\\nThreatened abortion\\nDomestic violence\\nAlcoholism\\nDrug abuse\\nDepression\\n\\nVaginal/perineal swab for microscopy, culture and\\nsensitivity\\n\\nSemen: DNAanalysis\\n\\nUrinalysis; urine microscopy, culture and sensitivity\\nPregnancy test (blood)\\nHIV screening\\n\\nEvaluate safety of the patient\\nAssess and treat physical injuries\\nProvide emotional support\\nAssess and deal with the risk of sexually transmitted\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nEarly\\n\\nLate\\n\\ninfections and pregnancy\\n\\nReassure patient\\nProvide information about legal services\\n\\nTreat physical injury (as appropriate)\\nTreat STIs, UTI (as appropriate)\\nTreat HIV infection (if detected); Post-exposure\\n\\nprophylaxis if clinical situation so requires\\n- See section on HIV infection\\n\\nManage pregnancy (as appropriate)\\nTreat depression (if present)\\n\\nPromote Basic Education forAll\\nReduce adult illiteracy\\nPromote family/community moral values\\nPromote Basic Health Education\\nPromote safe shelter and neighbourhoods\\nEnforce existing laws on rape\\nLegislate for new laws to deter potential rapists and\\n\\nprotect females\\nPromote socio-economic well-being for all\\n\\nIt is important to document clinical findings\\nNon-drug measures\\n\\nDrug treatment\\n\\nPrevention\\n\\nChapter 13: Obstetrics and Gynaecology Standard Treatment Guidelines for Nigeria 2008\\n\\n163 164\\n\\n\\n\\nCHAPTER 14: RESPIRATORY SYSTEM\\n\\nACUTE EPIGLOTTITIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nA life threatening, rapidly progressive cellulitis of the\\nepiglottis that may cause complete airway obstruction\\n\\nMost common in children, in whom\\nis the most common pathogen\\n\\nIn adults, is often caused by and\\ngroupAstreptococcus\\n\\nFulminant presentation in children with:\\nFever\\nIrritability\\nCough\\nDysphonia\\nAirway occlusion\\nDysphagia\\nDyspnoea\\nDrooling\\nStridor\\n\\nAdults\\' symptoms are less fulminant, presenting with:\\nSore throat\\nDysphagia\\nDyspnoea\\n\\nAcute laryngitis\\nLaryngo-tracheo-bronchitis (Croup)\\n\\nComplete airways obstruction and asphyxiation\\n\\nLateral X-ray of the neck\\n“Thumb sign” appearance of the enlarged epiglottis\\n\\nBlood culture\\n\\nSafeguard the airway\\nControl infection\\n\\nCefuroxime\\n250 mg orally every 12 hours for 5 - 10 days\\n125 mg orally every 12 hours for 5 - 10 days\\n\\nOr:\\nCeftriaxone\\n\\n250 - 500 mg intramuscularly or intravenously\\nfor 5 - 10 days\\n\\nneonate, infuse over 60 minutes, 20 - 50 mg/kg\\ndaily (maximum 50 mg/kg daily)\\nChild under 50 kg: 20 - 50 mg/kg daily by deep\\nintramuscular injection or by intravenous injection over\\n2 - 4 minutes, or by intravenous infusion; up to 80 mg/kg\\n\\nHaemophilus\\ninfluenzae\\n\\nStrept. pneumoniae\\n\\nAbsence of hoarseness distinguishes acute epiglottitis\\nfrom acute laryngitis\\n\\nDo not view the epiglottis using a tongue depressor: this\\nmay cause laryngospasm, with complete respiratory\\nobstruction\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\ndaily in severe infections\\n\\nOxygen\\nSteam inhalation\\nNasotracheal intubation may be required\\nMaintain adequate caloric intake and hydration\\n\\nCefuroxime: avoid in pregnancy and in patients with\\nrenal impairment\\nCeftriaxone: rashes, fever, gastrointestinal disturbances\\n- Dose reduction in the elderly\\n\\nHaemophilus influenzae vaccine\\n0.5 mL\\n\\n- Should be available as part of childhood immunization\\n\\nAn infection of the upper and lower respiratory tract\\naffecting children 2 - 3 years of age\\n\\nCauses significant sub-glottic oedema\\nMost common aetiology is parainfluenza virus\\n\\ninfection preceded by an upper respiratory tract\\ninfection\\n\\nFever\\nHoarseness\\n\\'Bovine cough\\'\\nInspiratory stridor\\n\\nAcute epiglottitis\\n\\nRespiratory obstruction\\n\\nRadiograph of the neck (postero-anterior view)\\n\\nPrevent asphyxiation\\nTreat inflammatory oedema\\n\\nHumidification\\nHospitalization may be necessary\\n\\nNebulized epinephrine\\n400 micrograms/kg (maximum 5 mg)\\n\\n- Repeat after 30 minutes if necessary\\nGlucocorticoids\\n\\n- Dexamethasone\\n10 - 100 micrograms/kg orally\\n\\ndaily in 1 - 2 divided doses, adju sted according to\\nresponse up to 300 micrograms/kg daily especially in\\nemergencies\\n- Give parenterally in more severe cases\\n- May repeat dose after 12 hours if necessary\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nACUTE LARYNGO-TRACHEO-BRONCHITIS\\n(Croup)\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnosis\\n\\nComplication\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nSupportive measures\\n\\nDrug treatment\\n\\nChild 2 months - 18 years:\\n\\nChild:\\n\\nChild 1 month - 18 years:\\n\\nCaution\\n\\nACUTE RHINITIS (Common cold)\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions\\n\\nBRONCHIALASTHMA\\nIntroduction\\n\\nEffects of nebulized epinephrine last 2 - 3 hours; the\\nchild should be monitored carefully for recurrence of the\\nobstruction\\n\\nInflammation of the mucosal surface of the nose, most\\ncommonly due to infection with respiratory viruses\\n\\nTickling sensation in the nose associated with itching\\nof the nose and palate\\n\\nWatery nasal discharge (rhinorrhoea), which may later\\nbecome purulent\\n\\nSneezing\\nHeadaches\\nNasal obstruction (usually alternating)\\n\\nAllergic rhinitis\\nVasomotor rhinitis\\n\\nBacterial rhinitis (often supervenes after the viral onset)\\n\\nSuperimposed bacterial rhinitis\\n- Suspect this if symptoms last longer than 7 - 10 days\\n\\nSinusitis\\nLower respiratory infection\\nOtitis media\\nObstruction of internal auditory meatus: may cause\\n\\ndeafness\\n\\nRelieve nasal mucosal oedema and obstruction\\nRelieve pain/discomfort\\nTreat complications\\n\\nAnalgesics\\n- Paracetamol\\n\\n1 g orally three times daily to relieve headaches or\\nfever\\n\\n120 - 250 mg; 6 -12 years: 250 - 500\\nmg; 12 - 18 years: 500 mg 4 - 6 hourly (maximum 4 doses\\nin 24 hours)\\n\\nAntibiotics\\n- Only if secondary bacterial infection occurs\\n\\nSteam inhalation with a drop of eucalyptus oil\\n\\nParacetamol: raised liver enzymes, renal papillary\\nnecrosis\\n\\nA chronic inflammatory disease of the airways that is\\ncharacterized by hyper-responsiveness of the tracheo-\\nbronchial tree to a multiplicity of stimuli\\n\\nAdult:\\n\\nChild 1 - 5 years:\\n\\nManifests physiologically by wide-spread airway\\nnarrowing and clinically by paroxysmal attacks of\\ndyspnoea, cough and wheezing\\n\\nAcute episodes are interspersed with symptom-free\\nperiods\\n\\nEpisodic dyspnoea\\nCough: unproductive, or productive of scanty sputum\\nWheezing\\nTachypnoea\\nTachycardia\\nPulsus paradoxus in severe attacks\\nMildly raised blood pressure\\nRhonchi: inspiratory and expiratory\\nProlonged expiration\\nSilent chest (an ominous sign)\\n\\nChronic bronchitis\\nLeft ventricular failure\\nGlottic dysfunction with respiratory obstruction\\nRecurrent pulmonary emboli\\nEosinophilic pneumonia\\nCarcinoid tumour\\n\\nSpontaneous pneumothorax\\nPneumo-mediastinum\\nAtelectasis\\n\\nDiagnosis is based on:\\nAirway reversibility to i aled β adrenergic agonist\\nIsocapnoeic response to hyperventilation of cold air\\nSputum eosinophilia\\nChest radiograph: hyperinflation\\n\\nArrest and reverse acute episodes\\nPrevent (or at least reduce) frequencies of asthmatic\\n\\nattacks\\nAchieve a stable asymptomatic state\\nMaintain the best pulmonary function possible\\n\\nAcute asthma episodes:\\nNebulised salbutamol\\n\\n2.5 mg repeated up to 4\\ntimes daily; may be increased to 5 mg if necessary\\n\\n1.25 - 2.5 mg up to 4 times daily\\n- More frequent administration may be needed in severe\\ncases\\n\\nIntravenous aminophylline\\n250 - 500 mg slowly (with close monitoring) over\\n\\n20 minutes\\nby intravenous injection\\n\\n5mg/kg (maximum 500 mg), and then by intravenous\\ninfusion\\n\\nIntravenous steroids\\nAdequate hydration\\nOxygen\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nnh\\n\\nAdult and child over 18 months:\\n\\nChild under 18 months:\\n\\nAdult:\\n\\nChild 1 month - 18 years:\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 14: Respiratory System\\n\\n165 166\\n\\n\\n\\nChronic management is based on severity:\\n\\nInhaled salbutamol on as-needed basis\\n\\nInhaled salbutamol\\n100 - 200 micrograms for persistent symptoms\\n\\nup, to 4 times daily\\n100 - 200 micrograms (1 - 2\\n\\npuffs) up to 4 times daily (for occasional use only)\\nPlus:\\n\\nInhaled corticosteroid\\n- Beclomethasone dipropionate 100 microgram 3 - 4\\ntimes daily\\n\\nInhaled salbutamol\\n100 - 200 micrograms for persistent symptoms\\n\\nup to 4 times daily\\n100 - 200 micrograms (1 - 2\\n\\npuffs) up to 4 times daily (for occasional use only)\\nPlus:\\n\\nInhaled corticosteroid\\n- Beclomethasone dipropionate\\n\\n100 microgram 3 - 4 times daily\\n50 micrograms every 12 hours; 2 -\\n\\n5 years: 100 - 200 micrograms every 12 hours; 5 - 12\\nyears: 100 -200 micrograms every 12 hours; 12 - 18\\nyears: 100 - 400 micrograms every 12 hours\\nPlus:\\nLong- acting ß agonist\\n\\n- Salmeterol\\n50 micrograms twice daily, up to 100\\n\\nmicrograms\\n25 micrograms (1 puff) every 12\\n\\nhours; 4 - 12 years: 50 micrograms (2 puffs) every 12\\nhours; 12 - 18 years 50 - 100 micrograms (2 - 4 puffs)\\nevery 12 hours\\n\\nInhaled salbutamol\\nnebulizer 2.5 mg\\n\\nrepeated up to 4 times daily; may be increased to 5 mg if\\nnecessary\\n\\n1.25 - 2.5 mg up to 4 times daily\\n- Repeated administration may be required in severe\\ncases\\n\\nLong- acting ß agonist\\n\\n50 micrograms twice daily up to 100 micrograms\\n25 micrograms (1 puff) every 12\\n\\nhours; 4 - 12 years: 50 micrograms (2 puffs) every 12\\nhours; 12 - 18 years 50 - 100 micrograms (2 - 4 puffs)\\nevery 12 hours\\n\\nOral corticosteroid\\n- Prednisolone\\n\\n40 - 50 mg orally daily for a few days, and then\\nreduce gradually\\n\\n1 - 2 mg/kg orally once daily for 3 - 5 days\\n\\nIntermittent symptoms\\n\\nMild persistent asthma\\n\\nModerate persistent asthma\\n\\nSevere persistent asthma\\n\\nAdult:\\n\\nChild 1 month - 18 years:\\n\\nAdult:\\n\\nChild 1 month - 18 years:\\n\\nAdult:\\nChild under 2 years:\\n\\nAdult:\\n\\nChild 2 - 4 years:\\n\\nAdult and child up over 18 months:\\n\\nChild under 18 months:\\n\\nAdult:\\nChild 2 - 4 years:\\n\\nAdult:\\n\\nChild:\\n\\n2\\n\\n2\\n\\nSupportive measures\\n\\nSupplemental oxygen\\nHydration\\nEducation on care and precipitating factors\\n\\nIn all cases, prescribers/dispensers should consult\\nproduct literature to confirm the strengths of various\\naerosol prepartations\\n\\nAminophylline\\n- Do not exceed 500 mg in 24 hours because of the risk\\nof cardiac arrhythmias\\n- May cause CNS stimulation with insomnia and\\nconvulsions\\n\\nSteroids\\n- Immunosuppression, metabolic derangements, etc\\n- Care should be taken in withdrawing steroids\\n\\nAvoid precipitating factors\\nAppropriate use of medicines\\nTraining of patients in the techniques of the proper use\\n\\nof aerosols/spacer devices is important\\n\\nAbnormal and permanent dilatation of medium sized\\nbronchi\\n\\nAconsequence of inflammation and destruction of the\\nstructural components of the bronchial wall, caused by\\nbacterial or viral infections\\n\\nMay be focal or diffuse\\n\\nPersistent or recurrent cough\\nPurrulent fetid sputum\\nHaemoptysis\\nPleuritic chest pain\\nWith or without a history of preceding pneumonic\\n\\nillness\\nDigital clubbing.\\nCrepitations, rhonchi and wheezes\\nCor pulmunale and right ventricular failure in\\n\\nchronically hypoxic patients\\n\\nPulmonary tuberculosis\\nLung abscess\\nChronic bronchitis\\nBullous emphysema\\n\\nMassive haemoptysis\\nLung abscess\\nMycotic brain abscess\\nPulmonary amyloidosis\\nVentilatory failure\\nCor pulmunale and right ventricular failure\\n\\nChest radiograph: cystic spaces with air-fluid levels\\nBronchography: saccular, cylindrical or varicose\\n\\nNotable adverse reactions, caution\\n\\nPrevention\\n\\nBRONCHIECTASIS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nbronchial dilatations\\nCT scan (of the chest)\\nBronchoscopy: biopsy of endobronchial lesion\\n\\nSputum microscopy, culture; Ziehl Nielson microscopy\\nVentilatory function test: obstructive pattern\\n\\nEliminate underlying pathology\\nImprove mucus clearance\\nControl infection\\nReverse airflow obstruction\\n\\nEmpirical antibiotics in acute exacerbations\\n- Amoxicillin\\n\\n500 mg -1 g orally every 8 hours for 5 - 7 days\\n40 mg/kg orally in 3 divided doses daily\\n\\n- Cotrimoxazole\\n960 mg orally every 12 hours for 5 - 7 days\\n6 weeks to 5 months: 120 mg orally; 6 months - 5\\n\\nyears: 240 mg; 6 - 12 years: 480 mg\\nAppropriate antibiotics as soon as culture results are\\n\\navailable\\nBronchodilators\\n\\n- Salmeterol xinafoate\\n2 puffs (50 micrograms) twice daily\\n\\n- Can be doubled in severe airway obstruction\\nsame as adult dose (for children > 4 years)\\n\\n- Salbutamol\\n1 - 2 puffs (100 - 200 micrograms) 3 - 4 times\\n\\ndaily\\nusually 100 microgram (1 puff) may be increased\\n\\nto 200 microgram with more severe symptoms\\n\\nSupplemental oxygen\\nPostural drainage or suction\\nCessation of cigarette smoking\\n\\nPrescribers/dispensers should consult product\\nliterature to confirm the strength of various aerosol\\nprepartations\\nSalbutamol: palpitations, tremors, nervous tension,\\n\\nmuscle cramps, sleep disturbances, tachycardia,\\nperipheral vasodilation, hypotension\\n\\nAvoidance of smoking\\nTimely and effective treatment of bacterial infections\\nRespiratory care during childhood measles\\n\\nAcommon clinical symptom that may or may not have\\nsignificant clinical implications\\n\\n(with )\\nSharp, lancinating lateral chest pain, worse with\\n\\nbreathing and coughing: pleurisy\\nDull aching lateral chest pain: chest wall pain, pleural\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution\\n\\nPrevention\\n\\nCHEST PAIN\\nIntroduction\\n\\nClinical features differential diagnoses\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\neffusion\\nCentral chest pain precipitated by a dry harking cough:\\n\\nsuggestive of tracheitis or tracheobronchitis\\nCentral chest discomfort/pain with sensation of\\n\\nheaviness or chest compression: suggestive of\\nmyocardial ischaemia\\n\\nLateral burning chest pain associated with tenderness\\non physical contact: Bornholm\\'s disease\\n\\nChest radiography\\nElectrocardiography\\nEchocardiography\\n\\nTreat primary cause\\nRelieve pain\\n\\nNon narcotic analgesics\\n- Paracetamol\\n\\n1 g orally every 8 hours\\n30 - 60 mg every 8 hours; 3 - 12\\n\\nmonths: up to 120 mg every 4 - 6 hours; 1 - 5 years: 120 -\\n250 mg every 4 - 6 hours; 6 - 12 years: 250 - 500 mg\\nevery 4 - 6 hours; 12 - 18 years: 500 mg every 4 - 6 hours\\n\\nNon-steroidal analgesics\\n- Diclofenac sodium\\n\\n25 - 50 mg orally three times (daily depending on\\nseverity)\\n\\n0 3 1 mg/kg by mouth or by\\nrectum 3 times daily (maximum total dose 150 mg daily)\\n\\nPain of more serious aetiology e.g.pain of lower or\\nupper respiratory tract infection, or pain of myocardial\\nischaemia\\n- Refer to an appropriate specialist\\n\\nApulmonary disorder of adults characterized by chronic\\nairflow limitation in the small airways\\n\\nComplicates chronic bronchitis and emphysema\\nObstruction to air flow is only partially reversible with\\n\\nbronchodilator therapy\\nTwo extreme types of COAD are recognized although\\n\\nthere is a lot of overlap\\n\\nDepending on the predominant syndromes, could be\\ndescribed as follows:\\n\\nSlowly progressive dyspnoea\\nCough with scanty sputum\\nAesthenic features\\nBarrel-shaped chest\\nWheeze\\nThese patients mainly have emphysema\\n\\nProlonged periods of cough and copious sputum\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nCHRONIC OBSTRUCTIVEAIRWAYS DISEASE\\nIntroduction\\n\\nClinical features\\n\\nAdult:\\nChild 1 - 3 months:\\n\\nAdult:\\n\\nChild 6 months - 18 years: .\\n\\nPink puffers\\n\\nBlue bloaters\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 14: Respiratory System\\n\\n167 168\\n\\n\\n\\nproduction\\nDyspnoea\\nFrequent respiratory infections\\nCentral cyanosis\\nThese patients mainly have chronic bronchitis\\n\\nChronic persistent asthma\\nCystic fibrosis\\n\\nRespiratory failure\\nRecurrent bronchial infections with\\n\\nand\\nCor pulmonale\\nLeft ventricular failure\\nPulmonary thromboembolism\\n\\nChest radiograph: hyperinflation, pulmonary\\nhypertension\\n\\nVentricular function tests: FEV /FVC ratio\\n\\nBlood gas analysis\\nBlood pH\\nHaematocrit\\nSputum microscopy and culture (during symptom\\n\\nexacerbation)\\nElectrocardiogram\\nAirways reversibility test\\n\\nMaintain optimal level of oxygenation and ventilation\\n- Supplemental oxygen, at 24 - 28% or 1 - 2 litres/minute\\n\\nTreat infections\\nReverse airways obstruction\\nClear airways secretions\\n\\nLong acting ß - agonist\\n\\n- See bronchial asthma\\nTheophylline\\n\\n- Aminophylline (see bronchial asthma)\\nAntibiotics (when necessary to control infection)\\n\\n- Erythromycin\\n250 - 500 mg orally every 6\\n\\nhours, or 500 mg - 1 g every 12 hours (up to 4 g daily in\\nsevere infections)\\n\\n2 - 8 years: 250 mg orally every 6 hours\\nUp to 2 years: 125 mg every 6 hours\\n- Co-amoxiclavulanate\\n\\n500/125 mg orally every 12 hours\\n0.25 mL/kg of 125/31 mg\\n\\nsuspension orally every 8 hours; dose doubled in severe\\ninfections\\n1 - 6 years: 5 mLof 250/62 mg suspension every 8 hours;\\ndose doubled in severe infections\\n6 - 12 years: 5 mL of 250/62 mg suspension every 8\\nhours; dose doubled in severe infections\\n12 - 18 years: one 250/125 mg strength tablet every 8\\nhours, daily increased in severe infection to one 500/125\\nstrength tablet every 8 hours daily\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nHaemophilus\\ninfluenzae Streptococcus pneumooniae\\n\\nAdult and child over 8 years:\\n\\nChild:\\n\\nAdult:\\nChild 1 month -1 year:\\n\\n1\\n\\n2\\n\\nSupportive measures\\n\\nPrevention\\n\\nCOUGH\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nAssisted ventilation\\nHydration\\nPulmonary physiotherapy\\n\\nAvoidance of cigarette smoking\\nAvoid / remove atmospheric pollutants\\n\\nThe explosive expiration that clears the tracheo-\\nbronchial tree of secretions and foreign particles or\\nnoxious gaseous materials\\n\\nAdefensive reflex reaction\\nComes to medical attention only when it becomes\\n\\ntroublesome, affects life style and/or when there is\\nconcern about its cause\\n\\nCough may be:\\nAcute or chronic\\nSeasonal\\nAssociated with breathlessness and or wheezing\\nProductive of sputum: note colour, smell; haemoptysis\\nAssociated with fever\\nAssociated with chest pain: note location and character\\n\\nof pain\\nAssociated with risk factors, e.g. cigarette smoking\\nAssociated with the use of drugs for other illnesses\\nAssociated with other constitutional symptoms\\n\\nTriggers of cough may rise from the upper or lower\\nairways, or lung parenchyma\\n\\nUpper airways:\\n- Inhaled irritants: dust, fumes, smoke\\n- Upper airways secretion\\n- Gastric reflux\\n\\nLower airways:\\n- Inflammation\\n- Viral bronchitis\\n- Bronchiectaesis\\n- Bacterial infection\\n- Bronchial asthma\\n- Endobronchial tuberculosis\\n- Bronchial infiltration/compression\\n\\nParenchymal lung disease\\n- Pneumonia\\n- Lung abscess\\n- Interstitial or endobronchial oedema due to heart\\ndisease\\n\\nDrugs:\\n- ACE inhibitors\\n\\nMacroscopic and microscopic examination of sputum\\nSputum culture\\n\\nExclude tuberculosis if cough is chronic\\nSputum cytology for malignant cells\\nChest radiograph where indicated\\nHIV screen if history and clinical features are\\n\\nsuggestive\\n\\nIdentify and treat the underlying cause(s)\\nAbolish cough\\n\\nAdequate rehydration to prevent inspissation\\nEncourage expectoration for productive cough\\nDo not use antitussives unless cough is dry,\\n\\nunproductive and distressing\\n\\nCough suppressants: for dry, unproductive cough\\n- Codeine cough linctus\\n\\n5 - 10 mL3 - 4 times daily\\n- Not recommended in children\\n\\nAppropriate antibiotics for bacterial infections\\n\\nCodeine cough linctus: sedation, constipation\\n\\nAn abnormal and uncomfortable awareness of\\nbreathing\\n\\nEffort of breathing is out of proportion with exertion\\nneeds\\n\\nPatients often have difficulties in describing the\\ndiscomfort of dyspnoea\\n\\nWill depend on the underlying cause(s) of dyspnoea\\n\\nPulmonary:\\n-Obstructive airways disease: asthma, chronic\\nbronchitis, emphysema\\n- P a r e n c h y m a l l u n g d i s e a s e : p n e u m o n i a ,\\npneumoconiosis, pulmonary fibrosis\\n- Pulmonary vascular obstruction: pulmonary emboli\\n- Chest wall disorders: respiratory muscle paralysis,\\nkyphoscoliosis\\n\\nCardiogenic:\\n- Congestive cardiac failure\\n- Left ventricular failure\\n\\nMetabolic:\\n- Diabetic ketoacidosis\\n\\nNeurogenic:\\n- Anxiety neurosis\\n\\nTreat cause(s) of dyspnoea\\nRestore normal respiration\\n\\nOxygen in appropriate concentration\\nO t h e r t r e a t m e n t w i l l d e p e n d o n t h e\\n\\nTreatment objectives\\n\\nNon-drug measures\\n\\nDrug treatment\\n\\nNotable adverse drug reactons, caution\\n\\nDYSPNOEA\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nAdult:\\n\\nunderlying/precipitating cause\\n\\nSuppuration of the lung parenchyma\\nMay be due to:\\n\\nInfection by aspirated oro-pharyngeal anaerobes\\nInadequately treated pneumonia caused by\\n\\n,\\nBronchial obstruction.\\n\\nSymptoms are indolent lasting several weeks:\\nCough, with purulent offensive sputum\\nFever, chills\\nNight sweats\\nWeight loss\\nPleurtic chest pain\\n\\nSigns:\\nDigital clubbing\\nCrepitations\\nPleural friction rub\\n\\nLocalized bronchiectasis\\nPneumonia\\nTuberculosis\\n\\nCerebral abscess\\nEmpyema\\nPulmonary amyloid\\n\\nSputum: Gram stain and culture\\nBronchoscopy\\nTransthoracic aspiration\\nBlood culture\\nChest radiograph\\n\\nEradicate bacterial cause\\nDrain abscess\\nPreserve normal lung function\\n\\nHydration\\nPain relief\\nPhysiotherapy\\n\\nAntibiotics\\n- Metronidazole\\n\\n500 mg orally every 8 hours\\nneonate, initially 15 mg/kg orally then 7.5 mg/kg\\n\\nevery 12 hours; 1 month - 12 years: 7.5 mg/kg\\n(maximum 400 mg) every 8 hours; 12 - 18 years: 400\\nmg every 8 hours\\nPlus:\\nAmoxicillin\\n\\n500 mg orally every 8 hours for 7 - 10 days\\na quarter adult dose; 5 - 10\\n\\nLUNGABSCESS\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nStaphylococcus aureus Mycobacterium tuberculosis\\n\\nAdult:\\nChild:\\n\\nAdult:\\nChild less than 5 years:\\n\\nChapter 14: Respiratory System Standard Treatment Guidelines for Nigeria 2008\\n\\n169 170\\n\\n\\n\\nyears: half adult dose\\nOr:\\nAmoxicillin/clavulanic acid\\n\\n1 g/200 mg orally every 8 hours for 7 - 10 days\\n(Definitive antibiotic therapy should be based on culture\\nand sensitivity results)\\n\\nGood dental care\\nAdequate treatment of acute pneumonia\\nPrevent pneumonia with vaccination in persons at risk\\n\\n- HIV infected patients who are still capable of\\nresponding to a vaccine challenge\\n- Patients with recurrent sinopulmonary infection\\n- Patients with or acquired hypogammaglobulinaemia\\n\\nAn inflammation of the lung parenchyma\\nVarious bacterial species, fungi and viruses may cause\\n\\npneumonia\\nThe setting in which infection is acquired could be a\\n\\npredictor of the infecting pathogen\\nis the most common\\n\\npathogen in community-acquired pneumonia\\nOther causative organisms:\\n\\n(usually implicated in\\nnosocomial pneumonia)\\n\\nTypical pneumonia:\\nSudden onset fever, chills and rigors\\nCough with purulent sputum production\\nPleuritic chest pain\\nBreathlessness with short inspiratory efforts\\n\\nSigns:\\nFever\\nHerpes labialis\\nTachypnoea\\nSigns of lung consolidation\\nPleural friction rubs\\n\\nAtypical pneumonia:\\nGradual onset\\nDry cough\\nProminent extra-pulmonary symptoms\\nHeadache\\nSore throat\\nFatigue\\nMyalgia\\nChest crackles or rales\\n\\nPulmonary embolism\\nSepticaemia\\n\\nLung abscess\\n\\nAdult:\\n\\nStreptococcus pneumoniae\\n\\nHaemophilus influenzae\\nMycoplasma pneumoniae\\nPseudomonas aeruginosa\\n\\nPrevention\\n\\nPNEUMONIA\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nPleural effusion\\nEmpyema thoracis\\nSepticaemia\\nEndocarditis\\nMeningitis\\n\\nSputum examination\\nHaematological evaluation\\nSputum culture\\nChest radiograph\\nBlood cultures\\nSerologic studies\\n\\nEliminate the infection\\nReturn to normal lung function\\n\\nAntibiotics\\n- Co-amoxiclavulanate\\n\\n1 g/200 mg orally every 12 hours for 5 -7 days\\nneonate and premature infants, 25 mg/kg every\\n\\n12 hours; infants up to 3 months, 25 mg/kg every 8\\nhours, 3 months to 12 years, 25 mg/kg every 8 hours\\nincreased to 25 mg/kg every 6 hours in more severe\\ninfections\\nOr:\\n- Benzyl penicillin\\n\\ninitially 1.2 g (2 million units) intravenously\\nevery 6 hours\\n\\npreterm and neonate under 7 days, 25 mg/kg by\\nintramuscular injection or by slow intravenous injection\\nor infusion every 12 hours; dose doubled in severe\\ninfection\\nNeonate 7 - 28 days: 25 mg/kg every 8 hours; dose\\ndoubled in severe infection\\n1 month - 18 years: 25 mg/kg every 4 - 6 hours, increased\\nto 50 mg/kg every 4 - 6 hours (maximum 2.4 g every 4\\nhours) in severe infection\\n- Commence oral therapy as soon as practicable\\nOr:\\n- Cefuroxime axetil\\n\\n500 mg orally every 8 hours for 5 - 7 days\\n10 mg/kg (maximum 125 mg)\\n\\norally every 12 hours; 2 - 12 years: 15 mg/kg (maximum\\n250 mg) every 12 hours daily; 12 - 18 years: 250 mg\\nevery 12 hours; dose doubled in severe infection\\n\\nAnalgesics\\nHospitalization may be necessary in severe infection\\nAdequate hydration.\\nSupplemental oxygen if cyanosis is present\\n\\nCo-amoxiclavulanate: nausea, diarrhoea, skin rashes\\n- Contra indicated in penicillin-hypersensitive\\nindividuals\\n\\nCefuroxime: nausea, vomiting, abdominal discomfort,\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\nChild 3 months - 2 years:\\n\\nheadaches\\n- Rarely, antibiotic-associated colitis\\n\\nPneumococcal vaccine\\nHaemophilus influenzae vaccine\\n\\nOccurs when a venous thrombus is dislodged from its\\nsite of formation (thrombotic embolus) or a fat globule\\nfrom a long bone fracture or crush tissue injury or even a\\ntumour fragment (non-thrombotic embolism), is carried\\nin the blood stream to the pulmonary arterial circulation\\ncausing obstruction to alveolar perfusion\\n\\nMassive embolus in main pulmonary artery:\\nSudden death\\nSudden onset dyspnoea\\nTachypnoea\\nTachycardia\\nSmall volume pulse\\nHypotension\\nCirculatory collapse\\nRaised jugular venous pressure\\n\\nSmall-to-moderate embolus:\\nCough\\nPleurtic chest pain\\nHaemoptysis\\nTachycardia\\nLeft parasternal heave\\nLoud pulmonary component of second heart sound\\nFever\\nSigns of lung consolidation\\nPleural friction rubs\\n\\nMyocardial infarction\\nUnstable angina\\nPericarditis\\nExacerbation of chronic bronchitis\\nCongestive cardiac failure\\nPneumothorax\\n\\nSudden death\\nPulmonary infarction\\nLung abscess\\n\\nElectrocardiography\\n- Sinus tachycardia\\n- Atrial fibrillation\\n- Right bundle branch block\\n- Right axis deviation <90°\\n- T wave inversion\\n- Q waves in leads III,AVF, V3\\n\\nChest radiograph\\nMay be normal or show:\\n\\nPrevention\\n\\nPULMONARYEMBOLISM\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\n- Focal oligaemia\\n- Pleural effusion\\n- Wedge-shaped opacity (Hampton\\'s hump)\\n\\nVentilation/perfusion scan\\nArterial blood gas analysis: hypoxaemia, respiratory\\n\\nalkalosis\\nFull Blood Count: leucocytosis\\nRaised ESR\\nRaised LDH levels\\n\\nPrevent fatality\\nRestore normal lung perfusion\\n\\nPrimary measures:\\nEmbolectomy\\nSupplemental oxygen\\nPsychological support\\n\\nAnticoagulants\\n- Heparin\\n\\n5,000 units (10,000 in severe pulmonary\\nembolism) loading dose then continuous infusion at a\\nrate of 15 - 25 units/kg/hour\\n\\nneonate, initially 75 units/kg (50 units/kg if under\\n35 weeks post-menstrual age), then 25 units/kg/hour by\\nintravenous injection, adjusted according toAPTT\\n1 month - 1 year: same as for neonate\\n1 year - 18 years: initially 75 units/kg by intravenous\\ninjection, then 20 units/kg/hour by continuous\\nintravenous infusion, adjusted according toAPTT\\nOr:\\n- Enoxaparin\\n\\n1.5 mg/kg (or 150 units/kg) by subcutaneous\\ninjection every 24 hours, for at least 5 days (until\\nadequate oral anticoagulation is established)\\n\\nneonate, 1.5 - 2 mg/kg by subcutaneous injection\\ntwice daily; 1 - 2 months: 1.5 mg/kg twice daily; 2\\nmonths - 18 years: 1 mg/kg twice daily\\n- Warfarin\\n\\ninitially 10 mg orally daily for 2 days\\nneonate (under specialist advice), 200\\n\\nmicrograms/kg once daily as a single dose on first day,\\nthen on the following 2 days\\n1 month - 18 years: 200 micrograms/kg (maximum 10\\nmg) as a single dose on first day, reduced to 100\\nmicrograms/kg (maximum 5 mg) once daily for\\nfollowing 2 days\\n- Usual maintenance dose: 100 - 300 micrograms/kg\\nonce daily\\n- Subsequent doses depend on prothrombin time (INR)\\n\\nThrombolytic agents\\n- Recombinant tissue plasminogen activator\\n\\n10 mg by intravenous injection given over 1 - 2\\nminutes; then intravenous infusion of 90 mg given over\\n2 hours\\n- Not exceeding 1.5 mg/kg in persons less than 65 kg\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\nChild:\\n\\nAdult:\\n\\nChapter 14: Respiratory System Standard Treatment Guidelines for Nigeria 2008\\n\\n171 172\\n\\n\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nHeparin:\\n- Thrombocytopaenia and haemorrhage\\n- Osteopaenia\\n- Osteoporosis\\n- Pathologic fractures\\n- May cause hyperkalaemia (inhibition of aldosterone\\nsecretion)\\n- Contraindicated after recent surgery or trauma, in\\nhaemophilia and other bleeding disorders, peptic ulcer,\\nsevere liver disease, acute bacterial endocarditis\\n\\nEnoxaparin :\\n- Haemorrhage\\n- May cause hyperkalaemia (inhibition of aldosterone\\nsecretion)\\n\\nWarfarin:\\n- Haemorrhage\\n- Skin necrosis\\n- Avoid during pregnancy\\n\\nRecombinant tissue plasminogen activator\\n- Intracranial haemorrhage\\n\\nProphylactic warfarin or heparin in patients at risk\\nInferior vena cava filters, when anticoagulation cannot\\n\\nbe undertaken because of active bleeding\\n\\nCHAPTER 15: INJURIES AND ACUTE\\nTRAUMA\\n\\nDog bites\\n\\nCat bites\\n\\nRats, mice, gerbils and animals that prey on them\\n\\nBITESAND STINGS\\nIntroduction\\n\\nClinical features\\n\\nBites occur from:\\nHumans\\nDomestic animals such as cats and dogs\\nWild animals e.g. snakes, sharks and crocodiles\\n\\nStings often occur from:\\nBees, wasps and other insects\\nMarine invertebrates such as the jellyfish, corals,\\n\\nscorpions and anemones\\nThe microbiology of bite wound infections reflects the\\n\\noro-pharyngeal flora of the biting animal\\n- Organisms from the soil, skin of the animal and\\nvictims, animal feaces may also be present\\n\\nDepend on the type of injury, and the delay before\\npresentation in hospital\\n\\nBites from common domestic animals usually result in\\nbruises, lacerations and haemorrhage;\\n\\nRabies may complicate dog bites\\n\\nResponsible for 80% of bite wounds\\nBacteriology usually mixed\\n\\n- Alpha haemolytic streptococci, pasteurella species,\\nstaphylococci,\\nfusobacterium, prevotella, pophyomonas species,\\n\\n15 - 20 % of wounds become infected\\nLower limbs are most commonly affected\\n\\nInfections occur 8 - 24 hours after bite and may manifest\\nas:\\n- Pain\\n- Fever\\n- Lymphadenopathy\\n- Cellulitis\\nIf the canine tooth penetrates synovium or bone:\\n- Septic arthritis\\n- Osteomyelitis\\n\\nLess common\\nMore than 50% result in infection\\nFemales are more affected than males\\nThe hands and arms are more commonly affected\\nUsual organisms include and those ones\\n\\nfollowing dog bites\\n\\nMay transmit or\\n\\nUsually affect hunters or laboratory handlers of rats\\nManifests as:\\n\\nFever\\nChills\\n\\nEikenella chorrodeus, actinomyces,\\n\\nCapnocytophaga canimorsus\\n\\nP. mutocida\\n\\nStreptobacillus moniliformis Spirillus\\nminor\\n\\nMyalgias\\nHeadaches\\nSevere migratory arthralgia\\nAmaculopapular rash involving the palms and soles\\n\\nMay be:\\nSelf-inflicted\\nSustained by medical personnel caring for patients\\nSustained during fights, rapes or during sexual activity\\nMay become infected more than bites from other\\n\\nanimals\\nThe oral microflora include multiple species of\\n\\naerobic and anaerobic bacteria\\nThose of hospitalized and debilitated patients often\\n\\ninclude\\nHIV, HBV have been reported due to human bites\\n\\nInAfrica, often occur among farmers who walk unshod\\nOccasionally occur around homes when snakes are\\n\\naccidentally stepped upon\\nPoisonous snakes belong to the families of:\\nViperidae :\\n\\n- Subfamily viperinae (the Old World vipers)\\n- Crotalinae (the New World vipers,Asian pit vipers)\\n\\nElapidae (e. g. cobras)\\nColubridae (e. g. boomslang)\\n\\n- A large group; only a few species are dangerously\\ntoxic to humans\\n\\nHydrophidae (sea snakes)\\nInAfrica the vipers are responsible for most snake bites.\\n\\n- Depend on the type of snake, location of bite and\\npromptness of intervention\\nLocal effects:\\n\\nPain\\nSwelling\\nBruising\\nTender enlargement of regional lymph nodes\\n\\nSystemic effects:\\nEarly anaphylactoid symptoms\\nTransient hypotension with syncope\\nAngioedema\\nUrticaria\\nAbdominal colic\\nDiarrhoea\\nVomiting\\nLate persistent or recurrent hypotension\\nElectrocardiograph abnormalities\\nSpontaneous systemic bleeding\\nCoagulopathy\\nAdult respiratory distress syndrome\\nAcute renal failure\\n\\nLocal and systemic bleeding\\nImpairment of organ function\\nReduction of cardiac output\\n\\nHuman bites\\n\\nSnake bites\\n\\nEnterobacteriacae\\n\\nClinical features\\n\\nViperidae and crotalidae\\n\\nInhibition of peripheral nerve impulses\\nMultisystem effects\\nRhabdomyolysis\\nHaemolysis\\nBlood vessel damage\\n\\nNeurotoxic effects\\nSnake bite wounds may become secondarily infected\\nwith:\\n\\ncausing tetanus\\n, causing gas gangrene\\n\\nHypotension\\nVomiting\\nHand or foot bite swellings extending beyond the wrist\\n\\nor ankle within 4 hours of the bite\\nElectrocardiograph abnormalities\\n\\nCause death by:\\nTissue destruction\\nCrush syndrome\\nHaemorrhage\\nInfection\\n\\nAre the most common causes of stings\\nThey leave their stinging apparatus behind in the skin\\nThe symptoms that follow bee stings are those due to\\n\\nanaphylaxis to their venom\\n\\nHave specialized organelles called nematocysts for\\npoisoning and capturing prey\\n\\nMay cause serious ill health and death\\n\\nCareful history\\nContact local authorities to determine if the specie is\\n\\nrabid; if possible locate animal for observation\\nAntibiotic allergy, immunization of patient and other\\n\\nmorbid condition(s) should be documented\\nInspect wound for evidence of infection.\\nConduct general physical examination, including vital\\n\\nsigns\\n\\nDepend on the type of injury, the clinical presentation\\nand the onset/type of complications:\\n\\nFull Blood Count\\nElectrolytes and Urea\\nBlood clotting profile\\nArterial blood gas estimations\\nChest radiographs\\nWound and blood cultures\\n\\nNeutralize envenomation\\nLimit systemic effects\\nLocal wound care\\nPrevent onset of complications\\n\\nElapidae\\n\\nIndications for antivenom treatment\\n\\n- Clostridium tetani,\\n- Clostridium welchi\\n\\nSharks and crocodiles\\n\\nBees and wasps\\n\\nMarine invertebrates\\n\\nInitial assessement\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 15: Injuries and Acute Trauma\\n\\n173 174\\n\\n\\n\\nPrevent specific infections such as rabies in high risk\\ncases\\n\\nLimb splinting (and rest the limb)\\nUse of venom detection kit (if available)\\nApplication of pressure bandage\\nControl/care of the airway\\n\\nIdentification of the snake would help in the choice of\\nantivenom (where specific antivenoms are available)\\n\\nWound debridement and fasciotomy for compartment\\nsyndrome may become necessary\\n\\nAdministration of high flow oxygen\\nIntravenous fluid administration to maintain\\n\\ncirculation: use colloids or cystalloids as clinically\\nappropriate\\n\\nTreatment of anaphylaxis with antihistamines (H\\n\\nblockers), epinephrine (adrenaline) and corticosteroids\\nAnalgesia\\nProphylactic antibiotics as appropriate\\nTetanus prophylaxis\\nFor animal bites in which rabies is considered a\\n\\nsignificant risk it is imperative that anti-rabies\\nprophylaxis be instituted\\n- If the patient is not previously vaccinated local wound\\ncleansing should be done, rabies immune globulin\\nadministered and the vaccine given\\n\\nRabies immune globulin\\n20 units/kg body weight by infiltration\\n\\nin and around the cleansed wound; if whole volume not\\nexhausted, give remainder by intramuscular injection\\ninto anterior-lateral thigh (distant from vaccine site)\\n- Half of the dose is infiltrated around the wound and\\nthe rest given intramuscularly into the gluteal muscles\\n\\nHuman Diploid Cell Vaccine (HDCV) or Rabies\\nVaccineAdsorbed (RVA)\\n- 1 mL is given into the deltoid on days 0, 3, 7, 14, and\\n28\\n- Should not be administered in the gluteal area\\n- If the patient has previously been vaccinated clean the\\nwound and give the vaccine given on days 0 and 3 only\\n\\nSymptoms or signs of systemic envenoming:\\nhypotension, angioedema, urticaria, diarrhoea and\\nvomiting, spontaneous bleeding, adult respiratory\\ndistress syndrome, acute renal failure, etc\\n\\nElectrocardiograph abnormalities\\nMarked local envenoming e.g. swelling extending\\n\\nbeyond wrist within 4 hours of bite on hand, or beyond\\nankle after bite on foot\\n\\ncontents of the antivenom vial diluted\\nin sodium chloride 0.9% intravenous infusion, and\\ninfused intravenously over 30 minutes\\n\\nNon-drug measures\\n\\nDrug treatment\\n\\nIncision is discouraged; the mouth should not be used to\\nsuction\\n\\nAdult and child:\\n\\nAdult and child:\\n\\n1\\n\\nAntirabies prophylaxis\\n\\nIndications for anti-snake venom treatment\\n\\nAdrenaline (epinephrine), hydrocortisone must be\\nimmediately on hand for the treatment of anaphylaxis\\nif it occurs\\nPrevention\\n\\nBURNS\\nIntroduction\\n\\nClinical features and complications\\n\\nInvestigations\\n\\nAppropriate clothing and footwear while outdoors\\nAttention and care to observe general safety measures\\n\\nAcommon form of trauma in our environment\\nInvolves coagulative necrosis of tissue cells following\\n\\nvaried insults\\n- Flames\\n- Chemicals\\n- Electricity\\n- Friction\\n- Cold or hot fluids\\n\\nThe various types occur with varying frequencies in\\nvarious segments of the population\\n- For example scalds occur with great frequency in\\nchildren while flame burns occur commonly in young\\nadults\\n\\n( )\\nExtensive skin loss with dehydration\\n\\nAirway burns leading to dyspnoea, tachypnoea, stridor,\\nhypoxia, hypercarbia, airway obstruction and death\\nBreathing difficulties from circumferential chest burns\\nAcute respiratory distress syndrome, acute lung injury\\n\\nand pulmonary oedema\\nMassive fluid losses from evaporation and interstitial\\n\\nfluid shifts leading to hypovolaemic shock\\nAcute renal failure from pre renal failure, acute tubular\\n\\nnecrosis, and the crush syndrome\\nElectrolyte abnormalities: hyper or hypokalaemia with\\n\\ncardiac dysrhythmias and/or arrest\\nAnaemia from destruction of red cells.Also nutritional\\n\\nanaemia\\nHypothermia\\nImmune dysfunction\\nBurns wound sepsis and septicaemia\\nTetanus\\nAcute gastric dilatation\\nStress ulcerations in the gastrointestinal system\\nLimb compartment syndrome\\nCrush syndrome\\nDeep vein thrombosis\\nSystemic Inflammatory Response Syndrome (SIRS)\\nMultiple Organ Dysfunction Syndrome (MODS)\\n\\nFull Blood Count\\nElectrolytes and Urea\\nGrouping and cross-matching\\nArterial blood gases\\nChest radiograph\\nElectrocardiogram\\n\\nWound swab for microscopy, culture and sensitivity\\nBlood culture\\nIntracompartmental pressure monitoring\\n\\nAt the scene: to stop the burning process or remove\\nvictim from the burn situation\\n\\nTransfer the patient to hospital as soon as possible\\nIn the hospital identify life threatening injuries and\\n\\ntreat\\nPerform a detailed survey\\nRestore patient\\'s physiology as much as possible\\nPromote wound healing\\nPrevent complications\\nRehabilitation\\n\\nCopiously irrigate the wound with cold water (not ice\\ncold) for 10 - 15 minutes\\n\\nAvoid hypothermia and the use of agents such as raw\\neggs and palm oil\\n- They are not useful and may promote wound sepsis\\n\\nIn hospital perform a quick primary survey\\nCheck:\\n- irway\\n- reathing\\n- irculation\\n- isability\\n- xposure\\n\\nCorrect problems identified\\nGive patient 100% oxygen\\nPass an endotracheal tube if there is risk of airway\\n\\nobstruction\\nObtain specimens for investigations as detailed above\\nDetermine percentage total body surface area (TBSA)\\n\\nburned\\n- Wallace rule of nines is recommended in adults\\n- In children there are several charts e. g Lund and\\nBrowder charts\\n\\nCalculate the total fluid requirement in the first 24\\nhours using appropriate formulae\\n- We recommend the Parkland\\'s\\n\\nDetermine burn depth\\nApply burns dressing\\nPass all relevant tubes and gadgets\\n\\n- Nasogastric tube, urethral catheter, etc\\nPerform a detailed secondary survey (especially if\\n\\ncombined with other trauma)\\n- Obtain the history\\n\\nllergies,\\nedications,\\n\\nast medical history, pregnancy,\\nast meal\\nnvironment (including details of the incident)\\n\\nAdminister tetanus prophylaxis depending on immune\\nstatus\\n\\nApply relevant splintage\\n\\nTreatment objectives\\n\\nTreatment\\n\\nA\\nB\\nC\\nD\\nE\\n\\nAMPLE\\nA\\nM\\nP\\nL\\nE\\n\\nCommence prophylaxis against deep venous\\nthrombosis\\n\\nPhysiotherapy\\nDecide whether patient should go to a burns unit or\\n\\nburns centre following standard criteria\\n\\nOxygen\\nTetanus toxoid\\n\\nAnti tetanus serum, antitetanus globulin as appropriate\\nNarcotic analgesics e. g. morphine, pethidine, tramadol\\n\\nNonsteroidal anti inflammatory analgesics e. g.\\ndiclofenac\\n\\nH receptor antagonists e. g ranitidine\\n\\nProphylactic antibiotics e. g cephalosporins\\nTopical wound dressing agents e. g with zinc oxide\\n\\nbased creams, antibiotic-containing dressings\\n\\nHealth education to promote healthy life style and\\navoidance of risky behaviour\\n\\nInstallation of fire warning systems such as smoke\\ndetectors in buildings\\n\\nControl of petroleum products\\nAn efficient fire service\\nFire protocols in all establishments\\n\\nA disaster is an event which causes serious disruption\\nto community life, threatens or causes death or injury in\\nthat community, and/or damage to property\\n\\nIt is beyond the day-to-day capacity of the prescribed\\nstatutory authorities and requires special resources other\\nthan those normally available to those authorities\\nCould arise from natural causes cyclones, earthquakes\\nand tsunamis or from man-made situations such as plane\\ncrashes and wars\\n\\nOccur with little or no warning\\n- Only well-prepared systems will be able to limit the\\ndamages and losses that follow disasters\\n\\nThe effectiveness and quality of response to a disaster\\nis highly dependent on the level of preparation\\n\\nAn ill-prepared system will lead to an ineffective and\\nuncoordinated response\\n\\nApart from an effective response, other advantages of\\npreparation include cost savings and an improved and\\nalert system\\nThere are four phases of disaster management:\\n\\nPrevention\\nPreparation\\nResponse\\nRecovery\\n\\nEssentially the evolution and implementation of\\nstrategies to prevent or mitigate the impact of disasters\\n\\nDrug treatment\\n\\nPrevention\\n\\nDISASTER PLAN\\nIntroduction\\n\\nPrevention\\n\\n2\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 15: Injuries and Acute Trauma\\n\\n175 176\\n\\n\\n\\nif/when they arise e.g. designing tsunami warning\\nsystems or fire alarm systems\\n\\nInvolves system upgrade, overhaul, protocol design,\\nimplementation and quality assessment for disaster\\nmanagement\\n\\nInvolves the interaction of the various emergency\\nresponse agencies to the disaster to save as many\\ncasualties as possible; quick transfer to hospitals,\\ncoordination of the hospitals and creation of temporary\\nshelters\\n\\nA phase that involves rebuilding, reconstruction and\\nrehabilitation, with a goal to restoring the community to\\nits pre-event state or as close to it as possible\\n\\nFor a disaster plan to be effective it needs to involve all\\nthe stake holders in its design\\n\\nDisaster plan is necessary at various levels of health\\ncare and political terrain: national, regional, state and\\nlocal government levels\\n\\nThere should be disaster plans within organizations\\nsuch as the hospitals, fire service, Army, Air force and\\nNavy; the Ministries of health, the police and the\\nEmergency Medical Service (EMS)\\n\\nThere is need for a coordinating agency such as the\\nNational Emergency ManagementAgency (NEMA) to\\nsupervise, monitor and coordinate inter-agency\\nprocedures, protocols, joint training sessions and drills\\n\\nPersonnel in all the relevant response agencies must be\\nfamiliar with the policies, protocols and procedures to\\nbe implemented following a disaster\\n\\nTraining and retraining is essential\\n\\nThere should be a Disaster Committee in the hospital\\nwhich should:\\n\\nDesign a disaster plan for the hospital\\nPut in place procedures and protocols to be\\n\\nimplemented in a disaster situation\\nSupervise staff training for disaster management\\nBe engaged in capacity building\\nPromote staff awareness regarding disaster prevention\\n\\nand preparation\\nPromote inter-departmental interaction regarding\\n\\ndisaster management\\nDetermine staff competency levels in disaster\\n\\nmanagement\\nAllocate staff roles in disaster management\\nEnsure regular drills, seminars, tabletop exercises,\\n\\ncomputer simulations and interactions on disasters\\nEnsure stockpile of drugs and equipment to be\\n\\nmobilized in disaster situation\\nEnsure quality assurance and audit\\nPromote inter-hospital and inter-agency interaction\\n\\nwithin the municipality with regard to disaster\\nmanagement\\n\\nPreparation\\n\\nResponse\\n\\nRecovery\\n\\nThe hospital disaster plan\\n\\nEnsure management commitment to disaster\\nmanagement\\n\\nThe committee should be composed of the following:\\nThe Hospital Trauma Director\\nThe Emergency Department Chief\\nThe Head of Surgery\\nThe Head ofAnaesthesia\\nThe Chief of Nursing services\\nThe Head of Security\\nThe Head of Stores\\nThe Head of Pharmacy\\nArepresentative of the Hospital Manager\\n\\nThe disaster protocol in the hospital should address the\\nfollowing principal issues:\\n\\nWho activates the disaster protocol?\\nWhat are the criteria for activation?\\nInformation relay to critical departments: laboratories,\\n\\nblood bank, theatres, ICU, radiology, anaesthesia,\\nEmergency Department (ED) Management, Hospital\\nManagement, Portage and Security\\n\\nPattern of staff call up to the Emergency Department\\nin a disaster situation\\n\\nMethod of staff call\\nPre-determined plan for Emergency Department\\n\\nevacuation\\nInformation centre constitution for distressed relatives\\nDepartmental disaster procedures\\nLogistic issues in a disaster situation\\n“Standing down” criteria and procedure\\n\\nThe term refers to any injury to the head\\n- Includes bruises and lacerations to the scalp\\nFor practical purposes it is preferable to talk of:\\n\\nTraumatic brain injury (TBI)\\nCraniocerebral injury\\nCraniofaciocerebral injury\\n\\n- This section will focus on TBI\\nTBI is common in trauma patients\\n\\n- Present in up to 50% of multiply injured patients\\nIsolated TBI is uncommon\\n\\nIn up to 50% of cases of severe TBI there is\\nmultisystem trauma\\n\\nCan be considered from the point of view of :\\nMechanism of injury\\nSeverity of injury\\nMorphology\\n\\nMechanism:\\nBlunt or penetrating\\n\\nSeverity:\\n- Depends on the patient\\'s position on the Glasgow\\nComa Scale (GCS).\\n\\nCommittee composition\\n\\nHEAD INJURY\\nIntroduction\\n\\nClassification\\n\\n13 - 15: mild\\n9 - 12: moderate\\n8 or less: severe\\n\\nMorphology:\\nSkull fractures\\nIntracranial lesions\\n\\n- Skull fractures could involve the vault or base of the\\nskull\\n- Vault fractures may be linear, stellate, depressed or\\nnon-depressed; open or closed\\n- Basilar fractures may be with or without CSF leaks\\nand also with or without facial nerve palsy\\n- Intracranial lesions may be focal or diffuse.\\n- Focal lesions include epidural, subdural and\\nintracerebral haematomas\\n- Diffuse lesions include concussions and diffuse axonal\\ninjury (DAI)\\n\\nThe brain is covered by the meninges: dura, arachnoid\\nand pia mater with the subdural and the subarachnoid\\nspaces\\n\\nCSF is produced in the lateral ventricles\\n- The normal circulating volume of CSF is 140 mL\\nThe brain normally regulates its blood flow by a process\\nof autoregulation, which is for the most time\\nundisturbed in TBI\\n\\nNormal CBF is 800 mL/min or 20% of total cardiac\\noutput\\n- CBF = CPP/CVR = 50 mL/100 g of brain tissue/min\\n- CPPis the Cerebral Perfusion Pressure\\n- CVR is Cerebral Vascular Resistance\\n- CPP= MAP- ICP\\n- MAPis MeanArterial Pressure\\n- ICPis Intracranial Pressure\\n\\nThe normal ICPis 10 mmHg (136 mm H O)\\n\\n- Changes in intracranial volume result in compensation,\\nwith alterations in CSF volume and blood volume within\\nthe cranium but with minimal change in intracranial\\npressure\\n\\nAt some point minimal changes in volume result in\\ngeometric increases in ICP (The Monro-Kellie\\ndoctrine), and decompensation occurs\\n\\nAn expanding intracranial mass (such as a subdural\\nhaematoma) leads to :\\n- Uncal herniation through the incisura in the tentorium\\nwith compression of the oculomotor nerve and the motor\\ntracts in the mid brain\\n- This leads to ipsilateral pupllary dilatation and\\ncontralateral hemiparesis or hemiplegia\\n\\nIn the Kernohan\\'s notch syndrome which occasionally\\noccurs there isipsilateral papillary dilatation and\\nhemiparesis.\\n\\nWith progressive expansion of an intracranial mass the\\ncerebellar tonsils eventually herniate through the\\nforamen magnum (coning)\\n\\nPathophysiology\\n\\n2\\n\\n- This is associated with hypertension and bradycardia\\n(Cushing\\'s reflex)\\n- Sequentially apnoea, arrythmias, hypotension and\\ndeath ensue\\n\\nThese patients may present with:\\nFeatures of multisystem trauma\\nAltered level of consciousness\\n\\nSkull fractures and mass effect from intracranial lesions\\nFeatures of raised intracranial pressure\\n\\n- Headaches\\n- Nausea\\n- Projectile vomiting\\n- Drowsiness\\n- Papilloedema\\n\\nComplications of TBI:\\nAlucid interval (often occurs in extradural haematoma)\\n- Post injury, the patients maintain a satisfactory level\\nof consciousness until suddenly consciousness is lost\\n\\nRare; overall, occurs in less than 1% of head injuries\\nMore common in young patients\\nOften results from torn middle meningeal vessels\\nCT shows a biconvex or lenticular opacity\\n\\nMore common\\nOccurs in 20 - 30% of severe head injuries, more\\n\\ncommonly in the elderly (due to brain atrophy)\\nResults from torn bridging veins\\nThe opacity on CT follows the contour of the brain\\n\\nMay be suggested by:\\nPeriorbital ecchymosis (racoon eyes)\\nRetroauricular ecchymosis (Battle sign)\\nCSF leaks\\nFacial nerve palsy\\n\\nEarly:\\nComa\\nPost concussion headaches\\nPost traumatic amnesia\\nRetrograde amnesia\\nAbnormalities of salt and water metabolism such as\\n\\ndiabetes insipidus and syndrome of inappropriateADH\\nAnterior pituitary dysfunction such as ACTH\\n\\nabnormalities and poor cortisol stress response\\nLate:\\n\\nChronic subdural haematoma\\nInfections such as meningitis and brain abscess\\nHydrocephalus\\nEpilepsy\\nCSF leaks\\nCarotico-cavernous fistulae\\nTraumatic aneurysms\\nChronic headaches\\nPersonality changes\\n\\nClinical features\\n\\nComplications of TBI\\n\\nExtradural haematoma\\n\\nSubdural haematoma\\n\\nBasal skull fracture\\n\\nChapter 15: Injuries and Acute Trauma Standard Treatment Guidelines for Nigeria 2008\\n\\n177 178\\n\\n\\n\\nTreatment objectives\\nIdentify life threatening injuries and treat\\nLimit primary injury\\nPrevent secondary brain injury\\nProvide critical care\\nRehabilitate\\n\\nAssess airway and maintain patency\\n- Suctioning and manoeuvers to elevate the tongue (jaw\\nthrust and chin lift) may be useful\\n- A patent airway is important in optimizing outcome\\nin TBI\\n\\nVentilation is next addressed\\n- Administer 100% oxygen\\n- Hypoxia is one of the causes of secondary head injury\\nand must be avoided\\n- Conduct a quick chest examination to identify tension\\npneumothorax, pneumothorax, haemothorax, flail chest\\netc\\n- Institute urgent treatment as may be indicated\\n\\nMaintenance of the circulation\\n- Equally important in optimizing outcomes\\n- Hypotension is a cause of secondary brain injury and\\nmust be avoided\\n- Intravenous lines should be set up; administer\\ncrystalloids\\n\\nAsses the GCS and the state of the pupils\\nExpose the patient to perform a quick general\\n\\nexamination but avoid hypothermia.\\nSecondary Survey:\\n(See section on multiple injuries)\\n\\nNeuronal injury that is not present at the time of the\\nprimary insult but develops in response to subsequent\\nintracranial or extracranial events\\nExtracranial causes:\\n\\nHypoxia\\nHypotension\\nSeizures\\nHyperthermia\\nHyponatraemia\\nHypernatraemia\\nHypoglycaemia\\nHyperglycaemia\\n\\nIntracranial causes:\\nExtradural haematoma\\nSubdural haematoma\\nIntracerebral haematoma\\nCerebral oedema\\nCerebral contusion\\nHydrocephalus\\nMeningitis\\nBrain abscess\\n\\nHas revolutionalized the management of traumatic\\nbrain injury as it can readily diagnose intracranial\\n\\nPrimary survey\\n\\nSecondary brain injury\\n\\nCT scan in TBI\\n\\nhaematomas and skull fractures\\nIn trauma it is advisable to do a non-contrast CT scan\\n\\nGCS of 14 or less\\nGCS of 15 with:\\n\\n- Loss of consciousness > 5minutes\\n- Amnesia for injury\\n- Focal neurological deficit\\n- Signs of calvarial or basal skull fracture\\n\\nBest done through a ventriculostomy catheter, with or\\nwithout concomitant intraparenchymal transducer\\n\\nPatients with post resuscitation GCS of 8 or less\\nIntubated patients in ICU\\n\\nPatients with intracranial haematomas but are\\nadjudged not to need surgery\\n\\nEndotracheal intubation\\nControlled ventilation to a pCO of 35 mmHg\\n\\nVolume resuscitation\\nMaintain normal blood pressure\\nNarcotic sedation\\nNeuromuscular blockade\\nBolus mannitol (1 g/kg)\\n\\n- See Meningitis\\nHead up tilt at 30 degrees\\nControlled hypothermia\\n\\nOften indicated in head injury for the evacuation of\\nintracranial haematomas or elevation of depressed skull\\nfractures\\n\\nIndications may depend on the centre and the\\nneurosurgeon, but all agree that an intracranial\\nhaematoma causing significant mass effect should be\\nremoved\\n\\nA midline shift of more than 5 mm is considered\\nsignificant\\nIndications for surgery will depend on:\\n- The neurological status of the patient\\n- Findings on CT\\n- Extent of intracranial injury\\n- Intracranial pressure.\\nThe procedures include:\\n\\nBurr holes\\nCraniotomy\\nCraniectomy\\nElevation of depressed skull fractures\\n\\nDiuretics to reduce intracranial pressure e.g. mannitol\\n(see Meningitis)\\n\\nSedatives e.g. diazepam (see Tetanus)\\nMuscle relaxants e.g. diazepam, suxamethonium\\nAnticonvulsants e.g. phenytoin, phenobarbital (see\\n\\nEpilepsy)\\nAntibiotics as appropriate\\n\\nIndications for CT scan\\n\\nIntracranial pressure monitoring\\n\\nIndications for ICPmonitoring in TBI\\n\\nEmergency management of raised intracranial pressure\\n\\nSurgery in TBI\\n\\nDrugs in TBI\\n\\n2\\n\\nVasopressors e.g. noradrenaline, dobutamine if there\\nis hypotension, and in collaboration with a physician\\n\\nMeasures aimed at reducing accidents in transportation\\n(especially road traffic accidents), in homes and in\\nfactories:\\n- Motorbike crash helmet laws and enforcement\\n- Alcohol laws\\n- Speed limits\\n- Better motor licensing rules\\n- Health education\\n- Better motor engineering\\n- Good road designs\\n- Safety procedures at work and a good EMS and trauma\\nsystem\\n\\nThe multiply injured patient is that patient with injury\\nto more than one organ system\\n\\nOften victims of motor vehicle crashes, motor bike\\naccidents, pedestrians hit by cars, or falls from heights\\n\\nPresent a challenge to the managing team in terms of\\npriority of medical intervention\\n- If the priorities are not well ordered the results can be\\ncatastrophic\\n\\nDifficult to outline clinical features for these patients\\nas virtually any injury is possible\\n\\nIdentify life threatening injuries and treat\\nIdentify all injuries, institute primary management\\n\\nand limit progress of injuries and further tissue damage\\nRestore patient\\'s physiology paying special attention\\n\\nto the triad of , and\\nFormat a prioritized plan of definitive treatment and\\n\\nrehabilitation\\n\\nAdvanced trauma life support (ATLS) principles\\nshould apply\\n\\nPatient should be received by a trauma team\\nconsisting of at least :\\n- Atrauma team leader\\n- An airway and a procedure doctor\\n- Two nurses in similar capacity\\n- Aradiographer\\n- Ascrub nurse\\n- Asocial worker\\n\\nIt is important that hospitals which regularly manage\\ntrauma patients should maintain a standing trauma team\\non a 24- hour basis\\n- This helps to optimize outcomes in patient\\nmanagement\\n\\nThe trauma team needs this information from the\\nprehospital team\\n\\nPrevention\\n\\nMULTIPLE INJURIES\\nIntroduction\\n\\nTreatment objectives\\n\\nhypothermia acidosis coagulopathy\\n\\nManagement\\n\\nPrehospital information\\n\\n- Relayed in the format, preferably before the\\npatient\\'s arrival to enable adequate preparation to be\\nmade before hand\\n\\n: Mechanism of injury\\n: Injuries sustained\\n: Prehospital vital signs: pulse, blood pressure,\\n\\nrespiratory rate, oxygen saturation, temperature\\n: Treatment given e. g cervical collar, intravenous\\n\\nfluids etc\\n\\n- Quick survey to identify life threatening injuries and\\ntreat\\n\\nAirway\\n- Talking? Assume airway is alright. If not suction,\\nGuedel\\'s airways\\n- Careful with airway manoeuvers such as the jaw thrust\\nand chin lift\\n- Always protect the cervical spine\\n- Apply rigid cervical collar\\n- May need endotracheal intubation.\\n\\nBreathing\\n- Check the breathing, respiratory rate, oxygen\\nsaturation\\nExamine the chest:\\n- Tension pneumothorax? Haemothorax? Flail chest?\\nChest tube decompression?\\n- Always obtain a chest radiograph before\\ndecompression if possible\\n- Perform arterial blood gas estimations\\n\\nCirculation:\\n- Check the pulse, blood pressure, capillary refill\\n- Listen to the heart sounds\\n- Apply electrocardiograph leads\\n- Set up an intravenous line with a large bore cannula\\nsize 14 or 16 FG\\n- Collect blood for investigations: ABGs, FBC,\\nelectrolytes and urea, grouping and cross matching;\\npregnancy tests\\n- Focused Assessment using Sonography in Trauma\\n(FAST)\\n\\nDisability and Neurology\\n- Assess patient\\'s level of consciousness using the\\nGlasgow coma scale\\n- Check the state of the pupils and their reaction to light\\n- Expose the patient to perform a quick general\\nexamination but prevent hypothermia\\n- Cover with warm blanket or put on artificial warmer if\\navailable\\n- Record core temperature\\n\\nThe trauma series of radiographs is part of the primary\\nsurvey. These are\\n- A-Pchest view\\n- A-Ppelvic view\\n- Lateral cervical view\\n- (In the above order)\\n\\nMIST\\n\\nM\\nI\\nS\\n\\nT\\n\\nPrimary Survey\\n\\nChapter 15: Injuries and Acute Trauma Standard Treatment Guidelines for Nigeria 2008\\n\\n179 180\\n\\n\\n\\nSecondary survey\\n\\nAMPLE\\n\\nThis is a total body examination to detect injuries\\nsustained\\n\\nInvolves obtaining the history (allergies,\\nmedications, past medical history, pregnancy, last\\nmeal, environment including details of the accident)\\n\\nHead:\\n- Check for scalp haematomas, lacerations, skull\\nfractures, CSF leaks (rhinorrhoea, otorhoea); facial\\nfractures, raccoon eyes\\n- Remove contact lenses; examine pupils, oral\\nexamination; Battle sign\\n\\nNeck:\\n- Perform a careful neck examination\\n- Leave in collar if there is a high index of suspicion for\\ncervical injury\\n\\nChest:\\n- Inspect for dyspnoea, tachypnoea, chest movements,\\nflail chest, open pneumothorax or obvious penetration\\n- Palpate for chest expansion, crepitus (subcutaneous\\nemphysema) and rib fractures\\n- Assess position of the trachea and determine any\\ntracheal shift\\n- Determine percussion notes in both lung fields (dull\\nin haemothorax and hyperresonant in pneumothorax)\\n- Auscultate for breath sounds and air entry\\n\\nAbdomen:\\n- Examination findings often unreliable in the multiply\\ninjured patient\\n- This may be as a result of altered sensorium due to\\nhead injury, inebriation or drugs, neurological injury, or\\ndistracting injury\\n- There is need to augment examination with bedside\\ninvestigations like FAST and DPL (Diagnostic\\nPeritoneal Lavage) if indicated\\n- In the haemodynamically stable patient the best\\nimaging modality is the CT scan with contrast\\n- for seat belt marks, lacerations, abdominal\\ncontour and movements with respiration\\n- for tenderness, rebound tenderness and\\nrigidity\\n- if indicated\\n- for bowel sounds\\n- Pass a nasogastric tube\\n\\nPelvis:\\n- Perform anteroposterior and lateral compression tests\\nto check for pelvic fractures\\n- If fracture is suspected, apply a pelvic girdle or pelvic\\nsheet to decrease pelvic volume, improve tamponade\\nand decrease pelvic haemorrhage\\n\\nExamine the perineum:\\n- Check for perineal bruising, bogginess, scrotal\\nhaematomas, and blood at the tip of the penis\\n- If there is blood at the tip of the penis it is inadvisable\\nto pass a urethral catheter: a partial urethral rupture may\\nbe converted to a complete rupture. Do an\\n\\nInspect\\n\\nPalpate\\n\\nPercuss\\nAuscultate\\n\\nCHAPTER 16: SURGICAL CARE AND\\nASSOCIATED DISORDERS\\n\\nACUTEABDOMEN\\nIntroduction\\n\\nAetiology\\n\\nAn abdominal condition of sudden onset requiring\\nimmediate (urgent) attention\\n\\nAcommon surgical emergency\\n\\nSurgical:\\nInflammatory/infective conditions:\\n\\n- Acute appendicitis: the commonest cause of acute\\nabdomen\\n- Acute salpingitis: a common cause in sexually active\\nyoung females\\n- Acute cholecystitis\\n- Acute pancreatitis\\n- Acute diverticulitis: not very common in this\\nenvironment\\nThese conditions usually begin with a localized\\nperitonitis which progresses to generalized peritonitis if\\nleft untreated.\\n\\nPerforation of hollow viscera:\\n- Perforated chronic duodenal ulcer\\n- Perforated typhoid ileitis: a common cause in this\\nenvironment\\n- Traumatic gastrointestinal perforation\\n- Perforated gastrointestinal malignancies\\n\\nIntestinal obstruction:\\n- Strangulated external and internal hernias\\n- Intussusception\\n- Peritoneal adhesions and bands (congenital or\\nacquired)\\n- Gastrointestinal tumours\\n\\nIntra-abdominal haemorrhage\\n- Trauma (injury to solid viscera e.g. spleen and liver)\\n- Ruptured abdominal aortic aneurysm\\n- Haemorrhage from tumours (e.g. primary liver cell\\ncarcinoma)\\nObstruction to urinary/biliary tract:\\nThese usually present as colics due to stones\\n- Ureteric colic\\n- Biliary colic\\n\\nGynaecologic (outside those listed above)\\n- Bleeding Graffian follicle\\n- Twisted ovarian cyst\\n- Ectopic pregnancy\\n- Salpingitis\\n- Degenerating fibroids\\n\\nNon-specific abdominal pain:\\n- Includes a variety of conditions that do not come\\nunder the above causes\\n\\nMedical:\\nThese should always be borne in mind so as to avoid\\nunnecessary surgery\\n\\nMetabolic disorders:\\n- Diabetes mellitus\\n- Porphyria\\nHaematologic conditions:\\n- Sickle cell disease\\n- Leukaemia\\nInfections and infestations:\\n- Lower lobe pneumonia\\n- Gastroenteritis\\n- Malaria\\n- Parasitic infestations\\n\\nAcute abdominal pain\\nNote the following:\\n- Location\\n- Onset and progression\\n- Nature and character\\n- Aggravating and relieving factors\\n- Abdominal distension\\n- Apast history of similar pain suggests complication of\\nan underlying condition\\n- In typhoid perforation, fever precedes abdominal\\npain, while the reverse is true for acute appendicitis\\n\\nNausea and vomiting:\\n- Afrequent finding\\n- Common in intestinal obstruction\\n\\nAltered bowel habits\\n- Diarrhoea may suggest an infective/inflammatory\\ncondition\\n- Constipation occurs in intestinal obstruction and late\\nin peritonitis\\n- The presence or absence of blood, mucus in stool\\nshould be ascertained\\n\\nFever:\\n- An early feature in inflammatory/infective conditions\\n- Alate feature in most other causes of acute abdomen\\n\\nGynaecologic history:\\n- In every female, the following should be ascertained\\n- Last menstrual period: this will help in the suspicion\\nof ectopic gestation and bleeding Graffian follicle\\n- Vaginal discharge: salpingitis\\n\\nUrinary symptoms:\\n- Ascertain the presence or absence of the following\\n- Pain on micturition\\n- Pus in urine or cloudy urine\\n- Urethral discharge\\n- Loin pain\\n\\nPast medical history:\\n- Diabetes mellitus\\n- Sickle cell disease\\n\\nPhysical examination:\\nGeneral examination\\n\\n- Dehydration\\n- Temperature (the exact temperature should be taken\\nwith a thermometer: oral, axillary or rectal temperature)\\n- Pallor\\n\\nClinical features\\n\\nurethrocystogram to confirm urethral rupture\\n- If not contraindicated pass an indwelling urethral\\ncatheter to monitor urinary output and tissue perfusion\\n- Haematuria is suggestive of bladder or kidney injury\\n\\nPerform a vaginal examination, checking for bleeding\\nand lacerations\\n\\nLower limb examination:\\n- Check for obvious lacerations, deformity, fractures\\nand dislocations\\n- Undertake an appropriate neurovascular assessment\\n- Assess muscle power in each limb\\n\\nUpper limb examination:\\n- Same as for lower limb\\n\\n\\'LOG ROLL\\'\\n- The patient is now log rolled by four persons so as to\\nexamine the back\\n- The spine is examined from the occiput to the coccyx\\nchecking for deformity, swellings, steppings, and\\ntenderness\\n- While still in this position perform a digital rectal\\nexamination to assess anal tone, presence of blood in the\\nrectum and the position of the prostate\\n- Ahigh riding prostate is suggestive of urethral rupture\\n- Return patient to the supine position\\n\\nNeurological examination:\\n- Perform a detailed neurological examination as\\nindicated\\n\\nThe trauma team should now note all the observed\\ninjuries and format a plan for:\\n- The further management of the patient\\n- Removal from the emergency department and\\n- Definitive management of the patient under the\\nappropriate surgical units and consultants\\n\\nChapter 15: Injuries and Acute Trauma Standard Treatment Guidelines for Nigeria 2008\\n\\n181 182\\n\\n\\n\\n- Jaundice\\n- Foetor (as in diabetic ketoacidosis etc.)\\nHaemodynamic status:\\n- Pulse rate: >100/minute is abnormal\\n- Blood pressure: <100 mmHg systolic and <60 mmHg\\ndiastolic pressures indicate hypotension in an adult\\n\\nChest:\\n- Examine carefully for evidence of chest infection\\n\\nAbdomen:\\n- Distension\\n- Presence of scars of previous surgery or bruising in\\ntrauma\\n- Visible peristalsis (suggests intestinal obstruction)\\n- General peritonitis: there may be no movement with\\nrespiration\\n\\nAscertain the site of tenderness\\nLocalized:\\n- Right iliac fossa (appendicitis, gynaecologic\\nconditions etc.)\\n- Right hypochondrium (cholecystitis)\\nGeneralised: varied causes\\nAs much as possible any palpable mass should be\\n\\ncharacterized\\nIf tenderness is not too marked, ascertain the presence\\n\\nof free fluid in the peritoneal cavity by shifting dullness\\nor fluid thrill (ascites)\\n\\nListen for bowel sounds\\n- Diminished or absent in peritonitis; exaggerated in\\nearly stages of intestinal obstruction\\n\\nRectal examination:\\n- Look for perianal soilage\\n- Presence or absence of faeces in rectum\\n- Palpate rectovesical pouch or rectouterine pouch (of\\nDouglas) for bogginess and tenderness indicating a\\npelvic collection of pus or blood\\n\\nExamine the faeces on the examining finger for blood,\\nmucus\\n\\nVaginal examination:\\n- May be necessary to exclude gynaecological\\nconditions\\n\\nPlain radiography\\nAbdomen:\\n- Supine and upright films to identify features of\\nintestinal obstruction (dilated bowel loops and multiple\\nfluid levels)\\n- A radio-opaque shadow may be seen in the region of\\nthe urinary tract in ureteric colic\\nChest:\\n- An upright film may identify gas under the diaphragm\\nin gastrointestinal perforation\\n- Chest infection should also be looked for\\nAbdomino-pelvic ultrasonography:\\nShould help to ascertain the cause of pain in a proportion\\nof the patients (e.g. cholecystitis, gynaecologic\\nconditions, urinary calculi, and degenerating masses)\\n\\nInvestigations\\n\\n- May identify injured solid organ in trauma\\nDiagnostic peritoneal lavage:\\n\\n- Useful in abdominal trauma to identify\\nhaemoperitoneum and leakage of gastrointestinal\\ncontents and secretions of other organs into the\\nperitoneal cavity\\n\\nBiochemical tests:\\n- Urinalysis: test the urine for sugar, protein, ketones,\\netc\\n- Random blood sugar to exclude diabetes mellitus\\n- Serum electrolytes and urea; correction may be needed\\n- Serum amylase to exclude acute pancreatitis\\n\\nHaematological tests:\\n- Haemogram to exclude anaemia\\n- Packed cell volume may not be reliable because of\\nhaemoconcentration from dehydration\\n- If there is suspicion of sickle cell disease, the\\nhaemoglobin genotype should be obtained\\n- A complete blood count may show evidence of acute\\ninfection (leucocytosis, neutrophilia)\\n- Blood should be grouped, and compatible blood\\ncross-matched and made ready\\n\\nOther investigations:\\n- Computed tomography may be needed when there is\\ndiagnostic confusion\\n- Cultures: any suspicious fluid and materials should be\\nobtained and sent for microbiology and culture (e.g.\\nvaginal discharge, peritoneal fluid)\\n\\nFollow a detailed evaluation (as above) and make a\\nreasonable (probable) list of not more than 3 - 5\\ndifferential diagnoses\\n\\nResuscitation\\nRehydration and correction of electrolyte\\n\\nderangements\\nCorrect shock by giving crystalloids (sodium chloride\\n\\n0.9%, Ringer\\'s lactate) or colloid (e.g. dextran)\\nMaintenance fluids are calculated based on degree of\\n\\ndehydration\\nCorrect electrolyte deficits (especially potassium)\\nNasogastric decompression: the largest possible size of\\n\\ntube for patient\\nAspirate intermittently using low pressure suction or\\n\\nlarge syringe\\nUrethral catheterization (to monitor urine output)\\nCorrect anaemia (by blood transfusion)\\nCommence broad spectrum, intravenous antibiotics\\n\\neffective against likely microorganisms\\n- Do not give aminoglycosides until urine output is\\nadequate\\n\\nMonitor the following parameters to ensure adequate\\nrehydration:\\n- Cardio-respiratory stability\\n- Pulse rate\\n- Blood pressure\\n\\nDifferential diagnoses\\n\\nGeneral measures\\n\\n- Central venous pressure\\n- Pulmonary capillary wedge pressure\\n- Urine output, volume, colour\\n- Hydration status\\n- Skin turgor\\n- Sensorium\\n\\nAscertain level of consciousness\\n\\n- Pulse rate begins to fall towards, or below 100\\nbeats/minute\\n- Blood pressure: begins to towards normal\\n- Urine output: 50 - 100mL/hr (1 - 2 mL/kg/hr); clear or\\namber\\n\\nSurgical conditions:\\nMost of the surgical conditions will require urgent\\n\\nlaparotomy after adequate resuscitation\\n- Evacuation of pus, blood and all infected material\\n- Meticulous examination of all organs and recesses\\n- Identify primary pathology\\n- Identify other associated/coexisting pathology\\n- Treat identified pathologies on their merits\\n- Cleanse peritoneal cavity with large volumes of warm\\nsodium chloride 0.9%\\nMedical conditions:\\n\\nConsult a physician as appropriate, to treat the\\ncondition accordingly\\n\\nOutcome and survival depends on:\\nEarly presentation and diagnosis\\nPrompt and adequate resuscitation before surgery\\nAppropriate and meticulous surgery and other\\n\\ntreatments as indicated\\n\\nPostoperative surgical site infection (wound infection)\\nis a rather common, but undesirable occurence in this\\nenvironment\\n\\nSurgical site infection tends to increase postoperative\\nmorbidity and may lead to mortality\\n\\nEfforts therefore need to be made to prevent surgical\\nsite infection\\n\\nAntibiotic prophylaxis is not a substitute for adherence\\nto basic principles of surgical asepsis and meticulous\\nattention to technical details\\n\\nTo prevent postoperative infection in susceptible\\npatients\\n\\nShould be used only where there is a high risk of\\nbacterial contamination\\n\\nIntravenous route is preferred to achieve optimum\\neffect\\n\\nShould be given not >2 hours before surgical incision\\n\\nEvidence of adequate resuscitation\\n\\nDefinitive treatment\\n\\nPrognosis\\n\\nANTIMICROBIALPROPHYLAXIS IN SURGERY\\nIntroduction\\n\\nObjective of antibiotic prophylaxis\\n\\nPrinciples of antibiotic prophylaxis\\n\\n- Many surgeons prefer to give at the time of induction\\nof anaesthesia\\n\\nShould be repeated intraoperatively if the surgery lasts\\nfor >3 hours\\n\\nNot more than 2 - 3 doses (not longer than 24 hours)\\nshould be given after surgery\\n\\nAntibiotics should be reinstituted if infection occurs\\n\\nShould depend on the known prevalent bacteria in the\\npart of the body\\n\\nBroad spectrum antibiotics are preferred\\nCombination of antibiotics (with synergistic actions) is\\n\\npreferred to a single antibiotic\\nShould be used only when scientific evidence shows\\n\\nbenefit\\n\\nWhere endogenous contamination is expected\\n(breaching of hollow organs):\\n\\nOesophageal surgery\\nHepatobiliary surgery\\nColorectal surgery\\nUrinary tract surgery and procedures\\nVaginal and uterine surgery\\nPatients with valvular heart disease\\nUse of prostheses and implants\\nOrthopaedic implants\\nNeurosurgical implants\\nPatients with cardiac prostheses\\nOther prostheses\\n\\nImmunocompromised patients:\\nHIV/AIDS\\nDiabetes mellitus\\nCancer; patients on cytotoxic chemotherapy\\nPatients on steroids\\nSeverely malnourished patients\\n\\nOthers:\\nPatients with peripheral vascular disease undergoing\\n\\nsurgery on that limb\\n\\nAntibiotic misuse\\nAntibiotic resistance\\nComplications of antibiotics (e.g. pseudomembranous\\n\\ncolitis)\\nFalse sense of surgical security\\n\\nA condition in which there is failure of onward\\npropulsion of intestinal contents\\n\\nAcommon surgical emergency\\n\\nMechanical (dynamic):\\nExtra-luminal (compression from outside the intestinal\\n\\nwall)\\n\\nChoice of antibiotics\\n\\nIndications for antibiotic prophylaxis\\n\\nComplications\\n\\nINTESTINALOBSTRUCTION\\nIntroduction\\n\\nAetiology\\n\\nAntibiotic prophylaxis should be effective and efficient\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 16: Surgical Care and Associated Disorders\\n\\n183 184\\n\\n\\n\\n- Strangulated external hernias (e.g. inguinal hernia),\\ninternal hernias\\n- Volvulus\\n- Peritoneal adhesions and bands\\n- Intra-abdominal masses (e.g. lymph nodes, tumours)\\n\\nIntramural (due to causes within the wall of the\\nintestine):\\n- Intussusception\\n- Intestinal atresia and stenosis\\n- Strictures\\n- Hirschsprung\\'s disease\\n- Intestinal tumours\\n\\nIntraluminal (due to causes within the lumen of the\\nintestine):\\n- Impacted faeces\\n- Impacted worms (e.g. ascaris lumbricoides)\\n- Foreign bodies\\n- Pedunculated polyps\\nNon-mechanical (adynamic, paralytic ileus):\\n\\nElectrolyte derangements\\n- Hypokalaemia\\n\\nSepticaemia (especially in neonates and infants)\\nDiabetes mellitus\\nOther metabolic conditions e.g. uraemia\\n\\nOnly the intestinal lumen is affected; there is no\\nevidence of strangulation\\n\\nVascular compromise has occurred and may progress\\nto gangrene and/or perforation\\n\\nAsegment of intestine is blocked at 2 ends (e.g. colonic\\nobstruction with competent ileocaecal valve, intestinal\\nvolvulus)\\n- Dangerous because the risk of perforation is high\\n\\nIrrespective of the cause or type of obstruction, the\\nsymptoms, signs and physiologic consequences are the\\nresult of the following\\n- Stasis proximal to the level of obstruction (gases, fluid)\\n- Dilatation above level of obstruction\\n- Increased secretion from the involved segment(s)\\n- Compression of the veins and later arteries leading to\\nischaemia, gangrene, necrosis and perforation\\nThe end results are:\\n- Dehydration\\n- Electrolyte derangements\\n- Anaemia\\n- Peritonitis\\n- Septicaemia\\n\\nSymptoms:\\nColicky abdominal pain: not a prominent symptom in\\n\\nadynamic obstruction\\nAbdominal distension\\n\\nPathophysiology\\n\\nClinical features\\n\\nSimple obstruction\\n\\nStrangulated obstruction\\n\\nClosed loop obstruction\\n\\nVomiting: usually bilious and occurs early in small\\nintestinal obstruction\\n- Alate symptom in large intestinal obstruction\\n- May be faeculent in advanced obstruction\\nConstipation: occurs early in large intestinal obstruction\\nand late in small intestinal obstruction\\n\\nObstipation (non-passage of faeces or flatus) signifies\\ncomplete obstruction\\n\\nStools may be blood-stained (intussusception,\\nvolvulus, strangulation)\\nDiarrhoea: may be present in the face of obstruction\\n\\n(spurious diarrhoea)\\nFever: signifies strangulation or perforation\\n\\nSigns:\\nGeneral:\\n\\nDehydration\\nPyrexia\\nPallor\\n\\nCardiorespiratory: assess the following\\n- Lung fields\\n- Pulse rate\\n- Blood pressure\\n\\nAbdomen:\\n- Distension: usually marked in large intestinal\\nobstruction\\n- Visible peristalsis\\n- Tenderness\\n- Tympanitic percussion notes\\n- Bowel sounds: increased, diminished or absent\\n\\nRectal examination\\n- Perianal soilage\\n- Empty or full rectum\\n- Any palpable mass\\n- Examine finger for faeces, blood, mucus\\n\\nFluid and electrolyte derangements (especially\\nhypokalaemia)\\n\\nIntestinal gangrene\\nIntestinal perforation\\nPeritonitis\\nSepticaemia and septic shock\\n\\nPlain radiographs\\n- Abdomen\\nSupine:\\n\\nDilated bowel loops\\nShould identify affected bowel (jejunum, ileum, large\\n\\nintestine)\\nUpright (erect):\\n\\nMultiple fluid levels\\n- Chest\\n\\nTo identify gas under diaphragm (suggests perforation)\\nand chest infection\\n\\nBiochemical tests;\\n- Electrolytes and urea\\n- Blood Glucose\\n\\nComplications\\n\\nInvestigations\\n\\nHaematological:\\n- Haemogram\\n- Complete blood count (leucocytosis and neutrophilia\\nsuggest strangulation)\\n- Group and cross match blood and store appropriately\\n\\nUltrasonography\\n- Useful in intussusception, suspected intra-abdominal\\ntumours\\n\\nLaparoscopy:\\n- May be helpful in some instances to identify the cause\\nof obstruction\\n\\nIn difficult cases, other investigations may be necessary\\ndepending on the presentation and clinical suspicion\\n- Avoid contrast studies (as much as possible) in acute\\nintestinal obstruction\\n\\nResuscitate:\\n- Rehydrate and correct electrolyte deficits (especially\\npotassium)\\n- Nasogastric decompression using a wide bore\\nnasogastric tube\\n\\nUrethral catheterization to monitor urine output\\nBroad-spectrum intravenous antibiotics (anaerobes,\\n\\ngram negatives, gram positives)\\nCorrect anaemia by blood transfusion\\n\\nShould only be embarked upon after adequate\\nresuscitation\\n\\nMost of the causes will require laparotomy\\nTreat identified cause on its merits:\\n\\nGangrenous or perforated bowel: resect\\nSmall intestine:\\n\\nRe-anastomose if patient is fit\\nBring ends out as stomas if patient is too ill\\n\\nLarge intestine:\\nRe-anastomose if on right side\\nBring ends out as stomas if on left side\\nEvacuate any peritoneal collection\\nSuspicious lesions: take specimens for histopathology\\n\\nTreat accordingly\\nSurgery is not required\\n\\nThe assessment of a patient before surgery to ensure\\nthat the patient is in optimal physiologic state and fitness\\nfor the surgical procedure\\n\\nAmost important aspect of the care of a surgical patient\\nNo elective operation should be carried out without an\\n\\nGeneral measures\\n\\nDefinitive treatment\\n\\nP R E O P E R A T I V E E V A L U A T I O N a n d\\nPOSTOPERATIVE CARE\\n\\nIntroduction\\n\\nMechanical obstruction\\n\\nNon-mechanical (adynamic) obstruction\\n\\nPreoperative Evaluation\\n\\nadequate preoperative assessment\\nIn the emergency situation, all efforts must be made to\\n\\nensure that the patient can withstand anaesthesia and the\\nsurgical procedure\\n\\nOccasionally (e.g. with severe on-going haemorrhage,\\nairway obstruction) resuscitation, anaesthesia and\\nsurgery may commence simultaneously\\n\\nTo detect any fluid and electrolyte derangements\\nTo detect any haematological derangements (e.g.\\n\\nanaemia, bleeding diathesis, sickle cell disease)\\nTo detect any coexisting medical conditions that may\\n\\nadversely affect the outcome of anaesthesia and surgery\\n- All patients scheduled to have surgery should be in a\\nhaemodynamically stable condition before surgery\\n\\nThe above may not always be possible, but efforts must\\nbe made to improve cardiopulmonary and renal function\\n\\nCorrect any detected abnormality\\nPatient evaluation and correction of abnormalities may\\n\\nneed to be done in conjunction with others: the\\nanaesthetist, physician, paediatrician etc\\n\\nEfforts should be made to identify the following by\\nhistory and physical examination:\\nCardiopulmonary disorders:\\n\\nCough\\nChest infection\\nBronchial asthma\\nChronic obstructive airways disease\\nHypertension\\nCardiac failure\\n\\nMetabolic disorders:\\nDiabetes mellitus\\n\\nHaematologic disorders:\\nSickle cell disease\\n\\nAllergy:\\nDrug allergies (e.g. penicillins, talc, elastoplast,\\n\\nantiseptics etc.)\\nDrug history:\\n\\nPropranolol, diuretics, steroids and other hormonal\\nagents; prednisolone, oral contraceptives; tricyclic\\nantidepressants\\nSocial habits:\\n\\nCigarette smoking, alcohol use\\nPrevious anaesthetic experience:\\n\\nHow long ago, type of anaesthesia\\n\\nCardiopulmonary:\\nChest radiograph: especially for patients 60 years and\\n\\nabove, and those with chest infection\\n- Look for evidence of chest infection and cardiomegaly\\n\\nElectrocardiogram: especially for patients over 60\\nyears and those with heart disease or hypertension\\n\\nPulmonary function tests may be necessary in patients\\nwith obstructive airways disease\\nMetabolic:\\n\\nObjectives of preoperative evaluation\\n\\nClinical evaluation\\n\\nInvestigations\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 16: Surgical Care and Associated Disorders\\n\\n185 186\\n\\n\\n\\nUrine sugar to exclude diabetes mellitus\\n- All adults and patients with history suggestive of\\ndiabetes mellitus\\n\\nSerum Electrolytes and Urea\\nHaematologic:\\n\\nHaemogram/packed cell volume\\nHaemoglobin genotype\\nClotting profile (prothrombin time and kaolin cephalin\\n\\nclotting time) where there is suspicion of bleeding\\ndiathesis e.g. in jaundiced patients\\nOthers:\\n\\nOther investigations as may be indicated by individual\\nclinical circumstances\\n\\nCardiopulmonary:\\nRehydrate patient adequately, using appropriate fluids\\nControl blood pressure\\nTreat/control chest infections with appropriate\\n\\nantibiotics\\nControl obstructive airways disease\\n\\nMetabolic conditions and derangements:\\nCorrect electrolyte deficits, especially hypokalaemia\\nAcidosis is usually corrected by adequate rehydration\\n\\n(provided the patient has no renal disease)\\nDiabetes should be controlled\\n\\n- Patients already controlled will need their therapy to be\\nconverted to soluble insulin for long surgical procedures\\n(this should be done in conjuction with the physician and\\nanaesthetist)\\nHaematological:\\n\\nCorrect anaemia\\n- Cause(s) of anaemia should be identified and treated\\n- The minimum haemogram for a patient undergoing\\nelective surgery should be 10 g/dL\\n- Haemogram 6 - 9 g/dL: correction may be achieved by\\nhaematinics; reschedule surgery\\n- Haemogram <6 g/dL: correction may require blood\\ntransfusion\\n- Emergency surgery: correct anaemia by blood\\ntransfusion\\nBlood transfusion should be avoided as much as\\npracticable.\\n- Patient with sickle cell anaemia: haemogram should be\\nbrought up to 8 g/dL\\n- These patients must be adequately hydrated to avoid\\nsickling and sludging within the bloodstream\\n- Short day case procedure: imperative to admit the\\npatient with sickle cell anaemia at least a day before\\nsurgery to achieve adequate hydration\\n\\nSuspected bleeding diathesis\\n- Intramuscular vitamin K (10 mg daily), at least 48 - 72\\nhours before surgery\\n- For major surgery, blood should be grouped, cross-\\nmatched and stored\\nOther disorders:\\n\\nCorrection of abnormalities and preparation for\\nsurgery\\n\\nAny associated medical condition should be treated /\\ncontrolled before embarking on surgery\\n- This should be done in conjunction with the physician\\nas much as possible\\n\\nPatients who require nutritional rehabilitation\\n- If surgery is elective reschedule it, and give adequate\\ntime to achieve improved nutritional status, otherwise\\nmorbidity and mortality may be increased\\n\\nHigh- risk patients:\\n- At high risk of developing postoperative complications\\n- Deliberate and meticulous efforts should always be\\nmade to adequately evaluate them and ensure optimal\\nfitness for surgery\\n- Elderly patients (age >60 years): - risk of deep vein\\nthrombosis, atelectasis\\n- Obesity- risk of deep vein thrombosis, atelectasis\\n- Cancer-risk of deep vein thrombosis, atelectasis,\\nhaemorrhage\\n- Women on oral contraceptive pills-risk of deep vein\\nthrombosis\\n- Co-existing chronic medical conditions-risk of wide\\nranging complications\\n- Sickle cell anaemia-risk of sickling crises, deep vein\\nthrombosis\\n\\nDetails of the surgery should always be explained to the\\npatient (or relatives) in very simple language before\\nsurgery\\n\\nShould include a mention of the possible/common\\ncomplications\\n\\nA signed consent should be obtained, in the presence of\\na witness (usually a nurse)\\nObtaining consent should be done by the surgeon himself\\n\\nMeticulous and efficient care in the postoperative\\nperiod is paramount for adequate patient recovery and\\nsuccess of surgery\\n\\nA well-planned and supervised postoperative care\\nensures a smooth recovery, and helps to prevent or limit\\npostoperative morbidity and mortality\\n\\nPreoperative, intraoperative and postoperative care is a\\ncontinuum and interlinked\\n- Many of the instructions and therapy started in the\\npreoperative period may need to be continued into the\\npostoperative period\\n\\nThe surgeon himself must be involved in the\\npostoperative care and not leave it to others, who may not\\nhave much ideas or information about the surgery\\n\\nClose monitoring and observation:\\nThe first 4 - 6 hours after a major surgery and general\\n\\nanaesthesia are critical\\n- The patient is still drowsy and recovering from the\\n\\nConsent for surgery\\n\\nPostoperative Care\\n\\nInitial recovery\\n\\nIntroduction\\n\\neffects of anaesthesia\\nThe cardiopulmonary status (pulse rate, blood pressure,\\n\\nrespiration) needs to be monitored very closely (every 15\\nminutes) in order to promptly detect any abnormality\\n\\nWhere available, electronic monitors with an alarm\\nsystem should be used\\n\\nThe patient may still be under some effect of anaesthesia\\n- Airways need to be kept patent\\nPrevent the tongue from falling backwards by positioning\\npatient in the left lateral position\\n\\nThe neck should be prevented from falling on itself as\\nthis can occlude the airway\\n\\nSecretions should also be cleared using a low-pressure\\nsuction\\n\\nDifferent operations require specific positioning in the\\npostoperative period to reduce venous pressures, keep\\nairways patent, enhance drainage etc\\n\\nThe surgeon should be conversant with the specific\\npositions and give appropriate instructions\\n\\nPain is a most undesirable effect of surgery\\nPatients should not be allowed to suffer from pain unduly\\n\\nThe appropriate analgesic technique should be chosen\\nfor the nature of surgical procedure performed\\n\\nAdequate analgesia will ensure early ambulation and\\nhelp to limit atelectasis\\n\\nPatient taking orally:\\nParacetamol\\nNon steroidal antiinflammatory drugs\\n\\nPatient not taking orally:\\nInjectable nonsteroidal antiinflammatory drugs (e.g.\\n\\ndiclofenac sodium)\\nMajor surgery:\\n\\nParenteral analgesics\\n- Narcotic analgesics (e.g. morphine)\\n- NSAIDs (e.g. diclofenac sodium)\\n\\nThe stomach may need to be kept decompressed for 24 -\\n48 hours, particularly following gastrointestinal surgery\\n\\nDecompression prevents abdominal distension and\\ntension on abdominal fascial closure\\nIt also prevents splinting of the diaphragm and atelectasis\\nThe widest possible bore of nasogastric tube for patient\\'s\\n\\nage should be chosen\\nThe nasogastric tube should be removed as soon as it is no\\nlonger needed, evidenced by:\\n- Progressively diminishing effluent (<500 mL/24 hours\\nin an adult)\\n- Change from bilious colour to clear colour of gastric\\njuice\\n\\nEnsure that the patient receives adequate amounts of\\nintravenous fluids if oral intake is prohibited\\n\\nAirways management\\n\\nNursing position\\n\\nAnalgesia\\n\\nNasogastric decompression\\n\\nFluid and electrolyte balance\\n\\nMinor/moderate surgery\\n\\nChoose an appropriate fluid to provide enough calories\\nand electrolytes\\nGlucose 5% in sodium chloride 0.9% or lactated Ringer\\'s\\n\\nsolution is appropriate for most adults\\nAfter the 48 hours, the daily requirement of potassium\\n\\nshould be provided if oral intake is still prohibited,\\nespecially if nasogastric drainage is ongoing\\n- This should be in form of potassium chloride added to\\nintravenous fluids\\n\\nAssess fluid and electrolyte balance on a daily basis and\\ncorrect deficits\\n\\nAll intake (intravenous fluids, drugs, blood etc.) and\\noutput (urine, nasogastric drainage, other tubes, etc.) as\\nwell as insensible losses should be carefully recorded\\n\\nFollowing major surgery, adequate nutrition should be\\nprovided for the patient, particularly if oral intake is going\\nto be prohibited for more than 48 - 72 hours\\n- This can be done in the form of parenteral nutrition\\n\\nBed-ridden patients and patients who have had chest or\\nupper abdominal surgery are prone to basal atelectasis and\\nhypostatic pneumonia.\\n- These should be prevented by appropriate chest\\nphysiotherapy\\n- Ensure adequate analgesia to enhance chest excursion\\n- Encourage coughing and expectoration, with a hand\\nsupporting any abdominal wound\\n- Periodic chest percussion to loosen bronchial secretions\\n- Ambulate as early as possible\\n\\nMobilize and ambulate patients as early as is practicable\\nto avoid the complications of prolonged recumbency\\n\\nAmbulation should be gradual: prop up in bed, sit out of\\nbed, short walks etc.)\\n\\nEarly ambulation should help prevent hypostatic\\npneumonia and deep vein thrombosis (very important in\\nobese and elderly patients)\\n\\nAppropriate antibiotics as indicated\\nIrrational or indiscriminate use is not to be encouraged\\n\\nSpecific surgical wounds are cared for in different ways\\nClean surgeries: do not open wound (unless indicated)\\n\\nuntil day 5 - 7\\nInspect wounds immediately if there are features\\n\\nsuggestive of surgical site (wound) infection\\n- Undue pain\\n- Undue swelling\\n- Discharge of serosanguinous fluid or pus\\nInfected wounds:\\n\\nWound swab for microbiological culture and sensitivity\\ntests\\n\\nAdequate local wound care\\nAppropriate antibiotics\\nIf there are systemic features (e.g. fever, anorexia)\\n\\nNutrition\\n\\nChest physiotherapy\\n\\nMobilization and ambulation\\n\\nAntibiotics\\n\\nWound care\\n\\nChapter 16: Surgical Care and Associated Disorders Standard Treatment Guidelines for Nigeria 2008\\n\\n187 188\\n\\n\\n\\nsystemic treatment with antibiotics may be necessary\\n\\nAll indwelling catheters, tubes and drains should be\\nmonitored and appropriately managed to avoid infection,\\ndislodgement/displacement\\n\\nThey should be removed as soon as they have served\\ntheir purpose(s)\\n\\nLook out for general complications and treat accordingly\\nPostoperative pyrexia may be due to:\\n\\n- Malaria\\n- Atelectasis and hypostatic pneumonia\\n- Wound infection\\n- Urinary tract infection\\n- Deep vein thrombosis\\n- Wound infection\\n\\nBlood transfusion is the introduction of whole blood or\\nblood components into the blood stream of an individual\\n\\nShould be used appropriately because its use is not\\nwithout complications and untoward effects\\nBlood and its commonly used components:\\n\\nWhole blood\\nPacked red cells\\nFresh frozen plasma\\nClotting factor concentrates\\nPlatelet concentrate\\n\\nBasic principles of blood transfusion:\\nAppropriate use\\nAdequate evaluation before transfusion to ascertain the\\n\\nindication, amount and component required\\nScreening for communicable diseases (HIV, hepatitis,\\n\\netc.) before transfusion\\nAdequate grouping and cross-matching before\\n\\ntransfusion\\nStore under at appropriate temperature\\nUse blood fractions whenever possible to avoid wastage\\nUse autologous blood whenever possible to minimize\\n\\nrisk of transfusing communicable diseases\\n\\nTo replace lost blood volume\\n- Haemorrhage from trauma and other forms of blood\\nloss\\n- Operative haemorrhage\\n\\nTo improve oxygen carrying capacity\\n- Various types of anaemias\\n\\nTo replace clotting factors\\n- Some liver diseases\\n- Deficiency states\\n\\nCare of indwelling tubes, catheters and drains\\n\\nGeneral complications in the post-operative period\\n\\nIndications for blood transfusion\\n\\nUSE OF BLOOD TRANSFUSION IN SURGERY\\nIntroduction\\n\\nTransfusion is not a substitute for meticulous and\\nappropriate surgical techniques\\n\\nComplications\\nEarly complications:\\n\\nImmune reactions\\nABO incompatibility\\nRhesus incompatibility\\nFebrile reactions\\nAllergic reactions\\nReactions to plasma proteins\\n\\nBiochemical complications:\\nHyperkalaemia\\nCitrate toxicity (hypocalcaemia)\\nHaemoglobinaemia\\n\\nInfective complications:\\nBacteraemia\\nTransfusion of parasites (e.g. malaria)\\nTransfusion of viruses (HIV, Hepatitis B, C, D)\\n\\nPhysical complications:\\nVolume overload\\nAir embolism\\nHypothermia\\n\\nMassive transfusion refers to the single transfusion of\\n50 - 100% of the equivalent of an individual\\'s blood\\nvolume in less than 24 hours\\n- 2.5 - 5 litres in adults and 40 - 80 mL/kg body weight in\\nchildren\\nThe complications are related to:\\n\\nVolume overload\\nTransfusion of old blood\\nElectrolyte derangements (especially potassium and\\n\\ncalcium)\\nTransmission of infections\\nDelayed complications:\\nHaemosiderosis\\nPost transfusion purpura\\n\\nTransfusion of the patients\\' own blood\\n\\nReduced risk of transmitting communicable diseases\\nOvercomes the problem of shortage of blood\\n\\nPre-deposit blood\\n- Usually best done in conjunction with haematology\\nstaff\\n- The patient donates one unit of blood at a time (e.g.\\nweekly) several weeks before the elective surgery\\n- Following donation, the patient is given haematinics,\\nand sometimes erythropoietin to enhance bone marrow\\nfunction; the blood is stored for later use\\n\\nPre-operative isovolaemic haemodilution\\n- Just before elective surgery, 1 - 2 units of blood are\\ntaken from the patient and replaced by volume expanders\\nsuch as Ringer\\'s lactate, sodium chloride 0.9%, or colloid\\n- The blood taken is transfused intraoperatively after all\\nhaemostasis has been secured\\n\\nIntraoperative blood salvage\\n\\nComplications of massive blood transfusion\\n\\nAdvantages\\n\\nTypes and methods\\n\\nAutologous transfusion\\n\\n- Appropriate for patients undergoing laparotomy or\\nthoracotomy for haemorrhage into these cavities (e.g.\\ntraumatic haemothorax, splenic injury, ectopic gestation)\\n- The blood is collected in an appropriate blood bag and\\nthen transfused using a blood giving set with filter\\n- Special salvage equipment may be available sometimes\\n- Contaminated blood must not be transfused\\n\\nPregnancy\\nChronic medical conditions\\nCancer\\nSituations where the blood may have become\\n\\ncontaminated (this is for intraoperative blood salvage)\\nChildren:\\n\\nUmbilical cord blood\\n\\nSince blood transfusion is attended by several untoward\\neffects and complications, efforts are continuously being\\nmade to identify alternatives to transfusion\\n- Most of these are experimental at the moment and are\\nnot practicable in the clinical setting\\n\\nContraindications to autologous transfusion\\n\\nOther sources of blood\\n\\nAlternatives to blood transfusion\\n\\nChapter 16: Surgical Care and Associated Disorders Standard Treatment Guidelines for Nigeria 2008\\n\\nCHAPTER 17: PAEDIATRIC PERSPECTIVES\\n\\nMEASLES (Rubeola)\\nIntroduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nAn acute viral infection caused by an RNA virus of the\\ngenus Morbillivirus in the family Paramyxoviridae\\n- Only one serotype is known\\n\\nEndemic through out the world\\n30 - 40 million cases and 745,000 deaths for the year\\n\\n2001\\n- 50 - 60% of estimated deaths due to vaccine-\\npreventable diseases\\n\\nAlso a major cause of preventable blindness\\nTransmission is by droplet infection during the\\n\\nprodromal stage\\nIncubation period: 9 - 11 days\\nTime of exposure to appearance of rash: about 14 days\\n\\nThe essential lesion is found on the skin, mucous\\nmembranes of the nasopharynx, bronchi, intestinal tract\\nand conjunctivae\\nThree stages:\\n\\nIncubation period\\nProdromal stage with an enanthem\\nFinal stage\\n\\nIncubation period:\\nMild fever; 10 - 11 days\\n\\nProdromal stage:\\n3 - 5 days\\nLow grade to moderate fever\\nDry cough\\nCoryza\\nConjunctivitis\\nKoplik spots\\nPhotophobia\\n\\nFinal stage:\\nTemperature rises abruptly as the rash appears\\nRash begins from the upper lateral part of the neck,\\n\\nbehind the ears, along the hairline and posterior parts of\\nthe cheek then spreads to the rest of the body\\n\\nRash fades in the same pattern in 3 - 4 days\\nAssociated lymphadenopathy\\n\\nRubella\\nRoseola infantum\\nInfections from Echovirus, Coxsackie Virus and\\n\\nAdenovirus\\nInfectious mononucleosis\\nToxoplasmosis\\nMeningococcaemia\\nScarlet fever\\nRickettsial diseases\\nKawasaki disease\\nSerum sickness\\nDrug rashes\\n\\n189 190\\n\\n\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nNotable adverse drug reactions\\n\\nPrevention\\n\\nDiarrhoea\\nOtitis media\\nPneumonia\\nLaryngo-tracheobronchitis\\nEncephalitis\\nSeizures\\nBlindness\\nSubacute sclerosing panencephalitis\\n\\nIsolation of the virus by tissue culture\\nELISA: first IgM and later IgG response\\nDemonstration of Warthin Finkeldy giant cells in\\n\\nsmears of the nasal mucosa\\nFull Blood Count: low white blood cell count with\\n\\nrelative lymphocytosis\\nLumbar puncture: increase in CSF protein; and small\\n\\nincrease in lymphocytes, normal glucose level\\n\\nRelieve symptoms\\nHydrate adequately\\nTreat secondary bacterial infection\\nPrevent complications\\n\\nHumidification of the room for those with croup\\nProtection from strong light for those with\\n\\nphotophobia\\nNutrition\\nFluids\\n\\nNo specific drugs\\nSome children require supplemental vitaminA\\n\\n- 100,000 IU stat for age 6 months - 1 year\\n- 200,000 IU stat for age above 1year\\n- Repeat on days 2 and 14 for those with ophthalmologic\\nevidence of vitaminAdeficiency\\n\\nSpecific treatment of complications\\n\\nVitaminAmay cause features of pseudotumour cerebri\\n- Nausea, vomiting, drowsiness, bulging fontanelle,\\ndiplopia, papilloedema and cranial nerve palsies\\n\\nIsolation precaution from the 5th day of exposure until\\n5days after appearance of the rash\\n\\nMeasles vaccine at 9 months\\n- Vaccine may be given at 6 months for measles post-\\nexposure, and in outbreak prophylaxis\\n\\nPost-exposure prophylaxis\\n- Passive immunization with immune globulin within 6\\ndays of exposure\\n\\nPOLIOMYELITIS\\nIntroduction\\n\\nPathogenesis\\n\\nClinical features\\n\\nAn acute infectious disease of humans (particularly\\nchildren) caused by any of three serotypes of poliovirus\\nP1, P2, and P3\\n\\nImmunity to one serotype does not confer immunity to\\nothers\\n\\nOccurs in many regions of the developing world\\nThe global polio eradication initiative was launched in\\n\\n1988\\n- In 15 years, the number of cases has fallen by 99% and\\nthe number of infected countries reduced from 125 to 7\\n- There was an increase in global cases as a result of an\\nepidemic in India, and increase in cases in Nigeria\\n\\nEntry into mouth (via faecally-contaminated\\nfood/water)\\n\\nReplication in pharynx, gastrointestinal tract, local\\nlymphatics\\n\\nHaematologic spread to lymphatics and central nervous\\nsystem\\n\\nViral spread along nerve fibres\\nDestruction of motor neurons\\n\\nIncubation period: 6 - 20 days, with a range of 3 - 35\\ndays\\n\\nAsymptomatic infection: 95%\\nMinor non-specific symptoms: 4 - 8%\\nSymptoms occur in less than 2 %\\n\\n- Slight fever\\n- Headache\\n- Malaise\\n- Sore throat\\n- Vomiting\\n\\n(1-2%)\\n- Symptoms last 1- 2 weeks\\n\\nModerate fever\\nHeadache\\nVomiting\\nDiarrhoea\\nFatigue\\nIrritability\\nPain or stiffness of the back, arms, legs, abdomen\\nMuscle tenderness and spasms in any part of the body\\nNeck pain and stiffness\\nSkin rash\\n\\n3 types depending on the level of involvement\\n- Spinal polio: 79%\\n- Bulbar polio: 2%\\n- Bulbospinal: polio 19%\\n\\nFever 5 - 7 days before other symptoms\\nHeadache\\nStiff neck and back\\nAssymmetric muscle weakness\\nRapid onset\\n\\nNon-paralytic polio\\n\\nParalytic polio\\n\\nProgresses to paralysis\\n- Location of paralysis depends on region affected\\n\\nAbnormal sensation\\nHyperaesthesia\\nDifficulty in initiating micturition\\nConstipation\\nBloated abdomen\\nDysphagia\\nMuscle spasms\\nDrooling\\nDyspnoea\\nIrritability\\nPositive Babinski\\'s sign\\n\\nMultiple intestinal erosions\\nAcute gastric dilatation\\nHypertension\\nHypercalcaemia\\nNephrocalcinosis\\nVascular lesions\\nMyocarditis\\nPulmonary oedema\\nPulmonary embolism\\nParalysis of limbs, muscles of respiration and\\n\\nswallowing which can be fatal\\n\\nGuillain- Barré syndrome\\nLead toxicity\\nCranial nerve Herpes zoster\\nPost-diphtheric neuropathy\\nArthropod borne viral encephalitis\\nRabies\\nTetanus\\nBotulism\\nEncephalomyelitis: demyelinating type\\nNeoplasms in and around the spinal cord\\nFamilial periodic paralysis\\nMyasthenia gravis\\nAcute porphyrias\\nHysteria and malingering\\nConditions causing pseudoparalysis\\nUnrecognized trauma\\nTransient toxic synovitis\\nAcute osteomyelitis\\nAcute rheumatic fever\\nScurvy\\nCongenital syphilis: pseudoparalysis of Parrot\\n\\nMultiple intestinal erosions\\nAcute gastric dilatation\\nHypertension\\nHypercalcaemia\\nNephrocalcinosis\\nVascular lesions\\nMyocarditis\\nPulmonary oedema\\n\\nComplications\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nPulmonary embolism\\nParalysis of limbs, muscles of respiration and swallowing\\nwhich can be fatal\\n\\nViral isolation from stool, pharynx or cerebrospinal fluid\\nIf the virus is isolated from a person with acute flaccid\\n\\nparalysis, it must be tested further, using fingerprinting or\\ngenomic sequencing to determine if it is the wild type or\\nvaccine type\\n\\nSerology: a fourfold rise in antibody may be\\ndemonstrated\\n\\nCerebrospinal fluid examination:\\n\\n- Raised white cell count, 10 - 200 cells/mm (primarily\\nlymphocytes)\\n- Mild increase in protein: 40 - 50 mg/mL\\n\\nAllay fear\\nMinimize ensuing skeletal deformities\\nAnticipate and treat complications\\n\\nPrepare the child and family for a prolonged management\\nof permanent disability if it seems likely\\n\\nBed rest\\nAvoidance of exertion\\nApplication of hot packs\\nLying on a firm bed\\nHospitalization for those with paralytic disease\\nSuitable body alignment to avoid excessive skeletal\\n\\ndeformity\\nActive and passive motions as soon as pain disappears\\nManual compression of the bladder\\nAdequate dietary and fluid intake\\nReview by orthopaedist and psychiatrist\\nGravity drainage of accumulated secretions\\nTracheostomy in case of vocal cord paralysis\\n\\nBethanicol 5 - 10 mg orally 2.5 - 5 mg subcutaneously\\nfor bladder paralysis\\n\\nAnalgesics\\n- Avoid opiates if there is impairment of ventilation\\n\\nTreat urinary tract infecton with appropriate antibiotics\\n\\nHygienic practices\\n- To prevent / limit contamination of food and water by\\nthe virus\\n\\nVaccination\\n- The only effective method of prevention\\n\\nGiven at:\\nBirth\\n6 weeks\\n10 weeks\\n14 weeks\\n\\n- Highly effective\\n- 50% immune after 1 dose\\n- >95% immune after 3 doses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nPrevention\\n\\n3\\n\\nor\\n\\nOral Polio Vaccine\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 17: Paediatric Perspectives\\n\\n191 192\\n\\n\\n\\n- Confers herd immunity\\n- Immunity probably life long\\n- Limits spread of wild polio virus\\n\\nGiven at:\\n2 months\\n4 months\\n12 months\\n\\n- Highly effective\\n- >90% immune after 2 doses\\n- >99% immune after 3 doses\\n- Duration of immunity not known with certainty\\n\\nOral polio vaccine:\\n- Paralytic poliomyelitis\\n- Should not be administered to persons who are\\nimmunocompromised (it is a live vaccine)\\n\\nContra indicated in :\\n- Persons with history of severe allergic reaction to a\\nvaccine component or following prior dose\\n- Moderate or severe acute illness\\n\\nI n a c t i v a t e d v a c c i n e m a y b e u s e d i n\\nimmunocompromised persons\\n- It may (rarely) cause local reactions\\n\\nVitamin A was the first fat-soluble vitamin to be\\ndiscovered\\n\\nIt comprises a family of compounds called the retinoids\\nIn nature, the active retinoids occur in 3 forms\\n\\n- Alcohol (retinol), aldehyde (retinal or retinaldehyde)\\nand acid (retinoic acid)\\n\\nIn the human body, retinol is the predominant form,\\nand 11-cis-retinol is the active form\\n\\nRetinol-binding protein (RBP) binds vitamin A and\\nregulates its absorption and metabolism\\nVitaminAis essential for:\\n\\nVision (especially dark adaptation)\\nImmune response\\nEpithelial cell growth and repair\\nBone growth\\nReproduction\\nMaintenance of the surface linings of the eyes\\nEpithelial integrity of respiratory, urinary, and intestinal\\n\\ntracts\\nEmbryonic development\\nRegulation of adult genes\\n\\nIt functions as an activator of gene expression by\\nretinoid alpha-receptor transcription factor and ligand-\\ndependent transcription factor\\n\\nDeficiency of vitamin A is found among malnourished\\nchildren, the elderly, and chronically ill populations in\\n\\nInactivated Polio Vaccine\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nVITAMINADEFICIENCY\\nIntroduction\\n\\nthe United States, but it is more prevalent in developing\\ncountries.\\nAmong the first signs of vitaminAdeficiency (VAD) are:\\n\\nAbnormal dark adaptation\\nDry skin and dry hair\\nBroken fingernails\\nDecreased resistance to infections\\n\\nAn estimated 250 million children in developing\\ncountries are at risk for vitamin deficiency syndromes\\n\\nThe most widely affected group includes up to 10\\nmillion malnourished children who develop\\nxerophthalmia and have an increased risk of\\ncomplications and death from measles\\n\\nEach year 250,000 - 500,000 children become blind\\nbecause of VAD\\n\\nImproving the vitamin A status of children (aged 6 - 59\\nmonths) with deficiencies can reduce rates of death from\\nmeasles by 50%; from diarrhoea by 33%, and from of all\\ncauses of mortality by 23%\\n\\nVitaminAdeficiency may be secondary to:\\nDecreased ingestion\\nDefective absorption and altered metabolism\\nIncreased requirements\\nAn adult liver can store up to a year\\'s reserve of vitamin\\n\\nA, whereas a child\\'s liver may have enough stores to last\\nonly several weeks\\n\\nSerum retinol concentration reflects an individual\\'s\\nvitaminAstatus\\n\\nBecause serum retinol is homeostatically controlled,\\nits levels do not drop until the body\\'s stores are\\nsignificantly limited\\nThe serum concentration of retinol is affected by several\\nfactors:\\n- Synthesis of Retinol Binding Protein in the liver\\n- Infection\\n- Nutritional status\\n- Adequate levels of other nutrients such as zinc and\\niron\\n\\nInfant (1 year or younger)\\n- 375 micrograms\\n\\nChild 1 - 3 years\\n- 400 micrograms\\n\\nChild 4 - 6 years\\n- 500 micrograms\\n\\nChild 7 - 10 years\\n- 700 micrograms\\n\\nAll males older than 10 years\\n- 1000 micrograms\\n\\nAll females older than 10 years\\n- 800 micrograms\\n\\nMalnutrition\\n- The commonest cause of VAD in this part of the world\\n\\nEpidemiology\\n\\nPathophysiology\\n\\nAetiology\\n\\nRecommended DailyAllowance\\n\\nInadequate intake\\nMeasles infection\\n\\nIncreased risk of deficiency in:\\nFat malabsorption\\nCystic fibrosis\\nTropical sprue\\nPancreatic insufficiency\\nInflammatory bowel disease\\nCholestasis\\nSmall bowel bypass surgery\\nVegans\\nRefugees\\nRecent immigrants\\nAlcoholism\\nToddlers and pre-school children living below the\\n\\npoverty line\\n\\nVAD may be asymptomatic\\nIncreased risk of respiratory and diarrhoeal infections\\nDecreased growth rate\\nRetarded bone development\\nIncreased fatigue as a manifestation of VAD anaemia\\nBitot spots\\nPoor dark adaptation (nyctalopia)\\nDry skin\\nDry hair\\nPruritus\\nBroken fingernails\\nKeratomalacia\\nXerophthalmia\\nFollicular hyperkeratosis (phrynoderma) from blockage\\n\\nof hair follicles with plugs of keratin\\nExcessive deposition of periosteal bone secondary to\\n\\nreduced osteoclastic activity\\nAnaemia\\nKeratinization of mucous membranes\\n\\nCataract\\nRefractive errors\\nZinc deficiency\\n\\nBlindness\\nCorneal ulceration\\n\\nSerum retinol\\n- Costly but is a direct measure\\n- A value of less than 0.7 mg/L in children younger than\\n12 years is considered low\\n\\nSerum RBP\\n- Easier and less expensive to perform than retinol\\n- Less accurate because levels are affected by serum\\nprotein concentrations; types of RBP cannot be\\ndifferentiated\\n\\nSerum zinc\\n- Useful because zinc deficiency interferes with RBP\\nproduction\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nIron panel\\n- Useful because iron deficiency can affect the\\nmetabolism of vitaminA\\n\\nSerum albumin\\n- Levels are indirect measures of levels of vitaminA\\n\\nFull Blood Count with differentials\\n- If anaemia, infection, or sepsis is a possibility\\n\\nSerum electrolytes\\nLiver function tests\\n\\n- To evaluate nutritional status\\nRadiographs of the long bones\\n\\n- To evaluate bone growth and excessive deposition of\\nperiosteal bone\\n\\nClinical testing for dark-adaptation threshold\\n\\nReduce morbidity\\nPrevent complications\\nTreat complications\\n\\nEat foods rich in vitaminA\\n- Liver\\n- Beef\\n- Chicken\\n- Eggs\\n- Whole milk; fortified milk\\n- Carrots\\n- Mangoes\\n- Orange fruits\\n- Sweet potatoes\\n- Spinach\\n- Green vegetables\\n\\nAt least 5 servings of fruits and vegetables per day is\\nrecommended to provide a comprehensive distribution of\\ncarotenoids\\n\\nDaily oral supplements of vitaminA\\n\\nLess than, or 3 years\\n- 600 microgram (2,000 IU) orally once daily\\n\\n4 - 8 years\\n- 900 microgram (3,000 IU) orally once daily\\n\\n9 - 13 years\\n- 1,700 microgram (5,665 IU) orally once daily\\n\\n14 - 18 years\\n- 2,800 microgram (9,335 IU) orally once daily\\n\\nall ages 3,000 microgram (10,000 IU) orally once\\ndaily\\n\\n- 60,000 microgram (200,000 IU) orally for a minimum\\nof 2 days\\n- Has been shown to reduce child mortality rates by 35 -\\n70%\\n\\nRisk of teratogenicity increases in pregnant women at\\ndoses >800 micrograms/day (not recommended at these\\ndoses)\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution\\n\\nChild:\\n\\nAdult:\\n\\nSevere disease\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 17: Paediatric Perspectives\\n\\n193 194\\n\\n\\n\\nContraindicated in\\n- Documented hypersensitivity\\n- Hypervitaminosis A\\nParenteral vitamin A in infants of low birth weight may\\nbe associated with:\\n\\nThrombocytopenia\\nRenal dysfunction\\nHepatomegaly\\nCholestasis\\nAscites\\nHypotension\\nMetabolic acidosis (E-Ferol syndrome)\\n\\nEat foods rich in vitaminA, in adequate amounts\\nFamily and community health education\\n\\nPrevention\\n\\nCHAPTER 18: EMERGENCIES\\n\\nACUTE LEFT VENTRICULAR FAILURE\\nIntroduction\\n\\nAetiology\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nSudden diminution in the function of the left ventricle\\nPulmonary capillary and venous pressure increase\\n\\nbeyond plasma oncotic pressure\\nThere is resultant accumulation of oedema fluid in the\\n\\npulmonary interstitial spaces and alveoli\\n\\nInsipient left ventricular failure secondary to\\nhypertension\\n\\nArhythmias\\nMyocardial infarction\\n\\nDyspnoea\\nOrthoponea\\nParoxysmal nocturnal dyspnoea\\nCough\\nHeamoptysis\\nRestlessness\\nWheezes\\nHypoxia\\n\\nPulmonary thromboembolism\\nBronchial asthma\\nPulmonary tuberculosis\\nCardiac tamponade\\n\\nRight-sided heart failure\\nAcute renal failure\\nMyocardial infarction\\n\\nElectrocardiography\\nPlain chest radiograph\\nEchocardiography\\nCardiac catheterization\\nPulmonary function tests\\nArterial blood gasses\\nElectrolyte, Urea and Creatinine\\n\\nTo improve pump performance of the failing ventricle\\nTo reduce the cardiac workload\\nTo control salt and water retention\\n\\nAs in hypertension\\n\\nDiuretics\\n- Furosemide\\n\\n40 - 80 mg by slow intravenous injection stat\\n- Then 40 - 160 mg orally or intravenously daily in 1or 2\\ndivided doses for maintenance\\n\\nneonate, 0.5 - 1 mg/kg by slow intravenous\\ninjection every 12 - 24 hours (every 24 hours if post-\\nmenstrual age is under 31 weeks)\\n1 month - 12 years: 0.5 - 1 mg/kg (maximum 4 mg/kg),\\n\\nAdult:\\n\\nChild:\\n\\nrepeated every 8 hours as necessary\\n12 - 18 years: 20 - 40 mg every 8 hours; higher doses may\\nbe necessary in resistant cases\\n\\nAngiotensin converting enzyme inhibitors\\n- Captopril\\n\\n6.25 - 12.5 mg daily orally, then 25 mg in divided\\ndoses daily (maximum 150 mg daily) for maintenance\\n\\nnot licensed for use in children\\nOr:\\n- Lisinopril\\n\\n2.5 mg orally daily; 5 - 20 mg daily for\\nmaintenance\\n\\nneonate, initially 10 micrograms/kg orally once\\ndaily; monitor blood pressure carefully for 1 - 2 hours,\\nincreased as necessary up to 500 micrograms/kg daily in\\n1 - 3 divided doses\\n1 month - 12 years: initially 100 micrograms/kg orally\\nonce daily, monitor blood pressure carefully for 1 - 2\\nhours, increased as necessary up to a maximum of 1\\nmg/kg daily in 1 - 2 divided doses\\n12 - 18 years: initially 2.5 mg daily, monitor blood\\npressure carefully for 1 - 2 hours; usual maintenance dose\\n10 - 20 mg daily in 1 - 2 divided doses (maximum 40 mg\\ndaily if body weight is >50 kg)\\nMay require morphine\\n\\n5 - 10 mg orally, subcutaneously or\\nintramuscularly (usually a single initial dose)\\n\\nnot listed for this indication\\nDigoxin\\n\\n125 - 250 micrograms orally daily may be required\\nAminophylline\\n\\nup to 250 mg by slow intravenous injection stat\\n\\nOxygen\\nNurse in cardiac position\\n\\nUse ACE inhibitors, and aminophylline and digoxin\\nwith caution\\n- Monitor potassium levels closely\\n- Monitor fluid input and output\\n\\nAdequate control of hypertension\\n\\nSudden cessation of cardiac pump function\\nIf there is no spontaneous reversal or resuscitatory\\n\\nmeasure, death results\\nCommonest cause of cardiovascular deaths among\\n\\ncaucasions\\nPeaks between ages 0 - 6 months and 45 - 75 years\\n\\nCongenital and acquired structural defects of the heart\\nAbnormal electrical activities of the heart\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nChild:\\n\\nAdult:\\n\\nAdult:\\nSupportive measures\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nPrevention\\n\\nCARDIAC ARREST\\nIntroduction\\n\\nAetiology\\n\\nInflammatory, infiltrative, neoplastic and degenerative\\nprocesses\\n\\nFluids and electrolyte imbalances\\nDrugs and other substances of abuse\\nSudden infant death syndrome\\nMiscellaneous\\n\\nUsually sudden collapse\\nUnrecordable blood pressure\\nLoss of peripheral pulses\\nCessation of respiration\\nMay be asymptomatic\\nComplaints may be non-specific\\nPresentation may be that of underlying cause\\n\\nSyncope\\nSeizures\\n\\nDeath\\nSequelae involving the vital organs\\n\\n- Acute renal failure\\n- Myocardial infarction\\n- Cerebrovascular accident\\n\\n(after the initial rapid assessment and\\nresuscitation)\\n\\nElectrocardiography\\nEchocardiography\\nUrea, Electrolytes and Creatinine\\nLipid profile\\nBlood gases\\nChest radiograph\\n\\nPrompt restoration of cardiac and respiratory function\\nMonitoring of impact of cardiac arrest on the various\\n\\nassociated organs\\nIntervention to restore normal functions\\nFormulation of a broader and more comprehensive\\n\\ndiagnostic and treatment plan\\nEliminate/control aetiological factor(s) in order to\\n\\nreduce morbidity/prevent mortality\\n\\nEnsure clear airway by tilting the head backwards, lifting\\nthe chin and exploring to remove foreign bodies/dentures\\n\\nRemove wears/ornaments which may negate the above\\n\\nCardiac massage (80 - 100 per minute)\\nAssisted ventilation using a masked ambu bag\\n\\n- Twice in succession for every 15 cardiac massages\\n\\n(once every 5 massage when 2 people are in attendance)\\n- Watch out for spontaneous respiration during this\\nexercise\\n\\nIntubation with an endotracheal tube\\nDefibrillation/cardioversion for patients with\\n\\nventricular fibrillation/ventricular tachycardia\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon- drug treatment\\n\\nBasic life support (CPR)\\n\\nAdvanced life support\\n\\nEnsure that patient is lying on a firm/hard surface\\n\\nth\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 18: Emergencies\\n\\n195 196\\n\\n\\n\\n- Defibrillate with 200 J shock. Additional shock up to\\n360 J may be required\\n\\nEpinephrine (adrenaline) 1mg intravenously after\\nfailed defibrillation\\n\\nRepeat defibrillation\\nInsert intravenous line\\nMonitor arterial blood gases\\n\\nSodium bicarbonate\\n- 1 milliequivalent/kg\\n- Additional 50% of this dose every 10 to 15 minutes as\\ndeemed clinically appropriate\\n\\nLidocaine 1 mg/kg intravenously if there is unstable\\ncardiac electrical activity. Repeat as required\\n\\nOther antiarhythmic drugs if necessary\\nFor cardiac arrest secondary to bradyarrhythmias or\\nasystole:\\n\\nContinue CPR\\nInsert intravenous line\\n\\nFamily and community basic support education\\n\\nRefers to death by suffocation due to immersion in\\nwater\\n\\nMay be classified as “wet”- where the victim has\\ninhaled water or “dry”- a less common condition, but one\\nthat involves the closing of the airway due to spasms\\ninduced by water\\n\\nWet drowning could occur by either fresh or salt water\\nDrowning typically accounts for a small but significant\\n\\npercentage of accidental deaths\\nNear-drowning episodes refer to instances where\\n\\nrescue was successful and death prevented\\nNear-drowning can be associated with considerable\\n\\ndisability e.g. head injury, paralysis, and respiratory\\ncomplications\\n\\nSwimming in deep waters\\nFalling unexpectedly into water\\nNot being able to swim\\nBreath-holding swimming and diving\\nAlcohol consumption\\nHigh water temperatures\\nEasy, illicit access to pools\\nInadequate pool and spa covers\\nMuscle cramps or epileptic attacks developing during\\n\\nswimming\\n\\nInhalation of water results in ventilation-perfusion\\nimbalance with hypoxaemia and pulmonary oedema\\nAbsorption of hypotonic fresh water results in collapse\\n\\nDrug treatment\\n\\nPrevention\\n\\nDROWNINGAND NEAR-DROWNING\\nIntroduction\\n\\nContributory factors\\n\\nPathophysiology\\n\\nof the alveoli, resulting in right-to-left shunting of un-\\noxygenated blood\\n\\nAbsorption of hypertonic salt water results in alveolar\\noedema, but the overall effects are the same for both\\ninhalation of fresh and salt water\\n\\nInfection may develop subsequently and is more likely\\nwhen contaminated water is inhaled\\n\\nIf alive, patient is unconscious and not breathing\\nHypoxemia and tissue hypoxia\\nAcidosis\\nHypothermia\\nPneumonia\\nAcute renal failure\\nHemolysis\\n\\nHypoxic brain injury with cerebral oedema (which may\\noccur within 24 hours)\\n\\nCardiac arrhythmias\\nDehydration\\nAcute Respiratory Distress Syndrome (ARDS)\\nAcute renal failure\\nDisseminated Intravascular Coagulopathy\\n\\nFull Blood Count; ESR\\nChest radiograph\\nElectrolytes, Urea and Creatinine\\nLiver function tests\\nAcid base status evaluation\\nArterial blood gases\\nSkull and spine radiographs\\nCT Scan (if available)\\n\\nImmediate resuscitation and stabilization to prevent or\\nminimize complications\\n\\nAirway management\\nImmobilize the cervical spine, as trauma may be\\n\\npresent\\nTreat hypothermia vigorously\\nEndotracheal intubation with mechanical ventilation\\n\\nand Positive End-Expiratory Pressure if patient is apneic\\nor in severe respiratory distress or has oxygen-resistant\\nhypoxemia\\n\\nAdmission for observation for at least 24 hours if any of\\nthe complications are observed even if briefly\\n\\nVentilate with 100% oxygen\\nEstablish an intravenous infusion with 0.9% saline or\\n\\nlactated Ringer\\'s solution\\nManage pulmonary complications with the\\n\\nadministration of 100% oxygen initially, titrated\\nthereafter reviewing arterial blood gases\\n\\nBronchodilators if bronchospasm is present\\nManage metabolic acidosis: give NaHCO if pH is\\n\\npersistently less than 7.2\\n\\nClinical features\\n\\nComplications of near-drowning\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug measures\\n\\nDrug treatment\\n\\n3\\n\\nTreat cerebral oedema\\n- Hyperventilation\\n- Intravenous mannitol (1 - 2 g/kg every 4 hours)\\n\\nAppropriate management of pulmonary oedema\\n\\nTeach the unskilled to stay away from water\\nTeach persons not to swim beyond skill level\\nParental/caregiver supervision of children\\nDiving only under suitable conditions\\nEducation/public awareness\\nIsolation fences around outdoor pools, and locked doors\\n\\nfor indoor pools\\nLocked safety covers for spas and hot tubs\\n\\nDetection of deranged electrolytes and fluid balance\\ndoes not constitute a diagnosis\\n\\nEfforts should be made to determine the underlying\\ncauses in every case\\n\\nPlasma K concentration > 5 mmoles/L\\n\\nUsually occurs as a result of potassium release from\\ncells\\n\\nDecreased renal excretion of K as in renal failure\\nDecreased potassium secretion:\\n\\nImpaired sodium reabsorption in\\n- Primary hypoaldosteronism\\n- Adrenal insufficiency\\n- Secondary hypoaldosteronism\\n- Medications such as ACE inhibitors, NSAIDs and\\nheparin\\nEnhanced chloride reabsorption (chloride shunt) as seen\\n\\nin Gordon\\'s syndrome\\n\\nWeakness, flaccid paralysis, metabolic acidosis\\nECG changes\\n\\n- Increased T wave amplitude\\n- Peaked T waves\\n- Prolonged PR intervals, QRS duration\\n- Atrioventricular conduction delays\\n- Loss of Pwaves\\n- Ventricular fibrillation or asystole\\n\\nSerum Urea, Electrolytes and Creatinine\\nOther renal function tests\\nAcid base balance\\n\\nCorrection of hyperkalaemia\\nPreservation of cardiac function\\nTreatment of underlying cause(s)\\n\\nDepends on the degree of hyperkalaemia, associated\\nphysical features and ECG changes\\n\\nPrevention\\n\\nELECTROLYTE ABNORMALITIES\\nIntroduction\\n\\nAetiology\\n\\nClinical features\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nManagement\\n\\nHyperkalaemia\\n\\nThe measures are aimed at:\\nPromoting potassium loss\\nLimiting exogenous potassium intake\\nDiscontinuation of anti-kaliuretic drugs\\nShifting potassium into cells\\n\\nCalcium gluconate\\n- 10 ml of 10% solution intravenously over 2 - 3 minutes\\n\\nInsulin plus glucose infusion\\n- 10 - 20 units of regular insulin plus 25 - 50 g of glucose\\ngiven as 10 units in 100 ml of 50% glucose\\nOther alternatives to cause influx of potassium:\\nSodium bicarbonate (134mmoles/L) if there is metabolic\\nacidosis\\n- See CardiacAarrest\\nOr:\\nParenteral/nebulised salbutamol (see Bronchial asthma)\\nRemoval of potassium with diuretics (loop plus thiazide\\n\\ndiuretics in combination)\\nSodium polysterene sulphonate (a cation exchange\\n\\nresin)\\n- Administered as a retention enema of 50 g of resin and\\n50 ml of 70% sorbitol mixed in 150 ml of tap water\\n\\nHaemodialysis\\n- The most rapid and effective way of lowering plasma\\npotassium concentration\\n- Reserved for patients in renal failure and those with\\nsevere hyperkalaemia unresponsive to more conservative\\nmeasures\\n\\nDefined as plasma sodium > 145 mmoles/Litre\\nMajority of cases result from water loss in the absence of\\n\\nsodium loss, when the thirst mechanism is impaired, or\\n(infrequently) due to primary sodium gain\\n\\nMainly neurologic:\\nAltered mental status\\nWeakness\\nNeuromuscular irritability\\nFocal neurological deficits\\nOccasionally coma and seizures\\n\\nCorrect water deficit\\nStop on-going water loss\\n\\nDeficit (Plasma Na 140)/140 0.5(males) 0.4\\n(females) body weight in kg\\n\\nWater replacement in glomerulo nephropathy\\nMineralocorticoid excess (primary deficit should be\\n\\ncorrected slowly over 48 - 72 hours to prevent cerebral\\noedema\\n\\nDrug treatment\\n\\nIntroduction\\n\\nClinical features\\n\\nTreatment objectives\\n\\nHypernatraemia\\n\\n= - X or\\nX\\n\\nAs in hyponatraemia severity of the clinical features are\\nrelated to the rapidity of onset and the magnitude of the\\nrise in plasma sodium concentration\\n\\nCalculation of water deficit\\n+\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 18: Emergencies\\n\\n197 198\\n\\n\\n\\nWater replacement can be given by mouth or\\nnasogastric tube\\n- Glucose 5% injection is also suitable for water\\nreplacement, being a hypotonic fluid\\n\\nPlasma potassium less than 3.5 mmol/Litre\\nMostly associated with increase in potassium loss\\n\\nIncreased renal loss:\\nDiure t i cs and sa l t -was te and secondary\\n\\nhyperaldosteronism\\nIncreased distal delivery of non-reabsorbable anions\\n\\n(vomiting, DKA, renal tubular acidosis)\\nAmphotericin B\\nCushing’s syndrome, Bartter\\'s syndrome\\n\\nIncreased non-renal loss:\\nGIT loss (diarrhoea, integumentary sweat)\\n\\nRedistribution into cells:\\nMetabolic alkalosis\\nDrugs\\nInsulin\\n\\nadrenergic agonists\\nadrenergic antagonists\\n\\nDecreased intake:\\nStarvation\\n\\n- Vary between patients and depend on the level of\\npotassium loss\\nSerum K <3mmoles/Litre:\\n\\nFatigue\\nMyalgia\\nWeakness of the lower extremities\\nMore severe hypokalaemia results in\\n\\n- Progressive weakness\\n- Hypoventilation\\n- Complete paralysis\\n\\nECG changes are due to ventricular depolarisation and\\ndo not correlate with the plasma potassium levels\\n- Flattening/inversion of the T wave\\n- Aprominent U wave\\n- ST segment depression\\n- Prolonged QT interval\\n- Severe depletion results in prolonged PR interval\\n- Decreased voltage and widening of the QRS complex\\n\\nElectrocardiography\\nElectrolytes, Urea and Creatinine\\nAcid-base status\\nIdentifying the underlying disease\\n\\nCorrection of potassium deficit\\nMinimize/stop on-going loss\\n\\n(oral route preferred)\\nPotassium chloride\\n\\n- Doses depend on deficits, on-going losses and renal\\n\\nHypokalaemia\\nIntroduction\\n\\nClinical features\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nβ\\nα\\n\\nstatus\\nIntravenous potassium (given in an infusion)\\n\\n- Do not exceed 20 mmoles/L\\n\\nDeficit body weight (kg) 0.3\\n- Add daily requirement of potassium and correct over 3\\ndays\\n\\nOral potassium supplements should be taken in an\\nerect position or sitting upright and with plenty of water\\nto avoid oesophageal erosions\\n\\nPlasma Na < 135mmol/L\\nDifferent types with varied aetiologies\\n\\nPseudo-hyponatraemia:\\nWith normal plasma osmolality as seen in\\n\\nhyperlipidaemia or hyper-proteinaemia\\nWith increased plasma osmolality as seen in\\n\\nhyperglycaemia, infusion of mannitol\\nHypo-osmolar hyponatraemia:\\n\\nDue to a primary water gain and secondary sodium\\nloss, or a primary sodium loss and secondary water gain\\n\\nIntegumentary loss: sweating, burns\\nLoss from the GIT: vomiting, tube drainage, fistula\\nRenal loss: diuretics, hypoaldosteronism, salt wasting\\n\\nneuropathy, obstructive diuresis\\nPrimary polydypsia\\nCardiac failure\\nHepatic cirrhosis\\nNephritic syndrome\\n\\nDecreased solute intake:\\nSIADH\\nGlucocorticoid deficiency\\nHypothyroidism\\nChronic renal insufficiency\\n\\nCerebral oedema\\nMay be asymptomatic\\nOtherwise nausea, malaise, headache, lethargy,\\n\\nconfusion, and altered consciousness\\nComa when plasma sodium is less than 120 millimoles\\n\\nper litre\\n\\nCongestive cardiac failure\\nHepatic cirrhosis\\nNephritic syndrome\\n\\nDirected at establishing the cause and severity of\\nhyponatraemia\\n\\nTo correct plasma sodium concentration by restricting\\nwater intake and promoting water loss\\n\\nTo correct the underlying disorder\\n\\nMild asymptomatic hyponatraemia requires no\\ntreatment\\n\\nCalculation of potassium requirement\\n\\nCaution\\n\\nClinical features\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nManagement\\n\\nHyponatraemia\\n+\\n\\nMild hyponatraemia with ECF volume contraction:\\nSodium releption with isotonic saline infusion\\n\\nHyponatraemia associated oedematous states:\\nRestriction of both sodium and water intake\\nPromotion of water loss in excess of sodium by use of a\\n\\nloop diuretic\\nFor severe cases which are symptomatic (plasma sodium\\nconcentration <115 mmoles/L):\\nHypertonic saline to raise sodium concentration by 1 - 2\\n\\nmmol/L/hour for the first 3 hours, but not more than 12\\nmmoles/Lduring the first 24 hours\\n\\nAmount of sodium = (desired concentration -- actual\\nconcentration) X body weight X 0.6\\n\\nSeverely elevated blood pressure (>200/120 mmHg) with\\nevidence of target organ damage such as:\\nNeurologic (e.g. altered consciousness)\\nCardiovascular (myocardial ischeamia, left ventricular\\nfailure)\\n\\nRenal deterioration\\nFundoscopic abnormalities\\n\\nPresentations include:\\nAortic dissection\\nHypertensive encephalopathy\\nEclampsia\\nMalignant hypertension\\n\\nImproperly managed hypertension\\nRenal vascular disease\\nPheochromocytoma\\nAccelerated essential hypertension\\n\\nSeverely elevated blood pressure (>200/120mmHg)\\nHeadaches, malaise, vomiting, dizziness, blurred vision,\\n\\nchest pain, palpitations, dyspnoea, oliguria\\nFundoscopic changes\\nEvidence of left ventricular failure\\nChanges in level of consciousness\\n\\nTarget organ damage\\nCerebrovascular accident\\nMyocardial infarction\\nCardiac failure\\nRenal failure\\nDeath\\n\\nPlain chest radiograph\\nEchocardiography\\nFull Blood Count\\nUrea, Electrolytes and Creatinine\\nUrinalysis\\nEchocardiography\\n\\nCalculation of the total amount of sodium to administer\\n\\nHYPERTENSIVE EMERGENCIES\\nIntroduction\\n\\nAetiology\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nNotable adverse drug reactions, caution\\n\\nHYPOGLYCEMIA\\nIntroduction\\n\\nAetiology\\n\\nClinical features\\n\\nPrompt but gradual reduction in mean arterial pressure\\nby not more than 25% within the first 2 hours\\nFurther reduction of BPto (not less than) 160/100 mmHg\\n\\nwithin 2 to 6 hours\\n- Lower pressures may be indicated for patients with\\naortic dissection\\n\\nInitiate/re-initiate long term therapy to normotensive\\nlevels\\n\\nSodium niprusside\\n- 0.3 micrograms/kg/min intravenously initially, 0.5 - 6\\nmicrograms/kg/min maintenance (maximum of 6\\nmicrograms/kg/min)\\n\\nStop infusion if response is unsatisfactory after 10\\nminutes at maximum dose\\n\\nLower doses in patients already on anti-hypertensives\\nHypotension may occur\\nMonitor blood cyanide and thiocyanate concentrations\\nDiscontinue if adverse drug reaction to metabolites\\n\\ndevelop: tachycardia, sweating, hyperventilation,\\narrhythmias, acidosis)\\n\\nReduce infusion over 15 - 30 minutes to avoid rebound\\neffect when stopping therapy\\n\\nUse sodium nitroprusside with caution in ischaemic\\nheart disease, renal impairment, raised intracranial\\npressure and impaired pulmonary function\\n\\nBlood glucose level less than 2.5 mmol/L(45 mg/dL)\\nMay occur in a fasting state or may be post-prandial\\n\\nMost commonly iatrogenic\\nAntidiabetic drugs\\nAssociated with quinine, salicylates and sulphonamide\\n\\nuse\\nAfter overnight fast\\nMissed meal(s)\\nDuring exercise\\nCan be due to intensive insulin therapy\\nMay follow weight loss\\nMay follow alcohol ingestion\\nReduced insulin clearance\\nSepsis\\nSecondary to non-ß cell tumours/insulinoma\\n\\nThe two types are neuroglycopenic and neurogenic\\nNeurogenic manifestations:\\n\\nPalpitations\\nTremors\\nAnxiety\\nSweating\\nHunger\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 18: Emergencies\\n\\n199 200\\n\\n\\n\\nParesthesia\\nNeuroglycopenic manifestations:\\n\\nConfusion\\nFatigue\\nSeizures\\nLoss of consciousness\\nDeath\\n\\nThe Whipples\\'s triad provides a framework for diagnosis\\nof hypoglycaemia:\\n\\nSymptoms of hypoglycaemia\\nLow plasma glucose concentration (<2.5 mmole/L)\\nAlleviation of hypoglycemic symptoms after glucose\\n\\nadministration\\n\\nOther causes of acute confusional state\\n\\nRandom blood sugar on presentation\\nOther tests to confirm the cause of hypoglycaemia\\n\\nPrompt restoration of normal blood glucose level\\nPrevention of rebound or recurrent hypoglycaemia\\nPrevention of occurrence of neural damage or death\\n\\nUrgent treatment must be given if irreversible\\ncomplications are to be avoided\\n\\nOral glucose tablets or glucose drinks if tolerated (and\\nif patient is conscious)\\nIf there is neuroglycopaenia preventing the use of oral\\nglucose, give 50% glucose (dextrose)\\n- 50 ml/25 g in double dilution intravenously followed\\nby 5 - 10% glucose (dextrose) for at least 48 hours in\\nhypoglycaemia secondary to sulphonylurea therapy\\n\\nIntravenous glucagon 1mg stat (give subcutaneously\\nor intramuscularly if intravenous route is impractical)\\n\\nDiscontinue or reduce the dosage of causative drugs\\nTreat identified underlying cause(s)\\n\\nGlucagon is not effective in glycogen-depleted\\nindividuals e.g. those with alcohol induced-\\nhypoglycaemia\\n\\nAlife-threatening complication of hypothyroidism\\nFollows a background of long-standing\\n\\nhypothyroidism\\n\\nMay be precipitated by exposure to cold, infection,\\ntrauma and CNS suppressants\\n\\nComa with extreme hypothermia, temperatures 24 -\\n\\n32 C\\nSeizures\\nAreflexia\\n\\nDiagnosis\\n\\nDifferential diagnoses\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nTreatment\\n\\nSupportive measures\\n\\nPrecaution\\n\\nMYXOEDEMACOMA\\nIntroduction\\n\\nClinical features\\n\\no\\n\\nCO retention and respiratory depression due to\\n\\ndecreased cerebral blood flow\\n\\nComa due to CNS depressants\\nAdrenal insufficiency\\nMorbid depression\\n\\nCardiac failure\\nRespiratory failure\\nDeath\\n\\nT , T TSH assay\\n\\nTo restore normal body metabolism\\nTo prevent death\\n\\nTriiodothyronine\\n- 20 micrograms intravenously stat, then 20 micrograms\\nevery 8 hours until there is sustained clinical\\nimprovement\\n\\nMay also require hydrocortisone 100 mg intravenously\\nevery 8 hours\\n\\nMaintain therapy with oral thyroxine in a dose of 50\\nmicrograms per day\\n\\nTreat precipitating factor(s)\\n\\nPatients should not be re-warmed rapidly because of\\nrisk of cardiac arrhythmias\\n\\nRare but life-threatening\\nMortality rate is up to 30% even with treatment\\nCauses of death include cardiac failure, arrythmias and\\n\\nhyperthermia\\nPrecipitants include the following:\\n\\nInfections\\nTrauma\\nSurgery\\nStroke\\nDiabetic ketoacidosis\\nRadio iodine treatment of patients with partially treated\\n\\nor untreated hyperthyroidism\\n\\nFever\\nDiarrhoea\\nVomiting\\nJaundice\\nSeizures\\nComa\\n\\nCardiac failure\\nArrythmias\\nHyperthermias\\n\\nThyroid function tests\\n\\n2\\n\\n3 4,\\n\\nDifferential diagnoses\\n\\nComplications\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nPrecaution\\n\\nTHYROID STORM (THYROTOXIC CRISIS)\\n\\nClinical features\\n\\nComplications\\n\\nInvestigations\\n\\nOther tests to identify precipitating factors\\n\\nRequires intensive monitoring\\nSupportive care\\nIdentification and treatment of precipitating cause(s)\\n\\nReduction in T synthesis/action and restoration to\\n\\nnormal values\\nTreatment of identified precipitating factors\\nPrevention of complications\\n\\nPropylthiouracil\\n600 mg loading dose; 200 - 300 mg orally every 6\\n\\nhours by nasogastric tube or per rectum\\nInitially 50 mg orally 3 times daily\\n\\nuntil euthyroid then adjusted as necessary\\ninitially 100 mg 3 times daily administered\\n\\nuntil euthyroid then adjusted as necessary; higher doses\\nsometimes required\\n\\nSaturated Solution of Potassium Iodide (SSKI)\\n5 drops every 6 hours; to be commenced 1 hour\\n\\nafter the first dose of propylthiouracil\\n0.2 - 0.3 mLorally 3 times daily\\n\\n- Dilute well with milk and water\\nPropranolol\\n\\n40 - 60 mg orally every 4 hours or 2 mg\\nintravenously every 4 hours\\n\\nneonate, initially 250 - 500 micrograms/kg every 6\\n- 8 hours, adjusted according to response\\n1 month - 18 years: initially 250 - 500 micrograms/kg\\nevery 6 - 8 hours, adjusted according to response; doses\\nup to 1 mg/kg may be required; maximum 40 mg every 8\\nhours\\n\\nDexamethasone\\n- 2 mg intravenously every 6 hours\\n\\nAntibiotics (if infection is present)\\n\\nAdequate hydration with intravenous fluids and cooling\\n\\nThe ingestion by, or exposure of a patient to excessive\\ndoses of a medicine or other substances may cause harm\\nThis may be:\\n\\nSelf poisoning (may be suicidal)\\nAccidental\\nHomicidal\\n\\nDetermined (amongst others) by:\\nType of drug\\nInherent toxicity\\nDose and duration following exposure\\nConcurrent therapy\\nCo-existing disease states etc\\n\\nThis guideline provides only a brief overview.\\n\\nManagement\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nPOISONING\\nIntroduction\\n\\nClinical presentation\\n\\n3\\n\\nAdult:\\n\\nChild 5 - 12 years:\\n\\n12 - 18 years:\\n\\nAdult:\\n\\nChild 1 month - 1 year:\\n\\nAdult:\\n\\nChild:\\n\\nPractitioners are advised to seek advice from experts,\\nstandard texts in medicine and toxicology, in the absence\\nof a Poison Information Centre\\n\\nVerify, validate or confirm all of the events related to the\\npoisoning\\n\\nTake good clinical history\\n- Information from relatives, friends, emergency services\\npersonnel may be very useful especially where the patient\\nis unwilling or unable to provide useful information\\n\\nEmergency stabilization\\nQuick clinical evaluation\\nElimination of the poison or decontamination\\nEnhancing systemic clearance\\nAdministration of antidotes\\nSupportive measures\\nObservation\\nDisposition\\n\\nLife-saving measures take priority over all other\\ndecontamination techniques\\nThe followingABC approach is recommended:\\n\\nEstablish a clear irway\\nEnsure adequate reathing and ventilation\\nEnsure adequate irculation\\nAddress rug-induced depression of the\\ncentral nervous and respiratory systems\\nCorrect any lectrolyte and metabolic\\nabnormalities\\n\\nAquick clinical evaluation should be carried to:\\nObtain a good history of the drug ingestion/exposure\\n\\n- Amount, time, etc\\n- Circumstances surrounding the event (from the patient,\\nrelations and other eyewitnesses)\\n\\nThe patient may have no symptoms when seen early in\\nthe course of the poisoning\\n\\nA thorough physical examination may further provide\\nclues on the drug class causing toxicity e.g pinpoint pupils\\nwith opioid overdose\\n- The absence of a significant sign does not negate the\\ndiagnosis\\n\\nClinical laboratory patient data e.g. urine drug screens\\n- Useful in patients with coma of unknown aetiology\\n\\nThe removal of the offending substance from the patient\\nThe presumption is that both the dose and duration of\\n\\nexposure are determinants of toxicity, and limiting\\ncontinued exposure is beneficial\\n\\nRemove the patient from the toxic environment\\nProvide fresh air and oxygen (respiratory\\n\\ndecontamination)\\nFlushing the areas (e.g. skin and eyes) with large\\n\\nvolumes of fluid to remove the toxic substance\\nGastrointestinal decontamination:\\n\\nEmesis or lavage to evacuate the gastric contents\\n\\nPrinciples of management of poisoning\\n\\nA A\\nB B\\nC C\\nD D\\n\\nE E\\n\\nEmergency stabilization\\n\\nClinical evaluation\\n\\nElimination of poisons (or Decontamination)\\n\\nChapter 18: Emergencies Standard Treatment Guidelines for Nigeria 2008\\n\\n201 202\\n\\n\\n\\nAdminister activated charcoal as an absorbent to bind\\nthe toxic substance in the gastrointestinal tract\\nUse cathartics or whole bowel irrigation to increase the\\n\\nrectal elimination of unabsorbed drugs\\n\\nClearance of the toxic substances may be enhanced by:\\nManipulation of urine pH\\nHaemodialysis\\nHaemo perfusion\\n\\nAn antidote is a drug that antagonizes the toxicity of\\nanother substance in a specific manner\\nExamples:\\n- Naloxone for opioids\\n- N-acetylcysteine for paracetamol\\n\\nLooked out for, and address the peculiarities related to\\nspecific poisonings\\n- Important where multiple drugs are involved\\n\\nThe pattern of poisoning is influenced by age and\\ngender\\nCommon substances causing poisoning in the Nigeria\\ninclude (but are not limited to):\\n\\nPharmaceuticals\\n- Analgesics, hypnosedatives, antidepressants, alcohol\\n\\nPetroleum distillates\\nIndustrial chemicals\\nAgrochemicals\\nHousehold products\\nNatural toxins\\nToiletries\\n\\nToxicity often occurs following an acute ingestion\\n(within 24 hours) of =10 - 15 g (20 - 30 tablets) or 150\\nmg/kg\\n\\nIt could also in conditions with enhanced P enzyme\\n\\nactivity (e.g. on-going use of anticonvulsants,\\nrifampicin)\\n\\nLess often hepatotoxicity occurs following chronic\\ningestion of therapeutic or slightly greater amounts in\\nconditions with decreased gluthatione reserve\\n- Acute starvation\\n- Alcoholism\\n- Childhood\\n- Chronic malnutrition\\n\\nEarly manifestations are non-nspecific and also non-\\npredictive of subsequent hepatotoxicity. They include:\\n\\nNausea and vomiting\\nExcessive sweating\\nOnset of hepatotoxicity is heralded by right upper\\n\\nquandrant tenderness and hepatomegaly\\nFeatures of liver damage include:\\n\\nEncephalopathy\\n\\nA combination of the above methods may be used.\\nEnhancing systemic clearance\\n\\nAntidotes\\n\\nSPECIFIC POISONS\\nParacetamol\\n\\n450\\n\\nClinical features\\n\\nHaemorrhage\\nHypoglycaemia\\nCerebral oedema\\nDeath\\nThese symptoms are maximal in 3 - 4 days\\n\\nPoor prognostic indices:\\nEncephalopathy or hepatic failure\\n\\nGreater than two fold prolongation of Prothrombin\\ntime\\n\\nSerum bilirubin > 68 micromol/L(4 mg/dL)\\nSerum creatinine > 3.3\\nChronic poisoning is usually similar but alcoholics may\\n\\npresent with a syndrome of severe combined hepatic and\\nrenal insufficiency\\n\\nLFTs including prothrombin time and serum proteins\\nUrea, Electrolytes and Creatinine.\\nBlood sugar estimation\\n\\nBlood levels of paracetamol (where facility is available)\\nLaboratory evidence of hepatotoxicity includes:\\n\\nProlongation of prothrombin time\\nElevation of serum bilirubin and transaminase activity\\nRenal function may also be impaired\\n\\nTo prevent or reduce damage to organs\\nTo restore normal metabolic functions\\n\\nActivated charcoal, especially within 4 hours of\\ningestion\\n\\n50 g orally, repeated if necessary\\nunder 12 years, 25 g (50g in severe poisoning)\\n\\nAcetylcysteine\\ninitially 50 mg/kg by intravenous\\n\\ninfusion over 15 minutes, then 50 mg/kg over 4 hours and\\nthen 100 mg/kg over 16 hours\\n- Diluted 3:1 with a non-alcoholic, non-dairy beverage\\n- Loading dose is 140 mg/kg; maintenance dose 70\\nmg/kg every 4 hours for 17 doses\\n- Treatment is effective if started within 8 - 10 hours\\nAlternatively:\\n\\nMethionine\\n2.5 g orally followed by a\\n\\nfurther dose of 2.5 g every 4 hours\\nChild under 6 years: initially 1 g followed by 3 further\\ndoses of 1g every 4 hours\\n\\nAs for all cases of acute poisonings\\n\\nAcetylcysteine may cause nausea, vomiting and\\nepigastric discomfort. Antiemetics (metoclopramide)\\nmay be required\\n\\nMethionine may cause nausea, vomiting, drowsiness,\\nirritability\\n\\nToxic doses are associated with increased sensitivity of\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nDrug treatment\\n\\nSupportive measures\\n\\nNotable adverse drug reactions, caution and\\ncontraindications\\n\\nAspirin:\\n\\nAdult:\\nChild:\\n\\nAdult and child:\\n\\nAdult and child over 6 years:\\n\\nthe respiratory centre, incomplete oxidative\\nphosphorylation and increased rate of metabolism\\n\\nInitial manifestations (occur 3 - 6 hours after an overdose\\nof >150 mg/kg):\\n\\nVomiting\\nSweating\\nTachycardia\\nHyperventilation\\nTinnitus\\nFever\\nLethargy\\nConfusion\\nRespiratory alkalosis\\nImpaired renal function\\nIncreased anion gap\\nMetabolic acidosis may result\\n\\nSevere poisoning:\\nComa\\nRespiratory depression\\nSeizures\\nCardiovascular collapse\\nCerebral and pulmonary oedema\\n\\nFBC, ESR\\nElectrolytes, Urea and serum Creatinine\\nRandom Blood Glucose\\nLFTs including prothrombin time\\nBlood aspirin levels\\n\\nAs for paracetamol poisoning\\n\\nGastric lavage and whole bowel irrigation\\n\\nActivated charcoal can be used up to 12 - 24 hours after\\ningestion (see Paracetamol poisoning)\\n\\nIntravenous infusion of sodium chloride 0.9%\\n(preferably with glucose)\\n- To correct dehydration and produce brisk urine flow\\n(saline diuresis)\\n\\nSupplemental oxygen\\nSupplemental glucose\\nIntravenous vitamin K 10 mg daily for coagulopathy\\nIntravenous NaHCO to alkalinize urine (see Cardiac\\n\\nArrest for administration)\\nCorrection of other electrolyte derangements\\nHaemodialysis for severe salicylate poisoning\\n\\nSevere clinical toxicity\\nAspirin (acetylsalicylic acid) levels = 7 mmol/L (100\\n\\nmg/dL)\\nContraindications, failure of other treatment modalities\\n\\nMost commonly involves diaazepam and bromazepam\\nThese drugs potentiate the inhibitory effect of GABA on\\n\\nClinical features\\n\\nInvestigations\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\n3\\n\\nIndications for haemodialysis\\n\\nBenzodiazepines\\n\\nCNS neurons\\n\\nMainly CNS depression occuring within 30 minutes of\\nacute overdose\\n\\nRespiratory depression\\nComa, especially when benzodiazepines are combined\\n\\nwith other CNS depressants\\nParadoxical excitement may occur early in the course of\\n\\npoisoning\\n\\nAs for paracetamol poisoning\\n\\nRespiratory support\\n\\nActivated charcoal: method of choice for gastrointestinal\\ndecontamination\\n- See Paracetamol poisoning\\n\\nFlumazenil, a competitive benzodiazepine receptor\\nantagonist, can reverse CNS and respiratory depression\\n- Give 0.1 mg intravenously at 1 minute intervals until\\ndesired effect is achieved\\n\\nFlumazenil with tricyclic antidepressants can cause\\nseizures\\n\\nActivated charcoal colours stools black\\n\\n- Keep all medicine out of reach when not needed\\n- Label all medicines appropriately\\n- Kerosene poisoning prevention\\n\\nKeep kerosene and other hydrocarbons away from\\nchildren\\nUse dedicate on tenants kerosene and other hydrocarbon\\n\\nCo-poison prevention\\n(1) Keep working generator safely away from explosions\\n(2) Do not run mobile engine/vehicles within explosions\\n(3) Enact and enforce laws for safe engine/generator\\npurchasing and use\\n\\nUsually due to inhalation of smoke, car or generator\\nexhaust fumes caused by incomplete combustion in a\\nconfined space\\n\\nCarbon monoxide binds to haemoglobin, myoglobin\\nand to mitochondria, inhibiting cellular respiration\\n\\nToxic effects of carbon monoxide are related to hypoxia\\n\\nDyspnoea\\nTachypnoea\\nHeadache\\nEmotional lability\\nConfusion\\nImpaired judgement\\nClumsiness\\nSyncope\\nNausea, vomiting and diarrhoea may occur\\n\\nCardiovascular manifestations:\\n\\nClinical features\\n\\nTreatment objectives\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nNotable adverse drug reactions\\n\\nPrevention of Drug Poisoning\\n\\nClinical features\\n\\nCarbon monoxide poisoning\\n\\nChapter 18: Emergencies Standard Treatment Guidelines for Nigeria 2008\\n\\n203 204\\n\\n\\n\\nIschaemic chest pain, arrhythmias, heart failure and\\nhypotension\\nIn severe poisoning:\\n\\nCerebral oedema\\nPulmonary oedema\\nRespiratory depression\\nComa may be seen in severe poisoning\\nCherry-red colour of skin and mucus\\nRarely cyanosis\\n\\nTo identify complications and establish a diagnosis\\n- Full Blood Count and ESR\\n- Serum Urea, Electrolytes and Creatinine\\n- Liver function tests\\n- Acid-base status\\n- Blood gases\\n\\nRemove from carbon monoxide exposure; move to\\nfresh air\\n\\nOxygen administration - face mask in conscious\\npatients and endotracheal intubation in comatose\\npatients after clearing the airways\\n\\nTreat hypotension and arrhythmia\\nMannitol\\n\\n- 10 - 20%; 250 mL intravenously over 30 minutes.\\nRepeat every 8 hours\\n\\nSimilar to poisoning by other petroleum distillates\\nPetroleum distillate hydrocarbons are poorly absorbed\\n\\nfollowing ingestion but can be aspirated, causing\\nsignificant toxicity to the airways\\n\\nMore common in children\\n\\nCNS excitation in low doses; depression in high doses\\nRarely coma and seizures\\nOther effects: nausea, vomiting, abdominal pain and\\n\\ndiarrhoea\\nAspiration may occur and cause aspiration pneumonia\\n\\nElectrolytes, Urea and serum Creatinine\\nLiver function tests\\nChest radiograph\\nElectrocardiography\\n\\nOxygen administration\\nRespiratory support\\nMonitoring liver, renal and myocardial function\\nCorrect metabolic abnormalities\\n\\nAntibiotics for aspiration pneumonitis\\n\\nInvestigations\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nClinical features\\n\\nInvestigations\\n\\nNon-drug treatment\\n\\nSupportive measures\\n\\nDrug treatment\\n\\nKerosene poisoning\\n\\nGastric lavage and decongestion are contraindicated\\nbecause of the risk of aspiration\\n\\nGlucocorticoids are ineffective\\n\\nIntroduction\\n\\nClinical features\\n\\nNon-drug treatment\\n\\nDrug treatment\\n\\nOrganophosphate/insecticide poisoning\\n\\nT h e s e s u b s t a n c e s i r r e v e r s i b l y i n h i b i t\\nacetylcholinesterase and cause accumulation of\\nacetylcholine at muscarinic and nicotinic synapses and in\\nthe CNS\\nOrganophosphates are absorbed through the skin, lungs,\\n\\nand gastrointestinal tract and are distributed widely in\\ntissues\\n\\nElimination is slow- by hepatic metabolism\\n\\nOnset from exposure to toxicity is between 30 minutes -\\n2 hours\\nMuscarinic effects:\\n\\nNausea\\nVomiting\\nAbdominal cramps\\nIncreased urinary frequency; urinary and fecal\\n\\nincontinence\\nIncreased bronchial secretions\\nCough\\nDyspnoea\\nSweating\\nSalivation\\nMiosis\\nBlurred vision\\nLacrimation\\nBradycardia, hypotension, and pulmonary oedema may\\n\\noccur\\nNicotinic effects:\\n\\nTwitching\\nWeakness\\nHypertension\\nTachycardia\\nParalysis in severe cases\\n\\nCNS effects:\\nAnxiety\\nRestlessness\\nTremor\\nConfusion\\nWeakness\\nSeizure\\nComa\\n\\nRemove contaminated clothing\\nWash skin with soap and water\\nVentilatory support\\n\\nOxygen administration\\nAtropine\\n\\n0.5 - 2 mg intravenously every 5 - 15 minutes until\\nbronchial and other secretions have dried\\n\\n20 micrograms/kg (maximum 2 mg)\\nintramuscularly or intravenously depending on the\\n\\nAdult:\\n\\nChild:\\n\\nseverity of poisoning, every 5 - 10 minutes until the skin\\nbecomes flushed and dry, pupils dilate and tachycardia\\ndevelops\\n- Effective for muscarinic symptoms\\nPlus:\\n\\nPralidoxine\\n- Diluted to 10 - 15 mL with water for injection and\\nadministered by slow intravenous injection over 5 - 10\\nminutes\\n\\n1 - 2 g; can be repeated in 30 minutes\\ninitially 30 mg/kg, then either 30 mg/kg every 4\\n\\nhours or by intravenous infusion, 8 - 10 mg/kg/hour\\n(usual maximum 12 g in 24 hours)\\n\\nTreat seizures with intravenous diazepam 10 mg stat\\n\\nAdult:\\nChild:\\n\\nCHAPTER 19: THERAPEUTICS\\n\\nPRESCRIPTION WRITING\\nIntroduction\\n\\nThe writing of a prescription is the culmination of a\\nclinical encounter with a patient\\n\\nThe decision to issue a prescription follows a complex\\nprocess of professional analysis and must be based on the\\nfollowing considerations:\\n\\nKnowledge of the patient\\'s clinical state\\nFactors likely to influence the drug\\'s pharmacokinetics\\n\\nand pharmacodynamics; the efficacy, safety and cost of\\nthe drug\\nRational prescribing entails the following process with\\nvarious steps:\\nStep 1:\\n\\n- Define the patient\\'s problem\\nStep 2:\\n\\n- Specify the therapeutic objectives\\nStep 3:\\n\\n- Verify whether your proposed treatment is suitable for\\nthis patient\\n\\nStep 4:\\n- Start the treatment\\nIssuing a prescription is not conclusive treatment. Two\\nfurther steps must be considered:\\n\\nStep 5:\\n- Give information, instructions and warnings\\n\\nStep 6:\\n- Monitor (and/or stop) the treatment\\n\\nAprescription order should specify:\\nWhat is to be administered\\nTo whom\\nBy whom prescribed\\n\\nIt should clearly indicate:\\nHow much should be taken (the amount e.g. in\\n\\nmilligrams, grams)\\nHow often (frequency)\\nThe route of administration\\n\\nAnd:\\nDuration of therapy\\n\\nIdentity of prescriber :\\n- Name\\n- Address/institution of prescriber\\n- Telephone number\\n\\nDate of prescription:\\n- Near top/beginning of left margin of a chart order\\n\\nIdentity of patient:\\n- Name\\n\\nDetails of this process will be found in the WHO\\'s “Guide\\nto Good Prescribing”\\n\\nApart from its use in therapy, a prescription order is\\nimportant as a medico-legal document\\nEssential elements of a prescription order\\n\\nChapter 18: Emergencies Standard Treatment Guidelines for Nigeria 2008\\n\\n205 206\\n\\n\\n\\n- Age (especially in children)\\n- Gender\\n- Address of patient\\n- Hospital number\\n\\nElements specifying medication:\\n- Name of medication\\n- Strength and quantity\\n- Dosage\\n- Frequency\\n- Duration\\n- Directions for use (drug- and patient- specific)\\n- Refill instructions\\n- Waiver of requirements for child-proof containers\\n- Additional labelling instructions\\n\\nPrescriber\\'s signature and other identification data e.g\\ncode. Prescriptions may be hand written or computer-\\nissued:\\n- Hand written prescriptions should be written in\\nindelible ink and the hand writing should be legible\\n(important, to avoid medication errors)\\n- Any alteration(s) made in a computer-issued\\nprescription should be duly endorsed\\n\\nOnly standard, official abbreviations should be used.\\nThe following are some notable abbreviations\\na.c ante cibum (before food)\\nb.d bis die (twice daily)\\no.d omni die (every day)\\no.m omni mane ( every morning)\\np.c post cibum (after food)\\np.r.n pro re nata (when required)\\nq.d.s quarter die sumendum (to be taken four\\ntimes daily)\\nq.q.h quarter quaque hora (every four hours)\\nstat immediately\\nt.d.s ter die sumendum (to be taken three times\\n\\ndaily)\\nt.i.d ter in die (three times daily)\\n\\nAvoid abbreviations of drug names\\nDoses should be written in the metric system or in\\n\\ninternational units (IU) when metric doses are not\\npracticable\\n\\nIf a drug is to be administered \\'as required\\', specify the\\nminimum dose interval and the total amount of drug to be\\nadministered\\n\\nAvoid unnecessary use of decimal points\\n1 mg not 1.0 mg\\nIf >1 g state as g\\nIf < 1 g state as milligram e.g. 500 mg not 0.5 g\\nIf < 1 mg state as microgram: 100 microgram not 0.1 mg\\nIf the decimal point is unavoidable, insert zero (0) in\\n\\nfront of the point e.g 0.5 mLnot .5 mL\\nMicrogram and nanogram should not be abbreviated\\n\\nMillilitre (mL) should be used for volume and not\\n\\ncubic centimetre, c.c or cm\\n\\n(generic name)\\n(metric units)\\n\\nAbbreviations\\n\\nNOTE\\n\\n3\\n\\nPrescription for special cases\\nSpecial precaution should be taken in children\\n\\n(especially neonates and infants), and the elderly when\\nconsidering drug therapy\\n- There are differences in drug handl ing\\n(pharmacokinetics) and sensitivity in drug response\\n(pharmacodynamics) in the different age groups\\n\\nParticular care should also be taken when prescribing\\nfor pregnant women\\n\\nPrecaution should also be taken in clinical states\\nassociated with organ system failure (renal, hepatic)\\nwhere dosage adjustment may be required\\n\\nThere are notable differences in the proportions and\\nconstituents of body fluids between adults and children\\n\\nThe immature enzyme systems result in poor oxidation\\nand conjugation and may cause adverse effects\\n- Grey Baby syndrome with chloramphenicol is an\\nexample\\n\\nDrugs predominantly excreted by the kidneys e.g\\naminoglycosides, penicillins may require dose reduction\\n\\nUse appropriate formulations for various routes e.g\\nrectal route (for diazepam, theophylline) in the\\nuncooperative child\\n(See appendix IV for calculation of dose requirements for\\nchildren)\\n\\nPersons 65 years or over: a growing segment of the\\nNigerian population\\n\\nA number of factors interplay to increase the incidence\\nof adverse drug reactions in this group of patients\\n- Bodily changes affecting drug handling and tissue\\nresponse\\n- The increasing number of medicines prescribed to\\ntreat multiple diseases, each with a potential to cause an\\nadverse drug reaction as well as a drug-drug interaction\\n- Poor adherence to therapy due to factors inherent in the\\nelderly\\n\\nDosage reduction may be required for some drugs\\nbecause of\\n- Changes in volume of distribution\\n- Reduced metabolism\\n- Reduced renal elimination\\n\\nParticular care is necessary in administration of drugs\\nwhere sensitivity in the elderly is increased e.g:\\n- Hypno-sedatives\\n- Neuroleptics\\n- Diuretics\\n\\nWhere no drug is needed avoid unnecessary\\nprescriptions.\\n\\nRelevant drugs should be prescribed in the appropriate\\ndose and monitored closely\\n\\nConsideration should be given to the formulation that is\\nmost appropriate in the clinical circumstances\\n\\nThe possibility of drug-drug interactions should\\nalways be borne in mind\\n\\nChildren (including neonates and infants)\\n\\nThe Elderly\\n\\nPregnancy and Lactation\\n\\nAdverse drug reaction\\n\\nAdverse drug event\\n\\nAserious adverse event (experience, or reaction)\\n\\nSide effect\\n\\nChanges in fluid and tissue composition occur during\\npregnancy\\n\\nReduced gastrointestinal motility delays gastric\\nemptying and may delay drug absorption after oral\\nadministration\\n\\nVasodilation may result in enhanced absorption\\nfollowing drug administration by the intramuscular route\\n\\nThere is increased volume of distribution, increased\\nhepatic metabolism and increased elimination of drugs\\n\\nExtreme care must be taken when administering drugs\\nwith teratogenic potential to women in the reproductive\\nage group (See appendix IV)\\n\\nSome drugs may cause harm to infants when\\nadministered to nursing mothers (see appendix V)\\n\\nOther drugs e.g bromocripine inhibit lactation\\nDrugs excreted significantly in milk and likely to cause\\ntoxicity are shown in appendix V\\n\\nThe use of medicines is inextricably linked to\\nunintended responses\\n\\nThe safe use of medicines is therefore an important\\nconsideration in therapy\\n\\nIn this text the following WHO definitions will apply\\n\\nA response to a medicine which is noxious and\\nunintended\\n- Occurs at doses normally used in man for the\\nprophylaxis, diagnosis or therapy of disease, or for the\\nmodification of physiologic function\\n\\nAny untoward medical occurrence that may present\\nduring treatment with a pharmaceutical product, but\\nwhich does not necessarily have a causal relationship\\nwith the treatment\\n\\nAny untoward medical occurrence that at any dose\\n- Results in death\\n- Is life-threatening\\n- Requires patient hospitalization or prolongs existing\\nhospitalization\\n- Results in persistent or significant disability/incapacity\\n- Causes a congenital anomaly or birth defect\\n- Requires an intervention to prevent permanent\\nimpairment or damage\\n\\nAny unintended effect of a pharmaceutical product\\noccurring at doses normally used in humans\\n\\n- Is related to the pharmacological properties of the drug\\nThere is need to have a high index of suspicion during\\n\\ntherapy so as to recognize and adequately manage\\nadverse effects\\n\\nADVERSE DRUG REACTIONS\\nIntroduction\\n\\nReport any suspected adverse response to a drug to\\nthe hospitals\\'Adverse Reaction Registry or directly to\\nthe National Agency for Food and Drug\\nAdministration and Control (NAFDAC),Abuja\\n\\nAsample of theYellow Form is shown inAppendix VI\\nAnalysis of such reports enables appropriate decisions\\n\\nto ensure safe and judicious use of medicines\\nIn the text a number of known adverse reactions are\\n\\nlisted for medicines used for the treatment of the stated\\ndiseases\\n- This list is by no means complete or comprehensive\\n- There may be unknown adverse reactions peculiar to\\nour population\\n\\nStandard Treatment Guidelines for Nigeria 2008Chapter 19: Therapeutics\\n\\n207 208\\n\\n\\n'), ('status', 200)])\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "SI4Nl9vnoK0Z",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 52
        },
        "outputId": "3357de0c-2c4c-481d-fe01-aa13e4aac7d8"
      },
      "source": [
        "rawList = rawText['content'].splitlines()                        \n",
        "rawList = [item.lower() for item in rawList if item.strip()]    \n",
        "print(len(rawList))   #About 23229 sentences in total\n",
        "print(rawList[23222])   #sample sentence"
      ],
      "execution_count": 11,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "23229\n",
            "listed for medicines used for the treatment of the stated\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "ui0C3_Sdp5kH",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 34
        },
        "outputId": "9e22dd8d-ce2c-4a39-ebed-b6a4e1013348"
      },
      "source": [
        "stg_str = ' '.join(rawList)     #Join list of sentences into string\n",
        "for c in string.punctuation:\n",
        "    stg_str = stg_str.replace(c, \"\")  #remove punctuations\n",
        "len(stg_str)                                      #About 693967 strings in total   "
      ],
      "execution_count": 12,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "676670"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 12
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "wSIicXqqZjxA",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "with open(\"stg2008.txt\", \"w\") as text_file:\n",
        "    text_file.write(stg_str)                                       #write string as text file"
      ],
      "execution_count": 0,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "w2WX8M5J6s1L",
        "colab_type": "text"
      },
      "source": [
        "##Train unsupervised fastText models  at  10,20,30 epochs"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "wOken7oXI0lz",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 52
        },
        "outputId": "26fa5806-7776-4327-9d90-bcf14ba97233"
      },
      "source": [
        "%%time\n",
        "stgmodel_10 = fasttext.train_unsupervised('stg2008.txt',epoch=10,dim=300)    #train model using fasttext\n",
        "stgmodel_10.save_model('stg2008_10.bin')    #save trained model"
      ],
      "execution_count": 49,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "CPU times: user 55.8 s, sys: 1.44 s, total: 57.2 s\n",
            "Wall time: 1min 23s\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "DgmLUWkw7R-5",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 52
        },
        "outputId": "7e05ead3-36b6-4932-b826-2a33dac26830"
      },
      "source": [
        "%%time\n",
        "stgmodel_20 = fasttext.train_unsupervised('stg2008.txt',epoch=20,dim=300)    #train model using fasttext\n",
        "stgmodel_20.save_model('stg2008_20.bin')    #save trained model"
      ],
      "execution_count": 50,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "CPU times: user 1min 42s, sys: 1.79 s, total: 1min 44s\n",
            "Wall time: 2min 11s\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "pO4m2ITd7e2w",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 52
        },
        "outputId": "40b278d4-422d-4684-e155-6ee3047c7dd5"
      },
      "source": [
        "%%time\n",
        "stgmodel_30 = fasttext.train_unsupervised('stg2008.txt',epoch=30,dim=300)    #train model using fasttext\n",
        "stgmodel_30.save_model('stg2008_30.bin')    #save trained model"
      ],
      "execution_count": 51,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "CPU times: user 2min 32s, sys: 2.5 s, total: 2min 35s\n",
            "Wall time: 3min 2s\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "jwzsX92ubVUb",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "fasttext_trained_model_10 = FastText.load_fasttext_format('stg2008_10.bin') #Load Model using gensim's Fasttext \n",
        "fasttext_trained_model_20 = FastText.load_fasttext_format('stg2008_20.bin') #Load Model using gensim's Fasttext \n",
        "fasttext_trained_model_30 = FastText.load_fasttext_format('stg2008_30.bin') #Load Model using gensim's Fasttext "
      ],
      "execution_count": 0,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "CZ4lSi5FrgVy",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "608c3127-b37a-461f-ccb1-cb7e9c73ab08"
      },
      "source": [
        "fasttext_trained_model.wv.vocab"
      ],
      "execution_count": 22,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'of': <gensim.models.keyedvectors.Vocab at 0x7ff780659710>,\n",
              " 'the': <gensim.models.keyedvectors.Vocab at 0x7ff780659748>,\n",
              " 'and': <gensim.models.keyedvectors.Vocab at 0x7ff780659240>,\n",
              " 'in': <gensim.models.keyedvectors.Vocab at 0x7ff7806594e0>,\n",
              " 'to': <gensim.models.keyedvectors.Vocab at 0x7ff780659be0>,\n",
              " 'or': <gensim.models.keyedvectors.Vocab at 0x7ff7806595c0>,\n",
              " 'for': <gensim.models.keyedvectors.Vocab at 0x7ff780659208>,\n",
              " 'with': <gensim.models.keyedvectors.Vocab at 0x7ff780659908>,\n",
              " 'a': <gensim.models.keyedvectors.Vocab at 0x7ff780659048>,\n",
              " 'mg': <gensim.models.keyedvectors.Vocab at 0x7ff780659080>,\n",
              " 'treatment': <gensim.models.keyedvectors.Vocab at 0x7ff780659940>,\n",
              " 'is': <gensim.models.keyedvectors.Vocab at 0x7ff7804b74a8>,\n",
              " 'be': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7550>,\n",
              " 'may': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7588>,\n",
              " 'daily': <gensim.models.keyedvectors.Vocab at 0x7ff7804b75c0>,\n",
              " 'hours': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7710>,\n",
              " 'as': <gensim.models.keyedvectors.Vocab at 0x7ff7804b76d8>,\n",
              " 'by': <gensim.models.keyedvectors.Vocab at 0x7ff7804b77b8>,\n",
              " 'orally': <gensim.models.keyedvectors.Vocab at 0x7ff7804b77f0>,\n",
              " 'every': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7470>,\n",
              " '1': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7908>,\n",
              " '2': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7400>,\n",
              " 'blood': <gensim.models.keyedvectors.Vocab at 0x7ff7804b78d0>,\n",
              " 'years': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7630>,\n",
              " 'are': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7978>,\n",
              " '12': <gensim.models.keyedvectors.Vocab at 0x7ff7804b79e8>,\n",
              " 'drug': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7a58>,\n",
              " 'on': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7ac8>,\n",
              " 'adult': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7b38>,\n",
              " '3': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7b70>,\n",
              " 'if': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7be0>,\n",
              " '5': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7c18>,\n",
              " 'clinical': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7c50>,\n",
              " 'days': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7cc0>,\n",
              " 'complications': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7cf8>,\n",
              " 'child': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7d68>,\n",
              " '4': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7da0>,\n",
              " '6': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7dd8>,\n",
              " 'not': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7e48>,\n",
              " 'disease': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7eb8>,\n",
              " 'from': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7f28>,\n",
              " 'should': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7f98>,\n",
              " 'infection': <gensim.models.keyedvectors.Vocab at 0x7ff7804b7fd0>,\n",
              " 'at': <gensim.models.keyedvectors.Vocab at 0x7ff781825080>,\n",
              " 'features': <gensim.models.keyedvectors.Vocab at 0x7ff7818250b8>,\n",
              " 'patients': <gensim.models.keyedvectors.Vocab at 0x7ff7818250f0>,\n",
              " 'acute': <gensim.models.keyedvectors.Vocab at 0x7ff781825160>,\n",
              " '10': <gensim.models.keyedvectors.Vocab at 0x7ff7818251d0>,\n",
              " 'mgkg': <gensim.models.keyedvectors.Vocab at 0x7ff781825240>,\n",
              " '8': <gensim.models.keyedvectors.Vocab at 0x7ff781825278>,\n",
              " 'eg': <gensim.models.keyedvectors.Vocab at 0x7ff7818252e8>,\n",
              " 'other': <gensim.models.keyedvectors.Vocab at 0x7ff781825358>,\n",
              " 'introduction': <gensim.models.keyedvectors.Vocab at 0x7ff781825390>,\n",
              " 'investigations': <gensim.models.keyedvectors.Vocab at 0x7ff7818253c8>,\n",
              " 'dose': <gensim.models.keyedvectors.Vocab at 0x7ff781825438>,\n",
              " 'an': <gensim.models.keyedvectors.Vocab at 0x7ff7818254a8>,\n",
              " 'g': <gensim.models.keyedvectors.Vocab at 0x7ff7818254e0>,\n",
              " 'pain': <gensim.models.keyedvectors.Vocab at 0x7ff781825550>,\n",
              " 'objectives': <gensim.models.keyedvectors.Vocab at 0x7ff781825588>,\n",
              " 'after': <gensim.models.keyedvectors.Vocab at 0x7ff7818255f8>,\n",
              " 'severe': <gensim.models.keyedvectors.Vocab at 0x7ff781825668>,\n",
              " 'differential': <gensim.models.keyedvectors.Vocab at 0x7ff7818256a0>,\n",
              " 'prevention': <gensim.models.keyedvectors.Vocab at 0x7ff7818256d8>,\n",
              " 'cause': <gensim.models.keyedvectors.Vocab at 0x7ff781825748>,\n",
              " 'chronic': <gensim.models.keyedvectors.Vocab at 0x7ff7818257b8>,\n",
              " '50': <gensim.models.keyedvectors.Vocab at 0x7ff781825828>,\n",
              " 'therapy': <gensim.models.keyedvectors.Vocab at 0x7ff781825898>,\n",
              " 'diagnoses': <gensim.models.keyedvectors.Vocab at 0x7ff7818258d0>,\n",
              " 'usually': <gensim.models.keyedvectors.Vocab at 0x7ff781825940>,\n",
              " 'failure': <gensim.models.keyedvectors.Vocab at 0x7ff7818259b0>,\n",
              " 'use': <gensim.models.keyedvectors.Vocab at 0x7ff781825a20>,\n",
              " 'skin': <gensim.models.keyedvectors.Vocab at 0x7ff781825a90>,\n",
              " 'prevent': <gensim.models.keyedvectors.Vocab at 0x7ff781825b00>,\n",
              " 'intravenous': <gensim.models.keyedvectors.Vocab at 0x7ff781825b38>,\n",
              " 'over': <gensim.models.keyedvectors.Vocab at 0x7ff781825ba8>,\n",
              " 'treat': <gensim.models.keyedvectors.Vocab at 0x7ff781825c18>,\n",
              " '25': <gensim.models.keyedvectors.Vocab at 0x7ff781825c88>,\n",
              " 'reactions': <gensim.models.keyedvectors.Vocab at 0x7ff781825cc0>,\n",
              " '500': <gensim.models.keyedvectors.Vocab at 0x7ff781825d30>,\n",
              " 'more': <gensim.models.keyedvectors.Vocab at 0x7ff781825da0>,\n",
              " 'infections': <gensim.models.keyedvectors.Vocab at 0x7ff781825dd8>,\n",
              " 'causes': <gensim.models.keyedvectors.Vocab at 0x7ff781825e48>,\n",
              " '20': <gensim.models.keyedvectors.Vocab at 0x7ff781825eb8>,\n",
              " 'patient': <gensim.models.keyedvectors.Vocab at 0x7ff781825f28>,\n",
              " 'adverse': <gensim.models.keyedvectors.Vocab at 0x7ff781825f98>,\n",
              " 'doses': <gensim.models.keyedvectors.Vocab at 0x7ff781826048>,\n",
              " 'than': <gensim.models.keyedvectors.Vocab at 0x7ff7818260b8>,\n",
              " 'caution': <gensim.models.keyedvectors.Vocab at 0x7ff781826128>,\n",
              " '100': <gensim.models.keyedvectors.Vocab at 0x7ff781826198>,\n",
              " 'up': <gensim.models.keyedvectors.Vocab at 0x7ff781826208>,\n",
              " 'symptoms': <gensim.models.keyedvectors.Vocab at 0x7ff781826240>,\n",
              " '7': <gensim.models.keyedvectors.Vocab at 0x7ff781826278>,\n",
              " 'avoid': <gensim.models.keyedvectors.Vocab at 0x7ff7818262e8>,\n",
              " 'lesions': <gensim.models.keyedvectors.Vocab at 0x7ff781826358>,\n",
              " 'times': <gensim.models.keyedvectors.Vocab at 0x7ff7818263c8>,\n",
              " 'pregnancy': <gensim.models.keyedvectors.Vocab at 0x7ff781826400>,\n",
              " 'common': <gensim.models.keyedvectors.Vocab at 0x7ff781826470>,\n",
              " 'children': <gensim.models.keyedvectors.Vocab at 0x7ff7818264a8>,\n",
              " 'maximum': <gensim.models.keyedvectors.Vocab at 0x7ff781826518>,\n",
              " 'nigeria': <gensim.models.keyedvectors.Vocab at 0x7ff781826588>,\n",
              " 'weeks': <gensim.models.keyedvectors.Vocab at 0x7ff7818265f8>,\n",
              " 'nondrug': <gensim.models.keyedvectors.Vocab at 0x7ff781826668>,\n",
              " 'standard': <gensim.models.keyedvectors.Vocab at 0x7ff7818266a0>,\n",
              " 'there': <gensim.models.keyedvectors.Vocab at 0x7ff781826710>,\n",
              " 'increased': <gensim.models.keyedvectors.Vocab at 0x7ff781826748>,\n",
              " 'fever': <gensim.models.keyedvectors.Vocab at 0x7ff7818267b8>,\n",
              " 'cases': <gensim.models.keyedvectors.Vocab at 0x7ff781826828>,\n",
              " 'notable': <gensim.models.keyedvectors.Vocab at 0x7ff781826898>,\n",
              " 'renal': <gensim.models.keyedvectors.Vocab at 0x7ff781826908>,\n",
              " 'cardiac': <gensim.models.keyedvectors.Vocab at 0x7ff781826978>,\n",
              " 'diabetes': <gensim.models.keyedvectors.Vocab at 0x7ff7818269b0>,\n",
              " 'risk': <gensim.models.keyedvectors.Vocab at 0x7ff781826a20>,\n",
              " 'that': <gensim.models.keyedvectors.Vocab at 0x7ff781826a90>,\n",
              " 'drugs': <gensim.models.keyedvectors.Vocab at 0x7ff781826b00>,\n",
              " 'injection': <gensim.models.keyedvectors.Vocab at 0x7ff781826b38>,\n",
              " 'chest': <gensim.models.keyedvectors.Vocab at 0x7ff781826ba8>,\n",
              " 'guidelines': <gensim.models.keyedvectors.Vocab at 0x7ff781826be0>,\n",
              " '15': <gensim.models.keyedvectors.Vocab at 0x7ff781826c50>,\n",
              " '18': <gensim.models.keyedvectors.Vocab at 0x7ff781826cc0>,\n",
              " 'appropriate': <gensim.models.keyedvectors.Vocab at 0x7ff781826cf8>,\n",
              " 'chapter': <gensim.models.keyedvectors.Vocab at 0x7ff781826d68>,\n",
              " 'oral': <gensim.models.keyedvectors.Vocab at 0x7ff781826dd8>,\n",
              " 'syndrome': <gensim.models.keyedvectors.Vocab at 0x7ff781826e10>,\n",
              " 'once': <gensim.models.keyedvectors.Vocab at 0x7ff781826e80>,\n",
              " 'count': <gensim.models.keyedvectors.Vocab at 0x7ff781826ef0>,\n",
              " 'measures': <gensim.models.keyedvectors.Vocab at 0x7ff781826f28>,\n",
              " 'all': <gensim.models.keyedvectors.Vocab at 0x7ff781826f98>,\n",
              " 'can': <gensim.models.keyedvectors.Vocab at 0x7ff781829048>,\n",
              " 'most': <gensim.models.keyedvectors.Vocab at 0x7ff7818290b8>,\n",
              " '250': <gensim.models.keyedvectors.Vocab at 0x7ff781829128>,\n",
              " 'twice': <gensim.models.keyedvectors.Vocab at 0x7ff781829198>,\n",
              " 'months': <gensim.models.keyedvectors.Vocab at 0x7ff781829208>,\n",
              " 'e': <gensim.models.keyedvectors.Vocab at 0x7ff781829240>,\n",
              " 'c': <gensim.models.keyedvectors.Vocab at 0x7ff781829278>,\n",
              " 'when': <gensim.models.keyedvectors.Vocab at 0x7ff7818292e8>,\n",
              " 'liver': <gensim.models.keyedvectors.Vocab at 0x7ff781829358>,\n",
              " 'it': <gensim.models.keyedvectors.Vocab at 0x7ff7818293c8>,\n",
              " '30': <gensim.models.keyedvectors.Vocab at 0x7ff781829438>,\n",
              " 'care': <gensim.models.keyedvectors.Vocab at 0x7ff7818294a8>,\n",
              " 'pressure': <gensim.models.keyedvectors.Vocab at 0x7ff7818294e0>,\n",
              " 'cell': <gensim.models.keyedvectors.Vocab at 0x7ff781829550>,\n",
              " 'secondary': <gensim.models.keyedvectors.Vocab at 0x7ff781829588>,\n",
              " 'which': <gensim.models.keyedvectors.Vocab at 0x7ff7818295f8>,\n",
              " 'bleeding': <gensim.models.keyedvectors.Vocab at 0x7ff781829630>,\n",
              " 'but': <gensim.models.keyedvectors.Vocab at 0x7ff7818296a0>,\n",
              " 'loss': <gensim.models.keyedvectors.Vocab at 0x7ff781829710>,\n",
              " 'often': <gensim.models.keyedvectors.Vocab at 0x7ff781829780>,\n",
              " 'minutes': <gensim.models.keyedvectors.Vocab at 0x7ff7818297f0>,\n",
              " 'under': <gensim.models.keyedvectors.Vocab at 0x7ff781829860>,\n",
              " 'initially': <gensim.models.keyedvectors.Vocab at 0x7ff781829898>,\n",
              " 'associated': <gensim.models.keyedvectors.Vocab at 0x7ff7818298d0>,\n",
              " 'examination': <gensim.models.keyedvectors.Vocab at 0x7ff781829908>,\n",
              " 'obstruction': <gensim.models.keyedvectors.Vocab at 0x7ff781829940>,\n",
              " 'management': <gensim.models.keyedvectors.Vocab at 0x7ff781829978>,\n",
              " 'necessary': <gensim.models.keyedvectors.Vocab at 0x7ff7818299b0>,\n",
              " 'culture': <gensim.models.keyedvectors.Vocab at 0x7ff781829a20>,\n",
              " 'full': <gensim.models.keyedvectors.Vocab at 0x7ff781829a90>,\n",
              " 'abdominal': <gensim.models.keyedvectors.Vocab at 0x7ff781829ac8>,\n",
              " '2008': <gensim.models.keyedvectors.Vocab at 0x7ff781829b38>,\n",
              " 'glucose': <gensim.models.keyedvectors.Vocab at 0x7ff781829ba8>,\n",
              " 'occur': <gensim.models.keyedvectors.Vocab at 0x7ff781829c18>,\n",
              " 'heart': <gensim.models.keyedvectors.Vocab at 0x7ff781829c88>,\n",
              " 'weight': <gensim.models.keyedvectors.Vocab at 0x7ff781829cf8>,\n",
              " 'trauma': <gensim.models.keyedvectors.Vocab at 0x7ff781829d68>,\n",
              " 'surgery': <gensim.models.keyedvectors.Vocab at 0x7ff781829dd8>,\n",
              " 'body': <gensim.models.keyedvectors.Vocab at 0x7ff781829e48>,\n",
              " 'i': <gensim.models.keyedvectors.Vocab at 0x7ff781829e80>,\n",
              " 'water': <gensim.models.keyedvectors.Vocab at 0x7ff781829ef0>,\n",
              " 'also': <gensim.models.keyedvectors.Vocab at 0x7ff781829f60>,\n",
              " 'any': <gensim.models.keyedvectors.Vocab at 0x7ff781829fd0>,\n",
              " 'respiratory': <gensim.models.keyedvectors.Vocab at 0x7ff78182c048>,\n",
              " '40': <gensim.models.keyedvectors.Vocab at 0x7ff78182c0b8>,\n",
              " 'month': <gensim.models.keyedvectors.Vocab at 0x7ff78182c128>,\n",
              " 'anaemia': <gensim.models.keyedvectors.Vocab at 0x7ff78182c198>,\n",
              " 'early': <gensim.models.keyedvectors.Vocab at 0x7ff78182c208>,\n",
              " 'serum': <gensim.models.keyedvectors.Vocab at 0x7ff78182c278>,\n",
              " 'reduce': <gensim.models.keyedvectors.Vocab at 0x7ff78182c2e8>,\n",
              " 'no': <gensim.models.keyedvectors.Vocab at 0x7ff78182c358>,\n",
              " 'adequate': <gensim.models.keyedvectors.Vocab at 0x7ff78182c390>,\n",
              " 'intravenously': <gensim.models.keyedvectors.Vocab at 0x7ff78182c3c8>,\n",
              " 'less': <gensim.models.keyedvectors.Vocab at 0x7ff78182c438>,\n",
              " 'infusion': <gensim.models.keyedvectors.Vocab at 0x7ff78182c470>,\n",
              " 'have': <gensim.models.keyedvectors.Vocab at 0x7ff78182c4e0>,\n",
              " 'supportive': <gensim.models.keyedvectors.Vocab at 0x7ff78182c518>,\n",
              " 'acid': <gensim.models.keyedvectors.Vocab at 0x7ff78182c588>,\n",
              " 'food': <gensim.models.keyedvectors.Vocab at 0x7ff78182c5f8>,\n",
              " 'into': <gensim.models.keyedvectors.Vocab at 0x7ff78182c668>,\n",
              " 'antibiotics': <gensim.models.keyedvectors.Vocab at 0x7ff78182c6a0>,\n",
              " 'systemic': <gensim.models.keyedvectors.Vocab at 0x7ff78182c6d8>,\n",
              " 'one': <gensim.models.keyedvectors.Vocab at 0x7ff78182c748>,\n",
              " 'fluid': <gensim.models.keyedvectors.Vocab at 0x7ff78182c7b8>,\n",
              " '24': <gensim.models.keyedvectors.Vocab at 0x7ff78182c828>,\n",
              " 'disorders': <gensim.models.keyedvectors.Vocab at 0x7ff78182c860>,\n",
              " '200': <gensim.models.keyedvectors.Vocab at 0x7ff78182c8d0>,\n",
              " 'occurs': <gensim.models.keyedvectors.Vocab at 0x7ff78182c940>,\n",
              " 'then': <gensim.models.keyedvectors.Vocab at 0x7ff78182c9b0>,\n",
              " 'due': <gensim.models.keyedvectors.Vocab at 0x7ff78182ca20>,\n",
              " 'especially': <gensim.models.keyedvectors.Vocab at 0x7ff78182ca58>,\n",
              " 'function': <gensim.models.keyedvectors.Vocab at 0x7ff78182ca90>,\n",
              " 'factors': <gensim.models.keyedvectors.Vocab at 0x7ff78182cb00>,\n",
              " 'recommended': <gensim.models.keyedvectors.Vocab at 0x7ff78182cb38>,\n",
              " 'present': <gensim.models.keyedvectors.Vocab at 0x7ff78182cba8>,\n",
              " 't': <gensim.models.keyedvectors.Vocab at 0x7ff78182cbe0>,\n",
              " 'vomiting': <gensim.models.keyedvectors.Vocab at 0x7ff78182cc18>,\n",
              " 'women': <gensim.models.keyedvectors.Vocab at 0x7ff78182cc88>,\n",
              " 'oedema': <gensim.models.keyedvectors.Vocab at 0x7ff78182ccf8>,\n",
              " 'used': <gensim.models.keyedvectors.Vocab at 0x7ff78182cd68>,\n",
              " 'apply': <gensim.models.keyedvectors.Vocab at 0x7ff78182cdd8>,\n",
              " 'urine': <gensim.models.keyedvectors.Vocab at 0x7ff78182ce48>,\n",
              " 'divided': <gensim.models.keyedvectors.Vocab at 0x7ff78182ceb8>,\n",
              " 'pulmonary': <gensim.models.keyedvectors.Vocab at 0x7ff78182cef0>,\n",
              " 'before': <gensim.models.keyedvectors.Vocab at 0x7ff78182cf60>,\n",
              " 'microscopy': <gensim.models.keyedvectors.Vocab at 0x7ff78182cf98>,\n",
              " 'type': <gensim.models.keyedvectors.Vocab at 0x7ff78182e048>,\n",
              " 'response': <gensim.models.keyedvectors.Vocab at 0x7ff78182e080>,\n",
              " 'during': <gensim.models.keyedvectors.Vocab at 0x7ff78182e0f0>,\n",
              " 'see': <gensim.models.keyedvectors.Vocab at 0x7ff78182e160>,\n",
              " 'transfusion': <gensim.models.keyedvectors.Vocab at 0x7ff78182e198>,\n",
              " 'such': <gensim.models.keyedvectors.Vocab at 0x7ff78182e208>,\n",
              " 'diarrhoea': <gensim.models.keyedvectors.Vocab at 0x7ff78182e240>,\n",
              " 'discharge': <gensim.models.keyedvectors.Vocab at 0x7ff78182e278>,\n",
              " 'diagnosis': <gensim.models.keyedvectors.Vocab at 0x7ff78182e2b0>,\n",
              " 'given': <gensim.models.keyedvectors.Vocab at 0x7ff78182e320>,\n",
              " 'low': <gensim.models.keyedvectors.Vocab at 0x7ff78182e390>,\n",
              " 'bacterial': <gensim.models.keyedvectors.Vocab at 0x7ff78182e3c8>,\n",
              " 'kg': <gensim.models.keyedvectors.Vocab at 0x7ff78182e438>,\n",
              " 'etc': <gensim.models.keyedvectors.Vocab at 0x7ff78182e4a8>,\n",
              " '14': <gensim.models.keyedvectors.Vocab at 0x7ff78182e518>,\n",
              " 'cells': <gensim.models.keyedvectors.Vocab at 0x7ff78182e588>,\n",
              " 'some': <gensim.models.keyedvectors.Vocab at 0x7ff78182e5f8>,\n",
              " 'normal': <gensim.models.keyedvectors.Vocab at 0x7ff78182e668>,\n",
              " 'urea': <gensim.models.keyedvectors.Vocab at 0x7ff78182e6d8>,\n",
              " 'sensitivity': <gensim.models.keyedvectors.Vocab at 0x7ff78182e710>,\n",
              " 'conditions': <gensim.models.keyedvectors.Vocab at 0x7ff78182e748>,\n",
              " 'electrolytes': <gensim.models.keyedvectors.Vocab at 0x7ff78182e780>,\n",
              " 'first': <gensim.models.keyedvectors.Vocab at 0x7ff78182e7f0>,\n",
              " 'history': <gensim.models.keyedvectors.Vocab at 0x7ff78182e860>,\n",
              " 'only': <gensim.models.keyedvectors.Vocab at 0x7ff78182e8d0>,\n",
              " 'age': <gensim.models.keyedvectors.Vocab at 0x7ff78182e940>,\n",
              " 'sodium': <gensim.models.keyedvectors.Vocab at 0x7ff78182e9b0>,\n",
              " 'system': <gensim.models.keyedvectors.Vocab at 0x7ff78182ea20>,\n",
              " 'who': <gensim.models.keyedvectors.Vocab at 0x7ff78182ea90>,\n",
              " 's': <gensim.models.keyedvectors.Vocab at 0x7ff78182eac8>,\n",
              " 'diseases': <gensim.models.keyedvectors.Vocab at 0x7ff78182eb00>,\n",
              " 'hypertension': <gensim.models.keyedvectors.Vocab at 0x7ff78182eb38>,\n",
              " 'high': <gensim.models.keyedvectors.Vocab at 0x7ff78182eba8>,\n",
              " 'stage': <gensim.models.keyedvectors.Vocab at 0x7ff78182ec18>,\n",
              " 'until': <gensim.models.keyedvectors.Vocab at 0x7ff78182ec88>,\n",
              " 'primary': <gensim.models.keyedvectors.Vocab at 0x7ff78182ecf8>,\n",
              " 'physical': <gensim.models.keyedvectors.Vocab at 0x7ff78182ed30>,\n",
              " 'this': <gensim.models.keyedvectors.Vocab at 0x7ff78182eda0>,\n",
              " 'following': <gensim.models.keyedvectors.Vocab at 0x7ff78182edd8>,\n",
              " 'micrograms': <gensim.models.keyedvectors.Vocab at 0x7ff78182ee10>,\n",
              " 'b': <gensim.models.keyedvectors.Vocab at 0x7ff78182ee48>,\n",
              " 'hiv': <gensim.models.keyedvectors.Vocab at 0x7ff78182eeb8>,\n",
              " 'brain': <gensim.models.keyedvectors.Vocab at 0x7ff78182ef28>,\n",
              " 'tests': <gensim.models.keyedvectors.Vocab at 0x7ff78182ef98>,\n",
              " 'required': <gensim.models.keyedvectors.Vocab at 0x7ff78182efd0>,\n",
              " 'dermatitis': <gensim.models.keyedvectors.Vocab at 0x7ff78182f048>,\n",
              " 'nausea': <gensim.models.keyedvectors.Vocab at 0x7ff78182f0b8>,\n",
              " 'about': <gensim.models.keyedvectors.Vocab at 0x7ff78182f128>,\n",
              " 'affected': <gensim.models.keyedvectors.Vocab at 0x7ff78182f160>,\n",
              " 'gastrointestinal': <gensim.models.keyedvectors.Vocab at 0x7ff78182f1d0>,\n",
              " 'day': <gensim.models.keyedvectors.Vocab at 0x7ff78182f208>,\n",
              " 'tract': <gensim.models.keyedvectors.Vocab at 0x7ff78182f278>,\n",
              " '125': <gensim.models.keyedvectors.Vocab at 0x7ff78182f2e8>,\n",
              " 'pruritus': <gensim.models.keyedvectors.Vocab at 0x7ff78182f320>,\n",
              " 'eye': <gensim.models.keyedvectors.Vocab at 0x7ff78182f390>,\n",
              " 'red': <gensim.models.keyedvectors.Vocab at 0x7ff78182f400>,\n",
              " 'contact': <gensim.models.keyedvectors.Vocab at 0x7ff78182f470>,\n",
              " 'bone': <gensim.models.keyedvectors.Vocab at 0x7ff78182f4e0>,\n",
              " 'levels': <gensim.models.keyedvectors.Vocab at 0x7ff78182f550>,\n",
              " 'possible': <gensim.models.keyedvectors.Vocab at 0x7ff78182f588>,\n",
              " 'plus': <gensim.models.keyedvectors.Vocab at 0x7ff78182f5f8>,\n",
              " 'ear': <gensim.models.keyedvectors.Vocab at 0x7ff78182f668>,\n",
              " 'agents': <gensim.models.keyedvectors.Vocab at 0x7ff78182f6d8>,\n",
              " 'include': <gensim.models.keyedvectors.Vocab at 0x7ff78182f748>,\n",
              " 'alcohol': <gensim.models.keyedvectors.Vocab at 0x7ff78182f7b8>,\n",
              " 'inflammation': <gensim.models.keyedvectors.Vocab at 0x7ff78182f7f0>,\n",
              " 'single': <gensim.models.keyedvectors.Vocab at 0x7ff78182f860>,\n",
              " '60': <gensim.models.keyedvectors.Vocab at 0x7ff78182f8d0>,\n",
              " 'upper': <gensim.models.keyedvectors.Vocab at 0x7ff78182f940>,\n",
              " 'n': <gensim.models.keyedvectors.Vocab at 0x7ff78182f978>,\n",
              " 'three': <gensim.models.keyedvectors.Vocab at 0x7ff78182f9e8>,\n",
              " '400': <gensim.models.keyedvectors.Vocab at 0x7ff78182fa58>,\n",
              " 'caused': <gensim.models.keyedvectors.Vocab at 0x7ff78182fac8>,\n",
              " 'contraindications': <gensim.models.keyedvectors.Vocab at 0x7ff78182fb00>,\n",
              " 'above': <gensim.models.keyedvectors.Vocab at 0x7ff78182fb70>,\n",
              " 'surgical': <gensim.models.keyedvectors.Vocab at 0x7ff78182fba8>,\n",
              " 'health': <gensim.models.keyedvectors.Vocab at 0x7ff78182fc18>,\n",
              " 'injury': <gensim.models.keyedvectors.Vocab at 0x7ff78182fc88>,\n",
              " 'urinary': <gensim.models.keyedvectors.Vocab at 0x7ff78182fcf8>,\n",
              " 'death': <gensim.models.keyedvectors.Vocab at 0x7ff78182fd68>,\n",
              " 'creatinine': <gensim.models.keyedvectors.Vocab at 0x7ff78182fda0>,\n",
              " 'mellitus': <gensim.models.keyedvectors.Vocab at 0x7ff78182fdd8>,\n",
              " 'effects': <gensim.models.keyedvectors.Vocab at 0x7ff78182fe48>,\n",
              " 'without': <gensim.models.keyedvectors.Vocab at 0x7ff78182feb8>,\n",
              " 'inflammatory': <gensim.models.keyedvectors.Vocab at 0x7ff78182fef0>,\n",
              " 'poisoning': <gensim.models.keyedvectors.Vocab at 0x7ff78182ff28>,\n",
              " 'ml': <gensim.models.keyedvectors.Vocab at 0x7ff78182ff98>,\n",
              " 'adults': <gensim.models.keyedvectors.Vocab at 0x7ff781833048>,\n",
              " '75': <gensim.models.keyedvectors.Vocab at 0x7ff7818330b8>,\n",
              " 'haemorrhage': <gensim.models.keyedvectors.Vocab at 0x7ff7818330f0>,\n",
              " 'least': <gensim.models.keyedvectors.Vocab at 0x7ff781833160>,\n",
              " 'test': <gensim.models.keyedvectors.Vocab at 0x7ff7818331d0>,\n",
              " 'abscess': <gensim.models.keyedvectors.Vocab at 0x7ff781833240>,\n",
              " 'life': <gensim.models.keyedvectors.Vocab at 0x7ff7818332b0>,\n",
              " 'where': <gensim.models.keyedvectors.Vocab at 0x7ff781833320>,\n",
              " 'potassium': <gensim.models.keyedvectors.Vocab at 0x7ff781833358>,\n",
              " 'mgm': <gensim.models.keyedvectors.Vocab at 0x7ff7818333c8>,\n",
              " 'underlying': <gensim.models.keyedvectors.Vocab at 0x7ff781833400>,\n",
              " 'maintenance': <gensim.models.keyedvectors.Vocab at 0x7ff781833438>,\n",
              " 'education': <gensim.models.keyedvectors.Vocab at 0x7ff781833470>,\n",
              " 'exposure': <gensim.models.keyedvectors.Vocab at 0x7ff7818334a8>,\n",
              " 'metabolic': <gensim.models.keyedvectors.Vocab at 0x7ff7818334e0>,\n",
              " 'has': <gensim.models.keyedvectors.Vocab at 0x7ff781833550>,\n",
              " '300': <gensim.models.keyedvectors.Vocab at 0x7ff7818335c0>,\n",
              " 'insulin': <gensim.models.keyedvectors.Vocab at 0x7ff781833630>,\n",
              " 'within': <gensim.models.keyedvectors.Vocab at 0x7ff7818336a0>,\n",
              " 'lower': <gensim.models.keyedvectors.Vocab at 0x7ff781833710>,\n",
              " 'vaginal': <gensim.models.keyedvectors.Vocab at 0x7ff781833780>,\n",
              " 'small': <gensim.models.keyedvectors.Vocab at 0x7ff7818337f0>,\n",
              " 'malaria': <gensim.models.keyedvectors.Vocab at 0x7ff781833860>,\n",
              " 'radiograph': <gensim.models.keyedvectors.Vocab at 0x7ff781833898>,\n",
              " 'time': <gensim.models.keyedvectors.Vocab at 0x7ff781833908>,\n",
              " 'ulcer': <gensim.models.keyedvectors.Vocab at 0x7ff781833978>,\n",
              " 'control': <gensim.models.keyedvectors.Vocab at 0x7ff7818339e8>,\n",
              " 'indicated': <gensim.models.keyedvectors.Vocab at 0x7ff781833a20>,\n",
              " 'result': <gensim.models.keyedvectors.Vocab at 0x7ff781833a90>,\n",
              " 'asymptomatic': <gensim.models.keyedvectors.Vocab at 0x7ff781833ac8>,\n",
              " 'cough': <gensim.models.keyedvectors.Vocab at 0x7ff781833b38>,\n",
              " 'medical': <gensim.models.keyedvectors.Vocab at 0x7ff781833ba8>,\n",
              " 'those': <gensim.models.keyedvectors.Vocab at 0x7ff781833c18>,\n",
              " 'week': <gensim.models.keyedvectors.Vocab at 0x7ff781833c88>,\n",
              " 'prophylaxis': <gensim.models.keyedvectors.Vocab at 0x7ff781833cc0>,\n",
              " 'aetiology': <gensim.models.keyedvectors.Vocab at 0x7ff781833cf8>,\n",
              " 'wound': <gensim.models.keyedvectors.Vocab at 0x7ff781833d68>,\n",
              " 'arthritis': <gensim.models.keyedvectors.Vocab at 0x7ff781833da0>,\n",
              " 'intracranial': <gensim.models.keyedvectors.Vocab at 0x7ff781833dd8>,\n",
              " 'give': <gensim.models.keyedvectors.Vocab at 0x7ff781833e48>,\n",
              " 'intramuscular': <gensim.models.keyedvectors.Vocab at 0x7ff781833e80>,\n",
              " 'urethral': <gensim.models.keyedvectors.Vocab at 0x7ff781833eb8>,\n",
              " 'o': <gensim.models.keyedvectors.Vocab at 0x7ff781833ef0>,\n",
              " 'recurrent': <gensim.models.keyedvectors.Vocab at 0x7ff781833f28>,\n",
              " 'mild': <gensim.models.keyedvectors.Vocab at 0x7ff781833f98>,\n",
              " 'haemoglobin': <gensim.models.keyedvectors.Vocab at 0x7ff781833fd0>,\n",
              " 'metronidazole': <gensim.models.keyedvectors.Vocab at 0x7ff781835048>,\n",
              " 'hourly': <gensim.models.keyedvectors.Vocab at 0x7ff7818350b8>,\n",
              " 'important': <gensim.models.keyedvectors.Vocab at 0x7ff7818350f0>,\n",
              " 'year': <gensim.models.keyedvectors.Vocab at 0x7ff781835160>,\n",
              " 'units': <gensim.models.keyedvectors.Vocab at 0x7ff7818351d0>,\n",
              " 'd': <gensim.models.keyedvectors.Vocab at 0x7ff781835208>,\n",
              " 'its': <gensim.models.keyedvectors.Vocab at 0x7ff781835278>,\n",
              " 'iron': <gensim.models.keyedvectors.Vocab at 0x7ff7818352e8>,\n",
              " 'headache': <gensim.models.keyedvectors.Vocab at 0x7ff781835320>,\n",
              " 'topical': <gensim.models.keyedvectors.Vocab at 0x7ff781835390>,\n",
              " 'andor': <gensim.models.keyedvectors.Vocab at 0x7ff781835400>,\n",
              " 'signs': <gensim.models.keyedvectors.Vocab at 0x7ff781835470>,\n",
              " 'volume': <gensim.models.keyedvectors.Vocab at 0x7ff7818354e0>,\n",
              " 'these': <gensim.models.keyedvectors.Vocab at 0x7ff781835550>,\n",
              " 'p': <gensim.models.keyedvectors.Vocab at 0x7ff781835588>,\n",
              " 'taken': <gensim.models.keyedvectors.Vocab at 0x7ff7818355f8>,\n",
              " 'intake': <gensim.models.keyedvectors.Vocab at 0x7ff781835668>,\n",
              " 'deep': <gensim.models.keyedvectors.Vocab at 0x7ff7818356d8>,\n",
              " 'night': <gensim.models.keyedvectors.Vocab at 0x7ff781835748>,\n",
              " 'airway': <gensim.models.keyedvectors.Vocab at 0x7ff7818357b8>,\n",
              " 'because': <gensim.models.keyedvectors.Vocab at 0x7ff781835828>,\n",
              " 'adjusted': <gensim.models.keyedvectors.Vocab at 0x7ff781835860>,\n",
              " 'regimen': <gensim.models.keyedvectors.Vocab at 0x7ff7818358d0>,\n",
              " 'viral': <gensim.models.keyedvectors.Vocab at 0x7ff781835940>,\n",
              " 'contraindicated': <gensim.models.keyedvectors.Vocab at 0x7ff781835978>,\n",
              " '80': <gensim.models.keyedvectors.Vocab at 0x7ff7818359e8>,\n",
              " 'per': <gensim.models.keyedvectors.Vocab at 0x7ff781835a58>,\n",
              " 'specific': <gensim.models.keyedvectors.Vocab at 0x7ff781835a90>,\n",
              " 'vitamin': <gensim.models.keyedvectors.Vocab at 0x7ff781835b00>,\n",
              " 'results': <gensim.models.keyedvectors.Vocab at 0x7ff781835b70>,\n",
              " 'total': <gensim.models.keyedvectors.Vocab at 0x7ff781835be0>,\n",
              " 'general': <gensim.models.keyedvectors.Vocab at 0x7ff781835c50>,\n",
              " 'seen': <gensim.models.keyedvectors.Vocab at 0x7ff781835cc0>,\n",
              " 'correct': <gensim.models.keyedvectors.Vocab at 0x7ff781835d30>,\n",
              " 'presence': <gensim.models.keyedvectors.Vocab at 0x7ff781835d68>,\n",
              " 'between': <gensim.models.keyedvectors.Vocab at 0x7ff781835dd8>,\n",
              " 'onset': <gensim.models.keyedvectors.Vocab at 0x7ff781835e48>,\n",
              " 'intestinal': <gensim.models.keyedvectors.Vocab at 0x7ff781835e80>,\n",
              " 'must': <gensim.models.keyedvectors.Vocab at 0x7ff781835ef0>,\n",
              " 'could': <gensim.models.keyedvectors.Vocab at 0x7ff781835f60>,\n",
              " 'cerebral': <gensim.models.keyedvectors.Vocab at 0x7ff781835f98>,\n",
              " 'do': <gensim.models.keyedvectors.Vocab at 0x7ff781838048>,\n",
              " 'steroids': <gensim.models.keyedvectors.Vocab at 0x7ff781838080>,\n",
              " 'maintain': <gensim.models.keyedvectors.Vocab at 0x7ff7818380b8>,\n",
              " 'particularly': <gensim.models.keyedvectors.Vocab at 0x7ff7818380f0>,\n",
              " 'perforation': <gensim.models.keyedvectors.Vocab at 0x7ff781838128>,\n",
              " 'infected': <gensim.models.keyedvectors.Vocab at 0x7ff781838160>,\n",
              " 'nasal': <gensim.models.keyedvectors.Vocab at 0x7ff7818381d0>,\n",
              " 'central': <gensim.models.keyedvectors.Vocab at 0x7ff781838240>,\n",
              " 'r': <gensim.models.keyedvectors.Vocab at 0x7ff781838278>,\n",
              " '05': <gensim.models.keyedvectors.Vocab at 0x7ff7818382e8>,\n",
              " 'elderly': <gensim.models.keyedvectors.Vocab at 0x7ff781838358>,\n",
              " 'm': <gensim.models.keyedvectors.Vocab at 0x7ff781838390>,\n",
              " 'long': <gensim.models.keyedvectors.Vocab at 0x7ff781838400>,\n",
              " 'h': <gensim.models.keyedvectors.Vocab at 0x7ff781838438>,\n",
              " 'repeated': <gensim.models.keyedvectors.Vocab at 0x7ff781838470>,\n",
              " 'rate': <gensim.models.keyedvectors.Vocab at 0x7ff7818384e0>,\n",
              " 'plasma': <gensim.models.keyedvectors.Vocab at 0x7ff781838550>,\n",
              " 'hypotension': <gensim.models.keyedvectors.Vocab at 0x7ff781838588>,\n",
              " 'dyspnoea': <gensim.models.keyedvectors.Vocab at 0x7ff7818385c0>,\n",
              " 'provide': <gensim.models.keyedvectors.Vocab at 0x7ff781838630>,\n",
              " 'characterized': <gensim.models.keyedvectors.Vocab at 0x7ff781838668>,\n",
              " 'scan': <gensim.models.keyedvectors.Vocab at 0x7ff7818386d8>,\n",
              " 'bladder': <gensim.models.keyedvectors.Vocab at 0x7ff781838748>,\n",
              " 'foetal': <gensim.models.keyedvectors.Vocab at 0x7ff7818387b8>,\n",
              " 'head': <gensim.models.keyedvectors.Vocab at 0x7ff781838828>,\n",
              " 'occasionally': <gensim.models.keyedvectors.Vocab at 0x7ff781838860>,\n",
              " 'local': <gensim.models.keyedvectors.Vocab at 0x7ff7818388d0>,\n",
              " 'sexual': <gensim.models.keyedvectors.Vocab at 0x7ff781838940>,\n",
              " 'available': <gensim.models.keyedvectors.Vocab at 0x7ff781838978>,\n",
              " 'effective': <gensim.models.keyedvectors.Vocab at 0x7ff7818389b0>,\n",
              " 'joint': <gensim.models.keyedvectors.Vocab at 0x7ff781838a20>,\n",
              " 'according': <gensim.models.keyedvectors.Vocab at 0x7ff781838a58>,\n",
              " 'identify': <gensim.models.keyedvectors.Vocab at 0x7ff781838a90>,\n",
              " 'cervical': <gensim.models.keyedvectors.Vocab at 0x7ff781838ac8>,\n",
              " 'face': <gensim.models.keyedvectors.Vocab at 0x7ff781838b38>,\n",
              " 'relieve': <gensim.models.keyedvectors.Vocab at 0x7ff781838ba8>,\n",
              " 'damage': <gensim.models.keyedvectors.Vocab at 0x7ff781838c18>,\n",
              " 'persons': <gensim.models.keyedvectors.Vocab at 0x7ff781838c88>,\n",
              " 'abnormal': <gensim.models.keyedvectors.Vocab at 0x7ff781838cc0>,\n",
              " 'state': <gensim.models.keyedvectors.Vocab at 0x7ff781838d30>,\n",
              " 'amoxicillin': <gensim.models.keyedvectors.Vocab at 0x7ff781838d68>,\n",
              " 'status': <gensim.models.keyedvectors.Vocab at 0x7ff781838dd8>,\n",
              " 'depression': <gensim.models.keyedvectors.Vocab at 0x7ff781838e10>,\n",
              " 'electrolyte': <gensim.models.keyedvectors.Vocab at 0x7ff781838e48>,\n",
              " 'commonly': <gensim.models.keyedvectors.Vocab at 0x7ff781838e80>,\n",
              " 'will': <gensim.models.keyedvectors.Vocab at 0x7ff781838ef0>,\n",
              " 'initial': <gensim.models.keyedvectors.Vocab at 0x7ff781838f60>,\n",
              " 'level': <gensim.models.keyedvectors.Vocab at 0x7ff781838fd0>,\n",
              " 'hepatic': <gensim.models.keyedvectors.Vocab at 0x7ff78043d080>,\n",
              " 'poor': <gensim.models.keyedvectors.Vocab at 0x7ff78043d0f0>,\n",
              " 'oxygen': <gensim.models.keyedvectors.Vocab at 0x7ff78043d160>,\n",
              " 'neonate': <gensim.models.keyedvectors.Vocab at 0x7ff78043d1d0>,\n",
              " 'marrow': <gensim.models.keyedvectors.Vocab at 0x7ff78043d240>,\n",
              " 'urinalysis': <gensim.models.keyedvectors.Vocab at 0x7ff78043d278>,\n",
              " 'pneumonia': <gensim.models.keyedvectors.Vocab at 0x7ff78043d2b0>,\n",
              " 'reaction': <gensim.models.keyedvectors.Vocab at 0x7ff78043d2e8>,\n",
              " 'absence': <gensim.models.keyedvectors.Vocab at 0x7ff78043d358>,\n",
              " 'psoriasis': <gensim.models.keyedvectors.Vocab at 0x7ff78043d390>,\n",
              " '150': <gensim.models.keyedvectors.Vocab at 0x7ff78043d400>,\n",
              " 'l': <gensim.models.keyedvectors.Vocab at 0x7ff78043d438>,\n",
              " 'ultrasound': <gensim.models.keyedvectors.Vocab at 0x7ff78043d470>,\n",
              " 'slow': <gensim.models.keyedvectors.Vocab at 0x7ff78043d4e0>,\n",
              " 'stroke': <gensim.models.keyedvectors.Vocab at 0x7ff78043d550>,\n",
              " 'including': <gensim.models.keyedvectors.Vocab at 0x7ff78043d588>,\n",
              " 'antibiotic': <gensim.models.keyedvectors.Vocab at 0x7ff78043d5c0>,\n",
              " 'conjunctivitis': <gensim.models.keyedvectors.Vocab at 0x7ff78043d5f8>,\n",
              " 'virus': <gensim.models.keyedvectors.Vocab at 0x7ff78043d668>,\n",
              " 'out': <gensim.models.keyedvectors.Vocab at 0x7ff78043d6d8>,\n",
              " 'activity': <gensim.models.keyedvectors.Vocab at 0x7ff78043d710>,\n",
              " 'period': <gensim.models.keyedvectors.Vocab at 0x7ff78043d780>,\n",
              " 'differentials': <gensim.models.keyedvectors.Vocab at 0x7ff78043d7b8>,\n",
              " 'paracetamol': <gensim.models.keyedvectors.Vocab at 0x7ff78043d7f0>,\n",
              " 'delivery': <gensim.models.keyedvectors.Vocab at 0x7ff78043d828>,\n",
              " 'eyes': <gensim.models.keyedvectors.Vocab at 0x7ff78043d898>,\n",
              " 'increase': <gensim.models.keyedvectors.Vocab at 0x7ff78043d8d0>,\n",
              " 'syphilis': <gensim.models.keyedvectors.Vocab at 0x7ff78043d908>,\n",
              " 'mouth': <gensim.models.keyedvectors.Vocab at 0x7ff78043d978>,\n",
              " 'using': <gensim.models.keyedvectors.Vocab at 0x7ff78043d9e8>,\n",
              " 'exercise': <gensim.models.keyedvectors.Vocab at 0x7ff78043da20>,\n",
              " 'monitor': <gensim.models.keyedvectors.Vocab at 0x7ff78043da90>,\n",
              " 'leukaemia': <gensim.models.keyedvectors.Vocab at 0x7ff78043dac8>,\n",
              " 'microgramskg': <gensim.models.keyedvectors.Vocab at 0x7ff78043db00>,\n",
              " 'weekly': <gensim.models.keyedvectors.Vocab at 0x7ff78043db70>,\n",
              " 'large': <gensim.models.keyedvectors.Vocab at 0x7ff78043dbe0>,\n",
              " 'neck': <gensim.models.keyedvectors.Vocab at 0x7ff78043dc50>,\n",
              " 'concentration': <gensim.models.keyedvectors.Vocab at 0x7ff78043dc88>,\n",
              " 'later': <gensim.models.keyedvectors.Vocab at 0x7ff78043dcf8>,\n",
              " 'sickle': <gensim.models.keyedvectors.Vocab at 0x7ff78043dd68>,\n",
              " 'tuberculosis': <gensim.models.keyedvectors.Vocab at 0x7ff78043dda0>,\n",
              " 'administration': <gensim.models.keyedvectors.Vocab at 0x7ff78043ddd8>,\n",
              " 'swelling': <gensim.models.keyedvectors.Vocab at 0x7ff78043de10>,\n",
              " 'ensure': <gensim.models.keyedvectors.Vocab at 0x7ff78043de80>,\n",
              " 'tb': <gensim.models.keyedvectors.Vocab at 0x7ff78043def0>,\n",
              " 'progressive': <gensim.models.keyedvectors.Vocab at 0x7ff78043df28>,\n",
              " 'multiple': <gensim.models.keyedvectors.Vocab at 0x7ff78043df60>,\n",
              " 'generalized': <gensim.models.keyedvectors.Vocab at 0x7ff78043df98>,\n",
              " 'usual': <gensim.models.keyedvectors.Vocab at 0x7ff78043f048>,\n",
              " 'raised': <gensim.models.keyedvectors.Vocab at 0x7ff78043f0b8>,\n",
              " 'two': <gensim.models.keyedvectors.Vocab at 0x7ff78043f128>,\n",
              " 'disorder': <gensim.models.keyedvectors.Vocab at 0x7ff78043f160>,\n",
              " 'their': <gensim.models.keyedvectors.Vocab at 0x7ff78043f1d0>,\n",
              " 'cream': <gensim.models.keyedvectors.Vocab at 0x7ff78043f240>,\n",
              " 'various': <gensim.models.keyedvectors.Vocab at 0x7ff78043f2b0>,\n",
              " 'through': <gensim.models.keyedvectors.Vocab at 0x7ff78043f320>,\n",
              " 'changes': <gensim.models.keyedvectors.Vocab at 0x7ff78043f390>,\n",
              " 'dry': <gensim.models.keyedvectors.Vocab at 0x7ff78043f400>,\n",
              " 'meningitis': <gensim.models.keyedvectors.Vocab at 0x7ff78043f438>,\n",
              " 'been': <gensim.models.keyedvectors.Vocab at 0x7ff78043f4a8>,\n",
              " 'followed': <gensim.models.keyedvectors.Vocab at 0x7ff78043f4e0>,\n",
              " 'injuries': <gensim.models.keyedvectors.Vocab at 0x7ff78043f518>,\n",
              " 'throat': <gensim.models.keyedvectors.Vocab at 0x7ff78043f588>,\n",
              " 'spread': <gensim.models.keyedvectors.Vocab at 0x7ff78043f5f8>,\n",
              " 'monitoring': <gensim.models.keyedvectors.Vocab at 0x7ff78043f630>,\n",
              " 'arrhythmias': <gensim.models.keyedvectors.Vocab at 0x7ff78043f668>,\n",
              " 'site': <gensim.models.keyedvectors.Vocab at 0x7ff78043f6d8>,\n",
              " 'deficiency': <gensim.models.keyedvectors.Vocab at 0x7ff78043f710>,\n",
              " 'same': <gensim.models.keyedvectors.Vocab at 0x7ff78043f780>,\n",
              " 'tetanus': <gensim.models.keyedvectors.Vocab at 0x7ff78043f7f0>,\n",
              " 'need': <gensim.models.keyedvectors.Vocab at 0x7ff78043f860>,\n",
              " 'bed': <gensim.models.keyedvectors.Vocab at 0x7ff78043f8d0>,\n",
              " 'hepatitis': <gensim.models.keyedvectors.Vocab at 0x7ff78043f908>,\n",
              " 'areas': <gensim.models.keyedvectors.Vocab at 0x7ff78043f978>,\n",
              " 'acquired': <gensim.models.keyedvectors.Vocab at 0x7ff78043f9b0>,\n",
              " 'nsaids': <gensim.models.keyedvectors.Vocab at 0x7ff78043fa20>,\n",
              " 'rest': <gensim.models.keyedvectors.Vocab at 0x7ff78043fa90>,\n",
              " 'vaccine': <gensim.models.keyedvectors.Vocab at 0x7ff78043fb00>,\n",
              " 'regular': <gensim.models.keyedvectors.Vocab at 0x7ff78043fb70>,\n",
              " 'human': <gensim.models.keyedvectors.Vocab at 0x7ff78043fbe0>,\n",
              " 'organisms': <gensim.models.keyedvectors.Vocab at 0x7ff78043fc18>,\n",
              " 'impairment': <gensim.models.keyedvectors.Vocab at 0x7ff78043fc50>,\n",
              " 'coma': <gensim.models.keyedvectors.Vocab at 0x7ff78043fcc0>,\n",
              " 'discomfort': <gensim.models.keyedvectors.Vocab at 0x7ff78043fcf8>,\n",
              " 'dehydration': <gensim.models.keyedvectors.Vocab at 0x7ff78043fd30>,\n",
              " 'prednisolone': <gensim.models.keyedvectors.Vocab at 0x7ff78043fd68>,\n",
              " 'mortality': <gensim.models.keyedvectors.Vocab at 0x7ff78043fda0>,\n",
              " 'ectopic': <gensim.models.keyedvectors.Vocab at 0x7ff78043fe10>,\n",
              " 'hour': <gensim.models.keyedvectors.Vocab at 0x7ff78043fe80>,\n",
              " 'acne': <gensim.models.keyedvectors.Vocab at 0x7ff78043fef0>,\n",
              " 'abnormalities': <gensim.models.keyedvectors.Vocab at 0x7ff78043ff28>,\n",
              " 'rectal': <gensim.models.keyedvectors.Vocab at 0x7ff78043ff98>,\n",
              " 'become': <gensim.models.keyedvectors.Vocab at 0x7ff780441048>,\n",
              " 'many': <gensim.models.keyedvectors.Vocab at 0x7ff7804410b8>,\n",
              " 'frequency': <gensim.models.keyedvectors.Vocab at 0x7ff7804410f0>,\n",
              " 'diet': <gensim.models.keyedvectors.Vocab at 0x7ff780441160>,\n",
              " 'sputum': <gensim.models.keyedvectors.Vocab at 0x7ff7804411d0>,\n",
              " 'jaundice': <gensim.models.keyedvectors.Vocab at 0x7ff780441208>,\n",
              " 'further': <gensim.models.keyedvectors.Vocab at 0x7ff780441278>,\n",
              " 'excessive': <gensim.models.keyedvectors.Vocab at 0x7ff7804412b0>,\n",
              " 'side': <gensim.models.keyedvectors.Vocab at 0x7ff780441320>,\n",
              " 'young': <gensim.models.keyedvectors.Vocab at 0x7ff780441390>,\n",
              " 'infective': <gensim.models.keyedvectors.Vocab at 0x7ff7804413c8>,\n",
              " 'nutrition': <gensim.models.keyedvectors.Vocab at 0x7ff780441400>,\n",
              " 'persistent': <gensim.models.keyedvectors.Vocab at 0x7ff780441438>,\n",
              " 'sudden': <gensim.models.keyedvectors.Vocab at 0x7ff7804414a8>,\n",
              " 'condition': <gensim.models.keyedvectors.Vocab at 0x7ff7804414e0>,\n",
              " 'recurrence': <gensim.models.keyedvectors.Vocab at 0x7ff780441518>,\n",
              " 'hydration': <gensim.models.keyedvectors.Vocab at 0x7ff780441550>,\n",
              " '120': <gensim.models.keyedvectors.Vocab at 0x7ff7804415c0>,\n",
              " 'disaster': <gensim.models.keyedvectors.Vocab at 0x7ff7804415f8>,\n",
              " 'erythromycin': <gensim.models.keyedvectors.Vocab at 0x7ff780441630>,\n",
              " 'congenital': <gensim.models.keyedvectors.Vocab at 0x7ff780441668>,\n",
              " 'very': <gensim.models.keyedvectors.Vocab at 0x7ff7804416d8>,\n",
              " 'tissue': <gensim.models.keyedvectors.Vocab at 0x7ff780441748>,\n",
              " 'significant': <gensim.models.keyedvectors.Vocab at 0x7ff780441780>,\n",
              " 'analgesics': <gensim.models.keyedvectors.Vocab at 0x7ff7804417b8>,\n",
              " 'consciousness': <gensim.models.keyedvectors.Vocab at 0x7ff7804417f0>,\n",
              " 'tumours': <gensim.models.keyedvectors.Vocab at 0x7ff780441860>,\n",
              " 'people': <gensim.models.keyedvectors.Vocab at 0x7ff7804418d0>,\n",
              " 'late': <gensim.models.keyedvectors.Vocab at 0x7ff780441940>,\n",
              " 'restore': <gensim.models.keyedvectors.Vocab at 0x7ff7804419b0>,\n",
              " 'drops': <gensim.models.keyedvectors.Vocab at 0x7ff780441a20>,\n",
              " 'cancer': <gensim.models.keyedvectors.Vocab at 0x7ff780441a90>,\n",
              " 'cardiovascular': <gensim.models.keyedvectors.Vocab at 0x7ff780441ac8>,\n",
              " 'muscle': <gensim.models.keyedvectors.Vocab at 0x7ff780441b38>,\n",
              " 'swab': <gensim.models.keyedvectors.Vocab at 0x7ff780441ba8>,\n",
              " 'types': <gensim.models.keyedvectors.Vocab at 0x7ff780441c18>,\n",
              " 'tachycardia': <gensim.models.keyedvectors.Vocab at 0x7ff780441c50>,\n",
              " 'complete': <gensim.models.keyedvectors.Vocab at 0x7ff780441c88>,\n",
              " 'lesion': <gensim.models.keyedvectors.Vocab at 0x7ff780441cf8>,\n",
              " 'itching': <gensim.models.keyedvectors.Vocab at 0x7ff780441d68>,\n",
              " 'presentation': <gensim.models.keyedvectors.Vocab at 0x7ff780441da0>,\n",
              " 'both': <gensim.models.keyedvectors.Vocab at 0x7ff780441e10>,\n",
              " 'phase': <gensim.models.keyedvectors.Vocab at 0x7ff780441e80>,\n",
              " 'emergency': <gensim.models.keyedvectors.Vocab at 0x7ff780441eb8>,\n",
              " 'affects': <gensim.models.keyedvectors.Vocab at 0x7ff780441f28>,\n",
              " 'prolonged': <gensim.models.keyedvectors.Vocab at 0x7ff780441f60>,\n",
              " 'seizures': <gensim.models.keyedvectors.Vocab at 0x7ff780441f98>,\n",
              " 'require': <gensim.models.keyedvectors.Vocab at 0x7ff780445048>,\n",
              " 'corneal': <gensim.models.keyedvectors.Vocab at 0x7ff7804450b8>,\n",
              " 'paralysis': <gensim.models.keyedvectors.Vocab at 0x7ff7804450f0>,\n",
              " 'improve': <gensim.models.keyedvectors.Vocab at 0x7ff780445160>,\n",
              " 'causing': <gensim.models.keyedvectors.Vocab at 0x7ff7804451d0>,\n",
              " 'intramuscularly': <gensim.models.keyedvectors.Vocab at 0x7ff780445208>,\n",
              " 'done': <gensim.models.keyedvectors.Vocab at 0x7ff780445278>,\n",
              " 'administered': <gensim.models.keyedvectors.Vocab at 0x7ff7804452b0>,\n",
              " 'surface': <gensim.models.keyedvectors.Vocab at 0x7ff780445320>,\n",
              " 'infants': <gensim.models.keyedvectors.Vocab at 0x7ff780445390>,\n",
              " 'hypoglycaemia': <gensim.models.keyedvectors.Vocab at 0x7ff7804453c8>,\n",
              " 'pregnant': <gensim.models.keyedvectors.Vocab at 0x7ff780445400>,\n",
              " 'cd4': <gensim.models.keyedvectors.Vocab at 0x7ff780445470>,\n",
              " 'depending': <gensim.models.keyedvectors.Vocab at 0x7ff7804454a8>,\n",
              " 'rupture': <gensim.models.keyedvectors.Vocab at 0x7ff780445518>,\n",
              " 'peripheral': <gensim.models.keyedvectors.Vocab at 0x7ff780445550>,\n",
              " 'septicaemia': <gensim.models.keyedvectors.Vocab at 0x7ff780445588>,\n",
              " 'evidence': <gensim.models.keyedvectors.Vocab at 0x7ff7804455c0>,\n",
              " 'reduced': <gensim.models.keyedvectors.Vocab at 0x7ff780445630>,\n",
              " 'tablets': <gensim.models.keyedvectors.Vocab at 0x7ff7804456a0>,\n",
              " 'bowel': <gensim.models.keyedvectors.Vocab at 0x7ff780445710>,\n",
              " 'airways': <gensim.models.keyedvectors.Vocab at 0x7ff780445780>,\n",
              " 'around': <gensim.models.keyedvectors.Vocab at 0x7ff7804457f0>,\n",
              " 'exclude': <gensim.models.keyedvectors.Vocab at 0x7ff780445860>,\n",
              " 'eradicate': <gensim.models.keyedvectors.Vocab at 0x7ff780445898>,\n",
              " 'chloride': <gensim.models.keyedvectors.Vocab at 0x7ff7804458d0>,\n",
              " 'lymphadenopathy': <gensim.models.keyedvectors.Vocab at 0x7ff780445908>,\n",
              " 'tube': <gensim.models.keyedvectors.Vocab at 0x7ff780445978>,\n",
              " 'treated': <gensim.models.keyedvectors.Vocab at 0x7ff7804459e8>,\n",
              " 'remove': <gensim.models.keyedvectors.Vocab at 0x7ff780445a58>,\n",
              " 'toxicity': <gensim.models.keyedvectors.Vocab at 0x7ff780445a90>,\n",
              " 'maternal': <gensim.models.keyedvectors.Vocab at 0x7ff780445ac8>,\n",
              " 'rabies': <gensim.models.keyedvectors.Vocab at 0x7ff780445b38>,\n",
              " 'last': <gensim.models.keyedvectors.Vocab at 0x7ff780445ba8>,\n",
              " 'hygiene': <gensim.models.keyedvectors.Vocab at 0x7ff780445c18>,\n",
              " 'repeat': <gensim.models.keyedvectors.Vocab at 0x7ff780445c88>,\n",
              " 'attacks': <gensim.models.keyedvectors.Vocab at 0x7ff780445cf8>,\n",
              " 'hair': <gensim.models.keyedvectors.Vocab at 0x7ff780445d68>,\n",
              " 'pelvic': <gensim.models.keyedvectors.Vocab at 0x7ff780445dd8>,\n",
              " 'they': <gensim.models.keyedvectors.Vocab at 0x7ff780445e48>,\n",
              " 'resulting': <gensim.models.keyedvectors.Vocab at 0x7ff780445e80>,\n",
              " 'ulcers': <gensim.models.keyedvectors.Vocab at 0x7ff780445ef0>,\n",
              " 'urticaria': <gensim.models.keyedvectors.Vocab at 0x7ff780445f28>,\n",
              " 'developing': <gensim.models.keyedvectors.Vocab at 0x7ff780445f60>,\n",
              " 'solution': <gensim.models.keyedvectors.Vocab at 0x7ff780445f98>,\n",
              " 'testis': <gensim.models.keyedvectors.Vocab at 0x7ff780447048>,\n",
              " 'several': <gensim.models.keyedvectors.Vocab at 0x7ff7804470b8>,\n",
              " 'known': <gensim.models.keyedvectors.Vocab at 0x7ff780447128>,\n",
              " 'infectious': <gensim.models.keyedvectors.Vocab at 0x7ff780447160>,\n",
              " 'removal': <gensim.models.keyedvectors.Vocab at 0x7ff7804471d0>,\n",
              " 'good': <gensim.models.keyedvectors.Vocab at 0x7ff780447240>,\n",
              " 'sites': <gensim.models.keyedvectors.Vocab at 0x7ff7804472b0>,\n",
              " 'ct': <gensim.models.keyedvectors.Vocab at 0x7ff780447320>,\n",
              " 'tinea': <gensim.models.keyedvectors.Vocab at 0x7ff780447390>,\n",
              " 'dysfunction': <gensim.models.keyedvectors.Vocab at 0x7ff7804473c8>,\n",
              " 'headaches': <gensim.models.keyedvectors.Vocab at 0x7ff780447400>,\n",
              " 'form': <gensim.models.keyedvectors.Vocab at 0x7ff780447470>,\n",
              " 'foreign': <gensim.models.keyedvectors.Vocab at 0x7ff7804474e0>,\n",
              " 'immune': <gensim.models.keyedvectors.Vocab at 0x7ff780447550>,\n",
              " 'sometimes': <gensim.models.keyedvectors.Vocab at 0x7ff780447588>,\n",
              " 'painful': <gensim.models.keyedvectors.Vocab at 0x7ff7804475f8>,\n",
              " 'support': <gensim.models.keyedvectors.Vocab at 0x7ff780447668>,\n",
              " 'eliminate': <gensim.models.keyedvectors.Vocab at 0x7ff7804476a0>,\n",
              " 'involvement': <gensim.models.keyedvectors.Vocab at 0x7ff7804476d8>,\n",
              " 'gastric': <gensim.models.keyedvectors.Vocab at 0x7ff780447748>,\n",
              " 'peptic': <gensim.models.keyedvectors.Vocab at 0x7ff7804477b8>,\n",
              " 'output': <gensim.models.keyedvectors.Vocab at 0x7ff780447828>,\n",
              " 'found': <gensim.models.keyedvectors.Vocab at 0x7ff780447898>,\n",
              " 'otitis': <gensim.models.keyedvectors.Vocab at 0x7ff780447908>,\n",
              " 'thrombosis': <gensim.models.keyedvectors.Vocab at 0x7ff780447940>,\n",
              " 'protein': <gensim.models.keyedvectors.Vocab at 0x7ff7804479b0>,\n",
              " 'group': <gensim.models.keyedvectors.Vocab at 0x7ff780447a20>,\n",
              " 'lung': <gensim.models.keyedvectors.Vocab at 0x7ff780447a90>,\n",
              " 'combination': <gensim.models.keyedvectors.Vocab at 0x7ff780447ac8>,\n",
              " 'cellulitis': <gensim.models.keyedvectors.Vocab at 0x7ff780447b00>,\n",
              " 'bacteria': <gensim.models.keyedvectors.Vocab at 0x7ff780447b38>,\n",
              " 'below': <gensim.models.keyedvectors.Vocab at 0x7ff780447ba8>,\n",
              " 'cold': <gensim.models.keyedvectors.Vocab at 0x7ff780447c18>,\n",
              " 'prostate': <gensim.models.keyedvectors.Vocab at 0x7ff780447c50>,\n",
              " 'parenteral': <gensim.models.keyedvectors.Vocab at 0x7ff780447c88>,\n",
              " 'herpes': <gensim.models.keyedvectors.Vocab at 0x7ff780447cf8>,\n",
              " 'growth': <gensim.models.keyedvectors.Vocab at 0x7ff780447d68>,\n",
              " '48': <gensim.models.keyedvectors.Vocab at 0x7ff780447dd8>,\n",
              " 'rarely': <gensim.models.keyedvectors.Vocab at 0x7ff780447e48>,\n",
              " 'medicines': <gensim.models.keyedvectors.Vocab at 0x7ff780447e80>,\n",
              " 'temperature': <gensim.models.keyedvectors.Vocab at 0x7ff780447eb8>,\n",
              " 'cns': <gensim.models.keyedvectors.Vocab at 0x7ff780447f28>,\n",
              " 'identified': <gensim.models.keyedvectors.Vocab at 0x7ff780447f60>,\n",
              " 'labour': <gensim.models.keyedvectors.Vocab at 0x7ff780447fd0>,\n",
              " 'effect': <gensim.models.keyedvectors.Vocab at 0x7ff780449080>,\n",
              " 'doubled': <gensim.models.keyedvectors.Vocab at 0x7ff7804490f0>,\n",
              " 'tenderness': <gensim.models.keyedvectors.Vocab at 0x7ff780449128>,\n",
              " 'dental': <gensim.models.keyedvectors.Vocab at 0x7ff780449198>,\n",
              " 'countries': <gensim.models.keyedvectors.Vocab at 0x7ff7804491d0>,\n",
              " 'birth': <gensim.models.keyedvectors.Vocab at 0x7ff780449240>,\n",
              " 'ointment': <gensim.models.keyedvectors.Vocab at 0x7ff780449278>,\n",
              " 'anaesthesia': <gensim.models.keyedvectors.Vocab at 0x7ff7804492b0>,\n",
              " 'penicillin': <gensim.models.keyedvectors.Vocab at 0x7ff7804492e8>,\n",
              " 'fluids': <gensim.models.keyedvectors.Vocab at 0x7ff780449358>,\n",
              " 'shock': <gensim.models.keyedvectors.Vocab at 0x7ff7804493c8>,\n",
              " 'u': <gensim.models.keyedvectors.Vocab at 0x7ff780449400>,\n",
              " 'among': <gensim.models.keyedvectors.Vocab at 0x7ff780449470>,\n",
              " 'gestation': <gensim.models.keyedvectors.Vocab at 0x7ff7804494a8>,\n",
              " 'salt': <gensim.models.keyedvectors.Vocab at 0x7ff780449518>,\n",
              " 'hypersensitivity': <gensim.models.keyedvectors.Vocab at 0x7ff780449588>,\n",
              " '9': <gensim.models.keyedvectors.Vocab at 0x7ff780449550>,\n",
              " 'against': <gensim.models.keyedvectors.Vocab at 0x7ff7804495f8>,\n",
              " 'different': <gensim.models.keyedvectors.Vocab at 0x7ff780449630>,\n",
              " 'screening': <gensim.models.keyedvectors.Vocab at 0x7ff780449668>,\n",
              " 'depend': <gensim.models.keyedvectors.Vocab at 0x7ff7804496d8>,\n",
              " 'moderate': <gensim.models.keyedvectors.Vocab at 0x7ff780449710>,\n",
              " 'erythema': <gensim.models.keyedvectors.Vocab at 0x7ff780449748>,\n",
              " 'visit': <gensim.models.keyedvectors.Vocab at 0x7ff7804497b8>,\n",
              " 'take': <gensim.models.keyedvectors.Vocab at 0x7ff780449828>,\n",
              " 'asthma': <gensim.models.keyedvectors.Vocab at 0x7ff780449898>,\n",
              " 'stop': <gensim.models.keyedvectors.Vocab at 0x7ff780449908>,\n",
              " 'echocardiography': <gensim.models.keyedvectors.Vocab at 0x7ff780449978>,\n",
              " 'stool': <gensim.models.keyedvectors.Vocab at 0x7ff7804499b0>,\n",
              " 'forms': <gensim.models.keyedvectors.Vocab at 0x7ff780449a20>,\n",
              " 'lymph': <gensim.models.keyedvectors.Vocab at 0x7ff780449a90>,\n",
              " 'spontaneous': <gensim.models.keyedvectors.Vocab at 0x7ff780449ac8>,\n",
              " 'abdomen': <gensim.models.keyedvectors.Vocab at 0x7ff780449b38>,\n",
              " 'line': <gensim.models.keyedvectors.Vocab at 0x7ff780449ba8>,\n",
              " 'nerve': <gensim.models.keyedvectors.Vocab at 0x7ff780449c18>,\n",
              " 'area': <gensim.models.keyedvectors.Vocab at 0x7ff780449c88>,\n",
              " 'likely': <gensim.models.keyedvectors.Vocab at 0x7ff780449cf8>,\n",
              " 'obstructive': <gensim.models.keyedvectors.Vocab at 0x7ff780449d30>,\n",
              " 'well': <gensim.models.keyedvectors.Vocab at 0x7ff780449da0>,\n",
              " 'indications': <gensim.models.keyedvectors.Vocab at 0x7ff780449dd8>,\n",
              " 'carcinoma': <gensim.models.keyedvectors.Vocab at 0x7ff780449e10>,\n",
              " 'weakness': <gensim.models.keyedvectors.Vocab at 0x7ff780449e48>,\n",
              " 'sweating': <gensim.models.keyedvectors.Vocab at 0x7ff780449e80>,\n",
              " 'esr': <gensim.models.keyedvectors.Vocab at 0x7ff780449ef0>,\n",
              " 'aspirin': <gensim.models.keyedvectors.Vocab at 0x7ff780449f60>,\n",
              " 'transmitted': <gensim.models.keyedvectors.Vocab at 0x7ff780449f98>,\n",
              " 'calcium': <gensim.models.keyedvectors.Vocab at 0x7ff78044d048>,\n",
              " 'others': <gensim.models.keyedvectors.Vocab at 0x7ff78044d0b8>,\n",
              " 'acidosis': <gensim.models.keyedvectors.Vocab at 0x7ff78044d0f0>,\n",
              " 'th': <gensim.models.keyedvectors.Vocab at 0x7ff78044d160>,\n",
              " 'resistance': <gensim.models.keyedvectors.Vocab at 0x7ff78044d198>,\n",
              " 'organs': <gensim.models.keyedvectors.Vocab at 0x7ff78044d208>,\n",
              " 'family': <gensim.models.keyedvectors.Vocab at 0x7ff78044d278>,\n",
              " 'white': <gensim.models.keyedvectors.Vocab at 0x7ff78044d2e8>,\n",
              " 'back': <gensim.models.keyedvectors.Vocab at 0x7ff78044d358>,\n",
              " 'reduction': <gensim.models.keyedvectors.Vocab at 0x7ff78044d390>,\n",
              " 'rash': <gensim.models.keyedvectors.Vocab at 0x7ff78044d400>,\n",
              " 'gastritis': <gensim.models.keyedvectors.Vocab at 0x7ff78044d438>,\n",
              " 'whole': <gensim.models.keyedvectors.Vocab at 0x7ff78044d4a8>,\n",
              " 'dizziness': <gensim.models.keyedvectors.Vocab at 0x7ff78044d4e0>,\n",
              " 'mass': <gensim.models.keyedvectors.Vocab at 0x7ff78044d550>,\n",
              " 'eczema': <gensim.models.keyedvectors.Vocab at 0x7ff78044d5c0>,\n",
              " 'obesity': <gensim.models.keyedvectors.Vocab at 0x7ff78044d630>,\n",
              " 'severity': <gensim.models.keyedvectors.Vocab at 0x7ff78044d668>,\n",
              " 'groups': <gensim.models.keyedvectors.Vocab at 0x7ff78044d6d8>,\n",
              " 'nodes': <gensim.models.keyedvectors.Vocab at 0x7ff78044d748>,\n",
              " 'constipation': <gensim.models.keyedvectors.Vocab at 0x7ff78044d780>,\n",
              " 'sleep': <gensim.models.keyedvectors.Vocab at 0x7ff78044d7f0>,\n",
              " 'develop': <gensim.models.keyedvectors.Vocab at 0x7ff78044d860>,\n",
              " 'emotional': <gensim.models.keyedvectors.Vocab at 0x7ff78044d898>,\n",
              " 'useful': <gensim.models.keyedvectors.Vocab at 0x7ff78044d908>,\n",
              " 'inhibitors': <gensim.models.keyedvectors.Vocab at 0x7ff78044d940>,\n",
              " 'leading': <gensim.models.keyedvectors.Vocab at 0x7ff78044d9b0>,\n",
              " 'always': <gensim.models.keyedvectors.Vocab at 0x7ff78044da20>,\n",
              " 'frequent': <gensim.models.keyedvectors.Vocab at 0x7ff78044da58>,\n",
              " 'rare': <gensim.models.keyedvectors.Vocab at 0x7ff78044dac8>,\n",
              " 'ventricular': <gensim.models.keyedvectors.Vocab at 0x7ff78044db00>,\n",
              " 'soon': <gensim.models.keyedvectors.Vocab at 0x7ff78044db70>,\n",
              " 'promote': <gensim.models.keyedvectors.Vocab at 0x7ff78044dbe0>,\n",
              " 'vascular': <gensim.models.keyedvectors.Vocab at 0x7ff78044dc18>,\n",
              " 'incidence': <gensim.models.keyedvectors.Vocab at 0x7ff78044dc50>,\n",
              " 'allergic': <gensim.models.keyedvectors.Vocab at 0x7ff78044dc88>,\n",
              " 'rapidly': <gensim.models.keyedvectors.Vocab at 0x7ff78044dcf8>,\n",
              " 'venous': <gensim.models.keyedvectors.Vocab at 0x7ff78044dd68>,\n",
              " 'major': <gensim.models.keyedvectors.Vocab at 0x7ff78044ddd8>,\n",
              " 'immediately': <gensim.models.keyedvectors.Vocab at 0x7ff78044de10>,\n",
              " 'diazepam': <gensim.models.keyedvectors.Vocab at 0x7ff78044de48>,\n",
              " 'active': <gensim.models.keyedvectors.Vocab at 0x7ff78044deb8>,\n",
              " 'fractures': <gensim.models.keyedvectors.Vocab at 0x7ff78044def0>,\n",
              " 'abortion': <gensim.models.keyedvectors.Vocab at 0x7ff78044df28>,\n",
              " 'replacement': <gensim.models.keyedvectors.Vocab at 0x7ff78044df60>,\n",
              " 'procedures': <gensim.models.keyedvectors.Vocab at 0x7ff78044df98>,\n",
              " 'serious': <gensim.models.keyedvectors.Vocab at 0x7ff78044e048>,\n",
              " 'decreased': <gensim.models.keyedvectors.Vocab at 0x7ff78044e080>,\n",
              " 'generally': <gensim.models.keyedvectors.Vocab at 0x7ff78044e0b8>,\n",
              " 'rheumatic': <gensim.models.keyedvectors.Vocab at 0x7ff78044e0f0>,\n",
              " 'new': <gensim.models.keyedvectors.Vocab at 0x7ff78044e160>,\n",
              " 'even': <gensim.models.keyedvectors.Vocab at 0x7ff78044e1d0>,\n",
              " 'sinus': <gensim.models.keyedvectors.Vocab at 0x7ff78044e240>,\n",
              " 'myocardial': <gensim.models.keyedvectors.Vocab at 0x7ff78044e278>,\n",
              " 'ciprofloxacin': <gensim.models.keyedvectors.Vocab at 0x7ff78044e2b0>,\n",
              " '01': <gensim.models.keyedvectors.Vocab at 0x7ff78044e320>,\n",
              " 'fasting': <gensim.models.keyedvectors.Vocab at 0x7ff78044e390>,\n",
              " 'retention': <gensim.models.keyedvectors.Vocab at 0x7ff78044e3c8>,\n",
              " 'while': <gensim.models.keyedvectors.Vocab at 0x7ff78044e438>,\n",
              " 'electrocardiography': <gensim.models.keyedvectors.Vocab at 0x7ff78044e470>,\n",
              " 'malaise': <gensim.models.keyedvectors.Vocab at 0x7ff78044e4e0>,\n",
              " 'warts': <gensim.models.keyedvectors.Vocab at 0x7ff78044e550>,\n",
              " 'assessment': <gensim.models.keyedvectors.Vocab at 0x7ff78044e588>,\n",
              " 'females': <gensim.models.keyedvectors.Vocab at 0x7ff78044e5f8>,\n",
              " 'subcutaneous': <gensim.models.keyedvectors.Vocab at 0x7ff78044e630>,\n",
              " 'disturbances': <gensim.models.keyedvectors.Vocab at 0x7ff78044e668>,\n",
              " '2008chapter': <gensim.models.keyedvectors.Vocab at 0x7ff78044e6a0>,\n",
              " 'biopsy': <gensim.models.keyedvectors.Vocab at 0x7ff78044e710>,\n",
              " 'region': <gensim.models.keyedvectors.Vocab at 0x7ff78044e780>,\n",
              " 'diuretics': <gensim.models.keyedvectors.Vocab at 0x7ff78044e7b8>,\n",
              " 'assess': <gensim.models.keyedvectors.Vocab at 0x7ff78044e828>,\n",
              " 'commonest': <gensim.models.keyedvectors.Vocab at 0x7ff78044e860>,\n",
              " '�': <gensim.models.keyedvectors.Vocab at 0x7ff78044e898>,\n",
              " 'testing': <gensim.models.keyedvectors.Vocab at 0x7ff78044e908>,\n",
              " '16': <gensim.models.keyedvectors.Vocab at 0x7ff78044e978>,\n",
              " 'blindness': <gensim.models.keyedvectors.Vocab at 0x7ff78044e9b0>,\n",
              " 'nervous': <gensim.models.keyedvectors.Vocab at 0x7ff78044ea20>,\n",
              " 'achieve': <gensim.models.keyedvectors.Vocab at 0x7ff78044ea90>,\n",
              " 'breathing': <gensim.models.keyedvectors.Vocab at 0x7ff78044eac8>,\n",
              " 'diabetic': <gensim.models.keyedvectors.Vocab at 0x7ff78044eb00>,\n",
              " 'post': <gensim.models.keyedvectors.Vocab at 0x7ff78044eb70>,\n",
              " 'stat': <gensim.models.keyedvectors.Vocab at 0x7ff78044ebe0>,\n",
              " 'atopic': <gensim.models.keyedvectors.Vocab at 0x7ff78044ec50>,\n",
              " 'course': <gensim.models.keyedvectors.Vocab at 0x7ff78044ecc0>,\n",
              " 'joints': <gensim.models.keyedvectors.Vocab at 0x7ff78044ed30>,\n",
              " 'allergy': <gensim.models.keyedvectors.Vocab at 0x7ff78044eda0>,\n",
              " 'sulfate': <gensim.models.keyedvectors.Vocab at 0x7ff78044ee10>,\n",
              " 'cervix': <gensim.models.keyedvectors.Vocab at 0x7ff78044ee80>,\n",
              " 'nose': <gensim.models.keyedvectors.Vocab at 0x7ff78044eef0>,\n",
              " 'increasing': <gensim.models.keyedvectors.Vocab at 0x7ff78044ef28>,\n",
              " 'bites': <gensim.models.keyedvectors.Vocab at 0x7ff78044ef98>,\n",
              " 'stress': <gensim.models.keyedvectors.Vocab at 0x7ff780451048>,\n",
              " 'heparin': <gensim.models.keyedvectors.Vocab at 0x7ff7804510b8>,\n",
              " 'like': <gensim.models.keyedvectors.Vocab at 0x7ff780451128>,\n",
              " 'sensation': <gensim.models.keyedvectors.Vocab at 0x7ff780451160>,\n",
              " 'endocarditis': <gensim.models.keyedvectors.Vocab at 0x7ff780451198>,\n",
              " 'sinusitis': <gensim.models.keyedvectors.Vocab at 0x7ff7804511d0>,\n",
              " 'corticosteroids': <gensim.models.keyedvectors.Vocab at 0x7ff780451208>,\n",
              " 'ulceration': <gensim.models.keyedvectors.Vocab at 0x7ff780451240>,\n",
              " 'ceftriaxone': <gensim.models.keyedvectors.Vocab at 0x7ff780451278>,\n",
              " 'hospital': <gensim.models.keyedvectors.Vocab at 0x7ff7804512b0>,\n",
              " 'light': <gensim.models.keyedvectors.Vocab at 0x7ff780451320>,\n",
              " 'prompt': <gensim.models.keyedvectors.Vocab at 0x7ff780451390>,\n",
              " 'personal': <gensim.models.keyedvectors.Vocab at 0x7ff7804513c8>,\n",
              " 'smoking': <gensim.models.keyedvectors.Vocab at 0x7ff780451438>,\n",
              " 'tetracycline': <gensim.models.keyedvectors.Vocab at 0x7ff780451470>,\n",
              " 'formation': <gensim.models.keyedvectors.Vocab at 0x7ff7804514a8>,\n",
              " 'pulse': <gensim.models.keyedvectors.Vocab at 0x7ff780451518>,\n",
              " 'part': <gensim.models.keyedvectors.Vocab at 0x7ff780451588>,\n",
              " 'route': <gensim.models.keyedvectors.Vocab at 0x7ff7804515f8>,\n",
              " 'lateral': <gensim.models.keyedvectors.Vocab at 0x7ff780451668>,\n",
              " 'stones': <gensim.models.keyedvectors.Vocab at 0x7ff7804516d8>,\n",
              " 'impaired': <gensim.models.keyedvectors.Vocab at 0x7ff780451710>,\n",
              " 'duration': <gensim.models.keyedvectors.Vocab at 0x7ff780451748>,\n",
              " 'predisposing': <gensim.models.keyedvectors.Vocab at 0x7ff780451780>,\n",
              " 'derangements': <gensim.models.keyedvectors.Vocab at 0x7ff7804517b8>,\n",
              " 'positive': <gensim.models.keyedvectors.Vocab at 0x7ff7804517f0>,\n",
              " 'manifestations': <gensim.models.keyedvectors.Vocab at 0x7ff780451828>,\n",
              " 'avoided': <gensim.models.keyedvectors.Vocab at 0x7ff780451898>,\n",
              " 'suspected': <gensim.models.keyedvectors.Vocab at 0x7ff7804518d0>,\n",
              " 'individuals': <gensim.models.keyedvectors.Vocab at 0x7ff780451908>,\n",
              " 'uric': <gensim.models.keyedvectors.Vocab at 0x7ff780451978>,\n",
              " 'gentamicin': <gensim.models.keyedvectors.Vocab at 0x7ff7804519b0>,\n",
              " 'bronchial': <gensim.models.keyedvectors.Vocab at 0x7ff7804519e8>,\n",
              " 'clear': <gensim.models.keyedvectors.Vocab at 0x7ff780451a58>,\n",
              " 'mmoll': <gensim.models.keyedvectors.Vocab at 0x7ff780451ac8>,\n",
              " 'radiographs': <gensim.models.keyedvectors.Vocab at 0x7ff780451b00>,\n",
              " 'classification': <gensim.models.keyedvectors.Vocab at 0x7ff780451b38>,\n",
              " 'left': <gensim.models.keyedvectors.Vocab at 0x7ff780451ba8>,\n",
              " 'transmission': <gensim.models.keyedvectors.Vocab at 0x7ff780451be0>,\n",
              " 'causative': <gensim.models.keyedvectors.Vocab at 0x7ff780451c18>,\n",
              " 'embolism': <gensim.models.keyedvectors.Vocab at 0x7ff780451c50>,\n",
              " 'difficulty': <gensim.models.keyedvectors.Vocab at 0x7ff780451c88>,\n",
              " 'direct': <gensim.models.keyedvectors.Vocab at 0x7ff780451cf8>,\n",
              " 'tooth': <gensim.models.keyedvectors.Vocab at 0x7ff780451d68>,\n",
              " 'postoperative': <gensim.models.keyedvectors.Vocab at 0x7ff780451da0>,\n",
              " 'furosemide': <gensim.models.keyedvectors.Vocab at 0x7ff780451dd8>,\n",
              " 'tumour': <gensim.models.keyedvectors.Vocab at 0x7ff780451e48>,\n",
              " 'physiotherapy': <gensim.models.keyedvectors.Vocab at 0x7ff780451e80>,\n",
              " 'half': <gensim.models.keyedvectors.Vocab at 0x7ff780451ef0>,\n",
              " 'tissues': <gensim.models.keyedvectors.Vocab at 0x7ff780451f60>,\n",
              " 'analysis': <gensim.models.keyedvectors.Vocab at 0x7ff780451f98>,\n",
              " 'infarction': <gensim.models.keyedvectors.Vocab at 0x7ff780451fd0>,\n",
              " 'becomes': <gensim.models.keyedvectors.Vocab at 0x7ff780455080>,\n",
              " 'gonorrhoea': <gensim.models.keyedvectors.Vocab at 0x7ff7804550b8>,\n",
              " 'destruction': <gensim.models.keyedvectors.Vocab at 0x7ff7804550f0>,\n",
              " 'based': <gensim.models.keyedvectors.Vocab at 0x7ff780455160>,\n",
              " 'metabolism': <gensim.models.keyedvectors.Vocab at 0x7ff780455198>,\n",
              " 'soft': <gensim.models.keyedvectors.Vocab at 0x7ff780455208>,\n",
              " 'loading': <gensim.models.keyedvectors.Vocab at 0x7ff780455278>,\n",
              " 'ie': <gensim.models.keyedvectors.Vocab at 0x7ff7804552e8>,\n",
              " 'necrosis': <gensim.models.keyedvectors.Vocab at 0x7ff780455320>,\n",
              " 'hands': <gensim.models.keyedvectors.Vocab at 0x7ff780455390>,\n",
              " 'made': <gensim.models.keyedvectors.Vocab at 0x7ff780455400>,\n",
              " 'nasogastric': <gensim.models.keyedvectors.Vocab at 0x7ff780455438>,\n",
              " 'eruption': <gensim.models.keyedvectors.Vocab at 0x7ff780455470>,\n",
              " '35': <gensim.models.keyedvectors.Vocab at 0x7ff7804554e0>,\n",
              " 'pityriasis': <gensim.models.keyedvectors.Vocab at 0x7ff780455518>,\n",
              " 'each': <gensim.models.keyedvectors.Vocab at 0x7ff780455588>,\n",
              " 'few': <gensim.models.keyedvectors.Vocab at 0x7ff7804555f8>,\n",
              " 'preparations': <gensim.models.keyedvectors.Vocab at 0x7ff780455630>,\n",
              " 'morbidity': <gensim.models.keyedvectors.Vocab at 0x7ff780455668>,\n",
              " 'safe': <gensim.models.keyedvectors.Vocab at 0x7ff7804556d8>,\n",
              " '800': <gensim.models.keyedvectors.Vocab at 0x7ff780455748>,\n",
              " 'depends': <gensim.models.keyedvectors.Vocab at 0x7ff7804557b8>,\n",
              " 'arrest': <gensim.models.keyedvectors.Vocab at 0x7ff780455828>,\n",
              " 'folic': <gensim.models.keyedvectors.Vocab at 0x7ff780455898>,\n",
              " 'continue': <gensim.models.keyedvectors.Vocab at 0x7ff7804558d0>,\n",
              " 'antidepressants': <gensim.models.keyedvectors.Vocab at 0x7ff780455908>,\n",
              " 'slowly': <gensim.models.keyedvectors.Vocab at 0x7ff780455978>,\n",
              " 'males': <gensim.models.keyedvectors.Vocab at 0x7ff7804559e8>,\n",
              " '09': <gensim.models.keyedvectors.Vocab at 0x7ff780455a58>,\n",
              " 'ingestion': <gensim.models.keyedvectors.Vocab at 0x7ff780455a90>,\n",
              " 'position': <gensim.models.keyedvectors.Vocab at 0x7ff780455ac8>,\n",
              " 'alternative': <gensim.models.keyedvectors.Vocab at 0x7ff780455b00>,\n",
              " 'considered': <gensim.models.keyedvectors.Vocab at 0x7ff780455b38>,\n",
              " 'vein': <gensim.models.keyedvectors.Vocab at 0x7ff780455ba8>,\n",
              " 'papules': <gensim.models.keyedvectors.Vocab at 0x7ff780455c18>,\n",
              " 'rectum': <gensim.models.keyedvectors.Vocab at 0x7ff780455c88>,\n",
              " 'immunization': <gensim.models.keyedvectors.Vocab at 0x7ff780455cc0>,\n",
              " 'microgram': <gensim.models.keyedvectors.Vocab at 0x7ff780455cf8>,\n",
              " 'either': <gensim.models.keyedvectors.Vocab at 0x7ff780455d68>,\n",
              " 'follows': <gensim.models.keyedvectors.Vocab at 0x7ff780455dd8>,\n",
              " 'needed': <gensim.models.keyedvectors.Vocab at 0x7ff780455e48>,\n",
              " '11': <gensim.models.keyedvectors.Vocab at 0x7ff780455eb8>,\n",
              " 'infertility': <gensim.models.keyedvectors.Vocab at 0x7ff780455ef0>,\n",
              " 'scalp': <gensim.models.keyedvectors.Vocab at 0x7ff780455f60>,\n",
              " '600': <gensim.models.keyedvectors.Vocab at 0x7ff780455fd0>,\n",
              " 'toxic': <gensim.models.keyedvectors.Vocab at 0x7ff780458080>,\n",
              " 'magnesium': <gensim.models.keyedvectors.Vocab at 0x7ff7804580b8>,\n",
              " 'erythematous': <gensim.models.keyedvectors.Vocab at 0x7ff7804580f0>,\n",
              " 'drainage': <gensim.models.keyedvectors.Vocab at 0x7ff780458128>,\n",
              " 'detection': <gensim.models.keyedvectors.Vocab at 0x7ff780458160>,\n",
              " 'problems': <gensim.models.keyedvectors.Vocab at 0x7ff780458198>,\n",
              " 'genitourinary': <gensim.models.keyedvectors.Vocab at 0x7ff7804581d0>,\n",
              " 'main': <gensim.models.keyedvectors.Vocab at 0x7ff780458240>,\n",
              " 'refer': <gensim.models.keyedvectors.Vocab at 0x7ff7804582b0>,\n",
              " '13': <gensim.models.keyedvectors.Vocab at 0x7ff780458320>,\n",
              " 'third': <gensim.models.keyedvectors.Vocab at 0x7ff780458390>,\n",
              " 'intrauterine': <gensim.models.keyedvectors.Vocab at 0x7ff7804583c8>,\n",
              " 'preferably': <gensim.models.keyedvectors.Vocab at 0x7ff780458400>,\n",
              " 'epilepsy': <gensim.models.keyedvectors.Vocab at 0x7ff780458438>,\n",
              " 'lead': <gensim.models.keyedvectors.Vocab at 0x7ff7804584a8>,\n",
              " 'canal': <gensim.models.keyedvectors.Vocab at 0x7ff780458518>,\n",
              " 'substances': <gensim.models.keyedvectors.Vocab at 0x7ff780458550>,\n",
              " 'membranes': <gensim.models.keyedvectors.Vocab at 0x7ff780458588>,\n",
              " 'procedure': <gensim.models.keyedvectors.Vocab at 0x7ff7804585c0>,\n",
              " 'right': <gensim.models.keyedvectors.Vocab at 0x7ff780458630>,\n",
              " 'specialist': <gensim.models.keyedvectors.Vocab at 0x7ff780458668>,\n",
              " 'frequently': <gensim.models.keyedvectors.Vocab at 0x7ff7804586a0>,\n",
              " 'emergencies': <gensim.models.keyedvectors.Vocab at 0x7ff7804586d8>,\n",
              " 'haemolytic': <gensim.models.keyedvectors.Vocab at 0x7ff780458710>,\n",
              " 'stages': <gensim.models.keyedvectors.Vocab at 0x7ff780458780>,\n",
              " 'improvement': <gensim.models.keyedvectors.Vocab at 0x7ff7804587b8>,\n",
              " 'complication': <gensim.models.keyedvectors.Vocab at 0x7ff7804587f0>,\n",
              " 'controlled': <gensim.models.keyedvectors.Vocab at 0x7ff780458828>,\n",
              " 'illness': <gensim.models.keyedvectors.Vocab at 0x7ff780458898>,\n",
              " 'sore': <gensim.models.keyedvectors.Vocab at 0x7ff780458908>,\n",
              " 'male': <gensim.models.keyedvectors.Vocab at 0x7ff780458978>,\n",
              " 'advanced': <gensim.models.keyedvectors.Vocab at 0x7ff7804589b0>,\n",
              " 'suppression': <gensim.models.keyedvectors.Vocab at 0x7ff7804589e8>,\n",
              " 'scarring': <gensim.models.keyedvectors.Vocab at 0x7ff780458a20>,\n",
              " 'genital': <gensim.models.keyedvectors.Vocab at 0x7ff780458a90>,\n",
              " '28': <gensim.models.keyedvectors.Vocab at 0x7ff780458b00>,\n",
              " 'saline': <gensim.models.keyedvectors.Vocab at 0x7ff780458b70>,\n",
              " 'benign': <gensim.models.keyedvectors.Vocab at 0x7ff780458be0>,\n",
              " 'leads': <gensim.models.keyedvectors.Vocab at 0x7ff780458c50>,\n",
              " 'v': <gensim.models.keyedvectors.Vocab at 0x7ff780458c88>,\n",
              " 'y': <gensim.models.keyedvectors.Vocab at 0x7ff780458cc0>,\n",
              " 'counselling': <gensim.models.keyedvectors.Vocab at 0x7ff780458cf8>,\n",
              " 'special': <gensim.models.keyedvectors.Vocab at 0x7ff780458d68>,\n",
              " 'gonococcal': <gensim.models.keyedvectors.Vocab at 0x7ff780458da0>,\n",
              " 'individual': <gensim.models.keyedvectors.Vocab at 0x7ff780458dd8>,\n",
              " 'lichen': <gensim.models.keyedvectors.Vocab at 0x7ff780458e48>,\n",
              " 'platelet': <gensim.models.keyedvectors.Vocab at 0x7ff780458e80>,\n",
              " 'acting': <gensim.models.keyedvectors.Vocab at 0x7ff780458ef0>,\n",
              " 'contaminated': <gensim.models.keyedvectors.Vocab at 0x7ff780458f28>,\n",
              " 'hypothyroidism': <gensim.models.keyedvectors.Vocab at 0x7ff780458f60>,\n",
              " 'administer': <gensim.models.keyedvectors.Vocab at 0x7ff780458f98>,\n",
              " 'muscles': <gensim.models.keyedvectors.Vocab at 0x7ff78045b048>,\n",
              " 'attention': <gensim.models.keyedvectors.Vocab at 0x7ff78045b080>,\n",
              " 'correction': <gensim.models.keyedvectors.Vocab at 0x7ff78045b0b8>,\n",
              " 'thyroid': <gensim.models.keyedvectors.Vocab at 0x7ff78045b128>,\n",
              " 'penis': <gensim.models.keyedvectors.Vocab at 0x7ff78045b198>,\n",
              " 'glands': <gensim.models.keyedvectors.Vocab at 0x7ff78045b208>,\n",
              " 'fat': <gensim.models.keyedvectors.Vocab at 0x7ff78045b278>,\n",
              " 'pus': <gensim.models.keyedvectors.Vocab at 0x7ff78045b2e8>,\n",
              " 'intermittent': <gensim.models.keyedvectors.Vocab at 0x7ff78045b320>,\n",
              " 'organ': <gensim.models.keyedvectors.Vocab at 0x7ff78045b390>,\n",
              " 'prostatitis': <gensim.models.keyedvectors.Vocab at 0x7ff78045b3c8>,\n",
              " 'rhinitis': <gensim.models.keyedvectors.Vocab at 0x7ff78045b400>,\n",
              " 'media': <gensim.models.keyedvectors.Vocab at 0x7ff78045b470>,\n",
              " 'animals': <gensim.models.keyedvectors.Vocab at 0x7ff78045b4e0>,\n",
              " 'arterial': <gensim.models.keyedvectors.Vocab at 0x7ff78045b518>,\n",
              " 'fresh': <gensim.models.keyedvectors.Vocab at 0x7ff78045b588>,\n",
              " 'so': <gensim.models.keyedvectors.Vocab at 0x7ff78045b5f8>,\n",
              " 'higher': <gensim.models.keyedvectors.Vocab at 0x7ff78045b668>,\n",
              " 'incubation': <gensim.models.keyedvectors.Vocab at 0x7ff78045b6a0>,\n",
              " 'suggestive': <gensim.models.keyedvectors.Vocab at 0x7ff78045b6d8>,\n",
              " 'polio': <gensim.models.keyedvectors.Vocab at 0x7ff78045b748>,\n",
              " 'hyperkalaemia': <gensim.models.keyedvectors.Vocab at 0x7ff78045b780>,\n",
              " 'population': <gensim.models.keyedvectors.Vocab at 0x7ff78045b7b8>,\n",
              " 'altered': <gensim.models.keyedvectors.Vocab at 0x7ff78045b828>,\n",
              " 'hot': <gensim.models.keyedvectors.Vocab at 0x7ff78045b898>,\n",
              " 'determine': <gensim.models.keyedvectors.Vocab at 0x7ff78045b8d0>,\n",
              " 'elevated': <gensim.models.keyedvectors.Vocab at 0x7ff78045b908>,\n",
              " 'short': <gensim.models.keyedvectors.Vocab at 0x7ff78045b978>,\n",
              " 'chemicals': <gensim.models.keyedvectors.Vocab at 0x7ff78045b9b0>,\n",
              " 'term': <gensim.models.keyedvectors.Vocab at 0x7ff78045ba20>,\n",
              " 'access': <gensim.models.keyedvectors.Vocab at 0x7ff78045ba90>,\n",
              " 'limited': <gensim.models.keyedvectors.Vocab at 0x7ff78045bb00>,\n",
              " 'haematuria': <gensim.models.keyedvectors.Vocab at 0x7ff78045bb38>,\n",
              " 'autoimmune': <gensim.models.keyedvectors.Vocab at 0x7ff78045bb70>,\n",
              " 'morning': <gensim.models.keyedvectors.Vocab at 0x7ff78045bbe0>,\n",
              " 'involved': <gensim.models.keyedvectors.Vocab at 0x7ff78045bc18>,\n",
              " 'intervals': <gensim.models.keyedvectors.Vocab at 0x7ff78045bc50>,\n",
              " 'hyperglycaemia': <gensim.models.keyedvectors.Vocab at 0x7ff78045bc88>,\n",
              " 'symptom': <gensim.models.keyedvectors.Vocab at 0x7ff78045bcf8>,\n",
              " 'viruses': <gensim.models.keyedvectors.Vocab at 0x7ff78045bd68>,\n",
              " 'anc': <gensim.models.keyedvectors.Vocab at 0x7ff78045bdd8>,\n",
              " 'feet': <gensim.models.keyedvectors.Vocab at 0x7ff78045be48>,\n",
              " 'episodes': <gensim.models.keyedvectors.Vocab at 0x7ff78045be80>,\n",
              " 'evaluation': <gensim.models.keyedvectors.Vocab at 0x7ff78045beb8>,\n",
              " 'subcutaneously': <gensim.models.keyedvectors.Vocab at 0x7ff78045bef0>,\n",
              " 'ph': <gensim.models.keyedvectors.Vocab at 0x7ff78045bf60>,\n",
              " 'million': <gensim.models.keyedvectors.Vocab at 0x7ff78045bfd0>,\n",
              " 'warm': <gensim.models.keyedvectors.Vocab at 0x7ff78045f080>,\n",
              " 'chlamydia': <gensim.models.keyedvectors.Vocab at 0x7ff78045f0b8>,\n",
              " 'second': <gensim.models.keyedvectors.Vocab at 0x7ff78045f128>,\n",
              " 'precipitating': <gensim.models.keyedvectors.Vocab at 0x7ff78045f160>,\n",
              " 'much': <gensim.models.keyedvectors.Vocab at 0x7ff78045f1d0>,\n",
              " ...}"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 22
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "072i7NvQnwnu",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "f255aa77-0162-4e09-a43b-462c1973f8b2"
      },
      "source": [
        "print(\"For 10 epochs model{}\\n\" .format(fasttext_trained_model_10.wv.most_similar([\"dizziness\"], topn=5)))\n",
        "print(\"For 20 epochs model{}\\n\" .format(fasttext_trained_model_20.wv.most_similar([\"dizziness\"], topn=5)))\n",
        "print(\"For 30 epochs model{}\\n\" .format(fasttext_trained_model_30.wv.most_similar([\"dizziness\"], topn=5)))\n"
      ],
      "execution_count": 58,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model[('drowsiness', 0.9582035541534424), ('headache', 0.936184287071228), ('dryness', 0.920276403427124), ('headaches', 0.9076910018920898), ('nausea', 0.8979116678237915)]\n",
            "\n",
            "For 20 epochs model[('drowsiness', 0.8123891353607178), ('shortness', 0.7257866859436035), ('syncope', 0.7250152826309204), ('dryness', 0.6867588758468628), ('lethargy', 0.661155104637146)]\n",
            "\n",
            "For 30 epochs model[('drowsiness', 0.6565455794334412), ('shortness', 0.64012211561203), ('dryness', 0.5671372413635254), ('syncope', 0.5500494241714478), ('weakness', 0.5497733354568481)]\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "Csdou-FL_61i",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "cd964a31-862a-40cb-984c-5fc0e9ecd67d"
      },
      "source": [
        "print(\"For 10 epochs model{}\\n\" .format(fasttext_trained_model_10.wv.most_similar([\"paracetamol\"], topn=5)))\n",
        "print(\"For 20 epochs model{}\\n\" .format(fasttext_trained_model_20.wv.most_similar([\"paracetamol\"], topn=5)))\n",
        "print(\"For 30 epochs model{}\\n\" .format(fasttext_trained_model_30.wv.most_similar([\"paracetamol\"], topn=5)))\n"
      ],
      "execution_count": 59,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model[('analgesics', 0.9049877524375916), ('acetylsalicylic', 0.8845304250717163), ('hourly', 0.8772410154342651), ('salbutamol', 0.8770194053649902), ('500', 0.8670943975448608)]\n",
            "\n",
            "For 20 epochs model[('analgesics', 0.640142560005188), ('g', 0.6355786323547363), ('480', 0.5870703458786011), ('acetylsalicylic', 0.5811442136764526), ('ibuprofen', 0.5797548890113831)]\n",
            "\n",
            "For 30 epochs model[('dosing', 0.5184269547462463), ('analgesics', 0.5020008683204651), ('480', 0.47163262963294983), ('240', 0.4574931561946869), ('acetylsalicylic', 0.455782949924469)]\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "0A6yn7Npoie0",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "a8746ef8-2a17-42b5-847b-bbff79f31352"
      },
      "source": [
        "print(\"For 10 epochs model{}\\n\" .format(fasttext_trained_model_10.wv.most_similar([\"pain\"], topn=5)))\n",
        "print(\"For 20 epochs model{}\\n\" .format(fasttext_trained_model_20.wv.most_similar([\"pain\"], topn=5)))\n",
        "print(\"For 30 epochs model{}\\n\" .format(fasttext_trained_model_30.wv.most_similar([\"pain\"], topn=5)))\n"
      ],
      "execution_count": 60,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model[('pains', 0.896994948387146), ('painless', 0.8674392700195312), ('aura', 0.8628156185150146), ('anorexia', 0.8565078973770142), ('stiffness', 0.8534125089645386)]\n",
            "\n",
            "For 20 epochs model[('pains', 0.7490514516830444), ('painful', 0.6681345701217651), ('painless', 0.5579604506492615), ('complaints', 0.5209423303604126), ('plain', 0.5186083912849426)]\n",
            "\n",
            "For 30 epochs model[('pains', 0.6535670161247253), ('painful', 0.525772213935852), ('painless', 0.47068706154823303), ('main', 0.40625637769699097), ('abdominal', 0.40297332406044006)]\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "e3Udok-PPrzA",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "738653cd-3154-4355-8b35-c06c60483de3"
      },
      "source": [
        "print(\"For 10 epochs model{}\\n\" .format(fasttext_trained_model_10.wv.most_similar([\"gastroenteritis\"], topn=5)))\n",
        "print(\"For 20 epochs model{}\\n\" .format(fasttext_trained_model_20.wv.most_similar([\"gastroenteritis\"], topn=5)))\n",
        "print(\"For 30 epochs model{}\\n\" .format(fasttext_trained_model_30.wv.most_similar([\"gastroenteritis\"], topn=5)))\n"
      ],
      "execution_count": 61,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model[('gastritis', 0.9290789365768433), ('gastrointestinal', 0.8811565637588501), ('pancreatitis', 0.8668469786643982), ('peptic', 0.8577708005905151), ('gastric', 0.8494676351547241)]\n",
            "\n",
            "For 20 epochs model[('gastritis', 0.8694455623626709), ('gastric', 0.7542743682861328), ('gastrointestinal', 0.7388126254081726), ('peptic', 0.6459965705871582), ('dysentery', 0.621463418006897)]\n",
            "\n",
            "For 30 epochs model[('gastritis', 0.824153482913971), ('gastrointestinal', 0.7180933952331543), ('gastric', 0.6840431094169617), ('dysentery', 0.6120988726615906), ('peptic', 0.5740396976470947)]\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "Q0lmlTuZU-Jb",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "33cbf3d9-15d4-4cab-d159-3caf4ba497f0"
      },
      "source": [
        "print(\"For 10 epochs model{}\\n\" .format(fasttext_trained_model_10.wv.most_similar([\"malaria\"], topn=5)))\n",
        "print(\"For 20 epochs model{}\\n\" .format(fasttext_trained_model_20.wv.most_similar([\"malaria\"], topn=5)))\n",
        "print(\"For 30 epochs model{}\\n\" .format(fasttext_trained_model_30.wv.most_similar([\"malaria\"], topn=5)))\n"
      ],
      "execution_count": 62,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model[('febrile', 0.855658769607544), ('crises', 0.7933704853057861), ('haemolytic', 0.7816790342330933), ('histology', 0.7796609401702881), ('haemolysis', 0.7777414321899414)]\n",
            "\n",
            "For 20 epochs model[('febrile', 0.5875685214996338), ('proteinuria', 0.5662850737571716), ('folic', 0.5509389638900757), ('splenomegaly', 0.5478829145431519), ('ovarian', 0.5325782895088196)]\n",
            "\n",
            "For 30 epochs model[('parasites', 0.45148569345474243), ('ovarian', 0.4451597332954407), ('folic', 0.44089698791503906), ('cerebral', 0.41459041833877563), ('oliguria', 0.4026787579059601)]\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "b2fkfUZIP2c6",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "51dd5c88-53fc-42cf-cbb2-483fe06f91d0"
      },
      "source": [
        "print(\"For 10 epochs model{}\\n\" .format(fasttext_trained_model_10.wv.most_similar([\"sepsis\"], topn=5)))\n",
        "print(\"For 20 epochs model{}\\n\" .format(fasttext_trained_model_20.wv.most_similar([\"sepsis\"], topn=5)))\n",
        "print(\"For 30 epochs model{}\\n\" .format(fasttext_trained_model_30.wv.most_similar([\"sepsis\"], topn=5)))\n"
      ],
      "execution_count": 63,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model[('fibrosis', 0.90422523021698), ('haemolysis', 0.8829312324523926), ('debris', 0.8793493509292603), ('sclerosis', 0.8668500185012817), ('leucocytosis', 0.8536408543586731)]\n",
            "\n",
            "For 20 epochs model[('basis', 0.6319530606269836), ('thrombosis', 0.5971360206604004), ('preexisting', 0.5717576742172241), ('atelectasis', 0.5651276707649231), ('crisis', 0.5633425712585449)]\n",
            "\n",
            "For 30 epochs model[('necrosis', 0.4591243863105774), ('vertigo', 0.4444141089916229), ('basis', 0.4327285885810852), ('crisis', 0.427929162979126), ('psychosis', 0.4185298979282379)]\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "vI_7g70CP9Es",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "687b1861-9d88-4995-9296-a31e118be69f"
      },
      "source": [
        "print(\"For 10 epochs model{}\\n\" .format(fasttext_trained_model_10.wv.most_similar([\"ciprofloxacin\"], topn=5)))\n",
        "print(\"For 20 epochs model{}\\n\" .format(fasttext_trained_model_20.wv.most_similar([\"ciprofloxacin\"], topn=5)))\n",
        "print(\"For 30 epochs model{}\\n\" .format(fasttext_trained_model_30.wv.most_similar([\"ciprofloxacin\"], topn=5)))\n"
      ],
      "execution_count": 64,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model[('fluconazole', 0.9416192770004272), ('gentamicin', 0.9365870952606201), ('aciclovir', 0.9346696138381958), ('doxycycline', 0.9343892335891724), ('ibuprofen', 0.9324017763137817)]\n",
            "\n",
            "For 20 epochs model[('azithromycin', 0.7529835104942322), ('480', 0.7024049162864685), ('every12', 0.6952436566352844), ('750', 0.6907142996788025), ('960', 0.6730709075927734)]\n",
            "\n",
            "For 30 epochs model[('azithromycin', 0.6300053596496582), ('rifampicin', 0.5873949527740479), ('every12', 0.5591945052146912), ('480', 0.5590738654136658), ('ceftriaxone', 0.5418074727058411)]\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "QYgjlo4-QDMy",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "c3c0eced-e768-4a9a-8f69-6174fe9d8f14"
      },
      "source": [
        "print(\"For 10 epochs model{}\\n\" .format(fasttext_trained_model_10.wv.most_similar([\"adverse effect\"], topn=5)))\n",
        "print(\"For 20 epochs model{}\\n\" .format(fasttext_trained_model_20.wv.most_similar([\"adverse effect\"], topn=5)))\n",
        "print(\"For 30 epochs model{}\\n\" .format(fasttext_trained_model_30.wv.most_similar([\"adverse effect\"], topn=5)))\n"
      ],
      "execution_count": 67,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model[('adverse', 0.9207590222358704), ('notable', 0.9050818681716919), ('drug', 0.9025295972824097), ('adjuvant', 0.8844457864761353), ('contraindications', 0.8697888255119324)]\n",
            "\n",
            "For 20 epochs model[('adverse', 0.8352594971656799), ('effect', 0.6851158142089844), ('effects', 0.6488581299781799), ('reactions', 0.6269594430923462), ('notable', 0.6092997789382935)]\n",
            "\n",
            "For 30 epochs model[('adverse', 0.7905198335647583), ('effect', 0.6326106190681458), ('notable', 0.6002745628356934), ('drug', 0.5545644164085388), ('effects', 0.5515033006668091)]\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "KDsLmlr0QKUR",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "4b2ad997-5e2e-45af-e6a7-8959b7ffdaeb"
      },
      "source": [
        "print(\"For 10 epochs model{}\\n\" .format(fasttext_trained_model_10.wv.most_similar([\"ulcer\"], topn=5)))\n",
        "print(\"For 20 epochs model{}\\n\" .format(fasttext_trained_model_20.wv.most_similar([\"ulcer\"], topn=5)))\n",
        "print(\"For 30 epochs model{}\\n\" .format(fasttext_trained_model_30.wv.most_similar([\"ulcer\"], topn=5)))\n"
      ],
      "execution_count": 68,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model[('ulcers', 0.8904516696929932), ('cancer', 0.8291261792182922), ('ulcerative', 0.8008972406387329), ('oesophagus', 0.7954973578453064), ('peptic', 0.787898600101471)]\n",
            "\n",
            "For 20 epochs model[('ulcers', 0.7880502939224243), ('ulcerative', 0.7118950486183167), ('ulceration', 0.7025587558746338), ('peptic', 0.5605218410491943), ('gastritis', 0.5325325727462769)]\n",
            "\n",
            "For 30 epochs model[('ulcers', 0.7061822414398193), ('ulcerative', 0.6691617369651794), ('ulceration', 0.6404780745506287), ('peptic', 0.5424119234085083), ('amoebic', 0.4882155656814575)]\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "MyLIRUo7QrC_",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "3dd69e55-76e7-4f58-b20a-a330f693514f"
      },
      "source": [
        "print(\"For 10 epochs model{}\\n\" .format(fasttext_trained_model_10.wv.most_similar([\"gonorhhoea\"], topn=5)))  #incorrect spelling of word\n",
        "print(\"For 20 epochs model{}\\n\" .format(fasttext_trained_model_20.wv.most_similar([\"gonorhhoea\"], topn=5)))\n",
        "print(\"For 30 epochs model{}\\n\" .format(fasttext_trained_model_30.wv.most_similar([\"gonorhhoea\"], topn=5)))\n"
      ],
      "execution_count": 71,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model[('gonorrhoea', 0.9814373254776001), ('gonorrhoeae', 0.9478224515914917), ('same', 0.88121497631073), ('gonococcal', 0.8597482442855835), ('candida', 0.8553809523582458)]\n",
            "\n",
            "For 20 epochs model[('gonorrhoea', 0.9735233783721924), ('gonorrhoeae', 0.9180431365966797), ('gonococcal', 0.7047483325004578), ('chlamydia', 0.6894460916519165), ('nongonococcal', 0.6429787874221802)]\n",
            "\n",
            "For 30 epochs model[('gonorrhoea', 0.9689017534255981), ('gonorrhoeae', 0.9023888111114502), ('gonococcal', 0.6111904978752136), ('nongonococcal', 0.5462511777877808), ('neisseria', 0.5353579521179199)]\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "32pnI9PpS92q",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "28ddfa31-12ec-4a96-c183-1c650b129813"
      },
      "source": [
        "print(\"For 10 epochs model{}\\n\" .format(fasttext_trained_model_10.wv.most_similar([\"insulin\"], topn=5)))  \n",
        "print(\"For 20 epochs model{}\\n\" .format(fasttext_trained_model_20.wv.most_similar([\"insulin\"], topn=5)))\n",
        "print(\"For 30 epochs model{}\\n\" .format(fasttext_trained_model_30.wv.most_similar([\"insulin\"], topn=5)))"
      ],
      "execution_count": 72,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model[('deficit', 0.844693660736084), ('intake', 0.8428065776824951), ('oglas', 0.8420634865760803), ('calories', 0.8406931757926941), ('iodine', 0.839836835861206)]\n",
            "\n",
            "For 20 epochs model[('oglas', 0.6434071063995361), ('sulphonylureas', 0.6225800514221191), ('metformin', 0.5981875658035278), ('added', 0.5503554344177246), ('mmoll', 0.5480923652648926)]\n",
            "\n",
            "For 30 epochs model[('sulphonylureas', 0.5322369933128357), ('oglas', 0.5095759034156799), ('added', 0.5016563534736633), ('acting', 0.4712255001068115), ('metformin', 0.4635075032711029)]\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "HursxXowDi-6",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "cb87dd2d-2105-46d1-fa2c-7fc00a45b077"
      },
      "source": [
        "print(\"For 10 epochs model{}\\n\" .format(fasttext_trained_model_10.wv.most_similar([\"diabetes\"], topn=5)))  #incorrect spelling of word\n",
        "print(\"For 20 epochs model{}\\n\" .format(fasttext_trained_model_20.wv.most_similar([\"diabetes\"], topn=5)))\n",
        "print(\"For 30 epochs model{}\\n\" .format(fasttext_trained_model_30.wv.most_similar([\"diabetes\"], topn=5)))"
      ],
      "execution_count": 73,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model[('states', 0.8773221969604492), ('diabetic', 0.8735930323600769), ('mellitus', 0.8661960363388062), ('managed', 0.8418309688568115), ('types', 0.8181455731391907)]\n",
            "\n",
            "For 20 epochs model[('mellitus', 0.7721080183982849), ('diabetic', 0.7190732955932617), ('goals', 0.6079843640327454), ('gdm', 0.6015347242355347), ('people', 0.5803878307342529)]\n",
            "\n",
            "For 30 epochs model[('mellitus', 0.7367488145828247), ('diabetic', 0.614261269569397), ('goals', 0.4828929603099823), ('gdm', 0.472972571849823), ('people', 0.45599836111068726)]\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "uDxfZhm-DvI5",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 210
        },
        "outputId": "36336153-fa01-494b-c221-a497cb4e0042"
      },
      "source": [
        "print(\"For 10 epochs model {}\\n\" .format(fasttext_trained_model_10.wv.doesnt_match([\"paracetamol\", \"headache\",\"diarrhoea\",\"dizziness\"])))  #incorrect spelling of word\n",
        "print(\"For 20 epochs model {}\\n\" .format(fasttext_trained_model_20.wv.doesnt_match([\"paracetamol\", \"headache\",\"diarrhoea\",\"dizziness\"])))\n",
        "print(\"For 30 epochs model {}\\n\" .format(fasttext_trained_model_30.wv.doesnt_match([\"paracetamol\", \"headache\",\"diarrhoea\",\"dizziness\"])))"
      ],
      "execution_count": 76,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model paracetamol\n",
            "\n",
            "For 20 epochs model paracetamol\n",
            "\n",
            "For 30 epochs model paracetamol\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/models/keyedvectors.py:895: FutureWarning: arrays to stack must be passed as a \"sequence\" type such as list or tuple. Support for non-sequence iterables such as generators is deprecated as of NumPy 1.16 and will raise an error in the future.\n",
            "  vectors = vstack(self.word_vec(word, use_norm=True) for word in used_words).astype(REAL)\n",
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "svfvdzc0Efwd",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 210
        },
        "outputId": "7de541d7-c6f2-4bbc-8a34-c3818584a4be"
      },
      "source": [
        "print(\"For 10 epochs model {}\\n\" .format(fasttext_trained_model_10.wv.doesnt_match([\"Hydrochorothiazide\", \"Furosemide\",\"Amlodipine\"])))  \n",
        "print(\"For 20 epochs model {}\\n\" .format(fasttext_trained_model_20.wv.doesnt_match([\"Hydrochorothiazide\", \"Furosemide\",\"Amlodipine\"])))\n",
        "print(\"For 30 epochs model {}\\n\" .format(fasttext_trained_model_30.wv.doesnt_match([\"Hydrochorothiazide\", \"Furosemide\",\"Amlodipine\"])))"
      ],
      "execution_count": 77,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model Amlodipine\n",
            "\n",
            "For 20 epochs model Amlodipine\n",
            "\n",
            "For 30 epochs model Amlodipine\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/models/keyedvectors.py:895: FutureWarning: arrays to stack must be passed as a \"sequence\" type such as list or tuple. Support for non-sequence iterables such as generators is deprecated as of NumPy 1.16 and will raise an error in the future.\n",
            "  vectors = vstack(self.word_vec(word, use_norm=True) for word in used_words).astype(REAL)\n",
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "wtdtyL8yE-yl",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 210
        },
        "outputId": "15be1ad3-95e1-40c7-b6db-811e23dfbe61"
      },
      "source": [
        "print(\"For 10 epochs model {}\\n\" .format(fasttext_trained_model_10.wv.doesnt_match([\"paracetamol\", \"headache\",\"diarrhoea\",\"dry cough\"])))  \n",
        "print(\"For 20 epochs model {}\\n\" .format(fasttext_trained_model_20.wv.doesnt_match([\"paracetamol\", \"headache\",\"diarrhoea\",\"dry cough\"])))\n",
        "print(\"For 30 epochs model {}\\n\" .format(fasttext_trained_model_30.wv.doesnt_match([\"paracetamol\", \"headache\",\"diarrhoea\",\"dry cough\"])))"
      ],
      "execution_count": 78,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model dry cough\n",
            "\n",
            "For 20 epochs model dry cough\n",
            "\n",
            "For 30 epochs model dry cough\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/models/keyedvectors.py:895: FutureWarning: arrays to stack must be passed as a \"sequence\" type such as list or tuple. Support for non-sequence iterables such as generators is deprecated as of NumPy 1.16 and will raise an error in the future.\n",
            "  vectors = vstack(self.word_vec(word, use_norm=True) for word in used_words).astype(REAL)\n",
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "OtPh6eLdFr9F",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "6238ad46-44bd-43c2-b9b5-6d2a78335ee5"
      },
      "source": [
        "print(\"For 10 epochs model {}\\n\" .format(fasttext_trained_model_10.wv.similarity(w1='drowsiness', w2='dizziness')))  \n",
        "print(\"For 20 epochs model {}\\n\" .format(fasttext_trained_model_20.wv.similarity(w1='drowsiness', w2='dizziness')))\n",
        "print(\"For 30 epochs model {}\\n\" .format(fasttext_trained_model_30.wv.similarity(w1='drowsiness', w2='dizziness')))"
      ],
      "execution_count": 79,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model 0.9582034349441528\n",
            "\n",
            "For 20 epochs model 0.812389075756073\n",
            "\n",
            "For 30 epochs model 0.6565455794334412\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "aJUh04NcFhHY",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "aac3b080-d8f0-45dd-f8dc-bfcca34ba7c8"
      },
      "source": [
        "print(\"For 10 epochs model {}\\n\" .format(fasttext_trained_model_10.wv.similarity(w1='drowsiness', w2='headache')))  \n",
        "print(\"For 20 epochs model {}\\n\" .format(fasttext_trained_model_20.wv.similarity(w1='drowsiness', w2='headache')))\n",
        "print(\"For 30 epochs model {}\\n\" .format(fasttext_trained_model_30.wv.similarity(w1='drowsiness', w2='headache')))"
      ],
      "execution_count": 80,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model 0.8723451495170593\n",
            "\n",
            "For 20 epochs model 0.579349160194397\n",
            "\n",
            "For 30 epochs model 0.38579708337783813\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "cVQvfCsMHTPK",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "51972d24-04c2-46d7-daaf-003ef1bf49ae"
      },
      "source": [
        "print(\"For 10 epochs model {}\\n\" .format(fasttext_trained_model_10.wv.similarity(w1='drowsiness', w2='amlodipine')))  \n",
        "print(\"For 20 epochs model {}\\n\" .format(fasttext_trained_model_20.wv.similarity(w1='drowsiness', w2='amlodipine')))\n",
        "print(\"For 30 epochs model {}\\n\" .format(fasttext_trained_model_30.wv.similarity(w1='drowsiness', w2='amlodipine')))"
      ],
      "execution_count": 81,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model 0.5793604254722595\n",
            "\n",
            "For 20 epochs model 0.541750431060791\n",
            "\n",
            "For 30 epochs model 0.4310232698917389\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "PdPD-ovyIYBy",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 176
        },
        "outputId": "5ec6f3bc-d1e6-47e4-c6df-a42ebc528547"
      },
      "source": [
        "print(\"For 10 epochs model {}\\n\" .format(fasttext_trained_model_10.wv.similarity(w1='amlodipine', w2='cephalexin')))  \n",
        "print(\"For 20 epochs model {}\\n\" .format(fasttext_trained_model_20.wv.similarity(w1='amlodipine', w2='cephalexin')))\n",
        "print(\"For 30 epochs model {}\\n\" .format(fasttext_trained_model_30.wv.similarity(w1='amlodipine', w2='cephalexin')))"
      ],
      "execution_count": 83,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "For 10 epochs model 0.6379944086074829\n",
            "\n",
            "For 20 epochs model 0.2934947907924652\n",
            "\n",
            "For 30 epochs model 0.24699269235134125\n",
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "vyTor2kAXeYN",
        "colab_type": "text"
      },
      "source": [
        "##Create Visualization after dimentionality Reduction using Principal Component Analysis (PCA) . Code snippets from Usman Malik https://stackabuse.com/python-for-nlp-working-with-facebook-fasttext-library/ "
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "6ba9iLJFXz4m",
        "colab_type": "text"
      },
      "source": [
        "###Generate semantically similar words for model with 10 epochs\n"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "N5A9eMrGw0W3",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 245
        },
        "outputId": "2572a130-3087-4049-c32c-31087f4f7b6d"
      },
      "source": [
        "semantically_similar_words = {words: [item[0] for item in fasttext_trained_model_10.wv.most_similar([words], topn=5)]\n",
        "                  for words in ['ringworm','paracetamol','Nurse' ,'pain', 'nausea', 'delivery', 'infection', 'orally','child',\"diabetes\"]}\n",
        "\n",
        "for k,v in semantically_similar_words.items():\n",
        "    print(k+\":\"+str(v))"
      ],
      "execution_count": 85,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "ringworm:['feels', 'worms', 'vulva', 'larvae', 'trunk']\n",
            "paracetamol:['analgesics', 'acetylsalicylic', 'hourly', 'salbutamol', '500']\n",
            "Nurse:['course', 'written', 'intercourse', 'average', 'areas']\n",
            "pain:['pains', 'painless', 'aura', 'anorexia', 'stiffness']\n",
            "nausea:['diarrhoea', 'vomiting', 'drowsiness', 'dizziness', 'cramps']\n",
            "delivery:['recovery', 'staff', 'postpartum', 'antenatal', 'birth']\n",
            "infection:['coinfection', 'reinfection', 'infections', 'section', 'infectious']\n",
            "orally:['mg', '400', 'omeprazole', '960', '8']\n",
            "child:['adult', 'adolescent', 'years', 'year', 'months']\n",
            "diabetes:['states', 'diabetic', 'mellitus', 'managed', 'types']\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/gensim/matutils.py:737: FutureWarning: Conversion of the second argument of issubdtype from `int` to `np.signedinteger` is deprecated. In future, it will be treated as `np.int64 == np.dtype(int).type`.\n",
            "  if np.issubdtype(vec.dtype, np.int):\n"
          ],
          "name": "stderr"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "LiIAvxgTp8_w",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 89
        },
        "outputId": "a56da43d-118b-4326-87e5-8dff75f73f39"
      },
      "source": [
        "all_similar_words = sum([[k] + v for k, v in semantically_similar_words.items()], [])\n",
        "\n",
        "print(all_similar_words)\n",
        "print(type(all_similar_words))\n",
        "print(len(all_similar_words))"
      ],
      "execution_count": 86,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "['ringworm', 'feels', 'worms', 'vulva', 'larvae', 'trunk', 'paracetamol', 'analgesics', 'acetylsalicylic', 'hourly', 'salbutamol', '500', 'Nurse', 'course', 'written', 'intercourse', 'average', 'areas', 'pain', 'pains', 'painless', 'aura', 'anorexia', 'stiffness', 'nausea', 'diarrhoea', 'vomiting', 'drowsiness', 'dizziness', 'cramps', 'delivery', 'recovery', 'staff', 'postpartum', 'antenatal', 'birth', 'infection', 'coinfection', 'reinfection', 'infections', 'section', 'infectious', 'orally', 'mg', '400', 'omeprazole', '960', '8', 'child', 'adult', 'adolescent', 'years', 'year', 'months', 'diabetes', 'states', 'diabetic', 'mellitus', 'managed', 'types']\n",
            "<class 'list'>\n",
            "60\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "9F9s-KAKL2GT",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "p_comps"
      ],
      "execution_count": 0,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "ah3Lb9mExsc2",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 646
        },
        "outputId": "83b496e4-eff2-4037-d017-beb3633eb11d"
      },
      "source": [
        "word_vectors = fasttext_trained_model_10[all_similar_words]\n",
        "\n",
        "pca = PCA(2)\n",
        "\n",
        "p_comps = pca.fit_transform(word_vectors)\n",
        "word_names = all_similar_words\n",
        "\n",
        "plt.figure(figsize=(18, 10))\n",
        "plt.scatter(p_comps[:, 0], p_comps[:, 1], c='b')\n",
        "\n",
        "for word_names, x, y in zip(word_names, p_comps[:, 0], p_comps[:, 1]):\n",
        "    plt.annotate(word_names, xy=(x+0.06, y+0.03), xytext=(0, 0), textcoords='offset points')"
      ],
      "execution_count": 90,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/ipykernel_launcher.py:1: DeprecationWarning: Call to deprecated `__getitem__` (Method will be removed in 4.0.0, use self.wv.__getitem__() instead).\n",
            "  \"\"\"Entry point for launching an IPython kernel.\n"
          ],
          "name": "stderr"
        },
        {
          "output_type": "display_data",
          "data": {
            "image/png": "iVBORw0KGgoAAAANSUhEUgAABBoAAAI/CAYAAADZbbrgAAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\nQmCC\n",
            "text/plain": [
              "<Figure size 1296x720 with 1 Axes>"
            ]
          },
          "metadata": {
            "tags": []
          }
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "ExLylc-3yQ_n",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        ""
      ],
      "execution_count": 0,
      "outputs": []
    }
  ]
}